

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/66126> holds various files of this Leiden University dissertation.

Author: Vorm, S. van der

Title: Reactivity and selectivity in glycosylation reactions

Issue Date: 2018-10-11

Reactivity and Selectivity in Glycosylation Reactions

PROEFSCHRIFT

ter verkrijging van
de graad van Doctor aan de Universiteit Leiden
op gezag van Rector Magnificus prof. mr. C. J. J. M. Stolker,
volgens besluit van het College voor Promoties
te verdedigen op donderdag 11 oktober 2018
klokke 13:45 uur

door

Stefan van der Vorm

Geboren te Rotterdam in 1988

Promotiecommissie

Promotor : prof. dr. G. A. van der Marel

Co-promotor : dr. J. D. C. Codée

Overige leden : prof. dr. H. S. Overkleef
prof. dr. J. Brouwer
prof. dr. M. C. Galan (University of Bristol)
dr. T. J. Boltje (Radboud Universiteit Nijmegen)

Gedrukt door Ridderprint BV

ISBN: 978-94-6375-079-0

Voor mijn vader

Table of contents

List of abbreviations	6
Chapter 1	9
General introduction	
Chapter 2	23
Acceptor reactivity in glycosylations	
Chapter 3	45
The influence of acceptor nucleophilicity on the glycosylation reaction mechanism	
Chapter 4	79
Stereoselectivity of conformationally restricted glucosazide donors	
Chapter 5	111
The impact of 3,4-tethering on the stereoselectivity of a glucosazide donor	
Chapter 6	125
Mapping glycosylation stereoselectivity by acceptor reactivity tuning	

Chapter 7	155
Synthesis of C-2- and C-5-modified furanosides	
Chapter 8	191
Stereoselectivity of C-2- and C-5-modified furanosides: a computational and experimental study	
Chapter 9	217
Summary and future prospects	
Samenvatting in het Nederlands	249
List of publications	254
Curriculum vitae	256
Appendix: General experimental procedures	258

List of abbreviations

Ac	acetyl	DMF	dimethylformamide
AIBN	2,2'-azobis(2-methyl-propionitrile)	DMM	dimethylmaleimide
All	allyl	DMSO	dimethylsulfoxide
APT	attached proton test	DNPY	dinitropyridone
aq.	aqueous	dq	double quartet
Ar	aryl	dt	double triplet
Ara	arabinose	dtd	doublet of triple doublets
AraA	arabinuronic acid	DTBMP	2,6-di- <i>tert</i> -butyl-4-methylpyridine
AraF	2-deoxy-2-fluoro arabinose	DTBS	di- <i>tert</i> -butylsilylidene
AraN ₃	2-azido-2-deoxy arabinose	E	energy
Arom	aromatic	<i>E</i>	envelope
<i>B</i>	boat	eq.	molar equivalent
B3LYP	Becke, 3-parameter, Lee-Yang-Parr	Et	ethyl
BAIB	(diacetoxyiodo)benzene	E-X	electrophilic activator system
BDA	butane-2,3-diacetal	<i>F</i>	field-inductive parameter
Bn	benzyl	<i>f</i>	Fukui value
bs	broad singlet	FT	Fourier transform
Bu	butyl	gg	gauche-gauche
Bz	benzoyl	gt	gauche-trans
C	chair	GATED	proton decoupling applied only during relaxation
cal	calorie	Gal	galactose
calcd	calculated	Glc	glucose
cat.	catalytic	GlcA	glucuronic acid
CBz	carboxybenzyl	GlcN	glucosamine
CEL	conformational energy landscape	GlcN ₃	2-azido-2-deoxy glucose
CIP	contact ion pair	GlcNAc	<i>N</i> -acetyl glucosamine
COSY	correlation spectroscopy	h	hour(s)
C _q	quaternary carbon atom	<i>H</i>	half-chair
CSA	camphor-10-sulfonic acid	HECADE	heteronuclear couplings from aSSCI-domain experiments with E.COSY-type cross peaks
Cy	cyclohexyl	HFIP	hexafluoro- <i>iso</i> -propanol
δ	chemical shift (ppm)	HMBC	heteronuclear multiple-bond correlation spectroscopy
d	doublet	HOMO	highest occupied molecular orbital
DAST	diethylaminosulfur trifluoride	HPLC	high performance liquid chromatography
DBU	1,8-diazabicyclo[5.4.0]undec-7-ene	HRMS	high-resolution mass spectroscopy
DCE	1,2-dichloroethane	HSQC	heteronuclear single quantum coherence
DCM	dichloromethane	IR	infrared
dd	double doublet	<i>J</i>	coupling constant
ddd	doublet of double doublets	KIE	kinetic isotope effect
dddd	double doublet of double doublets	LC-MS	liquid chromatography - mass spectrometry
ddt	doublet of double triplets		
DEAD	diethyl azocarcboxylate		
DFE	difluorethanol		
DFT	density function theory		
DiPEA	diisopropylethylamine		
DMAP	4-dimethylaminopyridine		

LG	leaving group	RRV	relative reactivity value
LTQ	linear trap quadrupole	s	singlet
LUMO	lowest unoccupied molecular orbital	s	chemical softness
Lyx	lyxose	S	skew boat
LyxA	lyxuronic acid	sat.	saturated
LyxF	2-deoxy-2-fluoro lyxose	S _N 1	uni-molecular nucleophilic substitution
LyxN ₃	2-azido-2-deoxy lyxose	S _N 2	bi-molecular nucleophilic substitution
M	molar	SSIP	solvent-separated ion pair
m	multiplet	t	triplet
m.s.	molecular sieves	<i>t</i>	<i>tert</i> -
m/z	mass over charge ratio	<i>T</i>	twist
min	minutes	Taz	tiazolinyl
Man	mannose	<i>tg</i>	trans-gauge
ManA	mannuronic acid	TBAF	tetrabutylammonium fluoride
Me	methyl	TBAI	tetrabutylammonium iodide
MFE	monofluoroethanol	TBAT	tetrabutylammonium triphenylsilyl difluoride
M.S.	molecular sieves	TBS	<i>tert</i> -butyldimethylsilyl
<i>N</i>	Mayr's nucleophilicity parameter	TBDMS	<i>tert</i> -butyldimethylsilyl
<i>N</i> -PSP	<i>N</i> -(phenylseleno)phthalimide	TBDPS	<i>tert</i> -butyldiphenylsilyl
Nap	2-methylnaphthyl	TCA	trichloroacetyl
NBS	<i>N</i> -bromosuccinimide	TES	triethylsilyl
NFM	<i>N</i> -formylmorpholine	TEMPO	2,2,6,6-tetramethylpiperidine
NIS	<i>N</i> -iodosuccinimide	TFA	trifluoroacetic acid
NMR	nuclear magnetic resonance	TFE	trifluoroethanol
NMP	<i>N</i> -methyl-2-pyrrolidone	Tf	triflyl; trifluoromethanesulfonyl
NOESY	nuclear Overhauser effect spectroscopy	THF	tetrahydrofuran
Nu	nucleophile	TIPS	tri- <i>iso</i> -propylsilyl
<i>p</i>	para	TLC	thin layer chromatography
P	protection group	TMEDA	tetramethylethylenediamine
PCM	polarizable continuum model	TMS	trimethylsilyl
PET	positron-emission tomography	TOCSY	total correlation spectroscopy
PFBS-F	perfluorobutanesulfonyl fluoride	Tol	tolyl; 4-methylphenyl
Ph	phenyl	Trt	trityl; triphenylmethyl
Phth	phthaloyl	Ts	tosyl; 4-methylbenzene-1-sulfonyl
pK _a	-log ₁₀ (acid dissociation constant)	TS	transition state
PMB	4-methoxybenzyl	td	triple doublet
ppm	parts per million	tt	triple triplet
q	quartet	TTBP	2,4,6-tri- <i>tert</i> -butylpyrimidine
<i>q</i>	atomic charge	UDP	uridine diphosphate
qd	quartet of doublets	UV	ultraviolet
r.t.	room temperature	VT	variable temperature
R _f	retention factor	Xyl	xylose
RDAS	reciprocal donor-acceptor selectivity	XylA	xyluronic acid
Rib	ribose	XylF	2-deoxy-2-fluoro xylose
RibA	riburonic acid	XylN ₃	2-azido-2-deoxy xylose
RibF	2-deoxy-2-fluoro ribose	ZPE	zero-point energy
RibN ₃	2-azido-2-deoxy ribose		

Chapter 1

General introduction

Introduction


Carbohydrates are the most diverse and abundant class of biomolecules on earth, and play important roles in all facets of life, amongst others in cell-cell recognition and activation of the immune system.^{1,2} Extracting carbohydrates from natural sources, if available at all, is a tedious and expensive process owing to the complex mixture of similar compounds present. Synthetic chemistry is one of the most important suppliers of well-defined carbohydrates and glycoconjugates, in sufficient quantities and free from contaminants that may interfere with or are detrimental to the activity. However, the assembly of complex oligosaccharides remains a complex task and gaining full control over the stereoselectivity in the crucial glycosylation reaction still is a major challenge in synthetic carbohydrate chemistry. This Thesis investigates the mechanisms of the glycosylation reaction by establishing structure-reactivity-selectivity relationships.

In a glycosylation reaction, a carbohydrate donor is activated to provide an electrophilic species to react with a nucleophilic acceptor molecule (see Scheme 1), which


can be as simple and small as water, or as structurally complex and large as a protein.³⁻⁸ In a chemical glycosylation, the glycosyl donor has protecting groups to temporarily inactivate the reactive carbohydrate alcohol groups and avoid side reactions, and a leaving group at the anomeric (C-1) position.^{9,10} This leaving group can be activated by a promotor to make it sufficiently reactive to be substituted by the nucleophilic acceptor, which also bears protecting groups to mask positions where reactions must be avoided. The additional synthetic steps to construct protected building blocks and exchange or remove them can in itself be a monumental undertaking, but one that is often unavoidable due to inherent similarities between the carbohydrate alcohols.¹¹⁻¹⁵

Scheme 1. Depiction of a glycosylation reaction: synthesis of lactose through enzymatic and chemical methods.⁴

Biological glycosylation



Chemical glycosylation




⁴UDP = uridine diphosphate. Numbers indicate the conventional labelling of glycosides. The biosynthetic pathway,¹⁶ and conditions for enzymatic biosynthesis¹⁷ and chemical synthesis¹⁸ are reported in cited references.

The glycosylation reaction mechanism

There is no single general reaction mechanism to describe every chemical glycosylation reaction. For over a century, and especially the past 50 years,^{19,20} many new glycosylation protocols have been developed and each of these requires different reagents and reaction conditions. The current mechanistic understanding, which was already formulated and proposed in the 1960s and 1970s,²¹⁻²⁴ centers on the equilibrium between a covalent glycosylating species, in which the anomeric leaving group is attached to the glycosyl donor, and the related ion pairs, in which the leaving group is dissociated from the donor (see Scheme 2). Substitution may take place on any of the intermediate states, with partially dissociated bonds, or in a geometry not generally depicted in a reaction scheme.²⁵ Although donors may look similar, their behavior in glycosylation reactions

may be very different. Whether a reaction is feasible is determined by many factors, not the least of which are the potential of ionization at the anomeric center, the geometry of the donor when it undergoes glycosylation, and the nucleophilicity of the acceptor.

Scheme 2. General glycosylation mechanism.^a



^aLG = leaving group. E-X = electrophilic activator. Donor and acceptor substituents are left out for clarification. The fate of the acceptor proton, donor leaving group and activator is ignored.

Earlier work on chemical glycosylations evolved around (modified) Koenings-Knorr reactions featuring glycosyl halides as glycosyl donors.^{20,26,27} When activated and sufficiently reactive, the covalently linked leaving group can be substituted in an S_N2 substitution reaction, or isomerized to the opposite anomer followed by an S_N2 substitution. The intermediacy of the oxocarbenium ion (solvent-separated ion pair, SSIP, Scheme 2) in a glycosylation reaction was largely ignored as it was argued that the lifetime of an oxonium-type ion in water is too short even for solvent equilibration, and for the typical low polarity glycosylation solvents the ion pairs would not separate sufficiently to allow the free oxocarbenium ion to play a role as an intermediate.^{28,29} Instead, exploded transition states with elongated bonds or tightly packed contact ion pairs (CIP) were deemed responsible for the interconversion of anomeric halides and some glycosylations.

Donor reactivity: electronic and conformational aspects

A large variety of anomeric leaving groups exists to date, each with its own reactivity and activation scheme.^{9,19} Using them in tandem enables orthogonal glycosylation strategies.³⁰ Chemically similar groups may be distinguished by their reactivity, resulting in chemoselective glycosylations. The difference in reactivity is a result of the cumulative electronic properties, the position and orientation of the ring substituents.³¹

The nature of the anomeric leaving group has a large impact on the outcome of a glycosylation reaction. In general, a better leaving group, for example a glycosyl bromide *versus* a glycosyl chloride, gives a more reactive donor.²⁰ The higher reactivity can lead to a faster S_N2 substitution, but also a faster anomerisation reaction to provide the opposite anomer. Generally, an equatorially oriented β-anomer, lacking the stabilizing anomeric effect, is more reactive than its α-anomer, which is often the most prevalent species present. The role of the more reactive β-anomer becomes more important when poor acceptors are to be glycosylated.^{22,32,33} When better leaving groups such as triflates are employed,³⁴ the potency to depart is high enough to cause a large degree of S_N2 substitution but also establish a fast equilibrium between various ionic species.

The reactivity of the donor is largely determined by the different protecting and functional groups present, a fact already known for over half a century.^{35–37} Inductive effects from electronegative atoms and electron-withdrawing groups destabilize the developing positive charge at the anomeric center upon departure of the leaving group. Ether-type protecting groups (benzyl, methyl, etc.) are less electron-withdrawing than esters (acetyl, benzoyl, etc.) and these are consequently termed “arming” and “disarming”, respectively (Figure 1D).^{38–40} Removing an oxygen substituent from the carbohydrate ring (e.g. in the common deoxysugars rhamnose and fucose) increases the reactivity of the donor.⁴¹ The configuration of the donor is important as well, with a pattern of hydrolysis reactivity following the order: α-galactose > α-mannose > α-glucose. This trend is in part related to the eclipsing interactions that develop between neighboring substituents, upon the formation of an oxocarbenium ion-type intermediate.⁴² More severe torsional strain may be imposed on the system by ring-fusing the carbohydrate ring with another five- or six-membered ring, which makes the system more rigid. The isopropylidene, benzylidene and butane diacetal (BDA) are examples of such torsionally restrained systems (Figure 1A).^{43,44} Trans-fused six-membered ring systems such as the benzylidene in **2** are unable to ring flip from their di-equatorial setting to a di-axial constellation: the atoms end up too far apart. Additional eclipsing interactions are developed in the secondary ring, which must now deviate from its preferred chair conformation to conform to the changing geometry associated with the transition to the oxocarbenium ion in the primary ring. These attributes come at the cost of an energy penalty and these fused-ring systems are therefore torsionally disarming. The cyclic protecting groups also severely limit the conformational space of the

oxocarbenium ion (Figure 1C), which is of critical importance to the stereoselectivity of the reaction (*vide infra*).

Besides torsionally disarming the system, cyclic diol protecting groups can also impose electronic effects. The 4,6-*O*-benzylidene system is interesting in this respect, since it fixes the C-6–O-6 dipole such that it is directed away from the anomeric center. This results in the most disarming orientation of the O-6 group: the *tg* rotamer (Figure 1B).^{45–47} The relative reactivity of different donors has been investigated by the groups of Fraser-Reid, Ley, and Bols complemented by an extensive study by the group of Wong, and by now a large set of relative reactivity values (RRV) exists (Figure 1D).^{38–40,48–59}




Figure 1. (A) Example structures of isopropylidene, benzylidene, and BDA cyclic protecting groups. (B) Top-view Newman projection of the C-6–C-5 bond, with *gg*-, *tg*-, *gt*-rotamers, the C-6–O-6 dipole is indicated by the small arrow, and partial charges are displayed. (C) Both oxocarbenium ion conformations available for a donor without torsional strain, only the ⁴H₃ conformation is available for benzylidene and BDA structures 2 and 3. (D) Armed-disarmed principle with relative reactivity values obtained by the laboratory of Wong, relative to tolyl tetraacetyl-1-thio- α -D-mannopyranoside.

Glycosylation stereoselectivity

There are numerous strategies that enable the stereoselective formation of glycosylation linkages, but unfortunately these are often not generally applicable and each new glycosylation presents another challenge. Two types of products can be formed in a glycosylation reaction: 1,2-*trans*- and 1,2-*cis*-linked glycosidic bonds. For the former

type, anchimeric assistance of an acyl-type protecting group on C-2 is usually sufficient to direct stereoselectivity (Figure 2). This form of neighboring group participation is reliable, but its efficiency does depend on the other groups on the carbohydrate ring.⁶⁰⁻⁶⁴ Double stereodifferentiation (see also next chapter) or severe steric hindrance (as is the case with 4,6-silylidene protected galactopyranosides) may thwart effective neighboring group participation.⁶⁵⁻⁶⁷




Figure 2. 1,2-*trans* and 1,2-*cis* glycosylation strategies.

1,2-*Cis*-glycosidic linkages are much more difficult to construct and can generally only be affected using a non-participating group at C-2. Several different approaches have been reported to date to install specific 1,2-*cis*-linkages, which for example make use of remote participation,⁶⁸⁻⁷⁰ site selective delivery of the acceptor,^{71,72} steric screening from one of the ring faces by a bulky group^{66,67,73}, or exploiting the anomeric effect during or after the glycosylation,⁷⁴⁻⁸⁰ among others.⁸¹⁻⁸³ From a mechanistic point of view, two pathways may be followed: inverting a 1,2-*trans*-leaving group in an S_N2 reaction, or exploiting the stereoselective addition on oxocarbenium ion-type intermediates in an S_N1 reaction.

Several examples have been reported using the S_N2 directed inversion of a leaving group. For example glycosyl halides can be used. Here, α -halides are generated and an equilibrium is set up with the more reactive β -halide.²² Substitution of the latter halide then provides the α -product. The same idea applies for other anomeric leaving groups and *in situ* formed anomeric functionalities, such as those formed in the presence of participating solvents, such as DMF, acetonitrile or diethyl ether.⁸⁴⁻⁸⁶ Inversion reactions also happen when the nucleophile is part of a chimeric activator, as was demonstrated for carboxylic acid and phosphate acceptors on the activation and inversion of trichloroimidates.^{87,88}

On the S_N1 side of the reaction continuum, oxocarbenium ions and their associated ion pairs can provide 1,2-*cis*-stereoselective glycosylations. Simple carbocations or oxocarbenium ions have long been regarded as “flat” and unselective but the recent appreciation of the effect of the rich stereochemical environment of (cyclic)

carbohydrate oxocarbenium ions has changed that perspective. The generation of an oxocarbenium ion is preceded by efficient orbital overlap of the ring oxygen's lone pair electrons and the antibonding σ^* -orbital of the leaving group. For an axial leaving group the orbitals readily overlap as they have an *anti*-periplanar orientation leading directly to an oxocarbenium ion in a half-chair conformation. The opposite anomer with equatorial orientation must change its conformation first to accommodate efficient orbital overlap (which may occur with *syn*-periplanar arrangement), and will provide a skew-boat conformation.⁸⁹⁻⁹² These initially formed oxocarbenium ion conformations can be attacked immediately, with or without steric screening from its counter ion. In the absence of an acceptor, or in reactions with poor nucleophiles, the oxocarbenium ion may change to its most stable conformation, which then dictates the stereochemical outcome.

A model system to account for the stereoselectivity of cyclic oxocarbenium ions was devised by Woerpel and co-workers, which was termed the two-conformer model.⁹³⁻⁹⁶ This model assumes that the most stable oxocarbenium ions will have a C-1–O-4/5 double bond and therefore a flat constellation of four atoms (C-2–C-1–O-5–C-5 in six-membered ring pyranoses and C-2–C-1–O-4–C-4 in five-membered ring furanoses). This gives rise to two low energy conformations of a five-membered ring (³E and E₃) and eight of a six-membered ring (³H₄, ⁴H₃, ^{2,5}B, B_{2,5}, ³E, E₃, ⁴E, E₄) excluding the completely flat geometry. For six-membered rings the ³H₄ and ⁴H₃ half-chair conformations are generally energetically most favorable as these have less steric (eclipsing and 1,3-diaxial) interactions than their relatives in the boat and envelope conformations, resulting in two conformations relevant for the stereoselectivity in this model. Central to this model are two possible approaches for the nucleophile: from the top or bottom side, arbitrarily defined for the D-glycosides in the representations in Figure 3. Since furanoses have only a single out-of-plane ring atom, the type of nucleophilic attack is also referred to as inside or outside attack, relating to the concave or convex face of C-3 respectively.⁹⁷ Without considering the type of substituents on the furanose ring, two things become readily apparent. Firstly, the incoming nucleophile has eclipsing interactions with the axially orientated substituent on C-2 when performing an outside attack, and 1,3-(*pseudo*)diaxial interactions with the axially orientated substituent of C-3 for the inside attack.




Figure 3. (top) The two-conformer model for furanoses and pyranoses. (bottom) Newman projections along the C-1–C-2 bond visualizing the movement of the nucleophile and equatorial substituents at C-1 and C-2, and consequently the eclipsing interactions that occur, indicated by crossed arrows.

Secondly, rehybridisation of the anomeric center will lead to an eclipsed C-1–C-2 situation upon outside attack, while inside attack will provide a staggered constellation. In the pyranose case, attack on the top face of the 4H_3 conformer will change the half-chair conformation to a skew-boat conformation with increasing eclipsing interactions between the *pseudo*-equatorial substituents on C-1 and C-2 in the transition state.⁹⁸ Attack from the top face of the alternative 3H_4 half chair, or bottom face of the 4H_3 however, will lead to a favorable chair conformation, free of eclipsing interactions, and has therefore a lower transition state energy. These arguments dictate the general rules for facial selectivity: in furanosides inside attack will be favorable where pyranosyl oxocarbenium ions will be preferentially attacked on the face that leads to a chair-like, lowest energy transition state.

Having established the face-selective preferences of oxocarbenium ions in the two-conformer model, the next goal was to qualitatively and ultimately quantitatively predict *which* conformation is preferentially formed and attacked. The group of Woerpel has made predictions based on experimental evidence and rationalization of relative (de)stabilization properties of the ring substituents. The individual substituent effects

were gauged by glycosylating allyltrimethylsilane with a series of (partially) substituted furanosides and pyranosides (“stripped-down carbohydrates”).^{93,94,99–102} In summary, the substituents prefer to occupy a *pseudo*-equatorial orientation to minimize steric interactions with its neighbors when the substituent is an electropositive/neutral group, such as carbon-substituent. When a substituent has an electronegative element bound to the cyclic oxocarbenium ion, which is the case for all carbohydrates, the preference for the orientation of the substituents at C-3 (for furanosides) and C-3 and C-4 (for pyranosides) changes dramatically. By placing them in a *pseudo*-axial orientation the oxygen (or another electronegative element) is brought closer in space to the oxocarbenium ion. In effect, this constellation has a more favorable dipole direction of the C–O bond and electrostatic stabilization from the lone electron pairs on oxygen towards the anomeric center. The preference for a *pseudo*-equatorial orientation of C-2 is enhanced by an electronegative substituent. The decisive effect at play here is the hyperconjugative stabilisation of the *pseudo*-axially orientated C–H or C–C bond, overlapping its σ -orbital with the p- or π^* -orbital of the oxocarbenium ion (a σ -bond of a carbon and an electronegative element is generally a very poor hyperconjugative σ -bond donor). For the C-4 position in furanosides and C-5 in pyranosides, steric and electronic effects strongly oppose each other and the rotation around the C-4–C-5 or C-5–C-6 bond also plays an important role. In general, most stabilization can be effected in the geometry that places the lone pairs on O-6 closest to the oxocarbenium ion anomeric carbon atom (*i.e.* the *gg*-rotamer, see Figure 1B).




Figure 4. Stereoelectronic effects of individual substituents. The preferred conformation is reflected in each case by the isolated product ratios (given below the equilibrium arrows) of glycosylation with allyltrimethylsilane, based on the inside-attack model.

With this set of preferences Woerpel and co-workers have formulated qualitative selectivity rules, and substantial experimental evidence has corroborated these (Figure 4). In some cases, an axial-rich half-chair conformation may have interfering 1,3-diaxial interactions with the incoming nucleophile, especially with the C-5 position (See Figure 4) and when C-3 has a methyl substituent.^{93,100,103} The validity of the two-conformer

model can be called into question when other conformations start to become relevant, including skew-boat and twist structures. A quantitative approach based on Density Functional Theory, predicts the favorable geometries of an oxocarbenium ion based on their relative energies, and their thermodynamic distribution can dictate the stereoselectivity behind the reaction.^{104–106} The contribution of unusual conformations and their selectivity are difficult to estimate and quantum mechanical calculations from these structures have yet to give a decisive answer. Ultimately, the energy difference of the transition states leading to the different products and their pre-equilibria in a Curtin-Hammett type scenario are the deciding factors in the reaction outcome.^{22,107}

Conclusions

The glycosylation reaction is not just a simple substitution reaction proceeding with either an S_N2 or S_N1 reaction profile. The buildup of positive charge at the anomeric center, a secondary carbon atom, can be sustained by the lone pairs of the ring oxygen atom, but is inductively destabilized by the oxygen ring-substituents. Overall, the intricate balance of stabilizing and destabilizing stereoelectronic effects in the system determines how well the positive charge can be accommodated during a glycosylation reaction. Depending on the nucleophilicity of the acceptor, stronger or weaker electrophilic species may be required for an effective glycosylation. Currently it is impossible to predict, up front, where on the S_N2 - S_N1 reaction continuum a glycosylation will take place and deeper insight into the factors that decide this position (reactivity of the activated donor, reactivity of the acceptor, role of the solvent) are dearly needed.

Outline of this thesis

In this thesis several approaches have been undertaken to systematically investigate the glycosylation mechanism. The main focus of the content described here is the origin of the stereoselectivity observed in glycosylation reactions and the constructions of models with a qualitative predictive value. Both reaction partners, the donor and acceptor, are systematically studied. **Chapter 2** provides an overview of the current ideas and findings regarding the reactivity of the acceptor nucleophile. Although many isolated cases have been reported on the influence of the acceptor on the outcome of a glycosylation reaction, a focused study on how to exploit acceptor reactivity has not before been reported. **Chapter 3** introduces a set of fluorinated ethanol-based nucleophiles to serve as model acceptor of gradually decreasing reactivity in a set of well-established model

glycosylation reactions. With the use of this model set it is shown how the selectivity of glycosylations of three types of glycosyl donors changes upon changing acceptor nucleophilicity, as a consequence of a change in reaction mechanism. **Chapter 4** expands on Chapter 3 with a focus on how the stereoselectivity of glucosazide-based donors changes depending on acceptor nucleophilicity. Both the reactivity of the donor and of the acceptor have impact on the outcome of the glycosylation reaction selectivity. Whereas the donors in Chapter 4 all had a 4,6-tethering group, in **Chapter 5** a glucosazide with a 3,4-tethering group (a butane diacetal, BDA) is investigated. Although the conformational restraint imposed by the 3,4- and 4,6-tethering protecting groups is similar, it is shown that the different torsional and electronic effects of the groups have a major effect on the glycosylation results. **Chapter 6** provides a systematic approach to establish a first set of relative reactivities for carbohydrate acceptors. Two donors from Chapters 3 and 4 are used as model donors because the stereoselectivity of glycosylations of these donors was shown to strongly correlate with the reactivity of the acceptor nucleophiles. A broad and systematic set of C-4-OH acceptors, varying in benzyl and benzoyl protecting groups, as well as the nature of the C-6 functionality are examined and structure-reactivity-stereoselectivity relationships are established. **Chapter 7** describes the syntheses, of the complete set of diastereoisomeric *ribo*-, *arabino*-, *xylo*- and *lyxofuranoside* donors, modified at the C-2 and C-5 position. These are used in **Chapter 8**, to establish the effect the substituents (C-2-N₃, C-2-F, C-5-CO₂Me) have on the stereochemical outcome of the glycosylations of these donors. The putative oxocarbenium ion intermediates are studied by DFT calculations. **Chapter 9** provides a concise summary of the results of this thesis, as well as an outlook for extended investigations and new paths to take to unravel the details of the glycosylation mechanism.

Footnotes and references

- (1) Varki, A. *Glycobiology* **1993**, 3 (2), 97–130.
- (2) Boltje, T. J.; Buskas, T.; Boons, G.-J. *Nat. Chem.* **2009**, 1 (8), 611–622.
- (3) Sinnott, M. *Carbohydrate Chemistry and Biochemistry: Structure and Mechanism*; The Royal Society of Chemistry, 2007.
- (4) Bennett, C. S. *Selective Glycosylations: Synthetic Methods and Catalysts*; Wiley VCH Verlag GmbH, 2017.
- (5) Davies, G.; Henrissat, B. *Structure* **1995**, 3 (9), 853–859.
- (6) Henrissat, B.; Davies, G. *Curr. Opin. Struct. Biol.* **1997**, 7 (5), 637–644.
- (7) Sinnott, M. L. *Chem. Rev.* **1990**, 90 (7), 1171–1202.
- (8) Bourne, Y.; Henrissat, B. *Curr. Opin. Struct. Biol.* **2001**, 11 (5), 593–600.
- (9) Davis, B. G.; Fairbanks, A. J. *Oxford Chemistry Primers: Carbohydrate Chemistry*; Oxford Chemistry Primers; Oxford University Press, 2002.

- (10) Demchenko, A. V. *Handbook of Chemical Glycosylation: Advances in Stereoselectivity and Therapeutic Relevance*; Wiley-VCH Verlag GmbH & Co. KGaA, 2008.
- (11) Ágoston, K.; Streicher, H.; Fügedi, P. *Tetrahedron Asymmetry* **2016**, *27* (16), 707–728.
- (12) Codée, J. D. C.; Ali, A.; Overkleef, H. S.; van der Marel, G. A. *Comptes Rendus Chim.* **2011**, *14* (2–3), 178–193.
- (13) Hung, S.-C.; Wang, C.-C. Protecting Group Strategies in Carbohydrate Synthesis. In *Glycochemical Synthesis*; Hung, S.-C., Zulueta, M. L., Eds.; John Wiley & Sons, Inc., 2016; pp 35–68.
- (14) Kulkarni, S. S. Regioselective, One-Pot Functionalization of Carbohydrates. In *Selective Glycosylations: Synthetic Methods and Catalysts*; Bennett, C. S., Ed.; Wiley-VCH Verlag GmbH & Co. KGaA, 2017; pp 255–276.
- (15) Lawandi, J.; Rocheleau, S.; Moitessier, N. *Tetrahedron* **2016**, *72* (41), 6283–6319.
- (16) Bode, L. *Glycobiology* **2012**, *22* (9), 1147–1162.
- (17) Panza, L.; Chiappini, P. L.; Russo, G.; Monti, D.; Riva, S. *J. Chem. Soc. [Perkin 1]* **1997**, *0* (9), 1255–1256.
- (18) Takeo, K.; Okushio, K.; Fukuyama, K.; Kuge, T. *Carbohydr. Res.* **1983**, *121*, 163–173.
- (19) Das, R.; Mukhopadhyay, B. *ChemistryOpen* **2016**, *5* (5), 401–433.
- (20) Paulsen, H. *Angew. Chem. Int. Ed. Engl.* **1982**, *21* (3), 155–173.
- (21) Lemieux, R. U.; Huber, G. *Can. J. Chem.* **1955**, *33* (1), 128–133.
- (22) Lemieux, R. U.; Hendriks, K. B.; Stick, R. V.; James, K. *J. Am. Chem. Soc.* **1975**, *97* (14), 4056–4062.
- (23) Rhind-Tutt, A. J.; Vernon, C. A. *J. Chem. Soc. Resumed* **1960**, *0* (0), 4637–4644.
- (24) Crich, D. *Acc. Chem. Res.* **2010**, *43* (8), 1144–1153.
- (25) Jencks, W. P. *Chem. Soc. Rev.* **1981**, *10* (3), 345–375.
- (26) Koenigs, W.; Knorr, E. *Berichte Dtsch. Chem. Ges.* **1901**, *34* (1), 957–981.
- (27) Helferich, B.; Zirner, J. *Chem. Ber.* **1962**, *95* (11), 2604–2611.
- (28) Sinnott, M. L.; Jencks, W. P. *J. Am. Chem. Soc.* **1980**, *102* (6), 2026–2032.
- (29) Amyes, T. L.; Jencks, W. P. *J. Am. Chem. Soc.* **1989**, *111* (20), 7888–7900.
- (30) Kanie, O.; Ito, Y.; Ogawa, T. *J. Am. Chem. Soc.* **1994**, *116* (26), 12073–12074.
- (31) Fraser-Reid, B.; López, J. C. Armed–Disarmed Effects in Carbohydrate Chemistry: History, Synthetic and Mechanistic Studies. In *Reactivity Tuning in Oligosaccharide Assembly*; Fraser-Reid, B., Cristóbal López, J., Eds.; Springer Berlin Heidelberg: Berlin, Heidelberg, 2011; pp 1–29.
- (32) Sinaý, P. *Pure Appl. Chem.* **1978**, *50* (11–1), 1437–1452.
- (33) Feather, M. S.; Harris, J. F. *J. Org. Chem.* **1965**, *30* (1), 153–157.
- (34) Frihed, T. G.; Bols, M.; Pedersen, C. M. *Chem. Rev.* **2015**, *115* (11), 4963–5013.
- (35) Frechet, J. M.; Schuerch, C. *J. Am. Chem. Soc.* **1972**, *94* (2), 604–609.
- (36) Paulsen, H.; Richter, A.; Sinnwell, V.; Stenzel, W. *Carbohydr. Res.* **1978**, *64* (Supplement C), 339–362.
- (37) Overend, W. G.; Rees, C. W.; Sequeira, J. S. *J. Chem. Soc. Resumed* **1962**, *0* (0), 3429–3440.
- (38) Mootoo, D. R.; Konradsson, P.; Udodong, U.; Fraser-Reid, B. *J. Am. Chem. Soc.* **1988**, *110* (16), 5583–5584.
- (39) Mootoo, D. R.; Date, V.; Fraser-Reid, B. *J. Am. Chem. Soc.* **1988**, *110* (8), 2662–2663.
- (40) Fraser-Reid, B.; Wu, Z.; Udodong, U. E.; Ottosson, H. *J. Org. Chem.* **1990**, *55* (25), 6068–6070.
- (41) Green, L. G.; Ley, S. V.; Ernst, B.; Hart, G. W.; Sinaý, P. Protecting Groups: Effects on Reactivity, Glycosylation Stereoselectivity, and Coupling Efficiency. In *Carbohydrates in Chemistry and Biology*; Wiley-VCH Verlag GmbH, 2000; pp 427–448.
- (42) Edward, J. *Chem. Ind.* **1955**, No. 36, 1102–1104.
- (43) Fraser-Reid, B.; Wu, Z.; Andrews, C. W.; Skowronski, E.; Bowen, J. P. *J. Am. Chem. Soc.* **1991**, *113* (4), 1434–1435.
- (44) Douglas, N. L.; Ley, S. V.; Osborn, H. M. I.; Owen, D. R.; Priepeke, H. W. M.; Warriner, S. L. *Synlett* **1996**, *1996* (08), 793–795.
- (45) Jensen, H. H.; Nordstrøm, L. U.; Bols, M. *J. Am. Chem. Soc.* **2004**, *126* (30), 9205–9213.
- (46) Moumé-Pymbock, M.; Furukawa, T.; Mondal, S.; Crich, D. *J. Am. Chem. Soc.* **2013**, *135* (38), 14249–14255.
- (47) Frihed, T. G.; Walvoort, M. T. C.; Codée, J. D. C.; van der Marel, G. A.; Bols, M.; Pedersen, C. M. *J. Org. Chem.* **2013**, *78* (6), 2191–2205.
- (48) Baeschlin, D. K.; Green, L. G.; Hahn, M. G.; Hinzen, B.; Ince, S. J.; Ley, S. V. *Tetrahedron Asymmetry* **2000**, *11* (1), 173–197.
- (49) Douglas, N. L.; Ley, S. V.; Lücking, U.; Warriner, S. L. *J. Chem. Soc. [Perkin 1]* **1998**, No. 1, 51–66.
- (50) Grice, P.; Ley, S. V.; Pietruszka, J.; Priepeke, H. W. M.; Walther, E. P. E. *Synlett* **1995**, *1995* (07), 781–784.

- (51) Pedersen, C. M.; Marinescu, L. G.; Bols, M. *Chem. Commun.* **2008**, No. 21, 2465–2467.
- (52) Olsen, J. I.; Kowalska, K.; Pedersen, C. M.; Bols, M. *Tetrahedron Lett.* **2016**, 57 (1), 35–38.
- (53) Heuckendorff, M.; Premathilake, H. D.; Pornsuriyasak, P.; Madsen, A. Ø.; Pedersen, C. M.; Bols, M.; Demchenko, A. V. *Org. Lett.* **2013**, 15 (18), 4904–4907.
- (54) Heuckendorff, M.; Pedersen, C. M.; Bols, M. *J. Org. Chem.* **2013**, 78 (14), 7234–7248.
- (55) Lee, H.-K.; Scanlan, C. N.; Huang, C.-Y.; Chang, A. Y.; Calarese, D. A.; Dwek, R. A.; Rudd, P. M.; Burton, D. R.; Wilson, I. A.; Wong, C.-H. *Angew. Chem. Int. Ed.* **2004**, 43 (8), 1000–1003.
- (56) Lee, J.-C.; Greenberg, W. A.; Wong, C.-H. *Nat. Protoc.* **2007**, 1 (6), 3143–3152.
- (57) Mong, K.-K. T.; Wong, C.-H. *Angew. Chem.* **2002**, 114 (21), 4261–4264.
- (58) Zhang, Z.; Ollmann, I. R.; Ye, X.-S.; Wischnat, R.; Baasov, T.; Wong, C.-H. *J. Am. Chem. Soc.* **1999**, 121 (4), 734–753.
- (59) Ritter, T. K.; Mong, K.-K. T.; Liu, H.; Nakatani, T.; Wong, C.-H. *Angew. Chem. Int. Ed.* **2003**, 42 (38), 4657–4660.
- (60) Nukada, T.; Berces, A.; Zgierski, M. Z.; Whitfield, D. M. *J. Am. Chem. Soc.* **1998**, 120 (51), 13291–13295.
- (61) Zeng, Y.; Wang, Z.; Whitfield, D.; Huang, X. *J. Org. Chem.* **2008**, 73 (20), 7952–7962.
- (62) Mydock, L. K.; Demchenko, A. V. *Org. Biomol. Chem.* **2010**, 8 (3), 497–510.
- (63) Garcia, A.; Otte, D. A. L.; Salamant, W. A.; Sanzone, J. R.; Woerpel, K. A. *J. Org. Chem.* **2015**, 80 (9), 4470–4480.
- (64) Garcia, A.; Otte, D. A. L.; Salamant, W. A.; Sanzone, J. R.; Woerpel, K. A. *Angew. Chem. Int. Ed.* **2015**, 54 (10), 3061–3064.
- (65) Spijker, N. M.; van Boeckel, C. A. A. *Angew. Chem. Int. Ed. Engl.* **1991**, 30 (2), 180–183.
- (66) Imamura, A.; Matsuzawa, N.; Sakai, S.; Udagawa, T.; Nakashima, S.; Ando, H.; Ishida, H.; Kiso, M. *J. Org. Chem.* **2016**, 81 (19), 9086–9104.
- (67) Gold H.; Boot R. G.; Aerts J. M. F. G.; Overkleeft H. S.; Codée J. D. C.; van der Marel G. A. *Eur. J. Org. Chem.* **2011**, 2011 (9), 1652–1663.
- (68) Komarova B. S.; Tsvetkov Y. E.; Nifantiev N. E. *Chem. Rec.* **2016**, 16 (1), 488–506.
- (69) Komarova, B. S.; Orekhova, M. V.; Tsvetkov, Y. E.; Nifantiev, N. E. *Carbohydr. Res.* **2014**, 384, 70–86.
- (70) Baek, J. Y.; Lee, B.-Y.; Jo, M. G.; Kim, K. S. *J. Am. Chem. Soc.* **2009**, 131 (48), 17705–17713.
- (71) Jia, X. G.; Demchenko, A. V. *Beilstein J. Org. Chem.* **2017**, 13 (1), 2028–2048.
- (72) Yasomane, J. P.; Demchenko, A. V. *Angew. Chem. Int. Ed.* **2014**, 53 (39), 10453–10456.
- (73) Hagen, B.; van Dijk, J. H. M.; Zhang, Q.; Overkleeft, H. S.; van der Marel, G. A.; Codée, J. D. C. *Org. Lett.* **2017**, 19 (10), 2514–2517.
- (74) Benakli, K.; Zha, C.; Kerns, R. J. *J. Am. Chem. Soc.* **2001**, 123 (38), 9461–9462.
- (75) Kerns, R. J.; Zha, C.; Benakli, K.; Liang, Y.-Z. *Tetrahedron Lett.* **2003**, 44 (44), 8069–8072.
- (76) Wei, P.; Kerns, R. J. *J. Org. Chem.* **2005**, 70 (10), 4195–4198.
- (77) Boysen, M.; Gemma, E.; Lahmann, M.; Oscarson, S. *Chem. Commun.* **2005**, 0 (24), 3044–3046.
- (78) Olsson, J. D. M.; Eriksson, L.; Lahmann, M.; Oscarson, S. *J. Org. Chem.* **2008**, 73 (18), 7181–7188.
- (79) Manabe, S.; Ito, Y. *Chem. Rec.* **2014**, 14 (3), 502–515.
- (80) Geng, Y.; Zhang, L.-H.; Ye, X.-S. *Tetrahedron* **2008**, 64 (22), 4949–4958.
- (81) Nigudkar, S. S.; Demchenko, A. V. *Chem. Sci.* **2015**, 6 (5), 2687–2704.
- (82) Kim, J.-H.; Yang, H.; Boons, G.-J. *Angew. Chem. Int. Ed.* **2005**, 44 (6), 947–949.
- (83) Mensink, R. A.; Boltje, T. J. *Chem. – Eur. J.* **2017**, 23 (70), 17637–17653.
- (84) Lu, S.-R.; Lai, Y.-H.; Chen, J.-H.; Liu, C.-Y.; Mong, K.-K. T. *Angew. Chem. Int. Ed.* **2011**, 50 (32), 7315–7320.
- (85) Ingle, A. B.; Chao, C.-S.; Hung, W.-C.; Mong, K.-K. T. *Org. Lett.* **2013**, 15 (20), 5290–5293.
- (86) Huang, M.; Garrett, G. E.; Birlirakis, N.; Bohé, L.; Pratt, D. A.; Crich, D. *Nat. Chem.* **2012**, 4 (8), 663–667.
- (87) Schmidt, R. R.; Stumpp, M. *Liebigs Ann. Chem.* **1984**, 1984 (4), 680–691.
- (88) Schmidt, R. R.; Michel, J. *Angew. Chem. Int. Ed. Engl.* **1980**, 19 (9), 731–732.
- (89) Sinnott, M. L. The Principle of Least Nuclear Motion and the Theory of Stereoelectronic Control. In *Advances in Physical Organic Chemistry*; Bethell, D., Ed.; Academic Press, 1988; Vol. 24, pp 113–204.
- (90) Andrews, C. W.; Fraser-Reid, B.; Bowen, J. P. *J. Am. Chem. Soc.* **1991**, 113 (22), 8293–8298.
- (91) Ratcliffe, A. J.; Mootoo, D. R.; Andrews, C. W.; Fraser-Reid, B. *J. Am. Chem. Soc.* **1989**, 111 (19), 7661–7662.
- (92) Sicher, J. *Angew. Chem. Int. Ed. Engl.* **1972**, 11 (3), 200–214.
- (93) Larsen, C. H.; Ridgway, B. H.; Shaw, J. T.; Woerpel, K. A. *J. Am. Chem. Soc.* **1999**, 121 (51), 12208–12209.
- (94) Romero, J. A. C.; Tabacco, S. A.; Woerpel, K. A. *J. Am. Chem. Soc.* **2000**, 122 (1), 168–169.

- (95) Shaw, J. T.; Woerpel, K. A. *Tetrahedron* **1999**, *55* (29), 8747–8756.
- (96) Shaw, J. T.; Woerpel, K. A. *J. Org. Chem.* **1997**, *62* (20), 6706–6707.
- (97) Smith, D. M.; Woerpel, K. A. *Org. Biomol. Chem.* **2006**, *4* (7), 1195–1201.
- (98) Yang, M. T.; Woerpel, K. A. *J. Org. Chem.* **2009**, *74* (2), 545–553.
- (99) Chamberland, S.; Ziller, J. W.; Woerpel, K. A. *J. Am. Chem. Soc.* **2005**, *127* (15), 5322–5323.
- (100) Ayala, L.; Lucero, C. G.; Romero, J. A. C.; Tabacco, S. A.; Woerpel, K. A. *J. Am. Chem. Soc.* **2003**, *125* (50), 15521–15528.
- (101) Smith, D. M.; Woerpel, K. A. *Org. Lett.* **2004**, *6* (12), 2063–2066.
- (102) Larsen, C. H.; Ridgway, B. H.; Shaw, J. T.; Smith, D. M.; Woerpel, K. A. *J. Am. Chem. Soc.* **2005**, *127* (31), 10879–10884.
- (103) Lucero, C. G.; Woerpel, K. A. *J. Org. Chem.* **2006**, *71* (7), 2641–2647.
- (104) van Rijssel, E. R.; van Delft, P.; van Marle, D. V.; Bijvoets, S. M.; Lodder, G.; Overkleef, H. S.; van der Marel, G. A.; Filippov, D. V.; Codée, J. D. C. *J. Org. Chem.* **2015**, *80* (9), 4553–4565.
- (105) van Rijssel, E. R.; van Delft, P.; Lodder, G.; Overkleef, H. S.; van der Marel, G. A.; Filippov, D. V.; Codée, J. D. C. *Angew. Chem. Int. Ed.* **2014**, *53* (39), 10381–10385.
- (106) Rhoad, J. S.; Cagg, B. A.; Carver, P. W. *J. Phys. Chem. A* **2010**, *114* (15), 5180–5186.
- (107) Seeman, J. I. *Chem. Rev.* **1983**, *83* (2), 83–134.

Chapter 2

Acceptor reactivity in glycosylations

Introduction

The chemical glycosylation reaction involving the union of two species to form a new glycosidic bond is dependent on a large set of variables.¹⁻³ The previous chapter introduced the basic concepts of reactivity and selectivity in glycosylation reactions, primarily from the perspective of the glycosyl donor. As amply illustrated by the vast amount of chemical carbohydrate literature, the donor is the reactant to which most of the attention has been directed and it is now well appreciated how the reactivity depends on the substitution pattern of the glycoside and how donor reactivity affects the outcome of a glycosylation reaction. The reactivity of the acceptor, on the other hand, is less well studied and detailed knowledge of this reaction partner may provide new mechanistic understanding and practical guidelines for glycosylation reactions. Although it was stated by Paulsen in 1982 that the nature of the acceptor is mostly *a priori* determined, differences in reactivity can influence the glycosylation outcome both in terms of stereoselectivity and isolated yield.⁴ Not many studies directed at understanding and


harnessing acceptor reactivity have been reported and, notwithstanding the systematic studies that have been reported and that will be described in this Chapter, the influence of the acceptor on the outcome of a glycosylation reaction is often neglected.

Numerous examples of glycosylation reactions indicate that the reactivity of the acceptor, like that of glycosyl donors, can be manipulated by changing protecting groups.⁵⁻¹⁵ Unfortunately, most studies that report on new glycosylation methods, strategies or mechanisms, employ a rather variable set of acceptors, often chosen because of ease of availability, or used because a target oriented approach is taken. As a result the acceptors used in these studies differ greatly in steric and electronic properties, making it difficult to establish structure-reactivity relationships.¹⁶⁻²¹ Unexpected stereoselectivities and/or poor yields, as a result of ill understood acceptor reactivity, continue to be reported,²²⁻²⁶ clearly indicating the need for more systematic and deeper insight into how glycosylations are influenced by the reactivity of the glycosyl acceptor. At a time when the mechanism of glycosylation and the reactivity of the donor is understood better than ever before, the details of the mechanism and the influence of the acceptor therein will be an important pursuit to arrive at a more complete and generalized picture of glycosylation reactions.²⁷ This Chapter surveys the systematic approaches that have been undertaken to probe the influence of the reactivity of the acceptor on the outcome of a glycosylation reaction and describes methods to analyze and quantify acceptor reactivity.

Observations on acceptor reactivity

In two early examples by Sinaÿ in 1978²⁸ and Paulsen in 1981,²⁹ the influence of the acceptor on the glycosylation outcome was recognized. The work of Sinaÿ clearly showed how the yield of glycosylations of galactosyl bromide **1** (Table 1) varied upon changing the protecting groups on the acceptor. *N*-acetyl-glucosamine acceptors **2-5**, with an *O*-benzyl (**2**) or *O*-allyl (**3**, **4**) group at C-3 gave good yields, regardless of the nature of

Table 1. Acceptor protecting groups influencing glycosylation yield. (Sinaÿ, 1978).

	acceptors 2-5		<i>N</i> -acetyl lactosamine 6-9	Acceptor Product Yield (%)		
	HgBr ₂			2	6	87
1	2	3	4	5	7	77
					8	78
					9	5

All glycosylations proceeded with exclusive β -selectivity.

the protecting group at C-6 (*O*-benzyl or *O*-acetyl). In contrast, the yield dropped to a mere 5% when the acceptor bearing an *O*-acetyl at the C-3 (**4**) was used.

Paulsen and Lockhoff examined a set of donors (**12-14**, Table 2) with two very similar rhamnosyl acceptors, differing only in the anomeric protection (*O*-benzyl in **10** vs *O*-trichloroethyl in **11**). In this set of experiments both the influence of the reactivity of the donor (**12**>**13**>**14**) and acceptor (**10**>**11**) was evident. The trichloroethyl protected rhamnosyl acceptor **11** provided relatively more of the α -linked products than the benzyl protected analogue **10**, which could be correlated to the lower reactivity of acceptor **11**. The more nucleophilic **10** can displace the α -bromide of 'armed' donor **12** to provide the β -product. Lowering the reactivity of either the donor or the acceptor hampers this direct substitution pathway and the less reactive acceptor can only substitute the more reactive β -bromide, formed by *in situ* anomerization with HgBr_2 , giving the α -galactosyl linkage.

Table 2. Decrease in acceptor reactivity leads to increase in α -selectivity. (Paulsen and Lockhoff, 1981).

		Acceptor 10		Acceptor 11		
		Donor	Product	$\alpha : \beta$ (yield)	Product	$\alpha : \beta$ (yield)
		12	15	19 : 81 (75%)	18	81 : 19 (82%)
10 : R = Ph 11 : R = CCl_3		13	16	34 : 66 (66%)	19	100 : 0 (54%)
12	13	14	17	100 : 0 (81%)	20	100 : 0 (87%)

Yields of combined isolated anomers. *Reagents and conditions*: donor (1 eq.), acceptor (1 eq.), powdered 4Å M.S., HgBr_2 (0.1 eq.), DCM, room temperature (**20**), 0°C (**17**), or -20°C (**15**, **16**, **18**, **19**).

In another example by Paulsen and Lebuhn the silver-silicate promoted glycosylation of mannosyl bromide **21** with different glucose and glucosamine acceptors was investigated (Table 3). While the conformationally locked glucosamine acceptor **23**

Table 3. Conformationally restricted acceptors provide more β -product. (Paulsen and Lebuhn, 1983).

		Acceptor	Product	Yield (%)	$\alpha : \beta$
		22	25	75	α only
21	23	24	26	65	1 : 6
22	24		27	63	1 : 5.5

Yields of the β -anomer. *Reagents and conditions*: donor (1.1 eq.), acceptor (1 eq.), powdered 4Å M.S., silver-silicate, DCM, room temperature (or 35°C for **25**).

and glucose acceptor **24** proved efficient acceptors for the synthesis of 1,2-*cis*-linked disaccharides **26** and **27**, likely formed through an S_N2-type displacement of the activated bromide, the use of *N*-acetyl glucosamine **22** only gave the undesired α -product.³⁰

Over the years it has become clear that *N*-acetylglucosamine C-4-OH acceptors are generally very poor nucleophiles.⁴ In a detailed study by Crich and co-workers, several glucosamine acceptors (**30-34**, Table 4) were used to investigate the underlying reasons why *N*-acetylglucosamine acceptors behave so poorly in glycosylation reactions.³¹ Glucosamine acceptors bearing various *N*-protecting groups were investigated (acetyl **30**, phthalimide **31**, azide **32**, and imides **33** and **34**). Glycosylations of these acceptors with mannosyl sulfoxide **28** are reported in Table 4 and the results showed the azide to be far superior to the imides, which in turn are superior to amide **30** in terms of isolated yield. Competition experiments of **30**, **31**, and **32** by glycosylating a mixture of an equimolar amount of all three acceptors and analyzing the product mixture

Table 4. Intermolecular hydrogen-bonding is detrimental to acceptor reactivity. (Crich and Dudkin, 2001).

		disaccharides	Acceptor	Product	Yield (%)	α : β
	acceptors 30-37 Tf ₂ O DTBMP	38-45	30	38	9	β only
	acceptors 36, 37 Ph ₂ SO, Tf ₂ O TTBP	46, 47	31	39	33	β only
			32	40	70	β only
			33	41	47 ^a	β only
			34	42	39 ^a	β only
			35	43	8	β only
			36	44	63	β only
			37	45	39	β only
			36	46	87	1 : 1.2
			37	47	18	1 : 2.4

Reagents and conditions: for **28**: donor (0.2 mmol), DTBMP (0.4 mmol), Tf₂O (0.22 mmol), DCM (8 mL), then acceptor (0.4 mmol, 2 mL DCM), -78°C to 0°C; for **29**: donor (0.1 mmol), Ph₂SO (0.28 mmol) Tf₂O (0.15 mmol), toluene/DCM (3/1, 1 mL), -78°C to -40°C then TTBP (0.5 mmol, 0.5 mL DCM), acceptor (0.1 mmol, 1 mL DCM), -78°C to room temperature.

by HPLC, revealed a ratio of 1:3:10 (**30**:**31**:**32**) supporting the results of the individual glycosylations. An intermolecular hydrogen-bonding network from the amide (NH and C=O) was hypothesized to be at the basis of the poor reactivity of **30** and to support this, picolyl protected **35** and **36** were prepared to disrupt this network by favoring intramolecular hydrogen-bonding. Glycosylation with C-4-OH acceptor **35** was as ineffective as with benzylated acceptor **30**. To account for this result the hydrogen-bond interaction between C-4-OH and the picolyl-*N* was forwarded as destructive for the acceptor reactivity, instead of making the acceptor more reactive. The C-6-OH derivatives **36** and **37** in comparison gave the anticipated result. Intramolecular hydrogen-bonding between the picolyl and amide provided a more reactive acceptor, leading to a higher yield in the glycosylation reaction with **36**, with respect to the coupling of C-3-O-benzyl acceptor **37** which is incapable of forming an intramolecular hydrogen-bond. The use of glucose donor **29**, activated under dehydrative conditions, corroborated these findings, and a good yield was obtained in the condensation with acceptor **36** while the coupling of **29** and acceptor **37** proceeded with poor yield. Cyclic carbamates have also been used as a protecting group to provide appropriate glucosamine C-4-OH acceptors. The cyclic nature of the 2-*N*-3-*O*-carbamate ties back the group at C-3, rendering the C-4-OH more accessible.³²⁻³⁴

Rúveda and co-workers investigated the relative reactivities of a series of dimethylmaleimide (DMM) protected glucosamine acceptors (**49**, **51**, and **52**, Table 5) by competition experiments.³⁵ The reactivity of these nucleophiles was compared to that of *N*-acetyl glucosamine acceptor **53** and cyclic carbamate **50**. From these results it

Table 5. Acceptor competitions revealed the effect of protecting groups on the reaction rates. (Rúveda, 2006).

		 NDMM =	Acceptors	Products	Ratio
			 49	 50	 51
 48		 54		 55	
 56		 57		 58	

Reagents and conditions: two acceptors (1 eq. each), donor (1.2 eq.), TMSOTf (1.25 eq.), 4Å M.S., DCM/CH₃CN (29/1, 0.34 M), -30°C.

becomes clear that benzoyl groups in the acceptor have a retarding effect on the glycosylation rate, as **49** proved to be the most reactive acceptor, followed by **51** and finally **52**. Also in this study the poor reactivity of *N*-actyl glucosamine **53** is apparent.

Another set of competition experiments, comparing benzylidene allosamine and glucosamine acceptors with the DMM *N*-protecting group, was conducted by the same research group (Table 6).³⁶ Allosamine **60** by far outcompeted its epimeric acceptors **61** and **62**. These results show that axially orientated hydroxyl groups, as in **60** (C-3-OH), although sterically more encumbered, are not always less reactive than their equatorial counterparts.³⁷ In this particular series, the relative reactivity results were supported by NMR and computational studies on the possibility of hydrogen-bond formation between the C-3-OH and the maleimide C=O.

Table 6. Acceptor competitions revealed the effect of protecting groups on the reaction rates. (Rúveda, 2011).


		Acceptors	Products	Ratio
		60 : 61	64 : 65	10 : 1
		60 : 62	64 : 66	13 : 1
		61 : 62	65 : 66	2 : 1
		61 : 63	65 : 67	5 : 1
		62 : 63	66 : 67	3 : 1

Reagents and conditions: two acceptors (1 eq. each), donor (1.1 eq.), TMSOTf (0.28 eq.), 4Å M.S., DCM, -25°C.

The influence of the C-6 protecting group on the regioselectivity of DMM protected glucosamine acceptors **68-70** when glycosylated with donors **48** and **57** was investigated by the group of Rúveda (Table 7).³⁸ The regioselectivity for the C-3-OH over the C-4-OH increased in the order of C-6-OBz > C-6-OTBDPS > C-6-OBn. The C-6-OBz in **68** makes the C-4-OH more electron poor than the C-3-OH, leading to the strong preference to glycosylate the latter alcohol (C-3/C-4, 1:0 for **48**, and 2:1 for **67**). The bulky TBDPS sterically hampers the nucleophilic attack of the C-4-OH, leading to improved C-3/C-4-regioselectivity with respect to the C-6-OBn (compare 5:1 for **70** and 3.2:1 for **69**, with donor **48**). Notably, the β -anomeric acceptors showed different regioselectivities (see also Table 16), which was again attributed to the difference in hydrogen-bonding capacity of the DMM group with the C-3-OH in the different

anomers.^{39,40} The conformational change at the reducing end of an acceptor in a monosaccharide, disaccharide or oligosaccharide, has been reported to influence reactivity of the nucleophilic hydroxyl on the other side of the acceptor.⁴¹⁻⁴³









Table 7. Stereoelectronic effects of protecting groups influence the regioselectivity of diols. (Rúveda, 2007).

			
Donor	Acceptor	Yield (%)	(1→3) : (1→4)
48	68	68	1 : 0
48	69	71	3.2 : 1
48	70	73	5 : 1
59	68	91	2 : 1
59	69	56	1 : 1
59	70	50	1.6 : 1

Reagents and conditions: donor (0.11 mmol, 1.1 eq.), acceptor (0.1 mmol, 1 eq.), 4Å M.S., TMSOTf (0.21 mmol, 2.1 eq.), DCM/CH₃CN (37/1), -25°C.

The group of Kononov investigated the difference in reaction rates by observing differences in the activation temperature of the reaction (Table 8).⁴⁴ Two donors of varying reactivity (**71** and **72**) were glycosylated with acceptor **73**, bearing two electron-withdrawing benzoyl groups, and with acceptor **74** having the cyclic silylidene protecting group. The activation temperature varied from -42°C to -22°C following the order of reactivity of both the donor and acceptor.


Table 8. The impact of acceptor reactivity on the temperature of activation. (Kononov, 2014).

donors		acceptors		Donor	Acceptor	Product	T_{act} (°C)	Yield (%)	α : β
		71	73	75	-22	66	1 : 2		
		71	74	76	-30	84	1 : 6.3		
		72	73	77	-39	92	1 : 4.5		
		72	74	78	-42	80	1 : 3		

Reagents and conditions: donor (0.042 mmol, 1.5 eq.), acceptor (0.028 mmol, 1 eq.), powdered 4Å M.S., NIS (0.042 mmol, 1.5 eq.), AgOTf (0.003 mmol, 0.1 eq.), DCM (1 mL), -78°C to T_{act} , then to +10°C.

In the early 90's Spijker and van Boeckel were the first to introduce the concept of double stereodifferentiation⁴⁵ in synthetic carbohydrate chemistry.⁴⁶ They unambiguously showed how the chirality of the coupling partners could impact the transition state of the glycosylation reaction. Carbohydrates experience different steric effects when coupled to different enantiomers of the same reaction partner. In their 1991 publication, two situations are highlighted (Scheme 1). Either two enantiomeric donors (D-fucosyl bromide **D-79** and L-fucosyl bromide **L-79**) were coupled to the same D-glucosamine acceptor **80**, or the absolute chirality of the acceptor was changed from D-diacetoneglucose **D-82** to its L-enantiomer **L-82** while keeping the donor the same (D-glucosyl bromide **81**). Remarkable results were obtained. While neighboring group participation to provide 1,2-*trans*-glycosides is generally a very powerful stereocontrolling phenomenon, the glycosylation of donor **D-79** and acceptor **80** provided an anomeric mixture ($\alpha:\beta$, 2:1). The use of the enantiomeric donor **L-79** restored the expected *trans*-selectivity ($\alpha:\beta$, 1:8.4). The difference in $\alpha:\beta$ product ratio is less pronounced in the second case, in which acceptor **D-82** provides more α -product than its enantiomer **L-82**. The observed changes in stereoselectivity are clearly the result of drastically different steric interactions in the diastereoisomeric transition states.

Scheme 1. Double stereodifferentiation in glycosylation reactions. (Spijker and van Boeckel, 1991).




Reagents and conditions: AgOTf, 2,6-di-*tert*-butylpyridine (0.8 eq.), 4Å M.S., DCM, -50°C.

Another clear manifestation of the effect of the shape of the acceptor on the outcome of a glycosylation reaction can be observed when carbohydrate acceptors are locked in 'inverted' chair conformations. As was shown above, conformationally locking a glucose/glucosamine acceptor in a ¹C₄ chair places the C-4-OH in a position that is well accessible leading to a better nucleophile.^{30,47} It is well established in the field of heparin synthesis that glycosylations of glucosazide donors with L-idose/L-iduronic acid acceptors, generally adopting a ¹C₄ chair conformation, proceed with excellent α -

selectivity (an important manifestation of double stereodifferentiation).^{48,49} Based on this knowledge Seeberger and co-workers decided to lock D-glucuronic acid ester acceptors for heparin synthesis in a similar ¹C₄ chair conformation (Table 9).⁵⁰ In condensations with glucosazide donor **84** D-glucuronic acid acceptor **85** provided an anomeric mixture (**88**; α:β, 3:1) in relatively low yield. By conformationally locking the glucuronate acceptor in the inverted ¹C₄ conformation (as in **86**), a high yield and excellent α-selectivity was obtained in the condensation with **84**. The use of L-iduronic acid acceptor **87** provided an analogous result.


Table 9. Conformational restriction leads to higher yields and α-selectivities. (Seeberger, 2002).

	Acceptors 85-87	disaccharides 88-90	Acceptor	Product	Yield (%)	α : β
	85		88	57	3 : 1	
86	89	86	α only			
87	90	91	α only			

Reagents and conditions: donor (1.25 eq.), acceptor (1 eq.), TBSOTf (0.125 eq.), 4Å M.S., DCM, -78°C to room temperature, 2.5 h.

A rigid conformational lock is not always necessary to mold an acceptor in a reactive conformation, as was described by Zhang *et al.* (Table 10).⁵¹ They showed that the conformational rigidity of disaccharide acceptor **92** hampered the glycosylation with donor **91**. Changing the reducing end of the disaccharide acceptor from a β-O-(azidopropyl) manuronic acid to an α-S-tolyl manuronic acid (**93**), provided a more

Table 10. Conformational flexibility of acceptor **161** dramatically increased glycosylation yield. (Codée, 2015).

	Acceptors 92-95	tetrasaccharides 96-99	Acceptor	Product	Yield (%)
	92		96	45	
93	97	91			
94	98	71			
95	99	95			

All glycosylations proceeded with exclusive β-selectivity. Reagents and conditions: donor (3 eq.), acceptor (1 eq.), TBSOTf (0.6 eq.), 4Å M.S., DCM, -78°C to -45°C.

flexible acceptor, as judged from the broadened resonances observed in NMR-spectroscopy. The flexible character of acceptor **93** led to greatly enhanced glycosylation productivity. The contribution of the 1C_4 structure in the conformational equilibrium of **93** was verified by the use of model disaccharide acceptors having a conformationally locked 1C_4 reducing end saccharide (either an α -O-methyl (**94**) or an α -S-tolyl (**95**)).

Systematic studies on acceptor reactivity

Although it is clear that the nature of the protecting groups has an influence on the glycosylation outcome it is often difficult to dissect electronic, steric and conformational effects.⁵² Woerpel and co-workers have reported a systematic study relating the effect of the nucleophilicity of the acceptor on the outcome of a glycosylation reaction, using both C- and O-model nucleophiles.⁵³⁻⁵⁷ Table 11 reports the results of both sets of nucleophiles, with 2-deoxyglucosyl acetate or ethanethiolate donors **108** and **109**. The trend that becomes apparent from these results is that poorer nucleophiles provide more α -product. To account for these results, it was reasoned that the poorest C- and O-nucleophiles **100** and **104**, as assessed by Mayr's nucleophilicity parameter N ,⁵⁸⁻⁶³ or the field inductive parameter F ,⁶⁴ react with the glucosyl oxocarbenium ion that

Table 11. Model C- and O-nucleophilic acceptors in glycosylations correlating nucleophilicity to stereoselectivity. (Woerpel, 2008-2010).


100	101	102	103	104	105	106	107	
				Acceptor	N^a	Product	Yield (%)	$\alpha : \beta$
				Acceptor	F^b	Product	Yield (%)	$\alpha : \beta$
				100	1.8	110	80	89 : 11
				101	4.4	111	79	43 : 57
				102	6.2	112	83	61 : 39
				103	8.2	113	83	45 : 55
				104	0.38	114	80	83 : 17
				105	0.29	115	78	67 : 33
				106	0.15	116	69	56 : 44
				107	0.0	117	82	51 : 49

^aMayr's nucleophilicity parameter. ^bField inductive parameter.⁶¹ *Reagents and conditions for acetyl donors:* donor (1 eq.), acceptor (4 eq.), $\text{BF}_3 \cdot \text{OEt}_2$ (1.5 eq.), DCM, -42°C to 0°C . *Reagents and conditions for thiodonors:* donor (1 eq.), acceptor (4 eq.), NIS (2 eq.), CH_3CN , 0°C .

preferentially takes up a 4H_3 conformation (**119**), in a stereoselective manner from the α -face. The selectivity is reduced when the nucleophilicity is increased. This erosion of stereoselectivity (from **110** to **113**, and from **114** to **117**) is caused by alternative reaction pathways becoming accessible for the stronger nucleophiles: either a non-selective S_N1 reaction in which both sides of oxocarbenium ion **119** are attacked, or an S_N2 -type substitution in which both sides of oxocarbenium ion **119** are attacked, or an S_N2 -type substitution.

In line with the results of Woerpel, a glycosylation study of linkers **121** and **122** with donor **120** by the group of Seeberger, found the more nucleophilic **121** to give high β -selectivity whereas the weaker nucleophile **122** gave mainly the α -product (Scheme 2).⁶⁵ These results can be explained by an S_N2 -type substitution of the reactive primary alcohol on the intermediately formed anomeric α -triflate, where attack of the weaker difluoro acceptor requires a more reactive electrophile, either an intermediate oxocarbenium ion or the corresponding β -triflate. By tweaking the reaction temperature and solvent, nearly complete α -stereoselectivity could be obtained. A variety of different donors provided a similar reactivity-stereoselectivity trend.

Scheme 2. Linkers of varying nucleophilicity gave opposite glycosylation stereoselectivity. (Seeberger, 2016).



Reagents and conditions: donor (1.5 eq.), acceptor (1 eq.), NIS (1.5 eq.), TfOH (0.2 eq.); a) DCM, -20°C ; b) CH_3CN -40°C ; c) toluene/dioxane (3/1), room temperature.

Le Mai Hoang and Liu introduced donors equipped with a 2-cyanobenzyl group at the C-2-OH and they investigated these donors, using a preactivation glycosylation scheme, with a panel of acceptors (Table 12).⁶⁶ Next to the model acceptors *n*-butanol **125** and trifluoroethanol **104**, this study also included carbohydrate acceptors with benzyl and acetyl protection groups. It was observed that the stronger nucleophiles stereoselectively provided the β -linked product, while the use of weaker nucleophiles led to the generation of the α -linked products in a fully stereoselective manner.⁶⁷ The stronger nucleophiles **24**, **125-127** can partake in an S_N2 -like substitution of the anomeric α -triflate, a closely related contact ion pair, or as suggested by the authors by a substitution of the intermediate α -nitrilium ion **131**, to provide selectively the β -product. The weaker, acetyl bearing acceptors **128** and **129** and trifluoroethanol **104** can be

directed by hydrogen-bonding with the cyano functionality on the C-2-O-protecting group to the α -face of the donor (as in **132**), as poorer nucleophiles are generally also stronger acids, forming hydrogen-bonds more readily. Alternatively, the weaker acceptors may also attack the oxocarbenium ion selectively on the α -diastereotopic face without coordination by the 2-cyanobenzyl group.

Table 12. Reactive acceptors give pure β -selectivity, weak acceptors pure α -selectivity. (Le Mai Hoang, 2014).

Acceptor	Product	Yield (%)	$\alpha : \beta$
125	133	90	β only
24	134	86	β only
126	135	89	β only
127	136	86	β only
128^a	137	87	α only
129	138	81	α only
104^a	139	71	α only

Reagents and conditions: donor (1 eq.), acceptor (1.3 eq.), Ph₂SO (1.4 eq.), TTBP (3 eq.), Tf₂O (2.8 eq.), toluene -60°C. ^aEt₂O was used as solvent.

A systematic study by Demchenko revealed the effect of acyl vs alkyl protecting groups and the position of the free alcohol on the carbohydrate acceptors on the stereochemistry of glycosylations with STaz donor **140** (Table 13).⁶⁸ The acceptors studied, varied from tri-*O*-benzyl protected acceptors **126**, **127**, **141**, and **142** to tri-*O*-benzoyl protected acceptors **143-146**. While the yields of the silver triflate mediated reactions proved independent of acceptor reactivity, the stereoselectivity of the glycosylations involving the *O*-benzyl protected acceptors is generally lower than the selectivity for the same acceptors bearing *O*-benzoyl groups. The latter group consistently give higher α -selectivities. It was observed that the *O*-benzyl protected acceptors were converted faster to their respective products than their *O*-benzoyl protected counterparts.

Table 13. Differentially substituted glucose acceptors provide a trend in reaction times and stereoselectivity. (Demchenko, 2010).

	acceptors		disaccharides	Time Yield		$\alpha : \beta$
	126, 127, 141-146	AgOTf		(h)	(%)	
140	126	147	1.5	81	2.7 : 1	
126	143	148	2	89	7.4 : 1	
141	141	149	14	90	6.8 : 1	
127	144	150	16	89	11.7 : 1	
142	127	151	8	85	6.5 : 1	
143	145	152	12	87	12.1 : 1	
144	142	153	6	87	9.3 : 1	
145	146	154	12	72	12.0 : 1	

Reagents and conditions: donor (0.11 mmol, 1.1 eq.), acceptor (0.10 mmol, 1 eq.), 3Å M.S., AgOTf (0.22 mmol, 2 eq.), 1,2-dichloroethane (2 mL), room temperature.

In an extension of the work of Demchenko, Kalikanda and Li investigated the effect of different configurations of the glycosyl acceptors. In one of the few systematic studies devoted to acceptor reactivity, they studied twelve tri-*O*-benzylated acceptors, having either a *gluco*-, *galacto*-, or *manno*-configuration in glycosylations with galactosazide donor **155** (Table 14).⁶⁹ Again, it becomes clear that the most reactive alcohols react in a β -selective manner, while the least reactive nucleophiles provide α -linked products. Although the exact mechanism of these glycosylations are not clear, the

Table 14. Systematic study of the impact of configuration of the acceptor reactivity. (Kalikanda and Li, 2011).


	acceptors		disaccharides	Yield		$\alpha : \beta$
	126, 127, 142, 156-163	TMSOTf		(%)		
155	126	164	98	β only		
126	141	165	56	1.8 : 1		
141	127	166	53	1 : 3.4		
127	142	167	68	α only		
142	156	168	75	1 : 4		
156	157	169	63	α only		
157	158	170	65	3 : 1		
158	159	171	90	1.3 : 1		
159	160	172	90	1 : 10		
160	161	173	81	1.2 : 1		
161	162	174	82	1 : 4.7		
162	163	175	93	α only		

Reagents and conditions: donor (1.2 eq.), acceptor (1 eq.), M.S., TMSOTf (0.15 eq.), DCM (0.2 M), -78°C.

result show that in general, the primary alcohols are the most reactive and the secondary, axially orientated hydroxyls are the least reactive. Notably, the reactivity order, as assessed from the α/β -product ratio, in the glucose series matches those established in Demchenko's study described above.⁶⁸ However, the relative order of reactivity may strongly depend on the donor used and the steric interactions between donor and acceptor in the product forming transition state.

In fact, the relative reactivity of two alcohol nucleophiles can even be reversed depending on the donor system used and it has already been suggested by Paulsen that for an optimal glycosylation outcome the reactivity of both reaction partners should be "matched".⁷⁰⁻⁷³ This becomes apparent from the following striking examples. Scheme 3 shows an attempted synthesis by van Boom and co-workers of a mycobacterial phospholipid using mannosyl donor **176** and *myo*-inositol acceptor **177**.⁷⁴ Glycosylation of the C-2-OH of this acceptor proved ineffective, but the construction of the desired pseudo-trisaccharide **179** in a different order was successful. In the event, pseudo-disaccharide **178**, in which the mannosyl substituent had already been installed at the C-2-OH, could be effectively glycosylated at the inositol C-6-OH with mannosyl donor **176** to give product **179** in 84% yield.⁷⁵ Similar results were later reported by Fraser-Reid, who noted a distinct preference of donors **181** and **183** for different alcohols on diol **180**.

Scheme 3. Donor-acceptor match and mismatch, led to the formulation of reciprocal donor-acceptor selectivity. (van Boom, 1990, 1992; Fraser-Reid, 2000).



Reagents and conditions: van Boom: donor (1.1 eq.), acceptor (1 eq.), NIS (1.2 eq.), TfOH (0.24 eq.), DCE, -10°C . Fraser-Reid: donor (1.3 eq.), acceptor (1 eq.), NIS (1.3 eq.), TBSOTf (cat), DCM, room temperature.

The preference of the equatorial hydroxyl in structures **178**, **180**, and **184** to be glycosylated with a donor bearing a participating group (**176** or **181**) is evident from the results in Scheme 3. However, donor **183**, bearing a non-participating benzyl group preferentially glycosylates the axial hydroxyl.^{76,77} From these observations Fraser-Reid developed the concept of reciprocal donor acceptor selectivity (RDAS), to classify reactions of diols that have different regioselective preferences towards different donors.^{78–81} The RDAS concept still awaits a better mechanistic explanation but the counter-intuitive outcome of several more recent reactions have been interpreted with this phenomenon.^{82–86}

Quantification of acceptor reactivity

Notwithstanding the progress that has been made in computational chemistry, only few attempts have been reported to investigate the nucleophilicity of glycosyl alcohol acceptors. The Fukui function, and its atom-condensed numerical indices provide a measure of change in electron density at the atom of interest when an electron is subtracted (or added). The Fukui indices have been reported as a measure for site selectivity of electrophilic (f^-) or nucleophilic (f^+) reactions. For the reaction of the OH-nucleophile on an electrophilic center, the index f^- can be computationally approached. Kalikanda and Li have computed Fukui f^- -indices for a series of mannosyl diol acceptors (Table 15).⁸⁷ The higher value of the two computed for each diol system will indicate the regioselectivity of the reaction. Indeed, the diols **187** and **189** are completely

Table 15. Fukui values determined for mannosyl diol acceptors. (Kalikanda and Li, 2010).


Entry	Electrophile	Ratio O3/O2	Ratio O3/O2	Ratio O3/O2
		 $f_M^- = 0.015$ $f_M^- = 0.042$ 187	 $f_M^- = 0.078$ $f_M^- = 0.070$ 188	 $f_M^- = 0.025$ $f_M^- = 0.052$ 189
1	Ac ₂ O (+pyridine)	6: 1	3: 2	1: 0
2	 186	1: 0	3: 1	1: 0

Thiophenyl and trichloroimidate donors also gave trisaccharide byproducts, the disaccharides were formed with the same selectivity regardless of the donor. Atom-condensed Fukui values f_m^- were based on Mulliken charges and were obtained by DFT (Q-CHEM 3.2, B3LYP/6-31+G⁺). *Reagents and conditions:* donor (1 eq.), acceptor (1 eq.), 3 Å M.S., AgOTf (1 eq.), DCM, -30°C.

stereoselective in experimental glycosylations with donor **186** and with acetic anhydride. When the Fukui values are close to each other a loss in stereoselectivity is observed (as for **188**), the preference then found can be a result of the different steric requirements and hydrogen-bonding capabilities.⁸⁸

The group of Rúveda and Stortz also employed Fukui functions, and discussed the chemical hardness/softness and atomic charges as indicators for the relative reactivity of a series of acceptors (**190-192**, Figure 1). They reached the conclusion that carbohydrate acceptors and donors are neither well described by hard-hard (atomic charges) interactions nor by soft-soft (Fukui functions) interactions.^{35,39} The chemical softness (s) in these examples provided the best correlation with experimental results (see Table 5), with the lowest s_{O-4} value in **190** corresponding to the most reactive acceptor (**49**).

Figure 1. Computation evaluation of relative acceptor reactivities. (Rúveda, 2006).













Atomic charge q , atom condensed Fukui value f and local chemical softness s are determined by multiple approaches, see the original publication for details.


In a different approach by the same group, the reactivity of the acceptors was assessed by calculation of the methylated regioisomeric acceptors (see examples **194** and **195**).⁸⁹ The charged structures served to mimic the glycosylation transition state and allow for the investigation of the influence of intramolecular hydrogen-bonding on the stability and geometry on the acceptor part.^{90,91} Table 16 reports the experimental and computational results of a variety of diol acceptors (see also Table 7 above). Galactopyranose and -furanose donors **59** and **48** were glycosylated with glucosamine acceptors **68**, **69**, **198**, and **199**, and allosamine acceptors **196** and **197**. Experimentally, acceptors **196** and **197** gave exclusive condensation with donor **59** at the axial C-3 position rather than the equatorial C-4 position. The calculated energy difference between the isomeric cationic structures **194** and **195** and their respective α -anomers provided evidence in support of the regioselectivities observed. Applying the same technique to glucosamine acceptors **68**, **69**, **198**, and **199**, the calculated energy

differences again correlated well with the experimentally observed regioselectivity ratios, bar the glycosylation pair **59** and **198**. The computational gas-phase approach may be a shortcoming in this case, and the steric hindrance in the transition state with a carbohydrate donor will be significantly different. In benzylidene allose diols **200** and **201** the C-3-OH also proved to be the most reactive nucleophile, both experimentally and computationally. Questioning whether the computational method would allow the comparison of the reactivity of individual acceptors with a single free hydroxyl group, the authors compared the energies of formation (from the neutral hydroxyl acceptor and methyl cation) of structures **202** and **203**. The energy difference $\Delta\Delta E$ of 7.9 kcal·mol⁻¹ between the two systems is in agreement with the observed reactivity difference (Table 6; **61/63**, 5:1). It appears that this relatively simple method is a promising way to estimate relative acceptor reactivities qualitatively when a higher level of theory, a larger set of acceptors, and an experimentally well-understood donor/activator system is used.

Table 16. Regioselectivity approach by glycosylations and computations. (Stortz, 2011).

Acceptor		O-3/O-4	O-3/O-4	O-3/O-4	E _{3-O-Me} -E _{4-O-Me}
Donor 59		Donor 48	Donor 193	(kcal·mol ⁻¹)	
	196	1 : 0			-8.64
	197	1 : 0			-6.93
	68	2 : 1	1 : 0		-4.60
	198	1 : 1	3.2 : 1		-1.85
	198	1 : 13	1 : 1		-0.03
	199	0 : 1	1 : 2.9		+2.15
	200			2.6 : 1	-4.39
	201			1.2 : 1	-2.25

Structure	Energy (kcal·mol ⁻¹)
	$\Delta E = -107.6$
	$\Delta E = -99.7$

NDMM = 

Energies obtained by DFT (Jaguar 6.0, B3LYP/6-31+G^{**}). Reagents and conditions: donor (1.1 eq.), acceptor (1 eq.), TMSOTf (2.1 eq.), 4 Å M.S., DCM/CH₃CN (29/1, 0.34 M), -25°C.



Figure 2. Anti-periplanar relationship between the ring oxygen and the C-4 substituent in methyl glucoside.

Bols and Inouye have taken a rather different approach to estimate the reactivity of different carbohydrate alcohols. They evaluated model systems in which specific hydroxyl groups were changed to amine functions.^{92,93} The pK_a s of their ammonium salts were determined by titration and the results are displayed in Table 17. The pK_a values indicate the 6-NH₂ group to be the most nucleophilic (towards H₃O⁺). The order of reactivity in glucose found with aminoglycosides **204-207a/b**, C-6-NH₃⁺ > C-3-NH₃⁺ > C-2-NH₃⁺ > C-4-NH₃⁺, roughly corresponds with the nucleophilicity on the parent hexoses.⁹⁴⁻⁹⁶ Using the pK_a data in Table 17, the authors established correlations between the effects of the neighboring substituent and the pK_a values of the ammonium group. It was pointed out that an anti-periplanar arrangement of the C-4-N and the C-5-O in **206a/b/d** (Figure 2), but also of C-2-N and C-1-O in **204a/b/d** led to a less basic NH₂ group.⁹⁷

Table 17. pK_a values of aminosugars. (Inouye, 1968; Bols, 2011).

	 204a-d		 205a-d		 206a-d		 207a-d		
Position	α -Glc	pK_a	β -Glc	pK_a	α -Gal	pK_a	α -Man	pK_a	
2-NH ₃ ⁺	204a	7.5	204b	7.2	204c	7.9	204d	7.2	
3-NH ₃ ⁺	205a	7.8	205b	7.6	205c	8.0	205d	8.1	
4-NH ₃ ⁺	206a	6.8	206b	6.7	206c	7.3	206d	7.2	
6-NH ₃ ⁺	207a	8.9	207b	8.6	207c	8.9	207d	9.0	

Conclusions

The reactivity of a glycosyl acceptor is of fundamental importance to the outcome of a glycosylation reaction. The nucleophilicity of a carbohydrate alcohol is influenced by electronic aspects, through inductive effects and hydrogen-bonding, and by steric and conformational effects. The protecting groups on the acceptor play a pivotal role in shaping the acceptor reactivity. In contrast to the reactivity of glycosyl donors, for which Relative Reactivity Values have been established^{98,99} to provide a numerical means to

compare their reactivity, the relative reactivity of glycosyl acceptors remains relatively poorly understood and no numerical scales are available to assess acceptor reactivity. The insightful competition experiments performed by Rúveda did provide relative acceptor reactivities based on kinetics but to be more generally useful should be significantly expanded.³⁸ It would also be of interest to see how relative acceptor values change with different donors. A systematic evaluation of different well established donor systems with the same set of acceptors may provide an accurate structure-reactivity-stereoselectivity map. Another approach would be to establish Kinetic Isotope Effects for donor-acceptor combinations or to perform cation-clock kinetics. Both methods have been used by the group of Crich, but only on the relatively nucleophilic and minimally intrusive *iso*-propanol.^{100–104} An extension of these methods spanning a wider range of acceptors, such as the model acceptors introduced by Woerpel and the set used in Chapter 3 of this Thesis, will provide the much needed insight how the reactivity of the acceptors determines the position of the operational reaction mechanisms along the S_N2-S_N1-continuum.

Footnotes and references

- (1) Demchenko, A. V. *Handbook of Chemical Glycosylation: Advances in Stereoselectivity and Therapeutic Relevance*; Wiley-VCH Verlag GmbH & Co. KGaA, 2008.
- (2) Mydock, L. K.; Demchenko, A. V. *Org. Biomol. Chem.* **2010**, *8* (3), 497–510.
- (3) Crich, D. *Acc. Chem. Res.* **2010**, *43* (8), 1144–1153.
- (4) Paulsen, H. *Angew. Chem. Int. Ed. Engl.* **1982**, *21* (3), 155–173.
- (5) Cid, M. B.; Alfonso, F.; Martín-Lomas, M. *Chem. – Eur. J.* **2005**, *11* (3), 928–938.
- (6) Islam, M.; Gayatri, G.; Hotha, S. J. *Org. Chem.* **2015**, *80* (16), 7937–7945.
- (7) Buda, S.; Nawój, M.; Gołębiowska, P.; Dyduch, K.; Michalak, A.; Mlynarski, J. *J. Org. Chem.* **2015**, *80* (2), 770–780.
- (8) Buda, S.; Gołębiowska, P.; Mlynarski, J. *Eur. J. Org. Chem.* **2013**, *2013* (19), 3988–3991.
- (9) Komarova, B. S.; Orekhova, M. V.; Tsvetkov, Y. E.; Nifantiev, N. E. *Carbohydr. Res.* **2014**, *384*, 70–86.
- (10) Baek, J. Y.; Lee, B.-Y.; Jo, M. G.; Kim, K. S. *J. Am. Chem. Soc.* **2009**, *131* (48), 17705–17713.
- (11) Kim, K. S.; Fulse, D. B.; Baek, J. Y.; Lee, B.-Y.; Jeon, H. B. *J. Am. Chem. Soc.* **2008**, *130* (26), 8537–8547.
- (12) Lee, Y. J.; Lee, K.; Jung, E. H.; Jeon, H. B.; Kim, K. S. *Org. Lett.* **2005**, *7* (15), 3263–3266.
- (13) Ryzhov, I. M.; Korchagina, E. Y.; Popova, I. S.; Tyrtysh, T. V.; Paramonov, A. S.; Bovin, N. V. *Carbohydr. Res.* **2016**, *430*, 59–71.
- (14) Schmidt, T. H.; Madsen, R. *Eur. J. Org. Chem.* **2007**, *2007* (23), 3935–3941.
- (15) Hashihayata, T.; Mandai, H.; Mukaiyama, T. *Chem. Lett.* **2003**, *32* (5), 442–443.
- (16) Dyapa, R.; Dockery, L. T.; Walczak, M. A. *Org. Biomol. Chem.* **2016**, *15* (1), 51–55.
- (17) Heuckendorff, M.; Jensen, H. H. *Carbohydr. Res.* **2018**, *455*, 86–91.
- (18) Geng, Y.; Kumar, A.; Faidallah, H. M.; Albar, H. A.; Mhkalid, I. A.; Schmidt, R. R. *Angew. Chem. Int. Ed.* **2013**, *52* (38), 10089–10092.
- (19) Hu, Y.; Yu, K.; Shi, L.-L.; Liu, L.; Sui, J.-J.; Liu, D.-Y.; Xiong, B.; Sun, J.-S. *J. Am. Chem. Soc.* **2017**, *139* (36), 12736–12744.
- (20) Medina, S.; Harper, M. J.; Balmont, E. I.; Miranda, S.; Crisenza, G. E. M.; Coe, D. M.; McGarrigle, E. M.; Galan, M. C. *Org. Lett.* **2016**, *18* (17), 4222–4225.
- (21) Kim, K. S.; Kim, J. H.; Lee, Y. J.; Lee, Y. J.; Park, J. *J. Am. Chem. Soc.* **2001**, *123* (35), 8477–8481.

- (22) Castelli, R.; Schindler, S.; Walter, S. M.; Kniep, F.; Overkleeft, H. S.; Van der Marel, G. A.; Huber, S. M.; Codée, J. D. C. *Chem. – Asian J.* **2014**, *9* (8), 2095–2098.
- (23) Joosten, A.; Boultaadakis-Arapinis, M.; Gandon, V.; Micouin, L.; Lecourt, T. J. *J. Org. Chem.* **2017**, *82* (6), 3291–3297.
- (24) Teumelsan, N.; Huang, X. *J. Org. Chem.* **2007**, *72* (23), 8976–8979.
- (25) Guazzelli, L.; McCabe, O.; Oscarson, S. *Carbohydr. Res.* **2016**, *433*, 5–13.
- (26) Sylla, B.; Descroix, K.; Pain, C.; Gervaise, C.; Jamois, F.; Yvin, J.-C.; Legentil, L.; Nugier-Chauvin, C.; Daniellou, R.; Ferrières, V. *Carbohydr. Res.* **2010**, *345* (10), 1366–1370.
- (27) Adero, P. O.; Amarasekara, H.; Wen, P.; Bohé, L.; Crich, D. *Chem. Rev.* **2018**.
- (28) Sinaÿ, P. *Pure Appl. Chem.* **1978**, *50* (11), 1437–1452.
- (29) Paulsen, H.; Lockhoff, O. *Chem. Ber.* **1981**, *114* (9), 3079–3101.
- (30) Paulsen, H.; Leubuh, R. *Liebigs Ann. Chem.* **1983**, *1983* (6), 1047–1072.
- (31) Crich, D.; Dudkin, V. *J. Am. Chem. Soc.* **2001**, *123* (28), 6819–6825.
- (32) Lucas, R.; Hamza, D.; Lubineau, A.; Bonnaffé, D. *Eur. J. Org. Chem.* **2004**, *2004* (10), 2107–2117.
- (33) Crich, D.; Vinod, A. U. *Org. Lett.* **2003**, *5* (8), 1297–1300.
- (34) Pertel, S. S.; Osel'skaya, V. Y.; Chirva, V. Y.; Kakayan, E. S. *Russ. Chem. Bull.* **2015**, *64* (5), 1119–1124.
- (35) Bohn, M. L.; Colombo, M. I.; Stortz, C. A.; Rúveda, E. A. *Carbohydr. Res.* **2006**, *341* (9), 1096–1104.
- (36) Colombo, M. I.; Stortz, C. A.; Rúveda, E. A. *Carbohydr. Res.* **2011**, *346* (5), 569–576.
- (37) Uriel Clara; Gómez Ana M.; López J. Cristóbal; Fraser-Reid Bert. *Eur. J. Org. Chem.* **2009**, *2009* (3), 403–411.
- (38) Bohn, M. L.; Colombo, M. I.; Pisano, P. L.; Stortz, C. A.; Rúveda, E. A. *Carbohydr. Res.* **2007**, *342* (17), 2522–2536.
- (39) Bohn, M. L.; Colombo, M. I.; Rúveda, E. A.; Stortz, C. A. *Org. Biomol. Chem.* **2008**, *6* (3), 554–561.
- (40) The β -anomers of DMM protected glucosamine 3,4-diols (see also Table 16) are selective towards O-4. Similar regioselectivity has been observed for the *N*-phthaloyl (O-3/O-4, 1:3.6) see Numomura, S.; Iida, M.; Numata, M.; Sugimoto, M.; Ogawa, T. *Carbohydr. Res.* **1994**, *263* (2), C1–C6, and *N*-tetrachlorophthaloyl (only O-4 reacted), see Lay, L.; Manzoni, L.; Schmidt, R. R. *Carbohydr. Res.* **1998**, *310* (3), 157–171, both with galactopyranose donors. The *N*-tetrachlorophthaloyl protected glucosamine diol reacted with an *L*-fucosyl donor with slight preference for O-3 (O-3/O-4, 2:1).
- (41) Magaud, D.; Dolmazon, R.; Anker, D.; Doutheau, A.; Dory, Y. L.; Deslongchamps, P. *Org. Lett.* **2000**, *2* (15), 2275–2277.
- (42) Castro-Palomino, J. C.; Tsvetkov, Y. E.; Schneider, R.; Schmidt, R. R. *Tetrahedron Lett.* **1997**, *38* (39), 6837–6840.
- (43) Thioethers at the reducing end of acceptors may change the reactivity of the acceptor (for example see: Zegeleaar-Jaarsveld, K.; Smits, S. A. W.; van der Marel, G. A.; van Boom, J. H. *Bioorg. Med. Chem.* **1996**, *4* (11), 1819–1832 and Liew, S.-T.; Wei, A. *Carbohydr. Res.* **2002**, *337* (14), 1319–1324.). Thioethers can also participate to the extend of aglycon transfer when the thiofunction is more reactive than the alcohol in the acceptor (for example see: de Jong, A.-R.; Hagen, B.; van der Ark, V.; Overkleeft, H. S.; Codée, J. D. C.; Van der Marel, G. A. *J. Org. Chem.* **2012**, *77* (1), 108–125, Li, Z.; Gildersleeve, J. C. *Tetrahedron Lett.* **2007**, *48* (4), 559–562 and Christensen, H. M.; Oscarson, S.; Jensen, H. H. *Carbohydr. Res.* **2015**, *408*, 51–95.). Such a migration may be inhibited by bulky anomeric thio ethers (Geurtsen, R.; Boons, G.-J. *Tetrahedron Lett.* **2002**, *43* (51), 9429–9431).
- (44) Abronina, P. I.; Fedina, K. G.; Podvalnyy, N. M.; Zinin, A. I.; Chizhov, A. O.; Kondakov, N. N.; Torgov, V. I.; Kononov, L. O. *Carbohydr. Res.* **2014**, *396*, 25–36.
- (45) Masamune, S.; Choy, W.; Petersen, J. S.; Sita, L. R. *Angew. Chem. Int. Ed. Engl.* **1985**, *24* (1), 1–30.
- (46) Spijker, N. M.; van Boeckel, C. A. A. *Angew. Chem. Int. Ed. Engl.* **1991**, *30* (2), 180–183.
- (47) Lafont, D.; Boullanger, P.; Fenet, B. *J. Carbohydr. Chem.* **1994**, *13* (4), 565–583.
- (48) Boeckel, V.; A, C. A.; Petitou, M. *Angew. Chem. Int. Ed.* **1993**, *32* (12), 1671–1690.
- (49) Petitou, M.; van, B. C. A. A. *Pure Appl. Chem.* **2009**, *69* (9), 1839–1846.
- (50) Orgueira, H. A.; Bartolozzi, A.; Schell, P.; Seeberger, P. H. *Angew. Chem. Int. Ed.* **2002**, *41* (12), 2128–2131.
- (51) Zhang, Q.; van Rijssel, E. R.; Walvoort, M. T. C.; Overkleeft, H. S.; van der Marel, G. A.; Codée, J. D. C. *Angew. Chem. Int. Ed.* **2015**, *54* (26), 7670–7673.
- (52) Crich, D.; Cai, W. *J. Org. Chem.* **1999**, *64* (13), 4926–4930.
- (53) Krumper, J. R.; Salamant, W. A.; Woerpel, K. A. *Org. Lett.* **2008**, *10* (21), 4907–4910.

- (54) Krumper, J. R.; Salamant, W. A.; Woerpel, K. A. *J. Org. Chem.* **2009**, *74* (21), 8039–8050.
- (55) Beaver, M. G.; Woerpel, K. A. *J. Org. Chem.* **2010**, *75* (4), 1107–1118.
- (56) Minehan, T. G.; Kishi, Y. *Tetrahedron Lett.* **1997**, *38* (39), 6815–6818.
- (57) Hinkle, R. J.; Lian, Y.; Litvinas, N. D.; Jenkins, A. T.; Burnette, D. C. *Tetrahedron* **2005**, *61* (49), 11679–11685.
- (58) Mayr, H.; Ofial, A. R. *Acc. Chem. Res.* **2016**, *49* (5), 952–965.
- (59) Ammer, J.; Mayr, H. *J. Phys. Org. Chem.* **2013**, *26* (1), 59–63.
- (60) Minegishi, S.; Kobayashi, S.; Mayr, H. *J. Am. Chem. Soc.* **2004**, *126* (16), 5174–5181.
- (61) Dilman, A. D.; Mayr, H. *Eur. J. Org. Chem.* **2005**, *2005* (9), 1760–1764.
- (62) Ammer, J.; Nolte, C.; Mayr, H. *J. Am. Chem. Soc.* **2012**, *134* (33), 13902–13911.
- (63) Mayr, H.; Kempf, B.; Ofial, A. R. *Acc. Chem. Res.* **2003**, *36* (1), 66–77.
- (64) Hansch, C.; Leo, A.; Taft, R. W. *Chem. Rev.* **1991**, *91* (2), 165–195.
- (65) Schumann, B.; Parameswarappa, S. G.; Lisboa, M. P.; Kottari, N.; Guidetti, F.; Pereira, C. L.; Seeberger, P. H. *Angew. Chem. Int. Ed.* **2016**, *55* (46), 14431–14434.
- (66) Le Mai Hoang, K.; Liu, X.-W. *Nat. Commun.* **2014**, *5*, 5051.
- (67) In a different study by the same group, the stereochemical outcome of palladium catalyzed glycosylations of glycol donors, was also shown to critically depend on the nucleophilicity of the acceptor. Weak nucleophiles, such as phenol or trifluoroethanol, solely provided α -products, whereas stronger nucleophiles, and moderately nucleophilic carbohydrate acceptors all predominantly gave the β -product. Xiang, S.; Hoang, K. L. M.; He, J.; Tan, Y. J.; Liu, X.-W. *Angew. Chem. Int. Ed.* **2015**, *54* (2), 604–607.
- (68) Kaeothip, S.; Akins, S. J.; Demchenko, A. V. *Carbohydr. Res.* **2010**, *345* (15), 2146–2150.
- (69) Kalikanda, J.; Li, Z. *Carbohydr. Res.* **2011**, *346* (15), 2380–2383.
- (70) Bohé L.; Crich D. *Trends Glycosci. Glycotechnol.* **2010**, *22* (123), 1–15.
- (71) Paulsen, H. Selectivity and Reactivity in Oligosaccharide Synthesis. In *Selectivity - a Goal for Synthetic Efficiency*; Bartmann, W., Trost, B. M., Eds.; Verlag Chemie, Weinheim, 1984; pp 169–190.
- (72) Paulsen, H.; Paal, M.; Hadamczyk, D.; Steiger, K.-M. *Carbohydr. Res.* **1984**, *131* (1), C1–C5.
- (73) Paulsen, H.; Hadamczyk, D.; Kutschker, W.; Büch, A. *Eur. J. Org. Chem.* **1985**, *1985* (1), 129–141.
- (74) Elie, C. J. J.; Verduyn, R.; Dreef, C. E.; Brounts, D. M.; van der Marel, G. A.; van Boom, J. H. *Tetrahedron* **1990**, *46* (24), 8243–8254.
- (75) Elie, C. J. J.; Verduyn, R.; Dreef, C. E.; Marel, G. A. van der; Boom, J. H. van. *J. Carbohydr. Chem.* **1992**, *11* (6), 715–739.
- (76) Anilkumar, G.; Gilbert, M. R.; Fraser-Reid, B. *Tetrahedron* **2000**, *56* (14), 1993–1997.
- (77) Anilkumar, G.; Nair, L. G.; Fraser-Reid, B. *Org. Lett.* **2000**, *2* (17), 2587–2589.
- (78) Fraser-Reid, B.; Lopez, J. C.; Radhakrishnan, K. V.; Mach, M.; Schlueter, U.; Gomez, A.; Uriel, C. *Can. J. Chem.* **2002**, *80* (8), 1075–1087.
- (79) Fraser-Reid, B.; López, J. C.; Radhakrishnan, K. V.; Nandakumar, M. V.; Gómez, A. M.; Uriel, C. *Chem. Commun.* **2002**, *0* (18), 2104–2105.
- (80) Uriel, C.; Gómez, A. M.; López, J. C.; Fraser-Reid, B. *Synlett* **2003**, *2003* (14), 2203–2207.
- (81) Fraser-Reid, B.; López, J. C.; Gómez, A. M.; Uriel, C. *Eur. J. Org. Chem.* **2004**, *2004* (7), 1387–1395.
- (82) Guilleminau, M.; Auzanneau, F.-I. *Carbohydr. Res.* **2012**, *357*, 132–138.
- (83) Forman, A.; Auzanneau, F.-I. *Carbohydr. Res.* **2016**, *425*, 10–21.
- (84) Fraser-Reid, B.; López, J. C. Armed–Disarmed Effects in Carbohydrate Chemistry: History, Synthetic and Mechanistic Studies. In *Reactivity Tuning in Oligosaccharide Assembly*; Fraser-Reid, B., Cristóbal López, J., Eds.; Springer Berlin Heidelberg: Berlin, Heidelberg, 2011; pp 1–29.
- (85) Della Felice, F.; Rùveda, E. A.; Stortz, C. A.; Colombo, M. I. *Carbohydr. Res.* **2013**, *380*, 167–173.
- (86) The group of Fraser-Reid has explained the regioselective preference of the different donors by the ability of participating groups to offer a more ‘diffuse’ anomeric charge (via an dioxo- or trioxolenium ion) compared to non-participating groups. See ref 77 and Anilkumar, G.;Jia, Z. J.; Kraehmer, R.; Fraser-Reid, B. *J. Chem. Soc., Perkin Trans. 1*, **1999**, *24*, 3591–3596.
- (87) Kalikanda, J.; Li, Z. *Tetrahedron Lett.* **2010**, *51* (12), 1550–1553.
- (88) The numerical values can provide a measure of regioselectivity within the same molecule. Comparing these values between different molecules does not seem to be valid. A 4,6-dimethyl substituted mannose diol acceptor gave values $f_M = 0.050$ for O-2 and $f_M = 0.078$ for O-3, which differ significantly from the ones reported for the dibenylated acceptor **187**, and are closer to the diacetyl acceptor **188**.

- (89) Colombo, M. I.; Rúveda, E. A.; Stortz, C. A. *Org. Biomol. Chem.* **2011**, *9* (8), 3020–3025.
- (90) Cid, M. B.; Alonso, I.; Alfonso, F.; Bonilla, J. B.; López-Prados, J.; Martín-Lomas, M. *Eur. J. Org. Chem.* **2006**, *2006* (17), 3947–3959.
- (91) Cid, M. B.; Alfonso, F.; Alonso, I.; Martín-Lomas, M. *Org. Biomol. Chem.* **2009**, *7* (7), 1471–1481.
- (92) Inouye, S. *Chem. Pharm. Bull. (Tokyo)* **1968**, *16* (6), 1134–1137.
- (93) Pedersen, C. M.; Olsen, J.; Brka, A. B.; Bols, M. *Chem. – Eur. J.* **2011**, *17* (25), 7080–7086.
- (94) Kulkarni, S. S. Regioselective, One-Pot Functionalization of Carbohydrates. In *Selective Glycosylations: Synthetic Methods and Catalysts*; Bennett, C. S., Ed.; Wiley-VCH Verlag GmbH & Co. KGaA, 2017; pp 255–276.
- (95) Taylor, M. S. Regioselective Glycosylation Methods. In *Selective Glycosylations: Synthetic Methods and Catalysts*; Bennett, C. S., Ed.; Wiley-VCH Verlag GmbH & Co. KGaA, 2017; pp 231–253.
- (96) Lawandi, J.; Rocheleau, S.; Moitessier, N. *Tetrahedron* **2016**, *72* (41), 6283–6319.
- (97) The order of reactivity roughly corresponds with calculated enthalpies of hydroxyl deprotonation (Brewster, M. E.; Huang, M.; Pop, E.; Pitha, J.; Dewar, M. J. S.; Kaminski, J. J.; Bodor, N. *Carbohydr. Res.* **1993**, *242*, 53–67), however, measured dissociation constants suggest a reversed order of reactivity (Matwiejuk, M.; Thiem, J. *Eur. J. Org. Chem.* **2012**, *2012* (11), 2180–2187). Regardless of both these studies, the reactivity of an acceptor glycoside is better estimated by its ability to accept positive charge than to lose a hydroxyl proton.
- (98) Lee, J.-C.; Greenberg, W. A.; Wong, C.-H. *Nat. Protoc.* **2007**, *1* (6), 3143–3152.
- (99) Hsu, C.-H.; Hung, S.-C.; Wu, C.-Y.; Wong, C.-H. *Angew. Chem. Int. Ed.* **2011**, *50* (50), 11872–11923.
- (100) Huang, M.; Retailleau, P.; Bohé, L.; Crich, D. *J. Am. Chem. Soc.* **2012**, *134* (36), 14746–14749.
- (101) Adero, P. O.; Furukawa, T.; Huang, M.; Mukherjee, D.; Retailleau, P.; Bohé, L.; Crich, D. *J. Am. Chem. Soc.* **2015**, *137* (32), 10336–10345.
- (102) Huang, M.; Furukawa, T.; Retailleau, P.; Crich, D.; Bohé, L. *Carbohydr. Res.* **2016**, *427*, 21–28.
- (103) Huang, M.; Garrett, G. E.; Birlirakis, N.; Bohé, L.; Pratt, D. A.; Crich, D. *Nat. Chem.* **2012**, *4* (8), 663–667.
- (104) Crich, D.; Chandrasekera, N. S. *Angew. Chem. Int. Ed.* **2004**, *43* (40), 5386–5389.

Chapter 3

The influence of acceptor nucleophilicity on the glycosylation reaction mechanism

Introduction

The connection of two carbohydrate building blocks to construct a glycosidic linkage in a glycosylation reaction is one of the most important and one of the most difficult steps in the assembly of an oligosaccharide.^{1–3} The stereoselective formation of 1,2-*cis*-glycosidic linkages remains a major synthetic challenge and often requires careful tuning of reaction conditions for a profitable outcome.⁴ The variation in stereochemical outcome of a chemical glycosylation reaction originates from the different mechanistic pathways that can be followed for the union of an activated donor glycoside and an acceptor. Figure 1 depicts the current understanding of the continuum of mechanisms operational during a glycosylation reaction. The activation of a donor glycoside leads to an array of reactive intermediates, formed from the donor glycoside and the activator derived counterion. α - and β -configured covalent reactive intermediates can be formed and these are in equilibrium with less stable and more reactive oxocarbenium ion based species. These can be either closely associated with the counterion providing close (or

contact) ion pairs (CIPs), or further separated from their counterion in solvent separated ion pairs (SSIPs). These reactive intermediates can be attacked by an incoming nucleophile following a reaction mechanism with both S_N1 and S_N2 features. The covalent species are displaced in a reaction mechanism having an associative S_N2 -character, while the oxocarbenium ion-like intermediates are engaged in an S_N1 -like reaction. The exact position(s) on the continuum where a given glycosylation reaction




Figure 1. The reaction mechanism manifold operational during glycosylation reactions.

takes place, and hence the stereoselectivity of the process, depends critically on the reactivity of both reaction partners: the donor and the acceptor glycoside. The impact of the reactivity of the donor glycoside on the stereochemical outcome has been studied extensively, and the effect of functional and protecting groups on glycosyl donor reactivity is well documented.⁵⁻¹⁰ In contrast, the influence of the reactivity of the nucleophile (the acceptor) on the outcome of a glycosylation reaction remains poorly understood.¹¹⁻¹⁸ This chapter presents a systematic study to determine the effect of acceptor nucleophilicity on the stereochemical course of a glycosylation reaction. It is shown how a simple “toolset” of partially fluorinated alcohols¹³ can be used to dissect reaction mechanisms that are operational during a glycosylation reaction. It is revealed that the stereoselectivity of some glycosylation systems varies more with changing acceptor nucleophilicity than others, and these differences are related to changes in reaction pathways that are followed. A panel of model carbohydrate acceptors is scrutinized to place the reactivity of these building blocks in the context of the nucleophilicity scale set by the series of fluorinated ethanols.

Results and discussion

In this study the effect of acceptor nucleophilicity on the glycosylation selectivity is systematically investigated by the hand of a set of model *O*-nucleophiles, encompassing ethanol, monofluoroethanol (MFE), difluoroethanol (DFE), trifluoroethanol (TFE),

hexafluoro-*iso*-propanol (HFIP) and cyclohexanol, as well as a C-nucleophile, allyltrimethylsilane (allyl-TMS), and a deuterium nucleophile, deuterated triethylsilane (TES-*d*).^{12,13} Next a series of carbohydrate acceptors is used to put the reactivity of these alcohols in the context of the reactivity of the ethanol model acceptors (See Figure 2B and C). Three glycosylation systems have been investigated with these acceptors: the benzylidene mannose and analogous benzylidene glucose system as well as the mannanuronic acid system (See Figure 2A). These systems have been selected because they have previously been studied in depth to provide insight into the major reaction pathways that operate during glycosylation reactions of these donors (*vide infra*). Although these three glycosylation systems all selectively provide 1,2-*cis*-products, the major product-forming pathways significantly differ.

The benzylidene mannose system, introduced by Crich and co-workers for the stereoselective construction of β -mannosidic linkages, represents the best studied




Figure 2. (A) The benzylidene mannose, benzylidene glucose and mannanuronic acid glycosylation systems studied and the major glycosylation pathways of these donors. (B) Set of model nucleophiles used in this study. (C) Set of carbohydrate alcohols used.

glycosylation system to date.^{19,20} It has been found that benzylidene mannose donors can be transformed into the corresponding α -anomeric triflate **4** upon activation. These triflates have been extensively characterized in variable temperature NMR studies.^{21–24} A significant body of evidence has been gathered through a vast amount of glycosylation reactions^{19–23,25–33}, the establishment of kinetic isotope effects in combination with computational methods^{34,35}, and the application of cation clock methodology^{36–38}, to indicate that these triflates can be substituted in an S_N2 -manner to provide β -mannosides. However, an alternative hypothesis to account for the β -selectivity of benzylidene mannose glycosylations has also been forwarded. This hypothesis is based on a $B_{2,5}$ -oxocarbenium ion as product forming intermediate.^{39–42}

The closely related benzylidene glucose system provides α -selective glycosylation reactions.^{21,22,29,40,43–47} It has been proposed that this selectivity originates from an *in situ* anomerization kinetic scheme, in which the initially formed α -triflate **5 α** anomerizes into its more reactive β -counterpart **5 β** .²¹ Substitution of this species provides the α -glucosyl products. Mechanistic studies, amongst others kinetic isotope effect and cation-clock experiments, using the reactive nucleophile *iso*-propanol have provided support for this pathway.^{34,37,38}

Glycosylations of mannuronic acids have been shown to proceed in a highly selective manner to provide α -mannuronic acid products. Based on the conformational behavior of the donors and the intermediate α -triflates **18 α** , adopting an 1C_4 conformation^{48,49}, the high reactivity of these donors^{50,51} and a large variety of glycosylation reactions, both in solution^{50,52–55}, and on fluorous⁵⁶ and solid supports⁵⁷, it has been postulated that the selectivity in these glycosylation reactions can be related to the intermediacy of an 4H_3 oxocarbenium ion-like intermediate.^{53,54,58}

The experimental setup that was used in this study is based on preactivation of the thioglycoside donors **1**⁵⁹, **2**²¹ and **3** using a slight excess of diphenyl sulfoxide and triflic anhydride (Ph_2SO/Tf_2O) at low temperature. This transforms all three donors into the corresponding anomeric triflates^{21–24,48,60}, prior to addition of the acceptor nucleophiles. The preactivation set-up generates a pool of reactive intermediates in the absence of the acceptor, thereby eliminating product forming pathways that originate from direct displacement reactions on the activated parent donor species. Table 1 summarizes the results obtained with the three donor systems and the set of model acceptors. As a measure for the reactivity of the used acceptors, Mayr's nucleophilicity parameters have been tabularized where available.^{61–63} The field inductive parameters for

the -CH₃, -CH₂F, -CHF₂ and -CF₃ groups have also been shown, to indicate the gradual increase of electron-withdrawing character of these groups.⁶⁴

From the results depicted in Table 1 it becomes immediately apparent that the stereoselectivity of the benzylidene mannose and mannuronic acid systems shows relatively little variation with changing nucleophilicity, where the stereoselectivity of the glycosylations involving the benzylidene glucose donor changes significantly depending on the reactivity of the used nucleophile. Reactive nucleophiles such as ethanol,

Table 1. Model acceptor glycosylations.

Acceptor	N ^a	F ^b			
			Product α:β (yield) ^c	Product α:β (yield)	Product α:β (yield)
	-	-	1A 1 : 6 (96%)	2A 1 : 5 (71 %)	3A 1 : 8 (83%)
	7.44	0.01	1B 1 : 5 (70 %)	2B 1 : 10 (68 %)	3B 1 : 8 (95 %)
	-	0.15	1C 1 : 5 (86 %)	2C 1 : 3 (70 %)	3C 1 : 6 (70 %)
	-	0.29	1D 1 : 5 (90 %)	2D 5 : 1 (70 %)	3D 1 : 5 (87 %)
	1.11	0.38	1E 1 : 4 (78 %)	2E > 20 : 1 (64 %)	3E 1 : 2.5 (85 %)
	-1.93	-	1F 3 : 1 (56 %)	2F > 20 : 1 (65 %)	3F 1 : 1 (52 %)
	3.58	-	1G < 1 : 20 (60 %)	2G > 20 : 1 (79 %)	3G < 1 : 20 (95 %)
	1.68	-	1H < 1 : 20 (44 %) ^d	2H > 20 : 1 (42 %) ^d	3H < 1 : 20 (40 %) ^d

^aMayr's nucleophilicity parameters. ^bField inductive parameters. ^cα/β-Ratios were established by NMR spectroscopy of the crude and purified reaction mixtures. ^dBoth anomers of donor glycoside were also found after the glycosylation reaction. Literature yields of **1H**⁴⁰: 57% and **2H**⁴⁰: 56%.

cyclohexanol and MFE predominantly provide β -linked products (**2A**,⁶⁵ **2B** and **2C**), where the use of less reactive nucleophiles such as DFE, TFE, HFIP, TES-*d* and allyl-TMS leads to the preferential formation of the α -glucosyl products (**2D-2H**). A clear trend becomes apparent between the reactivity of the non-fluorinated and partially fluorinated ethanols and the stereoselectivity of the glucosylations involving these acceptors. The formation of the β -linked products **2A**, **2B** and **2C** can be explained to originate from an S_N2 -like substitution on the intermediate α -triflate **5 α** (See Figure 3). The α -products in these glucosylations (**α -2A**, **α -2B**, **α -2C**) may be formed from the corresponding β -glucosyl triflate **5 β** , as postulated by Crich and co-workers and as supported by kinetic isotope effect and cation clock studies.^{34,35,37,66} It is however less likely that the unreactive *O*-nucleophiles, such as TFE and HFIP, and the weak *C*- and *D*-nucleophiles, are capable of displacing the anomeric triflate **5** in an S_N2 -manner. Woerpel and co-workers have previously shown that TFE requires a glycosylating agent bearing significant oxocarbenium ion character.¹³ An explanation for the observed α -selectivity in the glucosylations of these nucleophiles may be found in the S_N1 -like substitution on the benzyldene glucose oxocarbenium ion **15**. This ion preferentially adopts a ${}^4H_3/{}^4E$ -structure, as verified by several computational studies^{67,68}, that is attacked in a diastereoselective fashion from the bottom face, leading *via* a chair-like transition state to the α -linked products. As the reactivity of the nucleophile diminishes, it is likely that the amount of S_N2 -character in the substitution of the β -triflate **5 β** gradually




Figure 3. Mechanistic pathways to account for the selectivity in glycosylations of benzyldene glucose donors.

decreases and the amount of S_N1 -character with the intermediacy of the corresponding CIP and SSIP (**15**) increases.¹³ The least reactive nucleophiles require the most “naked” oxocarbenium ions, with the triflate counterions significantly, if not completely, dissociated from the carbohydrate ring.

The stereoselectivity of the benzylidene mannose system seems to be less sensitive to variation in nucleophilicity of the acceptor. Donor **1** provides β -selective glycosylations with the range of acceptors studied. There is a slight decrease in selectivity going from the reactive *O*-nucleophiles to the weak *O*-nucleophiles and the condensation of benzylidene mannose **1** with HFIP proceeds with moderate α -selectivity. The most likely explanation for the β -selectivity observed with the reactive *O*-nucleophiles is an associative S_N2 -type substitution of the intermediate α -triflate **4** (See Figure 4). As discussed above, it is unlikely that unreactive acceptors such as TFE and HFIP react in an S_N2 -type reaction, directly displacing the α -mannosyl triflate **4**. Formation of the β -linked products formed from the unreactive acceptors and donor **1** may be better explained with an oxocarbenium ion-like product forming intermediate. Various theoretical studies have indicated that the $B_{2,5}$ -oxocarbenium ion **16** is the most stable benzylidene mannose oxocarbenium ion conformer.^{67,68} This oxocarbenium ion is preferentially attacked from the convex top face, as attack from the bottom face would lead to unfavorable interactions with the *pseudo*-axial H-2 and to an eclipsed C-1–C-2 configuration upon rehybridization.^{36,40,69,70}




Figure 4. Mechanistic pathways to account for the selectivity in glycosylations of benzylidene mannose donors.

The α -products formed in the condensations of donors **1** likely originate from an oxocarbenium ion intermediate. Reactive *O*-nucleophiles may react with an oxocarbenium ion in a relatively indiscriminative manner leading to the formation of both α - and β -products.¹¹⁻¹³ Because unreactive *O*-nucleophiles are expected to react in a more diastereoselective fashion with an oxocarbenium ion, it is unlikely that the α -products derived from the weak *O*-nucleophiles, such as TFE and HFIP, originate from the $B_{2,5}$ -oxocarbenium ion **16**. Instead, α -face attack on the 4H_3 half-chair conformer **17** may be a plausible reaction pathway to account for the α -products of the less reactive *O*-nucleophiles. In a later transition state, product development control plays a more important role, and the developing anomeric effect and the low energy chair conformation that results from the α -face attack on the 4H_3 half-chair **17**, make this trajectory favorable⁷¹. For the weak *C*- and *D*-nucleophiles, which react in a highly β -selective manner, this latter pathway does not play a major role, and these nucleophiles attack the $B_{2,5}$ -oxocarbenium ion **16** selectively from the top face.^{40,72}

In line with the benzylidene mannose system, the mannuonic acid donor provides β -selective condensations with all acceptors explored, except with the very unreactive *O*-nucleophile HFIP where both anomers were formed in equal amounts. Where reactions with nucleophilic *O*-nucleophiles can be expected to form from the α -triflate **18 α** ,³⁴⁻³⁷ the weaker *O*-nucleophiles and allyl-TMS and TES-*d* will react preferentially with an oxocarbenium ion (Figure 5). It has been postulated that the 3H_4 half-chair mannuonic acid oxocarbenium ion **6** is the most stable oxocarbenium ion conformer.^{51,54,55} To substantiate this hypothesis, the energy associated with a range of mannuonic acid oxocarbenium ion conformers have been calculated using DFT-calculations at the B3LYP/6-311G level.⁷³ From these calculations the 3H_4 conformer **6** appears to be significantly more stable (by > 5 kcal·mol⁻¹) than other conformers such as the alternative 4H_3 half-chair **19** and the $B_{2,5}$ boat conformers. The relative stability of the 3H_4 half-chair oxocarbenium ion can be explained by favorable interaction of the ring substituents with the electron depleted carbocation. Hyperconjugative stabilization of the C-2-H bond and through space stabilization of the *pseudo*-axial C-3, C-4 oxygen atoms and the axial C-5 carboxylate each contribute to the stability of the half-chair oxocarbenium ion.^{51,54,74-76} This oxocarbenium ion is preferentially attacked from the top face to provide the β -linked products *via* a chair-like transition state. For the weaker *O*-nucleophiles, a later transition state leads to significant steric interactions with the axial substituents in the 3H_4 half-chair oxocarbenium **6** and a reaction pathway, involving

attack of the nucleophiles on the higher energy 4H_3 half-chair oxocarbenium ion **19** becomes relevant. In line with the discussion above, product development control is favorable for the formation of α -*O*-mannuronic acids.

Next, the set of carbohydrate acceptors depicted in Figure 2C was explored. The results of these condensation reactions are summarized in Table 2. Where it can be reasoned that the secondary carbohydrate acceptors **11**⁷⁷, **12**⁷⁸, **13**⁷⁷ and **14**⁷⁹ electronically resemble DFE and TFE, because of the amount of electron-withdrawing β - and/or γ - and δ -substituents, the size of the carbohydrate acceptors obviously differs significantly from the small ethanol based acceptors. The picture that emerges from Table 2 follows in broad lines the results described in Table 1 and corroborates this analysis. The benzylidene glucose donor system **2** shows most variation in stereoselectivity, where both the benzylidene mannose and mannuronic acid donors **1** and **3** provide β -selective reactions with all carbohydrate acceptors studied. The series of benzylidene glucose condensations again reveals that reactive *O*-nucleophiles can provide β -selective glycosylations, while less reactive *O*-nucleophiles give the α -linked products. The electron-withdrawing effect of the C-5 carboxylate in acceptor **12**, makes this acceptor less reactive and more α -selective than its C-5-benzyloxymethylene counterpart **11**. In line with the discussion above, formation of the β -linked products can be explained with triflate **5 α** as product forming intermediate. Less reactive acceptors require a glycosylating species that is more electrophilic and react in a more dissociative substitution reaction, with a substantial












Figure 5. Mechanistic pathways to account for the selectivity in glycosylations of mannuronic acid donors.

Table 2. Glycosylation of donors **1-3** with carbohydrate acceptors **10-14**.

			
	1	2	3
Acceptor	Product $\alpha:\beta$ (yield)	Product $\alpha:\beta$ (yield)	Product $\alpha:\beta$ (yield)
 10	20 1 : 10 (97 %)	25 1 : 3 (81 %)	30 < 1 : 20 (71 %)
 11	21 1 : 9 (75 %)	26 1 : 1 (79 %)	31 < 1 : 20 (61 %)
 12	22 1 : 10 (87 %)	27 5 : 1 (90 %)	32 1 : 10 (71 %)
 13	23 < 1 : 20 (70%)	28 > 20 : 1 (83 %)	33 < 1 : 20 (76%)
 14	24 < 1 : 20 (87 %)	29 > 20 : 1 (80 %)	34 1 : 7 (80 %)

amount of oxocarbenium ion character and the glucose ring taking up a 4H_3 -like structure (**15**).

The benzylidene mannose and mannuronic acid donors **1** and **3** provide very β -selective condensation reactions, in line with the vast amount of previously reported glycosylations of these two donors. Based on the results presented here and in previous work the following picture emerges. Reactive carbohydrate acceptors react in a reaction with significant S_N2 -character, displacing the anomeric α -triflate (**4** and **18 α**). Weaker nucleophiles, such as most secondary carbohydrate acceptors, will react with a species that bears more carbocation character. For the benzylidene mannose donor, this species will resemble $B_{2,5}$ boat oxocarbenium ion **16**, whereas the mannuronic acid reactive intermediate will be structurally close to 3H_4 oxocarbenium ion **6**. The minor α -products in these condensations likely arise from a higher energy 4H_3 oxocarbenium ion **19**, through a transition state that benefits from a developing anomeric effect and favorable conformational properties.

Conclusions


The influence of structural changes in a glycosyl donor on the outcome of a glycosylation reaction, in terms of yield and stereoselectivity, has received considerable attention over the years and many ingenious donor systems have been developed for the stereoselective construction of glycosidic bonds. The influence of the reactivity of the acceptor in glycosylation reactions, on the other hand, is less well understood. Here we have investigated in a systematic manner how the outcome of a glycosylation system can change depending on the gradually changing reactivity of the nucleophile. We have shown that a series of partially fluorinated alcohols of gradually decreasing nucleophilicity, can be used to map how the stereoselectivity of a glycosylation system varies with changing acceptor reactivity. The simple “toolset” of partially fluorinated ethanols represents a rapid and easy means to dissect S_N2 -type (for ethanol) and S_N1 -type (for trifluoroethanol and hexafluoro-*iso*-propanol) glycosylation reaction mechanisms.⁸⁰ It is expected that application of this set of model nucleophiles to newly developed glycosylation methodology or re-investigation of already established methods will bring detailed insight into the complex and intriguing glycosylation reaction mechanism. This will allow for more directed optimization of glycosylation reactions, taking away the trial and error component and ill-understood reaction protocols that have plagued carbohydrate chemistry for so long.

Experimental section

General procedure for Tf₂O/Ph₂SO mediated glycosylations: Donor (0.1 mmol), Ph₂SO (26 mg, 0.13 mmol, 1.3 eq.) and TTBP (62 mg, 0.25 mmol, 2.5 eq.) were coevaporated twice with dry toluene (4 Å molecular sieves) and dissolved in DCM (2 mL, 0.05 M donor). Activated 3 Å molecular sieves (rods, size 1/16 in.) were added and the reaction mixture stirred for 30 min at room temperature. The solution was cooled to -78°C and Tf₂O (22 µl, 0.13 mmol, 1.3 eq.) was slowly added. The reaction mixture was allowed to warm to -60°C in approximately 45 min, followed by recooling to -78°C and addition of the acceptor (0.2 mmol, 2 eq.) in DCM (0.4 mL, 0.5 M). The reaction mixture was allowed to warm to -40°C in approximately 60 min and stirred for an additional 0-18 h depending on the acceptor. The reaction was quenched with Et₃N (0.1 mL, 0.72 mmol, 7.2 eq.) at -40°C and diluted with DCM. The solution was transferred to a separatory funnel and water was added, the layers were separated and the water phase extracted once more with DCM. The combined organic layers were dried over MgSO₄, filtered, and concentrated *in vacuo*. Purification by silica gel flash column chromatography and when needed, sephadex™ LH-20 size exclusion chromatography yielded the glycosylation product as a mixture of anomers.


General computational procedure: Density functional theory (DFT) *ab initio* calculations were performed with the B3LYP model. Conformations were generated from a conformer distribution search option included in the Spartan 04 program⁸² in the gas phase at the 6-31G* basis set level. All generated geometries were further optimized with Gaussian 03⁸³ at the 6-311G** level, their zero-point energy (ZPE) corrections calculated and further optimized with incorporated polarizable continuum model (PCM) to correct for solvation in dichloromethane.

Preparation of donors **1**, **2**, and **3**.




Phenyl 2,3,4,6-tetra-O-acetyl-1-thio-β-D-mannopyranoside (S1). To a mixture of HBr (33 wt% in AcOH, 35 mL, 200 mmol, 1 eq.) and Ac₂O (93 mL, 1020 mmol, 5.1 eq.) and 10 drops of 70% aq. HClO₄, D-mannose (36.0 g, 200 mmol) was added portion wise at 0 °C. After 20 minutes an additional amount of HBr (33 wt% in AcOH, 70 mL, 400 mmol, 2 eq.) was added. After stirring for 16 h at r.t. the reaction mixture was concentrated *in vacuo* at 30 °C. The resulting black oil was co-evaporated with toluene until neutral pH was reached and was used in the following step without further purification. To a solution of the crude product in DMF (400 mL), thiophenol (21.5 mL, 210 mmol, 1.05 eq.) was added. The reaction mixture was cooled to 0 °C and NaH (60% dispersion in mineral oil, 8.4 g, 210 mmol, 1.05 eq.) was added portion wise. After 2 h stirring at r.t. the reaction was quenched by the addition of aq. HCl (1 M). To the resulting black suspension, 4 L of water was added and extracted 10 times with Et₂O. The combined organic layers were washed with water, dried with MgSO₄ and concentrated *in vacuo*. Flash column chromatography (9/1 to 7/3 pentane/EtOAc) afforded the title compound as an orange oil (57.3 g, 130 mmol, 65%). R_f: 0.70 (1/1 pentane/EtOAc). Spectroscopic data were in accord with those previously reported.^{84,85} [α]_D²⁶ = -44.4° (c = 0.5, CHCl₃); IR (neat): 1047, 1213, 1368, 1742; ¹H NMR (400 MHz, CDCl₃, HH-COSY, HSQC): δ 7.56 – 7.47 (m, 2H, CH_{arom} Sph), 7.34 – 7.30 (m, 3H, CH_{arom} Sph), 5.66 (dd, 1H, J = 3.5, 0.8 Hz, H-2), 5.28 (t, 1H, J = 10.0 Hz, H-4), 5.07 (dd, 1H, J = 10.1, 3.5 Hz, H-3), 4.94 (d, 1H, J = 1.0 Hz, H-1), 4.29 (dd, 1H, J = 12.2, 6.5 Hz, H-6), 4.17 (dd, 1H, J = 12.2, 2.4 Hz, H-6), 3.72 (ddd, 1H, J = 10.0, 6.4, 2.5 Hz, H-5), 2.20 (s, 3H, CH₃ OAc), 2.09 (s, 3H, CH₃ OAc), 2.04 (s, 3H, CH₃ OAc), 1.98 (s, 3H, CH₃, OAc); ¹³C-APT NMR (101 MHz, CDCl₃, HSQC): δ 170.5, 170.1, 167.0, 169.6


(C=O Ac), 133.2 (C_q SPh), 131.9, 129.1, 128.1 (CH_{arom} SPh), 85.5 (C-1), 76.4 (C-5), 71.8 (C-3), 70.6 (C-2), 65.8 (C-4), 62.8 (C-6), 20.7, 20.7, 20.6, 20.6 (CH₃ Ac); ¹³C-GATED NMR (101 MHz, CDCl₃): δ 85.5 (*J*_{C1,H1} = 153 Hz, C-1 β); HRMS: [M+Na]⁺ calcd for C₂₀H₂₄O₉SNa 463.10332, found 463.10305.




Phenyl 1-thio-β-D-mannopyranoside (S2). To a solution of **S1** (24.9 g, 56.5 mmol) in MeOH (280 mL), NaOMe (0.31 g, 5.7 mmol, 0.1 eq.) was added. The reaction mixture was stirred for 16 h. Amberlite IR120 H⁺ was added until pH 6 was reached and the mixture was filtered and concentrated *in vacuo*. This afforded the title compound (15.3 g, 56.4 mmol, 99%) as a white foam. *R*_f: 0.20 (9/1 DCM/MeOH). Spectroscopic data were in accord with those previously reported.^{86,87} IR (neat, cm⁻¹): 880, 1085, 1636, 2974, 3312; ¹H NMR (400 MHz, MeOD, HH-COSY, HSQC): δ 7.53–7.46 (m, 2H, CH_{arom} SPh), 7.34–7.17 (m, 3H, CH_{arom} SPh), 5.00 (s, 1H, H-1), 4.05 (dd, 1H, *J* = 3.4, 1.0 Hz, H-2), 3.88 (dd, 1H, *J* = 11.9, 2.4 Hz, H-6), 3.73 (dd, 1H, *J* = 12.1, 5.7 Hz, H-6), 3.63 (t, 1H, *J* = 9.5 Hz, H-4), 3.51 (dd, 1H, *J* = 9.5, 3.4 Hz, H-3), 3.29 (m, 1H, *J* = 5.8 Hz, H-5); ¹³C-APT NMR (101 MHz, MeOD, HSQC): δ 131.0, 130.0, 127.7 (CH_{arom} SPh), 88.8 (C-1), 82.4 (C-5), 76.2 (C-3), 74.3 (C-2), 68.3 (C-4), 62.9 (C-6); HRMS: [M+Na]⁺ calcd for C₁₂H₁₆O₅SNa 295.06107, found 295.06107.




Phenyl 2,3-di-O-benzyl-4,6-O-benzylidene-1-thio-β-D-mannopyranoside (1). To a solution of **S2** (1.36 g, 5 mmol) in DMF (50 mL), benzaldehyde dimethyl acetal (3.0 mL, 20 mmol, 4 eq.) and CSA (0.25 g, 1 mmol, 0.2 eq.) were added. After the solution was stirred for 16 h, benzyl bromide (2.4 mL, 20 mmol, 4 eq.) and NaH (60% dispersion in mineral oil, 0.48 g, 20 mmol, 4 eq.) were added at 0 °C. The suspension was allowed to warm up until r.t. and stirred for an additional 2 h. The reaction mixture was quenched with MeOH, followed by the addition of DCM (250 mL) and ice water (500 mL). The water layer was extracted once with DCM and the combined organic layers were washed with water and brine. The combined organic layers were dried over MgSO₄, filtered and concentrated under reduced pressure. Flash column chromatography (1/0 to 9/1 pentane/EtOAc) and subsequent recrystallization from EtOAc and pentane afforded the title compound as a white solid (1.38 g, 2.56 mmol, 51% over 2 steps). *R*_f: 0.27 (9/1 pentane/EtOAc). Spectroscopic data were in accord with those previously reported.⁵⁹ IR (neat): 733, 1026, 1069, 1452, 2864; ¹H NMR (400 MHz, CDCl₃, HH-COSY, HSQC, HMBC): δ 7.64–7.14 (m, 20H, CH_{arom}), 5.64 (s, 1H, CHPh), 5.12 (d, 1H, *J* = 11.1 Hz, CHH Bn), 4.89 (d, 1H, *J* = 12.3 Hz, CHH Bn), 4.86 (d, 1H, *J* = 11.1 Hz, CHH Bn), 4.85 (d, 1H, *J* = 1.3 Hz, H-1), 4.74 (d, 1H, *J* = 12.3 Hz, CHH Bn), 4.36–4.26 (m, 2H, H-4, H-6), 4.18 (dd, 1H, *J* = 3.1, 1.3 Hz, H-2), 3.95 (t, 1H, *J* = 10.3 Hz, H-6), 3.74 (dd, 1H, *J* = 9.8, 3.1 Hz, H-3), 3.42 (td, 1H, *J* = 9.7, 4.9 Hz, H-5); ¹³C-APT NMR (101 MHz, CDCl₃, HSQC, HMBC): δ 138.1, 137.6, 135.1 (C_q), 131.2, 129.1, 129.1, 128.8, 128.6, 128.4, 127.9, 127.9, 127.8, 127.6, 126.2 (CH_{arom}), 101.6 (CHPh), 89.2 (C-1), 79.9 (C-3), 79.1 (C-2), 78.8 (C-4), 76.0, 73.3 (CH₂ Bn), 71.8 (C-5), 68.6 (C-6); ¹³C-GATED NMR (101 MHz, CDCl₃) δ 89.2 (*J*_{C1,H1} = 152 Hz, C-1 β); HRMS: [M+NH₄]⁺ calcd for C₃₃H₃₆NO₅S 558.23087, found 558.23071.




Phenyl 2,3,4,6-tetra-O-acetyl-1-thio-β-D-glucopyranoside (S3). To a 140 °C solution of NaOAc (8.2 g, 100 mmol, 0.5 eq) in Ac₂O (190 mL, 2 mol, 10 eq.) D-glucose (36 g, 200 mmol, 1 eq.) was added portionwise and the reaction mixture was refluxed for an additional 15 min. The solution was cooled to r.t. and poured over crushed ice. The product was filtered, taken up in DCM, concentrated *in vacuo* and recrystallized from hot EtOH (750 mL) to give the pentaacetate as a white solid (69.4 g, 178 mmol, 89%). Spectroscopic data were in accord with those previously reported.^{88,89} Data for the β-anomer: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 5.72 (d, 1H, *J* = 8.3 Hz, H-1), 5.26 (t, 1H, *J* = 9.4 Hz, H-3), 5.19–5.08 (m, 2H, H-2, H-4), 4.30 (dd, 1H, *J* = 12.7, 3.8 Hz, H-6), 4.15–4.08 (m, 1H, H-6), 3.88–3.81 (m, 1H, H-5), 2.12 (s, 3H, CH₃ OAc), 2.09 (s, 3H, CH₃ OAc), 2.04 (s, 6H, 2xCH₃ OAc), 2.02 (s, 3H, CH₃ OAc); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 170.7, 170.2, 169.5, 169.4, 169.1 (C_q OAc), 91.8 (C-1), 72.9, 72.8 (C-3, C-5), 70.3, 67.9 (C-2, C-4), 61.6 (C-6), 21.0, 20.8, 20.7 (CH₃ OAc). D-glucose pentaacetate (20 g, 51 mmol) was dissolved in DCM (100 mL) and cooled to 0 °C. Thiophenol (7.8 mL, 76.5 mmol, 1.5 eq.) was added followed by addition of boron trifluoride diethyl etherate (10.9 mL, 76.5 mmol, 1.5 eq.) and the mixture was refluxed overnight. Sat. aq. NaHCO₃ (300 mL) and Et₂O (100 mL) were added and the mixture was extracted three times with Et₂O. The organic layer was washed with brine, dried with MgSO₄, filtered and concentrated under reduced pressure. The crude product was purified by crystallization from EtOAc/hexane (1/10) to obtain the title compound as a white solid. (16.8 g, 38.2 mmol, 75%). Spectroscopic data were in accord with those previously reported.^{77,90–92} ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.50 (dd, 2H, *J* = 6.6, 3.0 Hz, CH_{arom}), 7.34–7.28 (m, 3H, CH_{arom}), 5.24 (t, 1H, *J* = 9.3 Hz, H-3), 5.04 (t, 1H, *J* = 9.8 Hz, H-4), 4.97 (t, 1H, *J* = 9.6 Hz, H-2), 4.75 (d, 1H, *J* = 10.0 Hz, H-1), 4.23 (dd, 1H, *J* = 12.3, 5.1 Hz, H-6), 4.17 (dd, 1H, *J* = 12.3, 2.5 Hz, H-6), 3.76 (ddd, 1H, *J* = 10.0, 5.1, 2.5 Hz, H-5), 2.07 (s, 3H, CH₃ OAc), 2.06 (s, 3H, CH₃ OAc), 2.01 (s, 3H, CH₃ OAc), 1.98 (s, 3H, CH₃ OAc); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 170.2, 169.8, 169.2, 169.0 (C=O Ac), 132.8 (CH_{arom}), 131.5 (C_q), 128.8, 128.2 (CH_{arom}), 85.3 (C-1), 75.5 (C-5), 73.8 (C-3), 69.8 (C-2), 68.1 (C-4), 61.9 (C-6), 20.5, 20.5, 20.4, 20.4 (CH₃ Ac).




Phenyl 1-thio- β -D-glucopyranoside (S4). To a solution of **S3** (16.3 g, 37.0 mmol) in MeOH (200 mL) was added Na(s) (89 mg, 3.7 mmol, 0.1 eq) and the reaction was stirred for 18 h at r.t. The reaction mixture was neutralized with Amberlite H⁺, filtered and Celite[®] was added to the filtrate and the mixture concentrated *in vacuo*. The residue was purified by flash column chromatography (1% to 12% EtOH in EtOAc) to obtain a white solid (8.6 g, 31.6 mmol, 85%). Spectroscopic data were in accord with those previously reported.⁹³ ¹H NMR (MeOD, 400 MHz, HH-COSY, HSQC): δ 7.61 – 7.54 (m, 2H, CH_{arom}), 7.33 – 7.24 (m, 3H, CH_{arom}), 4.60 (d, 1H, *J* = 9.8 Hz, H-1), 3.87 (dd, 1H, *J* = 12.1, 1.8 Hz, H-6), 3.67 (dd, 1H, *J* = 12.2, 5.2 Hz, H-6), 3.39 (t, 1H, *J* = 8.5 Hz, H-3), 3.35 – 3.26 (m, 2H, H-4, H-5), 3.22 (dd, 1H, *J* = 9.8, 8.6 Hz, H-2); ¹³C-APT NMR (MeOD, 101 MHz, HSQC): δ 135.3 (C_q), 132.7, 129.9, 128.3 (CH_{arom}), 89.4 (C-1), 82.0 (C-4), 79.7 (C-3), 73.7 (C-2), 71.3 (C-5), 62.8 (C-6).




Phenyl 4,6-O-benzylidene-1-thio- β -D-glucopyranoside (S5). To a solution of **S4** (12.81 g, 47 mmol) and *p*-TsOH·H₂O (100 mg, 0.5 mmol, 0.01 eq.) in DMF (25 mL) and CH₃CN (100 mL) was added benzaldehyde dimethyl acetal (9.9 mL, 65.8 mmol, 1.4 eq.). The reaction was heated to 50 °C at 250 mbar for 5 hours and subsequently quenched with Et₃N (2 mL) and diluted with EtOAc (250 mL). The solution was washed with H₂O (2x 100 mL) and brine (100 mL). The organic layer was dried (MgSO₄) and concentrated *in vacuo*. Precipitation from EtOAc/petroleum ether formed a waxy material (12.0 g, 33.3 mmol) and the remaining mother liquors were purified by column chromatography (3/1 to 1/3 pentane/EtOAc) to give another batch of product (3.86 g, 10.7 mmol). Total yield 15.9 g, 44 mmol, 94%. R_f: 0.50 (1/2 pentane/EtOAc). Spectroscopic data were in accord with those previously reported.^{90–92} ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.59 – 7.51 (m, 2H, CH_{arom}), 7.51 – 7.44 (m, 2H, CH_{arom}), 7.40 – 7.31 (m, 6H, CH_{arom}), 5.54 (s, 1H, CHPh), 4.64 (d, 1H, *J* = 9.8 Hz, H-1), 4.39 (dd, 1H, *J* = 10.5, 4.4 Hz, H-6), 3.91 – 3.74 (m, 2H, H-4, H-6), 3.59 – 3.43 (m, 3H, H-2, H-3, H-5); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 137.0 (C_q), 133.2 (CH_{arom}), 131.4 (C_q), 129.5, 129.3, 128.7, 128.5, 126.4 (CH_{arom}), 102.1 (CHPh), 88.8 (C-1), 80.4 (C-3), 74.7 (C-4), 72.7 (C-2), 70.7 (C-5), 68.7 (C-6).



Phenyl 2,3-di-O-benzyl-4,6-O-benzylidene-1-thio- β -D-glucopyranoside (2). Diol **S5** (7.21 g, 20 mmol) was dissolved in DMF (100 mL) and cooled to 0 °C. Benzyl bromide (5.75 mL, 48 mmol, 2.4 eq.) and NaH (60% dispersion in mineral oil, 2.4 g, 60 mmol, 3 eq.) were added and the reaction mixture was allowed to stir overnight. MeOH was added to quench the reaction followed by H₂O (500 mL) and EtOAc (300 mL). The organic layer was washed with brine and dried with MgSO₄. After concentration of the organic layer under reduced pressure, the crude product was crystallized from EtOAc (50 mL) and hexane (100 mL) to obtain the title compound as a white solid (9.49 g, 17.4 mmol, 86%). Spectroscopic data were in accord with those previously reported.^{21,90–92} ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.56 – 7.51 (m, 2H, CH_{arom}), 7.51 – 7.46 (m, 2H, CH_{arom}), 7.42 – 7.26 (m, 16H, CH_{arom}), 5.59 (s, 1H, CHPh), 4.94 (d, 1H, *J* = 11.1 Hz, CHH Bn), 4.86 (d, 1H, *J* = 10.2 Hz, CHH Bn), 4.81 (d, 1H, *J* = 10.3 Hz, CHH Bn), 4.80 – 4.73 (m, 2H, CHH Bn, H-1), 4.39 (dd, 1H, *J* = 10.5, 5.0 Hz, H-6), 3.84 (dd, 1H, *J* = 9.3, 8.3 Hz, H-3), 3.80 (t, 1H, *J* = 10.3 Hz, H-6), 3.71 (t, 1H, *J* = 9.3 Hz, H-4), 3.56 – 3.42 (m, 2H, H-2, H-5); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 138.4, 138.1, 137.4, 133.2 (C_{q-arom}), 132.5, 129.1, 129.1, 128.5, 128.5, 128.4, 128.3, 128.2, 128.0, 127.9, 126.1 (CH_{arom}), 101.3 (CHPh), 88.4 (C-1), 83.1 (C-3), 81.6 (C-4), 80.6 (C-2), 76.0, 75.5 (CH₂ Bn), 70.4 (C-5), 68.8 (C-6); HRMS: [M+H]⁺ calcd for C₃₃H₃₃O₅S 541.20432, found 541.20392.




Phenyl 2,3-di-O-benzyl-1-thio- β -D-mannopyranoside (S6). To a solution of **1** (1.62 g, 3 mmol) in MeOH (30 mL), *p*-TsOH·H₂O (60 mg, 0.3 mmol, 0.1 eq.) was added. The suspension was stirred for 1 h at 50 °C and subsequently quenched with Et₃N. After concentration *in vacuo* the resulting product was purified by flash column chromatography (9/1 to 1/1 pentane/EtOAc) to yield the title compound as a colourless foam (1.26 g, 2.78 mmol, 93%). R_f: 0.10 (4/1 pentane/EtOAc). Spectroscopic data were in accord with those previously reported.⁵¹ $[\alpha]_D^{26} = -62.4^\circ$ (*c* = 0.5, CHCl₃); IR (neat): 734, 1026, 1119, 1454, 924, 3391; ¹H NMR (400 MHz, CDCl₃, HH-COSY, HSQC): δ 7.54 – 7.19 (m, 15H, CH_{arom}), 4.97 (d, 1H, *J* = 11.3 Hz, CHH Bn), 4.85 (s, 1H, H-1), 4.85 (d, 1H, *J* = 11.3 Hz, CHH Bn), 4.75 (d, 1H, *J* = 11.7 Hz, CHH Bn), 4.53 (d, 1H, *J* = 11.7 Hz, CHH Bn), 4.20 (d, 1H, *J* = 2.1 Hz, H-2), 4.05 (td, 1H, *J* = 9.5, 2.3 Hz, H-4), 3.93 (ddd, 1H, *J* = 11.0, 7.2, 3.6 Hz, H-6), 3.82 (dt, 1H, *J* = 12.1, 6.3 Hz, H-6), 3.46 (dd, 1H, *J* = 9.5, 2.8 Hz, H-3), 3.38 (ddd, 1H, *J* = 9.5, 6.0, 3.6 Hz, H-5), 2.33 (s, 1H, 4-OH), 2.14 (t, 1H, *J* = 6.4 Hz, 6-OH); ¹³C-APT NMR (101 MHz, CDCl₃, HSQC): δ 138.0, 137.6, 135.1 (C_q), 130.7, 129.2, 128.8, 128.5, 128.4, 128.3, 127.9, 127.9, 127.5 (CH_{arom}), 87.9 (C-1), 83.6 (C-3), 80.1 (C-5), 76.7 (C-2), 75.3, 72.3 (CH₂ Bn), 67.5 (C-4), 63.1 (C-6); ¹³C-GATED NMR (101 MHz, CDCl₃): δ 87.9 (*J* = 152 Hz, C-1 β); HRMS: [M+Na]⁺ calcd for C₂₆H₂₈O₅SNa 475.15497, found 475.15430.





Methyl (phenyl 2,3-di-O-benzyl-1-thio- β -D-mannopyranosyl uronate) (S7). To a two phase system of **S6** (1.25 g, 2.76 mmol) in DCM (10 mL) and H₂O (5 mL), TEMPO (86 mg, 0.55 mmol, 0.2 eq.), BAIB (2.22 g, 6.9 mmol, 2.5 eq.) and AcOH (50 μ L) were added. The reaction mixture was stirred for 6 h and was

quenched with sat. aq. $\text{Na}_2\text{S}_2\text{O}_3$. The resulting suspension was concentrated under reduced pressure and co-evaporated three times with toluene. The formed solid was dissolved in DMF (15 mL), K_2CO_3 (1.14 g, 8.28 mmol, 3 eq.) and methyl iodide (0.52 mL, 8.28 mmol, 3 eq.) were added. The suspension was stirred for 16 h at r.t. and followed by the addition of H_2O (150 mL). The aqueous layer was extracted three times with Et_2O and subsequently washed with sat. aq. NaHCO_3 and brine. The combined organic layers were dried over MgSO_4 , filtered and concentrated under reduced pressure. Flash column chromatography (1/0 to 3/1 pentane/ EtOAc) followed by recrystallization in EtOAc and pentane afforded the title compound as a white solid (0.48 g, 1.75 mmol, 63% over 2 steps). R_f : 0.70 (1/1 pentane/ EtOAc). Spectroscopic data were in accord with those previously reported.⁵¹ $[\alpha]_D^{26} = -72.0^\circ$ ($c = 0.5$, CHCl_3); IR (neat): 696, 735, 1026, 1064, 1123, 1429, 1454, 1744, 2855, 2924, 3462; ^1H NMR (400 MHz, CDCl_3 , HH-COSY, HSQC): δ 7.51 – 7.25 (m, 20H, CH_{arom}), 5.02 (d, 1H, $J = 11.4$ Hz, CHH Bn), 4.86 (d, 1H, $J = 11.3$ Hz, CHH Bn), 4.79 – 4.74 (m, 3H, CHH Bn, CHH Bn, H-1), 4.41 (td, 1H, $J = 9.5, 2.1$ Hz, H-4), 4.12 (dd, 1H, $J = 3.0, 1.0$ Hz, H-2), 3.84 – 3.77 (m, 4H, H-5, CH_3 CO_2Me), 3.50 (dd, 1H, $J = 9.5, 2.9$ Hz, H-3), 3.11 (d, 1H, $J = 2.3$ Hz, 4-OH); ^{13}C -APT NMR (101 MHz, CDCl_3 , HSQC): δ 138.0, 135.1 (C_q), 131.3, 129.1, 128.7, 128.6, 128.3, 128.1, 127.9, 127.6 (CH_{arom}), 89.0 (C-1), 82.4 (C-3), 78.3 (C-5), 77.0 (C-2), 75.4, 73.1 (CH_2 Bn), 68.6 (C-4), 52.9 (CH_3 CO_2Me); ^{13}C -GATED NMR (101 MHz, CDCl_3): δ 89.0 ($J_{\text{C}1,\text{H}1} = 154$ Hz, C-1 β). HRMS: $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{27}\text{H}_{29}\text{O}_6\text{S}$ 481,16794, found 481,16812.


 **Methyl (phenyl 4-O-acetyl-2,3-di-O-benzyl-thio- β -D-mannopyranosyl uronate) (3).** To a suspension of **S7** (1.20 g, 2.5 mmol) in pyridine (3.0 mL, 37.5 mmol, 15 eq.), Ac_2O (0.30 mL, 3.1 mmol, 1.25 eq.) was added. After stirring for 16 h at r.t., the reaction mixture was quenched with H_2O (25 mL). To the quenched reaction mixture, EtOAc was added and the layers were separated. The water layer was extracted for an additional 2 times with EtOAc . The combined organic layers were washed with sat. aq. NaHCO_3 and brine. The resulting organic layer was dried over MgSO_4 , filtered and concentrated under reduced pressure. Flash column chromatography (9/1 to 7/3 pentane/ EtOAc) afforded the title compound as a white solid (1.2 g, 2.3 mmol, 92%). R_f : 0.42 (7/3 pentane/ EtOAc). $[\alpha]_D^{26} = -84.0^\circ$ ($c = 0.5$, CHCl_3); IR (neat): 733, 1024, 1053, 1089, 1746, 2870; ^1H NMR (400 MHz, CDCl_3 , HH-COSY, HSQC): δ 7.50 – 7.23 (m, 15H, CH_{arom}), 5.61 (t, 1H, $J = 9.6$ Hz, H-4), 5.03 (d, 1H, $J = 11.6$ Hz, CHH Bn), 4.85 (d, 1H, $J = 11.6$ Hz, CHH Bn), 4.78 (d, 1H, $J = 1.1$ Hz, H-1), 4.67 (d, 1H, $J = 12.2$ Hz, CHH Bn), 4.57 (d, 1H, $J = 12.2$ Hz, CHH Bn), 4.15 (dd, 1H, $J = 2.8, 1.0$ Hz, H-2), 3.88 (d, 1H, $J = 9.6$ Hz, H-5), 3.74 (s, 3H, CH_3 CO_2Me), 3.61 (dd, 1H, $J = 9.7, 2.9$ Hz, H-3), 2.01 (s, 3H, CH_3 OAc); ^{13}C -APT NMR (101 MHz, CDCl_3 , HSQC): δ 169.7, 167.8 (C=O CO_2Me , Ac), 137.9, 137.7, 135.1 (C_q), 131.3, 129.1, 128.7, 128.6, 128.3, 128.1, 127.9, 127.7, 127.7 (CH_{arom}), 88.7 (C-1), 80.4 (C-3), 77.3 (C-5), 76.4 (C-2), 75.1, 72.6 (CH_2 Bn), 68.9 (C-4), 52.8 (CH_3 CO_2Me), 21.0 (CH_3 Ac); ^{13}C -GATED NMR (101 MHz, CDCl_3): δ 88.7 ($J_{\text{C}1,\text{H}1} = 152$ Hz, C-1 β); HRMS: $[\text{M}+\text{NH}_4]^+$ calcd for $\text{C}_{29}\text{H}_{34}\text{NO}_7\text{S}$ 540.20505, found 540.20515.

Preparation of acceptors **10**, **11**, and **12**.




 **Methyl 2,3,4-tri-O-benzyl- α -D-glucopyranoside (10).** To a solution of methyl- α -D-glucopyranoside (1.94 g, 10 mmol, 1 eq.) in DMF (50 mL), trityl chloride (3.1 g, 11 mmol, 1.1 eq.), Et_3N (2.1 mL, 15 mmol, 1.5 eq.) and DMAP (0.12 g, 1 mmol, 0.1 eq.) were added. After stirring for 6 h at 60 $^\circ\text{C}$ the reaction was cooled to 0 $^\circ\text{C}$ and followed by the addition of benzyl bromide (4.8 mL, 40 mmol, 4 eq.), NaH (2 g, 50 mmol, 5 eq.). The suspension was stirred for 16 h at r.t. and subsequently quenched with MeOH . The reaction mixture was concentrated under reduced pressure and the remaining oil was transferred to a separation funnel. Et_2O and H_2O were added and the layers were separated. The water layer was extracted three more times


with Et₂O. The combined organic layers were washed with water, sat. aq. NaHCO₃ and brine. The resulting organic layer was dried over MgSO₄, filtered and concentrated under reduced pressure. The crude product **5B** was suspended in MeOH (100 mL) followed by the addition of *p*-TsOH·H₂O (0.19 g, 1 mmol, 0.1 eq.). After stirring for 1 h at 50 °C the reaction mixture was quenched with sat. aq. NaHCO₃ and concentrated *in vacuo*. Flash column chromatography (1/0 to 7/3 pentane/EtOAc) afforded the title compound as a waxy solid (3.6 g, 7.7 mmol, 78% over 3 steps). Spectroscopic data were in accord with those previously reported.^{77,94} R_f: 0.57 (7/3 pentane/EtOAc). IR (neat): 880, 1043, 1086, 1381, 1636, 2893, 2974, 3312; ¹H NMR (400 MHz, CDCl₃, HH-COSY, HSQC): δ 7.42 – 7.24 (m, 15H, CH_{arom}), 4.99 (d, 1H, *J* = 10.8 Hz, *CHH* Bn), 4.92 – 4.77 (m, 3H, *CHH* Bn, *CHH* Bn, *CHH* Bn), 4.72 – 4.60 (m, 2H, *CHH* Bn, *CHH* Bn), 4.56 (d, 1H, *J* = 3.5 Hz, H-1), 4.01 (t, 1H, *J* = 9.3 Hz, H-4), 3.82 – 3.73 (m, 1H, H-6), 3.73 – 3.61 (m, 2H, H-6, H-5), 3.58 – 3.45 (m, 2H, H-6, H-2, H-3), 3.37 (s, 3H, CH₃ OMe), 1.61 (dd, 1H, *J* = 7.3, 5.4 Hz, 6-OH); ¹³C-APT NMR (101 MHz, CDCl₃, HSQC, HMBC): δ 138.8, 138.2 (C_q), 128.6, 128.6, 128.6, 128.3, 128.2, 128.1, 128.1, 128.0, 127.8 (CH_{arom}), 98.3 (C-1), 82.1 (C-4), 80.0 (C-2), 77.4 (C-3), 75.9, 75.2, 73.6 (CH₂ Bn), 70.7 (C-5), 62.0 (C-6), 55.3 (CH₃ OMe); ¹³C-GATED NMR (101 MHz, CDCl₃): δ 98.3 (*J*_{C1,H1} = 164 Hz, C-1 α); HRMS: [M+Na]⁺ calcd for C₂₈H₃₂O₆Na 487.20911, found 487.20851.



Methyl 4,6-O-benzylidene- α -D-glucopyranoside (59**).** To a solution of methyl α -D-glucopyranoside (38.8 g, 200 mmol) in acetonitrile (800 mL) was added PhCH(OMe)₂ (36 mL, 240 mmol, 1.2 eq.) and *p*-TsOH·H₂O (3.8 g, 20 mmol, 0.1 eq.). The solution was stirred overnight at ambient temperature followed by concentration *in vacuo* (60°C, 600 mbar, 1.5 h) to a quarter of its original volume. The reaction mixture was treated with Et₃N (3 mL), diluted with EtOAc (500 mL) and subsequently washed with H₂O (2x 150 mL), sat. aq. NaHCO₃ (50 mL) and brine (2x 100 mL). The organic layer was dried (MgSO₄), filtered and concentrated *in vacuo*. The resulting crude residue was crystallized from EtOAc/petroleum ether to give the title product in two crops (49.2 g, 174 mmol, 87%, white solid). Spectroscopic data were in accord with those previously reported.^{77,95} ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.51 – 7.45 (m, 2H, CH_{arom}), 7.36 (dd, 3H, *J* = 5.1, 2.0 Hz, CH_{arom}), 5.51 (s, 1H, *CHPh*), 4.75 (d, 1H, *J* = 3.8 Hz, H-1), 4.28 (dd, 1H, *J* = 9.6, 4.3 Hz, H-6), 3.91 (t, 1H, *J* = 9.2 Hz, H-3), 3.84 – 3.68 (m, 2H, H-5, H-6), 3.60 (dd, 1H, *J* = 9.2, 3.9 Hz, H-2), 3.47 (t, 1H, *J* = 9.3 Hz, H-4), 3.43 (s, 3H, CH₃ OMe), 2.87 (bs, 2H, OH); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 137.2 (C_q), 129.4, 128.4, 126.4 (CH_{arom}), 102.0 (CHPh), 99.9 (C-1), 81.1 (C-4), 72.9 (C-2), 71.7 (C-3), 69.0 (C-6), 62.5 (C-5), 55.7 (OMe).




Methyl 2,3-di-O-benzyl-4,6-O-benzylidene- α -D-glucopyranoside (S10**).** Benzyl bromide (10.5 mL, 88 mmol, 2.2 eq.) and sodium hydride (60% dispersion, 4.16 g, 104 mmol, 2.6 eq.) were added to a 0°C solution of diol **59** (11.29 g, 40 mmol) in DMF (200 mL) and the solution was stirred overnight. The reaction mixture was quenched by slow addition of MeOH, diluted with EtOAc (500 mL) and washed with H₂O (200 mL) and brine (200 mL). The organic layer was dried with MgSO₄, filtered and concentrated *in vacuo*. The solid residue was recrystallization from EtOAc/pentane to yield the title compound as a white solid (16.0 g, 34.6 mmol, 87%). R_f: 0.57 (4/1 pentane/EtOAc). Spectroscopic data were in accord with those previously reported.^{21,77} ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.52 – 7.46 (m, 2H, CH_{arom}), 7.41 – 7.25 (m, 13H, CH_{arom}), 5.55 (s, 1H, *CHPh*), 4.92 (d, 1H, *J* = 11.3 Hz, *CHH* Bn), 4.85 (d, 1H, *J* = 12.1 Hz, *CHH* Bn), 4.84 (d, 1H, *J* = 11.3 Hz, *CHH* Bn), 4.70 (d, 1H, *J* = 12.1 Hz, *CHH* Bn), 4.59 (d, 1H, *J* = 3.7 Hz, H-1), 4.26 (dd, 1H, *J* = 10.1, 4.7 Hz H-6), 4.05 (t, 1H, *J* = 9.3 Hz, H-3), 3.83 (td, 1H, *J* = 9.9, 4.7 Hz, H-5), 3.70 (t, 1H, *J* = 10.2 Hz, H-6), 3.60 (t, 1H, *J* = 9.4 Hz, H-4), 3.56 (dd, 1H, *J* = 9.3, 3.7 Hz, H-2), 3.40 (s, 3H, CH₃ OMe); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 138.8, 138.3, 137.5 (C_q), 129.0, 128.6, 128.4, 128.3, 128.2, 128.1, 128.0, 127.7, 126.1 (CH_{arom}), 101.4 (CHPh), 99.3 (C-1), 82.2 (C-4), 79.3 (C-2), 78.7 (C-3), 75.5, 73.9 (CH₂ Bn), 69.2 (C-6), 62.4 (C-5), 55.5 (OMe).




Methyl 2,3,6-tri-O-benzyl- α -D-glucopyranoside (11**).** Fully protected compound **S10** (3.24 g, 7.0 mmol) was dissolved in THF (100 mL) and NaCNBH₃ (4.0 g, 63 mmol, 9 eq.) was added. To this solution 4.0 M HCl in 1,4-dioxane (18 mL, 72 mmol, 10.3 eq.) was slowly added and the reaction was stirred for an additional hour. Ice cold H₂O (300 mL) was added and the mixture extracted with DCM (2x 120 mL). The combined organic layers were washed with sat. aq. NaHCO₃ (100 mL) and brine (100 mL), dried with MgSO₄ and concentrated *in vacuo*. Flash column chromatography (6/1 to 4/1 pentane/EtOAc) gave the title compound as a colorless oil (2.7 g, 5.85 mmol, 87%). R_f: 0.37 (4/1 pentane/EtOAc). Spectroscopic data were in accord with those previously reported.⁷⁷ IR (neat): 695, 732, 1027, 1047, 1453, 2910, 3477; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.41 – 7.23 (m, 15H, CH_{arom}), 4.99 (d, 1H, *J* = 11.4 Hz, *CHH* Bn), 4.75 (d, 1H, *J* = 12.1 Hz, *CHH* Bn), 4.73 (d, 1H, *J* = 11.4 Hz, *CHH* Bn), 4.68 – 4.60 (m, 2H, *CHH* Bn, H-1), 4.57 (d, 1H, *J* = 12.1 Hz, *CHH* Bn), 4.52 (d, 1H, *J* = 12.2 Hz, *CHH* Bn), 3.78 (dd, 1H, *J* = 9.6, 8.8 Hz, H-3), 3.74 – 3.63 (m, 3H, H-5, H-6, H-6), 3.59 (t, 1H, *J* = 9.2 Hz, H-4), 3.52 (dd, 1H, *J* = 9.6, 3.5 Hz, H-2), 3.37 (s, 3H, CH₃ OMe), 2.44 (bs, 1H, 4-OH); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 138.8, 138.1, 138.0 (C_q), 128.6, 128.5, 128.4, 128.1, 128.0, 128.0, 127.8, 127.6, 127.6 (CH_{arom}), 98.2 (C-1), 81.5 (C-3), 79.6 (C-2), 75.4, 73.6, 73.1

(CH₂ Bn), 70.7 (C-4), 69.9 (C-5), 69.5 (C-6), 55.2 (OMe); HRMS: [M+NH₄]⁺ calcd for C₂₈H₃₆NO₆ 482.25371, found 482.25357.




Methyl 2,3-di-O-benzyl-α-D-glucopyranoside (S11). Fully protected **S10** (9.25 g, 20 mmol) and *p*-TsOH·H₂O (380 mg, 2 mmol, 0.1 eq.) were added to MeOH (100 mL) and heated at 60°C for 15 min after all solids were dissolved and TLC analysis showed full conversion to a lower running spot. The reaction mixture was quenched with Et₃N (1 mL) and concentrated *in vacuo*. The crude product was purified by flash column chromatography (8/1 to 3/2 pentane/acetone) to give the title compound as a white solid (7.4 g, 19.8 mmol, 99%) as a white solid. R_f: 0.33 (2/1 pentane/acetone). Spectroscopic data were in accord with those previously reported.^{77,96} ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.37 – 7.26 (m, 10H, CH_{arom}), 5.00 (d, 1H, *J* = 11.4 Hz, *CHH* Bn), 4.75 (d, 1H, *J* = 12.2 Hz, *CHH* Bn), 4.71 (d, 1H, *J* = 11.5 Hz, *CHH* Bn), 4.64 (d, 1H, *J* = 12.1 Hz, *CHH* Bn), 4.59 (d, 1H, *J* = 3.5 Hz, H-1), 3.78 (dd, 1H, *J* = 9.6, 8.6 Hz, H-3), 3.78 – 3.69 (m, 2H, H-6), 3.61 – 3.56 (m, 1H, H-5), 3.51 (dd, 1H, *J* = 9.8, 8.6 Hz, H-4), 3.48 (dd, 1H, *J* = 9.5, 3.5 Hz, H-2), 3.36 (s, 3H, CH₃ OMe), 2.46 (bs, 2H, OH); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 138.8, 138.1 (C_{q-arom}), 128.7, 128.6, 128.2, 128.1, 128.0, 127.9 (CH_{arom}), 98.2 (C-1), 81.4 (C-3), 79.9 (C-2), 75.5, 73.2 (CH₂ Bn), 70.8 (C-5), 70.3 (C-4), 62.3 (C-6), 55.3 (OMe).




Methyl (methyl 2,3-di-O-benzyl-α-D-glucopyranosyl uronate) (12). To a solution of diol **S11** (6.95 g, 18.6 mmol) in DCM (70 mL) and AcOH (0.1 mL) was added BAIB (14.95 g, 46.4 mmol, 2.5 eq.), TEMPO (580 mg, 3.7 mmol, 0.2 eq.) and H₂O (30 mL). The solution was stirred vigorously for 2.5 hours at room temperature, quenched by the addition of Na₂S₂O₃ (10% aq.) and this suspension stirred for 15 min. The mixture was extracted two times with EtOAc and the combined organic fractions were dried (MgSO₄), filtered, concentrated *in vacuo* and coevaporated with toluene once. The crude carboxylic acid was dissolved in DMF (75 mL) and cooled to 0°C. K₂CO₃ (7.7 g, 55.7 mmol, 3 eq.) and MeI (3.5 mL, 55.7 mmol, 3 eq.) were added and the reaction mixture stirred overnight. H₂O was added and the reaction mixture was extracted twice with EtOAc. The combined organic layers were dried (MgSO₄), filtered and concentrated *in vacuo*. Purification by flash column chromatography (1/0 to 9/1 toluene/acetone) followed by recrystallization from DCM/EtOAc/petroleum ether (1/1/23) gave the title product as white needles (3.84 g, 9.54 mmol, 52%, 2 steps). Spectroscopic data were in accord with those previously reported.⁷⁸ [α]_D²³ = +19.0° (c=1.0, CHCl₃), lit.: [α]_D³⁰ = +17.9° (c=0.5, CHCl₃)⁷⁸; IR: 700, 738, 1040, 1061, 1738, 2918, 3532; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.39 – 7.26 (m, 10H, CH_{arom}), 4.92 (d, 1H, *J* = 11.3 Hz, *CHH* Bn), 4.81 (d, 1H, *J* = 11.4 Hz, *CHH* Bn), 4.79 (d, 1H, *J* = 12.1 Hz, *CHH* Bn), 4.67 – 4.62 (m, 2H, *CHH* Bn, H-1), 4.15 (d, 1H, *J* = 8.9 Hz, H-5), 3.87 – 3.76 (m, 5H, H-3, H-4, CH₃ CO₂Me), 3.53 (dd, 1H, *J* = 8.9, 3.4 Hz, H-2), 3.42 (s, 3H, CH₃ OMe), 2.89 (bs, 1H, 4-OH); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 170.8 (C=O CO₂Me), 138.7, 138.0 (C_{q-arom}), 128.6, 128.3, 128.1, 128.0, 127.9 (CH_{arom}), 98.8 (C-1), 80.5 (C-3), 78.6 (C-2), 75.6, 73.7 (CH₂ Bn), 71.9 (C-4), 70.6 (C-5), 56.0 (OMe), 52.8 (CO₂Me); HRMS: [M+Na]⁺ calcd for C₂₂H₂₆O₇Na 425.15707, found 425.15649.

Preparation of acceptors **13** and **14**.




Methyl 2,3,4,6-tetra-O-acetyl-β-D-galactopyranoside (S12). Following the procedure of Kartha *et al.*⁹⁷ D-galactose (4.5 g, 25 mmol) was portionwise added to a mixture of 70% aq. HClO₄ (cat., 5 drops) and Ac₂O (14.2 mL, 150 mmol, 6 eq.). After stirring overnight a 33 wt% solution of HBr in AcOH (13.1 mL, 75 mmol, 3 eq.) was added and the reaction stirred at r.t. for 5 h. Solvents were evaporated by a water aspirator and the crude product was dissolved in EtOAc and washed with cold sat. aq. NaHCO₃ and brine. The organic phase was dried (Na₂SO₄) and concentrated *in vacuo*. The crude bromide was dissolved in MeOH (100 mL) and cooled to 0°C. Iodine (3.17 g, 12.5 mmol, 0.5 eq.) was added and the reaction was stirred for 2 h. The reaction mixture was


quenched by sat. aq. $\text{Na}_2\text{S}_2\text{O}_3$ and extracted with Et_2O twice. The organic layer was washed with sat. aq. NaHCO_3 and brine, dried (MgSO_4), filtered, and concentrated *in vacuo*. Flash column chromatography (8/1 to 1/1 pentane/ EtOAc) gave the methyl galactoside as an anomericly pure yellow oil (4.31 g, 11.9 mmol, 48% over three steps). Spectroscopic data were in accord with those previously reported.^{98,99} ^1H NMR (CDCl_3 , 400 MHz, HH-COSY, HSQC): δ 5.40 (dd, 1H, $J = 3.4, 1.2$ Hz, H-4), 5.20 (dd, 1H, $J = 10.5, 7.9$ Hz, H-2), 5.03 (dd, 1H, $J = 10.5, 3.4$ Hz, H-3), 4.42 (d, 1H, $J = 7.9$ Hz, H-1), 4.25 – 4.11 (m, 2H, H-6), 3.93 (td, 1H, $J = 6.7, 1.2$ Hz, H-5), 3.52 (s, 3H, CH_3 OMe), 2.16 (s, 3H, CH_3 Ac), 2.07 (s, 3H, CH_3 Ac), 2.06 (s, 3H, CH_3 Ac), 1.99 (s, 3H, CH_3 Ac); ^{13}C -APT NMR (CDCl_3 , 101 MHz, HSQC): δ 170.4, 170.2, 170.1, 169.5 (C=O Ac), 102.0 (C-1), 71.0 (C-3), 70.6 (C-5), 68.8 (C-2), 67.1 (C-4), 61.3 (C-6), 57.0 (OMe), 20.8, 20.7, 20.7, 20.6 (CH_3 Ac).




Methyl β -D-galactopyranoside (S12). Acetylated **S12** (4.31 g, 11.9 mmol) was dissolved in MeOH (50 mL) and NaOMe (325 mg, 6.0 mmol, 0.5 eq.) was added. After 30 min Amberlite H^+ was added until neutral pH was achieved and the resin was subsequently filtered off. The solution was concentrated *in vacuo* to give the crude tetra-ol. Spectroscopic data were in accord with those previously reported.¹⁰⁰ ^1H NMR (D_2O , 400 MHz, HSQC): δ 4.79 (bs, 4H, OH), 4.30 (d, 1H, $J = 7.9$ Hz, H-1), 3.90 (d, 1H, $J = 3.5$ Hz, H-4), 3.81 – 3.73 (m, 2H, H-6), 3.75 – 3.64 (m, 1H, H-5), 3.63 (dd, 1H, $J = 9.9, 3.5$ Hz, H-3), 3.55 (s, 3H, CH_3 OMe), 3.48 (dd, 1H, $J = 9.9, 7.9$ Hz, H-2); ^{13}C NMR (D_2O , 101 MHz, HSQC): δ 103.8 (C-1), 75.2 (C-5), 72.8 (C-3), 70.8 (C-2), 68.7 (C-4), 61.0 (C-6), 57.2 (OMe).




Methyl 2,3-di-O-benzyl-4,6-O-benzylidene- β -D-galactopyranoside (S14). Crude **S13** (1.94 g, 10 mmol), benzaldehyde dimethyl acetal (0.30 mL, 20 mmol, 2 eq.) and *p*-TsOH- H_2O (475 mg, 2.5 mmol, 0.25 eq.) were dissolved in CH_3CN (50 mL) and DMF (15 mL) and the poorly soluble reaction mixture was stirred at 60°C , 350 mbar for 3 h. Et_3N (0.8 mL) was added and the reaction mixture was portioned between EtOAc and H_2O . The organic layer did not contain observable product, therefore the water layer was evaporated to give the crude product. Column chromatography (1:0 to 9/1 DCM/MeOH) gave the benzylidene protected galactoside as a waxy solid (1.73 g, 6.1 mmol, 61%). Spectroscopic data were in accord with those previously reported.^{77,95,101} ^1H NMR (CDCl_3 , 400 MHz): δ 7.55 – 7.46 (m, 2H), 7.40 – 7.34 (m, 3H), 5.55 (s, 1H), 4.36 (dd, 1H, $J = 12.5, 1.5$ Hz), 4.24 – 4.20 (m, 2H), 4.12 – 4.07 (m, 1H), 3.79 – 3.67 (m, 2H), 3.59 (d, 3H, $J = 0.7$ Hz), 3.49 (t, 1H, $J = 1.6$ Hz). The crude methyl 4,6-O-benzylidene- β -D-galactopyranoside was coevaporated with dry toluene twice before being dissolved in DMF (30 mL). Benzyl bromide (3.2 mL, 18.4 mmol, 3 eq.) and NaH (60% dispersion in mineral oil, 736 mg, 18.4 mmol, 3 eq.) were added and the reaction mixture was stirred overnight. H_2O was added and the mixture was extracted with EtOAc twice. The organic layer was washed with brine twice and dried (MgSO_4), filtered, and concentrated *in vacuo*. The crude product was purified by flash column chromatography (8/1 to 3/1 pentane/ EtOAc) to afford the benzylated product (2.11 g, 4.56 mmol, 75%). R_f: 0.63 (3/2 pentane/ EtOAc). Spectroscopic data were in accord with those previously reported.⁷⁷ ^1H NMR (CDCl_3 , 400 MHz, HH-COSY, HSQC): δ 7.59 – 7.53 (m, 2H, CH_{arom}), 7.42 – 7.26 (m, 13H, CH_{arom}), 5.50 (s, 1H, CHPh), 4.91 (d, 1H, $J = 10.9$ Hz, CHH Bn), 4.81 – 4.71 (m, 3H, CHH Bn , CH_2 Bn), 4.36 – 4.27 (m, 2H, H-1, H-6), 4.11 (dd, 1H, $J = 3.7, 1.1$ Hz, H-4), 4.02 (dd, 1H, $J = 12.3, 1.8$ Hz, H-6), 3.84 (dd, 1H, $J = 9.7, 7.7$ Hz, H-2), 3.60 – 3.53 (m, 4H, H-3, CH_3 OMe), 3.32 (d, 1H, $J = 1.3$ Hz, H-5); ^{13}C -APT NMR (CDCl_3 , 101 MHz, HSQC): δ 139.0, 138.5, 137.9 (C_q), 129.1, 128.5, 128.4, 128.2, 128.2, 127.9, 127.8, 127.6, 126.7 (CH_{arom}), 104.8 (C-1), 101.5 (CHPh), 79.3 (C-3), 78.6 (C-2), 75.4 (CH_2 Bn), 74.1 (C-4), 72.1 (CH_2 Bn), 69.4 (C-6), 66.5 (C-5), 57.2 (OMe).




Methyl 2,3,6-tri-O-benzyl- β -D-galactopyranoside (S13). To a solution of **S16** (2.10 g, 4.54 mmol) and NaNBH_3 (1.7 g, 27.2 mmol, 6 eq.) in THF (60 mL), 4.0 M HCl in 1,4-dioxane (9 mL, 36 mmol, 7.9 eq.) was added. The reaction mixture was stirred for 1 h and then H_2O was added. The solution was extracted twice with DCM and the organic layer was washed with brine, dried with MgSO_4 , concentrated *in vacuo*. Flash column chromatography (9/1 to 1/1 pentane/ EtOAc) provided the free alcohol as an oil (1.56 g, 3.36 mmol, 74%). R_f: 0.74 (3/2 pentane/ EtOAc). Spectroscopic data were in accord with those previously reported.^{77,102,103} ^1H NMR (CDCl_3 , 400 MHz, HH-COSY, HSQC): δ 7.41 – 7.21 (m, 15H, CH_{arom}), 4.88 (d, 1H, $J = 11.1$ Hz, CHH Bn), 4.71 (d, 1H, $J = 11.0$ Hz, CHH Bn), 4.67 (s, 2H, CH_2 Bn), 4.56 (s, 2H, CH_2 Bn), 4.26 (d, 1H, $J = 7.7$ Hz, H-1), 3.98 (d, 1H, $J = 3.4$ Hz, H-4), 3.79 (dd, 1H, $J = 9.9, 5.9$ Hz, H-6), 3.72 (dd, 1H, $J = 9.9, 6.0$ Hz, H-6), 3.64 (dd, 1H, $J = 9.4, 7.7$ Hz, H-2), 3.59 – 3.50 (m, 4H, H-5, CH_3 OMe), 3.46 (dd, 1H, $J = 9.4, 3.4$ Hz, H-3), 2.70 (s, 1H, 4-OH); ^{13}C -APT NMR (CDCl_3 , 101 MHz, HSQC): δ 138.6, 137.9, 137.8 (C_q), 128.4, 128.3, 128.0, 127.8, 127.8, 127.7, 127.7, 127.5 (CH_{arom}), 104.7 (C-1), 80.5 (C-3), 79.0 (C-2), 75.1, 73.6 (CH_2 Bn), 73.1 (C-5), 72.3 (CH_2 Bn), 69.2 (C-6), 66.8 (C-4), 56.9 (OMe); HRMS: $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{28}\text{H}_{33}\text{O}_6\text{Na}$ 487.20911, found 487.20848.




Methyl 2,3-exo;4,6-di-O-benzylidene- α -D-mannopyranoside (S15). To a solution of methyl α -D-mannoside (19.4 g, 100 mmol) in CH_3CN (120 mL) was added benzylidene dimethyl acetal (36 mL, 240 mmol, 2.4 eq.) and *p*-TsOH·H₂O (475 mg, 2.5 mmol, 0.025 eq.). The reaction mixture was stirred at 60°C and 500 mbar for 3 h and the volume was reduced by half. Sat. aq. NaHCO_3 was added to quench the reaction and the precipitate collected and washed with cold H₂O. The solids were recrystallized from EtOH/EtOAc to obtain two crops of white needles (total yield: 29.6 g, 80 mmol, 80% exo only). Spectroscopic data were in accord with those previously reported.¹⁰⁴ ¹H NMR (CDCl_3 , 400 MHz, HH-COSY, HSQC): δ 7.55 – 7.51 (m, 2H, CH_{arom}), 7.48 – 7.44 (m, 2H, CH_{arom}), 7.41 – 7.34 (m, 6H, CH_{arom}), 6.30 (s, 1H, $\text{CHPh}_{2,3 \text{ exo}}$), 5.64 (s, 1H, $\text{CHPh}_{4,6}$), 5.02 (s, 1H, H-1), 4.63 (dd, 1H, $J = 7.8, 5.4$ Hz, H-3), 4.40 – 4.32 (m, 1H, H-6), 4.14 (d, 1H, $J = 5.4$ Hz, H-2), 3.93 – 3.88 (m, 1H, H-4), 3.88 – 3.81 (m, 2H, H-5, H-6), 3.41 (s, 3H, CH_3 OMe); ¹³C-APT NMR (CDCl_3 , 101 MHz, HSQC): δ 138.7, 137.3 (C_q), 129.3, 128.5, 128.4, 126.4, 126.2 (CH_{arom}), 103.1 ($\text{CHPh}_{2,3 \text{ exo}}$), 102.2 ($\text{CHPh}_{4,6}$), 99.0 (C-1), 77.6 (C-4), 75.7 (C-3), 75.4 (C-2), 69.1 (C-6), 60.5 (C-5), 55.4 (OMe).



Methyl 3-O-benzyl-4,6-O-benzylidene- α -D-mannopyranoside (14). Compound **S15** (5.56 g, 15 mmol) was dissolved in 100 mL DCM and 150 mL Et₂O. A solution of LiAlH_4 (2.4 M in THF, 8 mL, 19.2 mmol, 1.3 eq.) was added to the reaction mixture at 0°C followed by addition of AlCl_3 (2.2 g, 16.4 mmol, 1.1 eq.). The reaction mixture was allowed to stir for 3 h at r.t. before being quenched by careful addition of EtOAc and H₂O. The mixture was extracted with EtOAc and the organic phase was washed with brine, dried MgSO_4 and concentrated under reduced pressure. Purification of the crude product by flash column chromatography (6/1 to 1/1 pentane/EtOAc) gave the title compound as a colorless oil (5.37 g, 14.4 mmol, 96%). *R*_f: 0.38 (2/1 pentane/EtOAc). Spectroscopic data were in accord with those previously reported.^{32,79,104} ¹H NMR (CDCl_3 , 400 MHz, HH-COSY, HSQC): δ 7.53 – 7.47 (m, 2H, CH_{arom}), 7.41 – 7.27 (m, 8H, CH_{arom}), 5.60 (s, 1H, CHPh), 4.84 (d, 1H, $J = 11.9$ Hz, CHH Bn), 4.73 (d, 1H, $J = 1.4$ Hz, H-1), 4.69 (d, 1H, $J = 11.9$ Hz, CHH Bn), 4.27 (dd, 1H, $J = 9.4, 4.0$ Hz, H-6), 4.09 (t, 1H, $J = 9.2$ Hz, H-4), 4.01 (dt, 1H, $J = 3.3, 1.6$ Hz, H-2), 3.93 – 3.75 (m, 3H, H-3, H-5, H-5), 3.35 (s, 3H, CH_3 OMe), 2.82 (d, 1H, $J = 1.7$ Hz, 2-OH); ¹³C-APT NMR (CDCl_3 , 101 MHz, HSQC): δ 138.1, 137.7 (C_q), 129.0, 128.6, 128.3, 128.0, 127.9, 126.2 (CH_{arom}), 101.7 (CHPh), 101.2 (C-1), 78.9 (C-4), 75.7 (C-3), 73.1 (CH_2 Bn), 69.9 (C-2), 69.0 (C-6), 63.3 (C-5), 55.0 (OMe); HRMS: $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{21}\text{H}_{24}\text{O}_6\text{Na}$ 395.14651, found 395.14638.




Cyclohexyl 2,3-di-O-benzyl-4,6-O-benzylidene- α/β -D-mannopyranoside (1A). Donor **1** and cyclohexanol were condensed using the general procedure for $\text{Tf}_2\text{O}/\text{Ph}_2\text{SO}$ mediated and purified by flash column chromatography (1/0 to 9/1 pentane/EtOAc) to yield glycosylation product **1A** (50.9 mg, 51 μmol , 96%, $\alpha:\beta = 1:5$). *R*_f: 0.43 (9/1 pentane/EtOAc). Spectroscopic data were in accord with those previously reported.^{105,106} IR (neat): 694, 733, 964, 1026, 1047, 1084, 1361, 1452, 2857, 2857, 2930; Data for the β -anomer: ¹H NMR (400 MHz, CDCl_3 , HH-COSY, HSQC): δ 7.55 – 7.23 (m, 15H, CH_{arom}), 5.61 (s, 1H, CHPh), 5.02 (d, 1H, $J = 12.5$ Hz, CHH Bn), 4.91 (d, 1H, $J = 12.5$ Hz, CHH Bn), 4.67 (d, 1H, $J = 12.5$ Hz, CHH Bn), 4.58 (s, 1H, H-1), 4.58 (d, 1H, $J = 12.5$ Hz, CHH Bn), 4.30 (dd, 1H, $J = 10.4, 4.9$ Hz, H-6), 4.22 (t, 1H, $J = 9.6$ Hz, H-4), 3.94 (t, 1H, $J = 10.3$ Hz, H-6), 3.87 (d, 1H, $J = 3.0$ Hz, H-2), 3.70 (dt, 1H, $J = 8.6, 4.7$ Hz, CH Cy), 3.58 (dd, 1H, $J = 9.9, 3.1$ Hz, H-3), 3.31 (td, 1H, $J = 9.9, 4.9$ Hz, H-5), 2.06 – 0.99 (m, 10H, CH_2 Cy); ¹³C-APT NMR (101 MHz, CDCl_3 , HSQC): δ 138.68, 138.54, 137.79 (C_q), 129.05, 128.92, 128.85, 128.49, 128.40, 128.28, 128.22, 128.19, 127.84, 127.68, 127.62, 127.60, 127.58, 127.53, 126.18, 126.14, 125.21 (CH_{arom}), 101.48 (CHPh), 100.12 (C-1), 78.76 (C-4), 78.25 (C-3), 76.84 (CH Cy), 76.31 (C-2), 74.71 (CH_2 Bn), 72.39 (CH_2 Bn), 68.82 (C-6), 67.68 (C-5), 33.48, 31.57, 25.78, 23.72 (CH_2 Cy); ¹³C-GATED NMR (101 MHz, CDCl_3): 100.1 ($J_{\text{C1,H1}} = 154$ Hz, C-1 β); Diagnostic peaks α -anomer: ¹H NMR (400 MHz, CDCl_3 , HH-COSY, HSQC): δ 5.64 (s, 0.20H, CHPh), 4.89 – 4.79 (m, 0.60H, CHH Bn , CHH Bn , C-1), 4.71 (d, 0.20H, $J = 12.3$ Hz, CHH Bn), 4.00 (dd, 0.20H, $J = 10.0, 3.2$ Hz, H-2), 3.78 (dd, 0.20H, $J = 3.1, 1.6$ Hz, H-3), 3.54 – 3.49 (m, 0.20H, CH Cy); ¹³C-APT NMR (101 MHz, CDCl_3 , HSQC): δ 97.41 (C-1), 64.36 (C-5), 33.38, 31.31, 25.69, 25.25, 24.11 (CH_2 Cy); HRMS: $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{33}\text{H}_{38}\text{O}_6\text{Na}$ 553.25606, found 553.25531.




Ethyl 2,3-di-O-benzyl-4,6-O-benzylidene- α/β -D-mannopyranoside (1B). Donor **1** and ethanol were condensed using the general procedure for $\text{Tf}_2\text{O}/\text{Ph}_2\text{SO}$ mediated glycosylations and purified by flash column chromatography (1/0 to 9/1 pentane/EtOAc) to yield glycosylation product **1B** (33.5 mg, 70 μmol , 70%, $\alpha:\beta = 1:5$). *R*_f: 0.43 (9/1 pentane/EtOAc). IR (neat): 696, 734, 893, 912, 968, 1004, 1049, 1088, 1373, 1452, 2866, 2926; Data for the β -anomer: ¹H NMR (400 MHz, CDCl_3 , HH-COSY, HSQC): δ 7.53 – 7.28 (m, 15H, CH_{arom}), 5.62 (s, 1H, CHPh), 4.99 (d, 1H, $J = 12.4$ Hz, CHH Bn), 4.89 (d, 1H, $J = 12.4$ Hz, CHH Bn), 4.68 (d, 1H, $J = 12.6$ Hz, CHH Bn), 4.58 (d, 1H, $J = 12.5$ Hz, CHH Bn), 4.46 (s, 1H, H-1), 4.31 (dd, 1H, $J = 10.4, 4.9$ Hz, H-6), 4.21 (t, 1H, $J = 9.6$ Hz, H-4), 4.02 – 3.89 (m, 3H, CHHCH_3 Et, H-2, H-6), 3.58 (dd, 1H, $J = 9.9, 3.1$ Hz, H-3), 3.56 – 3.47 (m, 1H, CHHCH_3 Et), 3.36 – 3.28 (m, 1H, H-5), 1.27 (t, 3H, $J = 7.0$ Hz, CH_3 Et); ¹³C-APT NMR (101 MHz, CDCl_3 , HSQC): δ 138.6, 138.5,

137.8 (C_q), 123.0, 128.9, 128.4, 128.3, 128.2, 127.7, 127.7, 127.6, 126.2, (CH_{arom}) 102.2 (C-1), 101.5 (CHPh), 78.8 (C-4), 78.0 (C-3), 75.9 (C-2), 74.8 (CH₂ Bn), 72.5 (CH₂ Bn), 68.8 (C-6), 67.7 (C-5), 65.7 (CH₂ Et), 15.3 (CH₃ Et); ¹³C-GATED NMR (101 MHz, CDCl₃): δ 102.2 (*J*_{C1,H1} = 153 Hz, C-1 β); Diagnostic peaks α-anomer: ¹H NMR (400 MHz, CDCl₃): δ 5.65 (s, 0.20H), 4.86 – 4.81 (m, 0.40H, *CHH* Bn, *CHH* Bn), 4.80 (d, 0.20H, *J* = 1.5 Hz, H-1), 4.74 (d, 0.20H, *J* = 12.3 Hz, *CHH* Bn), 3.74 – 3.66 (m, 0.20H, *CHHCH*₃), 3.46 – 3.39 (m, 0.20H, *CHHCH*₃ Et); ¹³C-APT NMR (101 MHz, CDCl₃, HSQC): δ 128.9, 128.5, 128.4, 128.3, 128.2, 127.9, 127.6, 126.2 (C_q), 101.6 (CHPh), 99.3 (C-1), 79.4 (C-3), 76.5 (C-4), 76.4 (C-2), 73.7 (CH₂ Bn), 73.3 (CH₂ Bn), 69.3 (C-6), 64.3 (C-5) 63.3 (CH₂ Et), 15.1 (CH₃ Et); HRMS: [M+Na]⁺ calcd for C₂₉H₃₂O₆Na 499.20911, found 499.20846.




2-Fluoroethyl 2,3-di-O-benzyl-4,6-O-benzylidene-α/β-D-mannopyranoside (1C). Donor **1** and 2-fluoroethanol were condensed using the general procedure for Tf₂O/Ph₂SO mediated and purified by flash column chromatography (1/0 to 4/1 pentane/EtOAc) to

yield glycosylation product **1C** (42.7 mg, 86 μmol, 86%, α:β = 1:5). R_f: 0.18 (9/1 pentane/EtOAc). IR (neat): 696, 738, 802, 887, 1025, 1043, 1066, 1086, 1261, 1371, 1454, 2870; Data for the β-anomer: ¹H NMR (400 MHz, CDCl₃, HH-COSY, HSQC): δ 7.66 – 7.32 (m, 15H, CH_{arom}), 5.62 (s, 1H, *CHPh*), 4.99 (d, 1H, *J* = 12.3 Hz, *CHH* Bn), 4.89 (d, 1H, *J* = 12.3 Hz, *CHH* Bn), 4.70 – 4.51 (m, 5H, *CHH* Bn, *CHH* Bn, H-1, CH₂CHHF, CH₂CHHF), 4.30 (dd, 1H, *J* = 10.4, 4.8 Hz, H-6), 4.22 (t, 1H, *J* = 9.6 Hz, H-4), 4.08 (ddt, 1H, *J* = 35.7, 12.2, 3.0 Hz, *CHHCH*₂F), 3.98 (d, 1H, *J* = 2.9 Hz, H-2), 3.92 (t, 1H, *J* = 10.3 Hz, H-6), 3.80 (dtd, 1H, *J* = 22.6, 11.9, 7.8, 2.4 Hz, *CHHCH*₂F), 3.59 (dd, 1H, *J* = 9.9, 3.1 Hz, H-3), 3.33 (td, 1H, *J* = 9.7, 4.9 Hz, H-5); ¹³C-APT NMR (101 MHz, CDCl₃, HSQC): δ 138.4, 138.4, 137.6 (C_q), 131.2, 129.4, 129.0, 128.8, 128.4, 128.3, 128.2, 127.7, 127.7, 126.2, 124.9 (CH_{arom}), 102.3 (C-1), 101.5 (CHPh), 82.8 (d, *J* = 169.74 Hz, CH₂F), 78.6 (C-4), 77.8 (C-3), 75.7 (C-2), 75.0 (CH₂ Bn), 72.5 (CH₂ Bn), 69.0 (d, *J* = 19.7 Hz, CH₂CH₂F), 67.7 (C-6). ¹³C-GATED NMR (101 MHz, CDCl₃): δ 102.3 (*J*_{C1,H1} = 156 Hz, C-1 β); Diagnostic peaks α-anomer: ¹H NMR (400 MHz, CDCl₃, HH-COSY, HSQC): δ 5.62 (s, 0.20H, *CHPh*), 4.93 – 4.80 (m, 0.60H, *CHH* Bn, *CHH* Bn, H-1); ¹³C-APT NMR (101 MHz, CDCl₃, HSQC): δ 99.7 (C-1), 82.5 (d, *J* = 170 Hz, CH₂F), 79.2 (C-4), 76.5 (C-3), 76.4 (C-2), 73.8 (CH₂ Bn), 73.3 (CH₂ Bn), 68.9 (C-6), 66.7 (d, *J* = 19.9 Hz, CH₂CH₂F), 64.4 (C-5); ¹³C-GATED NMR (101 MHz, CDCl₃): δ 99.7 (*J*_{C1,H1} = 170 Hz, C-1 α); HRMS: [M+Na]⁺ calcd for C₂₉H₃₁FO₆Na 517.19969, found 517.19888.



2,2-Difluoroethyl 2,3-di-O-benzyl-4,6-O-benzylidene-α/β-D-mannopyranoside (1D).


Donor **1** and 2,2-difluoroethanol were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations and purified by flash column chromatography (1/0 to 4/1 pentane/EtOAc) to yield glycosylation product **1D** (46.1 mg, 90 μmol, 90%, α:β = 1:5). R_f: 0.50 (9/1 pentane/EtOAc). IR (neat): 694, 744, 795, 1026, 1094, 1261, 1369, 1454, 2868; Data for the β-anomer: ¹H NMR (400 MHz, CDCl₃, HH-COSY, HSQC): δ 7.68 – 7.27 (m, 15H, CH_{arom}), 5.90 (dddd, 1H, *J* = 54.8, 5.1, 2.8, 1.5 Hz, CHF₂), 5.62 (s, 1H, *CHPh*), 4.94 (d, 1H, *J* = 12.2 Hz, *CHH* Bn), 4.86 (d, 1H, *J* = 12.2 Hz, *CHH* Bn), 4.70 (d, 1H, *J* = 12.5 Hz, *CHH* Bn), 4.60 (d, 1H, *J* = 12.4 Hz, *CHH* Bn), 4.51 (s, 1H, H-1), 4.31 (dd, 1H, *J* = 10.4, 4.9 Hz, H-6), 4.22 (t, 1H, *J* = 9.6 Hz, H-4), 4.05 (dtd, 1H, *J* = 20.7, 11.1, 2.9 Hz, *CHHCHF*₂), 3.98 – 3.88 (m, 2H, H-2, H-6), 3.82 – 3.65 (m, 1H, *CHHCHF*₂), 3.59 (dd, 1H, *J* = 9.9, 3.1 Hz, H-3), 3.33 (td, 1H, *J* = 9.7, 4.8 Hz, H-5); ¹³C-APT NMR (101 MHz, CDCl₃, HSQC): δ 138.3, 138.2, 137.5 (C_q), 128.8, 128.5, 128.3, 127.7, 126.2 (C_{arom}), 115.4 (t, *J* = 241.9, CHF₂), 102.3 (C-1), 101.6 (CHPh), 78.6 (C-4), 77.8 (C-3), 75.5 (C-2), 75.1 (CH₂ Bn), 72.6 (CH₂ Bn), 68.5 (t, *J* = 33.0 Hz, CH₂CHF₂), 68.5 (C-6), 67.8 (C-5); ¹³C-GATED NMR (101 MHz, CDCl₃): 102.3 (*J*_{C1,H1} = 156 Hz, C-1 β); Diagnostic peaks α-anomer: ¹H NMR (400 MHz, CDCl₃, HH-COSY, HSQC): δ 5.98 (dt, 0.03 H, *J* = 5.7, 4.1 Hz, CHF₂), 5.84 (dt, 0.10H, *J* = 5.9, 4.1 Hz, CHF₂), 5.70 (dt, 0.03H, *J* = 6.1, 4.1 Hz, CHF₂), 4.84 (m, 0.34H, C-1, *CHH* Bn), 4.72 (d, 0.17H, *J* = 12.1 Hz, *CHH* Bn), 4.66 (d, 0.17H, *J* = 12.2 Hz, *CHH* Bn); ¹³C-APT NMR (101 MHz, CDCl₃, HSQC): δ 115.4 (t, *J* = 240.10, CHF₂), 101.6 (CHPh), 100.1 (C-1), 79.0 (C-4), 76.3 (C-3), 76.2 (C-2), 73.9 (CH₂ Bn), 73.4 (CH₂ Bn), 68.5 (C-6), 64.8 (C-5); HRMS: [M+Na]⁺ calcd for C₂₉H₃₀F₂O₆Na 535.19027, found 535.18950.



2,2,2-Trifluoroethyl 2,3-di-O-benzyl-4,6-O-benzylidene-α/β-D-mannopyranoside (1E).


Donor **1** and 2,2,2-trifluoroethanol were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations and purified by flash column chromatography (1/0 to 9/1 pentane/EtOAc) to yield glycosylation product **1E** (41.7 mg, 79 μmol, 79%, α:β = 1:3.4). R_f: 0.60 (9/1 pentane/EtOAc). IR (neat): 696, 737, 1028, 1057, 1085, 1161, 1277, 1454, 2870; Data for the β-anomer: ¹H NMR (400 MHz, CDCl₃, HH-COSY, HSQC): δ 7.50 – 7.28 (m, 15H, CH_{arom}) 5.62 (s, 1H, *CHPh*), 4.96 (d, 1H, *J* = 12.2 Hz, *CHH* Bn), 4.87 (d, 1H, *J* = 12.1 Hz, *CHH* Bn), 4.69 (d, 1H, *J* = 12.5 Hz, *CHH* Bn), 4.59 (d, 1H, *J* = 12.5 Hz, *CHH* Bn), 4.57 (s, 1H, H-1), 4.31 (dd, 1H, *J* = 10.4, 4.9 Hz, C-6), 4.28 – 4.17 (m, 2H, C-4, *CHHCF*₃), 4.01 – 3.86 (m, 3H, H-2, H-6, *CHHCF*₃), 3.59 (dd, 1H, *J* = 9.9, 3.1 Hz, H-3), 3.34 (td, 1H, *J* = 9.8, 4.9 Hz, H-5); ¹³C-APT NMR (101 MHz, CDCl₃, HSQC): δ 138.2, 138.0, 137.5 (C_q), 129.1, 128.9, 128.5, 128.3, 127.9, 127.8, 127.7, 126.2 (C_{arom}), 123.7 (q, *J* = 277.6 Hz, CF₃) 101.9 (C-1), 101.6 (CHPh),

78.4 (C-4), 77.7 (C-3), 77.5 (C-2), 75.1 (CH₂ Bn), 75.0 (CH₂ Bn), 72.6 (C-6), 68.4 (C-5), 66.2 (q, *J* = 34.9 Hz, CH₂CF₃); ¹³C-GATED NMR (101 MHz, CDCl₃): 101.9 (*J*_{C1,H1} = 157 Hz, C-1 β); Diagnostic peaks α-anomer: ¹H NMR (400 MHz, CDCl₃, HH-COSY, HSQC): δ 5.64 (s, 0.29H, CHPh), 4.88 – 4.82 (m, 0.87H, CHH Bn, CHH Bn, H-1), 4.73 – 4.64 (m, 0.58H, CHH Bn, CHH Bn); ¹³C-APT NMR (101 MHz, CDCl₃, HSQC): δ 101.6 (CHPh), 100.1 (C-1), 78.9 (C-4), 76.2 (C-3), 76.0 (C-2), 74.1 (CH₂ Bn), 73.5 (CH₂ Bn), 68.7 (C-6), 65.0 (C-5); HRMS: [M+Na]⁺ calcd for C₂₉H₂₉F₃O₆Na 553.18084, found 553.18021.




1,1,1,3,3,3-Hexafluoro-2-propyl 2,3-di-O-benzyl-4,6-O-benzylidene-α/β-D-mannopyranoside (1F). Donor **1** and 1,1,1,3,3,3-hexafluoro-2-propanol were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (for an additional

120 hours at -40°C) and purified by flash column chromatography (1/0 to 9/1 pentane/EtOAc) to yield glycosylation product **1F** (33.6 mg, 34 μmol, 56%, α:β = 3.3:1). *R*_f: 0.81 (8/2 pentane/EtOAc). IR (neat): 694, 898, 977, 1058, 1091, 1195, 1217, 1287, 136, 2924; Data for the α-anomer: ¹H NMR (400 MHz, CDCl₃, HH-COSY, HSQC): δ 7.54 – 7.27 (m, 15H, CH_{arom}), 5.64 (s, 1H, CHPh), 4.95 (s, 1H, H-1), 4.86 (d, 1H, *J* = 5.5 Hz, CHH Bn), 4.82 (d, 1H, *J* = 8.9 Hz, CHH Bn), 4.69 (d, 1H, *J* = 2.8 Hz, CHH Bn), 4.65 (d, 1H, *J* = 7.7 Hz, CHH Bn), 4.38 – 4.19 (m, 3H, H-3, H-6, CH(CF₃)₂), 3.92 (d, 1H, *J* = 4.9 Hz, H-4), 3.89 – 3.83 (m, 2H, H-6, H-5); ¹³C-APT NMR (101 MHz, CDCl₃, HSQC): δ 138.5, 137.5, 137.4 (C_q), 129.1, 128.7, 128.5, 128.4, 128.3, 127.8, 127.7, 126.1 (CH_{arom}), 121.6 (q, *J* = 282.7 Hz, CF₃), 101.8 (C-1), 101.6 (CHPh), 78.4 (C-3), 76.1 (C-4), 75.5 (C-2), 74.3 (CH₂ Bn), 73.8 (CH₂ Bn), 72.4 (hept, *J* = 32.7 Hz, CH(CF₃)₂), 72.1 (CH₂ Bn), 68.3 (C-6), 65.8 (C-5); ¹³C-GATED NMR (101 MHz, CDCl₃): δ 101.8 (*J*_{C1,H1} = 175 Hz, C-1 α); Diagnostic peaks β-anomer: ¹H NMR (400 MHz, CDCl₃, HH-COSY, HSQC, HMBC): δ 5.61 (s, 0.30H, CHPh), 4.82 (d, 0.60H, *J* = 11.9 Hz, CHH Bn), 4.79 (s, 0.30H, H-1), 4.69 (d, 0.30H, *J* = 12.9 Hz, CHH Bn), 4.02 (d, 0.30H, *J* = 2.9 Hz, H-2), 3.61 (dd, 0.30H, *J* = 9.9, 3.1 Hz, H-3), 3.36 (td, 0.30H, *J* = 9.9, 4.9 Hz, H-5); ¹³C-APT NMR (101 MHz, CDCl₃, HSQC, HMBC): δ 101.3 (C-1), 72.6 (C-6), 68.2 (C-5); ¹³C HMBC-GATED NMR (101 MHz, CDCl₃): δ 101.3 (*J*_{C1,H1} = 159 Hz, C-1 β); HRMS: [M+Na]⁺ calcd for C₃₀H₂₈F₆O₆Na 621.16823, found 621.16790.




1-[²H]-1,5-anhydro-2,3-di-O-benzyl-4,6-O-benzylidene-α-D-mannitol (1G). Donor **1** and triethylsilane-D were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (for an additional 24 hours at -40°C) and purified by flash column

chromatography (19/1 to 3/1 pentane/Et₂O) to yield glycosylation product **42** (25.8 mg, 60 μmol, 60%, α:β = <1:20). *R*_f: 0.2 (4/1 pentane/Et₂O). Spectroscopic data of the non-deuterated mannitol were in accord with those previously reported.¹⁰⁷ [α]_D²² = -27.2° (*c* = 0.5, CHCl₃); IR (neat): 694, 733, 1092, 1119, 1452, 2349, 2866; Data for the β-anomer: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.54 – 7.48 (m, 2H, CH_{arom}), 7.44 – 7.26 (m, 13H, CH_{arom}), 5.65 (s, 1H, CHPh), 4.82 (d, 1H, *J* = 12.6 Hz, CHH Bn), 4.81 (d, 1H, *J* = 12.5 Hz, CHH Bn), 4.76 (d, 1H, *J* = 12.5 Hz, CHH Bn), 4.68 (d, 1H, *J* = 12.4 Hz, CHH Bn), 4.28 (dd, 1H, *J* = 11.2, 4.1 Hz, H-6), 4.25 (t, 1H, *J* = 10.1 Hz, H-4), 3.85 (t, 1H, *J* = 10.3 Hz, H-6), 3.79 (d, 1H, *J* = 3.3 Hz, H-2), 3.68 (dd, 1H, *J* = 9.8, 3.3 Hz, H-3), 3.42 (s, 1H, H-1), 3.34 (td, 1H, *J* = 9.7, 4.9 Hz, H-5); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 138.6, 138.3, 137.8 (C_q), 128.9, 128.5, 128.4, 128.3, 128.2, 127.9, 127.7, 127.7, 126.1 (CH_{arom}), 101.5 (CHPh), 79.4 (C-4), 78.6 (C-3), 74.4 (C-2), 72.7 (CH₂ Bn), 72.5 (C-5), 72.4 (CH₂ Bn), 68.8 (t, *J* = 22 Hz, C-1), 68.7 (C-6); ²H NMR (CHCl₃, 77 MHz): δ 4.08 (D-1); HRMS: [M+H]⁺ calcd for C₂₇H₂₈DO₅ 434.20723, found 434.20691.




Allyl 2,3-di-O-benzyl-4,6-O-benzylidene-1-deoxy-β-D-mannopyranose (1H). Donor **1** and allyl trimethylsilane were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (for an additional 96 hours at -40°C) and purified by flash column

chromatography (1/0 to 9/1 pentane/EtOAc) to yield glycosylation product **1H** (20.7 mg, 44 μmol, 44%, α:β = <1:20). *R*_f: 0.80 (9/1 pentane/EtOAc). Spectroscopic data were in accord with those previously reported.⁷² [α]_D²⁶ = -19.6° (*c* = 0.5, CHCl₃); IR (neat): 696, 1028, 1097, 1454, 2860, 2924; Data for the β-anomer: ¹H NMR (400 MHz, CDCl₃, HH-COSY, HSQC, NOESY): δ 7.52 – 7.26 (m, 15H, CH_{arom}), 5.76 – 5.59 (m, 1H, CHCH₂ allyl), 5.64 (s, 1H, CHPh), 5.11 – 4.98 (m, 3H, CHH Bn, CHCH₂ allyl), 4.92 (d, 1H, *J* = 12.3 Hz, CHH Bn), 4.76 (d, 1H, *J* = 12.3 Hz, CHH Bn), 4.69 (d, 1H, *J* = 11.4 Hz, CHH Bn), 4.35 – 4.16 (m, 2H, H-4, H-6), 3.84 (t, 1H, *J* = 10.3 Hz, H-6), 3.80 (d, 1H, *J* = 2.2 Hz, H-2), 3.73 (dd, 1H, *J* = 9.8, 2.9 Hz, H-3), 3.45 (t, 1H, *J* = 6.8 Hz, H-1), 3.38 (td, 1H, *J* = 9.8, 4.9 Hz, H-5), 2.46 (dt, 1H, *J* = 13.5, 6.7 Hz, CHHCH allylic), 2.25 (dt, 1H, *J* = 14.3, 7.2 Hz, CHHCH allylic); ¹³C-APT NMR (101 MHz, CDCl₃, HSQC, HMBC): δ 138.8, 138.6, 137.9 (C_q), 134.4 (CHCH₂ allyl), 128.9, 128.6, 128.5, 128.4, 128.3, 127.8, 127.7, 127.7, 126.2 (CH_{arom}), 117.6 (CHCH₂ allyl), 101.5 (CHPh), 80.9 (C-3), 79.8 (C-1), 79.7 (C-4), 76.6 (C-2), 75.1 (CH₂ Bn), 73.3 (CH₂ Bn), 72.1 (C-5), 68.8 (C-6), 35.6 (CH₂CH allylic); HRMS: [M+H]⁺ calcd for C₃₀H₃₃O₅ 473.23225, found 473.23219.




Methyl 6-O-(2,3-di-O-benzyl-4,6-O-benzylidene- α - β -D-mannopyranosyl)-2,3,4-tri-O-benzyl- α -D-glucopyranoside (20). Donor **1** and acceptor **10** were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (for an additional 16 hours at -40°C) and purified by flash column chromatography (9/1 to 7/3 pentane/EtOAc) to yield glycosylation product **20** (86.6 mg, 97 μ mol, 97%, α : β = 1:10).

R_f: 0.67 (7/3 pentane/EtOAc). Spectroscopic data were in accord with those previously reported.^{105,108,109} [α]_D²⁶ +5.2° (*c* = 1, CHCl₃, 546 nm), [α]_D²⁶ 0.0° (*c* = 1, CHCl₃, 589 nm), (lit.:¹⁰⁸ [α]_D²⁰ = -1.7° (*c* = 1.8, CHCl₃), lit.:¹⁰⁵ [α]_D²⁷ = -5.8° (*c* = 0.94, CHCl₃)); IR (neat): 731, 1026, 1049, 1084, 1452, 2872; Data for the β -anomer: ¹H NMR (400 MHz, CDCl₃, HH-COSY, HSQC): δ 7.58 – 7.05 (m, 30H, CH_{arom}), 5.59 (s, 1H, CHPh), 5.03 (d, 1H, *J* = 10.9 Hz, CHH Bn), 4.92 (d, 1H, *J* = 12.3 Hz, CHH Bn), 4.86 – 4.76 (m, 4H, CHH Bn, CHH Bn, CHH Bn, CHH Bn), 4.72 (d, 1H, *J* = 12.5 Hz, CHH Bn), 4.67 (d, 1H, *J* = 12.2 Hz, CHH Bn), 4.61 (d, 1H, *J* = 12.6 Hz, CHH Bn), 4.58 (d, 1H, *J* = 3.5 Hz, H-1), 4.50 (d, 1H, *J* = 11.6 Hz, CHH Bn), 4.25 (dd, 1H, *J* = 10.4, 4.8 Hz, H-6'), 4.18 (t, 1H, *J* = 9.6 Hz, H-4'), 4.08 (m, 2H, H-1', H-6), 4.02 (t, 1H, *J* = 9.3 Hz, H-4), 3.91 (t, 1H, *J* = 10.3 Hz, H-6'), 3.80 – 3.72 (m, 1H, H-2), 3.69 (d, 1H, *J* = 2.9 Hz, H-2'), 3.47 (m, 4H, H-3, H-3', H-5, H-6), 3.33 (s, 3H, CH₃ OMe), 3.22 (td, 1H, *J* = 9.8, 4.8 Hz, H-5'); ¹³C-APT NMR (101 MHz, CDCl₃): δ 138.9, 138.5, 138.5, 138.5, 138.1, 137.7 (C_q), 129.0, 128.7, 128.6, 128.5, 128.5, 128.5, 128.3, 128.3, 128.2, 128.1, 128.1, 127.8, 127.8, 127.7, 126.1 (CH_{arom}), 102.1 (H-1'), 101.5 (CHPh), 97.9 (C-1), 82.3 (C-4), 79.9 (C-3), 78.8 (C-4), 77.9 (C-3'), 76.8 (C-5), 75.8 (CH₂ Bn), 75.7 (C-2'), 74.8 (CH₂ Bn), 74.6 (CH₂ Bn), 73.5 (CH₂ Bn), 72.6 (CH₂ Bn), 69.7 (C-2), 68.7 (C-6'), 68.3 (C-6), 67.7 (C-5'), 55.2 (CH₃ OMe); HRMS: [M+Na]⁺ calcd for C₅₅H₅₈O₁₁Na 917.38713, found 917.38729.




Methyl 4-O-(2,3-di-O-benzyl-4,6-O-benzylidene- α - β -D-mannopyranosyl)-2,3,6-tri-O-benzyl- α -D-glucopyranoside (21). Donor **1** and acceptor **11** were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (for an additional 16 hours at -40°C) and purified by flash column chromatography (9/1 to 7/3 pentane/EtOAc) to yield glycosylation product **21** (67.4 mg, 75 μ mol, 75%, α : β = 1:9). R_f: 0.67 (7/3 pentane/EtOAc).

Spectroscopic data were in accord with those previously reported.^{105,108–110} [α]_D²⁵ –15.5° (*c* = 0.8, CHCl₃); IR (neat): 735, 1028, 1083, 1452, 2862; Data for the β -anomer: ¹H NMR (400 MHz, CDCl₃, HH-COSY, HSQC): δ 7.46 – 7.21 (m, 25H, CH_{arom}), 5.51 (s, 1H, CHPh), 5.05 (d, 1H, *J* = 10.6 Hz, CHH Bn), 4.84 – 4.70 (m, 5H, CHH Bn, CHH Bn, CHH Bn, CHH Bn, CHH Bn), 4.70 – 4.52 (m, 4H, CHH Bn, CHH Bn, CHH Bn, H-1), 4.36 (s, 1H, H-1'), 4.28 (d, 1H, *J* = 12.1 Hz, CHH Bn), 4.12 – 4.01 (m, 2H, H-4', H-6), 3.94 – 3.81 (m, 2H, H-3, H-4), 3.63 (d, 1H, *J* = 2.9 Hz, H-2'), 3.62 – 3.47 (m, 4H, H-5, H-2, H-6, H-6', H-6'), 3.47, 3.40 (s, 3H, CH₃ OMe), 3.32 (dd, 1H, *J* = 9.8, 3.0 Hz, H-3'), 3.05 (td, 1H, *J* = 9.7, 4.8 Hz, H-5'); ¹³C-APT NMR (101 MHz, CDCl₃, HSQC): δ 139.5, 138.8, 138.7, 138.4, 137.8, 137.6 (C_q), 128.9, 128.7, 128.6, 128.5, 128.5, 128.4, 128.3, 128.2, 128.1, 127.9, 127.8, 127.6, 127.6, 127.4, 127.3, 126.2 (CH_{arom}), 101.7 (C-1'), 101.4 (CHPh), 98.5 (C-1), 80.4 (C-4), 79.1 (C-2), 78.8 (C-4'), 78.4 (C-3'), 77.8 (C-3), 77.1 (C-2), 75.4 (CH₂ Bn), 75.1 (CH₂ Bn), 73.8 (CH₂ Bn), 73.7 (CH₂ Bn), 72.6 (CH₂ Bn), 69.7 (C-5), 68.7 (C-6), 68.4 (C-6'), 67.4 (C-5), 55.5 (CH₃ OMe); ¹³C-GATED NMR (101 MHz, CDCl₃): 101.7 (*J*_{C1,H1} = 156 Hz, C-1 β); Diagnostic peaks α -anomer: ¹H NMR (400 MHz, CDCl₃, HH-COSY, HSQC): δ 5.60 (s, 0.11H, CHPh), 5.30 (d, 0.11H, *J* = 1.3 Hz, C-1'); ¹³C-APT NMR (101 MHz, CDCl₃, HSQC): δ 101.5 (C-1'), 101.4 (CHPh); HRMS: [M+Na]⁺ calcd for C₅₅H₅₈O₁₁Na 917.38713, found 917.38706.




Methyl (methyl [4-O-(2,3-di-O-benzyl-4,6-O-benzylidene- α - β -D-mannopyranosyl)]-2,3-di-O-benzyl- α -D-glucopyranosyl uronate) (22). Donor **1** and acceptor **12** were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (for an additional 48 hours at -40°C) and purified by flash column chromatography


(9/1 to 7/3 pentane/EtOAc) to yield glycosylation product **22** (72.8 mg, 87 μ mol, 87%, α : β = 1:10). R_f: 0.65 (7/3 pentane/EtOAc); [α]_D²⁶ = -19.2° (*c* = 1, CHCl₃); IR (neat): 735, 1045, 1084, 1454, 1748, 2866; Data for the β -anomer: ¹H NMR (400 MHz, CDCl₃, HH-COSY, HSQC): δ 7.55 – 7.24 (m, 25H, CH_{arom}), 5.54 (s, 1H, CHPh), 5.06 (d, 1H, *J* = 10.6 Hz, CHH Bn), 4.88 – 4.71 (m, 5H, CHH Bn, CHH Bn, CHH Bn, CHH Bn, CHH Bn), 4.67 – 4.53 (m, 4H, CHH Bn, CHH Bn, H-1), 4.45 (s, 1H, H-1), 4.17 – 4.01 (m, 3H, H-4, H-4', H-6'), 3.95 – 3.85 (m, 2H, H-3, H-5), 3.82 – 3.75 (m, 1H, H-2'), 3.65 – 3.55 (m, 4H, H-6, H-6', CH₃ CO₂Me), 3.55 – 3.47 (m, 2H, H-2, H-3'), 3.44 (s, 3H, CH₃ OMe), 3.19 (td, 1H, *J* = 9.6, 4.8 Hz, H-5'); ¹³C-APT NMR (101 MHz, CDCl₃, HSQC): δ 170.2 (C=O CO₂Me), 139.2, 138.7, 138.5, 138.1, 137.7 (C_q), 128.6, 128.5, 128.4, 128.3, 128.2, 128.2, 128.1, 127.7, 127.7, 127.6, 127.4, 126.2 (CH_{arom}), 102.5 (H-1'), 101.5 (CHPh), 98.9 (C-1), 80.2 (C-3/C-5), 79.8 (C-3/C-5), 78.7 (C-4'), 78.5 (H-2, H-3'), 77.9 (C-2'), 77.2 (CH₂ Bn), 75.6 (CH₂ Bn), 75.2 (CH₂ Bn), 74.0 (CH₂ Bn), 72.7 (CH₂ Bn), 69.7 (C-6), 68.6 (C-6'), 67.7 (C-5'), 56.0 (CH₃ CO₂Me), 52.5 (CH₃ OMe); ¹³C-GATED NMR (101 MHz, CDCl₃): δ 102.5 (*J*_{C1,H1} = 157 Hz, C-1 β); Diagnostic peaks α -anomer: ¹H NMR (400 MHz, CDCl₃, HH-COSY, HSQC): δ 5.58 (s, 0.10H, CHPh), 5.27 (s, 0.10H, H-1'), 4.98 (d, 0.10H, *J* = 11.4 Hz, CHH Bn), 4.31 (d, 0.10H, *J* = 11.9 Hz, CHH Bn); ¹³C-APT NMR (101 MHz, CDCl₃): δ 101.54 (CHPh), 100.45 (C-1'), 98.63 (C-1); HRMS: [M+Na]⁺ calcd for C₄₉H₅₂O₁₂Na 855.33510, found 855.33507.




Methyl 4-O-(2,3-di-O-benzyl-4,6-O-benzylidene- β -D-mannopyranosyl)-2,3,6-tri-O-benzyl- β -D-galactopyranoside (23). Donor **1** and acceptor **13** were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (for an additional 16 hours at -40°C) and purified by flash column chromatography (9/1 to 7/3 pentane/EtOAc) to yield glycosylation product **23** (62.7 mg, 70 μ mol, 70%, α : β = <1:20). R_f: 0.80 (7/3 pentane/EtOAc); [α]_D²⁶ = -26.8° (*c* = 1, CHCl₃); IR (neat): 737, 1072, 1454, 2866; Data for the β -anomer: ¹H NMR (400 MHz, CDCl₃, HH-COSY, HSQC): δ 7.46 – 7.14 (m, 30H, CH_{arom}), 5.59 (s, 1H, CHPh), 4.96 (d, 1H, *J* = 12.4 Hz, CHH Bn), 4.91 (d, 1H, *J* = 11.0 Hz, CHH Bn), 4.86 (d, 1H, *J* = 12.4 Hz, CHH Bn), 4.79 (s, 1H, H-1'), 4.78 (d, 1H, *J* = 11.6 Hz, CHH Bn), 4.68 (d, 1H, *J* = 11.0 Hz, CHH Bn), 4.62 – 4.47 (m, 5H, CHH Bn, CHH Bn, CHH Bn, CHH Bn, CHH Bn), 4.31 (d, 1H, *J* = 7.7 Hz, H-1), 4.21 – 4.09 (m, 3H, H-4', H-6'), 4.01 (d, 1H, *J* = 3.0 Hz, H-2'), 3.90 – 3.81 (m, 2H, H-6, H-6'), 3.72 (dd, 1H, *J* = 9.8, 5.7 Hz, H-6), 3.67 (dd, 1H, *J* = 9.6, 7.7 Hz, H-2), 3.63 – 3.55 (m, 4H, H-5, CH₃ OMe), 3.52 (dd, 1H, *J* = 9.6, 3.0 Hz, H-3), 3.40 (dd, 1H, *J* = 9.9, 3.1 Hz, H-3'), 3.18 (td, 1H, *J* = 9.8, 4.9 Hz, H-5); ¹³C-APT NMR (101 MHz, CDCl₃, HSQC): δ 138.9, 138.8, 138.5, 138.4, 138.2, 137.6 (C_q), 129.0, 128.7, 128.7, 128.5, 128.4, 128.4, 128.3, 128.3, 128.2, 128.0, 127.8, 127.7, 127.6, 127.6, 127.5, 126.1 (CH_{arom}), 105.1 (C-1), 102.6 (C-1'), 101.4 (CHPh), 81.8 (H-3), 79.5 (H-2), 78.5 (C-3'), 78.5 (C-4'), 75.4 (C-2'), 75.1 (CH₂ Bn), 74.7 (CH₂ Bn), 73.7 (CH₂ Bn), 73.6 (H-5), 73.6 (CH₂ Bn), 73.3 (C-4), 72.2 (CH₂ Bn), 69.5 (C-6), 68.7 (C-6'), 67.8 (C-5), 57.2 (CH₃ OMe); ¹³C-GATED NMR (101 MHz, CDCl₃): δ 102.6 (*J*_{C1,H1} = 159 Hz, C-1 β); HRMS: [M+Na]⁺ calcd for C₅₅H₅₈O₁₁Na 917.38713, found 917.38696.



Methyl 2-O-(2,3-di-O-benzyl-4,6-O-benzylidene- β -D-mannopyranosyl)-3-O-benzyl-4,6-O-benzylidene- α -D-mannopyranoside (24). Donor **1** and acceptor **14** were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (for an additional 16 hours at -40°C) and purified by flash column chromatography (9/1 to 7/3 pentane/EtOAc) to yield glycosylation product **24** (70.2 mg, 87 μ mol, 87%, α : β = <1:20). R_f: 0.68 (7/3 pentane/EtOAc). Spectroscopic data were in accord with those previously reported.^{108–111} [α]_D²⁶ –44.4° (*c* = 1, CHCl₃); (lit.¹¹⁰ [α]_D²⁵ = –44.2° (*c* = 4.2, CHCl₃), lit.¹¹¹ [α]_D²⁰ = –44.8° (*c* = 3.9, CHCl₃)); IR (neat): 733, 1002, 1028, 1055, 1083, 1452, 2862; Data for the β -anomer: ¹H NMR (400 MHz, CDCl₃, HH-COSY, HSQC): δ 7.53 – 7.16 (m, 25H, CH_{arom}), 5.60 (s, 1H, CHPh), 5.51 (s, 1H, CHPh), 5.06 (d, 1H, *J* = 12.3 Hz, CHH Bn), 4.97 (d, 1H, *J* = 12.3 Hz, CHH Bn), 4.81 – 4.56 (m, 6H, CHH Bn, CHH Bn, CHH Bn, CHH Bn, H-1, H-1'), 4.30 – 4.18 (m, 4H, H-2, H-4', H-6, H-6'), 4.10 (t, 1H, *J* = 9.2 Hz, H-4), 3.98 (d, 1H, *J* = 2.8 Hz, H-2'), 3.94 (dd, 1H, *J* = 10.0, 3.2 Hz, H-3) 3.88 (t, 1H, *J* = 10.3 Hz, H-6'), 3.78 (m, 2H, H-5, H-6), 3.59 (dd, 1H, *J* = 9.9, 3.0 Hz, H-3'), 3.46 – 3.21 (m, 4H, H-5', CH₃ OMe); ¹³C-APT NMR (101 MHz, CDCl₃, HSQC): δ 139.0, 138.7, 138.5, 137.7, 137.7 (C_q), 129.0, 128.7, 128.4, 128.3, 128.3, 128.2, 127.7, 127.6, 127.6, 127.4, 126.2, 126.2 (CH_{arom}), 101.7 (CHPh), 101.5 (CHPh), 101.0 (C-1'), 99.6 (C-1), 78.8 (C-4), 78.6 (H-4'), 77.8 (C-3'), 76.1 (C-2'), 75.3 (H-2), 74.7 (H-3), 74.2 (CH₂ Bn), 72.4 (CH₂ Bn), 71.5 (CH₂ Bn), 69.1 (C-6), 68.7 (C-6'), 67.9 (C-5'), 64.2 (C-5), 55.1 (CH₃ OMe); ¹³C-GATED NMR (101 MHz, CDCl₃): δ 101.0 (*J*_{C1,H1} = 154 Hz, C-1' β); HRMS: [M+Na]⁺ calcd for C₄₈H₅₀O₁₁Na 825.32453, found 825.32425.




Cyclohexyl 2,3-di-O-benzyl-4,6-O-benzylidene- α / β -D-glucopyranoside (2A). Donor **2** and cyclohexanol were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations and purified by flash column chromatography (1/0 to 0/1 pentane/toluene to 6% EtOAc in toluene) to yield glycosylation product **2A** (37.8 mg, 71 μ mol, 71%, α : β = 1:5). R_f: 0.22 (toluene). Spectroscopic data were in accord with those previously reported.⁶⁵ IR (neat): 696, 735, 746, 997, 1028, 1049, 1072, 1366, 1452, 1497, 2857, 2930; Data for the β -anomer: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.51 – 7.46 (m, 2H, CH_{arom}), 7.41 – 7.24 (m, 13H, CH_{arom}), 5.56 (s, 1H, CHPh), 4.94 (d, 1H, *J* = 10.8 Hz, CHH Bn), 4.90 (d, 1H, *J* = 11.1 Hz, CHH Bn), 4.79 (d, 1H, *J* = 11.5 Hz, CHH Bn), 4.76 (d, 1H, *J* = 10.9 Hz, CHH Bn), 4.62 (d, 1H, *J* = 7.7 Hz, H-1), 4.33 (dd, 1H, *J* = 10.5, 5.0 Hz, H-6), 3.79 (t, 1H, *J* = 10.3 Hz, H-6), 3.76 – 3.65 (m, 3H, CH Cy, H-3, H-4), 3.46 (t, 1H, *J* = 8.1 Hz, H-2), 3.39 (td, 1H, *J* = 9.5, 5.0 Hz, H-5), 2.00 – 1.91 (m, 2H, CH₂ Cy), 1.82 – 1.72 (m, 2H, CH₂ Cy), 1.59 – 1.18 (m, 6H, CH₂ Cy); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 138.7, 138.6, 137.5 (C_q), 129.0, 128.4, 128.4, 128.3, 128.3, 128.1, 127.8, 127.7, 126.1 (CH_{arom}), 102.5 (C-1), 101.2 (CHPh), 82.3 (C-2), 81.6, 81.2 (C-3, C-4), 78.3 (CH Cy), 75.5, 75.2 (CH₂ Bn), 69.0 (C-6), 66.1 (C-5), 33.9, 32.1, 25.7, 24.2, 24.1 (CH₂ Cy); Diagnostic peaks α -anomer: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 4.69 (d, 1H, *J* = 12.1 Hz, CHH Bn), 4.26 (dd, 1H, *J* = 10.2, 4.9 Hz, H-6), 4.07 (t, 1H, *J* = 9.3 Hz, H-3), 3.96 (td, 1H, *J* = 10.0, 4.9 Hz, H-5), 3.61 (t, 1H, *J* = 9.4 Hz, H-4), 3.58 – 3.50 (m, 2H, CH Cy, H-2); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 101.3 (CHPh), 96.1 (C-1), 82.5 (C-4), 79.5 (C-2) 78.8 (C-3), 76.1 (CH Cy), 75.4, 73.4 (CH₂ Bn), 69.2 (C-6), 62.6 (C-5); HRMS: [M+H]⁺ calcd for C₃₃H₃₉O₆ 531.27412, found 531.27400.




Ethyl 2,3-di-O-benzyl-4,6-O-benzylidene- α / β -D-glucopyranoside (2B). Donor **2** and ethanol were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations and

purified by flash column chromatography (1/1 to 0/1 pentane/toluene to 6% EtOAc in toluene) to yield glycosylation product **2B** (32.2 mg, 68 μmol , 68%, $\alpha:\beta = 1:10$). R_f : 0.43 (6% EtOAc in toluene). IR (neat): 692, 743, 1006, 1028, 1183, 1364, 1453, 2872; Data for the β -anomer: $^1\text{H NMR}$ (CDCl_3 , 400 MHz, HH-COSY, HSQC): δ 7.52 – 7.46 (m, 2H, CH_{arom}), 7.41 – 7.24 (m, 13H, CH_{arom}), 5.56 (s, 1H, CHPh), 4.93 – 4.88 (m, 2H, 2xCHH Bn), 4.83 – 4.74 (m, 2H, 2xCHH Bn), 4.51 (d, 1H, $J = 7.7$ Hz, H-1), 4.34 (dd, 1H, $J = 10.5$, 5.0 Hz, H-6), 3.97 (dq, 1H, $J = 9.6$, 7.1 Hz, CHH Et), 3.79 (t, 1H, $J = 9.5$ Hz, H-6), 3.76 – 3.63 (m, 3H, H-3, H-4, CHH Et), 3.46 (t, 1H, $J = 8.1$ Hz, H-2), 3.40 (ddd, 1H, $J = 10.0$, 9.0, 5.0 Hz, H-5), 1.29 (t, 3H, $J = 7.0$ Hz, CH_3 Et); $^{13}\text{C-APT NMR}$ (CDCl_3 , 101 MHz, HSQC): δ 138.7, 138.6, 137.5 (C_q), 129.0, 128.5, 128.4, 128.4, 128.2, 128.1, 127.8, 127.7, 126.1 (CH_{arom}), 104.1 (C-1), 101.3 (CHPh), 82.3 (C-2), 81.7 (C-4), 81.0 (C-3), 75.5, 75.2 (CH_2 Bn), 69.0 (C-6), 66.2 (CH_2 Et), 66.2 (C-5), 15.5 (CH_3 Et); Diagnostic peaks α -anomer: $^1\text{H NMR}$ (CDCl_3 , 400 MHz, HH-COSY, HSQC): δ 5.55 (s, 1H, CHPh), 4.92 (d, 1H, $J = 11.2$ Hz, CHH Bn), 4.86 – 4.83 (m, 2H, CHH Bn , CHH Bn), 4.73 (d, 1H, $J = 3.8$ Hz, H-1), 4.68 (d, 1H, $J = 12.2$ Hz, CHH Bn), 4.25 (dd, 1H, $J = 10.2$, 4.8 Hz, H-6), 4.06 (t, 1H, $J = 9.3$ Hz, H-3), 3.88 (td, 1H, $J = 10.0$, 4.8 Hz, H-5), 3.63 – 3.60 (m, 1H, H-4), 3.59 – 3.52 (m, 2H, H-2, CHH Et); $^{13}\text{C-APT NMR}$ (CDCl_3 , 101 MHz, HSQC): δ 101.3 (CHPh), 97.9 (C-1), 82.4 (C-4), 79.5 (C-2), 78.8 (C-3), 73.7 (CH_2 Bn), 69.2 (C-6), 63.8 (CH_2 Et), 62.5 (C-5); HRMS: $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{29}\text{H}_{33}\text{O}_6$ 477.22717, found 477.22699.




2-Fluoroethyl 2,3-di-O-benzyl-4,6-O-benzylidene- α/β -D-glucopyranoside (**2C**). Donor **2**

and 2-fluoroethanol were condensed using the general procedure for $\text{Ti}_2\text{O}/\text{Ph}_2\text{SO}$ mediated glycosylations and purified by flash column chromatography (1/1 to 0/1 pentane/toluene to 6% EtOAc in toluene) to yield glycosylation product **2C** (34.7 mg, 70 μmol , 70%, $\alpha:\beta = 1:3$). R_f : 0.30 and 0.34 (4% EtOAc in toluene). IR (neat): 695, 744, 1000, 1028, 1072, 1085, 1177, 1452, 2868. Reported as a 0.33 : 1.00 mixture of anomers: $^1\text{H NMR}$ (CDCl_3 , 400 MHz, HH-COSY, HSQC): δ 7.52 – 7.44 (m, 2.66H, CH_{arom}), 7.42 – 7.24 (m, 17.29H, CH_{arom}), 5.56 (s, 1H, CHPh), 5.55 (s, 0.33H, CHPh_α), 4.92 (dd, 2.33H, $J = 11.1$, 3.4 Hz, 2xCHH Bn_β , CHH Bn_α), 4.87 – 4.73 (m, 2.99H, 2xCHH Bn_β , CHH Bn_α , CHH Bn_α , CHH Bn_α , H-1 α), 4.72 – 4.60 (m, 1.66H, CHH Bn_α , $\text{CHH-CH}_2\text{F}_\alpha$, $\text{CHH-CH}_2\text{F}_\beta$), 4.59 – 4.49 (m, 2.33H, $\text{CHH-CH}_2\text{F}_\alpha$, $\text{CHH-CH}_2\text{F}_\beta$, H-1 β), 4.34 (dd, 1H, $J = 10.5$, 5.0 Hz, H-6 β), 4.26 (dd, 0.33H, $J = 10.2$, 4.9 Hz, H-6 α), 4.13 (ddd, 0.50H, $J = 12.1$, 4.7, 2.6 Hz, CHHF_β), 4.10 – 4.02 (m, 0.83H, CHHF_β , H-3 α), 3.94 – 3.66 (m, 5.32H, CHHF_β , $\text{CH}_2\text{F}_\alpha$, H-3 β , H-4 β , H-5 α , H-6 α , H-6 β), 3.61 (t, 0.33H, $J = 9.4$ Hz, H-4 α), 3.58 (dd, 0.33H, $J = 9.3$, 3.8 Hz, H-2 α), 3.50 (t, 1H, $J = 8.1$ Hz, H-2 β), 3.41 (ddd, 1H, $J = 10.0$, 9.0, 5.0 Hz, H-5 β); $^{13}\text{C-APT NMR}$ (CDCl_3 , 101 MHz, HSQC): δ 138.9, 138.6, 138.4, 138.3, 137.5, 137.4 (C_q), 129.1, 129.0, 128.6, 128.5, 128.4, 128.4, 128.3, 128.2, 128.1, 128.1, 128.0, 127.7, 126.1 (CH_{arom}), 104.4 (C-1 β), 101.4 (CHPh_α), 101.3 (CHPh_β), 98.4 (C-1 α), 82.7 (d, $J = 170.2$ Hz, $\text{CH}_2\text{F}_\alpha$), 82.6 (d, $J = 170.2$ Hz, $\text{CH}_2\text{F}_\beta$), 82.2 (C-4 α), 82.1 (C-2 β), 81.5 (C-4 β), 80.9 (C-3 β), 79.4 (C-2 α), 78.6 (C-3 α), 75.5 (CH_2 Bn α,β), 75.2 (CH_2 Bn β), 73.7 (CH_2 Bn α), 69.4 (d, $J = 20.0$ Hz, $\text{CH}_2\text{-CH}_2\text{F}_\beta$), 69.1 (C-6 α), 68.8 (C-6), 67.3 (d, $J = 20.2$ Hz, $\text{CH}_2\text{-CH}_2\text{F}_\alpha$), 66.2 (C-5 β), 62.6 (C-5 α); HRMS: $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{29}\text{H}_{32}\text{FO}_6$ 495.21774, found 495.21745.



2,2-Difluoroethyl 2,3-di-O-benzyl-4,6-O-benzylidene- α/β -D-glucopyranoside (**2D**). Donor **2**


and 2,2-difluoroethanol were condensed using the general procedure for $\text{Ti}_2\text{O}/\text{Ph}_2\text{SO}$ mediated glycosylations and purified by flash column chromatography (1/1 to 0/1 pentane/toluene to 6% EtOAc in toluene) to yield glycosylation product **2D** (36 mg, 70 μmol , 70%, $\alpha:\beta = 5:1$). R_f : 0.32 and 0.36 (4% EtOAc in toluene). IR (neat): 696, 747, 996, 1028, 1071, 1086, 1369, 1453, 2865. Data for the α -anomer: $^1\text{H NMR}$ (CDCl_3 , 400 MHz, HH-COSY, HSQC): δ 7.48 (m, 2H, CH_{arom}), 7.41 – 7.26 (m, 13H, CH_{arom}), 5.95 (tt, 1H, $J = 55.4$, 4.2 Hz, CHF_2), 5.55 (s, 1H, CHPh), 4.92 (d, 1H, $J = 11.3$ Hz, CHH Bn), 4.84 (d, 1H, $J = 12.0$ Hz, CHH Bn), 4.83 (d, 1H, $J = 11.4$ Hz, CHH Bn), 4.75 (d, 1H, $J = 3.9$ Hz, H-1), 4.66 (d, 1H, $J = 12.0$ Hz, CHH Bn), 4.25 (dd, 1H, $J = 10.2$, 4.8 Hz, H-6), 4.03 (t, 1H, $J = 9.3$ Hz, H-3), 3.90 – 3.65 (m, 4H, $\text{CH}_2\text{-CHF}_2$, H-5, H-6), 3.62 (t, 1H, $J = 9.4$ Hz, H-4), 3.58 (dd, 1H, $J = 9.3$, 3.8 Hz, H-2); $^{13}\text{C-APT NMR}$ (CDCl_3 , 101 MHz, HSQC): δ 138.8, 138.2, 137.4 (C_q), 129.1, 128.6, 128.4, 128.4, 128.2, 128.1, 127.7, 126.1 (CH_{arom}), 114.2 (t, $J = 241.5$ Hz, CHF_2), 101.4 (CHPh), 98.9 (C-1), 82.0 (C-4), 79.3 (C-2), 78.4 (C-3), 75.5, 74.0 (CH_2 Bn), 69.0 (C-6), 67.4 (t, $J = 28.8$ Hz, $\text{CH}_2\text{-CHF}_2$), 63.0 (C-5); Diagnostic peaks β -anomer: $^1\text{H NMR}$ (CDCl_3 , 400 MHz, HH-COSY, HSQC): δ 5.90 (tdd, 1H, $J = 55.4$, 5.0, 3.4 Hz, CHF_2), 5.56 (s, 1H, CHPh), 4.54 (d, 1H, $J = 7.6$ Hz, H-1), 4.34 (dd, 1H, $J = 10.5$, 5.0 Hz, H-6), 3.48 (t, 1H, $J = 8.1$ Hz, H-2), 3.41 (td, 1H, $J = 9.6$, 5.0 Hz, H-5); $^{13}\text{C-APT NMR}$ (CDCl_3 , 101 MHz, HSQC): δ 104.5 (C-1), 101.3 (CHPh), 81.9 (C-2), 81.4, 80.8 (C-3, C-4), 75.6, 75.3 (CH_2 Bn), 68.7 (C-6), 66.3 (C-5); HRMS: $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{29}\text{H}_{31}\text{F}_2\text{O}_6$ 513.20832, found 513.20808.




2,2,2-Trifluoroethyl 2,3-di-O-benzyl-4,6-O-benzylidene- α -D-glucopyranoside (**2E**). Donor **2**

and 2,2,2-trifluoroethanol were condensed using the general procedure for $\text{Ti}_2\text{O}/\text{Ph}_2\text{SO}$ mediated glycosylations and purified by flash column chromatography (1/1 to 0/1 pentane/toluene to 6% EtOAc in toluene) to yield glycosylation product **2E** (33.7 mg, 64 μmol , 64%, $\alpha:\beta = >20:1$). R_f : 0.45 (4% EtOAc in toluene). $[\alpha]_D^{23} = +7.0^\circ$ ($c = 0.67$, DCM); IR (neat): 697, 747, 1001, 1029, 1077, 1161, 1279, 1373, 1454, 2864; Data for the α -anomer: $^1\text{H NMR}$ (CDCl_3 , 400 MHz, HH-COSY, HSQC): δ 7.51 – 7.46 (m, 2H, CH_{arom}), 7.41 –


7.26 (m, 13H, CH_{arom}), 5.55 (s, 1H, CHPh), 4.92 (d, 1H, *J* = 11.2 Hz, CHH Bn), 4.84 (d, 1H, *J* = 12.0 Hz, CHH Bn), 4.83 (d, 1H, *J* = 11.3 Hz, CHH Bn), 4.80 (d, 1H, *J* = 3.9 Hz, H-1), 4.67 (d, 1H, *J* = 12.0 Hz, CHH Bn), 4.25 (dd, 1H, *J* = 10.2, 4.8 Hz, H-6), 4.05 (t, 1H, *J* = 9.3 Hz, H-3), 3.92 (q, 2H, *J* = 8.7 Hz, CH₂-CF₃), 3.85 (td, 1H, *J* = 9.9, 4.8 Hz, H-5), 3.70 (t, 1H, *J* = 10.3 Hz, H-6), 3.63 (t, 1H, *J* = 9.4 Hz, H-4), 3.59 (dd, 1H, *J* = 9.3, 3.8 Hz, H-2); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 138.8, 138.2, 137.4 (C_q), 129.1, 128.6, 128.4, 128.4, 128.2, 128.1, 128.1, 127.8, 126.2 (CH_{arom}), 123.8 (q, *J* = 278.6 Hz, CF₃), 101.4 (CHPh), 99.0 (C-1), 81.9 (C-4), 79.2 (C-2), 78.3 (C-3), 75.5, 73.9 (CH₂ Bn), 68.9 (C-6), 65.2 (q, *J* = 35.0 Hz, CH₂-CF₃), 63.3 (C-5); Diagnostic peaks β-anomer: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 5.56 (s, 1H, CHPh), 4.73 (d, 1H, *J* = 10.7 Hz, CHH Bn), 4.60 (d, 1H, *J* = 7.7 Hz, H-1), 4.34 (dd, 1H, *J* = 10.5, 5.0 Hz, H-6), 3.51 (t, 1H, *J* = 8.0 Hz), 3.41 (td, 1H, *J* = 9.6, 5.2 Hz, H-5); HRMS: [M+H]⁺ calcd for C₂₉H₃₀F₃O₆ 531.19890, found 531.19857.




1,1,1,3,3,3-Hexafluoro-2-propyl 2,3-di-O-benzyl-4,6-O-benzylidene-α-D-glucopyranoside (2F). Donor **2** and 1,1,1,3,3,3-hexafluoroisopropanol were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (for an additional 144 hours at -40°C) and purified by flash column chromatography (1/1 to 0/1 pentane/toluene to 10% EtOAc in toluene) to yield glycosylation product **2F** (39 mg, 65 μmol, 65%, α:β = >20:1). R_f: 0.31 (4/1 pentane/Et₂O). [α]_D²⁵ = -40.9° (c = 0.68, CHCl₃); IR (neat): 689, 746, 997, 1086, 1196, 1219, 1368, 1454, 2868; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.51 – 7.47 (m, 2H, CH_{arom}), 7.40 – 7.27 (m, 13H, CH_{arom}), 5.55 (s, 1H, CHPh), 5.07 (d, 1H, *J* = 4.0 Hz, H-1), 4.93 (d, 1H, *J* = 11.1 Hz, CHH Bn), 4.83 (d, 1H, *J* = 11.1 Hz, CHH Bn), 4.79 (d, 1H, *J* = 11.7 Hz, CHH Bn), 4.73 (d, 1H, *J* = 11.7 Hz, CHH Bn), 4.41 (hept, 1H, *J* = 5.9 Hz, CH HFIP), 4.24 (dd, 1H, *J* = 10.2, 5.0 Hz, H-6), 4.06 (t, 1H, *J* = 9.4 Hz, H-3), 3.94 (td, 1H, *J* = 10.0, 4.9 Hz, H-5), 3.70 (t, 1H, *J* = 10.2 Hz, H-6), 3.75 – 3.60 (m, 2H, H-2, H-4); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 138.6, 137.7, 137.2 (C_q), 129.2, 128.6, 128.5, 128.4, 128.2, 128.1, 127.8, 126.1 (CH_{arom}), 121.7 (q, *J* = 285 Hz, CF₃), 121.2 (q, *J* = 285 Hz, CF₃), 101.4 (CHPh), 100.4 (C-1), 81.5 (C-4), 78.3 (C-2, C-3), 75.6, 74.1 (CH₂ Bn), 73.4 (hept, *J* = 32.9 Hz, CH HFIP), 68.5 (C-6), 64.0 (C-5); ¹³C-HMBC NMR (CDCl₃, 101 MHz): ³J(H_{HFIP}-C1) observed; HRMS: [2M-2(CF₃)₂CHO+H₂O+NH₄]⁺ calcd for (C₂₇H₂₇O₅)₂O 896.40044, found 896.40115; LC-MS: Rt = 10.09, no conclusive mass. TLC-MS: [M+Na]⁺ calcd for C₃₀H₂₈F₆O₆Na 621.17 found 621.2, and [M+H₂O-benzaldehyde+Na]⁺ calcd for C₂₃H₂₄F₆O₆Na 533.14 found 533.0.




1-[²H]-1,5-anhydro-2,3-di-O-benzyl-4,6-O-benzylidene-α-D-glucitol (2G). Donor **2** and triethylsilane-D were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (for an additional 144 hours at -40°C) and purified by flash column chromatography (19/1 to 4/1 Et₂O/pentane) to yield glycosylation product **2G** (34 mg, 79 μmol, 79%, α:β = >20:1). R_f: 0.38 (4/1 pentane/Et₂O). Spectroscopic data of the non-deuterated glucitol were in accord with those previously reported.¹¹² [α]_D²³ = +5.4° (c = 0.78, CHCl₃); IR (neat): 696, 748, 1009, 1028, 1088, 1368, 1454, 2868; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.51 – 7.48 (m, 2H, CH_{arom}), 7.41 – 7.34 (m, 5H, CH_{arom}), 7.34 – 7.26 (m, 7H, CH_{arom}), 5.55 (s, 1H, CHPh), 4.96 (d, 1H, *J* = 11.4 Hz, CHH Bn), 4.83 (d, 1H, *J* = 11.6 Hz, CHH Bn), 4.80 (d, 1H, *J* = 11.7 Hz, CHH Bn), 4.66 (d, 1H, *J* = 11.6 Hz, CHH Bn), 4.31 (dd, 1H, *J* = 10.4, 5.0 Hz, H-6), 3.98 (d, 1H, *J* = 5.6 Hz, H-1), 3.75 (t, 1H, *J* = 8.8 Hz, H-3), 3.70 – 3.63 (m, 2H, H-2, H-6), 3.61 (t, 1H, *J* = 9.2 Hz, H-4), 3.36 (ddd, 1H, *J* = 10.1, 9.2, 5.0 Hz, H-5); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 138.8, 138.3, 137.5 (C_q), 129.0, 128.6, 128.4, 128.4, 128.1, 128.0, 128.0, 127.7, 126.1 (CH_{arom}), 101.3 (CHPh), 82.5 (C-3), 82.2 (C-4), 77.7 (C-2), 75.1, 74.0 (CH₂ Bn), 71.4 (C-5), 69.0 (C-6), 68.7 (t, *J*_{C1,D1} = 22.3 Hz); ²H NMR (CHCl₃, 61 MHz): 3.34 (s, 1D, D-1); HRMS: [M+H]⁺ calcd for C₂₇H₂₈DO₅ 434.20723, found 434.20714.




Allyl 2,3-di-O-benzyl-1-deoxy-4,6-O-benzylidene-α-D-glucopyranoside (2H). Donor **2** and allyl trimethylsilane were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (for an additional 16 hours at -40°C) and purified by flash column chromatography (19/1 to 9/1 pentane/EtOAc) to yield glycosylation product **2H** (20 mg, 42 μmol, 42%, α:β = >1:20). Contaminated with a 1-OTMS glycoside by-product. α-Thio glycoside **2a** was formed as a by-product. R_f: 0.60 (9/1 pentane/EtOAc). Spectroscopic data were in accord with those previously reported.^{40,72} ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HH-NOESY, HSQC): δ 7.53 – 7.47 (m, 2H, CH_{arom}), 7.42 – 7.27 (m, 13H, CH_{arom}), 5.77 (ddt, 1H, *J* = 17.1, 10.2, 6.9 Hz, CH allyl), 5.57 (s, 1H, CHPh), 5.18 – 5.05 (m, 2H, CH₂ allyl), 4.93 (d, 1H, *J* = 11.4 Hz, CHH Bn), 4.81 (d, 1H, *J* = 11.4 Hz, CHH Bn), 4.78 (d, 1H, *J* = 11.7 Hz, CHH Bn), 4.64 (d, 1H, *J* = 11.7 Hz, CHH Bn), 4.27 – 4.21 (m, 1H, H-6), 4.08 (td, 1H, *J* = 7.7, 5.7 Hz, H-1), 3.92 – 3.85 (m, 1H, H-3), 3.76 (dd, 1H, *J* = 8.6, 5.7 Hz, H-2), 3.69 – 3.63 (m, 3H, H-4, H-5, H-6), 2.57 – 2.51 (m, 2H, CH₂ allylic); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC, HMBC): δ 138.7, 138.3, 137.5 (C_q-arom), 134.4 (CH allyl), 129.0, 128.6, 128.5, 128.4, 128.1, 128.0, 127.9, 127.8, 126.1 (CH_{arom}), 117.4 (CH₂ allyl), 101.3 (CHPh), 82.9 (C-4), 79.5 (C-2), 78.9 (C-3), 75.0 (C-1), 75.0, 73.7 (CH₂ Bn), 69.6 (C-6), 63.5 (C-5), 30.8 (CH₂ allylic); HRMS: [M+H]⁺ calcd for C₃₀H₃₃O₅ 473.23225, found 473.23228.



Phenyl 2,3-di-O-benzyl-4,6-O-benzylidene-1-thio- α -D-glucopyranoside (2a). R_f : 0.38 (4/1 pentane/Et₂O). Spectroscopic data were in accord with those previously reported.²¹ ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.53 – 7.44 (m, 4H, CH_{arom}), 7.43 – 7.36 (m, 7H, CH_{arom}), 7.36 – 7.27 (m, 9H, CH_{arom}), 5.59 (d, 1H, J = 5.5 Hz, H-1), 5.57 (s, 1H, CHPh), 4.92 (d, 1H, J = 11.3 Hz, CHH Bn), 4.86 (d, 1H, J = 11.3 Hz, CHH Bn), 4.81 (d, 1H, J = 11.8 Hz, CHH Bn), 4.76 (d, 1H, J = 11.8 Hz, CHH Bn), 4.39 (td, 1H, J = 9.9, 4.9 Hz, H-5), 4.19 (dd, 1H, J = 10.3, 5.0 Hz, H-6), 3.98 (t, 1H, J = 9.2 Hz, H-3), 3.90 (dd, 1H, J = 9.3, 5.5 Hz, H-2), 3.71 (t, J = 10.3 Hz, H-6), 3.66 (t, J = 9.3 Hz, H-4); HRMS: [M+NH₄]⁺ calcd for C₃₃H₃₆NO₅ 558.23087, found 558.23075.




Methyl 6-O-(2,3-di-O-benzyl-4,6-O-benzylidene- α / β -D-glucopyranosyl)-2,3,4-tri-O-benzyl- α -D-glucopyranoside (25). Donor **2** and acceptor **10** were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (for an additional 16 hours at -40°C) and purified by flash column chromatography (9/1 to 3/1 pentane/EtOAc) to yield glycosylation product **25** (72.1 mg, 81 μ mol, 81%, α : β = 1:2.7). R_f : 0.83 (6/4 pentane/EtOAc). Spectroscopic data were in accord with those previously reported.¹⁰⁸ ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC, HMBC): δ 7.51 – 7.44 (m, 2H, CH_{arom}), 7.41 – 7.12 (m, 28H, CH_{arom}), 5.54 (s, 1H, CHPh), 4.97 (d, 1H, J = 10.8 Hz, CHH Bn), 4.93 – 4.88 (m, 2H, 2xCHH Bn), 4.84 – 4.76 (m, 4H, 3xCHH Bn, CHH Bn), 4.73 – 4.63 (m, 2H, CHH Bn, CHH Bn), 4.61 (d, 1H, J = 3.6 Hz, H-1), 4.49 (d, 1H, J = 11.2 Hz, CHH Bn), 4.44 (d, 1H, J = 7.7 Hz, H-1'), 4.31 (dd, 1H, J = 10.5, 5.0 Hz, H-6'), 4.11 (dd, 1H, J = 10.7, 2.0 Hz, H-6), 3.99 (t, J = 9.3 Hz, 1H, H-3), 3.82 – 3.65 (m, 5H, H-3', H-4', H-5, H-6, H-6'), 3.56 – 3.48 (m, 3H, H-2, H-2', H-4), 3.40 – 3.34 (m, 1H, H-5'), 3.33 (s, 3H, CH₃ OMe); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC, HMBC): δ 138.9, 138.5, 138.4, 138.3, 138.2, 137.4 (C_q), 128.6, 128.5, 128.5, 128.4, 128.4, 128.4, 128.3, 128.3, 128.3, 128.2, 128.1, 128.1, 128.1, 128.1, 128.0, 128.0, 128.0, 127.7, 127.7, 127.7, 126.1 (CH_{arom}), 104.2 (C-1'), 101.2 (CHPh), 98.2 (C-1), 82.1 (C-3), 81.9 (C-2'), 81.5, 81.2 (C-3', C-4'), 79.8 (C-2), 77.9 (C-4), 75.8, 75.5, 75.2, 75.0, 73.5 (CH₂ Bn), 69.8 (C-5), 68.8 (C-6, C-6'), 66.2 (C-5'), 55.3 (OMe); Diagnostic peaks α -anomer: ¹H NMR (CDCl₃, 400 MHz): δ 5.53 (s, 0.33H), 4.57 (d, 0.33H, J = 3.6 Hz), 4.20 (dd, 0.33H, J = 10.1, 4.8 Hz), 3.89 (td, 0.33H, J = 10.0, 4.8 Hz), 3.43 (dd, 0.33H, J = 9.6, 3.6 Hz), 3.34 (s, 1H); ¹³C-APT NMR (CDCl₃, 101 MHz): δ 138.9, 138.8, 138.5, 138.3, 137.6, 129.0-126.2, 101.4, 98.3, 98.1, 82.3, 82.2, 80.2, 79.4, 78.0, 77.8, 75.8, 75.1, 75.1, 73.5, 73.0, 70.5, 69.2, 66.4, 62.6, 55.3; HRMS: [M+Na]⁺ calcd for C₅₅H₅₈O₁₁Na 917.38713, found 917.38678.



Methyl 4-O-(2,3-di-O-benzyl-4,6-O-benzylidene- α / β -D-glucopyranosyl)-2,3,6-tri-O-benzyl- α -D-glucopyranoside (26). Donor **2** and acceptor **11** were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (for an additional 16 hours at -40°C) and purified by flash column chromatography (19/1 to 4/1 pentane/EtOAc) to yield glycosylation product **26** (71 mg, 79 μ mol, 79%, α : β = 1:1). R_f : 0.54 (4/1 pentane/EtOAc).


Spectroscopic data were in accord with those previously reported for the α -anomer.¹⁰⁸ ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC, HMBC): δ 7.52 – 7.45 (m, 4H, CH_{arom}), 7.44 – 7.18 (m, 56H, CH_{arom}), 5.75 (d, 1H, J = 3.8 Hz, H-1' _{α}), 5.52 (s, 1H, CHPh _{α}), 5.49 (s, 1H, CHPh _{β}), 5.04 (d, 1H, J = 11.7 Hz, CHH Bn _{α}), 4.95 – 4.87 (m, 3H, 3xCHH Bn), 4.84 – 4.51 (m, 17H, 6xCHH Bn, 9xCHH Bn, H-1, H-1 _{β}), 4.36 (d, 1H, J = 7.8 Hz, H-1' _{β}), 4.30 (d, 1H, J = 12.0 Hz, CHH Bn _{β}), 4.19 (dd, 1H, J = 10.5, 5.0 Hz, H-6' _{β}), 4.15 – 4.09 (m, 3H, H-3 _{α} , H-4 _{α} , H-6' _{α}), 3.99 (t, 1H, J = 9.3 Hz, H-3' _{α}), 3.94 (t, 1H, J = 9.4 Hz, H-4 _{β}), 3.90 – 3.78 (m, 5H, H-2 _{β} , H-5 _{α} , H-5' _{α} , H-6 _{α} , H-6 _{β}), 3.69 – 3.41 (m, 11H, H-2 _{α} , H-2' _{α} , H-3 _{β} , H-3' _{β} , H-4' _{α} , H-4' _{β} , H-5 _{β} , H-6 _{α} , H-6 _{β} , H-6' _{α} , H-6' _{β}), 3.40 – 3.31 (m, 7H, CH₃ OMe, CH₃ OMe _{β} , H-2' _{β}), 3.10 (td, 1H, J = 9.5, 4.9 Hz, H-5' _{β}); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC, HMBC): δ 139.4, 139.0, 138.7, 138.6, 138.5, 138.4, 138.2, 138.0, 137.9, 137.9, 137.6, 137.5 (C_q), 129.0, 128.9, 128.6, 128.5, 128.5, 128.4, 128.3, 128.3, 128.3, 128.2, 128.2, 128.2, 128.1, 128.1, 128.0, 128.0, 127.9, 127.8, 127.7, 127.7, 127.5, 127.4, 127.3, 126.8, 126.1, 126.1 (CH_{arom}), 102.9 (C-1' _{β}), 101.2 (CHPh), 98.5, 97.8 (C-1 _{α} , C-1 _{β}), 97.2 (C-1' _{α}), 82.7 (C-2' _{β}), 82.4 (C-4' _{α}), 82.2 (C-3 _{α}), 81.8 (C-4' _{β}), 81.0 (C-3' _{β}), 80.3 (C-2 _{β}), 80.3, 78.9 (C-2 _{α} , C-3' _{α}), 78.8 (C-2' _{α} , C-3 _{β}), 76.9 (C-4 _{β}), 75.6, 75.5, 75.4, 75.0, 74.4, 73.9, 73.7, 73.4, 73.4 (CH₂ Bn), 71.6 (C-4 _{α}), 70.0 (C-5 _{β}), 69.4 (C-5 _{α}), 69.0, 68.9, 68.8 (C-6 _{α} , C-6' _{α} , C-6' _{β}), 67.7 (C-6 _{β}), 65.8 (C-5' _{β}), 63.4 (C-5' _{α}), 55.5 (OMe _{β}), 55.3 (OMe _{α}); HRMS: [M+NH₄]⁺ calcd for C₅₅H₆₂O₁₁N 912.43174, found 912.43282.



Methyl (methyl 4-O-(2,3-di-O-benzyl-4,6-O-benzylidene- α / β -D-glucopyranosyl)-2,3,6-tri-O-benzyl- α -D-glucopyranosyl uronate) (27). Donor **2** and acceptor **12** were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (for an additional 24 hours at -40°C) and purified by flash column chromatography


(19/1 to 4/1 pentane/EtOAc) to yield glycosylation product **27** (75.2 mg, 90 μ mol, 90%, α : β = 5:1). R_f : 0.77 (7/3 pentane/EtOAc). IR (neat): 694, 732, 912, 988, 1026, 1043, 1074, 1086, 1358, 1454, 1749, 28866, 2932; Data for the α -anomer: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC, HMBC): δ 7.48 – 7.43 (m, 2H, CH_{arom}), 7.40 – 7.16 (m, 23H, CH_{arom}), 5.51 (s, 1H, CHPh), 5.44 (d, 1H, J = 3.8 Hz, H-1'), 4.95 – 4.86 (m, 3H, CH₂ Bn, CHH Bn), 4.78 (d, 1H, J = 11.2 Hz,

CHH Bn), 4.71 (d, 1H, $J = 12.1$ Hz, CHH Bn), 4.67 (d, 1H, $J = 12.0$ Hz, CHH Bn), 4.59 – 4.53 (m, 3H, 2xCHH Bn, H-1), 4.28 (dd, 1H, $J = 6.5, 3.8$ Hz, H-6'), 4.25 (d, 1H, $J = 9.5$ Hz, H-5), 4.11 (t, 1H, $J = 9.1$ Hz, H-4), 4.05 (t, 1H, $J = 8.9$ Hz, H-3), 3.98 (t, 1H, $J = 9.1$ Hz, H-3'), 3.76 (s, 3H, CH₃ CO₂Me), 3.64 (t, 1H, $J = 10.0$ Hz, H-6'), 3.61 – 3.54 (m, 3H, H-2, H-4', H-5'), 3.48 (dd, 1H, $J = 5.6, 3.9$ Hz, H-2'), 3.40 (s, 3H, CH₃ OMe); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC, HMBC): δ 170.1 (C=O CO₂Me), 139.0, 138.6, 138.0, 137.8, 137.6 (C_q), 129.0, 128.6, 128.4, 128.4, 128.3, 128.3, 128.3, 128.2, 128.1, 128.1, 127.8, 127.7, 127.3, 127.0, 126.1 (CH_{arom}), 101.3 (CHPh), 98.6 (C-1), 98.4 (C-1'), 82.0 (C-4'), 80.8 (C-3), 79.2 (C-2), 78.7 (C-2'), 78.4 (C-3'), 76.1 (C-4), 75.3, 75.0, 73.7, 73.7 (CH₂ Bn), 70.3 (C-5), 68.6 (C-6'), 63.1 (C-5'), 55.8 (CH₃ OMe), 52.9 (CH₃ CO₂Me); ¹³C-HMBC NMR (CDCl₃, 101 MHz): δ 98.4 ($J_{C1',H1'} = 174$ Hz, C-1' α); Diagnostic peaks β-anomer: ¹H NMR (CDCl₃, 400 MHz): δ 5.47 (s, 0.18H, CHPh), 4.62 (d, 0.18H, $J = 12.1$ Hz), 3.87 (dd, 0.18H, $J = 9.6, 8.4$ Hz), 3.50 (s, 0.54H, CH₃ CO₂Me), 3.44 (s, 0.54H, CH₃ OMe), 3.38 – 3.28 (m, 0.36H, H-2', H-5'); ¹³C-APT NMR (CDCl₃, 101 MHz): δ 170.1, 139.2, 138.6, 138.2, 137.4, 129.0, 128.5, 128.3, 128.1, 127.7, 127.5, 126.1, 102.9 (C-1'), 101.2 (CHPh), 99.0 (C-1), 82.3, 81.8, 81.3, 79.6, 78.5, 78.2, 75.6, 75.5, 75.2, 73.9, 70.0, 68.8, 65.9, 55.9, 52.7; ¹³C-HMBC NMR (CDCl₃, 101 MHz): δ 102.9 ($J_{C1',H1'} = 164$ Hz, C-1' β); HRMS: [M+Na]⁺ calcd for C₄₉H₅₂O₁₂Na 855.33510, found 855.33496.




Methyl 4-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α-D-glucopyranosyl)-2,3,6-tri-O-benzyl-β-D-galactopyranoside (28). Donor **2** and acceptor **13** were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (for an additional 16 hours at -40°C) and purified by flash column chromatography (19/1 to 4/1 pentane/EtOAc) to yield glycosylation product **28** (74 mg, 83 μmol, 83%, α:β = >20:1).

R_f: 0.50 (4/1 pentane/EtOAc). [α]_D²³ = +38.4° (c = 1.0, CHCl₃); IR (neat): 696, 735, 997, 1028, 1072, 1366, 1452, 1497, 2859, 2922; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC, HMBC): δ 7.49 (dd, 2H, $J = 7.9, 1.8$ Hz, CH_{arom}), 7.42 – 7.16 (m, 28H, CH_{arom}), 5.50 (s, 1H, CHPh), 4.98 (d, $J = 3.7$ Hz, H-1'), 4.97 (d, $J = 11.0$ Hz, CHH Bn), 4.93 – 4.87 (m, 2H, 2xCHH Bn), 4.85 – 4.74 (m, 3H, 2xCHH Bn, CHH Bn), 4.72 – 4.63 (m, 2H, 2xCHH Bn), 4.31 – 4.22 (m, 4H, CH₂ Bn, H-1, H-5'), 4.18 (t, 1H, $J = 9.4$ Hz, H-3'), 4.06 – 3.97 (m, 2H, H-4, H-6), 3.84 (dd, 1H, $J = 10.1, 4.9$ Hz, H-6'), 3.72 (dd, 1H, $J = 10.0, 7.6$ Hz, H-2), 3.63 – 3.45 (m, 8H, CH₃ OMe, H-2', H-4', H-5, H-6, H-6'), 3.42 (dd, 1H, $J = 10.0, 2.9$ Hz, H-3); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC, HMBC): δ 138.9, 138.7, 138.6, 138.4, 138.2, 137.8 (C_q), 128.9, 128.5, 128.4, 128.4, 128.3, 128.3, 128.1, 128.0, 127.8, 127.7, 127.6, 126.2 (CH_{arom}), 105.1 (C-1), 101.2 (CHPh), 100.7 (C-1'), 83.0 (C-4'), 80.6 (C-3), 79.7 (C-2'), 78.9 (C-2, C-3'), 75.9 (C-4), 75.3, 75.2, 74.0 (CH₂ Bn), 73.5 (C-5), 73.2, 72.8 (CH₂ Bn), 69.1 (C-6'), 68.0 (C-6), 63.0 (C-5'), 57.2 (OMe); ¹³C-HMBC NMR (CDCl₃, 101 MHz): δ 105.1 ($J_{C1',H1'} = 159$ Hz, C-1 β), 100.7 ($J_{C1',H1'} = 170$ Hz, C-1' α); HRMS: [M+NH₄]⁺ calcd for C₅₅H₆₂O₁₁N 912.43174, found 912.43266.



Methyl 2-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α/β-D-glucopyranosyl)-3-O-benzyl-4,6-O-benzylidene-α-D-mannopyranoside (29). Donor **2** and acceptor **14** were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (for an additional 16 hours at -40°C) and purified by flash column chromatography (19/1 to 4/1 pentane/EtOAc) to yield glycosylation product **29** (64.3 mg, 80 μmol, 80%, α:β = >20:1). R_f: 0.27 (8/1 pentane/EtOAc).


Spectroscopic data were in accord with those previously reported.¹⁰⁸ IR (neat): 696, 748, 999, 1028, 1074, 1088, 1369, 1454, 1498, 2864, 2911; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC, HMBC): δ 7.49 (ddd, 4H, $J = 8.9, 5.8, 1.9$ Hz, CH_{arom}), 7.44 – 7.35 (m, 8H, CH_{arom}), 7.35 – 7.24 (m, 10H, CH_{arom}), 7.17 (dp, 3H, $J = 4.4, 1.6$ Hz, CH_{arom}), 5.60 (d, 1H, $J = 3.9$ Hz, H-1'), 5.57 (s, 1H, CHPh'), 5.43 (s, 1H, CHPh), 4.95 – 4.85 (m, 3H, CHH Bn, CH₂ Bn), 4.78 (d, 1H, $J = 11.2$ Hz, CHH Bn), 4.72 (d, 1H, $J = 11.7$ Hz, CHH Bn), 4.71 (d, 1H, $J = 1.7$ Hz, H-1), 4.47 (d, 1H, $J = 11.1$ Hz, CHH Bn), 4.33 – 4.26 (m, 2H, H-4, H-6'), 4.24 – 4.18 (m, 2H, H-2, H-6), 4.08 (t, 1H, $J = 9.3$ Hz, H-3'), 4.02 (dd, 1H, $J = 9.9, 2.9$ Hz, H-3), 3.93 – 3.70 (m, 4H, H-5, H-5', H-6, H-6'), 3.63 (t, 1H, $J = 9.4$ Hz, H-4'), 3.56 (dd, 1H, $J = 9.3, 3.9$ Hz, H-2'), 3.36 (s, 3H, CH₃ OMe); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC, HMBC): δ 139.1, 138.6, 138.5, 137.9, 137.5 (C_q), 129.1, 129.0, 128.5, 128.4, 128.3, 128.3, 128.3, 128.0, 127.9, 127.9, 127.8, 127.6, 127.6, 126.1, 126.1 (CH_{arom}), 101.3, 101.3, 101.2 (CHPh, C-1'), 98.0 (C-1), 82.1 (C-4'), 79.4 (C-2'), 79.3 (C-4), 77.9 (C-3'), 76.9 (C-3), 75.3 (CH₂ Bn), 74.4 (C-2), 74.0, 71.9 (CH₂ Bn), 69.1 (C-6'), 68.8 (C-6), 64.4 (C-5), 63.0 (C-5'), 54.9 (OMe); ¹³C-HMBC NMR (CDCl₃, 101 MHz): δ 101.3 ($J_{C1',H1'} = 168$ Hz, C-1' α), 98.0 ($J_{C1',H1'} = 170$ Hz, C-1' α); HRMS: [M+NH₄]⁺ calcd for C₄₈H₅₄NO₁₁ 820.36914, found 820.36958.



Methyl (cyclohexyl 4-O-acetyl-2,3-di-O-benzyl-α/β-D-mannopyranosyl uronate) (3A). Donor **3** and cyclohexanol were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (for an additional 16 hours at -40°C) and purified by flash column


chromatography (9/1 to 4/1 pentane/EtOAc) to yield glycosylation product **3A** (42.5 mg, 83 μmol, 83%, α:β = 1:8.3). R_f: 0.46 (7/3 pentane/EtOAc). IR (neat): 1026, 1047, 1105, 1238, 1368, 1452, 1740, 1751, 2855, 2930; Data for the β-anomer: ¹H NMR (400 MHz, CDCl₃, HH-COSY, HSQC): δ 7.48 – 7.18 (m, 10H, CH_{arom}), 5.50 (t, 1H, $J = 9.7$ Hz, H-4), 5.00 (d, 1H, $J = 12.8$ Hz, CHH Bn), 4.88 (d, 1H, $J = 12.8$ Hz, CHH Bn), 4.54 (s, 1H, H-1), 4.46 (d, 1H, $J = 12.4$ Hz, CHH Bn), 4.31

(d, 1H, $J = 12.4$ Hz, *CHH* Bn), 3.84 (d, 1H, $J = 2.8$ Hz, H-2), 3.82 (d, 1H, $J = 9.7$ Hz, H-5), 3.73 (s, 3H, $\text{CH}_3 \text{CO}_2\text{Me}$), 3.73 – 3.65 (m, 1H, *CH* Cy), 3.46 (dd, 1H, $J = 9.8, 2.9$ Hz, H-2), 2.02 (s, 3H, $\text{CH}_3 \text{OAc}$), 1.99 – 1.21 (m, 15H, $\text{CH}_2 \text{Cy}$); ^{13}C -APT NMR (101 MHz, CDCl_3 , HSQC): δ 169.7, 168.3 (C=O CO_2Me , Ac), 138.6, 138.0 (C_q), 128.7, 128.5, 128.2, 127.8, 127.5, 127.5 (CH_{arom}), 99.5 (C-1), 78.7 (C-3), 77.0 (*CH* Cy), 74.0 (C-5), 73.9 (CH_2 Bn), 73.4 (C-2), 71.4 (CH_2 Bn), 69.1 (C-4), 52.7 ($\text{CH}_3 \text{CO}_2\text{Me}$), 33.4, 31.4, 25.8, 23.9 ($\text{CH}_2 \text{Cy}$), 21.0 ($\text{CH}_3 \text{Ac}$); Diagnostic peaks α -anomer: ^1H NMR (400 MHz, CDCl_3 , HH-COSY, HSQC): δ 5.50 (t, 0.12H, $J = 9.7$ Hz, H-4), 5.24 (d, 0.12H, $J = 3.3$ Hz, H-1), 4.78 (d, 0.12H, $J = 12.0$ Hz, *CHH* Bn), 4.68 (d, 0.12H, $J = 12.4$ Hz, *CHH* Bn); ^{13}C -APT NMR (101 MHz, CDCl_3 , HSQC): δ 69.7 (C-1); HRMS: $[\text{M}+\text{NH}_4]^+$ calcd for $\text{C}_{29}\text{H}_{40}\text{NO}_8$ 530.27484, found 530.27495.




Methyl (ethyl 4-O-acetyl-2,3-di-O-benzyl- α/β -D-mannopyranosyl uronate) (3B). Donor **3** and ethanol were condensed using the general procedure for $\text{Ff}_2\text{O}/\text{Ph}_2\text{SO}$ mediated glycosylations

(for an additional 16 hours at -40°C) and purified by flash column chromatography (9/1 to 4/1 pentane/EtOAc) to yield glycosylation product **3B** (43.4 mg, 95 μmol , 95%, $\alpha:\beta = 1:8.3$). R_f : 0.36 (7/3 pentane/EtOAc). IR (neat): 735, 1026, 1047, 1103, 1229, 1369, 1454, 1744, 2924; Data for the β -anomer: ^1H NMR (400 MHz, CDCl_3 , HH-COSY, HSQC): δ 7.68 – 7.15 (m, 10H, CH_{arom}), 5.51 (t, 1H, $J = 9.5$ Hz, H-4), 4.96 (d, 1H, $J = 12.6$ Hz, *CHH*Bn), 4.84 (d, 1H, $J = 12.6$ Hz, *CHH* Bn), 4.48 (d, 1H, $J = 12.4$ Hz, *CHH* Bn), 4.43 (s, 1H, H-1), 4.33 (d, 1H, $J = 12.4$ Hz, *CHH* Bn), 4.02 (dq, 1H, $J = 9.2, 7.1$ Hz, *CHHCH}_3 \text{Et}), 3.88 (d, 1H, $J = 2.8$ Hz, H-2), 3.84 (d, 1H, $J = 9.5$ Hz, H-5), 3.73 (s, 3H, $\text{CH}_3 \text{CO}_2\text{Me}$), 3.54 – 3.44 (m, 2H, H-3, *CHHCH}_3 \text{Et}, H-3), 2.02 (s, 3H, $\text{CH}_3 \text{OAc}$), 1.27 (t, 3H, $J = 7.0$ Hz, $\text{CH}_3 \text{Et}$); ^{13}C -APT NMR (101 MHz, CDCl_3 , HSQC): δ 169.7, 168.2 (C=O CO_2Me , Ac), 138.5, 137.9 (C_q), 129.4, 128.6, 1285, 128.2, 124.9 (CH_{arom}), 101.5 (C-1), 78.2 (C-3), 73.9 (CH_2 Bn), 73.9 (C-5), 73.1 (C-2), 71.4 (CH_2 Bn), 69.1 (C-4), 65.9 ($\text{CH}_2 \text{Et}$), 52.7 ($\text{CH}_3 \text{CO}_2\text{Me}$), 21.0 ($\text{CH}_3 \text{Ac}$), 15.2 ($\text{CH}_3 \text{Et}$); ^{13}C -GATED NMR (101 MHz, CDCl_3): δ 101.5 ($J_{\text{C1,H1}} = 160$ Hz, C-1 β); Diagnostic peaks α -anomer: ^1H NMR (400 MHz, CDCl_3 , HH-COSY, HSQC): δ 5.51 (t, 0.12H, H-4), 5.13 (d, 0.12H, $J = 4.3$ Hz, H-1), 4.78 (d, 0.12H, $J = 12.4$ Hz, *CHH* Bn), 4.68 (d, 0.12H, $J = 12.3$ Hz, *CHH* Bn), 3.67 (s, 0.36H, $\text{CH}_3 \text{CO}_2\text{Me}$). ^{13}C -APT NMR (101 MHz, CDCl_3) δ 98.4 (C-1), 77.4 (C-3), 74.6 (C-5), 73.2 (CH_2 Bn), 72.5 (CH_2 Bn), 69.5 ($\text{CH}_2 \text{Et}$), 52.6 ($\text{CH}_3 \text{CO}_2\text{Me}$); HRMS: $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{25}\text{H}_{30}\text{O}_8\text{Na}$ 481.18329, found 481.18250.**



Methyl (2-fluoroethyl 4-O-acetyl-2,3-di-O-benzyl- α/β -D-mannopyranosyl uronate) (3C).


Donor **3** and 2-fluoroethanol were condensed using the general procedure for $\text{Ff}_2\text{O}/\text{Ph}_2\text{SO}$ mediated glycosylations (for an additional 16 hours at -40°C) and purified by flash column chromatography (9/1 to 7/3 pentane/EtOAc) to yield glycosylation product **3C** (33.2 mg, 70 μmol , 70%, $\alpha:\beta = 1:5$). R_f : 0.18 (7/3 pentane/EtOAc). IR (neat): 1045, 1103, 1231, 1369, 1454, 1746, 2895, 2924; Data for the β -anomer: ^1H NMR (400 MHz, CDCl_3 , HH-COSY, HSQC): δ 7.69 – 7.18 (m, 10H, CH_{arom}), 5.52 (t, 1H, $J = 9.3$ Hz, H-4), 4.95 (d, 1H, $J = 12.5$ Hz, *CHH* Bn), 4.83 (d, 1H, $J = 12.5$ Hz, *CHH* Bn), 4.76 – 4.94 (m, 2H, CH_2F), 4.54 (s, 1H, H-1), 4.49 (d, 1H, $J = 12.4$ Hz, *CHH* Bn), 4.34 (d, 1H, $J = 12.4$ Hz, *CHH* Bn), 4.13 (dddd, 1H, $J = 37.0, 12.2, 3.3, 2.2$ Hz, *CHHCH}_2\text{F}), 3.95 (d, 1H, $J = 2.6$ Hz, H-2), 3.86 (d, 1H, $J = 9.2$ Hz, H-5), 3.84 – 3.74 (m, 1H, *CHHCH}_2\text{F}), 3.72 (s, 3H, $\text{CH}_3 \text{CO}_2\text{Me}$), 3.49 (dd, 1H, $J = 9.4, 2.9$ Hz, H-3), 2.10 – 1.94 (s, 3H, $\text{CH}_3 \text{OAc}$); ^{13}C -APT NMR (101 MHz, CDCl_3 , HSQC): δ 169.7, 168.1 (C=O CO_2Me , Ac), 138.3, 137.81 (C_q), 131.2, 129.46, 128.6, 128.5, 128.4, 128.3, 128.0, 127.9, 127.7, 127.7, 127.6, 124.9 (CH_{arom}), 101.6 (C-1), 82.96 (d, $J = 169.5$ Hz, CH_2F), 77.9 (C-3), 74.5 (CH_2 Bn), 74.1 (C-5), 73.8 (C-2), 72.9 (CH_2 Bn), 69.01 (d, $J = 19.5$ Hz, $\text{CH}_2\text{CH}_2\text{F}$), 68.9 (C-4), 52.8 ($\text{CH}_3 \text{CO}_2\text{Me}$), 21.0 ($\text{CH}_3 \text{Ac}$). ^{13}C -GATED NMR (101 MHz, CDCl_3) δ 101.6 ($J_{\text{C1,H1}} = 156$ Hz, C-1); Diagnostic peaks α -anomer: ^1H NMR (400 MHz, CDCl_3 , HH-COSY, HSQC): δ 5.52 (t, 0.20H, $J = 9.3$ Hz, H-4), 5.19 (d, 0.20H, $J = 4.7$ Hz, H-1), 3.66 (s, 0.60H, $\text{CH}_3 \text{CO}_2\text{Me}$), 2.04 (s, 0.6H, $\text{CH}_3 \text{OAc}$); ^{13}C -APT NMR (101 MHz, CDCl_3): δ 98.9 (C-1); HRMS: $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{25}\text{H}_{29}\text{FO}_8\text{Na}$ 499.17387, found 499.17297.**



Methyl (2,2-difluoroethyl 4-O-acetyl-2,3-di-O-benzyl- α/β -D-mannopyranosyl uronate) (3D).


Donor **3** and 2,2-difluoroethanol were condensed using the general procedure for $\text{Ff}_2\text{O}/\text{Ph}_2\text{SO}$ mediated glycosylations (for an additional 16 hours at -40°C) and purified by flash column chromatography (9/1 to 7/3 pentane/EtOAc) to yield glycosylation product **3D** (43.1 mg, 87 μmol , 87%, $\alpha:\beta = 1:4.2$). R_f : 0.51 (7/3 pentane/EtOAc). IR (neat): 737, 1026, 1051, 1078, 1232, 1439, 1454, 1741, 2870, 2924; Data for the β -anomer: ^1H NMR (400 MHz, CDCl_3 , HH-COSY, HSQC): δ 7.57 – 7.12 (m, 10H, CH_{arom}), 5.94 (dddd, 1H, $J = 56.7, 54.4, 5.7, 2.5$ Hz, CH_2CHF_2), 5.54 (t, 1H, $J = 8.9$ Hz, H-4), 4.89 (d, 1H, $J = 12.4$ Hz, *CHH* Bn), 4.78 (d, 1H, $J = 12.4$ Hz, *CHH* Bn), 4.56 (s, 1H, H-1), 4.53 (d, 1H, $J = 12.3$ Hz, *CHH* Bn), 4.38 (d, 1H, $J = 12.4$ Hz, *CHH* Bn), 4.19 – 4.04 (m, 1H, *CHHCH}_2\text{F}), 3.92 (d, 1H, $J = 2.1$ Hz, H-2), 3.89 (d, 1H, $J = 8.7$ Hz, H-5), 3.80 – 3.67 (m, 1H, *CHHCH}_2\text{F}), 3.70 (s, 3H, $\text{CH}_3 \text{CO}_2\text{Me}$), 3.52 (dd, 1H, $J = 9.0, 2.9$ Hz, H-3), 2.03 (s, 3H, $\text{CH}_3 \text{OAc}$); ^{13}C -APT NMR (101 MHz, CDCl_3 , HSQC): δ 169.7, 167.9 (C=O CO_2Me , Ac), 138.1, 137.8 (C_q), 131.2, 129.5, 128.5, 128.3, 127.9, 127.8, 127.6, 124.9 (CH_{arom}), 114.3 (dd, $J = 242.2, 239.7$ Hz, CHF_2), 101.3 (C-1), 77.4 (C-3), 74.0 (CH_2 Bn), 73.6 (C-5), 72.8 (C-2), 71.7 (CH_2 Bn), 69.0 (C-4), 68.5 (dd, $J = 31.2, 25.6$ Hz, CH_2CHF_2), 52.8 ($\text{CH}_3 \text{CO}_2\text{Me}$), 21.0 ($\text{CH}_3 \text{Ac}$); ^{13}C -GATED NMR (101 MHz, CDCl_3): δ 101.3**

($J_{C1,H1} = 160$ Hz, C-1 β); Diagnostic peaks α -anomer: ^1H NMR (400 MHz, CDCl_3 , HH-COSY, HSQC): δ 5.52 (t, 0.24H, $J = 11.2$ Hz, H-4), 5.23 (d, 0.24H, $J = 5.6$ Hz, H-1), 3.64 (s, 0.72H, CH_3 CO_2Me); ^{13}C -APT NMR (101 MHz, CDCl_3 , HSQC): δ 99.31 (C-1), 75.45 (C-3), 74.47 (C-2), 73.41 (CH_2 Bn), 69.46 (C-4), 52.61 (CH_3 CO_2Me); HRMS: $[\text{M}+\text{NH}_4]^+$ calcd for $\text{C}_{25}\text{H}_{32}\text{F}_2\text{NO}_8$ 512.20905, found 512.20889.




Methyl (2,2,2-trifluoroethyl 4-O-acetyl-2,3-di-O-benzyl- α/β -D-mannopyranosyl uronate) (3E).

Donor **3** and 2,2,2-trifluoroethanol were condensed using the general procedure for $\text{Ti}_2\text{O}/\text{Ph}_2\text{SO}$ mediated glycosylations (for an additional 24 hours at -40°C) and purified by flash column chromatography (9/1 to 7/3 pentane/EtOAc) to yield glycosylation product **3E** (43.7 mg, 85 μmol , 85%, $\alpha:\beta = 1:2.6$). R_f: 0.60 (9/1 pentane/EtOAc). IR (neat): 741, 1058, 1161, 1234, 1280, 1371, 1443, 1748, 2854, 2924; Data for the β -anomer: ^1H NMR (400 MHz, CDCl_3 , HH-COSY, HSQC): δ 7.83 – 6.86 (m, 10H, CH_{arom}), 5.55 (t, 1H, $J = 8.6$ Hz, H-4), 4.90 (d, 1H, $J = 12.3$ Hz, CHH Bn), 4.78 (d, 1H, $J = 12.4$ Hz, CHH Bn), 4.65 (s, 1H, H-1), 4.54 (d, 1H, $J = 12.3$ Hz, CHH Bn), 4.37 (d, 1H, $J = 12.3$ Hz, CHH Bn), 4.35 – 4.23 (m, 1H, CHHCF_3), 3.98 – 3.94 (m, 2H, CHHCF_3 , H-2), 3.92 (d, 1H, $J = 8.3$ Hz, H-5), 3.69 (s, 3H, CH_3 CO_2Me), 3.54 (dd, 1H, $J = 8.8$, 2.8 Hz, H-3), 2.03 (s, 3H, CH_3 OAc); ^{13}C -APT NMR (101 MHz, CDCl_3 , HSQC): δ 169.7, 167.8 (C=O CO_2Me , Ac), 137.9, 137.8 (C_q), 131.2, 129.5, 129.5, 128.5, 128.5, 128.3, 128.0, 127.9, 127.8, 127.5 (CH_{arom}), 123.8 (q, $J = 278.7$ Hz, CF_3), 100.8 (C-1), 77.1 (C-3), 73.8 (CH_2 Bn), 73.6 (C-5), 72.4 (C-2), 71.7 (CH_2 Bn), 69.0 (C-4), 66.1 (q, $J = 34.8$ Hz, CH_2CF_3), 52.8 (CH_3 CO_2Me), 21.0 (CH_3 Ac); ^{13}C -GATED NMR (101 MHz, CDCl_3): δ 100.8 ($J_{C1,H1} = 160$ Hz, C-1 β); Diagnostic peaks α -anomer: ^1H NMR (400 MHz, CDCl_3 , HH-COSY, HSQC): δ 5.51 (t, 0.38H, $J = 5.5$ Hz, H-4), 5.27 (d, 0.38H, $J = 5.6$ Hz, H-1), 4.23 – 4.12 (m, 0.38H, CHHCH_2), 3.86 (dd, 0.38H, $J = 6.2$, 3.0 Hz, H-3); ^{13}C -APT NMR (101 MHz, CDCl_3 , HSQC): δ 99.1 (C-1), 75.4 (C-3), 74.3 (C-2), 73.5 (CH_2 Bn), 72.9 (CH_2 Bn), 69.4 (C-4), 52.6 (CH_3 CO_2Me), 21.0 (CH_3 Ac); ^{13}C -GATED NMR (101 MHz, CDCl_3): δ 99.1 ($J_{C1,H1} = 172$ Hz, C-1 α); HRMS: $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{25}\text{H}_{27}\text{F}_3\text{O}_8\text{Na}$ 535.15502, found 535.15415.




Methyl (1,1,1,3,3,3-hexafluoro-2-propyl 4-O-acetyl-2,3-di-O-benzyl- α/β -D-mannopyranosyl uronate) (3F).

Donor **3** and 1,1,1,3,3,3-hexafluoro-2-propanol were condensed using the general procedure for $\text{Ti}_2\text{O}/\text{Ph}_2\text{SO}$ mediated glycosylations (for an additional 240 hours at -40°C) and purified by flash column chromatography (9/1 to 4/1 pentane/EtOAc) to yield glycosylation product **3F** (30.1 mg, 52 μmol , 52%, $\alpha:\beta = 1:1$). R_f: 0.85 (α), 0.75 (β) (7/3 pentane/EtOAc). IR (neat): 1105, 1371, 1454, 1751, 2872, 2924; Data for the β -anomer: ^1H NMR (400 MHz, CDCl_3 , HH-COSY, HSQC): δ 7.72 – 7.13 (m, 10H, CH_{arom}), 5.55 (t, 1H, $J = 9.5$ Hz, H-4), 4.92 (d, 1H, $J = 12.3$ Hz, CHH Bn), 4.78 (d, 1H, $J = 12.1$ Hz, CHH Bn), 4.74 (s, 1H, H-1), 4.51 (d, 1H, $J = 12.3$ Hz, CHH Bn), 4.72 – 4.56 (m, 1H, $\text{CH}(\text{CF}_3)_2$), 4.36 (d, 1H, $J = 12.7$ Hz, CHH Bn), 3.99 (d, 1H, $J = 2.5$ Hz, H-2), 3.87 (d, 1H, $J = 9.4$ Hz, H-5), 3.73 (s, 3H, CH_3 CO_2Me), 3.50 (dd, 1H, $J = 9.6$, 2.8 Hz, H-3), 2.02 (s, 3H, CH_3 OAc); ^{13}C -APT NMR (101 MHz, CDCl_3 , HSQC): δ 169.6, 167.3 (C=O CO_2Me , Ac), 137.8, 137.5 (C_q), 128.6, 128.5, 128.4, 128.0, 128.0, 127.8, 127.6, 127.6 (CH_{arom}), 120.8 (q, $J = 281.0$ Hz, CF_3), 100.3 (C-1), 78.0 (C-3), 74.3 (CH_2 Bn), 73.9 (C-5), 72.8 (C-2), 72.4 (CH_2 Bn), 71.8 (hept, $J = 33.0$ Hz, $\text{CH}(\text{CF}_3)_2$), 68.5 (C-4), 53.0 (CH_3 CO_2Me), 20.9 (CH_3 Ac); ^{13}C -GATED NMR (101 MHz, CDCl_3): δ 100.3 ($J_{C1,H1} = 165$ Hz, C-1 β); Diagnostic peaks α -anomer: ^1H NMR (400 MHz, CDCl_3 , HH-COSY, HSQC): δ 5.49 (t, 0.90H, $J = 5.6$ Hz, H-4), 5.39 (d, 0.90H, $J = 5.5$ Hz, H-1), 4.72 – 4.56 (m, 4.5H, CHH Bn, CHH Bn, CHH Bn, CHH Bn, $\text{CH}(\text{CF}_3)_2$), 4.37 – 4.35 (m, 0.90H, H-5), 3.84 (dd, 0.90H, $J = 6.0$, 2.9 Hz, H-3), 3.68 (dd, 0.90H, $J = 5.5$, 2.8 Hz, H-2). ^{13}C -APT NMR (101 MHz, CDCl_3 , HSQC): δ 169.9, 168.3 (C=O CO_2Me , Ac), 137.8, 137.65 (C_q), 128.6, 128.5, 128.4, 128.0, 128.0, 127.9, 127.8, 127.6 (CH_{arom}), 100.0 (C-1), 75.4 (C-3), 74.3 (CH_2 Bn), 74.3 (C-2), 73.7 (C-2), 73.17 (d, $J = 32.8$ Hz, $\text{CH}(\text{CF}_3)_2$), 72.7 (C-5), 69.3 (C-4), 52.7 (CH_3 CO_2Me), 21.0 (CH_3 Ac); ^{13}C -GATED NMR (101 MHz, CDCl_3): δ 100.0 ($J_{C1,H1} = 175$ Hz, C-1 α); HRMS: $[\text{M}+\text{NH}_4]^+$ calcd for $\text{C}_{26}\text{H}_{30}\text{F}_6\text{NO}_8$ 598.18707, found 598.18711.




Methyl (4-O-acetyl-2,3-di-O-benzyl-1-deoxy- β -deuterio-D-mannopyranosyl uronate) (3G).

Donor **3** and triethylsilane-D were condensed using the general procedure for $\text{Ti}_2\text{O}/\text{Ph}_2\text{SO}$ mediated glycosylations (for an additional 240 hours at -40°C) and purified by flash column chromatography (9/1 to 7/3 pentane/EtOAc) to yield glycosylation product **3G** (39.6 mg, 95 μmol , 95%, $\alpha:\beta < 1:20$). R_f: 0.45 (7/3 pentane/EtOAc). $[\alpha]_D^{26} = -34.4^\circ$ ($c = 0.5$, CHCl_3); IR (neat): 698, 736, 1051, 1136, 1228, 1371, 1454, 1745, 2872, 2924; Data for the β -anomer: ^1H NMR (400 MHz, CDCl_3 , HH-COSY, HSQC, NOESY) δ 7.39 – 7.17 (m, 10H, CH_{arom}), 5.60 (dd, 1H, $J = 4.9$, 3.5 Hz, H-4), 4.63 (s, 2H, CH_2 Bn), 4.53 (s, 2H, CH_2 Bn), 4.19 (d, 1H, $J = 3.2$ Hz, H-5), 3.81 (m, 2H, H-2, H-3), 3.68 (d, 1H, $J = 3.9$ Hz, H-1), 3.61 (s, 3H, CH_3 CO_2Me), 2.06 (s, 3H, CH_3 OAc); ^2H NMR (61 MHz, CHCl_3) δ 4.73 (D-1); ^{13}C -APT NMR (101 MHz, CDCl_3 , HSQC, HMBSC): δ 169.9, 168.9 (C=O CO_2Me , Ac), 138.1, 137.8 (C_q), 131.2, 129.4, 128.6, 128.5, 128.4, 127.9, 127.8, 127.8, 127.8, 124.9 (CH_{arom}), 73.8 (C-5), 73.4 (C-3), 72.3 (CH_2 Bn), 71.4 (C-2), 71.3 (CH_2 Bn), 70.0 (C-4), 62.4 (C-1), 52.4 (CH_3 CO_2Me), 21.1 (CH_3 Ac). HRMS: $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{23}\text{H}_{25}\text{DO}_7\text{Na}$ 438.16335, found 438.16264.




Methyl (allyl 4-O-acetyl-2,3-di-O-benzyl-1-deoxy- β -D-mannopyranosyl uronate) (3H). Donor **3**

and allyl trimethylsilane were condensed using the general procedure for $\text{Ti}_2\text{O}/\text{Ph}_2\text{SO}$ mediated glycosylations (for an additional 96 hours at -40°C) and purified by flash column chromatography (9/1 to 7/3 pentane/EtOAc) to yield glycosylation product **3H** (18.3 mg, 40 μmol , 40%, $\alpha:\beta = <1:20$). R_f : 0.25 (8/2 pentane/EtOAc). $[\alpha]_D^{20} = -38.8^\circ$ ($c = 1$, CHCl_3); IR (neat): 696, 735, 1026, 1055, 1114, 1228, 1368, 1746, 2855, 2924; Data for the β -anomer: ^1H NMR (400 MHz, CDCl_3 , HH-COSY, HSQC, NOESY): δ 7.36 – 7.20 (m, 10H, CH_{arom}), 5.71 – 5.58 (m, 1H, CHCH_2 allyl), 5.53 (t, 1H, $J = 9.8$ Hz, H-4), 5.07 – 4.95 (m, 1H, CHCH_2 allyl), 5.01 (d, 1H, $J = 11.5$ Hz, CHH Bn), 4.72 (d, 1H, $J = 12.2$ Hz, CHH Bn), 4.66 (d, 1H, $J = 11.6$ Hz, CHH Bn), 4.61 (d, 1H, $J = 12.2$ Hz, CHH Bn), 3.83 (d, 1H, $J = 9.9$ Hz, H-5), 3.79 (d, 1H, $J = 2.3$ Hz, H-2), 3.71 (s, 3H, CH_3 CO_2Me), 3.60 (dd, 1H, $J = 9.9$, 2.7 Hz, H-3), 3.36 (t, 1H, $J = 7.1$ Hz, H-1), 2.56 – 2.48 (m, 1H, CHHCH allylic), 2.40 – 2.26 (m, 1H, CHHCH), 2.01 (s, 3H, CH_3 OAc); ^{13}C -APT NMR (101 MHz, CDCl_3 , HSQC, HMBC): δ 169.9, 168.5 (C=O CO_2Me , Ac), 138.3, 138.0 (C_q), 134.0 (CHCH_2 allyl), 131.3, 131.2, 129.4, 129.1, 128.6, 128.6, 128.5, 128.4, 128.3, 128.1, 128.1, 128.0, 127.9, 127.8, 127.7, 127.6, 127.6, 124.9 (CH_{arom}), 117.9 (CHCH_2 allyl), 88.6 (H-3), 79.1 (H-1), 77.6 (C-5), 74.5 (CH_2 Bn), 73.7 (C-2), 72.6 (CH_2 Bn), 69.5 (C-4), 52.7 (CH_3 CO_2Me), 35.4 (CH_2CH allyl), 21.0 (CH_3 Ac); HRMS: $[\text{M}+\text{NH}_4]^+$ calcd for $\text{C}_{26}\text{H}_{34}\text{NO}_7$ 472.23298, found 472.23294.




Methyl 6-O-(methyl [4-O-acetyl-2,3-di-O-benzyl- β -D-mannopyranosyl uronate])-2,3,4-tri-O-benzyl- α -D-glucopyranoside (30). Donor **3** and acceptor **10** were condensed using

the general procedure for $\text{Ti}_2\text{O}/\text{Ph}_2\text{SO}$ mediated glycosylations (for an additional 16 hours at -40°C) and purified by flash column chromatography (9/1 to 7/3 pentane/EtOAc) to yield glycosylation product **30** (57.5 mg, 66 μmol , 66%, $\alpha:\beta = <1:20$). R_f : 0.54 (7/3 pentane/EtOAc). Spectroscopic data were in accord with those previously reported.¹¹³ $[\alpha]_D^{26} = -11.6^\circ$ ($c = 1$, CHCl_3), (lit:¹¹³ $[\alpha]_D^{22} = -11.0^\circ$ ($c = 0.6$, CHCl_3)). IR (neat): 733, 906, 1028, 1055, 1101, 1242, 1361, 1452, 1748, 2908; Data for the β -anomer: ^1H NMR (400 MHz, CDCl_3 , HH-COSY, HSQC, HMBC): δ 7.40 – 7.19 (m, 25H, CH_{arom}), 5.48 (t, 1H, $J = 9.6$ Hz, H-4'), 5.02 (d, 1H, $J = 10.9$ Hz, CHH Bn), 4.91 (d, 1H, $J = 12.6$ Hz, CHH Bn), 4.83 (d, 1H, $J = 10.9$ Hz, CHH Bn), 4.82 (d, 1H, $J = 11.7$ Hz, CHH Bn), 4.80 – 4.71 (m, 3H, CHH Bn, CHH Bn, CHH Bn), 4.67 (d, 1H, $J = 12.2$ Hz, CHH Bn), 4.57 (d, 1H, $J = 3.5$ Hz, H-1), 4.50 (d, 1H, $J = 4.4$ Hz, CHH Bn), 4.47 (d, 1H, $J = 5.3$ Hz, CHH Bn), 4.36 (d, 1H, $J = 12.4$ Hz, CHH Bn), 4.16 – 4.09 (m, 2H, H-6, H-1'), 4.01 (t, 1H, $J = 9.2$ Hz, H-3), 3.79 (dq, 1H, $J = 7.3$, 2.8, 1.7 Hz, H-5), 3.74 (d, 1H, $J = 9.5$ Hz, H-5'), 3.72 – 3.66 (m, 4H, CH_3 CO_2Me , H-2'), 3.50 (dd, 1H, $J = 9.7$, 3.5 Hz, H-2), 3.45 – 3.34 (m, 3H, H-4, H-6, H-3'), 3.31 (s, 3H, CH_3 OMe), 2.02 (s, 3H, CH_3 OAc); ^{13}C -APT NMR (101 MHz, CDCl_3 , HSQC, HMBC): δ 169.7, 168.1 (C=O CO_2Me , Ac), 138.9, 138.4, 138.1, 137.8 (C_q), 128.6, 128.5, 128.5, 128.5, 128.3, 128.3, 128.2, 128.1, 128.1, 127.9, 127.8, 127.8, 127.6, 127.6 (CH_{arom}), 101.7 (C-1'), 97.9 (C-1), 82.2 (H-3), 79.9 (H-2), 78.3 (H-3'), 77.7 (H-4), 75.9 (CH_2 Bn), 74.9 (CH_2 Bn), 73.8 (C-5'), 73.7 (CH_2 Bn), 73.5 (CH_2 Bn), 72.9 (C-2'), 71.6 (CH_2 Bn), 69.8 (C-5), 69.0 (C-4'), 68.8 (C-6), 55.2 (CH_3 OMe), 52.7 (CH_3 CO_2Me), 21.0 (CH_3 Ac); ^{13}C -GATED NMR (101 MHz, CDCl_3) δ 101.7 ($J_{\text{C}1,\text{H}1} = 155$ Hz, C-1' β); HRMS: $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{51}\text{H}_{56}\text{O}_{13}\text{Na}$ 899.36131, found 899.36111.




Methyl 4-O-(methyl [4-O-acetyl-2,3-di-O-benzyl- β -D-mannopyranosyl uronate])-2,3,6-tri-O-benzyl- α -D-glucopyranoside (31). Donor **3** and acceptor **11** were condensed using

the general procedure for $\text{Ti}_2\text{O}/\text{Ph}_2\text{SO}$ mediated glycosylations (for an additional 16 hours at -40°C) and purified by flash column chromatography (9/1 to 7/3 pentane/EtOAc) to yield glycosylation product **31** (53.1 mg, 61 μmol , 61%, $\alpha:\beta = <1:20$). R_f : 0.65 (7/3 pentane/EtOAc); $[\alpha]_D^{26} = -30.2^\circ$ ($c = 1$, CHCl_3). IR (neat): 733, 1026, 1096, 1366, 1454, 1746, 2920; Data for the β -anomer: ^1H NMR (400 MHz, CDCl_3 , HH-COSY, HSQC, HMBC): δ 7.39 – 7.19 (m, 25H, CH_{arom}), 5.41 (t, 1H, $J = 9.7$ Hz, H-4'), 5.17 (d, 1H, $J = 11.3$ Hz, CHH Bn), 4.78 – 4.72 (m, 4H, CHH Bn, CHH Bn, CHH Bn, CHH Bn), 4.64 – 4.56 (m, 3H, CHH Bn, CHH Bn, H-1), 4.44 (d, 1H, $J = 12.3$ Hz, CHH Bn), 4.40 (s, 1H, H-1'), 4.36 (d, 1H, $J = 12.3$ Hz, CHH Bn), 4.28 (d, 1H, $J = 12.1$ Hz, CHH Bn), 3.89 (m, 2H, H-3, H-5), 3.68 – 3.63 (m, 1H,), 3.62 (d, 1H, $J = 2.7$ Hz, H-2'), 3.57 (d, 1H, $J = 9.7$ Hz, H-5'), 3.55 – 3.45 (m, 5H, H-2, CH_3 CO_2Me , C-6), 3.38 (s, 3H, CH_3 OMe), 3.18 (dd, 1H, $J = 9.7$, 2.8 Hz, H-3'), 2.01 (s, 3H, CH_3 OAc); ^{13}C -APT NMR (101 MHz, CDCl_3 , HSQC, HMBC): δ 169.7, 167.9 (C=O CO_2Me , Ac), 139.6, 138.5, 138.3, 138.1, 137.9 (C_q), 128.7, 128.5, 128.5, 128.2, 128.2, 128.2, 128.1, 128.0, 127.9, 127.9, 127.8, 127.5, 127.4, 127.1 (CH_{arom}), 101.1 (C-1'), 98.4 (C-1), 80.4 (C-3), 79.3 (H-2), 78.8 (C-3'), 78.2 (C-5), 75.4 (CH_2 Bn), 74.6 (C-2'), 74.2 (C-5'), 73.7 (CH_2 Bn), 73.7 (CH_2 Bn), 73.6 (CH_2 Bn), 71.8 (CH_2 Bn), 69.5 (H-4), 69.0 (C-4'), 68.7 (C-6), 55.4 (CH_3 OMe), 52.5 (CH_3 CO_2Me), 20.9 (CH_3 Ac); ^{13}C -GATED NMR (101 MHz, CDCl_3): δ 101.1 ($J_{\text{C}1,\text{H}1} = 158$ Hz, C-1' β); HRMS: $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{51}\text{H}_{56}\text{O}_{13}\text{Na}$ 899.36131, found 899.36094.




Methyl (methyl 4-O-[methyl (4-O-acetyl-2,3-di-O-benzyl- α / β -D-mannopyranosyl uronate)]-2,3-di-O-benzyl- α -D-glucopyranosyl uronate) (32). Donor **3** and acceptor **12**

were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (for an additional 48 hours at -40°C) and purified by flash column chromatography (9/1 to 7/3 pentane/EtOAc) to yield glycosylation product **32** (58.0 mg, 71 μ mol, 71%, α : β = 1:10). R_f: 0.38 (7/3 pentane/EtOAc); [α]_D²⁶ = -31.2° (*c* = 1, CHCl₃). IR (neat): 733, 1026, 1043, 1229, 1454, 1744, 2855, 2926; Data for the β -anomer: ¹H NMR (400 MHz, CDCl₃, HH-COSY, HSQC, HMBC): δ 7.42 – 7.23 (m, 20H, CH_{arom}), 5.44 (t, 1H, *J* = 9.8 Hz, H-4'), 5.19 (d, 1H, *J* = 11.3 Hz, CHH Bn), 4.88 – 4.69 (m, 4H, CHH Bn, CHH Bn, CHH Bn, CHH Bn), 4.62 – 4.38 (m, 5H, CHH Bn, CHH Bn, CHH Bn, H-1', H-1), 4.08 (d, 1H, *J* = 9.3 Hz, H-5), 3.96 – 3.85 (m, 2H, H-3, H-4), 3.76 (d, 1H, *J* = 2.7 Hz, H-2'), 3.70 (d, 1H, *J* = 9.7 Hz, H-5'), 3.59 (s, 3H, CH₃ CO₂Me), 3.53 – 3.46 (m, 4H, CH₃ CO₂Me, H-2), 3.46 – 3.37 (m, 4H, CH₃ OMe, H-3'), 2.00 (s, 3H, CH₃ OAc); ¹³C-APT NMR (101 MHz, CDCl₃, HSQC, HMBC): δ 170.2, 169.8, 167.8 (C=O CO₂Me, Ac), 139.4, 138.6, 138.1, 137.9 (C_q), 128.6, 128.5, 128.5, 128.5, 128.4, 128.3, 128.3, 128.2, 128.2, 128.1, 127.9, 127.8, 127.7, 127.6, 127.5, 127.2 (CH_{arom}), 102.3 (C-1'), 98.9 (C-1), 80.7 (C-4), 80.0 (C-3), 78.6 (C-2), 78.4 (C-3'), 75.7 (CH₂ Bn), 74.7 (C-2'), 74.5 (CH₂ Bn), 73.9 (CH₂ Bn, C-5'), 71.8 (CH₂ Bn), 69.6 (C-5), 69.0 (C-4'), 56.0 (CH₃ OMe), 52.6 (CH₃ CO₂Me), 52.5 (CH₃ CO₂Me), 20.9 (CH₃ Ac); ¹³C-GATED NMR (101 MHz, CDCl₃): δ 102.3 (*J*_{C1,H1} = 154 Hz, C-1' β); Diagnostic peaks α -anomer: ¹H NMR (400 MHz, CDCl₃, HH-COSY, HSQC): 5.44 (m, 0.20H, H-1', H-4'), 2.00 (s, 0.30H, CH₃ OAc); HRMS: [M+Na]⁺ calcd for C₄₅H₅₀O₁₄Na 837.30928, found 837.30903.



Methyl 4-O-(methyl [4-O-acetyl-2,3-di-O-benzyl- β -D-mannopyranosyl uronate])-2,3,6-tri-O-benzyl- β -D-galactopyranoside (33). Donor **3** and acceptor **13** were condensed

using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (for an additional 16 hours at -40°C) and purified by flash column chromatography (9/1 to 7/3 pentane/EtOAc) to yield glycosylation product **33** (66.8 mg, 76 μ mol, 76%, α : β < 1:20). R_f: 0.39 (7/3 pentane/EtOAc); [α]_D²⁶ = -31.6° (*c* = 1, CHCl₃). IR (neat): 735, 1026, 1051 1231, 1748, 2870; Data for the β -anomer: ¹H NMR (400 MHz, CDCl₃, HH-COSY, HSQC, HMBC): δ 7.35 – 7.22 (m, 25H, CH_{arom}), 5.45 (t, 1H, *J* = 9.8 Hz, H-4'), 4.95 (d, 1H, *J* = 12.7 Hz, CHH Bn), 4.93 (d, 1H, *J* = 10.9 Hz, CHH Bn), 4.85 (d, 1H, *J* = 12.7 Hz, CHH Bn), 4.78 (d, 1H, *J* = 11.7 Hz, CHH Bn), 4.75 (s, 1H, H-1'), 4.67 (d, 1H, *J* = 11.0 Hz, CHH Bn), 4.60 (d, 1H, *J* = 11.7 Hz, CHH Bn), 4.58 (d, 1H, *J* = 11.7 Hz, CHH Bn), 4.51 (d, 1H, *J* = 11.7 Hz, CHH Bn), 4.43 (d, 1H, *J* = 12.3 Hz, CHH Bn), 4.30 (d, 1H, *J* = 7.6 Hz, H-1), 4.22 (d, 1H, *J* = 12.3 Hz, CHH Bn), 4.15 (d, 1H, *J* = 2.5 Hz, H-2), 3.95 (d, 1H, *J* = 2.8 Hz, H-2'), 3.90 (dd, 1H, *J* = 9.7, 6.3 Hz, H-6), 3.74 (dd, 1H, *J* = 9.6, 5.7 Hz, H-6), 3.70 – 3.63 (m, 2H, H-5, H-5'), 3.63 – 3.56 (m, 7H, H-4, CH₃ OMe, CH₃ CO₂Me), 3.56 – 3.50 (m, 1H, H-3), 3.24 (dd, 1H, *J* = 9.8, 2.9 Hz, H-3'), 1.99 (s, 3H, CH₃ OAc); ¹³C-APT NMR (101 MHz, CDCl₃, HSQC, HMBC): δ 169.8, 168.1 (C=O CO₂Me, Ac), 138.8, 138.7, 138.3, 138.0 (C_q), 128.7, 128.6, 128.5, 128.3, 128.2, 128.0, 127.9, 127.8, 127.8, 127.7, 127.5, 127.5 (CH_{arom}), 105.1 (C-1), 101.9 (C-1'), 81.8 (C-3), 79.6 (C-5), 79.0 (C-3'), 75.1 (CH₂ Bn), 73.9 (C-5), 73.8 (CH₂ Bn), 73.6 (CH₂ Bn), 73.6 (C-4), 73.2 (C-2), 72.5 (C-2'), 71.3 (CH₂ Bn), 69.4 (C-6), 68.9 (C-4'), 57.2 (CH₃ CO₂Me), 52.6 (CH₃ OMe), 20.9 (CH₃ Ac); HRMS: [M+Na]⁺ calcd for C₅₁H₅₆O₁₃Na 899.36131, found 899.36109.



Methyl 2-O-(methyl [4-O-acetyl-2,3-di-O-benzyl- α / β -D-mannopyranosyl uronate])-3-O-benzyl-4,6-bezylidene- α -D-mannopyranoside (34). Donor **3** and acceptor **14** were condensed

using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (for an additional 16 hours at -40°C) and purified by flash column chromatography (9/1 to 7/3 pentane/EtOAc) to yield glycosylation product **34** (60.4 mg, 77 μ mol, 77%, α : β = 1:7.1). R_f: .34 (7/3 pentane/EtOAc); [α]_D²⁶ = -48.6° (*c* = 1, CHCl₃). IR (neat): 735, 1026, 1053, 1230, 1369, 1454, 1748, 2868, 2924; Data for the β -anomer: ¹H NMR (400 MHz, CDCl₃, HH-COSY, HSQC, HMBC): δ 7.51 – 7.22 (m, 15H, CH_{arom}), 5.60 – 5.53 (m, 2H, H-4', CHPh), 5.02 (d, 1H, *J* = 12.5 Hz, CHH Bn), 4.93 (d, 1H, *J* = 12.5 Hz, CHH Bn), 4.83 (d, 1H, *J* = 12.1 Hz, CHH Bn), 4.72 (d, 1H, *J* = 1.1 Hz, H-1), 4.64 (d, 1H, *J* = 12.1 Hz, CHH Bn), 4.62 (s, 1H, H-1'), 4.50 (d, 1H, *J* = 12.4 Hz, CHH Bn), 4.36 – 4.31 (m, 2H, CHH Bn, H-2), 4.29 – 4.24 (m, 1H, H-6), 4.15 – 4.07 (m, 1H, H-4), 4.01 – 3.91 (m, 2H, H-2', H-3), 3.85 (d, 1H, *J* = 9.7 Hz, H-5'), 3.82 – 3.75 (m, 2H, H-5, H-6), 3.63 (s, 3H, CH₃ CO₂Me), 3.48 (dd, 1H, *J* = 9.7, 2.9 Hz, H-3'), 3.35 (s, 3H, CH₃ OMe), 2.03 (s, 3H, CH₃ OAc); ¹³C-APT NMR (101 MHz, CDCl₃, HSQC, HMBC): δ 169.7, 167.9 (C=O CO₂Me, Ac), 138.8, 138.5, 137.8, 137.7 (C_q), 129.0, 128.7, 128.5, 128.4, 128.4, 128.4, 128.3, 128.3, 127.9, 127.9, 127.8, 127.8, 127.7, 127.6, 127.5, 127.4, 126.3, 126.2 (C_{arom}), 101.8 (CHPh), 99.8 (C-1'), 99.2 (C-1), 78.5 (C-4), 78.2 (C-3), 74.0 (C-5'), 73.9 (H-2), 73.9 (H-3), 73.9 (CH₂ Bn), 73.0 (H-2'), 71.3 (CH₂ Bn), 71.0 (CH₂ Bn), 69.0 (C-6), 68.8 (C-4'), 64.1 (H-5), 55.1 (CH₃ OMe), 52.7 (CH₃ CO₂Me), 21.0 (CH₃ Ac); ¹³C-GATED NMR (101 MHz, CDCl₃): δ 99.8 (*J*_{C1,H1} = 154 Hz, C-1' β); Diagnostic peaks α -anomer: ¹H NMR (400 MHz, CDCl₃, HH-COSY, HSQC, HMBC): 5.59 (s, 0.14H, CHPh), 5.50 (t, 0.14H, *J* = 7.5 Hz, H-4'), 5.45 (d, 0.14H, *J* = 4.0 Hz, H-1'), 3.66 (s, 0.42H, CH₃ CO₂Me), 3.35 (s, 0.42H, CH₃ OMe), 2.03 (s, 0.42H, CH₃ OAc); ¹³C-APT NMR (101 MHz, CDCl₃, HSQC, HMBC): δ 100.3 (C-1'), 69.5 (C-4'); HRMS: [M+NH₄]⁺ calcd for C₄₄H₅₂NO₁₃ 802.34332, found 802.34387.

Footnotes and references

- (1) Boltje, T. J.; Buskas, T.; Boons, G.-J. *Nat. Chem.* **2009**, *1* (8), 611–622.
- (2) Sinnott, M. *Carbohydrate Chemistry and Biochemistry: Structure and Mechanism*; The Royal Society of Chemistry, 2007.
- (3) Demchenko, A. V. *Handbook of Chemical Glycosylation: Advances in Stereoselectivity and Therapeutic Relevance*; Wiley-VCH Verlag GmbH & Co. KGaA, 2008.
- (4) Bennett, C. S. *Selective Glycosylations: Synthetic Methods and Catalysts*; Wiley VCH Verlag GmbH, 2017.
- (5) Cheung, M.-K.; Douglas, N.; Hinzen, B.; Ley, S.; Pannecoucke, X. *Synlett* **1997**, 1997 (3), 257–260.
- (6) Douglas, N. L.; Ley, S. V.; Lücking, U.; Warriner, S. L. *J. Chem. Soc. [Perkin 1]* **1998**, No. 1, 51–66.
- (7) Baeschlin, D. K.; Green, L. G.; Hahn, M. G.; Hinzen, B.; Ince, S. J.; Ley, S. V. *Tetrahedron Asymmetry* **2000**, *11* (1), 173–197.
- (8) Zhang, Z.; Ollmann, I. R.; Ye, X.-S.; Wischnat, R.; Baasov, T.; Wong, C.-H. *J. Am. Chem. Soc.* **1999**, *121* (4), 734–753.
- (9) Lee, J.-C.; Greenberg, W. A.; Wong, C.-H. *Nat. Protoc.* **2007**, *1* (6), 3143–3152.
- (10) Ritter, T. K.; Mong, K.-K. T.; Liu, H.; Nakatani, T.; Wong, C.-H. *Angew. Chem. Int. Ed.* **2003**, *42* (38), 4657–4660.
- (11) Krumper, J. R.; Salamant, W. A.; Woerpel, K. A. *Org. Lett.* **2008**, *10* (21), 4907–4910.
- (12) Krumper, J. R.; Salamant, W. A.; Woerpel, K. A. *J. Org. Chem.* **2009**, *74* (21), 8039–8050.
- (13) Beaver, M. G.; Woerpel, K. A. *J. Org. Chem.* **2010**, *75* (4), 1107–1118.
- (14) Kalikanda, J.; Li, Z. *Carbohydr. Res.* **2011**, *346* (15), 2380–2383.
- (15) Heuckendorff, M.; Jensen, H. H. *Eur. J. Org. Chem.* **2016**, 2016 (30), 5136–5145.
- (16) Bohn, M. L.; Colombo, M. I.; Stortz, C. A.; Rúveda, E. A. *Carbohydr. Res.* **2006**, *341* (9), 1096–1104.
- (17) Colombo, M. I.; Stortz, C. A.; Rúveda, E. A. *Carbohydr. Res.* **2011**, *346* (5), 569–576.
- (18) Schumann, B.; Parameswarappa, S. G.; Lisboa, M. P.; Kottari, N.; Guidetti, F.; Pereira, C. L.; Seeberger, P. H. *Angew. Chem. Int. Ed.* **2016**, *55* (46), 14431–14434.
- (19) Crich, D.; Sun, S. *J. Org. Chem.* **1996**, *61* (14), 4506–4507.
- (20) Crich, D.; Sun, S. *J. Org. Chem.* **1997**, *62* (5), 1198–1199.
- (21) Crich, D.; Cai, W. *J. Org. Chem.* **1999**, *64* (13), 4926–4930.
- (22) Crich, D.; Smith, M. *Org. Lett.* **2000**, *2* (25), 4067–4069.
- (23) Crich, D.; Smith, M. *J. Am. Chem. Soc.* **2001**, *123* (37), 9015–9020.
- (24) Frihed, T. G.; Bols, M.; Pedersen, C. M. *Chem. Rev.* **2015**, *115* (11), 4963–5013.
- (25) Crich, D.; Sun, S. *J. Am. Chem. Soc.* **1998**, *120* (2), 435–436.
- (26) Crich, D.; Dudkin, V. *J. Am. Chem. Soc.* **2001**, *123* (28), 6819–6825.
- (27) Crich, D.; Smith, M. *J. Am. Chem. Soc.* **2002**, *124* (30), 8867–8869.
- (28) Ohara, K.; Lin, C.-C.; Yang, P.-J.; Hung, W.-T.; Yang, W.-B.; Cheng, T.-J. R.; Fang, J.-M.; Wong, C.-H. *J. Org. Chem.* **2013**, *78* (13), 6390–6411.
- (29) Crich, D.; Vinod, A. U. *Org. Lett.* **2003**, *5* (8), 1297–1300.
- (30) Crich, D.; Li, W.; Li, H. *J. Am. Chem. Soc.* **2004**, *126* (46), 15081–15086.
- (31) Mukherjee, C.; Ranta, K.; Savolainen, J.; Leino, R. *Eur. J. Org. Chem.* **2012**, 2012 (15), 2957–2968.
- (32) Poláková, M.; Roslund, M. U.; Ekholm, F. S.; Saloranta, T.; Leino, R. *Eur. J. Org. Chem.* **2009**, 2009 (6), 870–888.
- (33) Crich, D.; Sun, S. *J. Am. Chem. Soc.* **1997**, *119* (46), 11217–11223.
- (34) Huang, M.; Garrett, G. E.; Birlirakis, N.; Bohé, L.; Pratt, D. A.; Crich, D. *Nat. Chem.* **2012**, *4* (8), 663–667.
- (35) Crich, D.; Chandrasekera, N. S. *Angew. Chem. Int. Ed.* **2004**, *43* (40), 5386–5389.
- (36) Huang, M.; Retailleau, P.; Bohé, L.; Crich, D. *J. Am. Chem. Soc.* **2012**, *134* (36), 14746–14749.
- (37) Adero, P. O.; Furukawa, T.; Huang, M.; Mukherjee, D.; Retailleau, P.; Bohé, L.; Crich, D. *J. Am. Chem. Soc.* **2015**, *137* (32), 10336–10345.
- (38) Huang, M.; Furukawa, T.; Retailleau, P.; Crich, D.; Bohé, L. *Carbohydr. Res.* **2016**, *427*, 21–28.
- (39) Bohé, L.; Crich, D. *Carbohydr. Res.* **2015**, *403*, 48–59.
- (40) Moumé-Pymbock, M.; Crich, D. *J. Org. Chem.* **2012**, *77* (20), 8905–8912.
- (41) Heuckendorff, M.; Bols, P. S.; Barry, C. B.; Frihed, T. G.; Pedersen, C. M.; Bols, M. *Chem. Commun.* **2015**, 51 (68), 13283–13285.
- (42) Heuckendorff, M.; Bendix, J.; Pedersen, C. M.; Bols, M. *Org. Lett.* **2014**, *16* (4), 1116–1119.

- (43) Crich, D.; de la Mora, M.; Vinod, A. U. *J. Org. Chem.* **2003**, *68* (21), 8142–8148.
- (44) Hogendorf, W. F. J.; Bos, L. J. V. den; Overkleef, H. S.; Codée, J. D. C.; Marel, G. A. V. *der. Bioorg. Med. Chem.* **2010**, *18* (11), 3668–3678.
- (45) Lourenço, E. C.; Maycock, C. D.; Rita Ventura, M. *Carbohydr. Res.* **2009**, *344* (15), 2073–2078.
- (46) Crich, D.; Sharma, I. *J. Org. Chem.* **2010**, *75* (24), 8383–8391.
- (47) Bousquet, E.; Khitri, M.; Lay, L.; Nicotra, F.; Panza, L.; Russo, G. *Carbohydr. Res.* **1998**, *311* (4), 171–181.
- (48) Walvoort, M. T. C.; Lodder, G.; Mazurek, J.; Overkleef, H. S.; Codée, J. D. C.; van der Marel, G. A. *J. Am. Chem. Soc.* **2009**, *131* (34), 12080–12081.
- (49) Rönnols, J.; Walvoort, M. T. C.; Marel, G. A. van der; Codée, J. D. C.; Widmalm, G. *Org. Biomol. Chem.* **2013**, *11* (46), 8127–8134.
- (50) Walvoort, M. T. C.; de Witte, W.; van Dijk, J.; Dinkelaar, J.; Lodder, G.; Overkleef, H. S.; Codée, J. D. C.; van der Marel, G. A. *Org. Lett.* **2011**, *13* (16), 4360–4363.
- (51) Codée, J. D. C.; van den Bos, L. J.; de Jong, A.-R.; Dinkelaar, J.; Lodder, G.; Overkleef, H. S.; van der Marel, G. A. *J. Org. Chem.* **2009**, *74* (1), 38–47.
- (52) van den Bos, L. J.; Dinkelaar, J.; Overkleef, H. S.; van der Marel, G. A. *J. Am. Chem. Soc.* **2006**, *128* (40), 13066–13067.
- (53) van den Bos, L. J.; Codée, J. D. C.; Litjens, R. E. J. N.; Dinkelaar, J.; Overkleef, H. S.; van der Marel, G. A. *Eur. J. Org. Chem.* **2007**, *2007* (24), 3963–3976.
- (54) Codée, J. D. C.; Walvoort, M. T. C.; Jong, A.-R. de; Lodder, G.; Overkleef, H. S.; Marel, G. A. van der. *J. Carbohydr. Chem.* **2011**, *30* (7–9), 438–457.
- (55) Dinkelaar, J.; de Jong, A. R.; van Meer, R.; Somers, M.; Lodder, G.; Overkleef, H. S.; Codée, J. D. C.; van der Marel, G. A. *J. Org. Chem.* **2009**, *74* (14), 4982–4991.
- (56) Tang, S.-L.; Pohl, N. L. B. *Org. Lett.* **2015**, *17* (11), 2642–2645.
- (57) Walvoort, M. T. C.; van den Elst, H.; Plante, O. J.; Kröck, L.; Seeberger, P. H.; Overkleef, H. S.; van der Marel, G. A.; Codée, J. D. C. *Angew. Chem. Int. Ed.* **2012**, *51* (18), 4393–4396.
- (58) Walvoort, M. T. C.; Dinkelaar, J.; van den Bos, L. J.; Lodder, G.; Overkleef, H. S.; Codée, J. D. C.; van der Marel, G. A. *Carbohydr. Res.* **2010**, *345* (10), 1252–1263.
- (59) Lee, Y. J.; Baek, J. Y.; Lee, B.-Y.; Kang, S. S.; Park, H.-S.; Jeon, H. B.; Kim, K. S. *Carbohydr. Res.* **2006**, *341* (10), 1708–1716.
- (60) Frihed, T. G.; Walvoort, M. T. C.; Codée, J. D. C.; van der Marel, G. A.; Bols, M.; Pedersen, C. M. *J. Org. Chem.* **2013**, *78* (6), 2191–2205.
- (61) Minegishi, S.; Kobayashi, S.; Mayr, H. *J. Am. Chem. Soc.* **2004**, *126* (16), 5174–5181.
- (62) Ammer, J.; Nolte, C.; Mayr, H. *J. Am. Chem. Soc.* **2012**, *134* (33), 13902–13911.
- (63) Ammer, J.; Mayr, H. *J. Phys. Org. Chem.* **2013**, *26* (1), 59–63.
- (64) Hansch, C.; Leo, A.; Taft, R. W. *Chem. Rev.* **1991**, *91* (2), 165–195.
- (65) Worm-Leonhard, K.; Larsen, K.; Jensen, K. J. *J. Carbohydr. Chem.* **2007**, *26* (7), 349–368.
- (66) Acid catalyzed anomerization reactions do not play a major role in the studied glycosylation reactions as the released acid is scavenged by tri-*tert*-butyl methyl pyrimidine (TTBP) and executed at low temperature. See ref.42.
- (67) Whitfield, D. M. *Carbohydr. Res.* **2007**, *342* (12–13), 1726–1740.
- (68) Hosoya, T.; Kosma, P.; Rosenau, T. *Carbohydr. Res.* **2015**, *411*, 64–69.
- (69) Wang, H.; Houk, K. N. *Chem. Sci.* **2013**, *5* (2), 462–470.
- (70) Crich, D. *Acc. Chem. Res.* **2010**, *43* (8), 1144–1153.
- (71) Seeman, J. I. *Chem. Rev.* **1983**, *83* (2), 83–134.
- (72) Crich, D.; Sharma, I. *Org. Lett.* **2008**, *10* (21), 4731–4734.
- (73) Calculated energies (kcal·mol⁻¹) of the methyl 2,3,4-tri-*O*-methyl manuronate oxocarbenium ion (B3LYP/6-311G, with a PCM model to correct for solvation in dichloromethane): ³H₄ = 0.0, ⁴H₃ = +5.0, B_{2,5} = +6.1.
- (74) Romero, J. A. C.; Tabacco, S. A.; Woerpel, K. A. *J. Am. Chem. Soc.* **2000**, *122* (1), 168–169.
- (75) Ayala, L.; Lucero, C. G.; Romero, J. A. C.; Tabacco, S. A.; Woerpel, K. A. *J. Am. Chem. Soc.* **2003**, *125* (50), 15521–15528.
- (76) Lucero, C. G.; Woerpel, K. A. *J. Org. Chem.* **2006**, *71* (7), 2641–2647.
- (77) Balmond, E. I.; Coe, D. M.; Galan, M. C.; McGarrigle, E. M. *Angew. Chem. Int. Ed.* **2012**, *51* (36), 9152–9155.
- (78) Ingle, A. B.; Chao, C.-S.; Hung, W.-C.; Mong, K.-K. T. *Org. Lett.* **2013**, *15* (20), 5290–5293.

- (79) Giordano, M.; Iadonisi, A. *J. Org. Chem.* **2014**, *79* (1), 213–222.
- (80) The concentration dependence of S_N2-type reactions indicates that this parameter should be carefully considered in optimizing these glycosylations. See for example ref. 36 and Fang, T.; Gu, Y.; Huang, W.; Boons, G.-J.; *J. Am. Chem. Soc.* **2016**, *138*, 3002–3011.
- (81) Crich, D.; Smith, M.; Yao, Q.; Picione, J. *Synthesis* **2001**, *2001* (02), 0323–0326.
- (82) Spartan '04; Kong, J. *et al.* **2004**, Wavefunction Inc.
- (83) Gaussian 03 (Revision E.01); Frisch, M. J. *et al.* **2004**, Gaussian, Inc.
- (84) Pedretti, V.; Veyrières, A.; Sinaÿ, P. *Tetrahedron* **1990**, *46* (1), 77–88.
- (85) Kametani, T.; Kawamura, K.; Honda, T. *J. Am. Chem. Soc.* **1987**, *109* (10), 3010–3017.
- (86) Kohata, K.; Meguro, H. *Agric. Biol. Chem.* **1982**, *46* (4), 919–925.
- (87) Emmadi, M.; Kulkarni, S. S. *J. Org. Chem.* **2011**, *76* (11), 4703–4709.
- (88) Smid, P.; Noort, D.; Broxterman, H. J. G.; van Straten, N. C. R.; van der Marel, G. A.; van Boom, J. H. *Recl. Trav. Chim. Pays-Bas* **1992**, *111* (12), 524–528.
- (89) Michihata, N.; Kaneko, Y.; Kasai, Y.; Tanigawa, K.; Hirokane, T.; Higasa, S.; Yamada, H. *J. Org. Chem.* **2013**, *78* (9), 4319–4328.
- (90) Blom, P.; Ruttens, B.; Van Hoof, S.; Hubrecht, I.; Van der Eycken, J.; Sas, B.; Van hemel, J.; Vandankerckhove, J. *J. Org. Chem.* **2005**, *70* (24), 10109–10112.
- (91) Raju, R.; Castillo, B. F.; Richardson, S. K.; Thakur, M.; Severins, R.; Kronenberg, M.; Howell, A. R. *Bioorg. Med. Chem. Lett.* **2009**, *19* (15), 4122–4125.
- (92) Janczuk, A. J.; Zhang, W.; Andreana, P. R.; Warrick, J.; Wang, P. G. *Carbohydr. Res.* **2002**, *337* (14), 1247–1259.
- (93) Gantt, R. W.; Goff, R. D.; Williams, G. J.; Thorson, J. S. *Angew. Chem. Int. Ed.* **2008**, *47* (46), 8889–8892.
- (94) Boonyarattanakalin, S.; Liu, X.; Michieletti, M.; Lepenies, B.; Seeberger, P. H. *J. Am. Chem. Soc.* **2008**, *130* (49), 16791–16799.
- (95) Yoza, K.; Amanokura, N.; Ono, Y.; Akao, T.; Shinmori, H.; Takeuchi, M.; Shinkai, S.; Reinhoudt, D. N. *Chem. – Eur. J.* **1999**, *5* (9), 2722–2729.
- (96) Michigami, K.; Hayashi, M. *Tetrahedron* **2013**, *69* (21), 4221–4225.
- (97) Kartha, K. P. R.; Aloui, M.; Field, R. A. *Tetrahedron Lett.* **1996**, *37* (48), 8807–8810.
- (98) Ren, B.; Dong, H.; Ramström, O. *Chem. – Asian J.* **2014**, *9* (5), 1298–1304.
- (99) Goux, W. J. *Carbohydr. Res.* **1988**, *184*, 47–65.
- (100) Bock, K.; Refn, S.; Pedersen, C.; Taft, R. W.; Fischer, G. W. *Acta Chem. Scand.* **1987**, *41b*, 469–472.
- (101) Wong, C.-H.; Moris-Varas, F.; Hung, S.-C.; Marron, T. G.; Lin, C.-C.; Gong, K. W.; Weitz-Schmidt, G. *J. Am. Chem. Soc.* **1997**, *119* (35), 8152–8158.
- (102) Attolino, E.; Catelani, G.; D'Andrea, F. *Eur. J. Org. Chem.* **2006**, *2006* (23), 5279–5292.
- (103) J. Garegg, P.; Hultberg, H.; Wallin, S. *Carbohydr. Res.* **1982**, *108* (1), 97–101.
- (104) Ennis, S. C.; Cumpstey, I.; Fairbanks, A. J.; Butters, T. D.; Mackeen, M.; Wormald, M. R. *Tetrahedron* **2002**, *58* (46), 9403–9411.
- (105) Nagai, H.; Sasaki, K.; Matsumura, S.; Toshima, K. *Carbohydr. Res.* **2005**, *340* (3), 337–353.
- (106) Sun, P.; Wang, P.; Zhang, Y.; Zhang, X.; Wang, C.; Liu, S.; Lu, J.; Li, M. *J. Org. Chem.* **2015**, *80* (8), 4164–4175.
- (107) Ella-Menye, J.-R.; Nie, X.; Wang, G. *Carbohydr. Res.* **2008**, *343* (10–11), 1743–1753.
- (108) Kim, K. S.; Fulse, D. B.; Baek, J. Y.; Lee, B.-Y.; Jeon, H. B. *J. Am. Chem. Soc.* **2008**, *130* (26), 8537–8547.
- (109) Baek, J. Y.; Choi, T. J.; Jeon, H. B.; Kim, K. S. *Angew. Chem. Int. Ed.* **2006**, *45* (44), 7436–7440.
- (110) Kim, K. S.; Kim, J. H.; Lee, Y. J.; Lee, Y. J.; Park, J. *J. Am. Chem. Soc.* **2001**, *123* (35), 8477–8481.
- (111) Crich, D.; Sun, S. *Tetrahedron* **1998**, *54* (29), 8321–8348.
- (112) Nie, X.; Wang, G. *J. Org. Chem.* **2005**, *70* (22), 8687–8692.
- (113) van den Bos, L. J.; Dinkelaar, J.; Overkleeft, H. S.; van der Marel, G. A. *J. Am. Chem. Soc.* **2006**, *128* (40), 13066–13067.

Chapter 4

Stereoselectivity of conformationally restricted glucosazide donors

Introduction

Glucosamine is a key constituent in numerous important oligosaccharides and glycoconjugates, where it can be either α - or β -linked.¹⁻⁵ Whereas the former type of linkage can be reliably installed through the use of neighboring-group participation of an C-2-amide- or carbamate based protecting group, the latter type continues to present a synthetic challenge.⁶⁻⁸ A thorough understanding of the glycosylation mechanism and the influence of both reaction partners and reaction conditions on glycosylation stereoselectivity is needed to enable reliable and predictable glycosylation reactions. The in-depth research conducted on conformationally restricted benzylidene mannose and glucose donors has provided important insight into the glycosylation mechanisms of this type of 1,2-*cis*-selective donor.⁹⁻¹⁷ To construct 1,2-*cis*-linkages of glucosamine donors, the C-2-amino group is most commonly masked as the nonparticipating azide.^{18,19} Notably, benzylidene glucosazides have not been systematically investigated with respect to the stereoselectivity of glycosylations in which they are employed. The extrapolation

of the stereoselectivity of benzylidene glucose donors to their glucosazide counterparts suggests that benzylidene or analogously protected glucosazides might represent an attractive class of 1,2-*cis*-selective glucosamine donor synthons.^{20,21}

In Chapter 3 a comprehensive set of partially fluorinated ethanols, of gradually decreasing nucleophilicity, that can be used to map how the stereoselectivity of a given glycosylation system is dependent on the nucleophilicity of the acceptor, was introduced.²² The stereoselectivity of the benzylidene glucose donor system proved to be greatly affected by the reactivity of the nucleophile.²³⁻²⁷ In light of the demand for 1,2-*cis*-selective glucosaminylations but also with the aim in mind of furthering the understanding of the stereoelectronic effects exerted by the azido group, this chapter sets out to systematically evaluate a series of glucosazide donors in a set of glycosylation reactions involving the toolset of partially fluorinated ethanols and a selection of carbohydrate acceptors. As is described here, changes in the structure and reactivity of the donor can be effectively mapped using the panel of model acceptors, and a clear reactivity-selectivity relationship for the stereoselectivity of the glycosylations, emerges for all donors studied. Differences among the donors and the stereochemical variation in the glycosylation outcome can be explained on the basis of competition experiments and the characterization of the reactive intermediates involved.

Results and discussion

The set of (partially) fluorinated ethanol acceptors that was employed in Chapter 3, to relate the glycosylation stereoselectivity to the acceptor nucleophilicity is depicted in Figure 1 (compounds **6-11**). Glycosylating these acceptors with benzylidene mannose, benzylidene glucose, and mannuronic acid donors, as well as fucosazide donors bearing various protecting groups, established the dependence of the stereoselectivity of the





Figure 1. Glucose-configured donors **1-5** and model acceptors **6-11** used in this study.

glycosylations with these donors on the nucleophilicity of the acceptor.^{22,28} For benzylidene protected glucose donor **1**, the gradual decrease in acceptor nucleophilicity going from ethanol, monofluoroethanol (MFE), difluoroethanol (DFE), trifluoroethanol (TFE), and hexafluoro-*iso*-propanol (HFIP) led to a gradual shift of the stereoselectivity from high β -selectivity to exclusive α -selectivity (See Table 3 below). Here, the results from investigating the set of conformationally restricted glucosamine donors depicted in Figure 1 (1-5) is presented. Variation in the structure of these donors is found in the cyclic protecting groups (benzylidene vs silylidene), in the functionality at the C-3-OH (benzyl vs benzoyl), and in the nature of the C-2-*N*-protecting group (azide vs the dinitropyridone [DNPY] group). The DNPY is introduced here as a nonparticipating *N*-protecting group.^{29,30} The reactivity and selectivity of the set of glucosamine donors are related to the corresponding properties of well-studied benzylidene glucose donor **1**.^{9,22}

Synthesis

Benzylidene-protected glucosazide donors **3**³¹ and **4**³² with an *O*-benzoyl and an *O*-benzoyl, respectively, at C-3, as well as silylidene-protected donor **2**, were prepared from common building block **12**³³ as depicted in Scheme 1. Hydrolysis of all acetyl esters and the trichloroacetamide was followed by a diazotransfer to install the desired C-2-azide.³⁴

Scheme 1. Preparation of donors 2-5.








Reagents and conditions: (a) *i.* K₂CO₃, EtOH, H₂O; *ii.* CuSO₄·5H₂O, imidazole-1-sulfonyl azide hydrochloride³⁴; (b) di-*tert*-butylsilyl bis(trifluoromethanesulfonate), pyridine, **14**: 71% (three steps); (c) PhCH(OMe)₂, *p*-TsOH·H₂O, **13**: 78% (three steps); (d) BnBr, NaH, DMF, **2**: 80%, **3**: 89%; (e) BzCl, DMAP, pyridine, DCM, 90%; (f) ethylenediamine, EtOH, 88%; (g) **18**, AcOH/pyridine (1/16, v/v), 98%; (h) K₂CO₃, NMP, 85%; (i) HNO₃, H₂SO₄, 60%.

Subsequent introduction of the di-*tert*-butylsilylidene (DTBS) and the benzylidene acetal gave intermediates **13**³¹ and **14**, respectively. Benzylation of **14** and **13** and benzylation of **13** gave the target donor compounds **2**, **3**, and **4**, respectively. Donor **5** was prepared in two steps from thioglucoside **15**³⁵ by exchange of the phthaloyl group for the DNPY functionality. To this end, compound **15** was treated with ethylenediamine to give amine **16**, which was treated with DNPY reagent **18**^{30,36} to furnish the target donor.

Observation of anomeric triflates

With these five donors in hand, the formation of potential covalent reactive intermediates was investigated by low-temperature NMR studies.³⁷ The donors were treated with the diphenyl sulfoxide/triflic anhydride (Ph₂SO/Tf₂O)³⁸ combination of reagents in deuterated dichloromethane. Figure 3 shows the results of these studies and Table 1 summarizes the anomeric chemical shifts of the observed triflates and the temperatures at which decomposition starts (T_{decomp}). Activation of reference donor **1** led

Table 1. Anomeric triflates observed.

Entry	Triflate	¹ H δ (ppm)	³ J _{H1-H2} ^a (Hz)	¹³ C δ (ppm)	T_{decomp} (°C)
1		6.09	3.4	106.1	-20
2		6.00	3.4	104.8	-30
3		6.07	3.5	105.0	-20
4		6.23	3.5	104.5	-10
5		6.06	n/a	102.2	-40

^avalues determined at -40°C




Figure 3. $^1\text{H-NMR}$ spectra at -40°C of activated donors **1-5** showing their respective anomeric triflates **19-23**.

to the formation of two species: In addition to the anomeric triflate **19**,⁹ the oxosulfonium triflate **19 α^*** (6.68 ppm, 3.6 Hz) was also formed, as was confirmed by the activation of a sample containing additional Ph_2SO . Donors **2** and **3** were cleanly converted to their anomeric α -triflates **20** and **21** respectively, by treatment at -80°C with the activation couple. Activation of donor **4** proceeded more slowly, and an increase of the temperature from -80°C to -35°C was required for complete activation. Donor **5** proved difficult to study by low-temperature NMR spectroscopy because of significant line broadening in the resonance sets for both the donor and the products formed upon activation. Complete activation of the thioglycoside could only be achieved at -40°C , but at this temperature, decomposition of the reactive intermediates also set in. Two anomeric signals can be discriminated in the spectrum of the activated DNPY donor **5** (Figure 3), and these were tentatively assigned as the intermediate triflate (6.06 ppm) and oxosulfonium triflate (6.54 ppm). Unfortunately, complete characterization was hampered by the severe line broadening.³⁹ The reactive intermediates formed all decomposed to give the glucal product **24** (Figure 2). The formation of the glucal double bond is relatively fast, as the proton at C-2 is readily eliminated to provide the enol ether double bond that is conjugated to the DNPY aromatic ring.




Figure 2. Structure of DNPY glucal **24**, cleanly forms as a decomposition product of activated donor **5**.

Competitive glycosylations and relative reactivities.

To investigate the reactivities of donors **1-5**, a series of competitive glycosylations were performed between the different thioglycosides.⁴⁰⁻⁴⁴ In these competition experiments, an *in situ* activation protocol was used, employing *N*-iodosuccinimide (NIS)/trifluoromethanesulfonic acid (TfOH) as activator and 2,3,4-tri-*O*-benzyl- α -*O*-methyl glucose (**25**) as the acceptor, as is commonly done to determine the reactivities of thioglycoside donors.^{45,46} It should be noted, however, that the reactivity of the thiophenyl donor does not directly compare with the reactivity of an intermediate triflate in the glycosylation, although it does provide an indication of the relative disarming or arming nature of the protecting groups present on the different donors. It is apparent from Table 2 that the azide has a profound effect on the reactivity of donor **3**, as it is completely outcompeted by the C-2-*O*-benzyl donor **1**.⁴⁶ Silylidene donor **2** is more reactive than donor **3**, and the disaccharide products derived from donor **2** and **3** are

Table 2. Competitive donor activations.

Entry	Donor I	Donor II	Products ^a	Ratios	Yield ^b (%)
1	1	2	1C/2C	14 : 1	65
2	1	3	1C/3C	1 : 0	80
3	2	3	2C/3C	6 : 1	37
4	3	4	3C/4C	1.6 : 1	39
5 ^c	4	5	4C/5C	1 : 0	64

^aDetermined by ¹H-NMR of the isolated disaccharide. ^bThe disaccharide fraction was quantified after isolation by size-exclusion chromatography and related to the limiting amount of NIS (see experimental section). ^cThe combined donor concentration for entry 5 was 0.1 M, triflic acid was added at -20°C and the reaction mixture was heated to +15°C overnight, and then the reaction was quenched (Et₃N).

















formed in a 6:1 ratio. C-3-O-Benzyl donor **3** in turn outcompetes benzoylated donor **4** slightly, as a result of the electron-withdrawing nature of the benzoate, giving a 1.6:1 ratio of the addition products **3C** and **4C**.⁴⁷⁻⁴⁹ DNPY-protected donor **5** is the least reactive of the set of donors, as it did not provide any disaccharide product in the competition experiment with donor **4**.

Glycosylations

With the reactivities of these five donors established, the series of glycosylations with model acceptors **6-11** and carbohydrate acceptors **25-29**⁵⁰⁻⁵² was undertaken using the Ph₂SO/Tf₂O preactivation procedure. Table 3 list all glycosylations ordered by acceptor and donor reactivity. A clear relation between acceptor nucleophilicity and stereochemical outcome of the glycosylation reactions of all studied glucosamine donors was observed, in line with the results previously obtained with donor **1**. Upon comparison of the outcomes of the coupling reactions of glucosazide **3** with the results obtained with C-2-O-benzyl donor **1**, it becomes apparent that the latter donor reacts with higher α -selectivity. Donor **2**, bearing the DTBS group, overall provides slightly more of the α -linked products than its benzylidene counterpart **3**. The stereoselectivity of the condensations of donor **4**, bearing an additional electron-withdrawing protecting group (*i.e.*, the C-3-O-benzoyl), is very similar to the stereoselectivity observed with C-3-O-benzyl donor **3**. Finally, donor **5**, carrying the strongly electron-withdrawing DNPY group, is the most β -selective of the series of donors listed in Table 3.⁵³

The selectivities of glycosylations with carbohydrate acceptors were also found to vary in a nucleophilicity-dependent fashion. The primary perbenzylated acceptor **25** reacts similarly to ethanol **7** to give primarily the β -linked products for all glucosamine donors studied. Secondary carbohydrate acceptors that were less nucleophilic showed variations in selectivity with the proportion of α -product increasing with decreasing acceptor reactivity. In line with the results from Chapter 3, the nucleophilicities of the secondary equatorial carbohydrate alcohols fall somewhere between the reactivities of MFE and DFE, with the reactivities of the axial hydroxyls approaching the reactivity of TFE. The differences in the reactivities of the donors are reflected in the stereoselectivities of both the glycosylations that involve the model acceptors and the glycosylations with the carbohydrate acceptors. A recurring trend is apparent for all acceptors, with the most reactive donor **1** providing most α -linked product and the least reactive donor **5** giving least α -linked product.

Table 3. Glycosylations of donors 1-5 with model acceptors 6-11 and carbohydrate acceptors 25-29.

					
	1	2	3	4	5
Acceptor	Product ^a $\alpha:\beta$ (yield) ^b	Product $\alpha:\beta$ (yield)	Product $\alpha:\beta$ (yield)	Product $\alpha:\beta$ (yield)	Product $\alpha:\beta$ (yield)
A 	1A 1 : 10 (68 %)	2A < 1 : 20 (65 %)	3A < 1 : 20 (83 %)	4A < 1 : 20 (86 %)	5A < 1 : 20 (59 %)
B 	1B 1 : 5.1 (71 %)	2B < 1 : 20 (77 %)	3B < 1 : 20 (93 %)	4B < 1 : 20 (91 %)	5B < 1 : 20 (63 %)
C 	1C 1 : 2.7 (81 %)	2C 1 : 14 (92 %)	3C < 1 : 20 (89 %)	4C 1 : 14 (79 %)	5C < 1 : 20 (57 %)
D 	1D 1 : 2.8 (70 %)	2D 1 : 5 (79 %)	3D 1 : 6.7 (90 %)	4D 1 : 6.5 (83 %)	5D < 1 : 20 (43 %)
E 	1E 1 : 1 (79 %)	2E 1 : 3 (81 %)	3E 1 : 7 (88 %)	4E 1 : 6 (71 %)	5E 1 : 20 (55 %)
F 	1F 5 : 1 (90 %)	2F 3.3 : 1 (84 %)	3F 1.1 : 1 (93 %)	4F 1 : 1.4 (59 %)	5F 1 : 3.6 (30 %)
G 	1G 5 : 1 (70 %)	2G 2.7 : 1 (76 %)	3G 2.9 : 1 (64 %)	4G 2.7 : 1 (84 %)	5G 1 : 1 (59 %)
H 	1H > 20 : 1 (83 %)	2H 7 : 1 (52 %)	3H 9 : 1 (75 %)	4H 4 : 1 (51 %)	5H < 1 : 20 (52 %)
I 	1I > 20 : 1 (80 %)	2I > 20 : 1 (85 %)	3I 9 : 1 (74 %)	4I 5 : 1 (73 %)	5I 1 : 1.3 (53 %)
J 	1J > 20 : 1 (64 %)	2J > 20 : 1 (82 %)	3J > 20 : 1 (94 %)	4J > 20 : 1 (86 %)	5J 4 : 1 (58 %)
K 	1K > 20 : 1 (65 %)	2K > 20 : 1 (34 %)	3K > 20 : 1 (53 %)	- ^c	32% 24

^aGlycosylation results of donor 1, are also reported in Chapter 2 of this thesis. ^bRatio and yield of isolated product after column chromatography, anomers were not separated. ^cOnly hydrolysed donor was found.

Mechanistic discussion

Two major trends become apparent from the table of glycosylations. First, with decreasing acceptor nucleophilicity the α/β ratio increases. Second, decreasing donor reactivity corresponds to a decrease in the α/β ratio. These trends also emerged in Chapter 3 and the work on fucosazide donors.^{22,28} The reactive intermediates that can play a role in the glycosylations of the conformationally restricted glucosamine donors and the reaction trajectories of the incoming nucleophiles are presented in Figure 4. Previous studies by the group of Crich have indicated that substitutions on the benzylidene glucosyl triflate **19** proceed in an S_N2 -like manner. In these mechanistic studies, which involved the determination of kinetic isotope effects and cation-clock methodology, isopropanol was used as an acceptor.^{12,14} In the kinetic scenario that was proposed the relatively stable α -triflate (observed by low-temperature NMR spectroscopy) is in equilibrium with its more reactive β -counterpart. In both species, the triflate can be displaced by alcohols if they are nucleophilic enough. The higher β -selectivity that is seen for the glucosazide and DNPY-glucosamine donors in comparison to donor **1** can be explained by the stronger electron-withdrawing effect of the azide with respect to the benzyl ether. This leads to a more stable covalent α -triflate and favors an associative displacement mechanism. A similar effect has been observed by the group of Crich in glycosylations of the analogous 2-deoxy-2-fluoro benzylidene glucosides.⁵⁴ The DNPY group is even more electron withdrawing, leading to a further increase in β -selectivity through associative displacement. However, an S_N2 -like reaction pathway is




Figure 4. Reactive intermediates and reaction pathways for the 4,6-tethered glucosazide donors.

less likely for the weaker nucleophiles, such as TFE and HFIP. The high α -selectivity for these acceptors can be explained perhaps more precisely by considering the involvement of more electrophilic intermediates such as the glycosyl oxocarbenium ion. The benzylidene and silylidene protecting groups restrict the conformational space that the donor pyranosides can adopt and the intermediate oxocarbenium ion likely adopt a ${}^4E/{}^4H_3$ -like conformation.^{55,56} Nucleophiles attack this envelope/half-chair conformer preferentially from the bottom face to lead to the α -linked products through a chair-like transition state.⁵⁷ The more reactive donors more readily dissociate to form an oxocarbenium ion, and this accounts for the increased α -selectivity for these donors. Donor **2**, bearing the silylidene group is the most reactive of the studied glucosamine donors. It also is slightly more flexible than the benzylidene restricted donors, and these two factors allow the activated donor to more readily form a flattened oxocarbenium ion-like intermediate. Consequently, it is the most α -selective of the studied glucosamine donors. Finally, it is notable that the C-3-*O*-benzoyl protected glucosazide **4** reacts in a slightly more β -selective fashion than its C-3-*O*-benzyl counterpart **3**. In light of the discussion above, this makes sense, as the electron-withdrawing benzoyl stabilizes the anomeric α -triflate. It contrasts, however, with the behavior of acyl groups at the C-3 position of benzylidene mannosyl donors. The 1,2-*cis*-selectivity generally observed for these donors can be completely changed to selectively give the α -linked products by installing a C-3-acyl group in the donor.^{58,59} The difference between the benzylidene mannose and benzylidene glucose series can be found in the different geometries that the oxocarbenium ions adopts. For the benzylidene mannose system, a $B_{2,5}$ -like structure is one of the lower-energy oxocarbenium ion conformers.^{12,55,56} In this constellation, the C-3-benzoate can fold over to the electron-depleted anomeric center to provide stabilization, without a major skeletal rearrangement. For the benzylidene glucose, on the other hand, a $B_{2,5}$ -like structure such as **32** is significantly less favorable because this puts the C-2-azide in a flagpole position. Given the selectivities observed for this donor, influences arising from this boat conformation do not play a significant role here.

Conclusions

A set of model acceptors of gradually changing nucleophilicity has been used to investigate how the stereochemistry of glycosylations involving 4,6-tethered glucosamine donors relates to the nucleophilicity of the acceptor. The set of acceptors was complemented by a suite of carbohydrate alcohols to translate the results obtained with


the model acceptors to a more relevant glycosylation setting. Four glucosamine donors were probed that differed in the type of tether spanning the C-4 and C-6-alcohols, the nature of the protecting group at the C-3-OH, and the amino functionality at C-2. Similarly to the previously described benzylidene glucose donor **1**, the stereoselectivity of the studied glucosamine donors show a strong correlation to the nucleophilicity of the acceptor, with strong nucleophiles providing completely β -selective condensations and weak nucleophiles selectively leading to the formation of the α -linked products. Benzylidene glucosazide donors are less α -selective than their C-2-O-benzyl congeners, because of the increased electron-withdrawing power of the azide, which retards the formation of an oxocarbenium ion species and favors a more associative mechanistic pathway. This chapter also introduced a novel protecting group for the C-2-amino group: the dinitropyridone functionality.^{29,30,36} Although this group is easily installed and removed from the C-2-amine, its strongly electron-withdrawing character limits its use. In the 4,6-benzylidene glucosamine donor studied here it disarms the donor glycoside to the extent that it turns into a suboptimal glycosyl donor. A major incentive for the reported study was the good to excellent α -selectivity that has previously been reported for benzylidene glucose donor **1**. Unfortunately, installation of a 4,6-benzylidene on the analogous glucosazide donors does not provide a reliable donor to affect 1,2-*cis*-selective glycosylations. Only with relatively poor nucleophiles are useful stereoselectivities obtained. Changing the benzylidene for a silylidene group, however, turns the donor into a more reactive glycosylating agent showing improved α -selectivity. This donor, attractive because of its fully orthogonal protecting group scheme, might find application in the future assembly of oligosaccharides featuring α -glucosamines. Finally, it is prudent to note that this study provides another illustration of the application of the toolset of partially fluorinated ethanols to efficiently map the reactivity-selectivity relationship of a class of donor glycosides. Implementation of this methodology to investigate novel donor systems will broaden the insight into the different mechanistic pathways at play during glycosylations and eventually generate a complete picture how to tune both reaction partners to achieve stereoselective glycosylation reactions in a predictable manner.

Experimental section

General procedure for Tf₂O/Ph₂SO mediated glycosylations: Donor (0.1 mmol), Ph₂SO (26 mg, 0.13 mmol, 1.3 eq.) and TTBP⁶⁰ (62 mg, 0.25 mmol, 2.5 eq.) were coevaporated twice with dry toluene and dissolved in dry DCM (2 mL, 0.05 M donor). Activated 3Å molecular sieves (rods, size 1/16 in.) were added, and the reaction mixture stirred for 1 h at room temperature under a nitrogen atmosphere. The solution was cooled to -78°C and Tf₂O (22 µL, 0.13 mmol, 1.3 eq.) was added. The reaction mixture was allowed to warm to -60°C (donor **1**, **2**, **3**), -45°C (donor **5**), -35°C (donor **4**), followed by recooling to -78°C and addition of the acceptor (0.2 mmol, 2 eq.) in DCM (0.4 mL, 0.5 M). The reaction mixture was allowed to warm to -40°C in approximately 90 min and stirred for an additional 0-18 h depending on the acceptor. The reaction was quenched with Et₃N (0.1 mL, 0.72 mmol, 5.5 eq.) at -40 °C and diluted with DCM. The solution was transferred to a separatory funnel and water was added, the layers were separated and the water phase extracted once more with DCM. The combined organic layers were dried over MgSO₄, filtered, and concentrated *in vacuo*. Purification by silica gel flash column chromatography and when needed, sephadexTM LH-20 size exclusion chromatography yielded the glycosylation product as a mixture of anomers.


General procedure for the NIS/TfOH mediated competition experiments: Donor I (0.1 mmol, 1 eq.), donor II (0.1 mmol, 1 eq.) and acceptor **25** (0.2 mmol, 2 eq.) were together coevaporated with dry toluene (2x). Dry DCM (4 mL, donor concentration 0.05 M), a Teflon stirring bar and 3Å activated molecular sieves (rods, size 1/16 in.) were added and the mixture was stirred under a nitrogen atmosphere for 1 h at room temperature. The mixture was cooled to -40°C and NIS (0.1 mmol, 1 eq.) was added. TfOH (50 µL of a freshly prepared 0.2 M stock solution in dry DCM, 0.1 eq.) was added and the mixture was allowed to warm to 0°C in 3 hours. Et₃N (0.1 mL) was added and the mixture was diluted with EtOAc, washed with sat. aq. Na₂O₃ and brine, dried over Na₂SO₄ and concentrated *in vacuo*. Size exclusion chromatography (Sephadex LH-20, 1/1 DCM/MeOH) enabled isolation of the disaccharide products and the monosaccharide rests, which were both analysed with NMR spectroscopy. The yield of the disaccharide fraction was determined. For the competition between donors **4** and **5**, a 0.1 M concentration, and a starting temperature of -20°C was used, which was allowed to warm to +15°C in 18h.

General procedure for the low temperature NMR experiments: A mixture of donor (30 µmol) and Ph₂SO (39 µmol) was coevaporated with dry toluene twice (for the activation of donor 1 also TTBP (75 µmol) was added). Under a nitrogen atmosphere, CD₂Cl₂ (0.6 mL) was added and the mixture transferred to a nitrogen flushed NMR tube and closed with a NMR tube septum. The NMR magnet was cooled to -80°C, locked and shimmed and the sample was measure prior to activation. In a long narrow cold bath (EtOH, -85°C) the sample was treated with Tf₂O (39 µmol), shaken thrice and cooled again after every shake. The cold sample was wiped dry and quickly inserted back in the cold magnet. The first ¹H NMR spectrum was immediately recorded. The sample was then reshimmmed and spectra were recorded in 10°C intervals with at least 5 min equilibration time for every temperature.




Phenyl 2-azido-4,6-O-benzylidene-2-deoxy-1-thio-β-D-glucopyranoside (13). To a suspension of thioglycoside **12**³³ (27.14 g, 50 mmol, 1 eq.) in EtOH (200 mL) was added K₂CO₃ (41.5 g, 300 mmol, 6 eq), and 20 mL H₂O and the mixture was refluxed overnight. The flask was cooled to r.t. and to the crude free amine⁶¹ was added the diazo transfer reagent imidazole-1-sulfonyl azide hydrochloride³⁴ (13.10 g, 62.5 mmol, 1.25 eq.) in 3 equal portions followed by a catalytic amount of CuSO₄·5 H₂O (125 mg, 0.5 mmol, 0.01 eq.). After stirring for 5 hours, the solution was filtered and reduced to 1/4 of its volume *in vacuo*. H₂O (150 mL) and 1 M aq. HCl (150 mL) were added to obtain an acidic (pH ≈ 3) solution which was extracted with EtOAc (3x 120 mL). The combined organic layers were washed with sat. aq. NaHCO₃ (150 mL) and brine (150 mL), dried with MgSO₄ and concentrated *in vacuo* to obtain crude azide; phenyl 2-azido-2-deoxy-1-thio-β-D-glucopyranoside.⁶² The crude azide (≤50 mmol) was coevaporated with toluene twice and subsequently dissolved in DMF (50 mL) and MeCN (200 mL) to which benzaldehyde dimethyl acetal (15 mL, 100 mmol, 2 eq.) and *p*-TsOH·H₂O (950 mg, 5 mmol, 0.1 eq.) were added. The reaction mixture was heated at 60°C overnight, followed by an additional 5 hours of heating at 60°C under reduced pressure (300 mbar) to reduce the volume to 1/3. The reaction was quench by the addition of triethylamine (1 mL), and diluted with EtOAc (350 mL), washed with H₂O (2x 100 mL), sat. aq. NaHCO₃ (1x 100 mL), and brine (1x 100 mL). The organic layer was dried (MgSO₄) and concentrated *in vacuo*. The crude mixture was purified by precipitation from hot EtOAc (100 mL) / heptane (300 mL) by adding petroleum ether (500 mL) while stirring and slowly cooling to 0°C to obtain the title compound as a white powder (11.38 g, 29.5 mmol, 59%). The mother liquors were purified by flash column chromatography (8/1 to 4/1 pentane/EtOAc) to obtain an additional batch of white solid product (3.8 g, 9.6 mmol, total yield = 39.1 mmol, 78%, 3 steps). A purified sample could be recrystallized from either hot MeOH or EtOAc/petroleum ether to obtain white cotton like needles. R_f: 0.50 (6/1 pentane/EtOAc). Spectroscopic

data were in accord with those previously reported.³¹ ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.64 – 7.52 (m, 2H, CH_{arom}), 7.50 – 7.43 (m, 2H, CH_{arom}), 7.42 – 7.32 (m, 6H, CH_{arom}), 5.53 (s, 1H, CHPh), 4.54 (d, 1H, *J* = 10.1 Hz, H-1), 4.38 (dd, 1H, *J* = 10.5, 4.6 Hz, H-6), 3.85 – 3.70 (m, 2H, H-3, H-6), 3.52 – 3.40 (m, 2H, H-4, H-5), 3.35 (dd, 1H, *J* = 10.2, 9.0 Hz, H-6), 2.75 (bs, 1H, 3-OH); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 136.8 (C_q CHPh), 133.8 (CH_{arom}), 130.9 (C_q SPh), 129.6, 129.3, 128.8, 128.5, 126.4 (CH_{arom}), 102.1 (CHPh), 86.9 (C-1), 80.3 (C-4), 74.2 (C-3), 70.4 (C-5), 68.5 (C-6), 65.2 (C-2); HRMS: [M+H]⁺ calcd for C₁₉H₂₀N₃O₄S 386.11690, found 386.11708.




Phenyl 2-azido-2-deoxy-4,6-O-di-tert-butylsilylidene-1-thio-β-D-glucopyranoside (14). Crude triol phenyl 2-azido-2-deoxy-1-thio-β-D-glucopyranoside (synthesized as described for compound **13**) (≤10 mmol) was dissolved in pyridine (15 mL) and cooled to 0°C. Di-tert-butylsilyl bis(trifluoromethanesulfonate) (3.6 mL, 11 mmol, 1.1 eq.) was slowly added and the reaction was stirred for 1 h before being quenched with MeOH. The reaction mixture

was diluted with 200 mL Et₂O and washed with 1M aq. HCl (3x 60 mL), sat. aq. NaHCO₃ (60 mL), and brine (60 mL). The organic layer was dried with Na₂SO₄, filtered and concentrated in vacuo. Purification by flash column chromatography (1-10% Et₂O/pentane) afforded the silylidene protected title compound as a colorless oil (3.10 g, 7.1 mmol, 71% over three steps). R_f: 0.18 (19/1 pentane/Et₂O). [α]_D²³ = -42.6° (c = 1.0, CHCl₃); IR (neat): 652, 733, 824, 1072, 1092, 1155, 1277, 1474, 2112, 2859, 2884, 2934, 2963, 3449; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC) δ 7.57 – 7.51 (m, 2H, CH_{arom}), 7.36 – 7.31 (m, 3H, CH_{arom}), 4.49 (d, 1H, *J* = 10.2 Hz, H-1), 4.21 (dd, 1H, *J* = 10.2, 5.1 Hz, H-6), 3.89 (t, 1H, *J* = 10.2 Hz, H-6), 3.64 (t, 1H, *J* = 9.1 Hz, H-4), 3.56 (td, 1H, *J* = 9.0, 1.2 Hz, H-3), 3.40 (ddd, 1H, *J* = 10.1, 9.3, 5.1 Hz, H-5), 3.31 (dd, 1H, *J* = 10.2, 9.1 Hz, H-2), 2.92 (d, 1H, *J* = 1.6 Hz, 3-OH), 1.04 (s, 9H, CH₃^tBu), 0.97 (s, 9H, CH₃^tBu); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 133.7 (CH_{arom}), 131.2 (C_q), 129.2, 128.7 (CH_{arom}), 86.8 (C-1), 77.4 (C-3), 76.6 (C-4), 74.4 (C-5), 66.0 (C-6), 64.4 (C-2), 27.5, 27.0 (CH₃^tBu), 22.8, 20.0 (C_q^tBu); HRMS: [M-N₂+H]⁺ calcd for C₂₀H₃₂N₂O₄SSi 410.18213, found 410.18220.



Phenyl 2-azido-3-O-benzyl-2-deoxy-4,6-O-di-tert-butylsilylidene-1-thio-β-D-glucopyranoside (2). Compound **14** (1.4 g, 3.2 mmol) was dissolved in DMF (15 mL) and cooled to 0°C. Benzyl bromide (421 μL, 3.52 mmol, 1.1 eq.) and NaH (60% dispersion in mineral oil, 166 mg, 4.16 mmol, 1.3 eq.) were added and the reaction was stirred for 2 h at 0°C and 1 h at r.t. The reaction mixture was quenched with MeOH and H₂O (100 mL) was added. The water phase


was extracted three times with 30 mL Et₂O and the combined organic layers were washed with brine (2x), dried with Na₂SO₄ and concentrated under reduced pressure. Purification by flash column chromatography (1%-8% Et₂O/pentane) yielded compound **2** as a colorless oil (1.35 g, 2.56 mmol, 80%). Additional impurities as observed by ¹H NMR originating from the previous crude steps could be removed by size exclusion chromatography (Sephadex™ LH-20, 1/1 DCM/MeOH). R_f: 0.51 (19/1 pentane/Et₂O). [α]_D²³ = -85.0° (c = 1.0, CHCl₃); IR (neat): 654, 694, 746, 766, 826, 1059, 1078, 1099, 1159, 1474, 2110, 2859, 2884, 2934, 2963; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.55 – 7.48 (m, 2H, CH_{arom}), 7.43 – 7.37 (m, 2H, CH_{arom}), 7.36 – 7.27 (m, 6H, CH_{arom}), 4.99 (d, 1H, *J* = 10.7 Hz, CHH Bn), 4.81 (d, 1H, *J* = 10.7 Hz, CHH Bn), 4.41 (d, 1H, *J* = 10.2 Hz, H-1), 4.21 (dd, 1H, *J* = 10.3, 5.1 Hz, H-6), 3.90 (t, 1H, *J* = 10.2 Hz, H-6), 3.87 (dd, 1H, *J* = 9.5, 8.7 Hz, H-4), 3.48 – 3.38 (m, 2H, H-3, H-5), 3.28 (dd, 1H, *J* = 10.2, 9.2 Hz, H-2), 1.07 (s, 9H, CH₃^tBu), 1.01 (s, 9H, CH₃^tBu); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 137.9 (C_q Bn), 133.9 (CH_{arom}), 130.9 (C_q SPh), 129.1, 128.7, 128.5, 128.5, 128.1 (CH_{arom}), 86.4 (C-1), 84.2 (C-3), 77.8 (C-4), 75.7 (CH₂ Bn), 74.7 (C-5), 66.2 (C-6), 64.2 (C-2), 27.5, 27.1 (CH₃^tBu), 22.7, 20.0 (CH₃^tBu); HRMS: [M+H]⁺ calcd for C₂₇H₃₈N₃O₄SSi 528.23468, found 528.23451. and [M-N₂+H]⁺ calcd for C₂₇H₃₈N₂O₄SSi 500.22853, found 500.22839.




Phenyl 2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-1-thio-β-D-glucopyranoside (3).

Compound **13** (4.36 g, 11.3 mmol) was coevaporated once with dry toluene and then dissolved in DMF (50 mL) and cooled to 0°C. Benzyl bromide (1.9 mL, 15.8 mmol, 1.4 eq.) and NaH (60% dispersion in mineral oil, 900 mg, 22.6 mmol, 2 eq.) were added in succession and the reaction mixture was stirred at r.t. for 4.5 h. MeOH (5 mL) was slowly added and the reaction mixture was diluted with EtOAc (150 mL) and washed with H₂O (2x 60 mL) and brine (50 mL). The organic layer was dried (MgSO₄), filtered, and concentrated *in vacuo*. The crude product was purified by crystallization (10 mL hot EtOAc, addition of 100 mL petroleum ether) to yield the title compound as a white cotton like solid (4.79 g, 10.1 mmol, 89%). R_f: 0.71 (8/1 pentane/EtOAc). Spectroscopic data were in accord with those previously reported.³¹ ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.56 (ddt, 2H, *J* = 5.0, 3.4, 1.5 Hz, CH_{arom}), 7.47 (dd, 2H, *J* = 7.5, 2.3 Hz, CH_{arom}), 7.42 – 7.26 (m, 11H, CH_{arom}), 5.57 (s, 1H, CHPh), 4.91 (d, 1H, *J* = 10.9 Hz, CHH Bn), 4.78 (d, 1H, *J* = 10.9 Hz, CHH Bn), 4.49 (d, 1H, *J* = 10.2 Hz, H-1), 4.39 (dd, 1H, *J* = 10.6, 5.0 Hz, H-6), 3.79 (t, 1H, *J* = 10.3 Hz, H-6), 3.71 – 3.59 (m, 2H, H-3, H-4), 3.52 – 3.42 (m, 1H, H-5), 3.41 – 3.32 (m, 1H, H-2); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 137.6, 137.1 (C_q), 134.0 (CH_{arom}), 130.6 (C_q SPh), 129.2,


129.2, 128.8, 128.5, 128.4, 128.4, 128.1, 126.0 (CH_{arom}), 101.3 (CHPh), 86.5 (C-1), 81.3, 81.0 (C-3, C-4), 75.3 (CH₂ Bn), 70.5 (C-5), 68.5 (C-6), 64.6 (C-2); HRMS: [M+H]⁺ calcd for C₂₆H₂₆N₃O₄S 476.16385, found 476.16375.




Phenyl 2-azido-3-O-benzoyl-4,6-O-benzylidene-2-deoxy-1-thio-β-D-glucopyranoside (4). To a 0°C solution of compound **13** (1.34 g, 3.48 mmol) in DCM (17 mL) and pyridine (1.4 mL, 34.8 mmol, 5 eq.) was added benzoyl chloride (0.61 mL, 5.22 mmol, 1.5 eq.) and DMAP (42 mg, 0.35 mmol, 0.1 eq.). The reaction mixture was allowed to stir overnight after which H₂O and DCM were added. The organic layer was separated and washed with sat. aq. NaHCO₃ and brine. The organic layer was dried with MgSO₄ and concentrated *in vacuo*. Flash column chromatography (19/1 to 8/1 pentane/EtOAc) afforded the title compound as a white solid (1.54 g, 3.15 mmol, 90%). The product could be recrystallized from EtOAc and petroleum ether to obtain a fluffy white solid. R_f: 0.53 (8/1 pentane/EtOAc). Spectroscopic data were in accord with those previously reported.⁶³ ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 8.05 (d, 2H, *J* = 7.3 Hz, CH_{arom}), 7.59 (dd, 2H, *J* = 6.5, 3.1 Hz, CH_{arom}), 7.53 (t, 1H, *J* = 7.4 Hz, CH_{arom}), 7.44–7.33 (m, 7H, CH_{arom}), 7.29–7.23 (m, 3H, CH_{arom}), 5.52 (t, 1H, *J* = 9.6 Hz, H-3), 5.46 (s, 1H, CHPh), 4.69 (d, 1H, *J* = 10.1 Hz, H-1), 4.38 (dd, 1H, *J* = 10.5, 4.9 Hz, H-6), 3.79 (t, 1H, *J* = 10.2 Hz, H-6), 3.71 (t, 1H, *J* = 9.5 Hz, H-4), 3.62–3.53 (m, 2H, H-2, H-5); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 165.3 (C=O Bz), 136.7 (C_q), 133.7, 133.4 (CH_{arom}), 130.8 (C_q), 129.9, 129.3 (CH_{arom}), 129.2 (C_q), 129.1, 128.8, 128.5, 128.2, 126.1 (CH_{arom}), 101.3 (CHPh), 87.1 (C-1), 78.4 (C-4), 73.5 (C-3), 70.7 (C-5), 68.3 (C-6), 63.9 (C-2); HRMS: [M+H]⁺ calcd for C₂₆H₂₄N₃O₅S 490.14312, found 490.14305.



Phenyl 2-amino-3-O-benzyl-4,6-O-benzylidene-2-deoxy-1-thio-β-D-glucopyranoside (16). Fully protected glycoside **15**³⁵ (9.11 g, 15.7 mmol) was dissolved in 160 ml EtOH and heated to reflux upon which ethylene diamine (52 mL, 785 mmol, 50 eq.) was added in three portions and reflux was maintained overnight. The reaction mixture was concentrated under reduced pressure and mixed with toluene (100 mL) and 45 g of silica gel, and the mixture evaporated to dryness. Column chromatography (8/2 to 2/1 pentane/EtOAc) gave the free amine as a white solid (6.19 g, 13.76 mmol, 88%) which could be recrystallized in EtOAc/petroleum ether. R_f: 0.40 (2/1 pentane/EtOAc). m.p. 136.1–137.5 °C. [α]_D²⁰ = -33.5° (c = 0.57, CHCl₃); IR (thin film): 698, 748, 1026, 1069, 1123, 1371, 1452, 1583, 2870, 3030, 3059; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.56–7.44 (m, 4H, CH_{arom}), 7.42–7.24 (m, 11H, CH_{arom}), 5.59 (s, 1H, CHPh), 4.99 (d, 1H, *J* = 11.3 Hz, CHH Bn), 4.68 (d, 1H, *J* = 11.2 Hz, CHH Bn), 4.58 (d, 1H, *J* = 9.9 Hz, H-1), 4.38 (dd, 1H, *J* = 10.5, 5.0 Hz, H-6), 3.81 (t, 1H, *J* = 10.3 Hz, H-6), 3.72 (t, 1H, *J* = 9.2 Hz, H-4), 3.59 (t, 1H, *J* = 9.0 Hz, H-3), 3.52 (td, 1H, *J* = 9.7, 4.9 Hz, H-5), 2.91 (t, 1H, *J* = 9.4 Hz, H-2), 1.75 (bs, 2H, NH₂); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 138.2, 137.4 (C_q), 133.0 (CH_{arom}), 131.8 (C_q SPh), 129.1, 128.6, 128.4, 128.3, 128.3, 128.0, 126.0 (CH_{arom}), 101.3 (CHPh), 89.6 (C-1), 82.2, 82.2 (C-3, C-4), 75.1 (CH₂ Bn), 70.7 (C-5), 68.8 (C-6), 55.5 (C-2); HRMS: [M+H]⁺ calcd for C₂₆H₂₈NO₄S 450.17336, found 450.17238.




1-(4-nitrophenyl)-4-pyridone (17). Following the procedure of You and Twieg⁶⁴ 4-hydroxypyridine (14.3 g, 150 mmol), 4-chloronitrobenzene (22.9 g, 145 mmol) and K₂CO₃ (20.7 g, 150 mmol) were suspended in *N*-methyl-2-pyrrolidone (110 mL) and heated at 150°C for 2 h. The hot solution was then poured directly onto ice and allowed to precipitate until all the ice had melted. The suspension was then filtered and washed four times with cold H₂O. The resulting solid was dried under vacuum at 100°C until dry. Yield: 26.6 g, 123 mmol, 85%. IR (neat): 606, 692, 741, 752, 843, 1015, 1111, 1198, 1285, 1339, 1495, 1514, 1582, 1638, 3071; ¹H NMR (DMSO, 400 MHz, HH-COSY, HSQC): δ 8.38 (d, 2H, *J* = 9.1 Hz), 8.14 (d, 2H, *J* = 7.8 Hz), 7.86 (d, 2H, *J* = 9.1 Hz), 6.29 (d, 2H, *J* = 7.8 Hz); ¹³C-APT NMR (DMSO, 101 MHz, HSQC): δ 177.6, 147.1, 145.9, 139.2, 125.3, 123.2, 118.3; HRMS: [M+H]⁺ calcd for C₁₁H₉N₂O₃ 217.06077, found 217.06074.




3,5-dinitro-1-(4-nitrophenyl)-4-pyridone (18). Modification of the procedure from Matsumura *et al.*³⁰, an ice cooled three-neck flask equipped with a condenser was charged with 120 mL H₂SO₄ (30% SO₃) followed by the slow addition of 120 mL fuming 99% HNO₃. To the cold mixture pyridone **17** (21.6 g, 100 mmol) was added in small portions. When addition was complete the mixture was slowly brought to 130°C and stirred for 40 h. The cooled down mixture was then poured over ice, stirred for 3 h, filtered, and washed three times with cold water. Yield: 18.4 g, 60 mmol, 60%. Purity (NMR): 90%. Tetra-nitro (3,5-dinitro-1-(2,4-dinitrophenyl)-4-pyridone ¹H NMR (DMSO, 400 MHz): δ 9.42 (s, 2H), 9.05 (d, 1H, *J* = 2.6 Hz), 8.87 (dd, 1H, *J* = 8.8, 2.6 Hz), 8.32 (d, 1H, *J* = 8.7 Hz) and di-nitro (3-nitro-1-(4-nitrophenyl)-4-pyridone ¹H NMR (DMSO, 400 MHz): δ 9.18 (d, 1H, *J* = 2.5 Hz), 8.43 (d, 2H, *J* = 9.0 Hz), 8.26 (dd, 1H, *J* = 7.8, 2.5 Hz), 7.99 (d, 2H, *J* = 9.1 Hz), 6.68 (d, 1H, *J* = 7.9 Hz)) impurities are present (ratios vary slightly upon repetition). IR (neat): 717, 768, 789, 853, 910, 1141, 1261, 1306, 1350, 1449, 1514, 1591, 1672, 3076; ¹H NMR (DMSO, 400 MHz): δ 9.38 (s,

1H), 8.47 (d, 1H, $J = 9.0$ Hz), 8.05 (d, 1H, $J = 9.1$ Hz); ^{13}C -APT NMR (DMSO, 101 MHz): δ 159.3, 147.6, 145.5, 142.1, 141.6, 125.7, 125.1; HRMS: $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{11}\text{H}_7\text{N}_4\text{O}_7$ 307.03093, found 307.03123.




Phenyl 2-(3,5-dinitro-4-pyridone)-3-O-benzyl-4,6-O-benzylidene-2-deoxy-1-thio- β -D-glucopyranoside (5). Free amine **16** (3.6 g, 8 mmol) and reagent **18** (2.7 g, 8.8 mmol, 1.1 eq.) were dissolved in pyridine (48 mL) and AcOH (4 mL) and left to stir for 30 min. The mixture was diluted with EtOAc and washed with 1M aq. HCl (5x) and once with sat. aq. NaHCO_3 . The organic layer was dried (MgSO_4), filtered and concentrated under reduced


pressure. Column chromatography: DCM until all the nitroanaline had been removed, then 1% to 5% acetone in DCM. Yield 4.84 g, 7.8 mmol (98%) as a yellow solid. R_f : 0.21 (DCM), $[\alpha]_D^{20} = 10.5^\circ$ ($c = 0.5$, CHCl_3); IR (thin film): 604, 696, 746, 989, 1055, 1094, 1211, 1300, 1329, 1516, 1674, 2856, 2926, 3034, 3059; ^1H NMR (Acetone- d_6 , 400 MHz, HH-COSY, HSQC): δ 8.74 (s, 2H, CH pyridone), 7.63 – 7.54 (m, 2H, CH_{arom}), 7.51 – 7.39 (m, 5H, CH_{arom}), 7.39 – 7.31 (m, 3H, CH_{arom}), 7.21 – 7.14 (m, 3H, CH_{arom}), 7.14 – 7.07 (m, 2H, CH_{arom}), 5.84 (s, 1H, CHPh), 5.73 (d, 1H, $J = 10.4$ Hz, H-1), 4.84 (d, 1H, $J = 12.1$ Hz, CHH Bn), 4.62 (d, 1H, $J = 12.1$ Hz, CHH Bn), 4.55 – 4.47 (m, 1H, H-3), 4.44 – 4.39 (m, 1H, H-6), 4.39 (t, 1H, $J = 8.9$ Hz, H-2), 4.06 – 3.91 (m, 3H, H-4, H-5, H-6); ^{13}C -APT NMR (Acetone- d_6 , 101 MHz, HSQC): δ 159.9 (C=O pyridone), 143.1 (C_q NO₂), 138.5, 137.8 (C_q), 133.4 (CH_{arom}), 131.7 (C_q SPh), 130.3, 129.7, 129.5, 129.2, 129.0, 129.0, 127.0 (CH_{arom}), 102.0 (CHPh), 85.9 (C-1), 83.0 (C-4), 77.0 (C-3), 74.7 (CH₂ Bn), 71.6 (C-2), 70.9 (C-5), 68.8 (C-6); HRMS: $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{31}\text{H}_{28}\text{N}_3\text{O}_9\text{S}$ 618.15408 found 618.15375.




Trifluoromethanesulfonyl 2,3-di-O-benzyl-4,6-O-benzylidene- α -D-glucopyranoside (19). ^1H NMR (CD_2Cl_2 , $T = 213$ K, 400 MHz, HH-COSY, HSQC): δ 6.08 (d, 1H, $J = 3.5$ Hz, H-1), 5.59 (s, 1H, CHPh), 4.89 (d, 1H, $J = 11.0$ Hz, CHH Bn), 4.85 – 4.69 (m, 3H, CHH Bn , CH_2 Bn), 4.29 (dd, 1H, $J = 10.3$, 4.8 Hz, H-6), 4.09 – 3.94 (m, 2H, H-3, H-5), 3.86 – 3.70 (m, 3H, H-2, H-4, H-6); ^{13}C -APT NMR (CD_2Cl_2 , $T = 213$ K, 101 MHz, HSQC): δ 106.1 (C-1), 100.8 (CHPh), 79.6 (C-4), 77.0 (C-3), 76.3 (C-2), 75.0, 74.1 (CH₂ Bn), 67.4 (C-6), 65.8 (C-5).




Trifluoromethanesulfonyl 2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy- α -D-glucopyranoside (20). ^1H NMR (CD_2Cl_2 , $T = 243$ K, 400 MHz, HH-COSY, HSQC): δ 6.08 (d, 1H, $J = 3.5$ Hz, H-1), 5.64 (s, 1H, CHPh), 4.98 (d, 1H, $J = 10.6$ Hz, CHH Bn), 4.78 (d, 1H, $J = 10.6$ Hz, CHH Bn), 4.32 (dd, 1H, $J = 10.4$, 4.9 Hz, H-6), 4.11 – 4.00 (m, 2H, H-3, H-5), 3.94 – 3.86 (m, 2H, H-2, H-4), 3.82 (t, 1H, $J = 10.3$ Hz, H-6); ^{13}C -APT NMR (CD_2Cl_2 , $T = 243$ K, 101 MHz, HSQC): δ 137.2, 136.7 (C_q), 130.5, 128.4, 128.4, 125.9 (CH_{arom}), 105.0 (C-1), 101.3 (CHPh), 80.6 (C-4), 76.4 (C-3), 75.3 (CH₂ Bn), 67.6 (C-6), 66.2 (C-5), 61.4 (C-2).



Trifluoromethanesulfonyl 2-azido-3-O-benzoyl-4,6-O-benzylidene-2-deoxy- α -D-glucopyranoside (21). ^1H NMR (CD_2Cl_2 , $T = 243$ K, 400 MHz, HH-COSY, HSQC): δ 6.23 (d, 1H, $J = 3.5$ Hz, H-1), 5.80 (t, 1H, $J = 10.0$ Hz, H-3), 5.54 (s, 1H, CHPh), 4.36 (dd, 1H, $J = 10.4$, 4.9 Hz, H-6), 4.21 (td, 1H, $J = 9.9$, 4.9 Hz, H-5), 4.12 (dd, 1H, $J = 10.2$, 3.5 Hz, H-2), 3.98 (t, 1H, $J = 9.8$ Hz, H-4), 3.86 (t, 1H, $J = 10.3$ Hz, H-6); ^{13}C -APT NMR (CD_2Cl_2 , $T = 243$ K, 101 MHz, HSQC): δ 104.5 (C-1), 101.8 (CHPh), 77.5 (C-4), 69.3 (C-3), 67.6 (C-6), 66.4 (C-5), 60.9 (C-2).




Trifluoromethanesulfonyl 2-azido-3-O-benzyl-2-deoxy-4,6-O-di-*tert*-butylsilylidene- α -D-glucopyranoside (22). ^1H NMR (CD_2Cl_2 , $T = 233$ K, 400 MHz, HH-COSY, HSQC, HMBC): δ 6.00 (d, 1H, $J = 3.4$ Hz, H-1), 5.08 (d, 1H, $J = 10.1$ Hz, CHH Bn), 4.81 (d, 1H, $J = 10.2$ Hz, CHH Bn), 4.15 – 4.06 (m, 2H, H-4, H-6), 3.95 – 3.84 (m, 3H, H-3, H-5, H-6), 3.79 (dd, 1H, $J = 10.1$, 3.4 Hz, H-2), 1.07 (s, 9H, CH_3 ^tBu), 1.00 (s, 9H, CH_3 ^tBu); ^{13}C -APT NMR (CD_2Cl_2 , $T = 233$ K, 101 MHz, HSQC, HMBC): δ 118.9 (q, $J = 317.6$ Hz, CF_3), 104.8 (C-1), 78.8 (C-3), 76.9 (C-4), 75.7 (CH₂ Bn), 70.0 (C-5), 65.3 (C-6), 60.6 (C-2), 27.0, 26.4 (CH_3 ^tBu), 22.5, 19.7 (C_q ^tBu); ^{13}C -HMBC NMR (CD_2Cl_2 , 101 MHz): δ 104.8 ($J_{\text{C1-H1}} = 187$ Hz, C-1).




3-O-benzyl-4,6-O-benzylidene-2-deoxy-2-(3,5-dinitro-4-pyridone)-D-glucal (24). Off-white solid. R_f : 0.20 (7/3 pentane/EtOAc). $[\alpha]_D^{23} = +85.9^\circ$ ($c = 0.32$, DCM); IR (thin film): 698, 720, 753, 1007, 1059, 1095, 1192, 1247, 1304, 1351, 1516, 1679, 2880, 2924, 3072; ^1H NMR (Acetone- d_6 , 500 MHz, HH-COSY, HSQC): δ 8.72 (s, 2H, CH pyridone), 7.62 – 7.53 (m, 2H, CH_{arom}), 7.49 – 7.37 (m, 4H, CH_{arom} , H-1), 7.29 – 7.14 (m, 5H, CH_{arom}), 5.88 (s, 1H, CHPh), 4.93 – 4.88 (m, 2H, CHH Bn , H-3), 4.68 (d, 1H, $J = 11.8$ Hz, CHH Bn), 4.46 (dd, 1H, $J = 10.5$, 5.2 Hz, H-6), 4.37 (dd, 1H, $J = 10.4$, 6.9 Hz, H-4), 4.30 (td, 1H, $J = 10.2$, 5.1 Hz, H-5), 4.03 (t, 1H, $J = 10.3$ Hz, H-6); ^{13}C -APT NMR (Acetone- d_6 , 101 MHz, HSQC): δ 160.0 (C=O pyridone), 149.3 (C-1), 144.7 (CH pyridone), 142.8 (C_q NO₂), 138.4 (C_q Bn, Ph), 129.8, 129.2,

129.1, 129.0, 128.8, 127.0 (CH_{arom}), 122.1 (C-2), 101.9 (CHPh), 80.2 (C-4), 74.7 (CH₂ Bn), 74.6 (C-3), 70.7 (C-5), 68.2 (C-6); HRMS: [M+H]⁺ calcd for C₂₅H₂₂N₃O₅ 508.13506, found 508.13465.




Ethyl 2-azido-3-O-benzyl-2-deoxy-4,6-O-di-tert-butylsilylidene-β-D-glucopyranoside (2A).

Donor **2** and ethanol were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations and purified by flash column chromatography (0% to 5% Et₂O in pentane) to yield glycosylation product **2A** (30 mg, 65 μmol, 65%, α:β = <1:20) as a colorless oil. R_f: 0.35 (5% Et₂O in pentane). [α]_D²³ = -69.6° (c = 0.5, CHCl₃); IR (neat): 652, 768, 827, 962, 1082, 1161, 1474, 2112, 2859, 2932; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.46 – 7.40 (m, 2H, CH_{arom}), 7.39 – 7.27 (m, 3H, CH_{arom}), 4.99 (d, 1H, J = 11.0 Hz, CHH Bn), 4.81 (d, 1H, J = 10.9 Hz, CHH Bn), 4.31 (dd, 1H, J = 7.7, 1.7 Hz, H-1), 4.16 (dd, 1H, J = 10.3, 5.0 Hz, H-6), 3.98 – 3.87 (m, 3H, CHH-CH₃ Et, H-4, H-6), 3.61 (dq, 1H, J = 9.5, 7.1 Hz, CHH-CH₃ Et), 3.41 – 3.28 (m, 3H, H-2, H-3, H-5), 1.26 (t, 3H, J = 7.1 Hz, CH₃ Et), 1.08 (s, 9H, CH₃^tBu), 1.01 (s, 9H, CH₃^tBu); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 138.3 (C_q), 128.5, 128.4, 128.0 (CH_{arom}), 102.1 (C-1), 82.4 (C-3), 78.1 (C-4), 75.4 (CH₂ Bn), 70.5 (C-5), 66.4 (C-6), 66.1 (CH₂ Et), 65.6 (C-2), 27.6, 27.2 (CH₃^tBu), 22.8, 20.1 (C_q^tBu), 15.2 (CH₃ Et); HRMS: [M-N₂+H]⁺ calcd for C₂₃H₃₈NO₅Si 436.25138, found 436.25132.




Cyclohexyl 2-azido-3-O-benzyl-2-deoxy-4,6-O-di-tert-butylsilylidene-β-D-glucopyranoside (2B).

Donor **2** and cyclohexanol were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations and purified by flash column chromatography (4/1 to 0/1 pentane/toluene) to yield glycosylation product **2B** (40 mg, 77 μmol, 77%, α:β = <1 : 20) as a colorless oil. R_f: 0.43 (5% Et₂O in pentane). [α]_D²⁰ = -44.3° (c = 1.0, CHCl₃); IR (thin film): 696, 768, 827, 961, 1080, 1163, 1364, 2112, 2859, 2934; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.45 – 7.40 (m, 2H, CH_{arom}), 7.38 – 7.27 (m, 3H, CH_{arom}), 4.97 (d, 1H, J = 11.1 Hz, CHH Bn), 4.81 (d, 1H, J = 11.1 Hz, CHH Bn), 4.42 (d, 1H, J = 7.8 Hz, H-1), 4.15 (dd, 1H, J = 10.3, 5.0 Hz, H-6), 3.99 – 3.89 (m, 2H, H-3, H-6), 3.64 (tt, 2H, J = 9.2, 3.8 Hz, CH Cy), 3.40 – 3.24 (m, 3H, H-2, H-4, H-5), 1.96 – 1.83 (m, 2H, CH₂ Cy), 1.80 – 1.71 (m, 2H, CH₂ Cy), 1.55 – 1.48 (m, 1H, CH₂ Cy), 1.47 – 1.37 (m, 2H, CH₂ Cy), 1.34 – 1.20 (m, 3H, CH₂ Cy), 1.08 (s, 9H, ^tBu), 1.01 (s, 9H, ^tBu); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 138.4 (C_q), 128.5, 128.3, 127.9 (CH_{arom}), 100.7 (C-1), 82.3 (C-4), 78.3 (CH Cy), 78.0 (C-3), 75.4 (CH₂ Bn), 70.5 (C-5), 66.4 (C-6), 65.8 (C-2), 33.6, 31.7 (CH₂ Cy), 27.6, 27.2 (CH₃^tBu), 25.6 (CH₂ Cy), 24.1, 23.9 (C_q^tBu), 22.8, 20.1 (CH₂ Cy); HRMS: [M-N₂+H]⁺ calcd for C₂₇H₄₄NO₅Si 490.29833, found 490.29811.



Methyl 6-O-(2-azido-3-O-benzyl-2-deoxy-4,6-O-di-tert-butylsilylidene-α/β-D-glucopyranosyl)-2,3,4-tri-O-benzyl-α-D-glucopyranoside (2C).


Donor **2** and acceptor **25** were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (for an additional 18 hours at -40°C) and purified by flash column chromatography (1/0 to 9/1 pentane/EtOAc) to yield glycosylation product **2C** (81 mg, 92 μmol, 92%, α:β = 1:14) as a white solid. R_f: 0.42 (4/1 pentane/EtOAc). [α]_D²³ = -18.6° (c = 1.0, CHCl₃); IR (thin film): 654, 969, 735, 827, 962, 1028, 1070, 1161, 1362, 1454, 2112, 2859, 2931; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC, HMBC): δ 7.45 – 7.39 (m, 2H, CH_{arom}), 7.38 – 7.25 (m, 18H, CH_{arom}), 4.99 (d, 1H, J = 11.0 Hz, CHH Bn), 4.98 (d, 1H, J = 10.9 Hz, CHH Bn), 4.94 (d, 1H, J = 11.1 Hz, CHH Bn), 4.85 – 4.76 (m, 3H, CHH Bn, 2xCHH Bn), 4.66 (d, 1H, J = 11.1 Hz, CHH Bn), 4.64 (d, 1H, J = 12.1 Hz, CHH Bn), 4.60 (d, 1H, J = 3.6 Hz, H-1), 4.17 (d, 1H, J = 7.9 Hz, H-1'), 4.15 – 4.10 (m, 1H, H-6'), 4.05 – 3.96 (m, 2H, H-3, H-6), 3.96 – 3.87 (m, 2H, H-4', H-6'), 3.76 (ddd, 1H, J = 9.9, 4.2, 1.7 Hz, H-5), 3.70 (dd, 1H, J = 10.7, 4.2 Hz, H-6), 3.59 (t, 1H, J = 9.5 Hz, H-4), 3.54 (dd, 1H, J = 9.6, 3.5 Hz, H-2), 3.40 (dd, 1H, J = 9.7, 7.9 Hz, H-2'), 3.37 – 3.26 (m, 5H, CH₃ Ome, H-3', H-5'), 1.07 (s, 9H, CH₃^tBu), 1.01 (s, 9H, CH₃^tBu); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC, HMBC): δ 138.9, 138.6, 138.2, 138.1 (C_q), 128.6, 128.5, 128.5, 128.4, 128.3, 128.1, 128.0, 127.9, 127.8, 127.7 (CH_{arom}), 102.2 (C-1'), 98.3 (C-1), 82.5 (C-3'), 82.2 (C-3), 79.9 (C-2), 77.9 (C-4'), 77.7 (C-4), 75.9, 75.4, 75.0, 73.6 (CH₂ Bn), 70.6 (C-5'), 69.7 (C-5), 68.6 (C-6), 66.3 (C-6'), 65.6 (C-2'), 55.3 (OMe), 27.5, 27.1 (CH₃^tBu), 22.8, 20.1 (C_q^tBu); Diagnostic peaks α-anomer: ¹H NMR (CDCl₃, 400 MHz): δ 4.87 (d, 1H, J = 3.6 Hz, H-1'), 4.52 (d, 1H, J = 3.4 Hz, H-1'); ¹³C-APT NMR (CDCl₃, 101 MHz): δ 98.1, 98.0, 68.3; HRMS: [M+NH₄]⁺ calcd for C₄₉H₆₇N₄O₁₀Si 899.46210, found 899.46246.



2-Fluoroethyl 2-azido-3-O-benzyl-2-deoxy-4,6-O-di-tert-butylsilylidene-α/β-D-glucopyranoside (2D).


Donor **2** and 2-fluoroethanol were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations and purified by flash column chromatography (1/0 to 0/1 pentane/toluene to 2% Et₂O in toluene) to yield glycosylation product **2D** (37.8 mg, 79 μmol, 79%, α:β = 1:5.5) as a colorless oil. R_f: 0.20

(toluene). Reported as a 1.00 : 0.18 mixture of anomers: IR (neat): 654, 768, 827, 962, 1080, 1161, 1472, 2112, 2859, 2932; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.45 – 7.40 (m, 2.36H, CH_{arom}), 7.39 – 7.27 (m, 3.54H, CH_{arom}), 5.06 (d, 0.18H, *J* = 10.7 Hz, *CHH* Bn_α), 4.99 (d, 1H, *J* = 10.9 Hz, *CHH* Bn_β), 4.86 (d, 0.18H, *J* = 3.6 Hz, H-1_α), 4.82 (d, 0.18H, *J* = 10.6 Hz, *CHH* Bn_α), 4.82 (d, 1H, *J* = 10.9 Hz, *CHH* Bn_β), 4.71 – 4.61 (m, 1.18H, *CHHF*_α, *CHHF*_β), 4.58 – 4.47 (m, 1.18H, *CHHF*_α, *CHHF*_β), 4.37 (d, 1H, *J* = 7.6 Hz, H-1_β), 4.17 (dd, 1H, *J* = 10.3, 5.1 Hz, H-6_β), 4.12 – 3.78 (m, 5.26H, *CH*₂-*CH*₂F_α, *CH*₂-*CH*₂F_β, H-3_α, H-4_α, H-4_β, H-5_α, H-6_α, H-6_β, H-6_β), 3.44 – 3.29 (m, 3.18H, H-2_α, H-2_β, H-3_β, H-5_β), 1.09 (s, 1.62H, CH₃¹Bu_α), 1.08 (s, 9H, CH₃¹Bu_β), 1.03 (s, 1.62H CH₃¹Bu_α), 1.01 (s, 9H, CH₃¹Bu_β); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 138.3 (C_{α,α}), 138.2 (C_{α,β}), 128.6 (CH_{arom} Bn_α), 128.5 (CH_{arom} Bn_β), 128.5 (CH_{arom} Bn_α), 128.4 (CH_{arom} Bn_β), 128.0 (CH_{arom} Bn_{α,β}), 102.4 (C-1_β), 98.3 (C-1_α), 82.7 (d, *J* = 170.0 Hz, CH₂F_β), 82.4 (d, *J* = 170.6 Hz, CH₂F_α), 82.3 (C-3_β), 79.3, 79.0 (C-3_α, C-4_α), 78.0 (C-4_β), 75.6 (CH₂ Bn_α), 75.5 (CH₂ Bn_β), 70.6 (C-5_β), 69.0 (d, *J* = 20.3 Hz, *CH*₂-*CH*₂F_β), 67.3 (d, *J* = 20.1 Hz, *CH*₂-*CH*₂F_α), 66.8 (C-5_α), 66.7 (C-6_α), 66.3 (C-6_β), 65.5 (C-2_β), 62.5 (C-2_α), 27.5, 27.1 (CH₃¹Bu_{α,β}), 23.1 (C_q¹Bu_α), 22.8 (C_q¹Bu_β), 20.1 (C_q¹Bu_α), 20.1 (C_q¹Bu_β); HRMS: [M-N₂+H]⁺ calcd for C₂₃H₃₇FNO₅Si 454.24195, found 454.24188.



Methyl 4-O-(2-azido-3-O-benzyl-2-deoxy-4,6-O-di-tert-butylsilylidene- α/β -D-glucopyranosyl)-2,3,6-tri-O-benzyl- α -D-glucopyranoside (2E). Donor **2** and acceptor **26**


were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (for an additional 18 hours at -40°C) and purified by flash column chromatography (1/0 to 9/1 pentane/EtOAc) to yield glycosylation product **2E** (72 mg, 82 μ mol, 82%, α/β = 1:3) as a colorless oil. R_f: 0.23 and 0.41 (9/1 pentane/EtOAc). IR (thin film): 654, 696, 735, 768, 827, 962, 1090, 1159, 1271, 1362, 1454, 2110, 2859, 2932; Data for the β -anomer: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC, HMBC): δ 7.44 – 7.39 (m, 2H, CH_{arom}), 7.39 – 7.21 (m, 18H, CH_{arom}), 4.98 (d, 1H, *J* = 10.8 Hz, *CHH* Bn), 4.83 – 4.74 (m, 4H, *CHH* Bn, CH₂ Bn, *CHH* Bn), 4.68 (d, 1H, *J* = 11.9 Hz, *CHH* Bn), 4.62 (d, 1H, *J* = 12.2 Hz, *CHH* Bn) 4.59 (d, 1H, *J* = 3.6 Hz, H-1), 4.44 (d, 1H, *J* = 11.9 Hz, *CHH* Bn), 4.23 (d, 1H, *J* = 8.0 Hz, H-1'), 3.97 (dd, 1H, *J* = 10.6, 3.0 Hz, H-6), 3.94 – 3.73 (m, 5H, H-3, H-4, H-4', H-5, H-6'), 3.71 – 3.66 (m, 1H, H-6), 3.55 – 3.47 (m, 2H, H-2, H-6'), 3.38 (s, 3H, CH₃ OMe), 3.27 – 3.21 (m, 1H, H-2'), 3.20 – 3.14 (m, 1H, H-3'), 3.06 (td, 1H, *J* = 9.9, 5.1 Hz, H-5'), 1.06 (s, 9H, CH₃¹Bu), 0.97 (s, 9H, CH₃¹Bu); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC, HMBC): δ 139.4, 138.4, 138.1, 137.9 (C_q), 128.5, 128.5, 128.5, 128.4, 128.4, 128.2, 128.1, 128.0, 128.0, 127.9, 127.4, 127.3 (CH_{arom}), 101.0 (C-1'), 98.4 (C-1), 82.6 (C-3'), 80.2 (C-3), 79.2 (C-2), 78.1 (C-4'), 77.0 (C-4), 75.3, 75.3, 73.6, 73.6 (CH₂ Bn), 70.2 (C-5'), 69.7 (C-5), 68.3 (C-6), 66.2 (C-6'), 66.1 (C-2'), 55.4 (OMe), 27.6, 27.1 (CH₃¹Bu), 22.7, 20.0 (C_q tBu); Diagnostic peaks α -anomer: ¹H NMR (CDCl₃, 400 MHz): δ 5.67 (d, 1H, *J* = 4.0 Hz, H-1), 5.11 (d, 1H, *J* = 10.6 Hz, *CHH* Bn), 5.06 (d, 1H, *J* = 10.6 Hz, *CHH* Bn), 4.87 (d, 1H, *J* = 10.6 Hz, *CHH* Bn), 4.79 (d, 1H, *J* = 10.6 Hz, *CHH* Bn), 4.75 (d, 1H, *J* = 12.0 Hz, *CHH* Bn), 4.09 (t, 1H, *J* = 9.0 Hz, H-3), 3.56 (dd, 1H, *J* = 9.6, 3.5 Hz, H-2), 3.38 (s, CH₃ OMe), 3.21 (dd, 1H, *J* = 10.2, 4.0 Hz, H-2'), 1.06 (s, 9H, CH₃¹Bu), 1.04 (s, 9H, CH₃¹Bu); ¹³C-APT NMR (CDCl₃, 101 MHz): δ 138.8, 138.3, 138.2, 138.0, 128.6, 128.4, 128.3, 128.1, 128.0, 128.0, 128.0, 127.9, 127.7, 127.6, 127.4, 127.3, 97.9, 97.7 (C-1, C-1'), 82.1 (C-3), 80.6 (C-2), 79.1, 79.0, 75.6, 75.1, 73.7, 73.4, 69.6, 69.2, 67.5, 66.5, 62.3 (C-2'), 55.4, 27.6, 27.2, 22.8, 20.1; HRMS: [M+NH₄]⁺ calcd for C₄₉H₆₇N₄O₁₀Si 899.46210, found 899.46246.



Methyl (methyl 4-O-[2-azido-3-O-benzyl-2-deoxy-4,6-O-di-tert-butylsilylidene- α/β -D-glucopyranosyl]-2,3-di-O-benzyl- α -D-glucopyranosyl uronate) (2F). Donor **2** and acceptor **27**


were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (for an additional 18 hours at -40°C) and purified by flash column chromatography (1/0 to 9/1 pentane/EtOAc) to yield glycosylation product **2F** (69 mg, 84 μ mol, 84%, α/β = 3.3:1) as a white solid. R_f: 0.36 and 0.39 (9/1 pentane/EtOAc). IR (thin film): 654, 696, 735, 827, 1042, 1144, 1387, 1751, 2108, 2859, 2934; Data for the α -anomer: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC, HMBC): δ 7.43 – 7.38 (m, 2H, CH_{arom}), 7.37 – 7.25 (m, 13H, CH_{arom}), 5.45 (d, 1H, *J* = 4.1 Hz, H-1'), 5.07 – 5.02 (m, 2H, 2x*CHH* Bn), 4.90 (d, 1H, *J* = 10.6 Hz, *CHH* Bn), 4.84 – 4.78 (m, 1H, *CHH* Bn), 4.75 (d, 1H, *J* = 12.0 Hz, *CHH* Bn), 4.59 (d, 1H, *J* = 12.2 Hz, *CHH* Bn), 4.57 (d, 1H, *J* = 3.5 Hz, H-1), 4.21 – 4.17 (m, 1H, H-5), 4.09 – 4.01 (m, 3H, H-3, H-4, H-6'), 3.91 – 3.85 (m, 1H, H-4'), 3.83 – 3.73 (m, 5H, CH₃ CO₂Me, H-3', H-6'), 3.62 (td, 1H, *J* = 10.1, 5.0 Hz, H-5'), 3.58 – 3.53 (m, 1H, H-2), 3.41 (s, 3H, CH₃ OMe), 3.23 (dd, 1H, *J* = 10.2, 4.1 Hz, H-2'), 1.07 (s, 9H, CH₃¹Bu), 1.05 (s, 9H, CH₃¹Bu); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC, HMBC): δ 169.2 (C=O CO₂Me), 138.7, 138.2, 137.8 (C_q), 128.7, 128.5, 128.5, 128.5, 128.3, 128.2, 128.0, 127.7, 127.6 (CH_{arom}), 98.5, 98.4 (C-1, C-1'), 81.0 (C-3), 79.9 (C-2), 79.0, 79.0 (C-3', C-4'), 76.2 (C-4), 75.5, 75.4, 73.6 (CH₂ Bn), 70.2 (C-5), 67.0 (C-5'), 66.4 (C-6'), 62.4 (C-2'), 55.9 (OMe), 52.9 (CO₂Me), 27.6, 27.2 (CH₃¹Bu), 22.9, 20.0 (C_q¹Bu); Diagnostic peaks β -anomer: ¹H NMR (CDCl₃, 400 MHz): δ 4.98 (d, 1H, *J* = 10.9 Hz, *CHH* Bn), 4.39 (d, 1H, *J* = 7.7 Hz, H-1'), 4.02 – 3.96 (m, 1H), 3.82 (s, 3H, CH₃ CO₂Me), 3.52 (dd, 1H, *J* = 9.5, 3.6 Hz, H-2), 1.05 (s, 9H, CH₃¹Bu), 0.97 (s, 9H, CH₃¹Bu); ¹³C-APT NMR (CDCl₃, 101 MHz): δ 170.2, 139.1, 138.1, 138.1, 128.6, 128.5, 128.4, 128.3, 128.3, 128.1, 128.0, 127.5, 127.3, 101.9 (C-1'), 98.9 (C-1), 82.5, 79.6,

79.4, 78.8, 78.0, 75.4, 73.9, 70.4, 69.9, 66.1, 55.9, 52.8, 27.5, 27.1, 22.8, 20.0; HRMS: $[M+NH_4]^+$ calcd for $C_{43}H_{61}N_4O_{11}Si$ 837.41006, found 837.41042.




2,2-Difluoroethyl 2-azido-3-O-benzyl-2-deoxy-4,6-O-di-tert-butylsilylidene- α/β -D-glucopyranoside (2G). Donor **2** and 2,2-difluoroethanol were condensed using the general procedure for Tf_2O/Ph_2SO mediated glycosylations and purified by flash column chromatography (1/0 to 0/1 pentane/toluene to 2% Et_2O in toluene) to yield glycosylation product **2G** (38.1 mg, 76 μ mol, 76%, $\alpha:\beta = 2.7:1$) in two fractions (24.3 mg

α only, 13.8 mg $\alpha:\beta = 0.3:1$) as white solids. R_f : 0.43 β , 0.31 α (toluene). IR (neat): 654, 766, 826, 1070, 1474, 2108, 2860, 2934; Data for the α -anomer: $[\alpha]_D^{23} = +35.6^\circ$ ($c = 0.86$, $CHCl_3$); 1H NMR ($CDCl_3$, 400 MHz, HH-COSY, HSQC): δ 7.45 – 7.40 (m, 2H, CH_{arom}), 7.39 – 7.27 (m, 3H, CH_{arom}), 5.95 (tt, 1H, $J = 55.2$, 4.1 Hz, CHF_2), 5.06 (d, 1H, $J = 10.6$ Hz, CHH Bn), 4.85 (d, 1H, $J = 3.6$ Hz, H-1), 4.82 (d, 1H, $J = 10.7$ Hz, CHH Bn), 4.13 – 4.08 (m, 1H, H-6), 3.98 – 3.92 (m, 1H, H-3/4), 3.92 – 3.72 (m, 5H, CH_2-CHF_2 , H-3/4, H-5, H-6), 3.35 (dd, 1H, $J = 10.1$, 3.6 Hz, H-2), 1.09 (s, 9H, CH_3 tBu), 1.03 (s, 9H, CH_3 tBu); ^{13}C -APT NMR ($CDCl_3$, 101 MHz, HSQC): δ 138.1 (C_4), 128.6, 128.5, 128.1 (CH_{arom}), 113.8 (t, $J = 241.6$ Hz, CHF_2), 98.7 (C-1), 79.0, 78.9 (C-3, C-4), 75.7 (CH_2 Bn), 67.3 (t, $J = 28.6$ Hz, CH_2-CHF_2), 67.1 (C-5), 66.6 (C-6), 62.4 (C-2), 27.5, 27.1 (CH_3 tBu), 22.8, 20.1 (C_q tBu); Data for the β -anomer: 1H NMR ($CDCl_3$, 400 MHz, HH-COSY, HSQC): δ 7.44 – 7.39 (m, 2H, CH_{arom}), 7.38 – 7.29 (m, 3H, CH_{arom}), 5.92 (tdd, 1H, $J = 55.3$, 5.1, 3.4 Hz, CHF_2), 4.99 (d, 1H, $J = 10.9$ Hz, CHH Bn), 4.81 (d, 1H, $J = 11.0$ Hz, CHH Bn), 4.35 (s, 1H, $J = 7.7$ Hz, H-1), 4.17 (dd, 1H, $J = 10.3$, 5.0 Hz, H-6), 4.02 – 3.74 (m, 4H, CH_2-CHF_2 , H-4, H-6), 3.42 – 3.30 (m, 3H, H-2, H-3, H-5), 1.09 (s, 9H, CH_3 tBu), 1.01 (s, 9H, CH_3 tBu); ^{13}C -APT NMR ($CDCl_3$, 101 MHz, HSQC): δ 138.1 (C_4), 128.5, 128.4, 128.1 (CH_{arom}), 114.1 (t, $J = 241.4$ Hz, CHF_2), 102.5 (C-1), 82.2 (C-3), 77.9 (C-4), 75.5 (CH_2 Bn), 70.7 (C-5), 68.8 (dd, $J = 29.3$, 28.8 Hz, CH_2-CHF_2), 66.2 (C-6), 65.4 (C-2), 27.5, 27.1 (CH_3 tBu), 22.8, 20.1 (C_q tBu); HRMS: $[M-N_2+H]^+$ calcd for $C_{23}H_{36}F_2NO_5Si$ 472.23253, found 472.23239.



Methyl 4-O-(2-azido-3-O-benzyl-2-deoxy-4,6-O-di-tert-butylsilylidene- α/β -D-glucopyranosyl)-2,3,6-tri-O-benzyl- β -D-galactopyranoside (2H). Donor **2** and acceptor **28** were condensed using the general procedure for Tf_2O/Ph_2SO mediated glycosylations (for an additional 18 hours at $-40^\circ C$) and purified by flash column chromatography (1/0 to 9/1 pentane/ $EtOAc$) to yield glycosylation product **2H** (46 mg, 52 μ mol, 52%, $\alpha:\beta = 7:1$) as a colorless oil. R_f : 0.33 and 0.51


(9/1 pentane/ $EtOAc$). IR (thin film): 652, 696, 735, 826, 1001, 1036, 1206, 1364, 1454, 2108, 2859, 2932; Data for the α -anomer: 1H NMR ($CDCl_3$, 400 MHz, HH-COSY, HSQC, HMBC): δ 7.46 – 7.41 (m, 2H, CH_{arom}), 7.41 – 7.23 (m, 18H, CH_{arom}), 5.10 (d, 1H, $J = 10.3$ Hz, CHH Bn), 4.89 – 4.81 (m, 3H, CHH Bn, 2x CHH Bn), 4.79 (d, 1H, $J = 3.7$ Hz, H-1'), 4.72 (d, 1H, $J = 10.6$ Hz, CHH Bn), 4.68 (d, 1H, $J = 13.0$ Hz, CHH Bn), 4.58 – 4.44 (m, 3H, CH_2 Bn, H-5'), 4.23 (d, 1H, $J = 7.6$ Hz, H-1), 4.07 – 3.99 (m, 2H, H-4, H-6), 3.99 – 3.88 (m, 3H, H-3', H-4', H-6'), 3.76 (t, 1H, $J = 10.1$ Hz, H-6'), 3.67 – 3.58 (m, 2H, H-2, H-6), 3.56 (s, 3H, CH_3 OMe), 3.48 (dd, 1H, $J = 8.9$, 5.5 Hz, H-5), 3.38 (dd, 1H, $J = 10.0$, 2.9 Hz, H-3), 3.33 (dd, 1H, $J = 9.7$, 3.7 Hz, H-2'), 1.06 (s, 9H, CH_3 tBu), 1.02 (s, 9H, CH_3 tBu); ^{13}C -APT NMR ($CDCl_3$, 101 MHz, HSQC, HMBC): δ 138.8, 138.4, 138.2, 137.7 (C_4), 128.6, 128.6, 128.5, 128.5, 128.5, 128.3, 128.2, 127.9, 127.8 (CH_{arom}), 105.1 (C-1), 99.2 (C-1'), 79.9, 79.9 (C-2, C-3'), 79.6, 79.4 (C-3, C-4'), 75.7, 75.6 (CH_2 Bn), 75.0 (C-4), 73.6 (CH_2 Bn), 72.9 (C-5), 72.6 (CH_2 Bn), 67.1, 67.0 (C-6, C-6'), 66.9 (C-5'), 63.2 (C-2'), 57.5 (OMe), 27.5, 27.3 (CH_3 tBu), 22.7, 20.2 (C_q tBu); Diagnostic peaks β -anomer: 1H NMR ($CDCl_3$, 400 MHz): δ 4.94 (d, 0.14H, $J = 11.1$ Hz, CHH Bn), 4.27 (d, 0.14H, $J = 7.7$ Hz, H-1), 3.22 – 3.16 (m, 0.28H), 3.20 – 3.09 (m, 2H); ^{13}C -APT NMR ($CDCl_3$, 101 MHz): δ 105.1 (C-1), 102.0 (C-1'), 82.3, 78.0, 75.4, 75.3, 73.7, 73.7, 73.5, 73.4, 70.4, 69.6, 66.4, 65.6, 57.3, 27.6, 27.2, 22.8, 20.1; HRMS: $[M+NH_4]^+$ calcd for $C_{49}H_{67}N_4O_{10}Si$ 899.46210, found 899.46243.



Methyl 2-O-(2-azido-3-O-benzyl-2-deoxy-4,6-O-di-tert-butylsilylidene- α -D-glucopyranosyl)-3-O-benzyl-4,6-O-benzylidene- α -D-mannopyranoside (2I). Donor **2** and acceptor **29** were condensed using the general procedure for Tf_2O/Ph_2SO mediated glycosylations (for an additional 18 hours at $-40^\circ C$) and purified by flash column chromatography (1/0 to 9/1 pentane/ $EtOAc$) to yield glycosylation product **2I** (67 mg, 85 μ mol, 85%, $\alpha:\beta = > 20:1$) as a white solid. R_f : 0.54 (9/1 pentane/ $EtOAc$). $[\alpha]_D^{20} = +44.3^\circ$ ($c = 1.34$, $CHCl_3$); IR (thin film): 696, 827, 937, 1040, 1088, 1130, 1364,


2108, 2859, 2957; Data for the α -anomer: 1H NMR ($CDCl_3$, 400 MHz, HH-COSY, HSQC, HMBC): δ 7.54 – 7.47 (m, 2H, CH_{arom}), 7.46 – 7.41 (m, 2H, CH_{arom}), 7.41 – 7.22 (m, 11H, CH_{arom}), 5.65 (s, 1H, $CHPh$), 5.23 (d, 1H, $J = 3.6$ Hz, H-1'), 5.09 (d, 1H, $J = 10.6$ Hz, CHH Bn), 4.89 – 4.82 (m, 2H, CHH Bn, CHH Bn), 4.74 – 4.65 (m, 2H, CHH Bn, H-1), 4.31 – 4.21 (m, 2H, H-4, H-6), 4.11 – 3.92 (m, 5H, H-2, H-3, H-3', H-4', H-6'), 3.92 – 3.76 (m, 4H, H-5, H-5', H-6, H-6'), 3.36 (s, 3H, CH_3 OMe), 3.27 (dd, 1H, $J = 10.0$, 3.7 Hz, H-2'), 1.09 (s, 9H), 1.05 (s, 9H); ^{13}C -APT NMR ($CDCl_3$, 101 MHz, HSQC, HMBC): δ

138.6, 138.4, 137.7 (C_q), 129.0, 128.5, 128.5, 128.4, 128.3, 128.3, 128.0, 127.6, 127.5, 127.4, 126.2, 126.1 (CH_{arom}), 101.7 (CHPh), 101.0 (C-1), 99.4 (C-1'), 79.3 (C-4), 79.1, 78.9 (C-3', C-4'), 76.0, 75.6 (C-2, C-3), 75.6, 73.0 (CH₂ Bn), 69.0 (C-6), 67.2 (C-5'), 66.6 (C-6'), 64.1 (C-5), 62.6 (C-2'), 55.2 (CH₃ OMe), 27.5, 27.2 (CH₃¹Bu), 22.8, 20.2 (C_q¹Bu); Diagnostic peaks β-anomer: ¹H NMR (CDCl₃, 400 MHz): δ 5.60 (s, 1H, CHPh), 4.98 (d, 1H, *J* = 11.3 Hz, CHH Bn), 4.39 (d, 1H, *J* = 8.2 Hz, H-1'), 3.57 – 3.48 (m, 1H); ¹³C-APT NMR (CDCl₃, 101 MHz): δ 101.6, 99.6, 81.8, 78.5, 77.8, 76.4, 75.2, 74.4, 72.3, 70.9, 65.7, 55.1, 27.5, 27.1; HRMS: [M+NH₄]⁺ calcd for C₄₂H₅₉N₄O₁₀Si 807.39950, found 807.39931.




2,2,2-Trifluoroethyl 2-azido-3-O-benzyl-2-deoxy-4,6-O-di-tert-butylsilylidene-α-D-glucopyranoside (2J).

Donor **2** and 2,2,2-trifluoroethanol were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (for an additional 30 min at -40°C) and purified by flash column chromatography (1/0 to 0/1 pentane/toluene to 2% Et₂O in toluene) to yield glycosylation product **2J** (42.4 mg, 82 μmol, 82%, α:β = >20:1) as a colorless oil. R_f: 0.36 (toluene). [α]_D²³ = +32.6° (*c* = 1.0, CHCl₃); IR (neat): 654, 766, 826, 1036, 1082, 1159, 1279, 1472, 2108, 2859, 2930; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.45 – 7.39 (m, 2H, CH_{arom}), 7.38 – 7.27 (m, 3H, CH_{arom}), 5.07 (d, 1H, *J* = 10.6 Hz, CHH Bn), 4.88 (d, 1H, *J* = 3.6 Hz, H-1), 4.82 (d, 1H, *J* = 10.6 Hz, CHH Bn), 4.14 – 4.07 (m, 1H, H-6), 4.03 – 3.93 (m, 3H, CH₂-CF₃, H-4), 3.92 – 3.80 (m, 3H, H-3, H-3, H-5, H-6), 3.36 (dd, 1H, *J* = 10.0, 3.6 Hz, H-2), 1.09 (s, 9H, CH₃¹Bu), 1.03 (s, 9H, CH₃¹Bu); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 138.1 (C_q), 128.6, 128.5, 128.1 (CH_{arom}), δ 123.5 (q, *J* = 278.4 Hz, CF₃), 98.8 (C-1), 78.9 (C-3), 78.8 (C-4), 75.7 (CH₂ Bn), 67.4 (C-5), 66.5 (C-6), 65.2 (q, *J* = 35.4 Hz, CH₂-CF₃), 62.2 (C-2), 27.5, 27.1 (CH₃¹Bu), 22.8, 20.1 (C_q¹Bu); HRMS: [M-N₂+H]⁺ calcd for C₂₃H₃₅F₃NO₅Si 490.22311, found 490.22292.




1,1,1,3,3,3-Hexafluoro-2-propyl 2-azido-3-O-benzyl-2-deoxy-4,6-O-di-tert-butylsilylidene-α-D-glucopyranoside (2K).

Donor **2** and 1,1,1,3,3,3-hexafluoro-2-propanol were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (for an additional 72 hours at -40°C) and purified by flash column chromatography (4/1 to 0/1 pentane/toluene) to yield glycosylation product **2K** (20 mg, 34 μmol, 34%, α:β = >20:1) as a white solid. R_f: 0.38 (9/1 pentane/Et₂O). [α]_D²⁰ = +31.2° (*c* = 0.50, CHCl₃); IR (thin film): 689, 827, 1030, 1098, 1221, 1288, 1368, 2112, 2860, 2934; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC, HMBC, NOESY): δ 7.45 – 7.28 (m, 5H, CH_{arom}), 5.12 – 5.04 (m, 2H, CHH Bn, H-1), 4.83 (d, 1H, *J* = 10.5 Hz, CHH Bn), 4.40 (hept, 1H, *J* = 5.7 Hz, CH HFIP), 4.09 (dd, 1H, *J* = 9.4, 4.0 Hz, H-6), 4.03 – 3.91 (m, 2H, H-4, H-5), 3.91 – 3.83 (m, 2H, H-3, H-6), 3.42 (dd, 1H, *J* = 10.2, 3.8 Hz, H-2), 1.08 (s, 9H, CH₃¹Bu), 1.03 (s, 9H, CH₃¹Bu); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC, HMBC): δ 138.0 (C_q), 128.6, 128.5, 128.2 (CH_{arom}), 100.4 (C-1), 78.7 (C-3), 78.4 (C-4), 75.8 (CH₂ Bn), 73.3 (p, *J* = 33.2 Hz), 68.1 (C-5), 66.1 (C-6), 61.9 (C-2), 27.5, 27.0 (CH₃¹Bu), 22.8, 20.1 (C_q¹Bu); HRMS: [M-N₂+H]⁺ calcd for C₂₄H₃₄F₆NO₅Si 558.21050, found 558.21009.



Ethyl 2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-β-D-glucopyranoside (3A).


Donor **3** and ethanol were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations and purified by flash column chromatography (1/0 to 0/1 hexane/toluene to 5% EtOAc in toluene) to yield glycosylation product **3A** (34.3 mg, 83 μmol, 83%, α:β = <1:20) as a white solid. R_f: 0.58 (9/1 toluene/EtOAc). [α]_D²³ = -79.6° (*c* = 0.69, CHCl₃); IR (neat): 692, 993, 1098, 1186, 1267, 1365, 1452, 2111, 2878, 2979; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.50 – 7.46 (m, 2H, CH_{arom}), 7.41 – 7.28 (m, 8H, CH_{arom}), 5.57 (s, 1H, CHPh), 4.91 (d, 1H, *J* = 11.2 Hz, CHH Bn), 4.79 (d, 1H, *J* = 11.3 Hz, CHH Bn), 4.37 (d, 1H, *J* = 8.2 Hz, H-1), 4.34 (dd, 1H, *J* = 10.6, 5.0 Hz, H-6), 3.96 (dq, 1H, *J* = 9.7, 7.1 Hz, CHH Et), 3.80 (t, 1H, *J* = 10.3 Hz, H-6), 3.70 (t, 1H, *J* = 9.0 Hz, H-4), 3.66 (dq, 1H, *J* = 9.7, 7.2 Hz, CHH Et), 3.54 (t, 1H, *J* = 9.3 Hz, H-3), 3.44 (dd, 1H, *J* = 9.5, 8.0 Hz, H-2), 3.39 (td, 2H, *J* = 9.8, 5.0 Hz, H-5), 1.29 (t, 3H, *J* = 7.1 Hz, CH₃ Et); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 138.0, 137.2 (C_q), 129.2, 128.5, 128.4, 128.3, 128.0, 126.1 (CH_{arom}), 102.5 (C-1), 101.4 (CHPh), 81.7 (C-4), 79.1 (C-3), 75.0 (CH₂ Bn), 68.7 (C-6), 66.3 (CH₂ Et), 66.3, 66.2 (C-2, C-5), 15.2 (CH₃ Et); ¹³C-HMBC-GATED NMR (CDCl₃, 101 MHz): δ 102.5 (*J*_{C1,H1} = 161 Hz, C-1); HRMS: [M+NH₄]⁺ calcd for C₂₂H₂₉N₄O₅ 429.21325, found 429.21321.



Cyclohexyl 2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-β-D-glucopyranoside (3B).


Donor **3** and cyclohexanol were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations and purified by flash column chromatography (1/1 to 0/1 hexane/toluene to 5% EtOAc in toluene) to yield glycosylation product **3B** (43 mg, 93 μmol, 93%, α:β = <1:20) as a white solid. R_f: 0.23 (toluene). [α]_D²³ = -60.5° (*c* = 0.86, DCM); IR (neat): 696, 748, 998, 1092, 1275, 1365, 1452, 2108, 2858, 2933; Data for the β-anomer: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.50 – 7.44 (m, 2H, CH_{arom}), 7.42 – 7.27 (m, 8H, CH_{arom}), 5.56 (s, 1H, CHPh), 4.90 (d, 1H, *J* = 11.4 Hz, CHH Bn), 4.79 (d, 1H, *J*

= 11.4 Hz, CHH Bn), 4.47 (d, 1H, J = 7.8 Hz, H-1), 4.32 (dd, 1H, J = 10.5, 5.0 Hz, H-6), 3.79 (t, 1H, J = 10.3 Hz, H-6), 3.74 – 3.64 (m, 2H, H-4, CH Cyc), 3.50 (t, 1H, J = 9.2 Hz, H-3), 3.44 (dd, 1H, J = 9.6, 7.8 Hz, H-2), 3.36 (td, 1H, J = 9.7, 5.0 Hz, H-5), 1.99 – 1.87 (m, 2H, CH₂ Cyc), 1.82 – 1.72 (m, 2H, J = 15.2, 4.4 Hz, CH₂ Cyc), 1.56 – 1.37 (m, 3H, CH₂ Cyc), 1.36 – 1.20 (m, 3H, CH₂ Cyc); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 138.0, 137.3 (C_q), 129.1, 128.5, 128.4, 128.3, 127.9, 126.1 (CH_{arom}), 101.4 (CHPh), 101.0 (C-1), 81.6 (C-4), 79.0 (C-3), 78.5 (CH Cyc), 75.0 (CH₂ Bn), 68.8 (C-6), 66.5 (C-2), 66.3 (C-5), 33.6, 31.8, 25.6, 24.1, 23.9 (CH₂ Cyc); Diagnostic peaks α -anomer: ¹H NMR (CDCl₃, 400 MHz): δ 5.59 (s, 0.04H, CHPh), 5.03 (d, 0.04H, J = 3.7 Hz, H-1), 4.12 (t, 0.04H, J = 9.5 Hz, H-3), 4.00 (td, 0.04H, J = 9.9, 4.8 Hz, H-5), 3.28 (dd, 0.04H, J = 10.0, 3.7 Hz, H-2); ¹³C-APT NMR (CDCl₃, 101 MHz): δ 101.4 (CHPh), 97.1 (C-1), 76.0 (C-3), 63.8 (C-2), 62.9 (C-5); HRMS: [M+NH₄]⁺ calcd for C₂₆H₃₅N₄O₅ 483.26020 found 483.25991.




Methyl 6-O-(2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy- β -D-glucopyranosyl)-2,3,4-tri-O-benzyl- α -D-glucopyranoside (3C). Donor **3** and acceptor **25** were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (for an additional 18 h at -40°C) and purified by flash column chromatography (19/1

to 4/1 pentane/EtOAc) to yield glycosylation product **3C** (73.7 mg, 89 μ mol, 89%, α : β = <1:20) as a white solid. R_f: 0.42 (4/1 pentane/EtOAc). Spectroscopic data were in accord with those previously reported.³⁸ [α]_D²³ = -32.2° (c = 1.0, CHCl₃); IR (neat): 696, 737, 999, 1028, 1070, 1090, 1277, 1362, 1497, 2108, 2876, 2926; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC, HMBC): δ 7.47 (dd, 2H, J = 7.3, 2.5 Hz, CH_{arom}), 7.42 – 7.25 (m, 23H, CH_{arom}), 5.55 (s, 1H, CHPh), 4.99 (d, 1H, J = 10.9 Hz, CHH 3-OBn), 4.95 (d, 1H, J = 11.2 Hz, CHH 4-OBn), 4.91 (d, 1H, J = 11.2 Hz, CHH 3'-OBn), 4.85 – 4.76 (m, 3H, CHH 3-OBn, CHH 2-OBn, CHH 3'-OBn), 4.70 – 4.63 (m, 2H, CHH 4-OBn, CHH 2-OBn), 4.61 (d, 1H, J = 3.6 Hz, H-1), 4.30 (dd, 1H, J = 10.5, 5.0 Hz, H-6'), 4.23 (d, 1H, J = 7.9 Hz, H-1'), 4.07 (d, 1H, J = 8.9 Hz, H-6), 4.00 (t, 1H, J = 9.3 Hz, H-3), 3.81 – 3.72 (m, 3H, H-5, H-6, H-6'), 3.69 (t, 1H, J = 9.1 Hz, H-4'), 3.60 (t, 1H, J = 9.3 Hz, H-4), 3.59 – 3.46 (m, 3H, H-2, H-2', H-3'), 3.37 (s, 3H, CH₃ OMe), 3.36 – 3.29 (m, 1H, H-5'); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC, HMBC): δ 138.8, 138.5, 138.2, 137.8, 137.2 (C_q), 129.2, 128.6, 128.5, 128.5, 128.4, 128.3, 128.3, 128.1, 128.1, 128.0, 127.9, 127.9, 127.7, 126.1 (CH_{arom}), 102.4 (C-1'), 101.4 (CHPh), 98.4 (C-1), 82.2 (C-3), 81.5 (C-4'), 79.8 (C-2), 79.3 (C-3'), 77.6 (C-4), 75.9 (CH₂ 3-OBn), 75.0, 75.0 (CH₂ 3'-OBn, 4-OBn), 73.6 (CH₂ 2-OBn), 69.6 (C-5), 68.7, 68.6 (C-6, C-6'), 66.3 (C-5'), 66.1 (C-2'), 55.4 (OMe); HRMS: [M+NH₄]⁺ calcd for C₄₈H₅₅N₄O₁₀ 847.39127, found 847.39224.



2-Fluoroethyl 2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy- α / β -D-glucopyranoside (3D).


Donor **3** and 2-fluoroethanol were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations and purified by flash column chromatography (1/0 to 0/1 pentane/toluene to 5% EtOAc in toluene) to yield glycosylation product **3D** (38.5 mg, 90 μ mol, 90%, α : β = 1:6.7) as a white solid. R_f: 0.40 (19/1 toluene/EtOAc). IR (neat): 696, 748, 996, 1028, 1072, 1091, 1174, 1276, 1368, 1454, 2108, 2873, 2917; Data for the β -anomer: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.50 – 7.46 (m, 2H, CH_{arom}), 7.41 – 7.36 (m, 5H, CH_{arom}), 7.36 – 7.25 (m, 3H, CH_{arom}), 5.57 (s, 1H, CHPh), 4.91 (d, 1H, J = 11.2 Hz, CHH Bn), 4.79 (d, 1H, J = 11.3 Hz, CHH Bn), 4.69 – 4.64 (m, 1H, CHHF), 4.55 (dt, 1H, J = 4.6, 2.9 Hz, CHHF), 4.42 (d, 1H, J = 7.9 Hz, H-1), 4.34 (dd, 1H, J = 10.5, 5.0 Hz, H-6), 4.11 (ddd, 0.5H, J = 12.2, 4.8, 2.9 Hz, CHH-CFHz), 4.03 (ddd, 0.5H, J = 12.2, 4.7, 3.0 Hz, CHH-CFHz), 3.92 (ddd, 0.5H, J = 12.2, 5.9, 3.2 Hz, CHH-CFHz), 3.86 (ddd, 0.5H, J = 12.2, 6.0, 3.3 Hz, CHH-CFHz), 3.80 (t, 1H, J = 10.3 Hz, H-6), 3.71 (t, 1H, J = 9.2 Hz, H-4), 3.56 (t, 1H, J = 9.2 Hz, H-3), 3.48 (dd, 1H, J = 9.5, 7.9 Hz, H-2), 3.39 (td, 1H, J = 9.7, 4.9 Hz, H-5); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 137.8, 137.1 (C_q), 129.2, 128.5, 128.4, 128.3, 128.0, 126.1 (CH_{arom}), 102.7 (C-1), 101.4 (CHPh), 82.6 (d, J = 170.1 Hz, CFHz), 81.5 (C-4), 79.0 (C-3), 75.1 (CH₂ Bn), 69.3 (d, J = 20.1 Hz, CH₂-CFHz), 68.6 (C-6), 66.3 (C-5), 66.1 (C-2); ¹³C-HMBC-GATED NMR (CDCl₃, 101 MHz): δ 102.7 ($J_{C1,H1}$ = 162 Hz, C-1); Diagnostic peaks α -anomer: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 5.58 (s, 0.15H, CHPh), 4.96 (d, 0.15H, J = 10.9 Hz, CHH Bn), 4.95 (d, 0.15H, J = 3.7 Hz, H-1), 4.81 (d, 0.15H, J = 11.0 Hz, CHH Bn), 4.29 (dd, 0.15H, J = 10.2, 4.9 Hz, H-6); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 101.5 (CHPh), 98.8 (C-1), 82.8 (C-4), 76.2 (C-3), 75.2 (CH₂ Bn), 68.9 (C-6), 63.0, 62.9 (C-2, C-5); ¹³C-HMBC-GATED NMR (CDCl₃, 101 MHz): δ 98.8 ($J_{C1,H1}$ = 172 Hz, C-1); HRMS: [M+NH₄]⁺ calcd for C₂₂H₂₈FNa₄O₅ 447.20382 found 447.20355.



Methyl 4-O-(2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy- α / β -D-glucopyranosyl)-2,3,6-tri-O-benzyl- α -D-glucopyranoside (3E). Donor **3** and acceptor **26** were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (for an additional 18 h at -40°C) and purified by flash column chromatography (19/1


to 4/1 pentane/EtOAc) to yield glycosylation product **3E** (73.3 mg, 88 μ mol, 88%, α : β = 1:7) as a white solid. R_f: 0.51 α , 0.43 β (4/1 pentane/EtOAc). IR (neat): 696, 737, 1049, 1092, 1362, 1454, 2110, 2868; Data for the β -anomer: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC, TOCSY): δ 7.68 – 7.60 (m, 2H, CH_{arom}), 7.52 – 7.18 (m, 23H, CH_{arom}), 5.47 (s, 1H, CHPh), 4.89 (d, 1H, J = 11.2 Hz, CHH Bn), 4.87 (d, 1H, J = 10.9 Hz, CHH Bn), 4.81 (d, 1H, J = 10.9 Hz, CHH Bn), 4.78

(d, 1H, $J = 12.2$ Hz, *CHH* Bn), 4.75 (d, 1H, $J = 11.2$ Hz, *CHH* Bn), 4.71 (d, 1H, $J = 12.0$ Hz, *CHH* Bn), 4.63 (d, 1H, $J = 12.1$ Hz, *CHH* Bn), 4.60 (d, 1H, $J = 3.7$ Hz, H-1), 4.41 (d, 1H, $J = 12.0$ Hz, *CHH* Bn), 4.19 (d, 1H, $J = 7.6$ Hz, H-1'), 4.11 (dd, 1H, $J = 10.6, 5.0$ Hz, H-6'), 4.00–3.90 (m, 2H, H-4, H-6), 3.85 (t, 1H, $J = 9.3$ Hz, H-3), 3.75 (dt, 1H, $J = 9.8, 2.4$ Hz, H-5), 3.69 (dd, 1H, $J = 10.8, 1.9$ Hz, H-6), 3.56 (t, 1H, $J = 9.0$ Hz, H-4'), 3.51 (dd, 1H, $J = 9.5, 3.7$ Hz, H-2), 3.45–3.38 (m, 4H, H-6', CH₃ OMe), 3.36–3.27 (m, 2H, H-2', H-3'), 3.00 (td, 1H, $J = 9.8, 5.0$ Hz, H-5'); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 139.3, 138.3, 137.8, 137.8, 137.3 (C_q), 131.1, 129.4, 128.6, 128.4, 128.3, 128.2, 128.2, 128.1, 128.1, 127.9, 127.9, 127.6, 126.0, 124.8 (CH_{arom}), 101.3, 101.2 (CHPh, C-1'), 98.4 (C-1), 81.7 (C-4'), 80.1 (C-3), 79.2 (C-3'), 79.0 (C-2), 76.9 (C-4), 75.4, 74.7, 73.6, 73.5 (CH₂ Bn), 69.7 (C-5), 68.6 (C-6'), 68.0 (C-6), 66.6 (C-2'), 65.8 (C-5'), 55.4 (OMe); Diagnostic peaks α-anomer: ¹H NMR (CDCl₃, 400 MHz): δ 5.71 (d, 1H, $J = 4.0$ Hz, H-1'), 5.53 (s, 1H, *CHPh*), 5.11 (d, 1H, $J = 10.7$ Hz, *CHH* Bn), 4.95 (d, 1H, $J = 10.9$ Hz, *CHH* Bn); ¹³C-APT NMR (CDCl₃, 101 MHz): δ 98.1, 97.8, 82.7, 82.1, 80.5, 76.2, 75.1, 73.3, 73.0, 69.4, 69.1, 68.7, 63.4, 62.9; HRMS: [M+Na]⁺ calcd for C₄₈H₅₁N₃O₁₀Na 852.34667, found 852.34668.




Methyl (Methyl 4-O-[2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-α/β-D-glucopyranosyl]-2,3-di-O-benzyl-α-D-glucopyranosyl uronate) (3F). Donor **3** and acceptor **27** were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (for an additional 18 h at -40°C) and purified by flash column

chromatography (19/1 to 4/1 pentane/EtOAc) to yield glycosylation product **3F** (71.8 mg, 93 μmol, 93%, α:β = 1.1:1) as a white solid. *R_f*: 0.54 (4/1 pentane/EtOAc). Spectroscopic data were in accord with those previously reported.²¹ IR (neat): 696, 735, 914, 989, 1028, 1045, 1090, 1267, 1369, 1454, 1749, 2108, 2870, 2916; Reported as a 1 : 1 mixture of anomers: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC, HMBC): δ 7.48–7.41 (m, 4H, CH_{arom}), 7.41–7.24 (m, 36H, CH_{arom}), 5.53 (s, 1H, *CHPh*_a), 5.51 (d, 1H, $J = 3.9$ Hz, H-1'_a), 5.47 (s, 1H, *CHPh*_b), 5.04 (d, 1H, $J = 10.5$ Hz, *CHH* Bn), 4.94 (d, 1H, $J = 11.0$ Hz, *CHH* Bn), 4.91–4.82 (m, 4H, 2*xCHH* Bn, 2*xCHH* Bn), 4.81–4.72 (m, 4H, 2*xCHH* Bn, 2*xCHH* Bn), 4.64–4.58 (m, 2H, 2*xCHH* Bn), 4.57 (d, 2H, $J = 3.5$ Hz, H-1_{α,β}), 4.43 (d, 1H, $J = 8.1$ Hz, H-1'_β), 4.26 (dd, 1H, $J = 10.3, 4.8$ Hz, H-6'_a), 4.24–4.19 (m, 2H, H-5_a, H-5_β), 4.09–3.99 (m, 4H, H-3_β, H-4_a, H-4_β, H-6'_β), 3.97 (t, 1H, $J = 9.5$ Hz, H-3'_a), 3.89 (t, 1H, $J = 9.2$ Hz, H-3_a), 3.82 (s, 3H, CH₃ CO₂Me), 3.81 (s, 3H, CH₃ CO₂Me), 3.72–3.56 (m, 4H, H-2_β, H-4'_a, H-4'_β, H-6'_a), 3.56–3.46 (m, 3H, H-2_a, H-3'_β, H-5'_a), 3.46–3.38 (m, 7H, 2*xCH*₃ OMe, H-6'_β), 3.36–3.29 (m, 2H, H-2'_a, H-2'_β), 3.26 (td, 1H, $J = 9.7, 5.0$ Hz, H-5'_β); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC, HMBC): δ 170.0, 170.0 (C=O CO₂Me), 139.1, 138.5, 138.0, 137.9, 137.9, 137.8, 137.4, 137.2 (C_q), 129.2, 129.1, 128.7, 128.6, 128.5, 128.5, 128.4, 128.3, 128.3, 128.3, 128.2, 128.1, 128.0, 128.0, 127.8, 127.7, 127.5, 127.4, 126.1, 126.1 (CH_{arom}), 102.3 (C-1'_β), 101.4 (CHPh_β), 101.3 (CHPh_a), 98.9, 98.6 (C-1_a, C-1_β), 98.5 (C-1'_a), 82.4 (C-4'_a), 81.6 (C-4'_β), 81.1 (C-3_β), 79.6 (C-2_β, C-4_β), 79.5 (C-3_a), 79.4 (C-3'_β), 78.7 (C-2_a), 76.3 (C-3'_a), 75.6 (CH₂ Bn), 75.5 (C-4_a), 75.1, 75.0, 73.9, 73.7 (CH₂ Bn), 70.0, 69.9 (C-5_a, C-5_β), 68.5, 68.5 (C-6_a, C-6_β), 66.7 (C-2'_β), 66.2 (C-5'_β), 63.0 (C-5'_a), 62.8 (C-2'_a), 55.9, 55.9 (OMe), 53.0, 52.8 (CO₂Me); HRMS: [M+NH₄]⁺ calcd for C₄₂H₄₉N₄O₁₁ 785.33923, found 785.34007.



2,2-Difluoroethyl 2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-α/β-D-glucopyranoside (3G). Donor **3** and 2,2-difluoroethanol were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations and purified by flash column chromatography (1/0 to 0/1 pentane/toluene to 5% EtOAc in toluene) to yield glycosylation product **3G** (28.8


mg, 64 μmol, 64%, α:β = 2.9:1) as a white solid. *R_f*: 0.15 and 0.18 (toluene). IR (neat): 698, 747, 998, 1070, 1093, 1372, 1454, 2109, 2867, 2934; Reported as a 1 : 0.35 mixture of anomers: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.52–7.45 (m, 2.70H, CH_{arom}), 7.43–7.26 (m, 10.80H, CH_{arom}), 5.95 (tt, 1H, $J = 55.2, 4.2$ Hz, CF₂H_a), 5.94 (tt, 0.35H, $J = 55.3, 3.8$ Hz, CF₂H_β), 5.58 (s, 1H, *CHPh*_a), 5.57 (s, 0.35H, *CHPh*_β), 4.96 (d, 1H, $J = 10.9$ Hz, *CHH* Bn_a), 4.93 (d, 1H, $J = 3.9$ Hz, H-1_a), 4.92 (d, 0.35H, $J = 11.3$ Hz, *CHH* Bn_β), 4.80 (d, 1H, $J = 11.0$ Hz, *CHH* Bn_a), 4.79 (d, 0.35H, $J = 11.3$ Hz, *CHH* Bn_β), 4.40 (d, 0.35H, $J = 7.9$ Hz, H-1_β), 4.34 (dd, 0.35H, $J = 10.5, 5.0$ Hz, H-6_β), 4.29 (dd, 1H, $J = 10.2, 4.8$ Hz, H-6_a), 4.08 (t, 1H, $J = 9.5$ Hz, H-3_a), 4.02–3.67 (m, 6.4H, H-4_a, H-4_β, H-5_a, H-6_a, H-6_β, CH₂-CF₂H_a, CH₂-CF₂H_β), 3.56 (t, 0.35H, $J = 9.2$ Hz, H-3_β), 3.50–3.35 (m, 1.70H, H-2_a, H-2_β, H-5_β); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 137.8, 137.8, 137.1, 137.1 (C_q), 129.4, 129.3, 129.1, 128.6, 128.5, 128.5, 128.4, 128.1, 126.1 (CH_{arom}), 114.0 (t, $J = 241.5$ Hz, CF₂H_β), 113.8 (t, $J = 241.6$ Hz, CF₂H_a), 102.8 (C-1_β), 101.6 (CHPh_a), 101.5 (CHPh_β), 99.3 (C-1_a), 82.6 (C-4_a), 81.4 (C-4_β), 78.9 (C-3_β), 76.0 (C-3_a), 75.3 (CH₂ Bn_a), 75.1 (CH₂ Bn), 69.0 (t, $J = 29.0$ Hz, CH₂-CF₂H_β), 68.8 (C-6), 68.5 (C-6), 67.5 (t, $J = 28.7$ Hz, CH₂-CF₂H_a), 66.4 (C-5_β), 66.0 (C-2_β), 63.3 (C-5_a), 62.9 (C-2_a); HRMS: [M+H]⁺ calcd for C₂₂H₂₄F₂N₃O₅ 448.16785, found 448.16761.



Methyl 4-O-(2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy- α/β -D-glucopyranosyl)-2,3,6-tri-O-benzyl- β -D-galactopyranoside (3H).

Donor **3** and acceptor **28** were condensed using the general procedure for $\text{TiF}_2/\text{Ph}_2\text{SO}$ mediated glycosylations (for an additional 18 h at -40°C) and purified by flash column chromatography (19/1 to 4/1 pentane/EtOAc) to yield glycosylation product **3H** (62.2 mg, 75 μmol , 75%,


$\alpha:\beta = 9:1$) as a white solid. R_f : 0.52 (4/1 pentane/EtOAc). IR (neat): 696, 735, 995, 1030, 1072, 1090, 1368, 1454, 1497, 2106, 2862, 2920; Data for the α -anomer: $^1\text{H NMR}$ (CDCl_3 , 400 MHz, HH-COSY, HSQC, HMBC): δ 7.50 – 7.46 (m, 2H, CH_{arom}), 7.42 – 7.25 (m, 23H, CH_{arom}), 5.51 (s, 1H, CHPh), 4.98 (d, 1H, $J = 10.7$ Hz, $\text{CHH } 3'\text{-OBn}$), 4.90 (d, 1H, $J = 11.0$ Hz, $\text{CHH } 2\text{-OBn}$), 4.88 (d, 1H, $J = 3.7$ Hz, $\text{H-1}'$), 4.84 – 4.76 (m, 3H, $\text{CHH } 2\text{-OBn}$, $\text{CHH } 3'\text{-OBn}$, $\text{CHH } 3\text{-OBn}$), 4.69 (d, 1H, $J = 12.4$ Hz, $\text{CHH } 3\text{-OBn}$), 4.59 – 4.51 (m, 2H, CH_2 6-OBn), 4.30 (td, 1H, $J = 10.1$, 4.9 Hz, $\text{H-5}'$), 4.25 (d, 1H, $J = 7.6$ Hz, H-1), 4.14 – 4.07 (m, 2H, $\text{H-3}'$, H-4), 4.03 (t, 1H, $J = 8.9$ Hz, H-6), 3.80 (dd, 1H, $J = 10.2$, 4.9 Hz, $\text{H-6}'$), 3.70 – 3.60 (m, 3H, H-2 , $\text{H-4}'$, H-6), 3.55 (s, 3H, CH_3 OMe), 3.54 – 3.48 (m, 2H, H-5 , $\text{H-6}'$), 3.44 – 3.36 (m, 2H, $\text{H-2}'$, H-3); $^{13}\text{C-APT NMR}$ (CDCl_3 , 101 MHz, HSQC, HMBC): δ 138.7, 138.3, 138.1, 137.7, 137.6 (C_q), 129.0, 128.6, 128.5, 128.5, 128.4, 128.3, 128.3, 128.2, 128.0, 127.7, 127.6, 126.1 (CH_{arom}), 105.3 (C-1), 101.2 (CHPh), 99.4 ($\text{C-1}'$), 83.1 ($\text{C-4}'$), 80.1 (C-3), 78.9 (C-2), 77.0 ($\text{C-3}'$), 75.3 (CH_2 3'-OBn), 75.1 (CH_2 2-OBn), 74.7 (C-4), 73.6 (CH_2 6-OBn), 73.0 (CH_2 3-OBn), 72.9 (C-5), 68.9 ($\text{C-6}'$), 67.1 (C-6), 63.8 ($\text{C-2}'$), 62.9 ($\text{C-5}'$), 57.4 (OMe); Diagnostic peaks β -anomer: $^1\text{H NMR}$ (CDCl_3 , 400 MHz): δ 5.54 (s, 1H, CHPh), 3.92 (dd, 1H, $J = 9.7$, 7.7 Hz, H-2), 3.76 – 3.71 (m, 1H, H-6), 3.22 (td, 1H, $J = 9.7$, 4.8 Hz, $\text{H-5}'$); $^{13}\text{C-APT NMR}$ (CDCl_3 , 101 MHz): δ 105.1 (C-1), 102.6 ($\text{C-1}'$), 101.4, 81.5, 81.3, 79.5, 79.0, 74.0, 73.4, 69.4, 68.6, 66.3, 66.0, 57.4; HRMS: $[\text{M}+\text{NH}_4]^+$ calcd for $\text{C}_{48}\text{H}_{55}\text{N}_4\text{O}_{10}$ 847.39127, found 847.39206.



Methyl 2-O-(2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy- α/β -D-glucopyranosyl)-3-O-benzyl-4,6-O-benzylidene- α -D-mannopyranoside (3I).

Donor **3** and acceptor **29** were condensed using the general procedure for $\text{TiF}_2/\text{Ph}_2\text{SO}$ mediated glycosylations (for an additional 18 h at -40°C) and purified by flash column chromatography (19/1 to 4/1 pentane/EtOAc) to yield glycosylation product **3I** (54.7 mg, 74 μmol , 74%, $\alpha:\beta = 9:1$) as a


white solid. R_f : 0.74 (7/2 pentane/EtOAc). IR (neat): 696, 746, 997, 1036, 1074, 1090, 1128, 1371, 1454, 2106, 2862, 2922; Data for the α -anomer: $^1\text{H NMR}$ (CDCl_3 , 400 MHz, HH-COSY, HSQC, HMBC): δ 7.54 – 7.47 (m, 4H, CH_{arom}), 7.44 – 7.25 (m, 16H, CH_{arom}), 5.66 (s, 1H, CHPh), 5.60 (s, 1H, CHPh'), 5.39 (d, 1H, $J = 3.7$ Hz, $\text{H-1}'$), 5.00 (d, 1H, $J = 11.0$ Hz, CHH Bn), 4.90 (d, 1H, $J = 12.2$ Hz, CHH Bn), 4.84 (d, 1H, $J = 10.9$ Hz, CHH Bn), 4.73 – 4.66 (m, 2H, H-1 , CHH Bn), 4.34 – 4.24 (m, 3H, H-4 , H-6 , $\text{H-6}'$), 4.17 (dd, 1H, $J = 10.2$, 9.0 Hz, $\text{H-3}'$), 4.09 (dd, 1H, $J = 3.1$, 1.7 Hz, H-2), 4.00 (dd, 1H, $J = 9.9$, 3.1 Hz, H-3), 3.95 – 3.86 (m, 2H, $\text{H-5}'$, H-6), 3.83 – 3.70 (m, 3H, $\text{H-4}'$, H-5 , $\text{H-6}'$), 3.36 (s, 3H, CH_3 OMe), 3.32 (dd, 1H, $J = 10.2$, 3.8 Hz, $\text{H-2}'$); $^{13}\text{C-APT NMR}$ (CDCl_3 , 101 MHz, HSQC, HMBC): δ 138.7, 138.0, 137.7, 137.2 (C_q), 129.2, 129.0, 128.6, 128.5, 128.4, 128.3, 128.2, 128.0, 127.6, 127.4, 126.2, 126.0 (CH_{arom}), 101.7 (CHPh), 101.5 (CHPh'), 101.0 (C-1), 99.8 ($\text{C-1}'$), 82.9 ($\text{C-4}'$), 79.4 (C-4), 75.9 (C-3), 75.6 ($\text{C-3}'$), 75.5 (C-2), 75.3, 73.3 (CH_2 Bn), 69.0, 68.9 (C-6 , $\text{C-6}'$), 64.1 (C-5), 63.3 ($\text{C-5}'$), 63.0 ($\text{C-2}'$), 55.0 (OMe); Diagnostic peaks β -anomer: $^1\text{H NMR}$ (CDCl_3 , 400 MHz): δ 4.43 (d, 0.1H, $J = 8.0$ Hz, $\text{H-1}'$), 3.62 (dd, 0.1H, $J = 9.6$, 8.0 Hz, $\text{H-2}'$), 3.51 (t, 0.1H, $J = 9.3$ Hz, H-4); $^{13}\text{C-APT NMR}$ (CDCl_3 , 101 MHz): δ 102.0 ($\text{C-1}'$), 78.5 (C-4), 66.4 ($\text{C-2}'$); HRMS: $[\text{M}+\text{NH}_4]^+$ calcd for $\text{C}_{41}\text{H}_{47}\text{N}_4\text{O}_{10}$ 755.32867, found 755.32921.




2,2,2-Trifluoroethyl 2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy- α -D-glucopyranoside (3J).

Donor **3** and 2,2,2-trifluoroethanol were condensed using the general procedure for


$\text{TiF}_2/\text{Ph}_2\text{SO}$ mediated glycosylations (for an additional 1 h at -40°C) and purified by flash column chromatography (1/0 to 0/1 pentane/toluene to 5% EtOAc in toluene) to yield glycosylation product **3J** (44 mg, 94 μmol , 94%, $\alpha:\beta = >20:1$) as a colorless oil. R_f : 0.24 (toluene). $[\alpha]_D^{23} = +25.9^\circ$ ($c = 0.88$, DCM); IR (neat): 697, 747, 1001, 1034, 1090, 1165, 1279, 1373, 2108, 2865, 2934; Data for the α -anomer: $^1\text{H NMR}$ (CDCl_3 , 400 MHz, HH-COSY, HSQC): δ 7.51 – 7.48 (m, 2H, CH_{arom}), 7.42 – 7.28 (m, 8H, CH_{arom}), 5.58 (s, 1H, CHPh), 4.99 – 4.94 (m, 2H, CHH Bn , H-1), 4.80 (d, 1H, $J = 10.9$ Hz, CHH Bn), 4.29 (dd, 1H, $J = 10.2$, 4.8 Hz, H-6), 4.10 (dd, 1H, $J = 10.0$, 9.0 Hz, H-3), 3.98 (qd, 2H, $J = 8.5$, 3.1 Hz, $\text{CH}_2\text{-CF}_3$), 3.91 (td, 1H, $J = 9.9$, 4.8 Hz, H-5), 3.79 – 3.70 (m, 2H, H-4 , H-6), 3.43 (dd, 1H, $J = 10.0$, 3.7 Hz, H-2); $^{13}\text{C-APT NMR}$ (CDCl_3 , 101 MHz, HSQC): δ 137.8, 137.1 (C_q), 129.3, 128.6, 128.5, 128.3, 128.1, 126.1 (CH_{arom}), 123.5 (q, $J = 278.5$ Hz), 101.6 (CHPh), 99.4 (C-1), 82.5 (C-4), 75.9 (C-3), 75.3 (CH_2 Bn), 68.7 (C-6), 65.4 (q, $J = 35.4$ Hz), 63.5 (C-5), 62.7 (C-2); $^{13}\text{C-HMBC-GATED NMR}$ (CDCl_3 , 101 MHz): δ 102.5 ($J_{\text{C-1,H-1}} = 173$ Hz, C-1); Diagnostic peaks β -anomer: $^1\text{H NMR}$ (CDCl_3 , 400 MHz): δ 4.44 (d, 0.03H, $J = 7.9$ Hz, H-1), 4.34 (dd, 0.03H, $J = 10.8$, 5.3 Hz, H-6), 3.56 (t, 0.03H, $J = 9.2$ Hz), 3.48 (dd, 0.03H, $J = 10.0$, 7.9 Hz, H-2); $^{13}\text{C-HMBC-GATED NMR}$ (CDCl_3 , 101 MHz): δ 102.4 ($J_{\text{C-H}} = 150$ Hz, C-1); HRMS: $[\text{M}+\text{NH}_4]^+$ calcd for $\text{C}_{22}\text{H}_{26}\text{F}_3\text{N}_4\text{O}_5$ 483.18498 found 483.18463.




1,1,1,3,3,3-Hexafluoro-2-propyl 2-azido-3-O-benzoyl-4,6-O-benzylidene-2-deoxy- α -D-glucopyranoside (3K). Donor **3** and 1,1,1,3,3,3-hexafluoroisopropanol were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (for an additional 72 h at -40°C) and purified by flash column chromatography (1/0 to 9/1 pentane/EtOAc) to yield glycosylation product **3K** (28.1 mg, 53 μ mol, 53%, α : β = >20:1) as a colorless oil. [α]_D²⁵ = +25.8° (c = 0.5, CHCl₃); IR (neat): 689, 748, 999, 1092, 1196, 1219, 1287, 1368, 2108, 2868, 2928; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.54 – 7.45 (m, 2H, CH_{arom}), 7.44 – 7.27 (m, 8H, CH_{arom}), 5.59 (s, 1H, CHPh), 5.13 (d, 1H, J = 3.9 Hz, H-1), 4.99 (d, 1H, J = 10.8 Hz, CHH Bn), 4.82 (d, 1H, J = 10.8 Hz, CHH Bn), 4.40 (hept, 1H, J = 5.9 Hz, CH HFIP), 4.26 (dd, 1H, J = 10.3, 4.9 Hz, H-6), 4.10 (dd, 1H, J = 10.0, 9.1 Hz, H-3), 3.98 (td, 1H, J = 10.0, 4.9 Hz, H-5), 3.80 – 3.73 (m, 2H, H-4, H-6), 3.51 (dd, 1H, J = 10.1, 3.9 Hz, H-2); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 137.6, 136.9 (C_q), 129.3, 128.6, 128.5, 128.4, 128.2, 126.1 (CH_{arom}), 120.9 (q, J = 283 Hz, CF₃), 101.6 (CHPh), 101.0 (C-1), 82.1 (C-4), 75.9 (C-3), 75.5 (CH₂ Bn), 74.0, 73.7 (hept, J = 32.8 Hz, CH HFIP), 68.3 (C-6), 64.2 (C-5), 62.5 (C-2); HRMS: [M+H]⁺ calcd for C₂₃H₂₁F₆N₃O₅ 534.14582, found 534.14569.



Ethyl 2-azido-3-O-benzoyl-4,6-O-benzylidene-2-deoxy- β -D-glucopyranoside (4A). Donor **4** and ethanol were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations and purified by flash column chromatography (1/1/0 to 0/1/0 to 0/19/1 pentane/toluene/EtOAc) to yield glycosylation product **4A** (36 mg, 85 μ mol, 85%, α : β = <1:20) as a white solid. R_f: 0.44 (19/1 toluene/EtOAc). [α]_D²⁵ = -53.7° (c = 1.04, DCM); IR (thin film): 709, 1001, 1026, 1070, 1094, 1180, 1263, 1375, 1726, 2110, 2872; Data for the β -anomer: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 8.11 – 8.05 (m, 2H, CH_{arom}), 7.60 – 7.55 (m, 1H, CH_{arom}), 7.48 – 7.43 (m, 2H, CH_{arom}), 7.40 – 7.35 (m, 2H, CH_{arom}), 7.32 – 7.27 (m, 3H, CH_{arom}), 5.50 (s, 1H, CHPh), 5.40 (t, 1H, J = 9.8 Hz, H-3), 4.59 (d, 1H, J = 7.9 Hz, H-1), 4.38 (dd, 1H, J = 10.6, 5.0 Hz, H-6), 4.02 (dq, 1H, J = 9.5, 7.1 Hz, CHH Et), 3.83 (t, 1H, J = 10.3 Hz, H-6), 3.80 – 3.67 (m, 2H, H-4, CHH Et), 3.64 (dd, 1H, J = 10.0, 7.9 Hz, H-2), 3.56 (td, 1H, J = 9.7, 5.0 Hz, H-5), 1.32 (t, 3H, J = 7.1 Hz, CH₃ Et); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 165.5 (C=O Bz), 136.9 (C_q), 133.4, 130.1 (CH_{arom}), 129.7 (C_q), 129.2, 128.6, 128.3, 126.2 (CH_{arom}), 102.8 (C-1), 101.6 (CHPh), 79.0 (C-4), 71.8 (C-3), 68.7 (C-6), 66.6, 66.6 (C-5, CH₂ Et), 65.0 (C-2), 15.2 (CH₃ Et); Diagnostic peaks α -anomer: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 5.88 (t, 0.03H, J = 9.9 Hz, H-3), 5.53 (s, 0.03H, CHPh), 5.06 (d, 0.03H, J = 3.6 Hz, H-1), 4.32 (dd, 0.03H, J = 10.4, 4.9 Hz, H-6), 3.32 (dd, 0.03H, J = 10.3, 3.6 Hz, H-2); HRMS: [M+NH₄]⁺ calcd for C₂₂H₂₇N₄O₆ 443.19251 found 443.19234.




Cyclohexyl 2-azido-3-O-benzoyl-4,6-O-benzylidene-2-deoxy- β -D-glucopyranoside (4B). Donor **4** and cyclohexanol were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations and purified by flash column chromatography (1/1/0 to 0/1/0 to 0/19/1 pentane/toluene/EtOAc) to yield glycosylation product **4B** (43.6 mg, 91 μ mol, 91%, α : β = <1:20) as a white solid. R_f: 0.18 (toluene). [α]_D²⁵ = -41.2° (c = 0.87, DCM); IR (thin film): 613, 708, 999, 1096, 1263, 1730, 2110, 2859, 2934; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 8.11 – 8.05 (m, 2H, CH_{arom}), 7.61 – 7.54 (m, 1H, CH_{arom}), 7.49 – 7.42 (m, 2H, CH_{arom}), 7.41 – 7.35 (m, 2H, CH_{arom}), 7.31 – 7.27 (m, 3H, CH_{arom}), 5.50 (s, 1H, CHPh), 5.38 (t, 1H, J = 9.9 Hz, H-3), 4.70 (d, 1H, J = 7.9 Hz, H-1), 4.37 (dd, 1H, J = 10.6, 5.0 Hz, H-6), 3.89 – 3.71 (m, 3H, H-4, H-6, CHO Cyc), 3.64 (dd, 1H, J = 10.1, 7.9 Hz, H-2), 3.55 (td, 1H, J = 9.8, 5.0 Hz, H-5), 2.04 – 1.90 (m, 2H, 2xCHH Cyc), 1.85 – 1.73 (m, 2H, 2xCHH Cyc), 1.58 – 1.40 (m, 3H, CHH Cyc, 2xCHH Cyc), 1.39 – 1.20 (m, 3H, 3xCHH Cyc); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 165.5 (C=O Bz), 136.9 (C_q), 133.4, 130.0 (CH_{arom}), 129.7 (C_q), 129.2, 128.5, 128.3, 126.2 (CH_{arom}), 101.6 (CHPh), 101.2 (C-1), 79.0 (C-4), 78.8 (CH Cyc), 71.8 (C-3), 68.7 (C-6), 66.6 (C-5), 65.2 (C-2), 33.7, 31.7, 25.6, 24.1, 23.9 (CH₂ Cyc); HRMS: [M+NH₄]⁺ calcd for C₂₆H₃₃N₄O₆ 497.23946 found 497.23932.




Methyl 6-O-(2-azido-3-O-benzoyl-4,6-O-benzylidene-2-deoxy- α / β -D-glucopyranosyl)-2,3,4-tri-O-benzyl- α -D-glucopyranoside (4C). Donor **4** and acceptor **25** were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (for an additional 18 h at -40°C) and purified by flash column chromatography (19/1 to 3/1 pentane/EtOAc) to yield glycosylation product **4C** (67 mg, 79 μ mol, 79%, α : β = 1:14) as a white solid. R_f: 0.24 (4/1 pentane/EtOAc). [α]_D²⁰ = -17.5° (c = 1.34, CHCl₃); IR (thin film): 696, 748, 1002, 1028, 1068, 1092, 1263, 1313, 1369, 1452, 1730, 2110, 2872, 2918; Data for the β -anomer: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC, HMBC): δ 8.09 – 8.04 (m, 2H, CH_{arom}), 7.60 – 7.53 (m, 1H, CH_{arom}), 7.48 – 7.41 (m, 2H, CH_{arom}), 7.40 – 7.24 (m, 20H, CH_{arom}), 5.47 (s, 1H, CHPh), 5.42 (t, 1H, J = 9.8 Hz, H-3'), 5.00 (d, 1H, J = 10.9 Hz, CHH Bn), 4.95 (d, 1H, J = 11.1 Hz, CHH Bn), 4.84 (d, 1H, J = 11.0 Hz, CHH Bn), 4.80 (d, 1H, J = 12.2 Hz, CHH Bn), 4.68 – 4.63 (m, 2H, 2xCHH Bn), 4.61 (d, 1H, J = 3.5 Hz, H-1), 4.43 (d, 1H, J = 8.0 Hz, H-1'), 4.33 (dd, 1H, J = 10.5, 5.0 Hz, H-6'), 4.12 (d, 1H, J = 9.1 Hz, H-6), 4.02 (t, 1H, J = 9.3 Hz, H-3), 3.84 – 3.72 (m, 4H, H-4', H-5, H-6, H-6'), 3.69 (dd, 1H, J = 9.9, 8.0 Hz, H-2'), 3.57 (t, 1H, J = 9.2

Hz, H-4), 3.54 (dd, 1H, $J = 9.7, 3.6$ Hz, H-2), 3.49 (td, 1H, $J = 9.8, 5.0$ Hz, H-5'), 3.39 (s, 3H, CH₃ OMe); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC, HMBC): δ 165.4 (C=O), 138.7, 138.3, 138.2, 136.7 (CH_{arom}), 133.5, 130.0 (CH_{arom}), 129.4 (C_q Bz), 129.1, 128.6, 128.6, 128.5, 128.5, 128.3, 128.3, 128.1, 128.0, 127.9, 127.9, 127.7, 126.1 (CH_{arom}), 102.6 (C-1'), 101.5 (CHPh), 98.3 (C-1), 82.1 (C-3), 79.8 (C-2), 78.7 (C-4'), 77.7 (C-4), 75.8, 75.0, 73.6 (CH₂ Bn), 71.9 (C-3'), 69.7 (C-5), 68.9 (C-6), 68.5 (C-6'), 66.6 (C-5'), 65.2 (C-2'), 55.4 (CH₃ OMe); Diagnostic peaks α-anomer: ¹H NMR (CDCl₃, 400 MHz): δ 5.79 (t, 0.07H, $J = 9.9$ Hz, H-3'), 5.50 (s, 0.07H, CHPh), 5.08 (d, 0.07H, $J = 3.5$ Hz, H-1'), 4.24 (dd, 0.07H, $J = 10.3, 4.8$ Hz, H-6'), 3.41 (s, 0.21H, CH₃ OMe); ¹³C-APT NMR (CDCl₃, 101 MHz): δ 101.7 (CHPh), 99.3 (C-1'), 98.1 (C-1), 82.1, 80.0, 79.7, 77.6, 75.8, 75.2, 70.0, 69.4, 67.0, 62.8, 62.1, 55.4; HRMS: [M+NH₄]⁺ calcd for C₄₈H₅₃N₄O₁₁ 861.37053, found 861.37064.




2-Fluoroethyl 2-azido-3-O-benzoyl-4,6-O-benzylidene-2-deoxy-α/β-D-glucopyranoside (4D). Donor **4** and 2-fluoroethanol were condensed using the general procedure for

Tf₂O/Ph₂SO mediated glycosylations and purified by flash column chromatography (1/1/0 to 0/1/0 to 0/16/1 pentane/toluene/EtOAc) to yield glycosylation product **4D** (36.6 mg, 83 μmol, 83%, α:β = 1:6.5) as a white solid. R_f: 0.41 (19/1 toluene/EtOAc). IR (thin film): 700, 748, 879, 1001, 1026, 1070, 1093, 1179, 1261, 1722, 2108, 2868; Data for the β-anomer: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 8.10 – 8.05 (m, 2H, CH_{arom}), 7.61 – 7.54 (m, 1H, CH_{arom}), 7.49 – 7.43 (m, 2H, CH_{arom}), 7.41 – 7.36 (m, 2H, CH_{arom}), 7.33 – 7.27 (m, 3H, CH_{arom}), 5.50 (s, 1H, CHPh), 5.41 (t, 1H, $J = 9.8$ Hz, H-3), 4.69 (ddt, 1H, $J = 4.6, 3.2, 1.8$ Hz, CHH-CH₂F), 4.65 (d, 1H, $J = 7.9$ Hz, H-1), 4.58 (ddt, 1H, $J = 4.5, 3.3, 1.8$ Hz, CHH-CH₂F), 4.38 (dd, 1H, $J = 10.5, 4.9$ Hz, H-6), 4.14 (dddd, 1H, $J = 30.3, 11.9, 4.6, 3.1$ Hz, CHHF), 3.95 (dddd, 1H, $J = 27.1, 12.1, 5.5, 3.4$ Hz, CHHF), 3.83 (t, 1H, $J = 10.3$ Hz, H-6), 3.79 (t, 1H, $J = 9.5$ Hz, H-4), 3.69 (dd, 1H, $J = 10.0, 7.9$ Hz, H-2), 3.57 (td, 1H, $J = 9.7, 5.0$ Hz, H-5); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 165.4 (C=O), 136.8 (C_q Ph), 133.5, 130.0 (CH_{arom}), 129.5 (C_q Bz), 129.2, 128.6, 128.5, 128.3, 126.3, 126.2 (CH_{arom}), 103.0 (C-1), 101.6 (CHPh), 82.5 (d, $J = 170.5$ Hz, CH₂F), 78.8 (C-4), 71.7 (C-3), 69.5 (d, $J = 20.2$ Hz, CH₂-CH₂F), 68.5 (C-6), 66.7 (C-5), 64.9 (C-2); Diagnostic peaks α-anomer: ¹H NMR (CDCl₃, 400 MHz): δ 5.89 (t, 0.17H, $J = 9.9$ Hz, H-3), 5.53 (s, 0.17H, CHPh), 5.12 (d, 0.17H, $J = 3.6$ Hz, H-1), 4.33 (dd, 0.17H, $J = 10.4, 5.0$ Hz, H-6), 3.38 (dd, 0.17H, $J = 10.4, 3.6$ Hz, H-2); ¹³C-APT NMR (CDCl₃, 101 MHz): δ 101.8, 99.5 (C-1), 82.4 (d, $J = 170.8$ Hz), 79.6, 68.9, 67.8 (d, $J = 20.2$ Hz), 63.1, 61.8; HRMS: [M+NH₄]⁺ calcd for C₂₂H₂₆FN₄O₆ 461.18309 found 461.18292.



Methyl 4-O-(2-azido-3-O-benzoyl-4,6-O-benzylidene-2-deoxy-α/β-D-glucopyranosyl)-2,3,6-tri-O-benzyl-α-D-glucopyranoside (4E). Donor **4** and acceptor **26** were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (for an additional 18 h at -40°C) and purified by flash column


chromatography (19/1 to 4/1 pentane/EtOAc) to yield glycosylation product **4E** (60 mg, 71 μmol, 71%, α:β = 1:6) as a white solid. R_f: 0.67 (4/1 pentane/EtOAc). IR (thin film): 696, 733, 914, 999, 1026, 1045, 1090, 1177, 1263, 1314, 1366, 1452, 1730, 2108, 2866, 2899; Data for the β-anomer: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC, HMBC): δ 8.10 – 8.04 (m, 2H, CH_{arom}), 7.61 – 7.53 (m, 1H, CH_{arom}), 7.49 – 7.24 (m, 22H, CH_{arom}), 5.40 (s, 1H, CHPh), 5.19 (t, 1H, $J = 9.8$ Hz, H-3'), 4.90 (d, 1H, $J = 10.8$ Hz, CHH Bn), 4.83 (d, 1H, $J = 10.8$ Hz, CHH Bn), 4.81 – 4.73 (m, 2H, 2XCHH Bn), 4.67 – 4.60 (m, 2H, CHH Bn, H-1), 4.42 (d, 1H, $J = 12.0$ Hz, CHH Bn), 4.31 (d, 1H, $J = 8.0$ Hz, H-1'), 4.17 (dd, 1H, $J = 10.6, 5.0$ Hz, H-6'), 4.08 – 3.98 (t, 1H, $J = 9.4$ Hz, H-4), 3.96 (dd, 1H, $J = 10.8, 2.4$ Hz, H-6), 3.86 (t, 1H, $J = 9.3$ Hz, H-3), 3.79 – 3.74 (m, 1H, H-5), 3.71 (dd, 1H, $J = 10.7, 1.7$ Hz, H-6), 3.61 (t, 1H, $J = 9.5$ Hz, H-4'), 3.54 (dd, 1H, $J = 9.6, 3.7$ Hz, H-2), 3.52 – 3.45 (m, 2H, H-2', H-6'), 3.39 (s, 3H, CH₃ OMe), 3.08 (td, 1H, $J = 9.7, 5.0$ Hz, H-5'); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC, HMBC): δ 165.3 (C=O), 139.3, 138.3, 137.6, 136.9 (C_q), 133.4, 129.9 (CH_{arom}), 128.9 (C_q Bz), 128.6, 128.5, 128.5, 128.3, 128.3, 128.2, 127.9, 127.8, 126.2 (CH_{arom}), 101.5, 101.4 (CHPh, C-1'), 98.4 (C-1), 80.1 (C-3), 79.1 (C-2), 78.9 (C-4'), 76.8 (C-4), 75.6, 73.7, 73.6 (CH₂ Bn), 72.0 (C-3'), 69.7 (C-5), 68.6 (C-6'), 67.8 (C-6), 66.1 (C-5'), 65.6 (C-2'), 55.5 (OMe); Diagnostic peaks α-anomer: ¹H NMR (CDCl₃, 400 MHz): δ 5.91 (d, 0.17H, $J = 3.9$ Hz, H-1'), 5.80 (t, 0.17H, $J = 10.0$ Hz, H-3'), 5.47 (s, 0.17H, CHPh), 5.15 (d, 0.17H, $J = 10.7$ Hz, CHH Bn), 4.74 (d, 0.17H, $J = 12.0$ Hz, CHH Bn), 4.09 (t, 0.17H, $J = 9.2$ Hz), 3.29 (dd, 0.17H, $J = 10.5, 3.9$ Hz, H-2'); ¹³C-APT NMR (CDCl₃, 101 MHz): δ 165.6, 138.6, 138.1, 137.9, 137.0, 133.4, 130.0, 129.6, 129.0, 128.6, 128.6, 128.5, 128.4, 128.2, 128.1, 127.6, 127.6, 127.4, 101.6 (CHPh), 98.6 (C-1'), 97.7 (C-1), 82.1, 80.7, 79.5, 75.0, 73.6, 73.3, 72.8, 69.5, 69.3, 68.9, 68.7, 63.7, 61.9, 55.5; HRMS: [M+NH₄]⁺ calcd for C₄₈H₅₃N₄O₁₁ 861.37053, found 861.37081.



Methyl (Methyl 4-O-(2-azido-3-O-benzoyl-4,6-O-benzylidene-2-deoxy-α/β-D-glucopyranosyl)-2,3-di-O-benzyl-α-D-glucopyranosyl uronate) (4F). Donor **4** and acceptor **27** were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (for an additional 18 h at -40°C) and purified by flash column


chromatography (19/1 to 4/1 pentane/EtOAc) to yield glycosylation product **4F** (46 mg, 59 μmol, 59%, α:β = 1:1.4) as

a white solid. R_f: 0.56 (4/1 pentane/EtOAc). IR (thin film): 698, 750, 991, 1026, 1047, 1092, 1178, 1263, 1452, 1730, 2110, 2868, 2938; Reported as a 0.7 : 1 mixture of anomers: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC, HMBC): δ 8.09–8.03 (m, 3.4H, CH_{arom}), 7.61–7.52 (m, 1.7H, CH_{arom}), 7.49–7.25 (m, 28.9H, CH_{arom}), 5.76 (dd, 0.7H, *J* = 9.5, 10.3 Hz, H-3'_α), 5.70 (d, 0.7H, *J* = 3.9 Hz, H-1'_α), 5.47 (s, 0.7H, CHPh_α), 5.41 (s, 1H, CHPh_β), 5.36 (t, 1H, *J* = 9.8 Hz, H-3'_β), 5.10 (d, 0.7H, *J* = 10.6 Hz, CHH Bn_α), 4.93 (d, 1H, *J* = 10.9 Hz, CHH Bn_β), 4.87 (d, 1H, *J* = 10.9 Hz, CHH Bn_β), 4.83 (d, 0.7H, *J* = 10.6 Hz, CHH Bn_α), 4.79 (d, 1H, *J* = 13.6 Hz, CHH Bn_β), 4.76 (d, 0.7H, *J* = 13.6 Hz, CHH Bn_α), 4.66–4.62 (m, 2H, CHH Bn_β, H-1'_β), 4.61–4.58 (m, 2.4H, CHH Bn_α, H-1_α, H-1_β), 4.31 (dd, 0.7H, *J* = 10.0, 4.6 Hz, H-6'_α), 4.28 (d, 0.7H, *J* = 9.7 Hz, H-5_α), 4.23 (d, 1H, *J* = 9.9 Hz, H-5_β), 4.19–4.06 (m, 3.4H, H-3_α, H-4_α, H-4_β, H-6'_β), 3.91 (t, 1H, *J* = 9.2 Hz, H-3), 3.85 (s, 2.1H, CH₃ CO₂Me_α), 3.83 (s, 3H, CH₃ CO₂Me_β), 3.79–3.59 (m, 3.8H, H-2_α, H-4'_α, H-4'_β, H-5'_α, H-6'_α), 3.59–3.44 (m, 4H, H-2_β, H-2'_β, H-5'_β, H-6'_β), 3.43 (s, 3H, CH₃ OMe_β), 3.42 (s, 2.1H, CH₃ OMe_α), 3.31 (dd, 1H, *J* = 10.4, 3.9 Hz, H-2'_α); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC, HMBC): δ 170.2, 169.9 (C=O CO₂Me), 165.5, 165.3 (C=O Bz), 139.1, 138.4, 138.0, 137.7, 137.0, 136.8 (C_q Bn, CHPh), 133.4, 133.4, 130.0, 130.0 (CH_{arom}), 129.5, 129.5 (C_q Bz), 129.1, 129.1, 128.7, 128.6, 128.5, 128.5, 128.5, 128.3, 128.3, 128.2, 128.1, 127.8, 127.7, 127.6, 127.5, 126.2, 126.2 (CH_{arom}), 102.3 (C-1'_β), 101.7 (CHPh_α), 101.5 (CHPh_β), 99.0 (C-1'_α), 98.8 (C-1_β), 98.5 (C-1_α), 81.1 (C-3_α), 79.9 (C-2_α), 79.5, 79.5 (C-3_β, C-4_β), 79.2 (C-4'_α), 78.9, 78.7 (C-2_β, C-4'_β), 75.7, 75.4 (CH₂ Bn), 75.2 (C-4_α), 73.9, 73.6 (CH₂ Bn), 71.9 (C-3'_β), 69.8, 69.8 (C-5_α, C-5_β), 69.6 (C-3'_α), 68.5, 68.4 (C-6'_α, C-6'_β), 66.5 (C-5'_β), 65.6 (C-2'_β), 63.2 (C-5'_α), 61.7 (C-2'_α), 56.0, 56.0 (CH₃ OMe), 53.1, 53.0 (CH₃ CO₂Me); HRMS: [M+NH₄]⁺ calcd for C₄₂H₄₇N₄O₁₂ 799.31850, found 799.31869.



2,2-Difluoroethyl 2-azido-3-O-benzoyl-4,6-O-benzylidene-2-deoxy- α/β -D-glucopyranoside (4G).


Donor **4** and 2,2-difluoroethanol were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations and purified by flash column chromatography (1/1/0 to 0/1/0 to 0/19/1 pentane/toluene/EtOAc) to yield glycosylation product **4G** (38.6 mg, 84 μ mol, 84%, $\alpha:\beta$ = 2.7:1) as a white solid. R_f: 0.49 (19/1 toluene/EtOAc). IR (thin film): 709, 997, 1026, 1069, 1094, 1265, 1726, 2108, 2870; Data for the α -anomer: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 8.11–8.05 (m, 2H, CH_{arom}), 7.63–7.53 (m, 1H, CH_{arom}), 7.50–7.36 (m, 4H, CH_{arom}), 7.34–7.27 (m, 3H, CH_{arom}), 6.02 (tt, 1H, *J* = 55.1, 4.2 Hz, CHF₂), 5.91–5.81 (m, 1H, H-3), 5.53 (s, 1H, CHPh), 5.11 (d, 1H, *J* = 3.6 Hz, H-1), 4.33 (dd, 1H, *J* = 10.4, 4.9 Hz, H-6), 4.07 (ddd, 1H, *J* = 14.8, 6.4, 3.7 Hz, H-5), 3.99–3.77 (m, 4H, H-4, H-6), 3.42 (dd, 1H, *J* = 10.4, 3.6 Hz, H-2); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 165.5 (C=O Bz), 136.8 (C_q), 133.5, 130.1 (CH_{arom}), 129.5 (C_q Bz), 128.5, 128.3, 126.2 (CH_{arom}), 113.7 (t, *J* = 241.7 Hz, CHF₂), 101.8 (CHPh), 99.8 (C-1), 79.4 (C-4), 69.3 (C-3), 68.7 (C-6), 67.6 (t, *J* = 29.0 Hz, CH₂-CHF₂), 63.5 (C-5), 61.8 (C-2); Data for the β -anomer: ¹H NMR (CDCl₃, 400 MHz): δ 5.97 (tdd, 0.37H, *J* = 55.2, 4.8, 3.5 Hz, CHF₂), 5.51 (s, 0.37H, CHPh), 5.42 (t, 0.37H, *J* = 9.8 Hz, H-3), 4.63 (d, 0.37H, *J* = 7.9 Hz, H-1), 4.38 (dd, 0.37H, *J* = 10.5, 5.0 Hz, H-6), 4.12–3.99 (m, 0.37H, CHH-CHF₂), 3.98–3.76 (m, 1.11H, CHH-CHF₂, H-4, H-6), 3.69 (dd, 0.37H, *J* = 10.0, 7.9 Hz, H-2), 3.58 (td, 0.37H, *J* = 9.8, 5.0 Hz, H-5); ¹³C-APT NMR (CDCl₃, 101 MHz): δ 165.4, 136.7, 133.5, 130.0, 129.4, 129.2, 128.6, 126.2, 113.8 (t, *J* = 241.5 Hz), 103.1, 101.7, 78.7 (C-4), 71.5 (C-3), 69.1 (t, *J* = 29.0 Hz, CH₂-CHF₂), 68.4 (C-6), 66.8 (C-5), 64.9 (C-2); HRMS: [M+H]⁺ calcd for C₂₂H₂₂F₂N₃O₆ 462.14712, found 462.14699.



Methyl 4-O-(2-azido-3-O-benzoyl-4,6-O-benzylidene-2-deoxy- α/β -D-glucopyranosyl)-2,3,6-tri-O-benzyl- β -D-galactopyranoside (4H).


Donor **4** and acceptor **28** were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (for an additional 18 h at -40°C) and purified by flash column chromatography (19/1 to 4/1 pentane/EtOAc) to yield glycosylation product **4H** (43 mg, 52 μ mol, 52%, $\alpha:\beta$ = 4:1) as a white solid. R_f: 0.36 (4/1 pentane/EtOAc). IR (thin film): 698, 737, 997, 1072, 1094, 1265, 1452, 1730, 2106, 2862, 2930; Data for the α -anomer: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC, HMBC): δ 8.12–8.05 (m, 2H, CH_{arom}), 7.57 (t, 1H, *J* = 7.4 Hz, CH_{arom}), 7.45 (t, 2H, *J* = 7.7 Hz, CH_{arom}), 7.42–7.20 (m, 20H, CH_{arom}), 5.85 (t, 1H, *J* = 9.9 Hz, H-3'), 5.44 (s, 1H, CHPh), 5.07 (d, 1H, *J* = 3.9 Hz, H-1'), 4.93 (d, 1H, *J* = 11.0 Hz, CHH Bn), 4.84 (d, 1H, *J* = 10.9 Hz, CHH Bn), 4.79 (d, 1H, *J* = 12.4 Hz, CHH Bn), 4.74 (d, 1H, *J* = 12.4 Hz, CHH Bn), 4.55 (s, 2H, CH₂ Bn), 4.46 (td, 1H, *J* = 9.9, 4.9 Hz, H-5'), 4.26 (d, 1H, *J* = 7.6 Hz, H-1), 4.17 (d, 1H, *J* = 3.1 Hz, H-4), 3.93 (t, 1H, *J* = 9.1 Hz, H-6), 3.85 (dd, 1H, *J* = 10.2, 5.0 Hz, H-6'), 3.81–3.70 (m, 2H, H-2, H-4'), 3.64 (dd, 2H, *J* = 9.1, 5.4 Hz, H-6), 3.57–3.50 (m, 5H, CH₃ OMe, H-5, H-6'), 3.47 (dd, 1H, *J* = 10.4, 3.9 Hz, H-2'), 3.42 (dd, 1H, *J* = 10.0, 3.0 Hz, H-3); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC, HMBC): δ 165.3 (C=O Bz), 138.7, 138.3, 137.6, 137.2 (C_q), 133.3, 130.0 (CH_{arom}), 129.8 (C_q), 128.9, 128.7, 128.6, 128.6, 128.5, 128.5, 128.4, 128.4, 128.3, 128.2, 128.2, 128.1, 127.9, 127.7, 127.6, 127.6, 126.3, 126.2 (CH_{arom}), 105.2 (C-1), 101.4 (CHPh), 99.4 (C-1'), 80.0 (C-4'), 79.8 (C-3), 79.0 (C-2), 75.2 (CH₂ Bn), 74.4 (C-4), 73.6, 73.2 (CH₂ Bn), 72.6 (C-5), 70.2 (C-3'), 68.8 (C-6'), 67.1 (C-6), 62.8, 62.7 (C-2', C-5'), 57.0 (OMe); Diagnostic peaks β -anomer: ¹H NMR (CDCl₃, 400 MHz): δ 5.47 (s, 0.25H, CHPh), 5.34 (t, 0.25H, *J* = 9.8 Hz, H-3'), 4.30 (d, 0.25H, *J* = 7.7 Hz, H-1'), 4.09 (d, 0.25H, *J* =

2.7 Hz, H-4); ^{13}C -APT NMR (CDCl_3 , 101 MHz): δ 105.1 (C-1), 102.7 (C-1'), 101.5 (CHPh), 81.2, 79.6, 78.9, 75.3, 74.6, 73.9, 73.6, 73.3, 71.7, 69.4, 68.5, 66.2, 65.0, 57.3; HRMS: $[\text{M}+\text{NH}_4]^+$ calcd for $\text{C}_{48}\text{H}_{53}\text{N}_4\text{O}_{11}$ 861.37053, found 861.37067.




Methyl 2-O-(2-azido-3-O-benzoyl-4,6-O-benzylidene-2-deoxy- α/β -D-glucopyranosyl)-3-O-benzyl-4,6-O-benzylidene- α -D-mannopyranoside (4I). Donor **4** and acceptor **29** were

condensed using the general procedure for $\text{Ti}_2\text{O}/\text{Ph}_2\text{SO}$ mediated glycosylations (for an additional 18 h at -40°C) and purified by flash column chromatography (19/1 to 3/1 pentane/EtOAc) to yield glycosylation product **4I** (55 mg, 73 μmol , 73%, $\alpha:\beta = 5:1$) as a white solid. R_f: 0.36 (4/1 pentane/EtOAc). IR (thin film): 671, 750, 1037, 1092, 1265, 1373, 1730, 2108, 2913; ^1H NMR (CDCl_3 , 400 MHz, HH-COSY, HSQC, HMBC): δ 8.15 – 8.04 (m, 2H, CH_{arom}), 7.59 – 7.53 (m, 1H, CH_{arom}), 7.53 – 7.25 (m, 17H, CH_{arom}), 5.92 (dd, 1H, $J = 10.4, 9.5$ Hz, H-3'), 5.67 (s, 1H, CHPh), 5.54 (s, 1H, CHPh'), 5.51 (d, 1H, $J = 3.8$ Hz, H-1'), 4.94 (d, 1H, $J = 12.2$ Hz, CHH Bn), 4.73 (d, 1H, $J = 1.5$ Hz, H-1), 4.69 (d, 1H, $J = 12.2$ Hz, CHH Bn), 4.39 (t, 1H, $J = 9.7$ Hz, H-4), 4.32 (dd, 1H, $J = 10.4, 4.9$ Hz, H-6'), 4.27 (dd, 1H, $J = 10.3, 4.7$ Hz, H-6), 4.14 (dd, 1H, $J = 3.1, 1.6$ Hz, H-2), 4.06 – 3.99 (m, 2H, H-3, H-5'), 3.95 (t, 1H, $J = 10.3$ Hz, H-6), 3.86 – 3.77 (m, 3H, H-4', H-5, H-6'), 3.38 – 3.33 (m, 4H, CH_3 OMe, H-2'); ^{13}C -APT NMR (CDCl_3 , 101 MHz, HSQC): δ 165.5 (C=O Bz), 138.8, 137.7, 136.8 (C_q), 133.4, 130.1 (CH_{arom}), 129.6 (C_q), 129.2, 128.9, 128.5, 128.4, 128.3, 128.3, 128.3, 127.6, 127.6, 127.4, 126.2, 126.2, 126.1 (CH_{arom}), 101.7, 101.6 (CHPh), 100.9 (C-1), 100.1 (C-1'), 79.7 (C-4'), 79.5 (C-4), 75.9, 75.9 (C-2, C-3), 73.6 (CH₂ Bn), 69.2 (C-3'), 68.9 (C-6), 68.8 (C-6'), 64.1 (C-5), 63.3 (C-5'), 61.9 (C-2'), 54.9 (OMe); Diagnostic peaks β -anomer: ^1H NMR (CDCl_3 , 400 MHz): δ 5.60 (s, 0.2H, CHPh), 5.50 (s, 0.2H, CHPh'), 5.40 (t, 0.2H, $J = 9.8$ Hz, H-3'), 4.87 (d, 0.2H, $J = 1.4$ Hz, H-1), 4.80 (d, 0.2H, $J = 12.3$ Hz, CHH Bn), 3.57 (td, 0.2H, $J = 9.9, 4.3$ Hz), 3.40 (s, 0.6H, CH_3 OMe); ^{13}C -APT NMR (CDCl_3 , 101 MHz): δ 101.8 (C-1'), 100.0 (CHPh), 99.4 (C-1), 78.7, 78.5, 76.4, 74.4, 72.4, 71.5, 68.9, 68.5, 66.9, 65.1, 64.2, 55.2; HRMS: $[\text{M}+\text{NH}_4]^+$ calcd for $\text{C}_{41}\text{H}_{45}\text{N}_4\text{O}_{11}$ 769.30793, found 769.30780.




2,2,2-Trifluoroethyl 2-azido-3-O-benzoyl-4,6-O-benzylidene-2-deoxy- α -D-glucopyranoside (4J). Donor **4** and 2,2,2-trifluoroethanol were condensed using the general procedure for

$\text{Ti}_2\text{O}/\text{Ph}_2\text{SO}$ mediated glycosylations (for an additional 30 min at -40°C) and purified by flash column chromatography (19/1 to 17/3 pentane/EtOAc) to yield glycosylation product **4J** (41 mg, 86 μmol , 86%, $\alpha:\beta = >20:1$) as a white solid. R_f: 0.15 (toluene). $[\alpha]_{\text{D}}^{20} = +78.9^\circ$ ($c = 1.03$, CHCl_3); IR (thin film): 702, 989, 1085, 1177, 1275, 1717, 2112, 2864; ^1H NMR (CDCl_3 , 400 MHz, HH-COSY, HSQC): δ 8.13 – 8.03 (m, 2H, CH_{arom}), 7.60 – 7.53 (m, 1H, CH_{arom}), 7.48 – 7.38 (m, 4H, CH_{arom}), 7.33 – 7.28 (m, 3H, CH_{arom}), 5.87 (t, 1H, $J = 10.0$ Hz, H-3), 5.53 (s, 1H, CHPh), 5.14 (d, 1H, $J = 3.6$ Hz, H-1), 4.33 (dd, 1H, $J = 10.4, 4.9$ Hz, H-6), 4.14 – 3.97 (m, 4H, CH_2CF_3 , H-5), 3.84 (t, 1H, $J = 9.5$ Hz, H-4), 3.80 (t, 1H, $J = 10.3$ Hz, H-6), 3.44 (dd, 1H, $J = 10.4, 3.6$ Hz, H-2); ^{13}C -APT NMR (CDCl_3 , 101 MHz, HSQC): δ 165.5 (C=O), 136.7 (C_q), 133.5, 130.0 (CH_{arom}), 129.5 (C_q Bz), 129.2, 128.5, 127.6, 126.2 (CH_{arom}), 123.42 (q, $J = 278.6$ Hz), 101.8 (CHPh), 99.9 (C-1), 79.3 (C-4), 69.1 (C-3), 68.6 (C-6), 65.41 (q, $J = 35.6$ Hz), 63.7 (C-5), 61.6 (C-2); HRMS: $[\text{M}+\text{NH}_4]^+$ calcd for $\text{C}_{22}\text{H}_{24}\text{F}_3\text{N}_4\text{O}_6$ 497.16425 found 497.16425.



Ethyl 3-O-benzyl-4,6-O-benzylidene-2-deoxy-2-(3,5-dinitro-4-pyridone)- β -D-glucopyranoside (5A). Donor **5** and ethanol were condensed using the general procedure for


$\text{Ti}_2\text{O}/\text{Ph}_2\text{SO}$ mediated glycosylations (for an additional 1 hour at -40°C) and purified by flash column chromatography (19/1 to 8/2 pentane/EtOAc) to yield glycosylation product **5A** (32 mg, 59 μmol , 59%, $\alpha:\beta = <1:20$) as a yellow solid alongside donor **5** (14 mg). R_f: 0.60 (7/3 pentane/EtOAc). $[\alpha]_{\text{D}}^{23} = +156.9^\circ$ ($c = 0.64$, CHCl_3); IR (thin film): 698, 998, 1093, 1213, 1303, 1330, 1516, 1679, 2930; ^1H NMR (CDCl_3 , 400 MHz, HH-COSY, HSQC): δ 8.58 (s, 2H, CH pyridone), 7.56 (dd, 2H, $J = 7.4, 2.2$ Hz, CH_{arom}), 7.45 – 7.38 (m, 3H, CH_{arom}), 7.06 – 6.97 (m, 5H, CH_{arom}), 5.66 (s, 1H, CHPh), 5.32 (d, 1H, $J = 8.3$ Hz, H-1), 4.70 (d, 1H, $J = 11.7$ Hz, CHH Bn), 4.57 (dd, 1H, $J = 10.2, 8.7$ Hz, H-3), 4.53 (d, 1H, $J = 11.6$ Hz, CHH Bn), 4.43 (dd, 1H, $J = 10.3, 4.6$ Hz, H-6), 3.99 – 3.81 (m, 4H, CHH Et, H-4, H-5, H-6), 3.72 (dd, 1H, $J = 10.3, 8.3$ Hz, H-2), 3.60 (dq, 1H, $J = 9.9, 7.1$ Hz, CHH Et), 1.08 (t, 3H, $J = 7.1$ Hz, CH_3 Et); ^{13}C -APT NMR (CDCl_3 , 101 MHz, HSQC): δ 160.6 (C=O pyridone), 141.7 (C_q NO_2 pyridone), 141.4 (CH pyridone), 137.1, 136.6 (C_q), 129.4, 128.9, 128.7, 128.5, 128.5, 126.3 (CH_{arom}), 101.9 (CHPh), 99.3 (C-1), 82.8 (C-4), 75.4 (C-3), 74.9 (CH₂ Bn), 73.8 (C-2), 68.7 (C-6), 66.5 (CH₂ Et), 65.7 (C-5), 15.1 (CH_3 Et); HRMS: $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{27}\text{H}_{28}\text{N}_3\text{O}_{10}$ 554.17692, found 554.17642.




Cyclohexyl 3-O-benzyl-4,6-O-benzylidene-2-deoxy-2-(3,5-dinitro-4-pyridone)- β -D-glucopyranoside (5B). Donor **5** and cyclohexanol were condensed using the general

procedure for $\text{Ti}_2\text{O}/\text{Ph}_2\text{SO}$ mediated glycosylations (for an additional 1 hour at -40°C) and purified by flash column chromatography (19/1 to 8/2 pentane/EtOAc) to yield 51 mg of glycosylation product **5B** as an inseparable mixture with donor **5** (13 mg **5**, 38 mg


5B, 63 μmol , 63%, $\alpha:\beta < 1:20$) as a yellow solid. R_f : 0.75 (7/3 pentane/EtOAc). R_f : 0.55 (7/3 pentane/EtOAc); IR: (thin film): 697, 718, 749, 789, 910, 997, 1092, 1212, 1302, 1330, 1516, 1623, 1674, 2931; $^1\text{H NMR}$ (CDCl_3 , 400 MHz, HH-COSY, HSQC): δ 8.60 (s, 2H, CH pyridone), 7.56 (d, 2H, $J = 4.7$ Hz, CH_{arom}), 7.48 – 7.33 (m, 3H, CH_{arom}), 7.10 – 6.96 (m, 5H, CH_{arom}), 5.65 (s, 1H, *CHPh*), 5.41 (d, 1H, $J = 8.2$ Hz, H-1), 4.71 (d, 1H, $J = 11.7$ Hz, *CHH Bn*), 4.66 – 4.50 (m, 2H, *CHH Bn*, H-3), 4.44 (dd, 1H, $J = 10.6$, 5.2 Hz, H-6), 3.98 – 3.80 (m, 3H, H-4, H-5, H-6), 3.79 – 3.61 (m, 2H, *CH Cy*, H-2), 1.91 – 1.77 (m, 1H, CH_2 Cy), 1.71 – 1.54 (m, 2H, CH_2 Cy), 1.54 – 1.45 (m, 1H, CH_2 Cy), 1.43 – 0.96 (m, 6H, CH_2 Cy); $^{13}\text{C-APT NMR}$ (CDCl_3 , 101 MHz, HSQC): δ 160.5 (C=O pyridone), 141.6 (C_q NO_2 pyridone), 141.4 (CH pyridone), 137.1, 136.7 (C_q), 128.8, 128.6, 128.4, 126.3 (CH_{arom}), 101.9 (*CHPh*), 98.1 (C-1), 82.7 (C-4), 78.8 (CH Cy), 75.6 (C-3), 74.8 (CH_2 Bn), 74.0 (C-2), 68.8 (C-6), 65.7 (C-5), 33.3, 31.7, 25.3, 23.9, 23.6 (CH_2 Cy); HRMS: $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{31}\text{H}_{34}\text{N}_3\text{O}_{10}$ 608.22387, found 608.22352.



Methyl 6-O-(3-O-benzyl-4,6-O-benzylidene-2-deoxy-2-(3,5-dinitro-4-pyridone)- β -D-glucopyranosyl)-2,3,4-tri-O-benzyl- α -D-glucopyranoside (5C). Donor **5** and acceptor **25** were condensed using the general procedure for $\text{Tf}_2\text{O}/\text{Ph}_2\text{SO}$ mediated glycosylations (for an additional 18 hours at -40°C) and purified by flash column chromatography (9/1 to 7/3 pentane/EtOAc) to yield glycosylation product **5C** (55 mg, 54 μmol , 54%, $\alpha:\beta < 1:20$) as a yellow solid. R_f : 0.45 (7/3 pentane/EtOAc). $[\alpha]_{\text{D}}^{20} = +90.5^\circ$ ($c = 0.92$, CHCl_3); IR (thin film): 698, 1001, 1069, 1094, 1213, 1331, 1454, 1522, 1678, 2868; $^1\text{H NMR}$ (CDCl_3 , 400 MHz, HH-COSY, HSQC, HMBC): δ 8.19 (s, 2H, CH pyridone), 7.54 (dd, 2H, $J = 7.6$, 2.1 Hz, CH_{arom}), 7.45 – 7.38 (m, 3H, CH_{arom}), 7.34 – 7.22 (m, 13H, CH_{arom}), 7.20 – 7.12 (m, 5H, CH_{arom}), 7.04 (dd, 2H, $J = 6.6$, 2.9 Hz, CH_{arom}), 5.66 (s, 1H, *CHPh*), 4.92 (d, 1H, $J = 11.0$ Hz, *CHH Bn*), 4.85 (d, 1H, $J = 8.3$ Hz, H-1'), 4.83 – 4.66 (m, 2H, 2x*CHH Bn*), 4.72 (d, 1H, $J = 10.9$ Hz, *CHH Bn*), 4.69 (d, 1H, $J = 12.0$ Hz, *CHH Bn*), 4.60 (d, 1H, $J = 12.2$ Hz, *CHH Bn*), 4.60 (d, 1H, $J = 12.0$ Hz, *CHH Bn*), 4.46 (d, 1H, $J = 3.4$ Hz, H-1''), 4.39 (dd, 1H, $J = 10.6$, 5.0 Hz, H-6''), 4.34 (d, 1H, $J = 11.3$ Hz, *CHH Bn*), 4.10 (t, 1H, $J = 7.9$ Hz, H-3''), 4.01 (dd, 1H, $J = 10.8$, 1.8 Hz, H-6), 3.91 (t, 1H, $J = 9.2$ Hz, H-3), 3.89 – 3.82 (m, 2H, H-4', H-6), 3.77 – 3.69 (m, 2H, H-2', H-5), 3.65 (td, 1H, $J = 9.7$, 5.0 Hz, H-5'), 3.52 (dd, 1H, $J = 10.8$, 7.1 Hz, H-6), 3.39 (dd, 1H, $J = 9.6$, 3.5 Hz, H-2), 3.21 (s, 3H, CH_3 OMe), 3.13 (dd, 1H, $J = 9.9$, 8.9 Hz, H-4); $^{13}\text{C-APT NMR}$ (CDCl_3 , 101 MHz, HSQC, HMBC): δ 159.4 (C=O pyridone), 141.7 (C_q NO_2 pyridone), 140.2 (CH pyridone), 138.6, 138.0, 138.0, 136.7, 135.8 (C_q), 129.5, 129.1, 129.0, 128.6, 128.5, 128.5, 128.2, 128.1, 128.0, 127.9, 127.7, 127.6, 126.1 (CH_{arom}), 101.8 (*CHPh*), 100.1 (C-1'), 97.9 (C-1), 82.3 (C-4'), 81.6 (C-3), 79.8 (C-2), 78.2 (C-4), 75.7, 74.8, 74.3, (CH_2 Bn), 74.0 (C-3'), 73.3 (CH_2 Bn), 72.7 (C-2'), 70.4 (C-6), 69.3 (C-5), 68.4 (C-6'), 66.1 (C-5'), 55.1 (OMe); $^{13}\text{C-HMBC-GATED NMR}$ (CDCl_3 , 101 MHz): δ 100.1 ($J = 163$ Hz, C-1'); HRMS: $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{53}\text{H}_{54}\text{N}_3\text{O}_{15}$ 972.35494, found 972.35546.




2-Fluoroethyl 3-O-benzyl-4,6-O-benzylidene-2-deoxy-2-(3,5-dinitro-4-pyridone)- β -D-glucopyranoside (5D). Donor **5** and 2-fluoroethanol were condensed using the general procedure for $\text{Tf}_2\text{O}/\text{Ph}_2\text{SO}$ mediated glycosylations (for an additional 1 hour at -40°C) and purified by flash column chromatography (19/1 to 8/2 pentane/EtOAc) to yield glycosylation product **5D** (24 mg, 43 μmol , 43%, $\alpha:\beta < 1:20$) as a yellow solid alongside donor **5** (15.6 mg). R_f : 0.42 (3/2 pentane/EtOAc). $[\alpha]_{\text{D}}^{23} = +142.9^\circ$ ($c = 0.48$, CHCl_3); IR (thin film): 698, 752, 1070, 1096, 1213, 1304, 1331, 1518, 1680, 2870, 3064; $^1\text{H NMR}$ (CDCl_3 , 400 MHz, HH-COSY, HSQC): δ 8.58 (s, 2H, CH pyridone), 7.63 – 7.49 (m, 2H, CH_{arom}), 7.47 – 7.36 (m, 3H, CH_{arom}), 7.09 – 6.96 (m, 5H, CH_{arom}), 5.66 (s, 1H, *CHPh*), 5.46 (d, 1H, $J = 8.3$ Hz, H-1), 4.71 (d, 1H, $J = 11.7$ Hz, *CHH Bn*), 4.57 (dd, 1H, $J = 10.3$, 8.7 Hz, H-3), 4.53 (d, 1H, $J = 11.7$ Hz, *CHH Bn*), 4.48 – 4.42 (m, 2H, *CHHF*, H-6), 4.33 (t, 1H, $J = 4.1$ Hz, *CHHF*), 4.09 – 3.81 (m, 5H, $\text{CH}_2\text{-CH}_2\text{F}$, H-4, H-5, H-6), 3.77 (dd, 1H, $J = 10.3$, 8.4 Hz, H-2); $^{13}\text{C-APT NMR}$ (CDCl_3 , 101 MHz, HSQC): δ 160.6 (C=O pyridone), 141.5, 141.5 (C_q NO_2 , CH pyridone), 137.0, 136.6 (C_q), 129.4, 129.0, 128.7, 128.6, 128.5, 126.3 (CH_{arom}), 101.9 (*CHPh*), 99.8 (C-1), 82.7 (C-4), 82.5 (d, $J = 169.4$ Hz, CH_2F), 75.3 (C-3), 74.9 (CH_2 Bn), 73.6 (C-2), 69.5 (d, $J = 19.5$ Hz, $\text{CH}_2\text{-CH}_2\text{F}$), 68.6 (C-6), 65.8 (C-5); HRMS: $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{27}\text{H}_{27}\text{FN}_3\text{O}_{10}$ 572.16760, found 572.16705.




Methyl 4-O-(3-O-benzyl-4,6-O-benzylidene-2-deoxy-2-(3,5-dinitro-4-pyridone)- β -D-glucopyranosyl)-2,3,6-tri-O-benzyl- α -D-glucopyranoside (5E). Donor **5** and acceptor **26** were condensed using the general procedure for $\text{Tf}_2\text{O}/\text{Ph}_2\text{SO}$ mediated glycosylations (for an additional 18 hours at -40°C) and purified by flash column chromatography (9/1 to 7/3 pentane/EtOAc) to yield glycosylation product **5E** (54 mg, 56 μmol , 56%, $\alpha:\beta < 1:20$) as a yellow solid. R_f : 0.37 (7/3 pentane/EtOAc). $[\alpha]_{\text{D}}^{23} = +83.3^\circ$ ($c = 0.84$, CHCl_3); IR (thin film): 696, 734, 997, 1028, 1039, 1092, 1209, 1302, 1327, 1454, 1522, 1682, 2862, 2900, 3030, 3065; $^1\text{H NMR}$ (CDCl_3 , 500 MHz, HH-COSY, HSQC, HMBC, NOESY): δ 7.74 (s, 2H, CH pyridone), 7.57 – 7.53 (m, 2H, CH_{arom}), 7.49 – 7.38 (m, 8H, CH_{arom}), 7.36 – 7.25 (m, 13H, CH_{arom}), 7.04 – 7.00 (m, 2H, CH_{arom}), 5.57 (s, 1H, *CHPh*), 4.90 (d, 1H, $J = 11.7$ Hz, *CHH*

Bn), 4.77 (d, 1H, $J = 12.1$ Hz, *CHH* Bn), 4.74 (d, 1H, $J = 12.3$ Hz, *CHH* Bn), 4.69 (d, 1H, $J = 11.7$ Hz, *CHH* Bn), 4.66 (d, 1H, $J = 12.0$ Hz, *CHH* Bn), 4.63 (d, 1H, $J = 12.1$ Hz, *CHH* Bn), 4.56 (d, 1H, $J = 12.3$ Hz, *CHH* Bn), 4.54 (d, 1H, $J = 3.6$ Hz, H-1), 4.35 (d, 1H, $J = 8.2$ Hz, H-1'), 4.27 – 4.20 (m, 2H, *CHH* Bn, H-6'), 3.92 (t, 1H, $J = 9.5$ Hz, H-4), 3.70 (t, 1H, $J = 9.3$ Hz, H-3), 3.67 (t, 1H, $J = 9.0$ Hz, H-4'), 3.58 (t, 1H, $J = 10.4$ Hz, H-6'), 3.53 – 3.45 (m, 2H, H-2, H-3'), 3.43 (dd, 1H, $J = 11.4$, 1.5 Hz, H-6), 3.40 – 3.34 (m, 1H, H-5), 3.31 (s, 2H, CH_3 OMe), 3.18 (dd, 1H, $J = 10.5$, 8.3 Hz, H-2'), 3.04 (dd, 1H, $J = 11.3$, 2.6 Hz, H-6), 2.92 (td, 1H, $J = 9.8$, 5.1 Hz, H-5'); ^{13}C -APT NMR (CDCl_3 , 126 MHz, HSQC, HMBC): δ 159.3 (C=O pyridone), 141.8 (C_4 NO_2 pyridone), 139.6 (CH pyridone), 139.4, 138.1, 137.8, 136.8, 135.7 (C_q), 129.6, 129.3, 129.2, 129.0, 128.9, 128.6, 128.5, 128.4, 128.1, 128.1, 127.8, 126.1 (CH_{arom}), 101.8 (*CHPh*), 98.1 (C-1), 97.6 (C-1'), 82.4 (C-4'), 79.7 (C-2), 79.2 (C-3), 75.3 (CH_2 Bn), 74.4 (C-4), 73.9, 73.6, 73.5 (CH_2 Bn), 73.0 (C-3'), 72.5 (C-2'), 69.2 (C-5), 68.4 (C-6'), 68.1 (C-6), 65.6 (C-5'), 55.7 (OMe); HRMS: $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{33}\text{H}_{54}\text{N}_3\text{O}_{15}$ 972.35494, found 972.35519.



Methyl (Methyl 4-O-[3-O-benzyl-4,6-O-benzylidene-2-deoxy-2-(3,5-dinitro-4-pyridone)- α/β -D-glucopyranosyl]-2,3-di-O-benzyl- α -D-glucopyranosyl uronate) (5F).


Donor **5** and acceptor **27** were condensed using the general procedure for $\text{Tf}_2\text{O}/\text{Ph}_2\text{SO}$ mediated glycosylations (for an additional 18 hours at -40°C) and purified by flash column chromatography (9/1 to 7/3 pentane/EtOAc) to yield glycosylation product **5F** (27 mg, 30 μmol , 30%, $\alpha/\beta = 1:3.6$) as a yellow solid. R_f : 0.51 (7/3 pentane/EtOAc). IR (thin film): 648, 698, 733, 789, 910, 995, 1090, 1171, 1209, 1302, 1331, 1454, 1520, 1678, 1744, 2932; Data for the β -anomer: ^1H NMR (CDCl_3 , 500 MHz, HH-COSY, HSQC, HMBC): δ 8.06 (s, 2H, CH pyridone), 7.50 (dd, 2H, $J = 7.3$, 2.0 Hz, CH_{arom}), 7.45 – 7.35 (m, 6H, CH_{arom}), 7.33 – 7.18 (m, 9H, CH_{arom}), 7.03 (dd, 2H, $J = 6.9$, 2.2 Hz, CH_{arom}), 6.96 (dd, 1H, $J = 14.5$, 6.9 Hz, CH_{arom}), 5.55 (s, 1H, *CHPh*), 5.17 (d, 1H, $J = 8.2$ Hz, H-1'), 4.92 (d, 1H, $J = 11.3$ Hz, *CHH* Bn), 4.82 – 4.72 (m, 3H, *CHH* Bn, 2*XCHH* Bn), 4.61 – 4.55 (m, 2H, 2*XCHH* Bn), 4.51 (d, 1H, $J = 3.3$ Hz, H-1), 4.14 (dd, 1H, $J = 10.6$, 4.8 Hz, H-6'), 3.97 – 3.88 (m, 2H, H-3', H-4), 3.83 (d, 1H, $J = 9.7$ Hz, H-5), 3.82 – 3.73 (m, 2H, H-3, H-4'), 3.54 – 3.43 (m, 6H, CH_3 CO_2Me , H-2, H-2', H-5'), 3.42 – 3.36 (m, 4H, CH_3 OMe, H-6'); ^{13}C -APT NMR (CDCl_3 , 126 MHz, HSQC, HMBC): δ 170.0 (C=O CO_2Me), 159.5 (C=O pyridone), 141.5 (C_q NO_2 pyridone), 140.4 (CH pyridone), 139.1, 137.8, 136.7, 135.7 (C_q), 129.5, 129.2, 129.2, 129.1, 129.0, 128.9, 128.7, 128.7, 128.6, 128.5, 128.4, 128.2, 128.2, 127.7, 127.7, 126.1, 126.0, 125.7 (CH_{arom}), 101.7 (*CHPh*), 98.8 (C-1'), 98.3 (C-1), 82.3 (C-4'), 79.1 (C-3), 78.8 (C-2), 77.8 (C-4), 75.5, 74.2 (CH_2 Bn), 74.0 (C-3'), 73.7 (CH_2 Bn), 72.9 (C-2'), 68.8 (C-5), 68.2 (C-6'), 65.9 (C-5'), 56.1 (OMe), 52.9 (CO_2Me); ^{13}C -HMBC-GATED NMR (CDCl_3 , 101 MHz): δ 98.8 ($J = 167$ Hz, C-1'); Diagnostic peaks α -anomer: ^1H NMR (CDCl_3 , 500 MHz, HH-COSY, HSQC): δ 5.74 (d, 0.28H, $J = 3.9$ Hz, H-1'), 5.61 (s, 0.28H, *CHPh*), 5.03 (d, 0.28H, $J = 12.7$ Hz, *CHH* Bn), 4.70 (d, 0.28H, $J = 12.3$ Hz), 4.62 (d, 0.28H, $J = 12.2$ Hz, *CHH* Bn), 4.46 (d, 0.28H, $J = 12.3$ Hz, *CHH* Bn), 4.37 (dd, 0.28H, $J = 10.5$, 4.9 Hz, H-6'), 4.29 (d, 0.28H, $J = 9.9$ Hz, H-5), 4.08 (t, 0.28H, $J = 9.4$ Hz), 3.69 (dd, 0.28H, $J = 10.6$, 3.9 Hz, H-2'), ^{13}C -APT NMR (CDCl_3 , 126 MHz, HSQC): δ 169.7, 159.2, 141.2, 101.8 (*CHPh*), 96.8 (C-1'), 82.6, 80.7, 79.8, 74.5, 74.4, 73.1, 72.2, 69.6, 69.5, 68.1, 63.0, 56.1, 53.3; ^{13}C -HMBC-GATED NMR (CDCl_3 , 101 MHz): δ 96.8 ($J = 181$ Hz, C-1'); HRMS: $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{47}\text{H}_{48}\text{N}_3\text{O}_{16}$ 910.30291, found 910.30315.



2,2-Difluoroethyl 3-O-benzyl-4,6-O-benzylidene-2-deoxy-2-(3,5-dinitro-4-pyridone)- α/β -D-glucopyranoside (5G).


Donor **5** and 2,2-difluoroethanol were condensed using the general procedure for $\text{Tf}_2\text{O}/\text{Ph}_2\text{SO}$ mediated glycosylations (for an additional 1 hour at -40°C) and purified by flash column chromatography (19/1 to 8/2 pentane/EtOAc) to yield glycosylation product **5G** (17.3 mg, 29 μmol α anomer, 17.8 mg 30 μmol β anomer. $\alpha/\beta = 1:1$, 59%) as a yellow solids alongside donor **5** (11 mg). R_f : 0.12 and 0.30 (7/3 pentane/EtOAc). IR (thin film): 698, 997, 1069, 1094, 1211, 1300, 1339, 1520, 1684, 2922; Data for the α -anomer: ^1H NMR (Acetone- d_6 , 400 MHz, HH-COSY, HSQC): δ 8.91 (s, 2H, CH pyridone), 7.61 – 7.53 (m, 2H, CH_{arom}), 7.48 – 7.37 (m, 3H, CH_{arom}), 7.25 – 7.10 (m, 5H, CH_{arom}), 6.16 (tt, 1H, $J = 55.0$, 3.7 Hz, CHF_2), 5.83 (s, 1H, *CHPh*), 5.56 (d, 1H, $J = 3.7$ Hz, H-1), 4.91 (d, 1H, $J = 11.9$ Hz, *CHH* Bn), 4.79 (dd, 1H, $J = 10.7$, 3.7 Hz, H-2), 4.71 – 4.62 (m, 2H, *CHH* Bn, H-3), 4.37 (dd, 1H, $J = 10.1$, 4.9 Hz, H-6), 4.18 – 4.06 (m, 2H, *CHH-CHF}_2, H-5), 4.03 (dd, 1H, $J = 9.6$, 8.6 Hz, H-4), 3.96 – 3.83 (m, 2H, *CHH-CHF}_2, H-6); ^{13}C -APT NMR (Acetone- d_6 , 101 MHz, HSQC): δ 160.0 (C=O pyridone), 142.9 (C_q NO_2 pyridone), 142.6 (CH pyridone), 138.6, 138.5 (C_q), 129.8, 129.2, 129.0, 129.0, 128.9, 127.0 (CH_{arom}), 115.0 (t, $J = 239.2$ Hz, CHF_2), 102.1 (*CHPh*), 98.8 (C-1), 83.5 (C-4), 75.0 (CH_2 Bn), 74.7 (C-3), 69.9 (C-2), 68.9 (C-6), 67.93 (t, $J = 27.3$ Hz, $\text{CH}_2\text{-CHF}_2$), 63.9 (C-5); Data for the β -anomer: ^1H NMR (CDCl_3 , 400 MHz, HH-COSY, HSQC): δ 8.67 (s, 2H, CH pyridone), 7.60 – 7.52 (m, 2H, CH_{arom}), 7.46 – 7.37 (m, 3H, CH_{arom}), 7.03 – 6.93 (m, 5H, CH_{arom}), 5.75 (tt, 1H, $J = 54.9$, 3.9 Hz, CHF_2), 5.65 (s, 1H, *CHPh*), 5.59 (d, 1H, $J = 8.3$ Hz, H-1), 4.76 – 4.64 (m, 2H, *CHH* Bn, H-3), 4.50 (d, 1H, $J = 11.6$ Hz, *CHH* Bn), 4.45 (dd, 1H, $J = 10.4$, 4.9 Hz, H-6), 4.05 (td, 1H, $J = 9.7$, 5.0 Hz, H-5), 4.00 – 3.80 (m, 4H, $\text{CH}_2\text{-CHF}_2$, H-4, H-6), 3.77 (dd, 1H, $J = 10.3$, 8.4 Hz, H-2); ^{13}C -APT NMR (CDCl_3 , 101 MHz, HSQC): δ 160.9 (C=O pyridone), 141.7 (C_q NO_2 pyridone), 141.5 (CH pyridone), 137.0, 136.7 (C_q), 129.4, 128.8, 128.6, 128.5, 128.4, 126.4 (CH_{arom}), 113.4 (t, $J = 241.5$ Hz, 102.0 (*CHPh*), 99.9 (C-1), 82.6 (C-4), 75.5 (C-**

3), 75.1 (CH₂ Bn), 73.7 (C-2), 68.9 (t, *J* = 27.8 Hz, CH₂-CHF₂), 68.6 (C-6), 65.8 (C-5); HRMS: [M+H]⁺ calcd for C₂₇H₂₆F₂N₃O₁₀ 590.15808, found 590.15741.




Methyl 4-O-(3-O-benzyl-4,6-O-benzylidene-2-deoxy-2-(3,5-dinitro-4-pyridone)-β-D-glucopyranosyl)-2,3,6-tri-O-benzyl-β-D-galactopyranoside (5H). Donor **5** and acceptor **28** were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (for an additional 18 hours at -40°C) and purified by flash column chromatography (9/1 to 7/3 pentane/EtOAc) to yield glycosylation

product **5H** (51 mg, 52 μmol, 52%, α:β = <1:20) as a yellow solid. R_f: 0.49 (7/3 pentane/EtOAc). [α]_D²⁰ = +35.5° (*c* = 0.85, CHCl₃); IR (thin film): 698, 750, 999, 1072, 1094, 1213, 1454, 1522, 1682, 2868; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC, HMBC): δ 8.20 (s, 2H, CH pyridone), 7.55 – 7.49 (m, 2H, CH_{arom}), 7.47 – 7.40 (m, 3H, CH_{arom}), 7.40 – 7.15 (m, 18H, CH_{arom}), 7.07 – 7.00 (m, 2H, CH_{arom}), 5.63 (s, 1H, CHPh), 5.03 (d, 1H, *J* = 8.3 Hz, H-1'), 4.80 (d, 1H, *J* = 12.2 Hz, CHH Bn), 4.64 (d, 1H, *J* = 10.4 Hz, CHH Bn), 4.61 (d, 1H, *J* = 12.3 Hz, CHH Bn), 4.57 (d, 1H, *J* = 12.2 Hz, CHH Bn), 4.50 (s, 2H, CH₂ Bn), 4.47 (d, 1H, *J* = 12.3 Hz, CHH Bn), 4.29 (d, 1H, *J* = 10.4 Hz, CHH Bn), 4.20 (dd, 1H, *J* = 10.5, 5.0 Hz, H-6'), 4.13 (d, 1H, *J* = 7.6 Hz, H-1), 3.91 (d, 1H, *J* = 2.6 Hz, H-4), 3.88 – 3.78 (m, 2H, H-3', H-4'), 3.74 (t, 1H, *J* = 10.3 Hz, H-6'), 3.70 (dd, 1H, *J* = 9.9, 8.4 Hz, H-2'), 3.66 – 3.52 (m, 2H, H-6, H-6), 3.46 (s, 4H, CH₃ OMe, H-5), 3.41 – 3.33 (m, 2H, H-3, H-5'), 2.93 (dd, 1H, *J* = 9.6, 7.6 Hz, H-2); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC, HMBC): δ 159.4 (C_q pyridone), 141.6 (C_q NO₂ pyridone), 140.5 (CH pyridone), 138.2, 138.0, 137.6, 136.6, 135.6 (C_q), 129.6, 129.3, 129.1, 129.1, 128.9, 128.7, 128.6, 128.6, 128.4, 128.4, 128.1, 128.0, 127.7, 127.5, 126.1 (CH_{arom}), 104.8 (C-1), 101.8 (CHPh), 99.6 (C-1'), 82.3 (C-4'), 80.2, 80.2 (C-2, C-3), 75.4 (CH₂ Bn), 74.6 (C-4), 74.5, 74.4 (CH₂ Bn), 74.2 (C-3'), 73.5 (CH₂ Bn), 72.5 (C-5), 72.3 (C-2'), 68.6 (C-6), 68.2 (C-6'), 66.2 (C-5'), 57.3 (OMe); ¹³C-HMBC-GATED NMR (CDCl₃, 101 MHz): δ 104.8 (*J* = 159 Hz, C-1), 99.6 (*J* = 165 Hz, C-1'); HRMS: [M+H]⁺ calcd for C₅₃H₅₄N₃O₁₅ 972.35494, found 972.35542.



Methyl 2-O-(3-O-benzyl-4,6-O-benzylidene-2-deoxy-2-(3,5-dinitro-4-pyridone)-α/β-D-glucopyranosyl)-3-O-benzyl-4,6-O-benzylidene-α-D-mannopyranoside (5I). Donor **5** and acceptor **29** were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (for an additional 18 hours at -40°C) and purified by flash column chromatography (9/1 to 7/3 pentane/EtOAc) to yield glycosylation product **5I** (47 mg, 53 μmol, 53%, α:β = 1:1.3) as a yellow solid. R_f: 0.34 and 0.49 (7/3

pentane/EtOAc). IR: (thin film): 646, 696, 731, 789, 908, 997, 1090, 1123, 1211, 1302, 1333, 1454, 1518, 1624, 1674, 2910; Reported as a 0.8 : 1 mixture of anomers. ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC, HMBC): δ 8.48 (s, 2H, pyridone_β), 8.33 (s, 1.6H, pyridone_α), 7.58 – 7.26 (m, 22.8H, CH_{arom}), 7.23 – 7.01 (m, 11.8H, CH_{arom}), 6.99 – 6.94 (m, 1.6H, CH_{arom}), 5.67 (s, 1.8H, CHPh'_α, CHPh'_β), 5.62 (s, 0.8H, CHPh_α), 5.53 (s, 1H, CHPh_β), 5.27 (d, 0.8H, *J* = 3.9 Hz, H-1'_α), 5.24 (d, 1H, *J* = 8.3 Hz, H-1'_β), 4.84 (d, 1H, *J* = 12.1 Hz, CHH Bn_β), 4.79 (d, 0.8H, *J* = 12.2 Hz, CHH Bn_α), 4.75 (d, 1H, *J* = 12.1 Hz, CHH Bn_β), 4.70 (d, 1H, *J* = 12.2 Hz, CHH Bn_α), 4.67 (d, 0.8H, *J* = 1.1 Hz, H-1_α), 4.64 (d, 1H, *J* = 12.1 Hz, CHH Bn_β), 4.57 (d, 0.8H, *J* = 12.2 Hz, CHH Bn_α), 4.52 (d, 0.8H, *J* = 11.1 Hz, CHH Bn_α), 4.50 (dd, 1H, *J* = 10.3, 8.2 Hz, H-3'_β), 4.46 – 4.41 (m, 1H, H-6'_β), 4.33 (d, 0.8H, *J* = 11.1 Hz, CHH Bn_α), 4.34 – 4.26 (m, 1.6H, H-6_α, H-6'_α), 4.22 – 4.15 (m, 2.8H, H-1_β, H-2_β, H-3'_α), 4.10 – 3.96 (m, 4.4H, H-2_α, H-2'_α, H-2'_β, H-5'_α, H-6_β), 3.95 – 3.83 (m, 8.2H, H-3_α, H-3_β, H-4_β, H-4'_α, H-4'_β, H-5'_β, H-6_α, H-6'_α, H-6'_β), 3.81 – 3.74 (m, 1.6H, H-4_α, H-5_α), 3.61 (dq, 1H, *J* = 9.0, 4.5 Hz, H-5_β), 3.50 (t, 1H, *J* = 10.3 Hz, H-6_β), 3.38 (s, 2.4H, CH₃ OMe_α), 3.15 (s, 3H, CH₃ OMe_β); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC, HMBC): δ 159.9, 159.7 (C=O pyridone), 142.1 (CH pyridone_α), 141.7 (C_q NO₂ pyridone), 140.9 (CH pyridone_β), 140.8 (C_q NO₂ pyridone), 138.2, 137.6, 137.4, 137.4, 136.8, 136.6, 136.5, 136.0 (C_q), 129.6, 129.4, 129.1, 129.0, 128.9, 128.8, 128.7, 128.6, 128.5, 128.4, 128.4, 128.3, 128.3, 127.8, 127.8, 127.6, 126.2, 126.1, 126.1 (CH_{arom}), 101.9, 101.8 (CHPh'_{α,β}), 101.6, 101.6 (CHPh_{α,β}), 100.7 (C-1_α), 99.8 (C-1'_α), 99.2 (C-1_β), 98.8 (C-1'_β), 83.1 (C-4'_α), 82.4 (C-4'_β), 79.6 (C-4_α), 79.1 (C-2_α), 78.5 (C-4_β), 76.1 (C-2_β), 75.0 (C-3_α), 74.5, 74.5, 74.3 (CH₂ Bn), 74.2 (C-3_β, C-3'_β), 72.9 (C-2'_β), 72.7 (CH₂ Bn), 72.5 (C-3'_α), 69.9 (C-2'_α), 68.5, 68.5, 68.4 (C-6_{α,β}, C-6'_{α,β}), 66.1 (C-5'_β), 63.7 (C-5_β), 63.3 (C-5_α), 63.1 (C-5'_α), 55.1, 55.1 (OMe); ¹³C-HMBC-GATED NMR (CDCl₃, 101 MHz): δ 99.8 (*J* = 176 Hz, C-1'_α), 98.8 (*J* = 164 Hz, C-1'_β); HRMS: [M+H]⁺ calcd for C₄₆H₄₆N₃O₁₅ 880.29234, found 880.29252.



2,2,2-Trifluoroethyl 3-O-benzyl-4,6-O-benzylidene-2-deoxy-2-(3,5-dinitro-4-pyridone)-α/β-D-glucopyranoside (5J). Donor **5** and 2,2,2-trifluoroethanol were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (for an additional 1 hour at -40°C) and purified by flash column chromatography (19/1 to 8/2 pentane/EtOAc) to yield glycosylation product **5J** (28 mg, 46 μmol α anomer and 7 mg, 12 μmol β anomer. α:β =

4:1, 58%) as a yellow solids alongside glucal **24** (4 mg) and donor **5** (13 mg). R_f: 0.15 and 0.67 (7/3 pentane/EtOAc). IR (thin film): 698, 754, 1001, 1071, 1096, 1169, 1215, 1279, 1304, 1331, 1520, 1680, 2855, 2924, 3065; Data for the α-

anomer: ^1H NMR (Acetone- d_6 , 400 MHz, HH-COSY, HSQC): δ 8.92 (s, 2H, CH pyridone), 7.60 – 7.54 (m, 2H, CH_{arom}), 7.47 – 7.37 (m, 3H, CH_{arom}), 7.24 – 7.13 (m, 5H, CH_{arom}), 5.84 (s, 1H, CHPh), 5.65 (d, 1H, J = 3.7 Hz, H-1), 4.92 (d, 1H, J = 11.8 Hz, CHH Bn), 4.84 (dd, 1H, J = 10.7, 3.7 Hz, H-2), 4.73 (dd, 1H, J = 10.7, 8.4 Hz, H-3), 4.70 (d, 1H, J = 11.8 Hz, CHH Bn), 4.51 – 4.38 (m, 1H, CHH-CF₃), 4.38 (dd, 1H, J = 10.1, 4.7 Hz, H-6), 4.30 – 4.17 (m, 1H, CHH-CF₃), 4.12 (dd, 1H, J = 9.8, 4.7 Hz, H-5), 4.09 – 4.02 (m, 1H, H-4), 3.93 (t, 1H, J = 10.0 Hz, H-6); ^{13}C -APT NMR (Acetone- d_6 , 101 MHz, HSQC): δ 160.0 (C=O pyridone), 142.9 (C_q NO₂ pyridone), 142.6 (CH pyridone), 138.6, 138.5 (C_q), 129.8, 129.2, 129.0, 129.0, 128.9, 127.0 (CH_{arom}), 124.72 (q, J = 277.4 Hz, CF₃), 102.1 (CHPh), 98.8 (C-1), 83.4 (C-4), 75.1 (CH₂ Bn), 74.6 (C-3), 69.8 (C-2), 68.8 (C-6), 65.84 (q, J = 35.0 Hz, CH₂-CF₃), 64.1 (C-5); Diagnostic peaks β -anomer: ^1H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 8.61 (s, 2H, CH pyridone), 7.56 (dd, 2H, J = 6.6, 2.9 Hz, CH_{arom}), 7.41 (dd, 3H, J = 5.0, 1.7 Hz, CH_{arom}), 7.00 (s, 5H, CH_{arom}), 5.66 (s, 1H, CHPh), 5.58 (d, 1H, J = 8.3 Hz, H-1), 4.75 – 4.62 (m, 2H, CHH Bn, H-3), 4.52 (d, 1H, J = 11.7 Hz, CHH Bn), 4.46 (dd, 1H, J = 10.5, 4.8 Hz, H-6), 4.17 – 3.99 (m, 3H, CH₂-CF₃, H-5), 3.91 – 3.82 (m, 2H, H-4, H-6), 3.78 (dd, 1H, J = 10.0, 8.5 Hz, H-2); HRMS: [M+H]⁺ calcd for C₂₇H₂₅F₃N₃O₁₀ 608.14865, found 608.14825.

Footnotes and references

- (1) Capila, I.; Linhardt, R. J. *Angew. Chem. Int. Ed.* **2002**, *41* (3), 390–412.
- (2) Spillmann, D.; Lindahl, U. *Curr. Opin. Struct. Biol.* **1994**, *4* (5), 677–682.
- (3) Griffiths, A. J.; Davies, D. B. *Carbohydr. Polym.* **1991**, *14* (3), 241–279.
- (4) Griffiths, A. J.; Davies, D. B. *Carbohydr. Polym.* **1991**, *14* (4), 339–365.
- (5) Boltje, T. J.; Buskas, T.; Boons, G.-J. *Nat. Chem.* **2009**, *1* (8), 611–622.
- (6) Christina, A. E.; van der Marel, G. A.; Codée, J. D. C. In *Modern Synthetic Methods in Carbohydrate Chemistry*; Werz, D. B., Vidal, S., Eds.; Wiley-VCH Verlag GmbH & Co. KGaA, 2013; pp 97–124.
- (7) Nigudkar, S. S.; Demchenko, A. V. *Chem. Sci.* **2015**, *6* (5), 2687–2704.
- (8) Bennett, C. S. *Selective Glycosylations: Synthetic Methods and Catalysts*; Wiley VCH Verlag GmbH, 2017.
- (9) Crich, D.; Cai, W. *J. Org. Chem.* **1999**, *64* (13), 4926–4930.
- (10) Crich, D.; Sun, S. *J. Am. Chem. Soc.* **1997**, *119* (46), 11217–11223.
- (11) Crich, D.; Sun, S. *J. Org. Chem.* **1996**, *61* (14), 4506–4507.
- (12) Huang, M.; Garrett, G. E.; Birlirakis, N.; Bohé, L.; Pratt, D. A.; Crich, D. *Nat. Chem.* **2012**, *4* (8), 663–667.
- (13) Crich, D.; Chandrasekera, N. S. *Angew. Chem. Int. Ed.* **2004**, *43* (40), 5386–5389.
- (14) Adero, P. O.; Furukawa, T.; Huang, M.; Mukherjee, D.; Retailleau, P.; Bohé, L.; Crich, D. *J. Am. Chem. Soc.* **2015**, *137* (32), 10336–10345.
- (15) Huang, M.; Furukawa, T.; Retailleau, P.; Crich, D.; Bohé, L. *Carbohydr. Res.* **2016**, *427*, 21–28.
- (16) Bohé, L.; Crich, D. *Carbohydr. Res.* **2015**, *403*, 48–59.
- (17) Huang, M.; Retailleau, P.; Bohé, L.; Crich, D. *J. Am. Chem. Soc.* **2012**, *134* (36), 14746–14749.
- (18) Bongat, A. F. G.; Demchenko, A. V. *Carbohydr. Res.* **2007**, *342* (3–4), 374–406.
- (19) For the use of C2-N-C3-O-carbamate-protected glucosamines, see, for example: ref 6 and Codée, J. D. C.; Ali, A.; Overkleef, H. S.; van der Marel, G. A. *Comptes Rendus Chim.* **2011**, *14* (2–3), 178–193.
- (20) Cid, M. B.; Alfonso, F.; Martín-Lomas, M. *Chem. – Eur. J.* **2005**, *11* (3), 928–938.
- (21) Li, J.; Dai, Y.; Li, W.; Laval, S.; Xu, P.; Yu, B. *Asian J. Org. Chem.* **2015**, *4* (8), 756–762.
- (22) van der Vorm, S.; Hansen, T.; Overkleef, H. S.; van der Marel, G. A.; Codee, J. D. C. *Chem. Sci.* **2017**, *8* (3), 1867–1875.
- (23) Hansch, C.; Leo, A.; Taft, R. W. *Chem. Rev.* **1991**, *91* (2), 165–195.
- (24) Ammer, J.; Mayr, H. *J. Phys. Org. Chem.* **2013**, *26* (1), 59–63.
- (25) Minegishi, S.; Kobayashi, S.; Mayr, H. *J. Am. Chem. Soc.* **2004**, *126* (16), 5174–5181.
- (26) Beaver, M. G.; Woerpel, K. A. *J. Org. Chem.* **2010**, *75* (4), 1107–1118.
- (27) Krumper, J. R.; Salamant, W. A.; Woerpel, K. A. *J. Org. Chem.* **2009**, *74* (21), 8039–8050.
- (28) Hagen, B.; Ali, S.; Overkleef, H. S.; van der Marel, G. A.; Codée, J. D. C. *J. Org. Chem.* **2017**, *82* (2), 848–868.
- (29) Matsumura, E.; Ariga, M.; Tohda, Y.; Kawashima, T. *Tetrahedron Lett.* **1981**, *22* (8), 757–758.
- (30) Matsumura, E.; Kobayashi, H.; Nishikawa, T.; Ariga, M.; Tohda, Y.; Kawashima, T. *Bull. Chem. Soc. Jpn.* **1984**, *57* (7), 1961–1965.
- (31) Lindberg, J.; Öhberg, L.; Garegg, P. J.; Konradsson, P. *Tetrahedron* **2002**, *58* (7), 1387–1398.

- (32) Emmadi, M.; Kulkarni, S. S. *J. Org. Chem.* **2011**, *76* (11), 4703–4709.
- (33) Coutant, C.; Jacquinet, J.-C. *J. Chem. Soc. [Perkin 1]* **1995**, No. 12, 1573–1581.
- (34) Goddard-Borger, E. D.; Stick, R. V. *Org. Lett.* **2007**, *9* (19), 3797–3800.
- (35) Chiara, J. L.; García, Á.; Cristóbal-Lumbroso, G. *J. Org. Chem.* **2005**, *70* (10), 4142–4151.
- (36) Trans-amination via double Michael addition-elimination with a nucleophilic amine ensures deprotection. Typical conditions included 0.2 M solution of DNPY-protected compound in pyridine at room temperature treated with amine (2 eq.) and stirred for 30 min. Extractive workup gave deprotected amines in excellent yield (>90%). Efficient nucleophilic amines are ethylenediamine (DNPY product water soluble), propylamine, hexylamine, and hydrazine.
- (37) Frihed, T. G.; Bols, M.; Pedersen, C. M. *Chem. Rev.* **2015**, *115* (11), 4963–5013.
- (38) Codée, J. D. C.; Litjens, R. E. J. N.; den Heeten, R.; Overkleeft, H. S.; van Boom, J. H.; van der Marel, G. A. *Org. Lett.* **2003**, *5* (9), 1519–1522.
- (39) The chemical shifts of the resonances in donor **5** are very sensitive to temperature, concentration and chemical environment. It was ensured that the sample had not precipitated during the low-temperature NMR experiments at all temperatures; the cause of the line broadening is therefore attributed to the poor solvation and mobility of the donor in dichloromethane.
- (40) Lee, J.-C.; Greenberg, W. A.; Wong, C.-H. *Nat. Protoc.* **2007**, *1* (6), 3143–3152.
- (41) Douglas, N. L.; Ley, S. V.; Lücking, U.; Warriner, S. L. *J. Chem. Soc. [Perkin 1]* **1998**, No. 1, 51–66.
- (42) Zhang, Z.; Ollmann, I. R.; Ye, X.-S.; Wischnat, R.; Baasov, T.; Wong, C.-H. *J. Am. Chem. Soc.* **1999**, *121* (4), 734–753.
- (43) Pedersen, C. M.; Marinescu, L. G.; Bols, M. *Chem. Commun.* **2008**, No. 21, 2465–2467.
- (44) Kamkhachorn, T.; Parameswar, A. R.; Demchenko, A. V. *Org. Lett.* **2010**, *12* (13), 3078–3081.
- (45) Walvoort, M. T. C.; de Witte, W.; van Dijk, J.; Dinkelaar, J.; Lodder, G.; Overkleeft, H. S.; Codée, J. D. C.; van der Marel, G. A. *Org. Lett.* **2011**, *13* (16), 4360–4363.
- (46) de Jong, A.-R.; Hagen, B.; van der Ark, V.; Overkleeft, H. S.; Codée, J. D. C.; Van der Marel, G. A. *J. Org. Chem.* **2012**, *77* (1), 108–125.
- (47) Mootoo, D. R.; Konradsson, P.; Udodong, U.; Fraser-Reid, B. *J. Am. Chem. Soc.* **1988**, *110* (16), 5583–5584.
- (48) Andrews, C. W.; Rodebaugh, R.; Fraser-Reid, B. *J. Org. Chem.* **1996**, *61* (16), 5280–5289.
- (49) Fraser-Reid, B.; López, J. C. In *Reactivity Tuning in Oligosaccharide Assembly*; Fraser-Reid, B., Cristóbal López, J., Eds.; Springer Berlin Heidelberg: Berlin, Heidelberg, 2011; pp 1–29.
- (50) Balmond, E. I.; Coe, D. M.; Galan, M. C.; McGarrigle, E. M. *Angew. Chem. Int. Ed.* **2012**, *51* (36), 9152–9155.
- (51) Ennis, S. C.; Cumpstey, I.; Fairbanks, A. J.; Butters, T. D.; Mackeen, M.; Wormald, M. R. *Tetrahedron* **2002**, *58* (46), 9403–9411.
- (52) Ingle, A. B.; Chao, C.-S.; Hung, W.-C.; Mong, K.-K. T. *Org. Lett.* **2013**, *15* (20), 5290–5293.
- (53) The moderate yields obtained in glycosylations with donor **5** are attributed the unidentified baseline (TLC) material when the reaction was activated and stirred at -40°C. For model acceptors **6–10** the donor was activated to -50°C and unreacted donor was consistently recovered.
- (54) Crich, D.; Li, L. *J. Org. Chem.* **2007**, *72* (5), 1681–1690.
- (55) Whitfield, D. M. *Carbohydr. Res.* **2007**, *342* (12–13), 1726–1740.
- (56) Hosoya, T.; Kosma, P.; Rosenau, T. *Carbohydr. Res.* **2015**, *411*, 64–69.
- (57) Smith, D. M.; Woerpel, K. A. *Org. Biomol. Chem.* **2006**, *4* (7), 1195–1201.
- (58) Crich, D.; Cai, W.; Dai, Z. *J. Org. Chem.* **2000**, *65* (5), 1291–1297.
- (59) This striking stereodirecting effect has been hypothesized to be caused by remote participation, but direct evidence for this type of participation on benzylidene mannose donors has not yet been found. Other stereo-electronic stabilizing effects might be responsible for the apparent stereoselectivity and await further study. For a discussion on remote participation, see: (a) Crich, D.; Hu, T.; Cai, F. *J. Org. Chem.* **2008**, *73* (22), 8942–8953. (b) Baek, J. Y.; Lee, B.-Y.; Jo, M. G.; Kim, K. S. *J. Am. Chem. Soc.* **2009**, *131* (48), 17705–17713. (c) Komarova, B. S.; Orekhova, M. V.; Tsvetkov, Y. E.; Nifantiev, N. E. *Carbohydr. Res.* **2014**, *384*, 70–86.
- (60) Crich, D.; Smith, M.; Yao, Q.; Picione, J. *Synthesis* **2001**, *2001* (02), 0323–0326.
- (61) Benakli, K.; Zha, C.; Kerns, R. J. *J. Am. Chem. Soc.* **2001**, *123* (38), 9461–9462.
- (62) Buskas, T.; Garegg, P. J.; Konradsson, P.; Maloisel, J.-L. *Tetrahedron Asymmetry* **1994**, *5* (11), 2187–2194.
- (63) Emmadi, M.; Kulkarni, S. S. *J. Org. Chem.* **2011**, *76* (11), 4703–4709.
- (64) You, F.; Twieg, R. J. *Tetrahedron Lett.* **1999**, *40* (50), 8759–8762.

Chapter 5

The stereoselectivity of 3,4-tethered glucosazide donors

Introduction

Both α - and β -linked glucosamine residues are widespread in naturally occurring carbohydrates.¹⁻⁵ While β -glucosamine linkages can be reliably installed using anchimeric assistance of a participating *N*-protecting group, the installation of the α -glucosamine bond commonly hinges on the use of a non-participating *N*-protecting group, where the azide is most commonly employed.⁶⁻⁸ In chapters 3 and 4, a set of fluorinated model acceptors was introduced to investigate how the stereoselectivity of glycosylations of 4,6-tethered glucosazide donors relates to acceptor nucleophilicity. This approach revealed that the combination of a reactive donor glycoside and a weak nucleophile led to α -selective glycosylation reactions. In the current chapter, the stereoselectivity of glycosylations of a 3,4-tethered glucosazide donor is studied in relation to the nucleophilicity of the acceptor. The reactivity of the donor is assessed using Variable-Temperature NMR (VT-NMR) and competition experiments, followed by a series of glycosylations. The set of partially fluorinated model acceptors and a panel

of carbohydrate acceptors, introduced in the previous chapters, are used to map reactivity-stereoselectivity relationships to provide a basis for α -glucosamylation reactions.⁹⁻¹²

Results and discussion

In an extension of the glucosazide donors described in the previous chapter, the butane diacetal (BDA)¹³⁻¹⁵ protected glucosazide donor **1** is glycosylated with the range of acceptors depicted in Figure 1 to investigate how the stereoselectivity of glycosylations of donor **1** depends on the reactivity of these acceptors. Benzyldiene glucose donor **2** and benzyldiene glucosazide donor **3** serve as a direct comparison for the reactivity and selectivity of donor **1**. The 3,4-*O*-BDA protecting group locks the donor in a *trans*-decalin constellation, conformationally disarming the system, as is also the case for the 4,6-*O*-benzyldiene in donors **2** and **3**. Severe conformational changes are prohibited, and the number of possible glycosylation reaction itineraries restricted.¹⁶⁻¹⁸ The difference in electronic properties between the BDA group and the benzyldiene acetal can be found in the rotational freedom of the C-6-substituent. In donor **1** the C-6-O-6 bond is not retained in its most electron withdrawing *tg*-conformation, as in donor **2** and **3** (Figure 1C).¹⁸⁻²⁰ The BDA protected donor **1** is therefore expected to be more reactive than benzyldiene glucosazide donor **3**. This has previously been demonstrated in the *manno*-series by Crich and co-workers, who reported highly α -selective mannosylations with BDA-protected mannosyl donors. They related this to the higher reactivity of the BDA donor over the benzyldiene donor and therefore a shift in the glycosylation reaction mechanism continuum from the β -selective S_N2-side for the latter donor to the α -selective S_N1-side for the former donor.²¹ In contrast, glycosylations of the related 3,4-*O*-BDA-glucosyl donors proceeded with β -selectivity, which they interpreted to arise from an S_N2-type reaction on the relatively stable α -triflate. Collapse into the α -selective oxocarbenium ion intermediate was prevented by the steric hindrance of the BDA-OMe group with the large C-2-OBn group (See Figure 3).²² It may be hypothesized that the smaller 2-azido group in donor **1** does not experience this unfavorable steric effect allowing for the easier formation of the oxocarbenium intermediate. On the other hand, Chapter 4 has revealed the azide to promote S_N2-type reactions as a result of its electron withdrawing nature.





Figure 1. (A) Glycoside donors and (B) acceptors used in the glycosylation study of this chapter. (C) Newman projections of the three staggered rotamer conformations along the C-5–C-6 bond.

Donor **1** is synthesized from acetylated thioglycoside **15** (Scheme 1), by alkaline hydrolysis of the TCA and acetyl groups followed by diazotransfer to give the crude glucosazide **16**. Installation of the BDA and benzyl groups gave donor **1** in good overall yield.

Scheme 1. Synthesis of BDA-donor **1**.



Reagents and conditions: (a) *i.* K₂CO₃, EtOH, H₂O; *ii.* CuSO₄·5H₂O, imidazole-1-sulfonyl azide hydrochloride²³; (b) 2,3-butadione, trimethyl orthoformate, CSA, MeOH, 64% (three steps); (c) BnBr, NaH, DMF, 85%.

The activation of donor **1** was studied by VT-NMR.²⁴ To this end donor **1** was treated with Ph₂SO/Tf₂O in the presence of TTBP in deuterated DCM.²⁵ Figure 2A displays the spectra of the reaction mixture at a range of temperatures. Interestingly, various species are generated upon activation, the two most predominant of which were assigned as the α -anomeric triflate **18** (labelled \diamond , ¹H δ = 6.09 ppm, *J*_{H-1-H-2} = 3.3 Hz, ¹³C δ = 105.8 ppm) and β -oxosulfonium triflate (labelled *, ¹H δ = 5.56 ppm, *J*_{H-1-H-2} = 7.6 Hz, ¹³C δ = 103.8 ppm) in a 3:1 ratio. Using either an equimolar amount or an excess of Ph₂SO (5 equivalents), the reaction mixture could be enriched in triflate **18** or

oxosulfonium triflate **19** (Figure 2B depicts the ^{19}F -NMR spectrum of the activation mixture using an excess Ph_2SO , showing full consumption of the anomeric triflate). When the sample (with 1.3 equivalents Ph_2SO) was heated to -50°C the signal of the β -oxosulfonium triflate disappeared irreversibly. Decomposition of the anomeric triflate started around -20°C , similar to the triflates reported in Chapter 4, and no specific product could be identified. The immediate formation of the β -oxosulfonium triflate, and the complete conversion of the anomeric triflate to this species when an excess of Ph_2SO is used, hints at the relatively high reactivity of the donor, in line with the observation made for the two most reactive donors in Chapter 4.




Figure 2. NMR activation study of donor **1**. (A) 1.3 eq. Ph_2SO , 1.3 eq. Tf_2O . The behavior of triflate **18** (\diamond) and oxosulfonium triflate **19** ($*$) between -80°C -10°C . (B) ^{19}F -NMR showing triflate **18** (\diamond) and its absence when 5 eq. Ph_2SO is added.

The relative reactivity of the BDA protected glucosazide versus its benzylidene counterpart was evaluated in a set of competition experiments (Table 1). The thioglycosides and acceptor **10** were mixed and made to compete for a limiting amount of NIS. This experiment revealed the BDA donor **1** to be six times more reactive than donor **3** towards NIS and, somewhat surprisingly given the stronger electron withdrawing capacity of the azide, two times more reactive than **2**. Apparently the combined disarming effect of the azide and BDA group, previously found to be semi-disarming,^{26,27} is smaller than the disarming effect of the benzylidene group in donor **2**.

Table 1: Activation competition experiments between donors **1**, **2**, and **3**.

		1 eq. Donor I + 1 eq. Donor II		 10 , 2 eq.		1 eq. NIS 0.1 eq. TfOH DCM		Disaccharide 1C , 2C , 3C	
Entry	Donor I	Donor II	Solvent (M)	Product ^a I : II	Recovered donor ^a I : II	Yield ^a %	α : β		
1	1	2	0.1 M DCM	1C/2C 2 : 1	1 : 1.4	75%	1C ; 1 : 6 2C ; 1 : 1		
2	1	3	0.1 M DCM	1C/3C 6 : 1	1 : 10	99%	1C ; 1 : 6 3C ; 1 : 3		
3	2	3	0.05 M DCM ^b	2C/3C 1 : 0	0 : 1	80%	1C ; 1.5 : 1		

^aIsolated ratios after size-exclusion chromatography, and yield of the disaccharide fraction. ^bReference relative reactivity between **2** and **3** (Chapter 4); selectivity increases with dilution.

Next, the BDA glucosazide donor **1** was glycosylated with the set of fluorinated model nucleophiles and a selection of carbohydrate acceptors. The results of the glycosylations are listed in Table 2 and compared with the glycosylation results of donors **2** and **3**. The reactions were carried out by preactivating the donor from -78°C to -50°C to remove the contribution of the oxosulfonium triflate on the stereoselectivity of the reaction. Despite the high reactivity observed in the competition and activation experiments, indicating that oxocarbenium ion character readily develops at the anomeric center, the reactions of donor **1** are very β -selective. It is not surprising to find the strong nucleophiles cyclohexanol **4**, ethanol **5** and carbohydrate acceptor **10** to react with full β -selectivity, but the other acceptors, especially trifluoroethanol **8** and axially orientated nucleophiles **13** and **14**, react with unexpected low α -selectivity.

Table 2. Glycosylations of donors **1-3** with model acceptors **4-9** and carbohydrate acceptors **10-14**. Ordered by their overall β - to α -selectivity.

Acceptor		Product ^a α : β (yield) ^b	Product α : β (yield)	Product α : β (yield)
A		2A 71 % 1 : 5.1	3A 93 % < 1 : 20	1A 87 % < 1 : 20
B		2B 68 % 1 : 10	3B 83 % < 1 : 20	1B 90 % < 1 : 20
C		2C 70 % 1 : 2.8	3C 90 % 1 : 6.7	1C 97 % 1 : 20
D		2D 70 % 5 : 1	3D 64 % 2.9 : 1	1D 84 % 1 : 3.5
E		2E 64 % > 20 : 1	3E 94 % > 20 : 1	1E 87 % 2.5 : 1
F		2F 65 % > 20 : 1	3F 53 % > 20 : 1	1F ^c 18% > 20 : 1
G		2G 81 % 1 : 2.7	3G 89 % < 1 : 20	1G 86 % < 1 : 20
H		2H 79 % 1 : 1	3H 88 % 1 : 7	1H 93 % 1 : 15
I		2I 90 % 5 : 1	3I 93 % 1.1 : 1	1I 83 % 1.5 : 1
J		2J 83 % > 20 : 1	3J 75 % 9 : 1	1J 86 % 1 : 1.8
K		2K 80 % > 20 : 1	3K 74 % 9 : 1	1K 93 % 1 : 1.7

^aGlycosylation results of donors **2** and **3**, are also reported in Chapter 3 and 4 of this thesis, respectively. ^bRatio and yield of isolated product after column chromatography, anomers were not separated. ^c α , β -Trehalose **24** (neotrehalose) was also isolated as a single anomer in 25% yield.

The high β -selectivity for donor **1** under preactivation conditions is also apparent when compared with the previously reported C-2-OBn analogue.²² Condensation (See Figure 3) of donor **20** and acceptor **11** provided an anomeric mixture (α/β , 1:4), whereas glycosylation of **1** and **11** led to a much higher β -selectivity (**1H**; α/β , 1:15). This observation is consistent with the scenario drawn in Chapter 4: the 2-azido group promotes an S_N2 pathway (via triflate **18**) due to additional electron-withdrawing from the anomeric center. Although the high β -selectivity appears contradictory to the high reactivity of the donor, it may also be that the BDA glucosazide oxocarbenium ion **22** (as part of a close ion pair) takes up a conformation favoring attack from the β -side.




Figure 3. Reactive species at play in the glycosylation reactions of donors **1** and **20**.

Conclusions


Condensations of butane diacetal (BDA) protected glucosazide donor **1** have been studied using the set of fluorinated model acceptors introduced in Chapters 3 and 4. The BDA protecting group in combination with the 2-azido functionality is highly β -directing in glycosylations without the need for a C-2 participating group. Despite the high β -selectivity, the model acceptors show the anticipated trend of reactivity of the acceptor versus glycosylation stereoselectivity, with less reactive acceptors providing more α -products as was established in Chapters 3 and 4, to provide yet another example of the importance of the reactivity of the acceptor in a glycosylation reaction. The exact underlying mechanism that causes the high β -selectivity has yet to be fully elucidated, but based on precedent, the high β -selective for donor **1** may arise from an S_N2 -like substitution of the anomeric α -triflate. How this exactly relates to the high reactivity of the donor remains to be established.

Experimental section

General procedure for Tf₂O/Ph₂SO mediated glycosylations: Donor (0.1 mmol), Ph₂SO (26 mg, 0.13 mmol, 1.3 eq.) and TTBP²⁹ (62 mg, 0.25 mmol, 2.5 eq.) were coevaporated twice with dry toluene and dissolved in dry DCM (2 mL, 0.05 M donor). Activated 3Å molecular sieves (rods, size 1/16 in.) were added, and the reaction mixture stirred for 1 h at room temperature under a nitrogen atmosphere. The solution was cooled to -78°C and Tf₂O (22 µL, 0.13 mmol, 1.3 eq.) was added. The reaction mixture was allowed to warm to -50°C followed by recooling to -78°C and addition of the acceptor (0.2 mmol, 2 eq.) in DCM (0.4 mL, 0.5 M). The reaction mixture was allowed to warm to -40°C in approximately 90 min and stirred for an additional 0-18 h depending on the acceptor. The reaction was quenched with Et₃N (0.1 mL, 0.72 mmol, 5.5 eq.) at -40 °C and diluted with DCM. The solution was transferred to a separatory funnel and water was added, the layers were separated and the water phase extracted once more with DCM. The combined organic layers were dried over MgSO₄, filtered, and concentrated *in vacuo*. Purification by silica gel flash column chromatography and when needed, sephadexTM LH-20 size exclusion chromatography yielded the glycosylation product as a mixture of anomers.


General procedure for the NIS/TfOH mediated competition experiments: Donor I (0.1 mmol, 1 eq.), donor II (0.1 mmol, 1 eq.) and acceptor **25** (0.2 mmol, 2 eq.) were together coevaporated with dry toluene (2x). Dry DCM (4 mL, donor concentration 0.1 M), a Teflon stirring bar and 3Å activated molecular sieves (rods, size 1/16 in.) were added and the mixture was stirred under a nitrogen atmosphere for 1 h at room temperature. The mixture was cooled to -40°C and NIS (0.1 mmol, 1 eq.) was added. TfOH (50 µL of a freshly prepared 0.2 M stock solution in dry DCM, 0.1 eq.) was added and the mixture was allowed to warm to 0°C in 3 hours. Et₃N (0.1 mL) was added and the mixture was diluted with EtOAc, washed with sat. aq. Na₂O₃ and brine, dried over Na₂SO₄ and concentrated *in vacuo*. Size exclusion chromatography (Sephadex LH-20, 1/1 DCM/MeOH) enabled isolation of the disaccharide products and the monosaccharide rests, which were both analysed with NMR spectroscopy. The yield of the disaccharide fraction was determined.

General procedure for the low temperature NMR experiments: A mixture of donor (30 µmol) and Ph₂SO (39 µmol) was coevaporated with dry toluene twice (for the activation of donor 1 also TTBP (75 µmol) was added). Under a nitrogen atmosphere, CD₂Cl₂ (0.6 mL) was added and the mixture transferred to a nitrogen flushed NMR tube and closed with a NMR tube septum. The NMR magnet was cooled to -80°C, locked and shimmed and the sample was measure prior to activation. In a long narrow cold bath (EtOH, -85°C) the sample was treated with Tf₂O (39 µmol), shaken thrice and cooled again after every shake. The cold sample was wiped dry and quickly inserted back in the cold magnet. The first ¹H NMR spectrum was immediately recorded. The sample was then reshimmed and spectra were recorded in 10°C intervals with at least 5 min equilibration time for every temperature.



Phenyl 2-azido-2-deoxy-3,4-O-(2,3-dimethoxybutane-2,3-diyl)-1-thio-β-D-glucopyranoside (**17**).

To a solution of crude triol **16** (synthesized as described in Chapter 4) (≤15 mmol) in dry MeOH (100 mL) was added butadiene (2.0 mL, 22.5 mmol, 1.5 eq.), trimethyl orthoformate (9.8 mL, 90 mmol, 6 eq.) and CSA (523 mg, 2.25 mmol, 0.15 eq.) and the solution was refluxed overnight. Et₃N was added (1 mL) and the volatiles were removed *in vacuo*. Crystallization from EtOAc/petroleum ether yielded the title compound as a white solid (3.94 g, 9.56 mmol, 64% over three steps). Spectroscopic data were in accord with those previously reported.³⁰ ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.62 – 7.54 (m, 2H, CH_{arom}), 7.41 – 7.34 (m, 3H, CH_{arom}), 4.47 (d, 1H, *J* = 9.9 Hz, H-1), 3.91 (ddd, 1H, *J* = 12.0, 5.6, 2.6 Hz, H-6), 3.81 – 3.70 (m, 2H, H-3, H-6), 3.66 (t, 1H, *J* = 9.7 Hz, H-4), 3.55 (ddd, 1H, *J* = 9.6, 4.5, 2.7 Hz, H-5), 3.43 (t, 1H, *J* = 9.8 Hz, H-2), 3.35 (s, 3H, CH₃ OMe), 3.27 (s, 3H, CH₃ OMe), 2.02 (dd, 1H, *J* = 7.6, 5.9 Hz, 6-OH), 1.35 (s, 3H, CH₃ Me), 1.31 (s, 3H, CH₃ Me); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 133.9 (CH_{arom}), 130.7 (C_q SPh), 129.3, 128.9 (CH_{arom}), 100.3, 99.9 (C_q BDA), 86.2 (C-1), 78.2 (C-5), 73.1 (C-3), 65.7 (C-4), 61.5 (C-2), 61.4 (C-6), 48.3, 48.2 (OMe), 17.7, 17.6 (Me).




Phenyl 2-azido-6-O-benzyl-2-deoxy-3,4-O-(2,3-dimethoxybutane-2,3-diyl)-1-thio-β-D-glucopyranoside (**1**).

Compound **17** was dissolved in DMF (45 mL) and cooled to 0°C. NaH (60% dispersion in mineral oil, 540 mg, 13.5 mmol, 1.5 eq.) and BnBr (1.4 mL, 11.7 mmol, 1.3 eq.) were added and the mixture was stirred at r.t. until complete conversion was observed (TLC).


Excess NaH was quenched with MeOH and the solution was reduced in volume under reduced pressure. H₂O was added to the residue and extracted with Et₂O twice and DCM once. Combined organic layers were washed with H₂O and brine, dried with MgSO₄, filtered and concentrated *in vacuo*. Flash column chromatography (1/0 to 9/1 pentane/EtOAc) and subsequently recrystallized (EtOAc, excess petroleum ether) gave the title compound as a white

solid in two batches (total yield 3.84 g, 7.66 mmol, 85%). R_f : 0.25 (19/1 pentane/EtOAc). m.p.: 146–149°C. $[\alpha]_D^{20} = +72.2^\circ$ ($c = 1.0$, CHCl₃); IR (thin film): 689, 735, 752, 851, 885, 960, 1032, 1107, 1128, 1265, 1275, 1366, 1375, 1437, 1452, 2110, 2868; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.63–7.57 (m, 2H, CH_{arom}), 7.36–7.27 (m, 5H, CH_{arom}), 7.26–7.21 (m, 3H, CH_{arom}), 4.63 (d, 1H, $J = 11.9$ Hz, CHH Bn), 4.56 (d, 1H, $J = 11.9$ Hz, CHH Bn), 4.41 (d, 1H, $J = 9.8$ Hz, H-1), 3.83–3.68 (m, 4H, H-3, H-4, H-6, H-6), 3.66–3.60 (m, 1H, H-5), 3.41 (t, 1H, $J = 9.8$ Hz, H-2), 3.32 (s, 3H, CH₃ OMe), 3.17 (s, 3H, CH₃ OMe), 1.32 (s, 3H, CH₃ Me), 1.27 (s, 3H, CH₃ Me); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 138.5 (C_q Bn), 134.2 (CH_{arom}), 130.8 (C_q Sph), 129.2, 128.7, 128.4, 127.6, 127.5 (CH_{arom}), 100.3, 99.9 (C_q BDA), 86.1 (C-1), 78.1 (C-5), 73.6 (CH₂ Bn), 73.3 (C-3), 68.3 (C-6), 65.7 (C-4), 61.4 (C-2), 48.3, 48.2 (OMe), 17.8, 17.7 (Me); HRMS: $[M+NH_4]^+$ calcd for C₂₅H₃₅N₃O₆S 519.22718, found 519.22695.




Cyclohexyl 2-azido-6-O-benzyl-2-deoxy-3,4-O-(2,3-dimethoxybutane-2,3-diyl)-β-D-glucopyranoside (1A). Donor **1** and cyclohexanol were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (for an additional 18 hours at -40°C) and purified by flash column chromatography (1/0 to 9/1 pentane/EtOAc) to yield

glycosylation product **1A** (43 mg, 87 μmol, 87%, $\alpha:\beta = <1:20$). R_f : 0.6 (9/1 pentane/EtOAc). $[\alpha]_D^{20} = +98.6^\circ$ ($c = 1.08$, CHCl₃); IR (thin film): 698, 849, 891, 959, 1047, 1121, 1368, 1452, 2108, 2932; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.35–7.26 (m, 5H, CH_{arom}), 4.61 (d, 1H, $J = 12.1$ Hz, CHH Bn), 4.57 (d, 1H, $J = 12.1$ Hz, CHH Bn), 4.41 (d, 1H, $J = 7.7$ Hz, H-1), 3.76 (dd, 1H, $J = 11.0$, 1.6 Hz, H-6), 3.74–3.63 (m, 3H, CH Cy, H-4, H-6), 3.61–3.51 (m, 2H, H-3, H-5), 3.43 (dd, 1H, $J = 10.4$, 7.7 Hz, H-2), 3.30 (s, 3H, CH₃ OMe), 3.18 (s, 3H, CH₃ OMe), 2.02–1.87 (m, 2H, CH₂ Cy), 1.82–1.71 (m, 2H, CH₂ Cy), 1.58–1.37 (m, 3H, CH₂ Cy), 1.33 (s, 3H, CH₃ Me), 1.31–1.19 (m, 6H, CH₃ Me, CH₂ Cy); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 138.4 (C_q), 128.4, 127.6, 127.6 (CH_{arom}), 101.2 (C-1), 100.0, 99.8 (C_q BDA), 78.3 (CH Cy), 74.0 (C-5), 73.6 (CH₂ Bn), 70.9 (C-3), 68.4 (C-6), 66.5 (C-4), 63.0 (C-2), 48.1, 48.1 (CH₃ OMe), 33.7, 31.8, 25.6, 24.1, 24.0 (CH₂ Cy), 17.7, 17.7 (CH₃ Me); HRMS: $[M+NH_4]^+$ calcd for C₂₅H₄₁N₄O₇ 509.29698, found 509.29668.




Ethyl 2-azido-6-O-benzyl-2-deoxy-3,4-O-(2,3-dimethoxybutane-2,3-diyl)-β-D-glucopyranoside (1B). Donor **1** and ethanol were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (for an additional 30 min at -40°C) and purified by flash column chromatography (1/0 to 9/1 pentane/EtOAc) to yield glycosylation product **1B**

(39.7 mg, 90 μmol, 90%, $\alpha:\beta = <1:20$). R_f : 0.48 (9/1 pentane/EtOAc). $[\alpha]_D^{20} = +105.2^\circ$ ($c = 0.85$, CHCl₃); IR (thin film): 698, 849, 1047, 1115, 1375, 2108, 2927; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.39–7.24 (m, 5H, CH_{arom}), 4.61 (d, 1H, $J = 12.2$ Hz, CHH Bn), 4.57 (d, 1H, $J = 12.2$ Hz, CHH Bn), 4.31 (d, 1H, $J = 7.7$ Hz, H-1), 3.98 (dq, 1H, $J = 9.5$, 7.1 Hz, CHH Et), 3.76 (dd, 1H, $J = 10.9$, 1.7 Hz, H-6), 3.71–3.64 (m, 2H, H-5, H-6), 3.64–3.55 (m, 3H, H-3, H-4, CHH Et), 3.46 (dd, 1H, $J = 10.5$, 7.7 Hz, H-2), 3.31 (s, 3H, CH₃ OMe BDA), 3.18 (s, 3H, CH₃ OMe BDA), 1.34 (s, 3H, CH₃ Me BDA), 1.28 (t, 4H, $J = 7.1$ Hz, CH₃ Et), 1.27 (s, 3H, CH₃ Me BDA); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 138.2 (C_q), 128.4, 127.6 (CH_{arom}), 102.4 (C-1), 100.1, 99.8 (C_q BDA), 74.0 (C-3/C-4), 73.6 (CH₂ Bn), 71.0 (C-3/C-4), 68.3 (C-6), 66.3 (C-5), 66.0 (CH₂ Et), 62.6 (C-2), 48.2, 48.1 (OMe BDA), 17.7, 17.7 (Me BDA), 15.2 (CH₃ Et); HRMS: $[M+NH_4]^+$ calcd for C₂₁H₃₅N₄O₇ 455.25003, found 455.24975.




2-Fluoroethyl 2-azido-6-O-benzyl-2-deoxy-3,4-O-(2,3-dimethoxybutane-2,3-diyl)-β-D-glucopyranoside (1C). Donor **1** and 2-fluoroethanol were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (for an additional 30 min at -40°C) and purified by flash column chromatography (1/0 to 9/1 pentane/EtOAc) to yield

glycosylation product **1C** (44 mg, 97 μmol, 97%, $\alpha:\beta = 1:20$). R_f : 0.30 (9/1 pentane/EtOAc). $[\alpha]_D^{20} = +96.4^\circ$ ($c = 1.10$, CHCl₃); IR (thin film): 698, 881, 1049, 1113, 1375, 1454, 2110, 2949; ¹H NMR (CDCl₃, 500 MHz, HH-COSY, HSQC): δ 7.35–7.27 (m, 5H, CH_{arom}), 4.71–4.62 (m, 1H, CHHF), 4.62–4.52 (m, 3H, CHHF, CH₂ Bn), 4.36 (d, 1H, $J = 7.7$ Hz, H-1), 4.08 (dddd, 1H, $J = 31.8$, 12.2, 4.7, 2.6 Hz, CHH-CH₂F), 3.88 (dddd, 2H, $J = 25.2$, 12.1, 6.8, 2.7 Hz, CHH-CH₂F), 3.76 (dd, 1H, $J = 11.0$, 1.7 Hz, H-6), 3.72 (t, 1H, $J = 10.0$ Hz, H-4), 3.68 (dd, 1H, $J = 11.0$, 5.3 Hz, H-6), 3.65–3.56 (m, 2H, H-3, H-5), 3.50 (dd, 1H, $J = 10.5$, 7.7 Hz, H-2), 3.31 (s, 3H, CH₃ OMe), 3.19 (s, 3H, CH₃ OMe), 1.34 (s, 3H, CH₃ Me), 1.28 (s, 3H, CH₃ Me); ¹³C-APT NMR (CDCl₃, 126 MHz, HSQC): δ 138.2 (C_q), 128.4, 127.7, 127.6 (CH_{arom}), 102.7 (C-1), 100.1, 99.8 (C_q BDA), 82.7 (d, $J = 169.9$ Hz, CH₂F), 74.1 (C-5), 73.6 (CH₂ Bn), 71.0 (C-3), 69.0 (d, $J = 20.3$ Hz, CH₂-CH₂F), 68.2 (C-6), 66.2 (C-4), 62.6 (C-2), 48.2, 48.2 (OMe), 17.7, 17.7 (Me); HRMS: $[M+NH_4]^+$ calcd for C₂₁H₃₄FN₄O₇ 473.24060, found 473.24041.




2,2-Difluoroethyl 2-azido-6-O-benzyl-2-deoxy-3,4-O-(2,3-dimethoxybutane-2,3-diyl)-α/β-D-glucopyranoside (1D). Donor **1** and 2,2-difluoroethanol were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (for an additional 30 min at -

40°C) and purified by flash column chromatography (1/0 to 9/1 pentane/EtOAc) to yield glycosylation product **1D** (40 mg, 84 μ mol, 84%, α : β = 1:3.5). *R*_f: 0.60 (9/1 pentane/EtOAc). IR (thin film): 698, 735, 849, 883, 1030, 1107, 1265, 1373, 1454, 2108, 2926; Data for the β -anomer: ¹H NMR (CDCl₃, 500 MHz, HH-COSY, HSQC): δ 7.38 – 7.27 (m, 5H, CH_{arom}), 6.10 – 5.82 (m, 1H, CHF₂), 4.62 – 4.54 (m, 2H, CH₂ Bn), 4.34 (d, 1H, *J* = 7.7 Hz, H-1), 4.05 – 3.93 (m, 1H, CHH-CHF₂), 3.90 – 3.78 (m, 1H, CHH-CHF₂), 3.77 – 3.65 (m, 3H, H-4, H-6, H-6), 3.64 – 3.56 (m, 2H, H-3, H-5), 3.49 (dd, 1H, *J* = 10.5, 7.7 Hz, H-2), 3.30 (s, 3H, CH₃ OMe), 3.19 (s, 3H, CH₃ OMe), 1.34 (s, 3H, CH₃ Me), 1.28 (s, 3H, CH₃ Me); ¹³C-APT NMR (CDCl₃, 126 MHz, HSQC): δ 138.1 (C_q), 128.5, 127.8, 127.6 (CH_{arom}), 114.2 (dd, *J* = 241.8, 240.8 Hz, CHF₂), 102.9 (C-1), 100.1, 99.9 (C_q BDA), 74.2 (C-5), 73.7 (CH₂ Bn), 70.9 (C-3), 68.8 (dd, *J* = 30.3, 28.1 Hz, CH₂-CHF₂), 68.1 (C-6), 66.0 (C-4), 62.6 (C-2), 48.2, 48.2 (OMe), 17.7, 17.7 (Me); Diagnostic peaks α -anomer: ¹H NMR (CDCl₃, 500 MHz): δ 4.97 (d, 0.3H, *J* = 3.6 Hz, H-1), 4.25 (dd, 0.3H, *J* = 10.8, 9.7 Hz, H-3), 3.39 (dd, 0.3H, *J* = 10.9, 3.6 Hz, H-2), 3.37 (s, 0.9H, CH₃ OMe), 1.35 (s, 0.9H, CH₃ Me), 1.30 (s, 0.9H, CH₃ Me); ¹³C-APT NMR (CDCl₃, 126 MHz, HSQC): δ 137.9, 128.4, 127.7, 127.6, 113.8 (t, *J* = 241.5 Hz), 100.2, 100.1 (C_q BDA), 99.4 (C-1), 73.7 (CH₂ Bn), 70.0 (C-5), 67.7 (C-6), 67.6 (t, *J* = 29.0 Hz, CH₂-CHF₂), 67.4 (C-3), 66.3 (C-4), 60.0 (C-2), 48.6, 17.9, 17.8; HRMS: [M+NH₄]⁺ calcd for C₂₁H₃₃F₂N₄O₇ 491.23118, found 491.23061.




2,2,2-trifluoroethyl 2-azido-6-O-benzyl-2-deoxy-3,4-O-(2,3-dimethoxybutane-2,3-diy)- α -D-glucopyranoside (1E**).** Donor **1** and 2,2,2-trifluoroethanol were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (for an additional 30 min at -40°C) and purified by flash column chromatography (1/0 to 9/1 pentane/EtOAc) to yield

glycosylation product **1E** (43 mg, 87 μ mol, 87%, α : β = 2.5:1). *R*_f: 0.35 9/1 (pentane/EtOAc). IR (thin film): 673, 737, 851, 885, 972, 1030, 1111, 1279, 1377, 2108, 2949; Data for the α -anomer: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC, HMBC): δ 7.38 – 7.24 (m, 5H, CH_{arom}), 5.01 (d, 1H, *J* = 3.6 Hz, H-1), 4.60 – 4.55 (m, 2H, CH₂ Bn), 4.28 (dd, 1H, *J* = 10.9, 9.5 Hz, H-3), 4.01 – 3.91 (m, 3H, CH₂CF₃, H-5), 3.89 – 3.82 (m, 1H, H-4), 3.78 – 3.66 (m, 2H, H-6, H-6), 3.41 – 3.35 (m, 4H, CH₃ OMe, H-2), 3.19 (s, 3H, CH₃ OMe), 1.35 (s, 3H, CH₃ Me), 1.30 (s, 3H, CH₃ Me); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC, HMBC): δ 137.9 (C_q), 128.4, 127.8, 127.6 (CH_{arom}), 123.5 (q, *J* = 278.4 Hz, CF₃), 100.2, 100.1 (C_q BDA), 99.3 (C-1), 73.7 (CH₂ Bn), 70.3 (C-5), 67.6 (C-6), 67.2 (C-3), 66.2 (C-4), 65.1 (q, *J* = 35.3 Hz, CH₂CF₃), 59.8 (C-2), 48.6, 48.2 (OMe), 17.8, 17.8 (Me); Diagnostic peaks β -anomer: ¹H NMR (CDCl₃, 400 MHz): δ 4.38 (d, 0.38H, *J* = 7.6 Hz, H-1), 4.16 (dq, 0.38H, *J* = 12.5, 8.7 Hz, CHH-CF₃), 3.65 – 3.56 (m, 2H, H-3, H-5), 3.50 (dd, 0.38H, *J* = 10.5, 7.6 Hz, H-2), 3.30 (s, 1.14H), 1.34 (s, 1.14H), 1.28 (s, 1.14H); ¹³C-APT NMR (CDCl₃, 101 MHz): δ 102.4 (C-1), 100.2, 99.9, 74.4, 70.7, 68.0, 66.5, 66.0 (q, *J* = 35.1 Hz), 62.6, 48.2, 48.2, 17.7, 17.6; HRMS: [M+NH₄]⁺ calcd for C₂₁H₃₂F₃N₄O₇ 509.22176, found 509.22116.



1,1,1,3,3,3-Hexafluoro-2-propyl 2-azido-6-O-benzyl-2-deoxy-3,4-O-(2,3-dimethoxybutane-2,3-diy)- α -D-glucopyranoside (1F**).** Donor **1** and hexafluoro-*iso*-propanol were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (for an additional 120 hours at -40°C) and purified by flash column chromatography (1/0 to 9/1 pentane/EtOAc) to yield glycosylation product **1F** (10 mg, 18 μ mol, 18%, α : β = >20:1). *R*_f: 0.7 (9/1 pentane/EtOAc). [α]_D²³ = +182.1° (*c* = 0.52, CHCl₃); ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC, HMBC): δ 7.36 – 7.28 (m, 5H, CH_{arom}), 5.17 (d, 1H, *J* = 3.9 Hz, H-1), 4.58 (d, 1H, *J* = 12.0 Hz, CHH Bn), 4.54 (d, 1H, *J* = 12.0 Hz, CHH Bn), 4.44 (hept, 1H, *J* = 5.8 Hz, CH HFIP), 4.23 (dd, 1H, *J* = 11.1, 9.6 Hz, H-3), 4.02 (ddd, 1H, *J* = 10.0, 3.5, 2.0 Hz, H-5), 3.92 (t, 1H, *J* = 9.9 Hz, H-4), 3.78 (dd, 1H, *J* = 11.2, 3.5 Hz, H-6), 3.64 (dd, 1H, *J* = 11.1, 2.0 Hz, H-6), 3.46 (dd, 1H, *J* = 11.0, 3.9 Hz, H-2), 3.38 (s, 3H, CH₃ OMe), 3.20 (s, 3H, CH₃ OMe), 1.36 (s, 3H, CH₃ Me), 1.31 (s, 3H, CH₃ Me); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC, HMBC): δ 137.8 (C_q Bn), 128.5, 127.8, 127.6 (CH_{arom} Bn), 101.1 (C-1), 100.3, 100.2 (C_q BDA), 73.8 (CH₂ Bn), 73.3 (CH HFIP), 71.3 (C-5), 67.2 (C-6), 66.9 (C-3), 65.9 (C-4), 59.8 (C-2), 48.8, 48.3 (OMe), 17.8, 17.8 (Me); HRMS: [M+NH₄]⁺ calcd for C₂₂H₃₁F₆N₄O₇ 577.20914, found 577.20899.


to yield glycosylation product **1F** (10 mg, 18 μ mol, 18%, α : β = >20:1). *R*_f: 0.7 (9/1 pentane/EtOAc). [α]_D²³ = +182.1° (*c* = 0.52, CHCl₃); ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC, HMBC): δ 7.36 – 7.28 (m, 5H, CH_{arom}), 5.17 (d, 1H, *J* = 3.9 Hz, H-1), 4.58 (d, 1H, *J* = 12.0 Hz, CHH Bn), 4.54 (d, 1H, *J* = 12.0 Hz, CHH Bn), 4.44 (hept, 1H, *J* = 5.8 Hz, CH HFIP), 4.23 (dd, 1H, *J* = 11.1, 9.6 Hz, H-3), 4.02 (ddd, 1H, *J* = 10.0, 3.5, 2.0 Hz, H-5), 3.92 (t, 1H, *J* = 9.9 Hz, H-4), 3.78 (dd, 1H, *J* = 11.2, 3.5 Hz, H-6), 3.64 (dd, 1H, *J* = 11.1, 2.0 Hz, H-6), 3.46 (dd, 1H, *J* = 11.0, 3.9 Hz, H-2), 3.38 (s, 3H, CH₃ OMe), 3.20 (s, 3H, CH₃ OMe), 1.36 (s, 3H, CH₃ Me), 1.31 (s, 3H, CH₃ Me); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC, HMBC): δ 137.8 (C_q Bn), 128.5, 127.8, 127.6 (CH_{arom} Bn), 101.1 (C-1), 100.3, 100.2 (C_q BDA), 73.8 (CH₂ Bn), 73.3 (CH HFIP), 71.3 (C-5), 67.2 (C-6), 66.9 (C-3), 65.9 (C-4), 59.8 (C-2), 48.8, 48.3 (OMe), 17.8, 17.8 (Me); HRMS: [M+NH₄]⁺ calcd for C₂₂H₃₁F₆N₄O₇ 577.20914, found 577.20899.




Methyl 6-O-(2-azido-6-O-benzyl-2-deoxy-3,4-O-(2,3-dimethoxybutane-2,3-diy)- β -D-glucopyranosyl)-2,3,4-tri-O-benzyl- α -D-glucopyranoside (1G**).** Donor **1** and acceptor **10** were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (for an additional 18 hours at -40°C) and purified by flash column chromatography (19/1 to 3/1 pentane/EtOAc) to yield glycosylation product **1G** (74

mg, 86 μ mol, 86%, α : β = <1:20). *R*_f: 0.41 (4/1 pentane/EtOAc). [α]_D²⁰ = +54.9° (*c* = 1.85, CHCl₃); IR (thin film): 696, 735, 849, 962, 1107, 1134, 1369, 1454, 2108, 2907; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC, HMBC): δ 7.38 – 7.24 (m, 20H, CH_{arom}), 4.98 (d, 1H, *J* = 10.9 Hz, CHH Bn), 4.92 (d, 1H, *J* = 11.1 Hz, CHH Bn), 4.84 – 4.76 (m, 2H, CHH Bn, CHH Bn), 4.66 (d, 1H, *J* = 11.0 Hz, CHH Bn), 4.65 (d, 1H, *J* = 12.1 Hz, CHH Bn), 4.62 (d, 1H, *J* = 3.5 Hz, H-1), 4.58 (d, 1H, *J* = 12.1 Hz, CHH Bn), 4.53 (d, 1H, *J* = 12.2 Hz, CHH Bn), 4.20 (d, 1H, *J* = 7.7 Hz, H-1'), 4.12 (dd, 1H, *J* = 10.9, 1.6 Hz, H-6), 4.00 (t, 1H, *J* = 9.3 Hz, H-3), 3.83 – 3.77 (m, 1H, H-5), 3.76 – 3.63 (m, 4H, H-4', H-6, H-6', H-6'), 3.63 – 3.52 (m, 4H, H-2, H-3',


H-4, H-5'), 3.50 (dd, 1H, $J = 10.3, 7.7$ Hz, H-2'), 3.38 (s, 3H, CH₃ OMe), 3.30 (s, 3H, CH₃ OMe BDA), 3.16 (s, 3H, CH₃ OMe BDA), 1.33 (s, 3H, CH₃ Me), 1.26 (s, 3H, CH₃ Me); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC, HMBC): δ 138.8, 138.5, 138.3, 138.2 (C_q), 128.5, 128.5, 128.5, 128.4, 128.2, 128.2, 128.1, 128.0, 127.8, 127.8, 127.6, 127.6, 127.5 (CH_{arom}), 102.7 (C-1'), 100.1, 99.8 (C_q BDA), 98.2 (C-1), 82.2 (C-3), 79.9 (C-2), 77.7 (C-4), 75.8, 74.9 (CH₂ Bn), 74.3 (C-5), 73.6, 73.5 (CH₂ Bn), 71.3 (C-3'), 69.8 (C-5), 68.6 (C-6), 68.3 (C-6'), 66.2 (C-4'), 62.8 (C-2'), 55.3 (CH₃ OMe), 48.1, 48.1 (CH₃ OMe BDA), 17.7, 17.6 (CH₃ Me BDA); HRMS: [M+NH₄]⁺ calcd for C₄₇H₆₁N₄O₁₂ 873.42805, found 873.42812.




Methyl 4-O-(2-azido-6-O-benzyl-2-deoxy-3,4-O-(2,3-dimethoxybutane-2,3-diylo)- α/β -D-glucopyranosyl)-2,3,6-tri-O-benzyl- α -D-glucopyranoside (1H). Donor **1** and acceptor **11** were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (for an additional 18 hours at -40°C) and purified by flash column chromatography (19/1 to 4/1 pentane/EtOAc) to yield glycosylation product **1H** (80 mg, 93 μ mol, 93%, $\alpha:\beta = 1:15$). R_f: 0.51 (4/1 pentane/EtOAc). IR (thin film): 696, 737, 1045, 1109, 1134, 1368, 1454, 1497, 2108, 2900; Data for the β -anomer: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC, HMBC): δ 7.37 – 7.19 (m, 20H, CH_{arom}), 5.00 (d, 1H, $J = 11.4$ Hz, CHH Bn), 4.80 (d, 1H, $J = 11.4$ Hz, CHH Bn), 4.74 (d, 1H, $J = 12.2$ Hz, CHH Bn), 4.62 (d, 1H, $J = 12.0$ Hz, CHH Bn), 4.58 (d, 1H, $J = 12.1$ Hz, CHH Bn), 4.57 (d, 1H, $J = 3.8$ Hz, H-1), 4.52 (d, 1H, $J = 12.1$ Hz, CHH Bn), 4.48 (d, 1H, $J = 12.4$ Hz, CHH Bn), 4.35 (d, 1H, $J = 7.8$ Hz, H-1'), 4.33 (d, 1H, $J = 12.2$ Hz, CHH Bn), 4.00 – 3.94 (m, 1H, H-4), 3.91 (t, 1H, $J = 9.1$ Hz, H-3), 3.87 (dd, 1H, $J = 10.8, 3.3$ Hz, H-6), 3.81 – 3.76 (m, 1H, H-5), 3.71 (dd, 1H, $J = 10.8, 1.6$ Hz, H-6), 3.68 (t, 1H, $J = 9.6$ Hz, H-4'), 3.63 (dd, 1H, $J = 11.1, 1.4$ Hz, H-6'), 3.55 (t, 1H, $J = 10.0$ Hz, H-3'), 3.48 – 3.35 (m, 7H, CH₃ OMe, H-2, H-2', H-5', H-6'), 3.32 (s, 3H, CH₃ OMe BDA), 3.17 (s, 3H, CH₃ OMe BDA), 1.33 (s, 3H, CH₃ Me BDA), 1.26 (s, 3H, CH₃ Me BDA); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC, HMBC): δ 139.5, 138.6, 138.3, 137.9 (C_q), 128.6, 128.5, 128.4, 128.4, 128.3, 128.2, 128.2, 128.1, 127.8, 127.8, 127.8, 127.8, 127.6, 127.5, 127.4, 127.3, 127.1 (CH_{arom}), 101.3 (C-1'), 100.1, 99.8 (C_q BDA), 98.4 (C-1), 80.3 (C-3), 79.1 (C-2), 76.7 (C-4), 75.4 (CH₂ Bn), 74.3 (C-5'), 73.7, 73.5 (CH₂ Bn), 71.6 (C-3'), 69.8 (C-5), 68.4 (C-6), 68.1 (C-6'), 66.2 (C-4'), 63.5 (C-2'), 55.3 (OMe), 48.2, 48.1 (OMe BDA), 17.7, 17.6 (Me BDA); Diagnostic peaks α -anomer: ¹H NMR (CDCl₃, 400 MHz): δ 5.72 (d, 0.1H, $J = 4.1$ Hz, H-1'), 5.09 (d, 0.1H, $J = 10.5$ Hz, CHH Bn), 4.84 (d, 0.1H, $J = 10.5$ Hz, CHH Bn), 4.17 – 4.11 (m, 0.1H), 4.06 (d, 0.1H, $J = 9.1$ Hz); ¹³C-APT NMR (CDCl₃, 101 MHz): δ 100.0 (C_q BDA), 98.6 (C-1'), 97.7 (C-1), 82.0, 80.6, 75.1, 74.2, 73.3, 70.2, 60.0, 55.4, 48.6; HRMS: [M+NH₄]⁺ calcd for C₄₇H₆₁N₄O₁₂ 873.42805, found 873.42783.




Methyl (Methyl 4-O-[2-azido-6-O-benzyl-2-deoxy-3,4-O-(2,3-dimethoxybutane-2,3-diylo)- α/β -D-glucopyranosyl]-2,3-di-O-benzyl- α -D-glucopyranosyl uronate) (1I). Donor **1** and acceptor **12** were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (for an additional 18 hours at -40°C) and purified by flash column chromatography (19/1 to 4/1 pentane/EtOAc) to yield glycosylation product **1I** (66 mg, 83 μ mol, 83%, $\alpha:\beta = 1.5:1$). R_f: 0.44 and 0.47 (4/1 pentane/EtOAc). IR (thin film): 698, 735, 1043, 1107, 1454, 1749, 2108, 2949; Reported as a 1 : 0.7 mixture of anomers: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC, HMBC): δ 7.34 – 7.21 (m, 31H), 5.58 (d, 1H, $J = 3.8$ Hz, H-1'_a), 5.05 – 4.98 (m, 1.7H, CHH Bn_a, CHH Bn_β), 4.85 (d, 1H, $J = 10.5$ Hz, CHH Bn_a), 4.82 – 4.71 (m, 2.4H, CHH Bn_a, CHH Bn_β, CHH Bn_β), 4.62 – 4.53 (m, 4.4H, CHH Bn_a, CHH Bn_a CHH Bn_β, H-1_a, H-1_β), 4.50 (d, 1H, $J = 12.0$ Hz, CHH Bn_a), 4.43 (d, 0.7H, $J = 12.2$ Hz, CHH Bn_β), 4.38 (d, 0.7H, $J = 7.8$ Hz, H-1'_β), 4.34 (d, 0.7H, $J = 12.1$ Hz, CHH Bn_β), 4.23 (d, 0.7H, $J = 9.8$ Hz, H-5_β), 4.18 (d, 1H, $J = 9.4$ Hz, H-5_a), 4.13 (dd, 1H, $J = 10.9, 9.7$ Hz, H-3'_a), 4.08 – 4.00 (m, 2.7H, H-3_a, H-4_a, H-4_β), 3.93 (t, 0.7H, $J = 9.1$ Hz, H-3_β), 3.83 (t, 1H, $J = 10.0$ Hz, H-4'_a), 3.81 (s, 2.1H, CH₃ CO₂Me_β), 3.73 – 3.67 (m, 4.7H, CH₃ CO₂Me_a, H-4'_β, H-6'_a), 3.61 – 3.44 (m, 6.5H, H-2_a, H-2_β, H-3'_β, H-5'_a, H-5'_β, H-6'_a, H-6'_β, H-6'_β), 3.41 – 3.36 (m, 5.8H, CH₃ OMe_a, CH₃ OMe_β, H-2'_β), 3.35 (s, 3H, CH₃ OMe BDA_a), 3.30 – 3.26 (m, 3.1H, CH₃ OMe BDA_β, H-2'), 3.16 (s, 2.1H, CH₃ OMe BDA_β), 3.15 (s, 3H, CH₃ OMe BDA_a), 1.32 (s, 5.1H, CH₃ Me BDA_a, CH₃ Me BDA_β), 1.25 (s, 2.1H, CH₃ Me BDA_β), 1.23 (s, 3H, CH₃ Me BDA_a); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC, HMBC): δ 170.1, 169.9 (C=O), 139.3, 138.5, 138.4, 138.1, 138.1, 137.8 (C_q), 128.6, 128.5, 128.5, 128.4, 128.3, 128.3, 128.2, 128.0, 128.0, 128.0, 127.8, 127.7, 127.7, 127.6, 127.6, 127.5, 127.4, 127.4, 127.2 (CH_{arom}), 102.1 (C-1'_β), 100.1, 99.8, 99.8 (C_q BDA), 98.9 (C-1_β), 98.6 (C-1_a), 98.3 (C-1'_a), 81.3 (C-3_a), 79.8 (C-3_β), 79.6 (C-2_a), 79.0 (C-4_β), 78.6 (C-2_β), 75.5, 75.4 (CH₂ Bn), 74.9 (C-4_a), 74.4 (C-5'_β), 73.9, 73.8, 73.7, 73.5 (CH₂ Bn), 71.3 (C-3'_β), 70.1 (C-5_a), 70.0 (C-5'_a), 69.9 (C-5_β), 68.0 (C-6'_β), 67.4 (C-3'_a), 67.3 (C-6'_a), 66.0 (C-4'_β), 65.8 (C-4'_a), 63.4 (C-2'_a), 60.1 (C-2'_β), 55.9, 55.8 (OMe), 52.7, 52.7 (CO₂ Me), 48.4, 48.2, 48.1, 48.1 (OMe BDA), 17.9, 17.7, 17.7, 17.6 (Me BDA); HRMS: [M+NH₄]⁺ calcd for C₄₁H₅₅N₄O₁₃ 811.37601, found 811.37610.



Methyl 4-O-(2-azido-6-O-benzyl-2-deoxy-3,4-O-(2,3-dimethoxybutane-2,3-diyl)- α/β -D-glucopyranosyl)-2,3,6-tri-O-benzyl- β -D-galactopyranoside (11**).** Donor **1** and acceptor **13** were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (for an additional 18 hours at -40°C) and purified by flash column chromatography (19/1 to 4/1 pentane/EtOAc) to yield glycosylation product **11** (74 mg, 86 μ mol, 86%, $\alpha:\beta = 1:1.7$). *R_f*: 0.48 and 0.54 (4/1 pentane/EtOAc). IR (thin film): 696, 737, 1034, 1109, 1368, 1454, 2108, 2930; Reported as a 1 : 1.5 mixture of anomers: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC, HMBC): δ 7.42 – 7.19 (m, 50H, CH_{arom}), 4.99 (d, 1H, *J* = 3.9 Hz, H-1'_a), 4.90 (d, 1H, *J* = 10.9 Hz, CHH Bn_a), 4.90 – 4.83 (m, 3H, 2xCHH Bn_β), 4.79 (d, 1H, *J* = 10.9 Hz, CHH Bn_a), 4.75 – 4.71 (m, 4H, CHH Bn_β, CHH Bn_a, H-1'_β), 4.66 (d, 1.5H, *J* = 12.2 Hz, CHH Bn_β), 4.62 (d, 1H, *J* = 12.5 Hz, CHH Bn_a), 4.53 (s, 2H, CH₂ Bn_a), 4.49 (s, 3H, CH₂ Bn_β), 4.48 – 4.40 (m, 4H, CH₂ Bn_β, CHH Bn_a), 4.32 (d, 1H, *J* = 12.2 Hz, CHH Bn_a), 4.28 (d, 1.5H, *J* = 7.8 Hz, H-1_β), 4.27 – 4.21 (m, 2H, H-3'_α, H-5'_α), 4.23 (d, 1H, *J* = 7.6 Hz, H-1_α), 4.14 (d, 1H, *J* = 3.0 Hz, H-4_α), 4.09 (d, 1.5H, *J* = 2.6 Hz, H-4_β), 3.98 – 3.87 (m, 3.5H, H-2_β, H-4'_α, H-6_α), 3.82 (dd, 1.5H, *J* = 10.5, 4.7 Hz, H-6'_β), 3.75 – 3.55 (m, 14H, CH₃ OMe_β, H-2_α, H-4'_β, H-5'_β, H-6'_β, H-6_α, H-6_β, H-6_β), 3.54 – 3.40 (m, 11H, CH₃ OMe_α, H-2'_β, H-3_β, H-3'_β, H-5_α, H-5_β, H-6'_α), 3.40 – 3.33 (m, 5H, CH₃ OMe BDA_α, H-2'_α, H-3_α), 3.31 (s, 4.5H, CH₃ OMe BDA_β), 3.18 – 3.10 (m, 8.5H, CH₃ OMe BDA_{α,β}, H-6'_α), 1.34 (s, 3H, CH₃ Me BDA_α), 1.34 (s, 4.5H, CH₃ Me BDA_β), 1.29 (s, 3H, CH₃ Me BDA_α), 1.27 (s, 4.5H, CH₃ Me BDA_β); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC, HMBC): δ 138.9, 138.8, 138.6, 138.5, 138.3, 138.2, 137.6 (C_q), 128.6, 128.4, 128.4, 128.4, 128.3, 128.3, 128.2, 128.2, 128.2, 128.1, 127.6, 127.6, 127.6, 127.6, 127.5, 127.5, 127.5, 127.3, 127.2 (CH_{arom}), 105.3 (C-1_α), 105.1 (C-1_β), 102.5 (C-1'_β), 100.1, 100.0, 99.9, 99.8 (C_q BDA), 99.4 (C-1'_α), 81.3 (C-3_β), 80.2 (C-3_α), 79.5 (C-2_β), 79.0 (C-2_α), 75.2, 75.0 (CH₂ Bn), 74.1 (C-4_α), 73.9 (C-5'_β), 73.9 (C-5_β), 73.7 (CH₂ Bn), 73.6 (C-4_β), 73.6, 73.6, 73.5, 73.4 (CH₂ Bn), 73.0 (C-5_α), 72.9 (CH₂ Bn), 70.7 (C-3'_β), 70.3 (C-6'_β), 69.5 (C-5'_α), 68.5 (C-6_β), 68.0 (C-3'_α), 67.2, 67.1 (C-6_α, C-6'_α), 66.2 (C-4'_β), 66.0 (C-4'_α), 62.7 (C-2'_β), 60.9 (C-2'_α), 57.3, 57.2 (OMe), 48.7, 48.2, 48.1, 48.1 (OMe BDA), 17.9, 17.9, 17.7, 17.7 (Me BDA); HRMS: [M+NH₄]⁺ calcd for C₄₇H₆₁N₄O₁₂ 873.42805, found 873.42801.




Methyl 2-O-(2-azido-6-O-benzyl-2-deoxy-3,4-O-(2,3-dimethoxybutane-2,3-diyl)- α/β -D-glucopyranosyl)-3-O-benzyl-4,6-O-benzylidene- α -D-mannopyranoside (1K**).** Donor **1** and acceptor **14** were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (for an additional 18 hours at -40°C) and purified by flash column chromatography (19/1 to 4/1 pentane/EtOAc) to yield glycosylation product **1K** (71 mg, 93 μ mol, 93%, $\alpha:\beta = 1:1.7$). *R_f*: 0.45 (4/1 pentane/EtOAc). IR (thin film): 698, 1038, 1109, 1126, 1375, 1454, 2110, 2912; Data for the β -anomer: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC, HMBC): δ 7.52 – 7.47 (m, 2H, CH_{arom}), 7.40 – 7.32 (m, 3H, CH_{arom}), 7.30 – 7.19 (m, 10H, CH_{arom}), 5.60 (s, 1H, CHPh), 4.86 – 4.78 (m, 2H, CHH Bn, H-1), 4.64 (d, 1H, *J* = 12.5 Hz, CHH Bn), 4.54 (d, 1H, *J* = 12.0 Hz, CHH Bn), 4.49 (d, 1H, *J* = 11.9 Hz, CHH Bn), 4.41 (d, 1H, *J* = 7.3 Hz, H-1'), 4.29 (dd, 1H, *J* = 3.3, 1.5 Hz, H-2), 4.24 (dd, 1H, *J* = 10.0, 4.6 Hz, H-6), 4.16 (t, 1H, *J* = 9.7 Hz, H-4), 3.93 (dd, 1H, *J* = 10.1, 3.4 Hz, H-3), 3.86 (t, 1H, *J* = 10.2 Hz, H-6), 3.82 – 3.61 (m, 6H, H-2', H-4', H-5, H-5', H-6', H-6'), 3.57 (dd, 1H, *J* = 10.8, 7.9 Hz, H-3'), 3.37 (s, 3H, CH₃ OMe), 3.30 (s, 3H, CH₃ OMe BDA), 3.18 (s, 3H, CH₃ OMe BDA), 1.34 (s, 3H, CH₃ Me BDA), 1.28 (s, 3H, CH₃ Me BDA); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC, HMBC): δ 138.5, 138.1, 137.8 (C_q), 128.4, 128.3, 128.2, 127.8, 127.6, 127.4, 127.3, 126.2, 126.2 (CH_{arom}), 101.6 (CHPh), 101.4 (C-1'), 100.0, 99.8 (C_q BDA), 99.3 (C-1), 78.1 (C-4), 74.7 (C-2), 74.4 (C-5'), 73.8 (CH₂ Bn), 73.7 (C-3), 71.0 (CH₂ Bn), 70.5 (C-3'), 68.9, 68.8 (C-6, C-6'), 66.4 (C-4'), 64.2 (C-5), 63.0 (C-2'), 55.0 (OMe), 48.1 (OMe BDA), 17.7, 17.7 (Me BDA); Data for the α -anomer: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC, HMBC): δ 7.51 – 7.43 (m, 2H, CH_{arom}), 7.40 – 7.23 (m, 13H, CH_{arom}), 5.62 (s, 1H, CHPh), 5.35 (d, 1H, *J* = 3.8 Hz, H-1'), 4.88 (d, 1H, *J* = 12.4 Hz, CHH Bn), 4.75 (d, 1H, *J* = 1.3 Hz, H-1), 4.69 (d, 1H, *J* = 12.4 Hz, CHH Bn), 4.57 (s, 2H, CH₂ Bn), 4.32 (dd, 1H, *J* = 10.9, 9.6 Hz, H-3'), 4.30 – 4.22 (m, 2H, H-4, H-6), 4.10 (dd, 1H, *J* = 3.0, 1.7 Hz, H-2), 4.03 (ddd, *J* = 10.2, 5.0, 1.7 Hz, 1H, H-5'), 3.96 (dd, 1H, *J* = 9.9, 3.1 Hz, H-3), 3.85 (t, 1H, *J* = 10.2 Hz, H-6), 3.80 – 3.66 (m, 4H, H-4', H-5, H-6', H-6'), 3.42 (s, 3H, CH₃ OMe BDA), 3.25 – 3.17 (m, 7H, CH₃ OMe BDA, CH₃ OMe, H-2'), 1.36 (s, 3H, CH₃ Me BDA), 1.32 (s, 3H, CH₃ Me BDA); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC, HMBC): δ 138.8, 138.0, 137.8 (C_q), 128.9, 128.8, 128.3, 128.2, 127.7, 127.7, 127.6, 127.4, 126.2 (CH_{arom}), 101.6 (CHPh), 100.9 (C-1), 100.2 (C-1'), 100.1, 100.0 (C_q BDA), 79.5 (C-4), 76.1 (C-2), 75.5 (C-3), 73.7, 73.1 (CH₂ Bn), 70.0 (C-5'), 69.0 (C-6), 68.2 (C-6'), 66.9 (C-4'), 66.5 (C-3'), 63.9 (C-5), 60.1 (C-2'), 54.8 (OMe), 48.7, 48.2 (OMe BDA), 17.9, 17.8 (Me BDA); HRMS: [M+NH₄]⁺ calcd for C₄₀H₅₃N₄O₁₂ 781.36545, found 781.36550.



Trifluoromethanesulfonyl 2-azido-6-O-benzyl-2-deoxy-3,4-O-(2,3-dimethoxybutane-2,3-diyl)- α -D-glucopyranoside (18**).** ¹H NMR (CD₂Cl₂, *T* = 243 K, 500 MHz, HH-COSY, HSQC): δ 6.10 (d, 1H, *J* = 3.3 Hz, H-1), 4.52 (d, 1H, *J* = 11.5 Hz, CHH Bn), 4.48 (d, 1H, *J* = 11.3 Hz, CHH Bn), 4.19 (t, 1H, *J* = 10.2 Hz, H-3), 4.07 (d, 1H, *J* = 10.4 Hz, H-5), 4.01 (t, 1H, *J* = 9.9 Hz, H-4), 3.87 (dd, 1H, *J* = 10.8, 3.5 Hz, H-2), 3.79 (dd, 1H, *J* = 11.1, 2.3 Hz, H-6), 3.67 (d, 1H, *J* = 11.1 Hz, H-6), 3.30 (s, 3H, CH₃ OMe), 3.19 (s, 3H, CH₃ OMe),

1.30 (s, 3H, CH₃ Me), 1.25 (s, 3H, CH₃ Me); ¹³C-APT NMR (CD₂Cl₂, 126 MHz, HSQC): δ 105.8 (C-1), 99.8, 99.6 (C_q BDA), 73.2 (C-5), 72.9 (CH₂ Bn), 67.5 (C-3), 65.9 (C-6), 63.6 (C-4), 58.6 (C-2), 48.3, 48.1 (OMe), 17.3, 17.2 (Me).



1-(2-azido-6-O-benzyl-2-deoxy-3,4-O-[2,3-dimethoxybutane-2,3-diy]- α -D-glucopyranosyl)-2-azido-6-O-benzyl-2-deoxy-3,4-O-[2,3-dimethoxybutane-2,3-diy]- β -D-glucopyranoside (24). IR (thin film): 698, 737, 883, 1032, 1107, 1134, 1263, 1279, 1375, 1454, 2108, 2926, 2947, 2994; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.36 – 7.21 (m, 10H, CH_{arom}), 5.20 (d, 1H, *J* = 3.6 Hz, H-1'), 4.53 – 4.46 (m, 2H, CH₂ Bn), 4.44 – 4.38 (m, 2H, CHH Bn, H-1), 4.35 – 4.28 (m, 2H, CHH Bn, H-3'), 4.23 (dt, 1H, *J* = 10.7, 2.4 Hz, H-5'), 3.93 (t, 1H, *J* = 10.0 Hz, H-4'), 3.74 – 3.52 (m, 8H, H-2, H-3, H-4, H-5, 2xH-6, 2xH-6'), 3.39 (dd, 1H, *J* = 7.3, 3.5 Hz, H-2'), 3.37 (s, 3H, CH₃ OMe), 3.32 (s, 3H, CH₃ OMe), 3.21 (s, 3H, CH₃ OMe), 3.16 (s, 3H, CH₃ OMe), 1.35 (s, 3H, CH₃ Me), 1.34 (s, 3H, CH₃ Me), 1.29 (s, 3H, CH₃ Me), 1.28 (s, 3H, CH₃ Me); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 138.3, 138.2 (C_q Bn), 128.5, 128.3, 127.7, 127.6 (CH_{arom}), 102.0 (C-1), 100.3, 100.2, 100.0, 99.9 (C_q BDA), 99.8 (C-1'), 74.4 (C-5), 73.6, 73.5 (CH₂ Bn), 71.6 (C-3), 70.6 (C-5'), 68.3 (C-6), 67.5 (C-3'), 67.4 (C-6'), 66.0 (C-4'), 65.9 (C-4), 63.3 (C-2), 60.1 (C-2'), 48.7, 48.2, 48.2, 48.2 (OMe), 17.9, 17.8, 17.8, 17.7 (Me); HRMS: [M+NH₄]⁺ calcd for C₃₈H₅₆N₄O₁₃ 818.39306, found 818.39310.

References and footnotes

- (1) Griffiths, A. J.; Davies, D. B. *Carbohydr. Polym.* **1991**, *14* (4), 339–365.
- (2) Griffiths, A. J.; Davies, D. B. *Carbohydr. Polym.* **1991**, *14* (3), 241–279.
- (3) Demchenko, A. V. *Handbook of Chemical Glycosylation: Advances in Stereoselectivity and Therapeutic Relevance*; Wiley-VCH Verlag GmbH & Co. KGaA, 2008.
- (4) Boltje, T. J.; Buskas, T.; Boons, G.-J. *Nat. Chem.* **2009**, *1* (8), 611–622.
- (5) Varki, A. *Glycobiology* **1993**, *3* (2), 97–130.
- (6) Bongat, A. F. G.; Demchenko, A. V. *Carbohydr. Res.* **2007**, *342* (3–4), 374–406.
- (7) Nigudkar, S. S.; Demchenko, A. V. *Chem. Sci.* **2015**, *6* (5), 2687–2704.
- (8) Enugala, R.; Carvalho, L. C. R.; Dias Pires, M. J.; Marques, M. M. B. *Chem. – Asian J.* **2012**, *7* (11), 2482–2501.
- (9) Manabe, S.; Ito, Y. *Chem. Rec.* **2014**, *14* (3), 502–515.
- (10) Benakli, K.; Zha, C.; Kerns, R. J. *J. Am. Chem. Soc.* **2001**, *123* (38), 9461–9462.
- (11) Boysen, M.; Gemma, E.; Lahmann, M.; Oscarson, S. *Chem. Commun.* **2005**, *0* (24), 3044–3046.
- (12) Geng, Y.; Zhang, L.-H.; Ye, X.-S. *Tetrahedron* **2008**, *64* (22), 4949–4958.
- (13) Hense, A.; Ley, S. V.; Osborn, H. M. I.; Owen, D. R.; Poisson, J.-F.; Warriner, S. L.; Wesson, K. E. *J. Chem. Soc. [Perkin 1]* **1997**, *0* (14), 2023–2032.
- (14) Montchamp, J.-L.; Tian, F.; Hart, M. E.; Frost, J. W. *J. Org. Chem.* **1996**, *61* (11), 3897–3899.
- (15) Douglas, N. L.; Ley, S. V.; Osborn, H. M. I.; Owen, D. R.; Priepeke, H. W. M.; Warriner, S. L. *Synlett* **1996**, *1996* (08), 793–795.
- (16) Fraser-Reid, B.; Wu, Z.; Andrews, C. W.; Skowronski, E.; Bowen, J. P. *J. Am. Chem. Soc.* **1991**, *113* (4), 1434–1435.
- (17) Andrews, C. W.; Rodebaugh, R.; Fraser-Reid, B. *J. Org. Chem.* **1996**, *61* (16), 5280–5289.
- (18) Jensen, H. H.; Nordstrøm, L. U.; Bols, M. *J. Am. Chem. Soc.* **2004**, *126* (30), 9205–9213.
- (19) Frihed, T. G.; Walvoort, M. T. C.; Codée, J. D. C.; van der Marel, G. A.; Bols, M.; Pedersen, C. M. *J. Org. Chem.* **2013**, *78* (6), 2191–2205.
- (20) Moumé-Pymbock, M.; Furukawa, T.; Mondal, S.; Crich, D. *J. Am. Chem. Soc.* **2013**, *135* (38), 14249–14255.
- (21) Crich, D.; Cai, W.; Dai, Z. *J. Org. Chem.* **2000**, *65* (5), 1291–1297.
- (22) Crich, D.; Subramanian, V.; Hutton, T. K. *Tetrahedron* **2007**, *63* (23), 5042–5049.
- (23) Goddard-Borger, E. D.; Stick, R. V. *Org. Lett.* **2007**, *9* (19), 3797–3800.
- (24) Frihed, T. G.; Bols, M.; Pedersen, C. M. *Chem. Rev.* **2015**, *115* (11), 4963–5013.
- (25) Codée, J. D. C.; Litjens, R. E. J. N.; den Heeten, R.; Overkleef, H. S.; van Boom, J. H.; van der Marel, G. A. *Org. Lett.* **2003**, *5* (9), 1519–1522.
- (26) Douglas, N. L.; Ley, S. V.; Lücking, U.; Warriner, S. L. *J. Chem. Soc. [Perkin 1]* **1998**, No. 1, 51–66.
- (27) Boons, G.-J.; Grice, P.; Leslie, R.; Ley, S. V.; Yeung, L. L. *Tetrahedron Lett.* **1993**, *34* (52), 8523–8526.

- (29) Crich, D.; Smith, M.; Yao, Q.; Picione, J. *Synthesis* **2001**, 2001 (02), 0323–0326.
- (30) Subramanian, V.; Moumé-Pymbock, M.; Hu, T.; Crich, D. *J. Org. Chem.* **2011**, 76 (10), 3691–3709.

Chapter 6

Mapping glycosylation stereoselectivity by acceptor reactivity tuning


Introduction

The union of two carbohydrates to generate larger oligosaccharides is arguably one of the most important reactions in glycochemistry.^{1–4} Although the glycosylation reaction has been actively studied for more than half a century, many aspects that affect this reaction, both in terms of yield and stereoselectivity, remain enigmatic.^{5–10} The reactivity of the carbohydrate building blocks is one of the most important determinants that influence the outcome of a glycosylation reaction.^{11,12} The reactivity of donor glycosides has been very well documented: the relative reactivity value (RRV) of hundreds of thioglycosides has been established and hundreds of anomeric triflates and other covalent reactive species, key reactive intermediates formed *in situ* during the reaction, have been characterized.^{13–18} The reactivity of acceptor glycosides is less well understood and systematic studies investigating this important reaction parameter are extremely scarce.^{19–24} At the same time, it is common practice to change protecting groups on the acceptor building block to influence the yield or change the stereoselectivity of a

glycosylation reaction.^{25–28} Often this is done in a time consuming, trial-and-error manner as well defined guidelines how to tune the reactivity of an acceptor and how this effects the glycosylation reaction are absent.^{29–31}

In Chapters 3 and 4 of this thesis the profound influence acceptor nucleophilicity has on the stereoselectivity of glycosylation reactions with 4,6-*O*-benzylidene protected glucose and glucosamine donors was demonstrated.^{32,33} In these studies a panel of partially fluorinated ethanols (ethanol, mono-, di- and trifluoroethanol) was used to reveal a donor's stereoselectivity dependency on acceptor nucleophilicity and described the change in the underlying continuum of mechanisms (Scheme 1).^{21,34,35} An intimate relation between model acceptor reactivity and glycosylation stereoselectivity was evident. Whereas some donors are highly sensitive towards acceptor reactivity, other donors are more reluctant to changes in stereochemical outcome. They all have in common that eventually the poorest of *O*-nucleophiles lead them to converge to α -selectivity. These results have been explained by stereoelectronic properties of both the donor and acceptor molecules. In a general sense, the strongest acceptors are able to substitute an anomeric leaving group (α -triflate) in an S_N2 -like substitution reaction. Somewhat weaker acceptors preferentially react with the more reactive β -triflate, and upon reducing acceptor reactivity further the mechanism shifts towards the S_N1 -side of the reactivity spectrum as increasingly stronger electrophiles are required.











Scheme 1. General glycosylation mechanism, with distinct oxocarbenium ion conformations for the solvent-separated ion pairs. P = protecting group.



Results and discussion

Among the various donors evaluated in Chapters 3-5, the benzylidene glucose (**A**) and glucosazide donors (**B**) were identified to be the most susceptible to acceptor reactivity, based on the stereochemical results of the fluorinated ethanol model system and a few carbohydrate acceptors (See Table 1). An extension of the set of carbohydrate acceptors was envisioned, bearing protecting groups differing in electron-withdrawing properties to closely follow the trend set by the model nucleophiles, determined by the stereoselectivities in glycosylations with donors **A** and **B**. Simultaneously, the variety of acceptors can provide an accurate scale of relative acceptor reactivities to which any desired acceptor can be set against and reveal its potential stereoselectivity in glycosylation.

Table 1. Glycosylations of donor **A** and **B** with fluorinated model acceptors and carbohydrate acceptors **1-4**.

					
Acceptor	Product ^a α:β (yield)	Product α:β (yield)	Acceptor	Product α:β (yield)	Product α:β (yield)
	1 : 10 (68%)	<1 : 20 (83%)	 1	1A 1 : 1 (82%)	1B 1 : 7 (88%)
	1 : 2.8 (70%)	1 : 6.7 (90%)	 2	2A 2 : 1 (85%)	2B 1 : 5 (69%)
	5 : 1 (70%)	2.9 : 1 (64%)	 3	3A 4 : 1 (92%)	3B 1 : 1.1 (67%)
	>20 : 1 (64%)	>20 : 1 (94%)	 4	4A 5 : 1 (90%)	4B 1.1 : 1 (93%)

^aRatios and yields of the isolated product after SiO₂ and LH-20 size-exclusion chromatography, anomers were not separated. Ratios were determined by integration of representative signals for each anomer in the mixture of anomers.

To keep steric and other structural effects to a minimum for comparison throughout the scope of acceptors, the primary focus was laid on a diverse set of C-4-OH glucoside acceptors (Figure 1, 1-20). The other alcohol functions are protected as either *O*-benzyl or *O*-benzoyl groups, and in addition to these two groups, the primary alcohol is also either reduced or oxidized to give C-6-deoxy and C-6-CO₂Me species respectively to provide for a difference in electron-withdrawing properties. The glycosylation method used throughout this study is based on preactivation of donors **A** and **B** in DCM with the Ph₂SO/Tf₂O activation couple in the presence of hindered weak base TTBP at -80°C^{36,37}, followed by addition of a solution of the acceptor. Applying this protocol, the generation of an equilibrium of reactive species (Scheme 1) is ensured, enabling the rationalization of the stereoselectivity in terms of the set of reactive species, and furthermore avoids competitive alternative pathways present in the *in situ* activation scenarios (direct substitution of the activation thioglycoside, its ion pair or the first formed oxocarbenium ion conformer contribute to an increased complexity of the reaction mechanism).
























Figure 1. Donors and gluco C-4-OH acceptors used in this chapter.

In Table 1 results previously obtained with the fluorinated model alcohols are directly compared with glycosylation results of 2,3-di-*O*-benzyl acceptors **1-4**. A clear transition from β- to α-selectivity, following the electron-withdrawing tendency of the protecting group at the C-6 position, arises. The uronic acid having its electron-withdrawing carbonyl function closer to the acceptor's nucleophilic center than the 6-*O*-benzoyl has, is more α-directing than the latter, which in turn gives higher α-selectivity than the 6-*O*-benzyl. Changing the configuration of the remote anomeric position of the acceptor to a β-glucoside (**17-20**), or protecting the C-2 position with a benzoyl (**5-8**) rather than a benzyl has no apparent effect on the glycosylation stereoselectivities (Table 2).³⁸⁻⁴¹ However, the C-3 position has a dramatic effect on the stereoselectivity; complete

Table 2. Glycosylations of donor **A** and **B** with β -acceptors **17-20** and α -acceptors bearing a benzoyl on C-2 (**5-8**), C-3 (**9-12**), or both (**13-16**).







					
Acceptor	Product $\alpha:\beta$ (yield)	Product $\alpha:\beta$ (yield)	Acceptor	Product $\alpha:\beta$ (yield)	Product $\alpha:\beta$ (yield)
	17A 1 : 1 (79%)	17B 1 : 7 (80%)		5A 1 : 1.1 (81%)	5B 1 : 6 (88%)
	18A 1.1 : 1 (87%)	18B 1 : 5.6 (86%)		6A 1.1 : 1 (86%)	6B 1 : 5 (88%)
	19A 3.3 : 1 (73%)	19B 1 : 1.2 (70%)		7A 3.5 : 1 (88%)	7B 1.3 : 1 (87%)
	20A 5 : 1 (83%)	20B 1.2 : 1 (85%)		8A 4.8 : 1 (96%)	8B 1.2 : 1 (82%)
	9A >20 : 1 (95%)	9B 6.7 : 1 (77%)		13A >20 : 1 (90%)	13B 10 : 1 (93%)
	10A >20 : 1 (93%)	10B 14 : 1 (81%)		14A >20 : 1 (83%)	14B >20 : 1 (96%)
	11A >20 : 1 (95%)	11B >20 : 1 (85%)		15A >20 : 1 (91%)	15B >20 : 1 (69%)
	12A >20 : 1 (86%)	12B >20 : 1 (93%)		16A >20 : 1 (84%)	16B >20 : 1 (99%)
	21A 1 : 2.7 (90%)	21B <1 : 20 (93%)		22A 3 : 1 (86%)	22B 1 : 1.5 (95%)

α -selectivity is found only by changing the C-3-OBn group to a C-3-OBz group (Table 2, **9-12**). Even the more β -selective donor **B** reacts with high to complete α -selectivity with the C-3-OBz acceptors (**9-16**). Only exchanging the two C-H bonds for a C=O bond, by replacing a benzyl ether for a benzoyl ester, a marked change in stereoselectivity is achieved. This effect is most pronounced at the nearby C-3 position, whereas position C-6 offers slight fine-tuning of the acceptor reactivity, and position C-2 has only a negligible influence.⁴²

The concept of reactivity tuning of the acceptors works consistently well for C-4-OH *gluco*-configured acceptors. The more reactive primary acceptors **21** and **22** (Table 2) showed similar behavior and upon benzylation significantly more α -product is obtained, however the C-6 nucleophilic position remains too reactive to give complete α -selectivity.

To examine the extent of influence the protecting group on the C-6 position exerts, more electronegative elements were introduced on the benzoyl aromatic ring (Table 3, **23-26**).⁴³ A series of mono-nitrobenzoyl esters were found to marginally increase α -selectivity, but acceptor **26** bearing a 2,6-dinitrobenzoyl group enhanced α -selectivity even more than the uronic acid acceptor **4**.⁴⁴

Table 3. Glycosylations of donor **A** and **B** with acceptor **23-26** bearing electron-withdrawing C-6 benzoates.

 A		 A	
Acceptor	Product α : β (yield)	Acceptor	Product α : β (yield)
 23	23A 3 : 1 (92%)	 25	25A 3.5 : 1 (83%)
 24	24A 3.3 : 1 (49%)	 26	26A 5.6 : 1 (83%)

Conclusions

The translation from a set of fluorinated model nucleophiles providing a reactivity-selectivity glycosylation picture, to a selection of carbohydrate acceptors occurs without difficulty. These carbohydrate acceptors can be tuned in reactivity just like donors have been in the past by manipulation of their protecting groups, and their reactivity exploited in obtaining stereoselectivity in glycosylations. Everyday protecting- and functional groups were successfully used to moderate the reactivity of the glycosyl acceptors. The most electron-withdrawing groups turned the acceptor into a poor nucleophile and steered the glycosylation utilizing these acceptors to the α -product. The concept of acceptor reactivity tuning holds for all the example acceptors displayed in this chapter. By using this panel of reference acceptors and the two model donors, any other relevant acceptor can have its reactivity compared with the current set of acceptors and appropriately adjusted for the desired reactivity and functional group pattern.

Experimental section

General experimental procedures:

A: reductive opening benzylidene acetal. The benzylidene protected compound (1 eq.) was coevaporated with dry toluene (2x) and dissolved at r.t. in dry THF (0.07 M). NaCNBH₃ (5 eq.) was added followed by drop-wise addition of a 4 M HCl solution in 1,4-dioxane (5.2 eq. pH<4). After stirring for an additional hour, the reaction was quenched by the addition of ice water (40 mL/mmol) and extracted with DCM (2x 15 mL/mmol). The combined organic layers were washed with sat.aq. NaHCO₃ and sat.aq. NaCl. The organic fraction was dried (MgSO₄), filtered, concentrated *in vacuo*, and purified by column chromatography (pentane/EtOAc mixtures).


B: iodination-deoxygenation. To a 0°C solution of the diol (1 eq.) in pyridine (0.2 M) was added *p*-TsCl (1.5 eq.) and the reaction stirred until completion (TLC, 3-14 h). MeOH was added (1 mL/mmol), and the reaction mixture diluted with Et₂O (15 mL/mmol). The organic layer was washed with 5 M aq. HCl (3x), H₂O, sat.aq. NaHCO₃, and sat.aq. NaCl. The organic fraction was dried (MgSO₄), filtered and concentrated *in vacuo*. The crude compound was dissolved in butanone (0.2 M) and NaI (2 eq.) was added. The reaction mixture was heated for 3h at 80°C after which it was diluted with EtOAc and washed with 10% aq. Na₂S₂O₃ and H₂O. The organic fraction was dried (MgSO₄), filtered, concentrated *in vacuo*, and purified by column chromatography (pentane/EtOAc mixtures). The intermediate iodo compound (1 eq.) was coevaporated with dry toluene and dissolved in toluene (0.07 M) under a nitrogen atmosphere. AIBN (0.05 eq.) and Bu₃SnH (2 eq.) were added and the reaction refluxed (120°C) for 3-7 h. The cooled solution was diluted with EtOAc and washed with H₂O and sat.aq. NaCl. The organic fraction was dried (MgSO₄), filtered, concentrated *in vacuo*, and purified by column chromatography (pentane/EtOAc mixtures).

C: regioselective benzoylation. To a 0°C solution of the diol (1 eq.) in DCM (0.35 M) was added pyridine (5 eq.) followed by a solution of benzoyl chloride (1.05 eq.) in DCM (1.6 M), slowly added over 15 min. After stirring overnight, the reaction mixture was diluted with DCM, washed with 1 M HCl (2x), H₂O and sat.aq. NaHCO₃. The organic fraction was dried (MgSO₄), filtered, concentrated *in vacuo*, and purified by column chromatography (pentane/EtOAc mixtures).


D: regioselective oxidation. To a 0°C solution of the diol (1 eq.) in DCM/H₂O (5/1, v/v, 0.20 M) was added (diacetoxy)iodobenzene (2.5 eq.) and TEMPO (0.2 eq.). The mixture was vigorously stirred for 2-5 h, and quenched by the addition of 10% aq. Na₂S₂O₃. The reaction mixture was extracted twice with DCM. The water layer was acidified (pH 1) with 1 M aq. HCl and extracted once with DCM. The combined organic layers were washed with H₂O, then dried (MgSO₄), filtered, and concentrated *in vacuo*. The crude carboxylic acid was coevaporated twice with dry toluene and dissolved in DMF (0.35 M). MeI (2 eq.) and K₂CO₃ (2 eq.) were added and stirred for 3 h. The reaction was quenched with AcOH (3 eq.), and diluted with H₂O. The mixture was extracted thrice with EtOAc, and the combined organic layers were washed with H₂O and sat.aq. NaCl. The organic fraction was dried (MgSO₄), filtered, concentrated *in vacuo*, and purified by column chromatography (pentane/EtOAc mixtures).


E: Tf₂O/Ph₂SO mediated pre-activation glycosylation. Donor (0.1 mmol), Ph₂SO (26 mg, 0.13 mmol, 1.3 equiv), and *tert*-butylpyrimidine (TTBP) (62 mg, 0.25 mmol, 2.5 equiv) were coevaporated twice with dry toluene and dissolved in dry DCM (2 mL, 0.05 M donor). Activated 3 Å molecular sieves (rods, 1 /16 in. in size) were added, and the reaction mixture was stirred for 1 h at room temperature under a nitrogen atmosphere. The solution was cooled to -78 °C, and Tf₂O (22 µL, 0.13 mmol, 1.3 equiv) was added. The reaction mixture was allowed to warm to -60 °C and then re-cooled to -78 °C, after which the acceptor (0.2 mmol, 2 equiv) in DCM (0.4 mL, 0.5 M) was added. The reaction mixture was allowed to warm to -40 °C in approximately 90 min and stirred overnight at that temperature. The reaction was quenched with Et₃N (0.1 mL, 0.72 mmol, 5.5 equiv) at -40 °C, and the mixture was diluted with DCM. The solution was transferred to a separatory funnel, water was added, the layers were separated, and the water phase was extracted once more with DCM. The combined organic layers were dried over MgSO₄, filtered, and concentrated *in vacuo*. Purification by silica gel flash column chromatography and sephadex LH-20 size-exclusion chromatography yielded the glycosylation product as a mixture of anomers.


Scheme S1: Synthesis of all C-4-OH acceptors.^{a,b}




^aAcceptors **17-20** follow the same four procedures from the corresponding β -methyl glycoside, acceptors **23-25** follow procedure C with the appropriate nitrobenzoyl chloride. ^bAcceptor **2** was made via an alternative route.


 **Methyl 2,3,6-tri-O-benzyl- α -D-glucopyranoside (1).** Methyl 2,3-di-O-benzyl-4,6-O-benzylidene- α -D-glucopyranoside³² (4.67 g, 10 mmol) was converted to the title compound **1** following general procedure **A**. Yield: 3.5 g, 7.5 mmol, 75%. R_r 0.20 (9/1 pentane/EtOAc). Spectroscopic data were in accord with those previously reported.³² ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.40 – 7.24 (m, 15H, CH_{arom}), 5.00 (d, 1H, *J* = 11.4 Hz, *CHH* Bn), 4.77 (d, 1H, *J* = 12.1 Hz, *CHH* Bn), 4.73 (d, 1H, *J* = 11.4 Hz, *CHH* Bn), 4.66 (d, 1H, *J* = 12.1 Hz, *CHH* Bn), 4.63 (s, 1H, H-1), 4.59 (d, 1H, *J* = 12.2 Hz, *CHH* Bn), 4.54 (d, 1H, *J* = 12.2 Hz, *CHH* Bn), 3.78 (t, 1H, *J* = 9.1 Hz, H-3), 3.74 – 3.64 (m, 3H, H-5, H-6), 3.60 (td, 1H, *J* = 9.1, 2.3 Hz, H-4), 3.53 (dd, 1H, *J* = 9.5, 3.5 Hz, H-2), 3.38 (s, 3H, CH₃ OMe); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 138.9, 138.2 (C_q), 128.7, 128.6, 128.6, 128.5, 128.3, 128.3, 128.1, 128.1, 128.0, 127.8, 127.8 (CH_{arom}), 98.3 (C-1), 81.6 (C-3), 79.7 (C-2), 75.6, 73.7, 73.3 (CH₂ Bn), 70.9 (C-4), 70.0 (C-5), 69.6 (C-6), 55.4 (OMe).

 **Methyl 2,3-di-O-benzyl-6-deoxy- α -D-glucopyranoside (2).** Methyl 2,3-di-O-benzyl- α -D-glucopyranoside³² (581 mg, 1.5 mmol) and *p*-TsCl (343 mg, 1.8 mmol, 1.2 eq.) were dissolved in pyridine (3 mL) and stirred overnight. The reaction mixture was poured in 1 M aq. HCl and extracted twice with Et₂O. The organic layers were washed with 1 M aq. HCl, H₂O, and sat. aq. NaCl, then dried (MgSO₄), filtered and concentrated under reduced pressure. The crude was coevaporated twice with dry toluene and 12 mL Et₂O was added, followed by LiAlH₄ (1 mL, 4 M in Et₂O, 2.6 eq.) and refluxed for 4 h. The reaction was quenched by addition of EtOAc and 1 M aq. HCl. The reaction mixture was washed with 1 M aq. HCl, H₂O and sat. aq. NaCl. The organic layer was dried (MgSO₄), filtered, and concentrated in vacuo. Purification by column chromatography (5% to 30% EtOAc in pentane) gave the title compound **2** as an oil. (430 mg, 1.2 mmol, 80%). R_r 0.32 (3/1 pentane/EtOAc). Spectroscopic data were in accord with those previously reported.⁴⁵ ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.42 – 7.23 (m, 10H, CH_{arom}), 5.03 (d, 1H, *J* = 11.5 Hz, *CHH* Bn), 4.76 (d, 1H, *J* = 12.1 Hz, *CHH* Bn), 4.72 – 4.63 (m, 2H, 2*x*CHH Bn), 4.56 (d, 1H, *J* = 3.5 Hz, H-1), 3.73 (t, 1H, *J* = 9.2 Hz, H-3), 3.69 – 3.54 (m, 1H, H-5), 3.55 – 3.48 (m, 1H, H-2), 3.37 (s, 3H, CH₃ OMe), 3.15 (t, 1H, *J* = 9.2 Hz, H-4), 2.19 (d, 1H, *J* = 18.3 Hz, 4-OH), 1.23 (d, 3H, *J* = 6.2 Hz, H-6); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 138.8, 138.1 (C_q), 128.8, 128.6, 128.2, 128.1, 128.1, 128.1 (CH_{arom}), 98.1 (C-1), 81.4 (C-3), 80.2 (C-2), 75.4 (CH₂ Bn), 75.4 (C-4), 73.1 (CH₂ Bn), 66.9 (C-5), 55.2 (OMe), 17.8 (C-6).


 **Methyl 2,3-di-O-benzyl-6-O-benzoyl- α -D-glucopyranoside (3).** Methyl 2,3-di-O-benzyl- α -D-glucopyranoside³² (3.37 g, 9 mmol) was converted to the title compound **3** following general procedure **C**. Yield: 3.94 g, 8.24 mmol, 92%. R_r 0.18 (4/1 pentane/EtOAc). Spectroscopic data were in accord with those previously reported.⁴⁵ ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 8.03 (d, 2H, *J* = 7.6 Hz, CH_{arom}), 7.59 – 7.26 (m, 13H, CH_{arom}), 5.01 (dd, 1H, *J* = 11.3, 2.1 Hz, *CHH* Bn), 4.83 – 4.72 (m, 2H, *CHH* Bn, *CHH* Bn), 4.70 – 4.54 (m, 3H, H-1, *CHH* Bn, H-6), 4.51 (d, 1H, *J* = 11.7 Hz, H-6), 3.91 – 3.79 (m, 2H, H-5, H-3), 3.60 – 3.49 (m, 2H, H-4, H-2), 3.40 (s, 3H, CH₃ OMe), 2.64 (s, 1H, 4-OH); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 166.9 (C=O), 138.7, 138.1 (C_q), 133.3, 129.8, 128.8, 128.6, 128.5, 128.2, 128.2, 128.1, 128.1 (CH_{arom}), 98.3 (C-1), 81.3 (C-3), 79.8 (C-2), 75.8, 73.3 (CH₂ Bn), 70.2 (C-4), 69.6 (C-5), 63.8 (C-6), 55.4 (OMe).




Methyl (methyl 2,3-di-O-benzyl- α -D-glucopyranosyl uronate) (4). Methyl 2,3-di-O-benzyl- α -D-glucopyranoside³² (6.95 g, 18.6 mmol) was converted to the title compound **4** following general procedure **D**. Yield: 3.84 g, 9.54 mmol, 52%. Spectroscopic data were in accord with those previously reported.³² ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.39 – 7.26 (m, 10H, CH_{arom}), 4.92 (d, 1H, J = 11.3 Hz, CHH Bn), 4.81 (d, 1H, J = 11.4 Hz, CHH Bn), 4.79 (d, 1H, J = 12.1 Hz, CHH Bn), 4.67 – 4.62 (m, 2H, CHH Bn, H-1), 4.15 (d, 1H, J = 8.9 Hz, H-5), 3.87 – 3.76 (m, 5H, H-3, H-4, CH₃ CO₂Me), 3.53 (dd, 1H, J = 8.9, 3.4 Hz, H-2), 3.42 (s, 3H, CH₃ OMe), 2.89 (bs, 1H, 4-OH); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 170.8 (C=O CO₂Me), 138.7, 138.0 (C_q), 128.6, 128.3, 128.1, 128.0, 127.9 (CH_{arom}), 98.8 (C-1), 80.5 (C-3), 78.6 (C-2), 75.6, 73.7 (CH₂ Bn), 71.9 (C-4), 70.6 (C-5), 56.0 (OMe), 52.8 (CO₂Me); HRMS: [M+Na]⁺ calcd for C₂₂H₂₆O₇Na 425.15707, found 425.15649.



Methyl 2-O-benzoyl-3,6-di-O-benzyl- α -D-glucopyranoside (5). Methyl 2-O-benzoyl-3-O-benzyl-4,6-O-benzylidene- α -D-glucopyranoside⁴⁶ (3.36 g, 7 mmol) was converted to the title compound **5** following general procedure **A**. Yield: 3.07 g, 6.42 mmol, 92%. R_f 0.38 (4/1 pentane/EtOAc). Spectroscopic data were in accord with those previously reported.⁴⁷ ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 8.12 – 8.03 (m, 2H, CH_{arom}), 7.62 – 7.15 (m, 13H, CH_{arom}), 5.09 (dd, 1H, J = 9.7, 3.6 Hz, H-2), 5.05 (d, 1H, J = 3.7 Hz, H-1), 4.86 (d, 1H, J = 11.4 Hz, CHH Bn), 4.74 (d, 1H, J = 11.4 Hz, CHH Bn), 4.64 (d, 1H, J = 12.1 Hz, CHH Bn), 4.58 (d, 1H, J = 12.1 Hz, CHH Bn), 4.02 (dd, 1H, J = 9.7, 8.2 Hz, H-3), 3.86 – 3.71 (m, 4H, H-5, H-6, H-4, H-6), 3.38 (s, 3H, CH₃ OMe), 2.62 (d, 1H, J = 2.4 Hz, 4-OH); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 166.0 (C=O), 138.4, 138.0 (C_q), 133.5, 133.4, 129.9 (CH_{arom}), 129.8 (C_q), 128.6, 128.6, 128.5, 128.0, 128.0, 127.8, 127.8, 127.1 (CH_{arom}), 97.4 (C-1), 79.8 (C-3), 75.3 (CH₂ Bn), 74.0 (C-2), 73.8 (CH₂ Bn), 71.6 (C-5), 69.9 (C-4), 69.8 (C-6), 55.4 (OMe).




Methyl 2-O-benzoyl-3-O-benzyl-6-deoxy- α -D-glucopyranoside (6). Methyl 2-O-benzoyl-3-O-benzyl-4,6-O-benzylidene- α -D-glucopyranoside⁴⁶ (5.56 g, 17.96 mmol, 1 eq.) was dissolved in 100 ml MeOH and *p*-TsOH·H₂O (0.35 g) was added. The reaction mixture was stirred at 50°C for 3 h, after which it was quenched by addition of Et₃N (0.25 ml) and concentrated *in vacuo*. The crude product was purified by column chromatography (2:1 to 4:6 pentane/EtOAc) to yield Methyl 2-O-benzoyl-3-O-benzyl- α -D-glucopyranoside as a white solid (5.98 g, 15.39 mmol, 86%). R_f 0.26 (4/6 pentane/EtOAc). ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 8.13 – 8.04 (m, 2H, CH_{arom}), 7.63 – 7.56 (m, 1H, CH_{arom}), 7.51 – 7.42 (m, 2H, CH_{arom}), 7.31 – 7.19 (m, 5H, CH_{arom}), 5.08 – 5.01 (m, 2H, H-1, H-2), 4.88 (dd, 1H, J = 11.4, 1.0 Hz, CHH Bn), 4.70 (dd, 1H, J = 11.4, 0.9 Hz, CHH Bn), 4.07 – 4.00 (m, 1H, H-3), 3.91 – 3.78 (m, 2H, H-6, H-6), 3.77 – 3.67 (m, 2H, H-4, H-5), 3.38 (s, 3H, CH₃ OMe), 2.13 (d, 1H, J = 10.0 Hz, 4-OH); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 166.1 (C=O), 138.3 (C_q), 133.5, 130.0 (CH_{arom}), 129.7 (C_q), 128.7, 128.7, 128.1, 128.0 (CH_{arom}), 97.5 (C-1), 79.9 (C-3), 75.4 (CH₂ Bn), 74.2 (C-2), 70.9 (C-4), 70.7 (C-5), 62.5 (C-6), 55.5 (OMe). HRMS: [M+Na]⁺ calcd for C₂₁H₂₄O₇Na 411.1414, found 411.1421. Methyl 2-O-benzoyl-3-O-benzyl- α -D-glucopyranoside (3.01 g, 7.75 mmol) was converted to the 6-iodo intermediate following general procedure **B**. Yield: 3.21 g, 6.43 mmol, 83%. R_f 0.64 (3/1 pentane/EtOAc). Spectroscopic data were in accord with those previously reported.⁴⁸ ¹H NMR (CDCl₃, 400 MHz, HH-COSY): δ 8.13 – 8.06 (m, 2H, CH_{arom}), 7.64 – 7.26 (m, 8H, CH_{arom}), 5.12 – 5.03 (m, 2H, H-2, H-1), 4.88 (d, 1H, J = 11.4 Hz, CHH Bn), 4.65 (d, 1H, J = 11.4 Hz, CHH Bn), 4.02 (dd, 1H, J = 9.6, 8.1 Hz, H-3), 3.59 (dd, 1H, J = 10.6, 2.1 Hz, H-6), 3.56 – 3.52 (m, 1H, H-5), 3.52 – 3.46 (m, 1H, H-4), 3.44 (s, 3H, CH₃ OMe), 3.34 (dd, 1H, J = 10.5, 6.4 Hz, H-6), 2.33 (d, 1H, J = 2.5 Hz, 4-OH). Subsequent deoxygenation gave the title compound **6**. Yield: 2.03 g, 5.45 mmol, 85%. [α]_D²⁰ = +112.3° (c = 0.90, CHCl₃); IR (thin film): 712, 1027, 1051, 1108, 1271, 1452, 1721, 2933, 3486; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 8.13 – 8.06 (m, 2H, CH_{arom}), 7.62 – 7.55 (m, 1H, CH_{arom}), 7.50 – 7.42 (m, 2H, CH_{arom}), 7.29 – 7.24 (m, 5H, CH_{arom}), 5.08 (dd, 1H, J = 9.9, 3.7 Hz, H-2), 4.98 (d, 1H, J = 3.7 Hz, H-1), 4.87 (d, 1H, J = 11.4 Hz, CHH Bn), 4.68 (d, 1H, J = 11.4 Hz, CHH Bn), 3.97 (dd, 1H, J = 9.9, 8.9 Hz, H-3), 3.76 (dq, 1H, J = 9.6, 6.2 Hz, H-5), 3.37 (s, 3H, CH₃ OMe), 3.33 (dd, 1H, J = 9.2, 2.7 Hz, H-4), 2.32 (d, 1H, J = 2.8 Hz, 4-OH), 1.32 (d, 3H, J = 6.2 Hz, H-6); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 166.0 (C=O), 138.3 (C_q), 133.4, 129.9 (CH_{arom}), 129.8 (C_q), 128.7, 128.6, 128.1, 128.1 (CH_{arom}), 97.3 (C-1), 80.0 (C-3), 75.6 (C-4), 75.3 (CH₂ Bn), 74.6 (C-2), 67.0 (C-5), 55.3 (OMe), 17.7 (C-6); HRMS: [M+Na]⁺ calcd for C₂₁H₂₄O₆Na 395.1465, found 395.1472.




Methyl 2,6-di-O-benzoyl-3-O-benzyl- α -D-glucopyranoside (7). Methyl 2-O-benzoyl-3-O-benzyl- α -D-glucopyranoside (0.93 g, 2.4 mmol) was converted to the title compound **7** following general procedure **C**. Yield: 1.25 g, 2.4 mmol, 100%. R_f 0.25 (4/1 pentane/EtOAc). Spectroscopic data were in accord with those previously reported.⁴⁵ ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 8.13 – 8.01 (m, 4H, CH_{arom}), 7.62 – 7.17 (m, 11H, CH_{arom}), 5.11 – 5.04 (m, 2H, H-1, H-2), 4.87 (d, 1H, J = 11.3 Hz, CHH Bn), 4.78 – 4.70 (m, 2H, CHH Bn, H-6), 4.54 (dd, 1H, J = 12.1, 2.2 Hz, H-6), 4.07 (t, 1H, J = 9.0 Hz, H-3), 3.97 (ddd, 1H, J = 10.0, 4.5, 2.1 Hz, H-5), 3.70 (t, 1H, J = 9.4 Hz, H-4), 3.40 (s, 3H, CH₃ OMe), 2.83 (s, 1H, 4-OH); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 167.1, 166.0


(C=O), 138.2 (C_q), 133.5, 133.4, 130.0, 129.9, 129.8 (CH_{arom}), 129.7 (C_q), 128.7, 128.6, 128.1, 128.1 (CH_{arom}), 97.5 (C-1), 79.6 (C-3), 75.6 (CH₂ Bn), 74.0 (C-2), 70.4 (C-4), 69.7 (C-5), 63.6 (C-6), 55.5 (OMe).




Methyl (methyl 2-O-benzoyl-3-O-benzyl- α -D-glucopyranosyl uronate) (8). Methyl 2-O-benzoyl-3-O-benzyl- α -D-glucopyranoside (1.55 g, 4 mmol) was converted to the title compound **8** following general procedure **D**. Yield: 1.01 g, 2.4 mmol, 61%. $[\alpha]_D^{20} = +137.4^\circ$ ($c = 0.95$, CHCl₃); IR (thin film): 711, 1028, 1046, 1105, 1270, 1452, 1723, 1749, 2937, 3508; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 8.08 – 8.02 (m, 2H, CH_{arom}), 7.62 – 7.18 (m, 9H, CH_{arom}), 5.14 (d, 1H, $J = 3.6$ Hz, H-1), 5.08 (dd, 1H, $J = 9.6, 3.6$ Hz, H-2), 4.84 (s, 2H, CH₂ Bn), 4.24 (d, 1H, $J = 9.6$ Hz, H-5), 4.05 (dd, 1H, $J = 9.7, 8.6$ Hz, H-3), 3.98 (td, 1H, $J = 9.2, 1.9$ Hz, H-4), 3.86 (s, 3H, CH₃ CO₂Me), 3.43 (s, 3H, CH₃ OMe), 3.03 (s, 1H, 4-OH); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 170.8 (C=O CO₂Me), 166.0 (C=O OBz), 138.3 (C_q), 133.5, 130.0 (CH_{arom}), 129.6 (C_q), 128.6, 128.6, 128.1, 127.9 (CH_{arom}), 97.8 (C-1), 78.6 (C-3), 75.4 (CH₂ Bn), 73.1 (C-2), 72.4 (C-4), 70.2 (C-5), 56.0 (OMe), 53.0 (CO₂Me); HRMS: [M+Na]⁺ calcd for C₂₂H₂₄O₈Na 439.1363, found 439.1374.




Methyl 3-O-benzoyl-2,6-di-O-benzyl- α -D-glucopyranoside (9). Methyl 3-O-benzoyl-2-O-benzyl-4,6-O-benzylidene- α -D-glucopyranoside⁴⁷ (3.34 g, 7 mmol) was converted to the title compound **9** following general procedure **A**. Yield: 2.11 g, 4.40 mmol, 63%. R_f 0.20 (4/1 pentane/EtOAc). Spectroscopic data were in accord with those previously reported.⁴⁷ ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 8.07 – 8.00 (m, 2H, CH_{arom}), 7.64 – 7.21 (m, 13H, CH_{arom}), 5.50 (ddd, 1H, $J = 9.9, 7.5, 1.3$ Hz, H-3), 4.75 (d, 1H, $J = 3.5$ Hz, H-1), 4.69 – 4.52 (m, 4H, 2xCH₂ Bn), 3.86 – 3.66 (m, 5H, H-2, H-4, H-5, H-6, H-6), 3.42 (s, 3H, CH₃ OMe), 3.01 – 2.91 (m, 1H, 4-OH); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 167.7 (C=O), 138.0, 137.8 (C_q), 133.4, 130.1, 129.8, 128.5, 128.5, 128.1, 128.1, 127.8, 127.8 (CH_{arom}), 98.0 (C-1), 76.6 (C-2), 76.4 (C-3), 73.8 (CH₂ Bn), 73.1 (CH₂ Bn), 70.5 (C-4), 70.5 (C-5), 69.3 (C-6), 55.5 (OMe).



Methyl 2-O-benzoyl-3-O-benzoyl-6-deoxy- α -D-glucopyranoside (10). Methyl 3-O-benzoyl-2-O-benzyl- α -D-glucopyranoside⁴⁹ (3.63 g, 9.34 mmol) was converted to the 6-iodo intermediate following general procedure **B**. Yield: 3.89 g, 7.80 mmol, 84%. ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 8.06 – 7.99 (m, 2H, CH_{arom}), 7.65 – 7.23 (m, 8H, CH_{arom}), 5.47 (dd, 1H, $J = 9.8, 8.5$ Hz, H-3), 4.75 (d, 1H, $J = 3.6$ Hz, H-1), 4.69 (d, 1H, $J = 12.4$ Hz, CHH Bn), 4.63 (d, 1H, $J = 12.4$ Hz, CHH Bn), 3.69 (dd, 1H, $J = 9.8, 3.6$ Hz, H-6), 3.61 (dd, 1H, $J = 10.7, 2.3$ Hz, H-2), 3.57 – 3.52 (m, 1H, H-5), 3.52 – 3.48 (m, 1H, H-4), 3.48 (s, 3H, CH₃ OMe), 3.34 (dd, 1H, $J = 10.6, 6.4$ Hz, H-6), 3.19 (dq, 1H, $J = 5.0, 1.6$ Hz, 4-OH); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 168.1 (C=O), 137.7, 133.7 (C_q), 130.1, 128.6, 128.1 (CH_{arom}), 97.9 (C-1), 76.7 (C-2), 76.1 (C-3), 74.0 (C-4), 73.2 (CH₂ Bn), 70.5 (C-5), 60.5 (C-6), 55.8 (OMe), 7.0 (C-6). Subsequent deoxygenation gave the title compound **10**. Yield: 1.08 g, 2.90 mmol, 37%. $[\alpha]_D^{20} = +93.3^\circ$ ($c = 1.0$, CHCl₃); IR (thin film): 710, 748, 988, 1053, 1103, 1269, 1369, 1450, 1720, 2909, 3460; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 8.06 – 7.99 (m, 2H, CH_{arom}), 7.64 – 7.22 (m, 8H, CH_{arom}), 5.43 (t, 1H, $J = 9.5$ Hz, H-3), 4.71 – 4.61 (m, 3H, CH₂ Bn, H-1), 3.77 (dq, 1H, $J = 9.5, 6.2$ Hz, H-5), 3.68 (dd, 1H, $J = 9.8, 3.6$ Hz, H-2), 3.42 (s, 3H, CH₃ OMe), 3.34 (td, 1H, $J = 9.3, 5.3$ Hz, H-4), 2.82 (d, 1H, $J = 5.3$ Hz, 4-OH), 1.31 (d, 3H, $J = 6.2$ Hz, H-6); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 168.1 (C=O), 137.8, 133.5 (C_q), 130.1 (CH_{arom}), 129.8 (C_q), 128.6, 128.1, 128.1 (CH_{arom}), 97.8 (C-1), 76.9 (C-2), 76.7 (C-3), 75.7 (C-4), 73.1 (CH₂ Bn), 67.6 (C-5), 55.4 (OMe), 17.7 (C-6); HRMS: [M+NH₄]⁺ calcd for C₂₁H₂₈NO₆ 390.19111, found 390.19132.




Methyl 2-O-benzoyl-3,6-di-O-benzyl- α -D-glucopyranoside (11). Methyl 3-O-benzoyl-2-O-benzyl- α -D-glucopyranoside⁴⁹ (1.36 g, 3.5 mmol) was converted to the title compound **11** following general procedure **C**. Yield: 1.47 g, 3.0 mmol, 85%. R_f 0.28 (4/1 pentane/EtOAc). $[\alpha]_D^{20} = +78.4^\circ$ ($c = 1.13$, CHCl₃); IR (thin film): 709, 1051, 1070, 1097, 1107, 1275, 1452, 1724, 1749, 2945, 3493; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 8.08 – 8.02 (m, 4H, CH_{arom}), 7.65 – 7.54 (m, 2H, CH_{arom}), 7.49 – 7.41 (m, 4H, CH_{arom}), 7.30 – 7.22 (m, 5H, CH_{arom}), 5.54 (t, 1H, $J = 9.5$ Hz, H-3), 4.76 (d, 1H, $J = 3.5$ Hz, H-6), 4.73 – 4.63 (m, 3H, CHH Bn, H-1, H-6), 4.63 – 4.54 (m, 1H, CHH Bn), 4.02 (ddd, 1H, $J = 10.0, 5.1, 2.3$ Hz, H-5), 3.73 – 3.61 (m, 2H, H-2, H-4), 3.44 (s, 3H, CH₃ OMe), 3.35 – 3.20 (m, 1H, 4-OH); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 167.8, 166.9 (C=O), 137.8 (C_q), 133.5, 130.1, 129.9 (CH_{arom}), 129.7 (C_q), 128.6, 128.6, 128.5, 128.1, 128.1 (CH_{arom}), 97.9 (C-1), 76.7 (C-2), 76.1 (C-3), 73.2 (CH₂ Bn), 70.2 (C-4), 70.1 (C-5), 63.8 (C-6), 55.5 (OMe); HRMS: [M+Na]⁺ calcd for C₂₈H₂₈O₈Na 515.1676, found 515.1680.




Methyl (methyl 2-O-benzoyl-3-O-benzoyl- α -D-glucopyranosyl uronate) (12). Methyl 3-O-benzoyl-2-O-benzyl- α -D-glucopyranoside⁴⁹ (2.14 g, 5.5 mmol) was converted to the title compound **12** following general procedure **D**. Yield: 1.70 g, 4.08 mmol, 74%. $[\alpha]_D^{20} = +65.6^\circ$ ($c = 1.0$, CHCl₃); IR (thin film): 714, 748, 910, 1049, 1111, 1200, 1269, 1450, 1724, 2932, 3472; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): 8.07 –

8.00 (m, 2H, CH_{arom}), 7.62 – 7.56 (m, 1H, CH_{arom}), 7.50 – 7.41 (m, 2H, CH_{arom}), 7.28 – 7.22 (m, 5H, CH_{arom}), 5.58 (t, 1H, *J* = 9.3 Hz, H-3), 4.79 (d, 1H, *J* = 3.4 Hz, H-1), 4.67 (d, 1H, *J* = 12.4 Hz, CHH Bn), 4.61 (d, 1H, *J* = 12.4 Hz, CHH Bn), 4.28 (d, 1H, *J* = 9.5 Hz, H-5), 3.96 (td, 1H, *J* = 9.4, 2.7 Hz, H-4), 3.80 (s, 3H, CH₃ CO₂Me), 3.70 (dd, 1H, *J* = 9.6, 3.4 Hz, H-2), 3.47 (s, 3H, CH₃ OMe), 3.28 (d, 1H, *J* = 4.3 Hz, 4-OH); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 170.4 (C=O CO₂Me), 166.8 (C=O OBz), 137.6 (C_q), 133.4, 130.0 (CH_{arom}), 129.7 (C_q), 129.5, 128.6, 128.5, 128.2 (CH_{arom}), 98.4 (C-1), 76.0 (C-2), 74.3 (C-3), 73.3 (CH₂ Bn), 71.0 (C-4), 70.9 (C-5), 56.1 (OMe), 52.9 (CO₂Me); HRMS: [M+NH₄]⁺ calcd for C₂₁H₂₈NO₆ 479.20643, found 479.20618.




Methyl 2,3-di-O-benzoyl-6-O-benzyl- α -D-glucopyranoside (13). Methyl 2,3-di-O-benzoyl-4,6-O-benzylidene- α -D-glucopyranoside⁵⁰ (4.68 g, 9.54 mmol) was converted to the title compound **13** following general procedure **A**. Yield: 3.74 g, 7.62 mmol, 80%. R_f 0.30 (4/1 pentane/EtOAc).

Spectroscopic data were in accord with those previously reported.⁵¹ ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 8.02 – 7.94 (m, 4H, CH_{arom}), 7.55 – 7.27 (m, 11H, CH_{arom}), 5.74 (dd, 1H, *J* = 10.1, 8.4 Hz, H-3), 5.26 (dd, 1H, *J* = 10.2, 3.7 Hz, H-2), 5.13 (d, 1H, *J* = 3.7 Hz, H-1), 4.67 (d, 1H, *J* = 12.0 Hz, CHH Bn), 4.61 (d, 1H, *J* = 12.0 Hz, CHH Bn), 4.03 – 3.91 (m, 2H, H-5, H-4), 3.86 (dd, 1H, *J* = 10.4, 3.9 Hz, H-6), 3.81 (dd, 1H, *J* = 10.4, 3.4 Hz, H-6), 3.43 (s, 3H, CH₃ OMe), 3.02 (d, 1H, *J* = 3.5 Hz, 4-OH); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 167.5, 166.1 (C=O), 137.0 (C_q), 133.5, 133.1, 130.0 (CH_{arom}), 129.9, 129.2 (C_q), 128.6, 128.4, 128.3, 126.3 (CH_{arom}), 97.2 (C-1), 74.3 (C-3), 73.9 (CH₂ Bn), 71.6 (C-2), 70.8 (C-4), 70.3 (C-5), 69.6 (C-6), 55.6 (OMe).




Methyl 2,3-di-O-benzoyl-6-deoxy- α -D-glucopyranoside (14). Methyl 2,3-di-O-benzoyl- α -D-glucopyranoside⁵⁰ (1.49 g, 3.7 mmol) was converted to the 6-iodo intermediate following general procedure **B**. Yield: 1.38 g, 2.7 mmol, 73%. ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 8.01 –

7.93 (m, 4H, CH_{arom}), 7.55 – 7.48 (m, 2H, CH_{arom}), 7.41 – 7.34 (m, 4H, CH_{arom}), 5.69 (dd, 1H, *J* = 10.1, 8.7 Hz, H-3), 5.29 (dd, 1H, *J* = 10.1, 3.7 Hz, H-2), 5.12 (d, 1H, *J* = 3.7 Hz, H-1), 3.76 – 3.63 (m, 3H, H-4, H-5, H-6), 3.49 (s, 3H, CH₃ OMe), 3.46 – 3.41 (m, 1H, H-6), 3.29 – 3.12 (m, 1H, 4-OH); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 168.0, 166.0 (C=O), 133.8, 133.6, 130.0, 130.0 (CH_{arom}), 129.2, 129.0 (C_q), 128.6, 128.6 (CH_{arom}), 97.2 (C-1), 74.4 (C-3), 73.9 (C-4), 71.3 (C-2), 70.6 (C-5), 55.8 (OMe), 6.5 (C-6). Subsequent deoxygenation gave the title compound **14**. Yield: 0.43 g, 1.12 mmol, 41%. Spectroscopic data were in accord with those previously reported.⁵² ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 8.02 – 7.93 (m, 4H, CH_{arom}), 7.56 – 7.47 (m, 2H, CH_{arom}), 7.42 – 7.32 (m, 4H, CH_{arom}), 5.65 (dd, 1H, *J* = 10.2, 9.2 Hz, H-3), 5.27 (dd, 1H, *J* = 10.1, 3.7 Hz, H-2), 5.05 (d, 1H, *J* = 3.6 Hz, H-1), 3.89 (dq, 1H, *J* = 9.5, 6.2 Hz, H-5), 3.55 (td, 1H, *J* = 9.3, 5.0 Hz, H-4), 3.43 (s, 3H, CH₃ OMe), 2.84 (d, 1H, *J* = 5.1 Hz, 4-OH), 1.40 (d, 3H, *J* = 6.2 Hz, CH₃-6); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 167.9, 166.1 (C=O), 133.6, 133.5, 130.0 (CH_{arom}), 130.0, 129.3 (C_q), 128.6, 128.5 (CH_{arom}), 97.1 (C-1), 75.4 (C-4), 74.8 (C-3), 71.7 (C-2), 67.7 (C-5), 55.4 (OMe), 17.6 (C-6).




Methyl 2,3,6-tri-O-benzoyl- α -D-glucopyranoside (15). Methyl 2,3-di-O-benzoyl- α -D-glucopyranoside⁵⁰ (2.84 g, 7 mmol) was converted to the title compound **15** following general procedure **C**. Yield: 2.3 g, 4.5 mmol, 66%. R_f 0.27 (4/1 pentane/EtOAc). Spectroscopic data were in

accord with those previously reported.⁵³ ¹H NMR (400 MHz, CDCl₃) δ 8.14 – 8.05 (m, 2H, CH_{arom}), 8.03 – 7.93 (m, 4H, CH_{arom}), 7.64 – 7.12 (m, 9H, CH_{arom}), 5.79 (dd, 1H, *J* = 10.1, 9.2 Hz, H-3), 5.27 (dd, 1H, *J* = 10.2, 3.6 Hz, H-2), 5.14 (d, 1H, *J* = 3.6 Hz, H-1), 4.81 (dd, 1H, *J* = 12.1, 4.5 Hz, H-6), 4.63 (dd, 1H, *J* = 12.2, 2.3 Hz, H-6), 4.12 (ddd, 1H, *J* = 9.9, 4.5, 2.2 Hz, H-5), 3.88 (t, 1H, *J* = 9.6 Hz, H-4), 3.46 (s, 3H, CH₃ OMe), 3.39 (s, 1H, 4-OH). ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 167.5, 167.1, 166.1 (C=O), 133.6, 133.5, 133.5, 130.0, 130.0 (CH_{arom}), 129.7, 129.3, 129.2 (C_q), 128.6, 128.6, 128.5 (CH_{arom}), 97.2 (C-1), 74.0 (C-3), 71.4 (C-2), 70.2 (C-5), 69.8 (C-4), 63.6 (C-6), 55.6 (OMe).




Methyl (methyl 2,3-di-O-benzoyl- α -D-glucopyranosyl uronate) (16). Methyl 2,3-di-O-benzoyl- α -D-glucopyranoside⁵⁰ (0.72 g, 1.8 mmol) was converted to the title compound **16** following general procedure **D**. Yield: 0.57 g, 1.49 mmol, 83%. [α]_D²⁰ = +111.4° (*c* = 0.83, CHCl₃); IR (thin film): 710,

1026, 1064, 1270, 1452, 1701, 1719, 2895, 3486; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 8.03 – 7.92 (m, 4H, CH_{arom}), 7.55 – 7.30 (m, 6H, CH_{arom}), 5.85 (ddd, 1H, *J* = 11.2, 9.1, 1.7 Hz, H-3), 5.27 – 5.20 (m, 2H, H-1 H-2), 4.37 (d, 1H, *J* = 9.8 Hz, H-5), 4.16 (td, 1H, *J* = 9.6, 3.5 Hz, H-4), 3.88 (s, 3H, CH₃ CO₂Me), 3.49 (s, 3H, CH₃ OMe), 3.34 (d, 1H, *J* = 3.7 Hz, 4-OH). ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 170.4 (C=O CO₂Me), 166.7, 166.0 (C=O Bz), 133.6, 133.5, 130.0, 130.0 (CH_{arom}), 129.4, 129.1 (C_q), 128.6, 128.5 (CH_{arom}), 97.6 (C-1), 72.4 (C-3), 71.2 (C-2), 70.9 (C-4), 70.4 (C-5), 56.1 (OMe), 53.1 (CO₂Me); HRMS: [M+Na]⁺ calcd for C₂₇H₂₂O₉Na 453.1156, found 453.1165.




Methyl 2,3,6-tri-O-benzyl- β -D-glucopyranoside (17). Methyl 2,3-di-O-benzyl-4,6-O-benzylidene- β -D-glucopyranoside⁵⁴ (0.69 g, 1.5 mmol) was converted to the title compound **17** following

general procedure **A**. Yield: 0.45 g, 0.96 mmol, 64%. Spectroscopic data were in accord with those previously reported.⁵⁴ ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.39 – 7.22 (m, 15H, CH_{arom}), 4.94 – 4.90 (m, 2H, 2xCHH Bn), 4.73 – 4.69 (m, 2H, 2xCHH Bn), 4.63 – 4.53 (m, 2H, CH₂ Bn), 4.33 (d, 1H, *J* = 7.4 Hz, H-1), 3.77 (dd, 1H, *J* = 10.4, 3.8 Hz, H-6), 3.70 (dd, 1H, *J* = 10.4, 5.3 Hz, H-6), 3.63 – 3.58 (m, 1H, H-5), 3.57 (s, 3H, CH₃ OMe), 3.50 – 3.37 (m, 3H, H-3, H-4, H-2), 2.55 (d, 1H, *J* = 2.1 Hz, 4-OH); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 138.7, 138.6, 138.0 (C_q), 128.7, 128.5, 128.5, 128.1, 128.1, 128.0, 127.8, 127.8, 127.8 (CH_{arom}), 104.9 (C-1), 84.1 (C-3), 81.9 (C-2), 75.4 (CH₂ Bn), 74.8 (CH₂ Bn), 74.1 (C-4), 73.8 (CH₂ Bn), 71.6 (C-5), 70.4 (C-6), 57.3 (OMe).




Methyl 2,3-di-O-benzyl-6-deoxy-β-D-glucopyranoside (18). Methyl 2,3-di-O-benzyl-β-D-glucopyranoside⁵⁴ (1.18 g, 3.15 mmol) was converted to the 6-iodo intermediate⁵⁵ following general procedure **B**. Yield: 1.03 g, 2.12 mmol, 67%. ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC):

δ 7.44 – 7.18 (m, 10H, CH_{arom}), 5.01 – 4.89 (m, 2H, 2xCHH Bn), 4.73 – 4.58 (m, 2H, 2xCHH Bn), 4.38 – 4.34 (m, 1H, H-1), 3.61 (s, 3H, CH₃ OMe), 3.56 (dd, 1H, *J* = 10.6, 2.4 Hz, H-6), 3.46 – 3.41 (m, 2H, H-3, H-4), 3.37 – 3.30 (m, 1H, H-5), 3.25 (dd, 1H, *J* = 10.6, 7.8 Hz, H-2), 3.16 (ddd, 1H, *J* = 9.1, 7.8, 2.4 Hz, H-6), 2.18 (d, 1H, *J* = 2.4 Hz, OH). Subsequent deoxygenation gave the title compound **18**. Yield: 0.43 g, 1.21 mmol, 57%. [α]_D²⁰ = -21.2° (*c* = 1.0, CHCl₃); IR (thin film): 698, 737, 988, 1065, 1146, 1354, 1454, 2905, 3345; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.54 – 7.03 (m, 10H, CH_{arom}), 5.00 – 4.91 (m, 2H, 2xCHH Bn), 4.74 – 4.61 (m, 2H, 2xCHH Bn), 4.33 – 4.27 (m, 1H, H-1), 3.57 (s, 3H, CH₃ OMe), 3.45 – 3.27 (m, 3H, H-3, H-2, H-5), 3.21 (ddt, 1H, *J* = 9.0, 6.7, 2.2 Hz, H-4), 1.31 (d, 3H, *J* = 6.1 Hz, CH₃ 6); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 138.6 (C_q), 128.8, 128.5, 128.3, 128.1, 127.8 (CH_{arom}), 104.8 (C-1), 84.0 (C-2), 82.4 (C-3), 75.3 (CH₂ Bn), 75.0 (C-4), 74.7 (CH₂ Bn), 71.3 (C-5), 57.2 (OMe), 17.8 (C-6); HRMS: [M+Na]⁺ calcd for C₂₁H₂₆O₅Na 381.1672, found 381.1677.




Methyl 2,3-di-O-benzyl-6-O-benzoyl-β-D-glucopyranoside (19). Methyl 2,3-di-O-benzyl-β-D-glucopyranoside⁵⁴ (0.56 g, 1.5 mmol) was converted to the title compound **19** following general procedure **C**. Yield: 0.70 g, 1.47 mmol, 98%. Spectroscopic data were in accord with those

previously reported.⁵⁶ ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 8.08 – 8.01 (m, 2H, CH_{arom}), 7.60 – 7.23 (m, 13H, CH_{arom}), 4.99 – 4.89 (m, 2H, 2xCHH Bn), 4.77 – 4.67 (m, 2H, 2xCHH Bn), 4.67 – 4.53 (m, 2H, H-6), 4.37 (d, 1H, *J* = 7.5 Hz, H-1), 3.62 – 3.53 (m, 5H, H-4, CH₃ OMe, H-5), 3.50 (td, 1H, *J* = 8.1, 7.2, 1.3 Hz, H-2), 3.42 (dd, 1H, *J* = 8.9, 7.5 Hz, H-3), 2.64 (s, 1H, OH); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 167.0 (C=O), 138.5, 133.3 (C_q), 130.0, 129.9 (CH_{arom}), 128.8 (C_q), 128.5, 128.3, 128.2, 128.1, 127.9 (CH_{arom}), 105.0 (C-1), 83.8 (C-2), 81.9 (C-3), 75.6, 74.8 (CH₂ Bn), 73.7 (C-4), 70.1 (C-5), 63.9 (C-6), 57.3 (OMe).




Methyl (methyl 2,3-di-O-benzoyl-β-D-glucopyranosyl uronate) (20). Methyl 2,3-di-O-benzyl-β-D-glucopyranoside⁵⁴ (745 mg, 2.0 mmol) was converted to the title compound **20** following general procedure **D**. Yield: 689 g, 1.71 mmol, 85%. Spectroscopic data were in accord with those

previously reported.⁵⁷ ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.37 – 7.21 (m, 10H, CH_{arom}), 4.92 – 4.84 (m, 2H, 2xCHH Bn), 4.80 (d, 1H, *J* = 11.3 Hz, CHH Bn), 4.68 (d, 1H, *J* = 11.1 Hz, CHH Bn), 4.34 (d, 1H, *J* = 7.5 Hz, H-1), 3.87 – 3.79 (m, 2H, H-3, H-4), 3.76 (s, 3H, CH₃ CO₂Me), 3.55 (s, 3H, CH₃ OMe), 3.50 (ddd, 1H, *J* = 8.6, 6.7, 1.6 Hz, H-5), 3.42 (dd, 1H, *J* = 9.1, 7.5 Hz, H-2), 3.09 (s, 1H, 4-OH); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 169.7 (C=O CO₂Me), 138.4, 138.3 (C_q), 128.4, 128.3, 128.0, 127.9, 127.7 (CH_{arom}), 104.9 (C-1), 83.0 (C-5), 81.1 (C-2), 75.3, 74.7 (CH₂ Bn), 74.3, 71.7 (C-3, C-4), 57.4 (OMe), 52.7 (CO₂Me).




Methyl 2,3-di-O-benzyl-6-O-(4-nitrobenzoyl)-α-D-glucopyranoside (23). Methyl 2,3-di-O-benzyl-α-D-glucopyranoside³² (374 mg, 1.0 mmol, 1 eq.) was converted to the title compound **23** following general procedure **C** (4-nitrobenzoyl chloride; 195 μL, 1.05 mmol, 1.05 eq.). Yield: 460 mg, 0.88 mmol, 88%. [α]_D²⁰ = +28.3° (*c* = 0.6, CHCl₃); IR (thin film): 698, 719, 739, 1057, 1103, 1277, 1346, 1454, 1528, 1607, 1726, 2912, 3505; ¹H NMR (CDCl₃,


500 MHz, HH-COSY, HSQC): δ 8.30 – 8.26 (m, 2H, CH_{arom} pNO₂Bz), 8.21 – 8.17 (m, 2H, CH_{arom} pNO₂Bz), 7.39 – 7.30 (m, 10H, CH_{arom} Bn), 5.04 (d, 1H, *J* = 11.3 Hz, CHH Bn), 4.79 (d, 1H, *J* = 12.2 Hz, CHH Bn), 4.73 (d, 1H, *J* = 11.3 Hz, CHH Bn), 4.68 (d, 1H, *J* = 12.1 Hz, CHH Bn), 4.64 (d, 1H, *J* = 3.5 Hz, H-1), 4.63 – 4.56 (m, 2H, H-6, H-6), 3.90 (ddd, 1H, *J* = 10.0, 4.6, 2.7 Hz, H-5), 3.83 (t, 1H, *J* = 9.2 Hz, H-3), 3.54 (dd, 1H, *J* = 9.5, 3.6 Hz, H-2), 3.52 (ddd, 1H, *J* = 10.0, 8.9, 2.7 Hz, H-4), 3.40 (s, 3H, CH₃ OMe), 2.43 (d, 1H, *J* = 2.8 Hz, 4-OH); ¹³C-APT NMR (CDCl₃, 126 MHz, HSQC): δ 164.8 (C=O), 150.8 (C_q NO₂), 138.6, 138.0, 135.3 (C_q), 131.0, 128.9, 128.7, 128.3, 128.2, 123.7 (CH_{arom}), 98.3 (C-1), 81.3 (C-3), 79.8 (C-2), 75.8, 73.3 (CH₂ Bn), 70.1 (C-4), 69.3 (C-5), 64.7 (C-6), 55.5 (OMe); HRMS: [M+Na]⁺ calcd for C₂₈H₂₉NO₉Na 546.1740, found 546.1748.




Methyl 2,3-di-O-benzyl-6-O-(3-nitrobenzoyl)- α -D-glucopyranoside (24). Methyl 2,3-di-O-benzyl- α -D-glucopyranoside³² (300 mg, 0.8 mmol, 1 eq.) was converted to the title compound **24** following general procedure **C** (3-nitrobenzoyl chloride; 227 mg, 1.7 mmol, 1.6 eq.). Yield: 375 mg, 0.72 mmol, 90% (included 5% fully protected glycoside). $[\alpha]_D^{20} = +22.2^\circ$ ($c = 0.67$, CHCl_3); IR (thin film): 698, 718, 741, 1059, 1121, 1261, 1294, 1350, 1454, 1533, 1616, 1728, 2920, 3520; $^1\text{H NMR}$ (CDCl_3 , 500 MHz, HH-COSY, HSQC): δ 8.83 (ddd, 1H, $J = 2.2, 1.6, 0.4$ Hz, CH_{arom} NO_2Bz), 8.39 (ddd, 1H, $J = 8.2, 2.3, 1.1$ Hz, CH_{arom} NO_2Bz), 8.33 (ddd, 1H, $J = 7.7, 1.6, 1.2$ Hz, CH_{arom} NO_2Bz), 7.62 (td, 1H, $J = 8.0, 0.4$ Hz, CH_{arom} NO_2Bz), 7.40–7.27 (m, 10H, CH_{arom} Bn), 5.02 (d, 1H, $J = 11.4$ Hz, CHH Bn), 4.78 (d, 1H, $J = 12.1$ Hz, CHH Bn), 4.74 (d, 1H, $J = 11.4$ Hz, CHH Bn), 4.67 (d, 1H, $J = 12.1$ Hz, CHH Bn), 4.65 (d, 1H, $J = 3.6$ Hz, H-1), 4.61–4.58 (m, 2H, H-6, H-6), 3.91 (dt, 1H, $J = 10.0, 3.9$ Hz, H-5), 3.86–3.80 (m, 1H, H-3), 3.55 (dd, 1H, $J = 9.5, 3.6$ Hz, H-2), 3.53–3.48 (m, 1H, H-4), 3.42 (s, 3H, CH_3 OMe), 2.59 (d, 1H, $J = 2.7$ Hz, 4-OH); ^{13}C -APT NMR (CDCl_3 , 126 MHz, HSQC): δ 164.6 (C=O), 148.3 (C_q NO_2), 138.6, 138.0 (C_q Bn), 135.4 (CH_{arom}), 131.7 (C_q Bz), 129.7, 128.7, 128.6, 128.2, 128.2, 128.1, 128.1, 128.1, 127.6, 124.7 (CH_{arom}), 98.2 (C-1), 81.2 (C-3), 79.8 (C-2), 75.6, 73.3 (CH_2 Bn), 70.2 (C-4), 69.3 (C-5), 64.8 (C-6), 55.4 (OMe); HRMS: $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{28}\text{H}_{29}\text{NO}_9\text{Na}$ 546.1740, found 546.1752.



Methyl 2,3-di-O-benzyl-6-O-(2-nitrobenzoyl)- α -D-glucopyranoside (25). Methyl 2,3-di-O-benzyl- α -D-glucopyranoside³² (374 mg, 1.0 mmol, 1 eq.) was converted to the title compound **25** following general procedure **C** (2-nitrobenzoyl chloride; 140 μL , 1.05 mmol, 1.05 eq.). Yield: 450 mg, 0.86 mmol, 86%. $[\alpha]_D^{20} = +15.8^\circ$ ($c = 0.6$, CHCl_3); IR (thin film): 698, 737, 1059, 1117, 1257, 1292, 1350, 1533, 1734, 2907, 3503; $^1\text{H NMR}$ (CDCl_3 , 400 MHz, HH-COSY, HSQC): δ 7.85–7.81 (m, 1H, CH_{arom} NO_2Bz), 7.74–7.70 (m, 1H, CH_{arom} NO_2Bz), 7.64–7.55 (m, 2H, CH_{arom} NO_2Bz), 7.39–7.25 (m, 10H, CH_{arom} Bn), 4.99 (d, 1H, $J = 11.4$ Hz, CHH Bn), 4.78–4.73 (m, 2H, CHH Bn, CHH Bn), 4.64 (d, 1H, $J = 12.0$ Hz, CHH Bn), 4.62 (d, 1H, $J = 3.5$ Hz, H-1), 4.54 (d, 2H, $J = 3.7$ Hz, H-6, H-6), 3.86–3.78 (m, 2H, H-3, H-5), 3.51 (dd, 1H, $J = 9.6, 3.5$ Hz, H-2), 3.52–3.42 (m, 1H, H-4), 3.36 (s, 3H, CH_3 OMe), 2.65 (bs, 1H, 4-OH); ^{13}C -APT NMR (CDCl_3 , 101 MHz, HSQC): δ 165.3 (C=O), 148.3 (C_q - NO_2), 138.6, 137.9 (C_q Bn), 132.8, 132.0, 130.0, 128.6, 128.4, 128.0, 128.0, 127.9, 127.8 (CH_{arom}), 127.1 (C_q Bz), 123.8 (CH_{arom}), 98.1 (C-1), 81.1 (C-3), 79.5 (C-2), 75.4, 73.2 (CH_2 Bn), 69.9 (C-4), 69.0 (C-5), 65.3 (C-6), 55.4 (OMe); HRMS: $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{28}\text{H}_{29}\text{NO}_9\text{Na}$ 546.1740, found 546.1755.




Methyl 2,3-di-O-benzyl-6-O-(2,6-dinitrobenzoyl)- α -D-glucopyranoside (26). Methyl 2,3-di-O-benzyl- α -D-glucopyranoside³² (145 mg, 0.39 mmol, 1 eq.) was dissolved in 1.5 mL DCM and cooled to 0°C . To this solution was added 2,6-dinitrobenzoic acid (synthesized by $\text{K}_2\text{Cr}_2\text{O}_7/\text{H}_2\text{SO}_4$ oxidation of 2,6-dinitrotoluene)⁵⁸ (123 mg, 0.58 mmol, 1.5 eq.), Ph_3P (202 mg, 0.77 mmol, 2 eq.), and DEAD (~40% in toluene, ~0.8 mmol, 2 eq.). The reaction was stirred at room temperature for 2 days. The reaction mixture was diluted with H_2O and extracted with DCM twice. The combined organic layers were washed with sat. aq. NaHCO_3 , and brine, then dried (MgSO_4), filtered, and concentrated under reduced pressure. Flash column chromatography (8/2 to 7/3 pentane/EtOAc) and size-exclusion chromatography (Sephadex LH-20, 1/1 MeOH/DCM) provide the title compound as a yellow oil. Yield: 165 mg, 0.29 mmol, 74%. $[\alpha]_D^{20} = +22.5^\circ$ ($c = 1.25$, CHCl_3); IR (thin film): 698, 714, 743, 918, 1057, 1279, 1454, 1582, 1748, 2920, 3493; $^1\text{H NMR}$ (CDCl_3 , 400 MHz, HH-COSY, HSQC, HMBC): δ 8.46 (d, 2H, $J = 8.3$ Hz, CH_{arom} NO_2Bz), 7.79 (t, 1H, $J = 8.3$ Hz, CH_{arom} NO_2Bz), 7.39–7.26 (m, 10H, CH_{arom} Bn), 5.00 (d, 1H, $J = 11.4$ Hz, CHH Bn), 4.79 (dd, 1H, $J = 11.9, 4.8$ Hz, H-6), 4.77–4.73 (m, 2H, CHH Bn, CHH Bn), 4.66–4.60 (m, 3H, CHH Bn, H-1, H-6), 3.89 (ddd, 1H, $J = 10.0, 4.8, 2.1$ Hz, H-5), 3.86–3.76 (m, 1H, H-3), 3.57–3.50 (m, 1H, H-4), 3.49 (dd, 1H, $J = 9.6, 3.5$ Hz, H-2), 3.37 (s, 3H, CH_3 OMe), 2.51 (d, 1H, $J = 3.3$ Hz, 4-OH); ^{13}C -APT NMR (CDCl_3 , 101 MHz, HSQC, HMBC): δ 162.6 (C=O), 146.8 (C_q NO_2), 138.7, 138.0 (C_q Bn), 131.2, 129.8, 128.7, 128.5, 128.1, 128.1, 128.0, 128.0 (CH_{arom}), 125.6 (C_q Bz), 98.3 (C-1), 81.3 (C-3), 79.6 (C-2), 75.6, 73.2 (CH_2 Bn), 69.8 (C-4), 69.0 (C-5), 66.2 (C-6), 55.6 (OMe); HRMS: $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{28}\text{H}_{28}\text{N}_2\text{O}_{11}\text{Na}$ 591.1591, found 591.1602.




Methyl 4-O-(2,3-di-O-benzyl-4,6-O-benzylidene- α / β -D-glucopyranosyl)-2,3,6-tri-O-benzyl- α -D-glucopyranoside (1A). Donor **A** and acceptor **1** were condensed using the general procedure for $\text{Ti}_2\text{O}/\text{Ph}_2\text{SO}$ mediated glycosylations (E) yielding product **1A** (73 mg, 82 μmol , 82%, $\alpha:\beta = 1:1$) as a white solid. R_f: 0.55 (4/1 pentane/EtOAc); Spectroscopic data were in accord with those previously reported.³² $^1\text{H NMR}$ (CDCl_3 , 400 MHz, HH-COSY, HSQC, HMBC): δ 7.52–7.45 (m, 4H, CH_{arom}), 7.44–7.18 (m, 56H, CH_{arom}), 5.75 (d, 1H, $J = 3.8$ Hz, H-1' α), 5.52 (s, 1H, CHPh_α), 5.49 (s, 1H, CHPh_β), 5.04 (d, 1H, $J = 11.7$ Hz, CHH Bn), 4.95–4.87 (m, 3H, $3\times\text{CHH}$ Bn), 4.84–4.51 (m, 17H, $4\times\text{CHH}$ Bn, $5\times\text{CH}_2$ Bn CHH Bn, H-1 α , H-1 β), 4.36 (d, 1H, $J = 7.8$ Hz, H-1' β), 4.30 (d, 1H, $J = 12.0$ Hz, CHH Bn), 4.19 (dd, 1H, $J = 10.5, 5.0$ Hz, H-6' β), 4.15–4.09 (m, 3H, H-3 α , H-4 α , H-6' α), 3.99 (t, 1H, $J = 9.3$ Hz, H-3' α), 3.94 (t, 1H, $J = 9.4$ Hz, H-4 β), 3.90–

3.78 (m, 5H, H-2 β , H-5 α , H-5' α , H-6 α , H-6 β), 3.69 – 3.41 (m, 11H, H-2 α , H-2' α , H-3 β , H-3' β , H-4' α , H-4' β , H-5 β , H-6 α , H-6 β , H-6' α , H-6' β), 3.40 – 3.31 (m, 7H, CH₃ OMe α , CH₃ OMe β , H-2' β), 3.10 (td, 1H, *J* = 9.5, 4.9 Hz, H-5' β); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC, HMBC): δ 139.4, 139.0, 138.7, 138.6, 138.5, 138.4, 138.2, 138.0, 137.9, 137.9, 137.6, 137.5 (C $_q$), 129.0, 128.9, 128.6, 128.5, 128.4, 128.3, 128.3, 128.2, 128.2, 128.2, 128.1, 128.1, 128.0, 128.0, 127.9, 127.8, 127.7, 127.7, 127.5, 127.4, 127.3, 126.8, 126.1, 126.1 (CH $_{arom}$), 102.9 (C-1' β), 101.2 (CHPh $_{\alpha,\beta}$), 98.5, 97.8 (C-1 α , C-1 β), 97.2 (C-1' α), 82.7 (C-2' β), 82.4 (C-4' α), 82.2 (C-3 α), 81.8 (C-4' β), 81.0 (C-3' β), 80.3 (C-2 β), 80.3, 78.9 (C-2 α , C-3' α), 78.8 (C-2' α , C-3 β), 76.9 (C-4 β), 75.6, 75.5, 75.4, 75.0, 74.4, 73.9, 73.7, 73.4, 73.4 (CH₂ Bn), 71.6 (C-4 α), 70.0 (C-5 β), 69.4 (C-5 α), 69.0, 68.9, 68.8 (C-6 α , C-6' α , C-6' β), 67.7 (C-6 β), 65.8 (C-5' β), 63.4 (C-5' α), 55.5 (OMe β), 55.3 (OMe α); HRMS: [M+NH₄]⁺ calcd for C₅₅H₆₂O₁₁N 912.43174, found 912.43282.




Methyl 4-O-(2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy- α/β -D-glucopyranosyl)-2,3,6-tri-O-benzyl- α -D-glucopyranoside (1B). Donor **B** and acceptor **1** were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (E) yielding product **1B** (mg, 88 μ mol, 88%, $\alpha:\beta = 1:7$) as a white solid. R_f: 0.51 α , 0.43 β

(4:1 pentane/ EtOAc). Spectroscopic data were in accord with those previously reported.¹¹ IR (thin film): 696, 737, 1049, 1092, 1362, 1454, 2110, 2868. Data for the β -anomer: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC, TOCSY): δ 7.68–7.60 (m, 2H, CH $_{arom}$), 7.52–7.18 (m, 23H, CH $_{arom}$), 5.47 (s, 1H, CHPh), 4.89 (d, 1H, *J* = 11.2 Hz, CHH Bn), 4.87 (d, 1H, *J* = 10.9 Hz, CHH Bn), 4.81 (d, 1H, *J* = 10.9 Hz, CHH Bn), 4.78 (d, 1H, *J* = 12.2 Hz, CHH Bn), 4.75 (d, 1H, *J* = 11.2 Hz, CHH Bn), 4.71 (d, 1H, *J* = 12.0 Hz, CHH Bn), 4.63 (d, 1H, *J* = 12.1 Hz, CHH Bn), 4.60 (d, 1H, *J* = 3.7 Hz, H-1), 4.41 (d, 1H, *J* = 12.0 Hz, CHH Bn), 4.19 (d, 1H, *J* = 7.6 Hz, H-1'), 4.11 (dd, 1H, *J* = 10.6, 5.0 Hz, H-6'), 4.00 – 3.90 (m, 2H, H-4, H-6), 3.85 (t, 1H, *J* = 9.3 Hz, H-3), 3.75 (dt, 1H, *J* = 9.8, 2.4 Hz, H-5), 3.69 (dd, 1H, *J* = 10.8, 1.9 Hz, H-6), 3.56 (t, 1H, *J* = 9.0 Hz, H-4'), 3.51 (dd, 1H, *J* = 9.5, 3.7 Hz, H-2), 3.45–3.38 (m, 4H, H-6', CH₃ OMe), 3.36–3.27 (m, 2H, H-2', H-3'), 3.00 (td, 1H, *J* = 9.8, 5.0 Hz, H-5'). ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 139.3, 138.3, 137.8, 137.8, 137.3 (C $_q$), 131.1, 129.4, 128.6, 128.4, 128.3, 128.2, 128.2, 128.1, 128.1, 127.9, 127.9, 127.6, 126.0, 124.8 (CH $_{arom}$), 101.3, 101.2 (CHPh, C-1'), 98.4 (C-1), 81.7 (C-4'), 80.1 (C-3), 79.2 (C-3'), 79.0 (C-2), 76.9 (C-4), 75.4, 74.7, 73.6, 73.5 (CH₂ Bn), 69.7 (C-5), 68.6 (C-6'), 68.0 (C-6), 66.6 (C-2'), 65.8 (C-5'), 55.4 (OMe). Diagnostic peaks for the α -anomer: ¹H NMR (CDCl₃, 400 MHz): δ 5.71 (d, 1H, *J* = 4.0 Hz, H-1'), 5.53 (s, 1H, CHPh), 5.11 (d, 1H, *J* = 10.7 Hz, CHH Bn), 4.95 (d, 1H, *J* = 10.9 Hz, CHH Bn). ¹³C-APT NMR (CDCl₃, 101 MHz): δ 98.1, 97.8, 82.7, 82.1, 80.5, 76.2, 75.1, 73.3, 73.0, 69.4, 69.1, 68.7, 63.4, 62.9; HRMS: [M+Na]⁺ calcd for C₄₈H₅₁N₃O₁₀Na 852.34667, found 852.34668.



Methyl 4-O-(2,3-di-O-benzyl-4,6-O-benzylidene- α/β -D-glucopyranosyl)-2,3-di-O-benzyl-6-deoxy- α -D-glucopyranoside (2A). Donor **A** and acceptor **2** were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (E) yielding product **2A** (67 mg, 85 μ mol, 85%, $\alpha:\beta = 2:1$) as a colorless oil. R_f: 0.50 (4/1


pentane/EtOAc); IR (thin film): 698, 737, 910, 995, 1029, 1049, 1088, 1369, 1454, 2870, 3032; Data reported for a 2:1 mixture of anomers. ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC, HMBC): δ 7.65 – 6.84 (m, 37.5H, CH $_{arom}$), 5.76 (d, 1H, *J* = 4.1 Hz, H-1' α), 5.55 (s, 1H, CHPh α), 5.50 (s, 0.5H, CHPh β), 5.02 (d, 1H, *J* = 11.8 Hz, CHH Bn α), 4.96 – 4.88 (m, 2H, 2xCHH Bn β , CHH Bn α), 4.87 – 4.81 (m, 1.5H, CHH Bn β , CHH Bn α), 4.81 – 4.62 (m, 6.0H, CHH Bn β , 2xCHH Bn α , 2xCH₂ Bn β , CH₂ Bn α , H-1' β), 4.55 (d, 1H, *J* = 12.0 Hz, CHH Bn α), 4.57 – 4.47 (m, 2.5H, CHH Bn α , H-1 α , H-1 β), 4.26 (dd, 1H, *J* = 10.3, 4.8 Hz, H-6' α), 4.16 (dd, 1H, *J* = 10.5, 5.0 Hz, H-6' β), 4.08 – 3.99 (m, 2H, H-3 α , H-3' α), 3.98 – 3.78 (m, 2H, H-5 α , H-5' α), 3.78 – 3.66 (m, 2H, H-4' β , H-6' α , H-5 β), 3.63 (m, 2H, m, H-4 α , H-4' α), 3.58 – 3.50 (m, 2.5H, H-2' α , H-2 α , H-2 β), 3.50 – 3.40 (m, 1.5H, H-6' β , H-4 β , H-2' β), 3.39 (s, 1.5H, CH₃ OMe β), 3.37 (s, 3H, CH₃ OMe α), 3.29 (td, 0.5H, *J* = 9.7, 4.9 Hz, H-5' β), 1.34 (d, 3H, *J* = 6.2 Hz, H-6 α), 1.27 (d, 1.5H, *J* = 6.4 Hz, H-6 β); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC, HMBC): δ 139.1, 138.7, 138.6, 138.4, 138.3, 138.0, 137.4 (C $_q$), 129.0, 129.0, 128.5, 128.4, 128.3, 128.1, 127.7, 127.2, 126.6, 126.1, 126.1 (CH $_{arom}$), 103.7 (C-1' β), 101.2 (CHPh α), 101.2 (CHPh β), 98.1 (C-1 β), 97.9 (C-1' α), 97.6 (C-1 α), 83.8 (C-4 β), 82.8 (C-2' β), 82.3 (C-4 α), 81.8 (C-3 α), 81.4 (C-4' β), 80.7 (C-2' α), 80.0 (C-3 β), 79.5 (C-3' β), 79.0 (C-3' α), 78.8 (C-4' α), 78.3 (C-2 α), 75.8, 75.5, 75.4, 75.2, 74.2, 74.0, 73.6, 73.3 (CH₂ Bn), 68.9 (C-6' α), 68.8 (C-6' β), 66.6 (C-5 β), 66.0 (C-5' β), 65.7 (C-5 α), 63.3 (C-5' α), 55.4 (OMe β), 55.2 (OMe α), 19.2 (C-6 α), 18.0 (C-6 β); HRMS: [M+NH₄]⁺ calcd for C₄₈H₅₆N₃O₁₀ 806.38987, found 806.39030.



Methyl 4-O-(2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy- α/β -D-glucopyranosyl)-2,3-di-O-benzyl-6-deoxy- α -D-glucopyranoside (2B). Donor **B** and acceptor **2** were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (E) yielding product **2B** (50 mg, 69 μ mol, 69%, $\alpha:\beta = 1:5$) as a white solid. R_f: 0.50 (4/1


pentane/EtOAc); IR (thin film): 698, 737, 999, 1049, 1092, 1177, 1277, 1366, 1454, 2110, 2912, 3032; Data for the β -anomer: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC, HMBC): δ 7.51 – 7.20 (m, 20H, CH $_{arom}$), 5.48 (s, 1H, CHPh), 4.94 –

4.69 (m, 5H, 2xCH₂ Bn, CHH Bn), 4.66–4.58 (m, 1H, CHH Bn), 4.54–4.46 (m, 2H, H-1, H-1'), 4.07–3.98 (m, 1H, H-6'), 3.89–3.82 (m, 1H, H-3), 3.79 (dd, 1H, *J* = 9.7, 6.2 Hz, H-5), 3.63 (t, 1H, *J* = 9.1 Hz, H-4'), 3.57 (t, 1H, *J* = 9.1 Hz, H-3'), 3.51–3.48 (m, 1H, H-2), 3.48–3.39 (m, 3H, H-6', H-2', H-4), 3.38 (s, 3H, CH₃ OMe), 3.25–3.16 (m, 1H, H-5'), 1.35 (d, 3H, *J* = 6.2 Hz, H-6); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC, HMBC): δ 139.4, 138.3, 137.8, 137.2 (C_q), 129.2, 128.5, 128.4, 128.3, 128.2, 128.0, 128.0, 127.4, 127.2, 126.1 (CH_{arom}), 102.3 (CHPh), 97.9 (C-1), 84.0 (C-4), 81.7 (C-4'), 80.1 (C-3), 79.7 (C-2), 79.5 (C-3'), 75.3, 75.0, 73.5 (CH₂ Bn), 68.5 (C-6'), 67.2 (C-2'), 66.2 (C-5), 66.2 (C-5'), 55.3 (OMe), 18.1 (C-6); Diagnostic peaks for the α-anomer: ¹H NMR (CDCl₃, 400 MHz): δ 5.66 (d, 1H, *J* = 4.2 Hz, H-1'), 5.57 (s, 1H, CHPh), 5.10 (d, 1H, *J* = 10.6 Hz), 4.98 (d, 1H, *J* = 10.9 Hz), 4.22 (dd, 1H, *J* = 10.4, 4.9 Hz, H-6'), 3.92 (td, 1H, *J* = 10.1, 4.9 Hz, H-5'), 3.31 (dd, 1H, *J* = 10.1, 4.2 Hz, H-2'), 1.30 (d, 3H, *J* = 6.2 Hz, H-6); ¹³C-APT NMR (CDCl₃, 101 MHz): δ 101.3, 98.8, 97.7, 82.6, 80.9, 79.9, 76.3, 75.2, 75.1, 73.3, 68.6, 65.5, 63.3, 62.8, 18.8; HRMS: [M+NH₄]⁺ calcd for C₄₁H₄₉N₄O₉ 741.34941, found 741.34989.




Methyl 4-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α-β-D-glucopyranosyl)-2,3-di-O-benzyl-6-O-benzoyl-α-D-glucopyranoside (3A). Donor **A** and acceptor **3** were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (E) yielding product **3A** (84 mg, 92 μmol, 92%, α:β = 5:1) as a colorless oil. *R_f*: 0.49 (4/1

pentane/EtOAc); IR (thin film): 737, 999, 1026, 1049, 1092, 1273, 1454, 1721, 2928; Data for the α-anomer: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC, HMBC): δ 8.10–8.00 (m, 2H, CH_{arom}), 7.59–7.11 (m, 28H, CH_{arom}), 5.73 (d, 1H, *J* = 4.0 Hz, H-1'α), 5.47 (s, 1H, CHPh), 4.99 (d, 1H, *J* = 11.5 Hz, CHH Bn), 4.89 (d, 1H, *J* = 11.1 Hz, CHH Bn), 4.80 (d, 1H, *J* = 8.3 Hz, CHH Bn), 4.76–4.69 (m, 3H, 2xCHH Bn, H-6), 4.66 (d, 1H, *J* = 8.7 Hz, CHH Bn), 4.60 (d, 1H, *J* = 3.5 Hz, H-1), 4.59–4.50 (m, 3H, 2xCHH Bn, H-6), 4.16–4.08 (m, 1H, H-3), 4.07 (m, 4H, H-5, H-3', H-4, H-6'), 3.81 (td, 1H, *J* = 9.9, 4.7 Hz, H-5'), 3.63–3.52 (m, 4H, H-2, H-4', H-6', H-2'), 3.39 (s, 3H, CH₃ OMe); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC, HMBC): δ 166.2 (C=O), 138.9, 138.6, 137.8, 137.4 (C_q), 133.2 (CH_{arom}), 129.9 (C_q), 129.8, 128.9, 128.5, 127.7, 126.9, 126.2, 126.1 (CH_{arom}), 101.3 (CHPh), 98.2 (C-1'), 97.6 (C-1), 82.4 (C-2), 81.7 (C-3), 80.4 (C-4'), 78.7 (C-3'), 78.7 (C-2'), 75.3, 74.6, 74.2 (CH₂ Bn), 73.7 (C-4), 73.4 (CH₂ Bn), 68.8 (C-6'), 68.1 (C-5), 63.7 (C-5'), 62.8 (C-6), 55.4 (OMe); Diagnostic peaks β-anomer: ¹H NMR (CDCl₃, 400 MHz): δ 7.99–7.94 (m, 2H), 5.51 (s, 1H), 4.46 (dd, 1H, *J* = 12.1, 4.7 Hz), 4.19 (dd, 1H, *J* = 10.5, 5.0 Hz), 3.32–3.18 (m, 1H, H-5'β); ¹³C-APT NMR (CDCl₃, 101 MHz): δ 166.0, 139.1, 138.3, 138.2, 137.3, 129.6, 128.3, 127.3, 103.3, 101.2, 98.0, 82.7, 81.4, 80.1, 77.8, 75.8, 68.7, 66.1, 63.7, 41.1; HRMS: [M+NH₄]⁺ calcd for C₅₅H₆₀NO₁₂ 926.41100, found 926.41196.



Methyl 4-O-(2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-α-β-D-glucopyranosyl)-2,3-di-O-benzyl-6-O-benzoyl-α-D-glucopyranoside (3B). Donor **B** and acceptor **3** were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (E) yielding product **3B** (61 mg, 67 μmol, 67%, α:β = 1:1.1) as a colorless oil. *R_f*: 0.50


(4/1 pentane/EtOAc); IR (thin film): 698, 741, 914, 999, 1030, 1092, 1273, 1369, 1454, 1721, 2110, 2870, 3032; Data reported for a 0.9:1 mixture of anomers. ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC, HMBC): δ 8.04 (ddd, 3.8H, *J* = 8.4, 6.7, 1.4 Hz, CH_{arom}), 7.61–7.15 (m, 43.7H, CH_{arom}), 5.71 (d, 0.9H, *J* = 4.2 Hz, H-1'α), 5.50 (s, 0.9H, CHPhα), 5.49 (s, 1H, CHPhβ), 5.13 (d, 1H, *J* = 10.4 Hz, CHH Bn), 5.00–4.83 (m, 5H, CHH Bn, 2xCH₂ Bn, CHH Bn), 4.83–4.68 (m, 4.9H, H-6α, H-6β, CHH Bn, 2xCHH Bn), 4.68–4.54 (m, 4.8H, 2xCHH Bn, H-6α, H-1α, H-1β), 4.51–4.40 (m, 2H, H-6β, H-1'β), 4.13 (dd, 1H, *J* = 9.5, 8.4 Hz, H-3β), 4.08–3.88 (m, 7.5H, H-3α, H-3'α, H-4β, H-4α, H-5α, H-5β, H-6'α, H-6'β), 3.83 (td, 0.9H, *J* = 9.9, 4.8 Hz, H-5'α), 3.71–3.51 (m, 5H, H-2α, H-2β, H-3'β, H-4'β, H-4'β, H-6'α), 3.49 (t, 1H, *J* = 10.3 Hz, H-6'β), 3.46–3.41 (m, 1H, H-2'β), 3.41 (s, 3H, CH₃ OMeβ), 3.40 (s, 2.7H, CH₃ OMeα), 3.35 (dd, 0.9H, *J* = 10.1, 4.2 Hz, H-2'α), 3.22–3.10 (m, 1H, H-5'β); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC, HMBC): δ 166.2, 166.1 (C=O), 139.1, 138.6, 138.2, 137.9, 137.8, 137.7, 137.2, 137.1 (C_q), 133.4, 133.3 (CH_{arom}), 129.9 (C_q), 129.7, 129.2, 129.1, 128.7, 128.6, 128.6, 128.6, 128.5, 128.5, 128.4, 128.3, 128.3, 128.2, 128.2, 128.1, 128.0, 128.0, 127.9, 127.8, 127.6, 127.5, 126.1, 126.0 (CH_{arom}), 102.0 (C-1'β), 101.4 (CHPhα), 101.3 (CHPhβ), 99.0 (H-1α), 98.0, 97.7 (C-1α, C-1β), 82.7 (C-4'α), 81.6, 81.6 (C-3β, C-4'β), 80.8 (C-2α), 80.1 (C-3α), 79.7 (C-3'β), 79.6, (C-2β), 78.0 (C-4β), 76.1 (C-3'α), 75.7, 75.3, 75.2, 75.1 (CH₂ Bn), 74.9 (C-4α), 73.6, 73.4 (CH₂ Bn), 68.6, 68.5 (C-6'α,β), 68.5, 68.0 (C-5α, C-5β), 66.8 (C-2'β), 66.3 (C-5'β), 63.7 (C-5'α), 63.5 (C-6β), 63.1 (C-6α), 62.8 (C-2'α), 55.6 (OMeβ), 55.5 (OMeα); HRMS: [M+Na]⁺ calcd for C₄₈H₄₉N₃O₁₁Na 866.3290, found 866.3259.



Methyl (methyl 4-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α-β-D-glucopyranosyl)-2,3-di-O-benzyl-α-D-glucopyranosyl uronate) (4A). Donor **A** and acceptor **4** were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (E) yielding product **4A** (75.2 mg, 90 μmol, 90%, α:β = 5:1) as a white solid. *R_f*: 0.77 (7/3


pentane/EtOAc); Spectroscopic data were in accord with those previously reported.³² IR (thin film): 694, 732, 912, 988, 1026, 1043, 1074, 1086, 1358, 1454, 1749, 28866, 2932; Data for the α-anomer: ¹H NMR (CDCl₃, 400 MHz, HH-

COSY, HSQC, HMBC): δ 7.48 – 7.43 (m, 2H, CH_{arom}), 7.40 – 7.16 (m, 23H, CH_{arom}), 5.51 (s, 1H, CHPh), 5.44 (d, 1H, J = 3.8 Hz, H-1'), 4.95 – 4.86 (m, 3H, CH₂ Bn, CHH Bn), 4.78 (d, 1H, J = 11.2 Hz, CHH Bn), 4.71 (d, 1H, J = 12.1 Hz, CHH Bn), 4.67 (d, 1H, J = 12.0 Hz, CHH Bn), 4.59 – 4.53 (m, 3H, 2xCHH Bn, H-1), 4.28 (dd, 1H, J = 6.5, 3.8 Hz, H-6'), 4.25 (d, 1H, J = 9.5 Hz, H-5), 4.11 (t, 1H, J = 9.1 Hz, H-4), 4.05 (t, 1H, J = 8.9 Hz, H-3), 3.98 (t, 1H, J = 9.1 Hz, H-3'), 3.76 (s, 3H, CH₃ CO₂Me), 3.64 (t, 1H, J = 10.0 Hz, H-6'), 3.61 – 3.54 (m, 3H, H-2, H-4', H-5'), 3.48 (dd, 1H, J = 5.6, 3.9 Hz, H-2'), 3.40 (s, 3H, CH₃ OMe); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC, HMBC): δ 170.1 (C=O CO₂Me), 139.0, 138.6, 138.0, 137.8, 137.6 (C_q), 129.0, 128.6, 128.4, 128.4, 128.3, 128.3, 128.3, 128.2, 128.1, 128.1, 127.8, 127.7, 127.7, 127.3, 127.0, 126.1 (CH_{arom}), 101.3 (CHPh), 98.6 (C-1), 98.4 (C-1'), 82.0 (C-4'), 80.8 (C-3), 79.2 (C-2), 78.7 (C-2'), 78.4 (C-3'), 76.1 (C-4), 75.3, 75.0, 73.7, 73.7 (CH₂ Bn), 70.3 (C-5), 68.6 (C-6'), 63.1 (C-5'), 55.8 (OMe), 52.9 (CO₂Me); ¹³C-HMBC NMR (CDCl₃, 101 MHz): δ 98.4 ($J_{C1',H1'} = 174$ Hz, C-1'); Diagnostic peaks β -anomer: ¹H NMR (CDCl₃, 400 MHz): δ 5.47 (s, 1H, CHPh), 4.62 (d, 1H, J = 12.1 Hz), 3.87 (dd, 1H, J = 9.6, 8.4 Hz), 3.50 (s, 3H, CH₃ CO₂Me), 3.44 (s, 0.54H, CH₃ OMe), 3.38 – 3.28 (m, 2H, H-2', H-5'); ¹³CAPT NMR (CDCl₃, 101 MHz): δ 170.1, 139.2, 138.6, 138.2, 137.4, 129.0, 128.5, 128.3, 128.1, 127.7, 127.5, 126.1, 102.9 (C-1'), 101.2 (CHPh), 99.0 (C-1), 82.3, 81.8, 81.3, 79.6, 78.5, 78.2, 75.6, 75.5, 75.2, 73.9, 70.0, 68.8, 65.9, 55.9, 52.7; ¹³C-HMBC NMR (CDCl₃, 101 MHz): δ 102.9 ($J_{C1',H1'} = 164$ Hz, C-1'); HRMS: [M+Na]⁺ calcd for C₄₉H₅₂O₁₂Na 855.33510, found 855.33496.




Methyl (methyl 4-O-(2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy- α/β -D-glucopyranosyl)-2,3-di-O-benzyl- α -D-glucopyranosyl uronate (4B). Donor **B** and acceptor **4** were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (E) yielding product **4B** (mg, 93 μ mol, 93%, α/β = 1.1 : 1) as a white

solid. R_f 0.54 (4:1 pentane/EtOAc). Spectroscopic data were in accord with those previously reported.¹¹ IR (thin film): 696, 735, 914, 989, 1028, 1045, 1090, 1267, 1369, 1454, 1749, 2108, 2870, 2916. Data reported for a 1:1 mixture of anomers: ¹H NMR (CDCl₃, 400 MHz, H-H COSY, HSQC, HMBC): δ 7.48–7.41 (m, 4H, CH_{arom}), 7.41–7.24 (m, 36H, CH_{arom}), 5.53 (s, 1H, CHPh_a), 5.51 (d, 1H, J = 3.9 Hz, H-1'_a), 5.47 (s, 1H, CHPh_b), 5.04 (d, 1H, J = 10.5 Hz, CHH Bn), 4.94 (d, 1H, J = 11.0 Hz, CHH Bn), 4.91–4.82 (m, 4H, 2xCHH Bn, 2xCHH Bn), 4.81–4.72 (m, 4H, 2xCHH Bn, 2xCHH Bn), 4.64–4.58 (m, 2H, 2xCHH Bn), 4.57 (d, 2H, J = 3.5 Hz, H-1_{a,b}), 4.43 (d, 1H, J = 8.1 Hz, H-1'_b), 4.26 (dd, 1H, J = 10.3, 4.8 Hz, H-6'_a), 4.24–4.19 (m, 2H, H-5_a, H-5_b), 4.09–3.99 (m, 4H, H-3_b, H-4_a, H-4_b, H-6'_b), 3.97 (t, 1H, J = 9.5 Hz, H-3'_a), 3.89 (t, 1H, J = 9.2 Hz, H-3_a), 3.82 (s, 3H, CH₃ CO₂Me), 3.81 (s, 3H, CH₃ CO₂Me), 3.72–3.56 (m, 4H, H-2_b, H-4'_a, H-4'_b, H-6'_a), 3.56–3.46 (m, 3H, H-2_a, H-3'_b, H-5'_a), 3.46–3.38 (m, 7H, 2xCH₃ OMe_{a,b}, H-6'_b), 3.36–3.29 (m, 2H, H-2'_a, H-2'_b), 3.26 (td, 1H, J = 9.7, 5.0 Hz, H-5'_b); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC, HMBC): δ 170.0, 170.0 (C=O), 139.1, 138.5, 138.0, 137.9, 137.9, 137.8, 137.4, 137.2 (C_q), 129.2, 129.1, 128.7, 128.6, 128.5, 128.5, 128.4, 128.3, 128.3, 128.3, 128.3, 128.2, 128.1, 128.0, 128.0, 127.8, 127.7, 127.5, 127.4, 126.1, 126.1 (CH_{arom}), 102.3 (C-1'_b), 101.4 (CHPh_b), 101.3 (CHPh_a), 98.9, 98.6 (C-1_a, C-1_b), 98.5 (C-1'_a), 82.4 (C-4'_a), 81.6 (C-4'_b), 81.1 (C-3_b), 79.6 (C-2_b, C-4_b), 79.5 (C-3_a), 79.4 (C-3'_b), 78.7 (C-2_a), 76.3 (C-3'_a), 75.6 (CH₂ Bn), 75.5 (C-4_a), 75.1, 75.0, 73.9, 73.7 (CH₂ Bn), 70.0, 69.9 (C-5_a, C-5_b), 68.5, 68.5 (C-6_a, C-6_b), 66.7 (C-2'_b), 66.2 (C-5'_b), 63.0 (C-5'_a), 62.8 (C-2'_a), 55.9, 55.9 (OMe), 53.0, 52.8 (CO₂Me); HRMS: [M+NH₄]⁺ calcd for C₄₂H₄₉N₄O₁₁ 785.33923, found 785.34007.




Methyl 4-O-(2,3-di-O-benzyl-4,6-O-benzylidene- α/β -D-glucopyranosyl)-2-O-benzoyl-3,6-di-O-benzyl- α -D-glucopyranoside (5A). Donor **A** and acceptor **5** were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (E) yielding product **5A** (74 mg, 81 μ mol, 81%, α/β = 1:1) as a white solid. R_f: 0.50 (4/1

pentane/EtOAc); IR (thin film): 696, 737, 916, 995, 1047, 1088, 1271, 1366, 1452, 1721, 2926; Data reported for a 1:1.1 mixture of anomers: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC, HMBC): δ 8.02 (td, 4H, J = 8.2, 1.4 Hz, CH_{arom}), 7.60 – 6.99 (m, 56H, CH_{arom}), 5.64 (d, 1H, J = 3.8 Hz, H-1'_a), 5.54 (s, 1H, CHPh_a), 5.49 (s, 1.1H, CHPh_b), 5.18 (dd, 1H, J = 9.7, 3.7 Hz, H-2_a), 5.11 – 5.02 (m, 3.2H, H-2_b, H-1_b, H-1_a), 4.96 – 4.55 (m, 15.7H, 7xCH₂ Bn, CHH Bn_b), 4.45 (d, 1.1H, J = 7.8 Hz, H-1'_b), 4.38 (d, 1.1H, J = 12.0 Hz, CHH Bn_b), 4.32 (t, 1H, J = 9.2 Hz, H-3_a), 4.25 (t, 1H, J = 9.0 Hz, H-4_a), 4.21 – 4.08 (m, 3.2H, H-6_a, H-6'_b, H-3_b), 4.08 – 3.99 (m, 2.1H, H-3'_a, H-3_b), 3.99 – 3.82 (m, 4.1H, H-5'_a, H-6_a, H-6_b, H-5_a), 3.78 – 3.66 (m, 2.2H, H-6_a, H-5_b), 3.63 – 3.49 (m, 6.3H, H-6_b, H-4'_b, H-4_b, H-4'_a, H-6_a, H-2'_a), 3.45 (t, 1.1H, J = 10.3 Hz, H-6'_b), 3.41 – 3.38 (m, 7.4H, H-2'_b, CH₃ OMe_b, CH₃ OMe_a), 3.20 – 3.09 (m, 1.1H, H-5'_b); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC, HMBC): δ 166.0, 165.9 (C=O), 138.8, 138.8, 138.6, 138.5, 138.3, 138.3, 138.1, 138.0, 137.7 (C_q), 133.3, 133.2, 129.9, 129.9 (CH_{arom}), 129.7 (C_q), 129.1, 129.0, 128.6, 128.5, 128.4, 128.4, 128.4, 128.4, 128.3, 128.3, 128.2, 128.2, 128.1, 128.0, 128.0, 127.9, 127.9, 127.8, 127.8, 127.7, 127.6, 127.6, 127.5, 127.4, 127.0, 126.2 (CH_{arom}), 103.0 (C-1'_b), 101.2 (CHPh_{a,b}), 97.7 (C-1'_a), 97.3 (C-1_a), 97.0 (C-1_b), 82.7 (C-2'_b), 82.4 (C-4'_a), 81.9 (C-4'_b), 81.1 (C-3'_b), 80.6 (C-3_a), 79.0 (C-2'_a), 78.8 (C-3'_a), 77.9 (C-3_b), 76.9 (C-4_b), 75.6, 75.4, 75.3, 75.1 (CH₂ Bn), 74.2 (C-2_a), 74.1, 73.8, 73.6, 73.5 (CH₂ Bn), 73.4 (C-2_b), 72.7 (C-4_a), 70.3 (C-5_b), 69.8 (C-5_a), 69.0, 68.8, 68.8 (C-6'_{a,b}, C-6_b), 67.6 (C-6_a), 65.8 (C-5'_b), 63.5 (C-5'_a), 55.5 (OMe_a), 55.3 (OMe_b); HRMS: [M+NH₄]⁺ calcd for C₅₅H₆₀NO₁₂ 926.41100, found 926.41192.




Methyl 4-O-(2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy- α/β -D-glucopyranosyl)-2-O-benzoyl-3,6-di-O-benzyl- α -D-glucopyranoside (5B). Donor **B** and acceptor **5** were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (E) yielding product **5B** (74 mg, 88 μ mol, 88%, $\alpha/\beta = 1:6$) as a light yellow oil. R_f: 0.50

(4/1 pentane/EtOAc); IR (thin film): 698, 737, 999, 1092, 1173, 1273, 1366, 1454, 1721, 2110, 2870; Data for the β -anomer: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC, HMBC): δ 8.05 – 7.98 (m, 2H, CH_{arom}), 7.60 – 7.10 (m, 23H, CH_{arom}), 5.47 (s, 1H, CHPh), 5.12 – 5.03 (m, 2H, H-1, H-2), 4.90 (d, 1H, $J = 11.2$ Hz, CHH Bn), 4.85 (d, 1H, $J = 11.0$ Hz, CHH Bn), 4.78 (d, 1H, $J = 4.3$ Hz, CHH Bn), 4.75 (d, 1H, $J = 3.5$ Hz, CHH Bn), 4.70 (d, 1H, $J = 11.0$ Hz, CHH Bn), 4.47 (d, 1H, $J = 12.0$ Hz, CHH Bn), 4.29 – 4.24 (m, 1H, H-1'), 4.17 – 4.00 (m, 4H, H-3, H-6', H-3', H-6), 3.86 (dt, 1H, $J = 9.4, 2.3$ Hz, H-5), 3.77 (dd, 1H, $J = 11.0, 1.8$ Hz, H-6), 3.60 – 3.54 (m, 1H, H-4'), 3.44 – 3.34 (m, 2H, H-3', H-6', H-2', CH₃ OMe), 3.03 (td, 1H, $J = 9.8, 5.0$ Hz, H-5'); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC, HMBC): δ 165.9 (C=O), 138.7, 137.9, 137.3 (C_q), 133.3, 129.9 (CH_{arom}), 129.8 (C_q), 129.2, 128.7, 128.5, 128.5, 128.4, 128.4, 128.3, 128.3, 128.2, 128.1, 128.0, 127.7, 127.5, 126.1 (CH_{arom}), 101.3, 101.3 (C-1', CHPh), 97.3 (C-1), 81.8 (C-4'), 79.2 (C-3'), 77.9 (C-3), 76.9 (C-4), 75.3, 74.9, 73.6 (CH₂ Bn), 73.5 (C-2), 70.0 (C-5), 68.6 (C-6'), 67.9 (C-6), 66.7 (C-2'), 65.9 (C-5'), 55.5 (OMe); Diagnostic peaks for the α -anomer: ¹H NMR (CDCl₃, 400 MHz): δ 8.11 – 8.06 (m, 2H), 5.68 (d, 1H, $J = 4.0$ Hz, H-1'), 5.55 (s, 1H, CHPh), 5.17 (dd, 1H, $J = 9.8, 3.6$ Hz, H-2), 4.98 (d, 1H, $J = 10.9$ Hz), 4.33 (dd, 1H, $J = 9.8, 8.7$ Hz), 3.67 (t, 1H, $J = 9.3$ Hz); ¹³C-APT NMR (CDCl₃, 101 MHz): δ 165.9, 138.2, 137.9, 137.4, 133.4, 129.6, 129.1, 128.6, 127.6, 98.2, 97.1, 82.7, 80.9, 76.3, 75.2, 75.0, 74.7, 69.7, 69.1, 68.8, 63.5, 62.9; HRMS: [M+NH₄]⁺ calcd for C₄₈H₅₁N₄O₁₂ 861.37053, found 861.37082.



Methyl 4-O-(2,3-di-O-benzyl-4,6-O-benzylidene- α/β -D-glucopyranosyl)-2-O-benzoyl-3-O-benzyl-6-deoxy- α -D-glucopyranoside (6A). Donor **A** and acceptor **6** were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (E) yielding product **6A** (69 mg, 86 μ mol, 86%, $\alpha/\beta = 1:1:1$) as a white solid. R_f: 0.55 (4/1


pentane/EtOAc); IR (thin film): 696, 737, 995, 1051, 1086, 1273, 1366, 1452, 1720, 2932; Data reported for a 1.1:1 mixture of anomers: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 8.05 – 8.01 (m, 2H, CH_{arom}), 8.01 – 7.95 (m, 2.2H, CH_{arom}), 7.60 – 7.16 (m, 42.8H, CH_{arom}), 7.14 – 7.08 (m, 3.3H, CH_{arom}), 7.04 – 6.97 (m, 2.2H, CH_{arom}), 5.66 (d, 1.1H, $J = 4.0$ Hz, H-1'_a), 5.57 (s, 1.1H, CHPh_a), 5.50 (s, 1H, CHPh_b), 5.12 (dd, 1.1H, $J = 9.9, 3.7$ Hz, H-2_a), 5.06 (dd, 1H, $J = 10.0, 3.8$ Hz, H-2_b), 4.97 (d, 1.1H, $J = 3.8$ Hz, H-1_b), 4.95 (d, 1H, $J = 4.0$ Hz, H-1_b), 4.95 – 4.70 (m, 11.5H, 2xCH₂ Bn_a, 3xCH₂ Bn_b, CHH Bn_a), 4.67 (d, 1H, $J = 7.7$ Hz, H-1'_b), 4.57 (d, 1.1H, $J = 11.8$ Hz, CHH Bn_a), 4.33 – 4.22 (m, 2.2H, H-3_a, H-6'_a), 4.18 (dd, 1H, $J = 10.4, 4.8$ Hz, H-6'_b), 4.12 – 4.00 (m, 2.1H, H-3'_a, H-3_b), 4.03 – 3.89 (m, 2.2H, H-5_a, H-5'_a), 3.85 – 3.74 (m, 2H, H-3_b, H-5_b), 3.74 (t, 1.1H, $J = 10.3$ Hz, H-6'_a), 3.68 (dd, 1.1H, $J = 9.5, 8.6$ Hz, H-4_a), 3.68 – 3.61 (m, 2.1H, H-4'_a, H-4'_b), 3.58 (dd, 1H, $J = 9.7, 8.8$ Hz, H-4_b), 3.56 (dd, 1.1H, $J = 9.5, 4.1$ Hz, H-2_a), 3.48 (dd, 1H, $J = 8.8, 7.7$ Hz, H-2'_b), 3.45 (t, 1H, $J = 10.2$ Hz, H-6'_b), 3.38 (s, 3H, CH₃ OMe_b), 3.36 (s, 3.3H, CH₃ OMe_a), 3.32 (dt, 0.9H, $J = 9.7, 4.8$ Hz, H-5'_b), 1.42 (d, 3H, $J = 6.2$ Hz, H-6_a), 1.36 (d, 2.7H, $J = 6.3$ Hz, H-6_b); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC, HMBC): δ 166.0 (C=O), 138.8, 138.7, 138.6, 138.4, 138.3, 138.1, 137.4 (C_q), 133.3, 133.3 (CH_{arom}), 129.9 (C_q), 129.9, 129.1, 129.0, 128.5, 128.5, 128.4, 128.4, 128.4, 128.4, 128.4, 128.2, 128.2, 128.1, 127.9, 127.8, 127.7, 127.7, 127.5, 127.3, 126.7, 126.1, 126.1 (CH_{arom}), 103.8 (C-1'_b), 101.2 (CHPh_a), 101.2 (CHPh_b), 98.3 (C-1'_a), 97.0 (C-1_b), 96.9 (C-1_a), 83.6 (C-4_b), 82.9 (C-2'_b), 82.3 (C-4'_a), 81.8 (C-4'_b), 81.4 (C-3'_b), 80.3 (C-3_a), 79.2 (C-3'_a), 78.9 (C-4_a), 78.9 (C-2'_a), 77.8 (C-3_b), 75.8, 75.4, 75.3 (CH₂ Bn), 74.7 (C-2_a), 74.0 (CH₂ Bn), 73.8 (C-2_b), 68.9 (C-6'_a), 68.8 (C-6'_b), 66.8 (C-5_b), 66.0 (C-5'_b), 65.9 (C-5_a), 63.4 (C-5'_a), 55.4 (OMe_b), 55.2 (OMe_a), 19.1 (C-6_a), 17.9 (C-6_b); HRMS: [M+NH₄]⁺ calcd for C₄₈H₅₄N₄O₁₁ 820.36914, found 820.36967.



Methyl 4-O-(2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy- α/β -D-glucopyranosyl)-2-O-benzoyl-3-O-benzyl-6-deoxy- α -D-glucopyranoside (6B). Donor **B** and acceptor **6** were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (E) yielding product **6B** (65 mg, 88 μ mol, 88%, $\alpha/\beta = 1:5$) as a colorless


oil. R_f: 0.76 (4/1 pentane/EtOAc); IR (thin film): 698, 737, 995, 1092, 1273, 1366, 1454, 1721, 2110, 2878; Data for the β -anomer: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC, HMBC): δ 8.05 – 7.98 (m, 2H, CH_{arom}), 7.60 – 7.11 (m, 18H, CH_{arom}), 5.49 (s, 1H, CHPh), 5.06 (dd, 1H, $J = 10.0, 3.7$ Hz, H-2), 4.97 (d, 1H, $J = 3.8$ Hz, H-1), 4.94 – 4.82 (m, 2H, 2xCHH Bn), 4.79 (d, 1H, $J = 11.2$ Hz, CHH Bn), 4.74 (d, 1H, $J = 11.1$ Hz, CHH Bn), 4.53 (d, 1H, $J = 8.1$ Hz, H-1'), 4.12 – 4.01 (m, 2H, H-6', H-3), 3.89 (qd, 1H, $J = 6.3, 3.4$ Hz, H-5), 3.65 (t, 1H, $J = 9.0$ Hz, H-4'), 3.62 – 3.52 (m, 2H, H-3', H-4), 3.49 – 3.40 (m, 2H, H-2', H-6'), 3.37 (s, 3H, CH₃ OMe), 3.25 (td, 1H, $J = 9.6, 4.9$ Hz, H-5'), 1.43 (d, 3H, $J = 6.2$ Hz, H-6); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC, HMBC): δ 166.0 (C=O), 138.7, 137.8, 137.2 (C_q), 133.3, 129.9 (CH_{arom}), 129.8 (C_q), 129.2, 128.6, 128.6, 128.5, 128.4, 128.4, 128.3, 128.3, 128.0, 127.7, 127.5, 127.4, 126.1 (CH_{arom}), 102.4 (C-1'), 101.3 (CHPh), 96.9 (C-1), 83.8 (C-4), 81.7 (C-4'), 79.4 (C-3'), 78.1 (C-3), 75.3, 75.1 (CH₂ Bn), 74.0 (C-2), 68.5 (C-6'), 67.2 (C-2'), 66.4 (C-5), 66.2 (C-5'), 55.4 (OMe), 18.0 (CO₂Me); Diagnostic peaks for the α -anomer: ¹H NMR (CDCl₃, 400 MHz): δ 8.11 –

8.06 (m, 2H), 5.62 (d, 1H, $J = 4.2$ Hz, H-1'), 5.58 (s, 1H, CHPh), 5.12 (dd, 1H, $J = 9.8, 3.7$ Hz, H-2), 4.31 – 4.23 (m, 2H), 3.78 – 3.66 (m, 2H) 1.39 (d, 3H, $J = 6.2$ Hz); ^{13}C -APT NMR (CDCl₃, 101 MHz): δ 166.0, 138.1, 137.9, 137.2, 133.5, 129.6, 127.7, 126.0, 98.8, 82.6, 80.4, 80.1, 76.4, 75.2, 75.0, 68.6, 65.6, 63.4, 62.8, 18.8; HRMS: $[\text{M}+\text{Na}]^+$ calcd for C₄₁H₄₃N₃O₁₀Na 760.2841, found 760.2853.




Methyl 4-O-(2,3-di-O-benzyl-4,6-O-benzylidene- α/β -D-glucopyranosyl)-2,6-di-O-benzoyl-3-O-benzyl- α -D-glucopyranoside (7A). Donor **A** and acceptor **7** were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (E) yielding product **7A** (81 mg, 88 μmol , 88%, $\alpha:\beta = 3.5:1$) as a white solid. R_f: 0.67 (4/1

pentane/EtOAc); IR (thin film): 698, 712, 737, 995, 1026, 1090, 1271, 1371, 1452, 1720, 2920; Data for the α -anomer: ^1H NMR (CDCl₃, 500 MHz, HH-COSY, HSQC, HMBC): δ 8.12 – 8.06 (m, 2H, CH_{arom}), 8.01 – 7.97 (m, 2H, CH_{arom}), 7.61 – 6.99 (m, 26H, CH_{arom}), 5.57 (d, 1H, $J = 3.9$ Hz, H-1' _{α}), 5.49 (s, 1H, CHPh), 5.17 (dd, 1H, $J = 9.9, 3.7$ Hz, H-2), 5.02 (d, 1H, $J = 3.5$ Hz, H-1), 4.96 – 4.88 (m, 1H, CHH Bn), 4.87 – 4.82 (m, 1H, CHH Bn), 4.81 – 4.71 (m, 4H, CHH Bn, 2xCHH Bn, H-6), 4.65 – 4.55 (m, 2H, H-6, CHH Bn), 4.33 (ddd, 1H, $J = 9.9, 6.5, 1.7$ Hz, H-3), 4.17 – 4.02 (m, 4H, H-4, H-6', H-5, H-3'), 3.88 (td, 1H, $J = 9.8, 4.7$ Hz, H-5'), 3.63 – 3.57 (m, 2H, H-6', H-4'), 3.55 (dd, 1H, $J = 9.5, 3.9$ Hz, H-2'), 3.40 (s, 3H, CH₃ OMe); ^{13}C -APT NMR (CDCl₃, 126 MHz, HSQC, HMBC): δ 166.2, 165.9 (C=O), 138.7, 138.3, 138.2, 137.5 (C_q), 133.4, 133.3 (CH_{arom}), 129.9 (C_q), 129.9, 129.7 (CH_{arom}), 129.6 (C_q), 129.0, 128.6, 128.5, 128.4, 128.3, 128.3, 128.1, 127.9, 127.7, 127.7, 127.4, 127.0, 126.2 (CH_{arom}), 101.4 (CHPh), 98.9 (C-1'), 97.0 (C-1), 82.4 (C-4'), 80.2 (C-3), 78.8 (C-2'), 78.7 (C-3'), 75.3 (CH₂ Bn), 75.1 (C-4), 74.5 (CH₂ Bn), 74.1 (C-2), 74.1 (CH₂ Bn), 68.9 (C-6'), 68.4 (C-5), 63.8 (C-5'), 63.7 (C-6), 55.5 (OMe); Diagnostic peaks for the β -anomer: ^1H NMR (CDCl₃, 500 MHz): δ 8.06 – 8.01 (m, 2H), 5.50 (s, 1H, CHPh), 5.08 (dd, 1H, $J = 9.3, 3.8$ Hz, H-2), 4.53 (dd, 1H, $J = 12.1, 4.5$ Hz, H-6), 3.76 (t, 1H, $J = 9.0$ Hz, H-3'), 3.27 (td, 1H, $J = 9.1, 8.4, 4.3$ Hz, H-5'), ^{13}C -APT NMR (CDCl₃, 126 MHz): δ 166.0, 165.9 (C=O), 138.5, 138.5, 137.3, 133.4, 130.0, 130.0, 129.8, 129.1, 128.6, 128.4, 128.1, 127.8, 127.7, 126.1 (CH_{arom}), 103.4 (C-1'), 101.2 (CHPh), 97.1 (C-1), 82.8 (C-2'), 81.8 (C-4'), 81.4 (C-3'), 77.9, 77.8 (C-3, C-4), 75.9, 75.6, 75.3 (CH₂ Bn), 73.4 (C-2), 68.9 (C-5), 68.8 (C-6'), 66.2 (C-5'), 62.7 (C-6), 55.5 (OMe); HRMS: $[\text{M}+\text{NH}_4]^+$ calcd for C₅₅H₅₈NO₁₃ 940.39027, found 940.39106.



Methyl 4-O-(2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy- α/β -D-glucopyranosyl)-2,6-di-O-benzoyl-3-O-benzyl- α -D-glucopyranoside (7B). Donor **B** and acceptor **7** were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (E) yielding product **7B** (75 mg, 87 μmol , 87%, $\alpha:\beta = 1.3:1$) as a colorless oil. R_f: 0.66


(4/1 pentane/EtOAc); IR (thin film): 698, 737, 918, 995, 1026, 1092, 1173, 1269, 1369, 1450, 1721, 2110, 2866; Data reported for a 1.3:1 mixture of anomers: ^1H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC, HMBC): δ 8.14 – 7.98 (m, 9.2H, CH_{arom}), 7.64 – 7.13 (m, 48.3H, CH_{arom}), 5.67 (d, 1.3H, $J = 4.1$ Hz, H-1' _{α}), 5.51 (s, 1.3H, CHPh _{α}), 5.49 (s, 1H, CHPh _{β}), 5.18 (dd, 1.3H, $J = 9.8, 3.6$ Hz, H-2' _{α}), 5.12 (dd, 1H, $J = 9.6, 3.7$ Hz, H-2' _{β}), 5.05 (d, 1H, $J = 3.7$ Hz, H-1' _{β}), 5.03 (d, 1.3H, $J = 3.6$ Hz, H-1' _{α}), 4.98 (d, 1.3H, $J = 10.9$ Hz, CHH Bn _{α}), 4.96 – 4.85 (m, 4.6H, CH₂ Bn _{α} , 2xCHH Bn _{β}), 4.80 – 4.73 (m, 5.6H, H-6' _{β} , 2xCHH Bn _{β} , CHH Bn _{α} H-6' _{α} , H-6' _{β}), 4.67 (dd, 1H, $J = 12.2, 2.9$ Hz, H-6' _{β}), 4.53 (dd, 1.3H, $J = 12.0, 2.6$ Hz, H-6' _{α}), 4.49 (d, 1H, $J = 8.0$ Hz, H-1' _{β}), 4.42 – 4.33 (m, 1.3H, H-3' _{α}), 4.21 – 4.13 (m, 1H, H-3' _{β}), 4.12 – 4.01 (m, 8.2H, H-3' _{α} , H-4' _{α} , H-4' _{β} , H-5' _{β} , H-5' _{α} , H-6' _{α} , H-6' _{β}), 3.87 (td, 1.3H, $J = 9.9, 4.9$ Hz, H-5' _{α}), 3.72 – 3.53 (m, 4.6H, H-3' _{β} , H-4' _{α} , H-4' _{β} , H-6' _{α}), 3.51 – 3.40 (m, 8.9H, H-2' _{β} , H-6' _{β} , CH₃ OMe _{α} , CH₃ OMe _{β}), 3.36 (dd, 1.3H, $J = 10.0, 4.1$ Hz, H-2' _{α}), 3.18 (td, 1H, $J = 9.4, 4.9$ Hz, H-5' _{β}); ^{13}C -APT NMR (CDCl₃, 101 MHz, HSQC, HMBC): δ 166.2, 166.2, 165.9, 165.9 (C=O), 138.4, 137.9, 137.8, 137.7, 137.2, 137.1 (C_q), 133.6, 133.5, 133.4, 133.3 (CH_{arom}), 129.9, 129.9 (C_q), 129.8 (CH_{arom}), 129.8, 129.7 (C_q), 129.7, 129.5, 129.2, 129.1, 128.7, 128.6, 128.6, 128.5, 128.5, 128.4, 128.4, 128.3, 128.3, 128.0, 127.8, 127.8, 127.7, 127.6, 126.2, 126.0 (CH_{arom}), 102.0 (C-1' _{β}), 101.4 (CHPh _{α}), 101.3 (CHPh _{β}), 99.0 (C-1' _{α}), 97.1 (C-1 _{α}), 97.1 (C-1 _{β}), 82.6 (C-4' _{α}), 81.7 (C-4' _{β}), 80.4 (C-3 _{α}), 79.7 (C-3' _{β}), 78.1 (C-3 _{β}), 77.9 (C-4 _{β}), 76.2 (C-3' _{α}), 75.6, 75.2 (CH₂ Bn), 75.0 (C-4 _{α}), 74.6 (C-2 _{α}), 73.5 (C-2 _{β}), 68.6 (C-5 _{β}), 68.5, 68.5 (C-6' _{α} , C-6' _{β}), 68.1 (C-5 _{α}), 66.8 (C-2' _{β}), 66.3 (C-5' _{β}), 63.8 (C-5' _{α}), 63.4 (C-6 _{α}), 62.9 (C-6 _{β}), 62.8 (C-2' _{α}), 55.6 (OMe _{α}), 55.6 (OMe _{β}); HRMS: $[\text{M}+\text{NH}_4]^+$ calcd for C₄₈H₄₉N₄O₁₃ 875.34980, found 875.35039.



Methyl (methyl 4-O-(2,3-di-O-benzyl-4,6-O-benzylidene- α/β -D-glucopyranosyl)-2-O-benzoyl-3-O-benzyl- α -D-glucopyranosyl uronate) (8A). Donor **A** and acceptor **8** were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (E) yielding product **8A** (81 mg, 96 μmol , 96%, $\alpha:\beta = 4.8 : 1$) as a colorless oil. R_f: 0.57


(4/1 pentane/EtOAc); IR (thin film): 698, 914, 995, 1045, 1088, 1200, 1267, 1369, 1452, 1722, 1751, 2938; Data for the α -anomer: ^1H NMR (CDCl₃, 500 MHz, HH-COSY, HSQC, HMBC): δ 8.00 – 7.94 (m, 2H, CH_{arom}), 7.59 – 7.01 (m, 23H), 5.54 (s, 1H, CHPh), 5.28 (d, 1H, $J = 3.8$ Hz, H-1'), 5.16 – 5.12 (m, 1H, H-2), 5.06 (d, 1H, $J = 3.6$ Hz, H-1), 4.95 – 4.68 (m, 5H, 2xCH₂ Bn, CHH Bn), 4.60 (d, 1H, $J = 11.8$ Hz, CHH Bn), 4.31 (dd, 1H, $J = 8.9, 3.6$ Hz, H-6'), 4.28 – 4.19 (m, 3H, H-3, H-4, H-5), 4.02 (t, 1H, $J = 9.3$ Hz, H-3'), 3.78 (s, 3H, CH₃ CO₂Me), 3.74 – 3.63 (m, 2H, H-5', H-6'), 3.60 (t, 1H, $J = 9.2$ Hz,

H-4'), 3.52 (dd, 1H, $J = 9.5, 3.8$ Hz, H-2'), 3.41 (s, 3H, CH₃ OMe); ¹³C-APT NMR (CDCl₃, 126 MHz, HSQC, HMBC): δ 169.5 (C=O CO₂Me), 165.9 (C=O OBz), 138.6, 138.3, 138.0, 137.6 (C_q), 133.4 (CH_{arom}), 130.0, 129.9 (CH_{arom}), 129.6 (C_q), 129.0, 128.5, 128.5, 128.4, 128.3, 128.2, 128.1, 128.0, 127.8, 127.7, 127.4, 127.4, 126.1 (CH_{arom}), 101.3 (CHPh), 98.9 (C-1'), 97.6 (C-1), 82.1 (C-4'), 79.0 (C-2), 78.4 (C-4), 78.2 (C-3'), 77.8 (C-3), 75.2, 74.9, 73.7 (CH₂ Bn), 73.1 (C-2), 70.7 (C-5), 68.6 (C-6'), 63.4 (C-5'), 55.9 (OMe), 52.8 (CO₂Me); Diagnostic peaks for the β-anomer: ¹H NMR (CDCl₃, 500 MHz): δ 8.05–8.00 (m, 1H), 5.46 (s, 1H, CHPh), 5.10 (dd, 1H, $J = 9.4, 3.6$ Hz, H-2), 4.09 (ddd, 1H, $J = 9.4, 6.7, 1.5$ Hz, H-3), 3.34 (td, 1H, $J = 9.6, 4.7$ Hz, H-5'); ¹³C-APT NMR (CDCl₃, 126 MHz): δ 169.7 (C=O), 138.6, 138.5, 137.4 (C_q), 129.8, 128.3, 128.3, 128.1, 127.8, 127.7, 127.6, 126.1 (CH_{arom}), 103.1 (C-1'), 101.2 (CHPh), 97.6 (C-1), 82.4 (C-2'), 81.8, 81.3, 78.0, 77.0, 75.6 (C-3), 75.2, 72.6 (C-2), 70.4, 68.7, 65.9 (C-5'), 56.1 (OMe), 52.8 (CO₂Me); HRMS: [M+NH₄]⁺ calcd for C₄₉H₅₄NO₁₃ 864.35897, found 864.36009.




Methyl (methyl 4-O-(2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-α/β-D-glucopyranosyl)-2-O-benzoyl-3-O-benzyl-α-D-glucopyranosyl uronate) (8B). Donor **B** and acceptor **8** were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (E) yielding product **8B** (64 mg, 82 μmol, 82%, α:β = 1.18 :

1) as a colorless oil. R_f: 0.73 (4/1 pentane/EtOAc); IR (thin film): 698, 737, 918, 991, 1045, 1092, 1200, 1265, 1366, 1454, 1724, 1751, 2110, 2940; Data reported for a 1.18 : 1 mixture of anomers: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 8.11–8.04 (m, 2H, CH_{arom}), 8.04–7.97 (m, 2.2H, CH_{arom}), 7.63–7.09 (m, 39.6H, CH_{arom}), 5.55 (s, 1H), 5.48 (d, 2H, $J = 3.3$ Hz), 5.16 (dd, 1H, $J = 9.6, 3.6$ Hz), 5.55 (s, 1.2H, CHPh_α), 5.50–5.44 (m, 2.2H, H-1'_α, CHPh_β), 5.16 (dd, 1H, $J = 9.6, 3.6$ Hz, H-2_α), 5.12–5.07 (m, 3.2H, H-1_α, H-1_β, H-2_β), 4.96 (d, 1.2H, $J = 11.0$ Hz, CHH Bn_α), 4.93–4.83 (m, 4.4H, 2xCHH Bn_β, CH₂ Bn_α), 4.82–4.74 (m, 2.2H, CHH Bn_α, CHH Bn_β), 4.73 (d, 1H, $J = 11.1$ Hz, CHH Bn_β), 4.51 (d, 1H, $J = 8.1$ Hz, H-1'_β), 4.37–4.26 (m, 4.6H, H-5_α, H-5_β, H-3_α, H-6'_α), 4.26–4.16 (m, 2.2H, H-4_α, H-4_β), 4.16–4.05 (m, 2H, H-3_β, H-6'_β), 4.00 (dd, 1.2H, $J = 10.0, 9.0$ Hz, H-3'_α), 3.86 (s, 3H, CH₃ CO₂Me_β), 3.85 (s, 3.6H, CH₃ CO₂Me_α), 3.71–3.64 (m, 2.4H, H-6'_α, H-4'_α), 3.63–3.50 (m, 3.2H, H-3'_β, H-5'_α, H-4'_β), 3.47–3.33 (m, 8.8H, CH₃ OMe_α, CH₃ OMe_β, H-2'_α, H-2'_β, H-6'_β), 3.29 (td, 1H, $J = 9.5, 4.8$ Hz, H-5'_β); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC, HMBC): δ 169.7, 169.6 (C=O CO₂Me), 165.9, 165.8 (C=O OBz), 138.4, 137.9, 137.9, 137.8, 137.4, 137.2 (C_q), 133.6, 133.4, 129.9, 129.9 (CH_{arom}), 129.6, 129.4 (C_q), 129.2, 129.1, 128.7, 128.5, 128.5, 128.5, 128.4, 128.4, 128.3, 128.3, 128.2, 128.0, 128.0, 127.8, 127.8, 127.6, 127.6, 126.1, 126.1 (CH_{arom}), 102.3 (C-1'_β), 101.5 (CHPh_α), 101.4 (CHPh_β), 98.6 (C-1'_α), 97.7 (C-1_α), 97.7 (C-1_β), 82.5 (C-4'_α), 81.6 (C-3'_β), 79.6 (C-3_α), 79.4 (C-4'_β), 79.3 (C-4_β), 77.3 (C-3_β), 76.4 (C-3'_α), 75.7 (C-5'_β), 75.5, 75.4, 75.1, 75.1 (CH₂ Bn), 73.9 (C-2_α), 72.9 (C-2_β), 70.1 (C-5_α), 70.0 (C-5_β), 68.5 (C-6'_α), 66.7 (C-2'_β), 66.2 (C-5'_β), 63.2 (C-5'_α), 62.9 (C-2'_α), 56.0 (OMe_{α,β}), 53.1 (CO₂Me_α), 52.9 (CO₂Me_β); HRMS: [M+NH₄]⁺ calcd C₄₂H₄₇N₄O₁₂ for 799.31850, found 799.31937.



Methyl 4-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α-D-glucopyranosyl)-2,6-di-O-benzyl-3-O-benzoyl-α-D-glucopyranoside (9A). Donor **A** and acceptor **9** were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (E) yielding product **9A** (86 mg, 95 μmol, 95%, α:β = >20:1) as a colorless oil. R_f: 0.26 (4/1 pentane/EtOAc); [α]_D²⁰ = -0.9° (c = 1.0, CHCl₃); IR (thin film): 696, 746, 912, 995, 1047, 1088, 1269, 1369,


1452, 1728, 2924; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC, HMBC): δ 8.09–8.02 (m, 2H, CH_{arom}), 7.61–7.11 (m, 28H, CH_{arom}), 5.94 (t, 1H, $J = 9.6$ Hz, H-3), 5.46 (s, 1H, CHPh), 5.03 (d, 1H, $J = 3.5$ Hz, H-1'), 4.79–4.72 (m, 2H, H-1, CHH Bn), 4.63–4.50 (m, 5H, 2xCH₂ Bn, CHH Bn), 4.40 (d, 1H, $J = 12.1$ Hz, CHH Bn), 4.21 (t, 1H, $J = 9.4$ Hz, H-4), 4.13–4.04 (m, 2H, CHH Bn, H-6'), 3.97–3.88 (m, 3H, H-3', H-5, H-6), 3.85 (dd, 1H, $J = 9.9, 4.8$ Hz, H-5'), 3.71–3.67 (m, 1H, H-6), 3.65 (t, 1H, $J = 3.0$ Hz, H-2'), 3.55 (t, 1H, $J = 10.2$ Hz, H-6'), 3.44 (t, 1H, $J = 9.7$ Hz, H-4'), 3.41 (s, 3H, CH₃ OMe), 3.26 (dd, 1H, $J = 9.4, 3.5$ Hz, H-2'); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC, HMBC): δ 165.4 (C=O), 138.8, 138.0, 137.9, 137.8, 137.6 (C_q), 132.9 (CH_{arom}), 130.7 (C_q), 129.9, 128.9, 128.5, 128.4, 128.4, 128.4, 128.3, 128.3, 128.3, 128.2, 128.1, 127.9, 127.9, 127.8, 127.7, 127.6, 126.2 (CH_{arom}), 101.3 (CHPh), 98.0 (C-1'), 97.7 (C-1), 81.9 (C-4), 78.8 (C-2'), 78.3 (C-3'), 77.2 (C-2), 75.4 (CH₂ Bn), 73.9 (C-3), 73.7 (C-4), 73.6, 72.9, 72.8 (CH₂ Bn), 69.7 (C-5), 69.0 (C-6'), 68.3 (C-6), 63.6 (C-5'), 55.4 (OMe); HRMS: [M+NH₄]⁺ calcd for C₅₅H₆₀NO₁₂ 926.41100, found 926.41201.



Methyl 4-O-(2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-α/β-D-glucopyranosyl)-2,6-di-O-benzyl-3-O-benzoyl-α-D-glucopyranoside (9B). Donor **B** and acceptor **9** were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (E) yielding product **9B** (65 mg, 77 μmol, 77%, α:β = 6.7:1) as a light yellow oil. R_f: 0.28


(4/1 pentane/EtOAc); [α]_D²⁰ = -25.5° (c = 1.0, CHCl₃); IR (thin film): 698, 745, 995, 1092, 1165, 1269, 1369, 1454, 1732, 2110, 2866; Data for the α-anomer: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC, HMBC): δ 8.11–8.05 (m, 2H, CH_{arom}), 7.61–7.09 (m, 23H, CH_{arom}), 5.85 (t, 1H, $J = 9.6$ Hz, H-3), 5.50 (s, 1H, CHPh), 5.04 (d, 1H, $J = 3.7$ Hz, H-1'), 4.82 (d, 1H,

$J = 10.6$ Hz, *CHH* Bn), 4.75 (d, 1H, $J = 3.5$ Hz, H-1), 4.64 – 4.54 (m, 5H, *CHH* Bn, 2xCH₂ Bn), 4.10 (dd, 1H, $J = 10.3, 4.8$ Hz, H-6), 4.05 (t, 1H, $J = 9.5$ Hz, H-4), 3.96 – 3.81 (m, 4H, H-3', H-5', H-5, H-6), 3.76 – 3.67 (m, 1H, H-6'), 3.64 – 3.57 (m, 2H, H-2, H-6'), 3.56 (t, 1H, $J = 9.3$ Hz, H-4'), 3.42 (s, 3H, CH₃ OMe), 3.23 (dd, 1H, $J = 9.9, 3.7$ Hz, H-2'); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC, HMBC): δ 165.4 (C=O), 137.9, 137.8, 137.7, 137.2 (C_q), 132.8 (CH_{arom}), 130.7 (C_q), 129.7, 129.1, 128.7, 128.6, 128.5, 128.5, 128.4, 128.4, 128.3, 128.0, 127.9, 127.9, 127.8, 126.1 (CH_{arom}), 101.5 (CHPh), 99.5 (C-1'), 97.7 (C-1), 82.5 (C-4'), 77.1 (C-4), 76.7 (C-3'), 76.5 (C-2), 75.3, 73.7 (CH₂ Bn), 73.5 (C-3), 72.8 (CH₂ Bn), 69.6 (C-5), 68.8 (C-6'), 68.7 (C-6), 63.8 (C-5'), 63.5 (C-2'), 55.6 (OMe); Diagnostic peaks for the β -anomer: ¹H NMR (CDCl₃, 400 MHz): δ 5.66 (dd, 1H, $J = 10.0, 8.7$ Hz, H-3), 5.19 (s, 1H, *CHPh*), 4.70 (d, 1H, $J = 11.9$ Hz, *CHH* Bn), 4.69 (d, 1H, $J = 11.4$ Hz, *CHH* Bn), 4.44 (d, 1H, $J = 11.9$ Hz, *CHH* Bn), 3.99 (dd, 1H, $J = 10.8, 2.5$ Hz, H-6) 2.87 (td, 1H, $J = 9.3, 4.9$ Hz, H-5'), 2.52 (t, 1H, $J = 10.4$ Hz, H-6'); ¹³C-APT NMR (CDCl₃, 101 MHz): δ 101.5 (C-1'), 101.0 (CHPh), 98.0 (C-1), 81.2, 79.1, 76.1, 74.6, 73.7, 72.8, 72.6, 69.4, 67.8, 67.6, 65.9, 65.7; HRMS: [M+NH₄]⁺ calcd for C₄₈H₅₃N₄O₁₁ 861.37053, found 861.37106.




Methyl 4-O-(2,3-di-O-benzyl-4,6-O-benzylidene- α -D-glucopyranosyl)-2-O-benzyl-3-O-benzoyl-6-deoxy- α -D-glucopyranoside (10A). Donor **A** and acceptor **10** were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (E) yielding product **10A** (67 mg, 83 μ mol, 83%, α : β = >20:1) as a white solid. R_f: 0.38 (4/1 pentane/EtOAc); [α]_D²⁰ = -3.6° ($c = 1.0$, CHCl₃); IR (thin film): 698, 745, 995, 1053, 1092,

1269, 1454, 1728, 2866; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC, HMBC): δ 8.07 – 8.01 (m, 2H, CH_{arom}), 7.62 – 7.06 (m, 23H, CH_{arom}), 5.98 – 5.87 (m, 1H, H-3), 5.48 (s, 1H, *CHPh*), 5.10 (d, 1H, $J = 3.8$ Hz, H-1'), 4.80 (d, 1H, $J = 11.1$ Hz, *CHH* Bn), 4.70 – 4.62 (m, 2H, H-1, *CHH* Bn), 4.57 (d, 1H, $J = 12.5$ Hz, *CHH* Bn), 4.52 (d, 1H, $J = 12.5$ Hz, *CHH* Bn), 4.42 (d, 1H, $J = 12.0$ Hz, *CHH* Bn), 4.24 – 4.13 (m, 2H, H-6', *CHH* Bn), 4.02 – 3.85 (m, 3H, H-3', H-5, H-5'), 3.70 – 3.62 (m, 2H, H-4', H-6'), 3.62 – 3.55 (m, 1H, H-2), 3.49 (t, 1H, $J = 9.5$ Hz, H-4), 3.41 (s, 3H, CH₃ OMe), 3.33 (dd, 1H, $J = 9.5, 3.8$ Hz, H-2'), 1.36 (d, 3H, $J = 6.2$ Hz, H-6); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC, HMBC): δ 165.2 (C=O), 138.7, 137.8, 137.4 (C_q), 133.0 (CH_{arom}), 130.6 (C_q), 129.9, 129.0, 128.5, 128.4, 128.3, 128.3, 128.2, 128.1, 127.9, 127.7, 127.6, 126.1 (CH_{arom}), 101.3 (CHPh), 98.1 (C-1'), 97.3 (C-1), 81.9 (C-4), 79.4 (C-4'), 78.5 (C-2'), 78.4 (C-3'), 77.6 (C-2), 75.5 (CH₂ Bn), 73.9 (C-3), 73.1, 72.6 (CH₂ Bn), 68.9 (C-6'), 66.1 (C-5), 63.5 (C-5'), 55.3 (OMe), 18.7 (C-6); HRMS: [M+NH₄]⁺ calcd for C₄₈H₅₄N₄O₁₁ 820.36914, found 820.36983.



Methyl 4-O-(2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy- α -D-glucopyranosyl)-2-O-benzyl-3-O-benzoyl-6-deoxy- α -D-glucopyranoside (10B). Donor **B** and acceptor **10** were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (E) yielding product **10B** (60 mg, 81 μ mol, 81%, α : β = 14:1) as a colorless oil. R_f: 0.25 (4/1 pentane/EtOAc); [α]_D²⁰ = -30.0° ($c = 1.0$, CHCl₃); IR (thin film): 698, 748, 995, 1053,


1096, 1269, 1373, 1454, 1732, 2110, 2931; Data for the α -anomer: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC, HMBC): δ 8.07 – 8.01 (m, 2H, CH_{arom}), 7.61 – 7.09 (m, 18H, CH_{arom}), 5.84 (t, 1H, $J = 9.6$ Hz, H-3), 5.53 (s, 1H, *CHPh*), 5.07 (d, 1H, $J = 4.0$ Hz, H-1'), 4.87 (d, 1H, $J = 10.8$ Hz, *CHH* Bn), 4.71 – 4.64 (m, 2H, *CHH* Bn, H-1), 4.61 – 4.47 (m, 2H, CH₂ Bn), 4.21 (dd, 1H, $J = 10.4, 5.0$ Hz, H-6'), 4.00 – 3.83 (m, 3H, H-3', H-5', H-5), 3.69 (t, 1H, $J = 10.4$ Hz, H-6'), 3.61 (t, 1H, $J = 9.3$ Hz, H-4'), 3.57 – 3.46 (m, 2H, H-2, H-4), 3.42 (s, 3H, CH₃ OMe), 3.19 (dd, 1H, $J = 10.0, 4.0$ Hz, H-2'), 1.35 (d, 3H, $J = 6.2$ Hz, H-6); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC, HMBC): δ 165.3 (C=O), 137.8, 137.7, 137.1 (C_q), 132.8 (CH_{arom}), 130.6 (C_q), 129.6, 129.1, 128.5, 128.4, 128.4, 128.3, 128.0, 127.9, 127.9, 126.0 (CH_{arom}), 101.3 (CHPh), 100.0 (C-1'), 97.5 (C-1), 82.4 (C-4'), 82.4 (C-4), 77.4 (C-2), 76.6 (C-3'), 75.2 (CH₂ Bn), 73.5 (C-3), 72.6 (CH₂ Bn), 68.5 (C-6'), 65.7 (C-5), 63.5 (C-5'), 63.0 (C-2'), 55.4 (OMe), 18.3 (C-6); Diagnostic peaks for the β -anomer: ¹H NMR (CDCl₃, 400 MHz): δ 5.66 (t, 1H, $J = 9.5$ Hz, H-3), 5.23 (s, 1H, *CHPh*), 3.04 (td, 1H, $J = 9.7, 5.1$ Hz, H-5'), 2.63 (t, 1H, $J = 10.4$ Hz, H-6'), 1.38 (d, 3H, $J = 6.3$ Hz, H-6); ¹³C-APT NMR (CDCl₃, 101 MHz): δ 102.6 (C-1'), 101.0 (CHPh), 97.5 (C-1), 83.3, 81.3, 81.1, 79.2, 74.8, 72.7, 67.8, 66.4, 66.1, 65.9, 17.7; HRMS: [M+Na]⁺ calcd for C₄₁H₄₃N₃O₁₀Na 760.2841, found 760.2852.



Methyl 4-O-(2,3-di-O-benzyl-4,6-O-benzylidene- α -D-glucopyranosyl)-2-O-benzyl-3,6-di-O-benzoyl- α -D-glucopyranoside (11A). Donor **A** and acceptor **11** were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (E) yielding product **11A** (88 mg, 95 μ mol, 95%, α : β = >20:1) as a white solid. R_f: 0.25 (4/1 pentane/EtOAc); [α]_D²⁰ = +21.1° ($c = 1.0$, CHCl₃); IR (thin film): 698, 712, 748, 995, 1026,


1090, 1267, 1371, 1452, 1724; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 8.12 – 8.06 (m, 2H, CH_{arom}), 8.06 – 8.01 (m, 2H, CH_{arom}), 7.62 – 7.51 (m, 2H, CH_{arom}), 7.46 – 7.32 (m, 9H, CH_{arom}), 7.29 – 7.11 (m, 15H, CH_{arom}), 5.99 (dd, 1H, $J = 9.9, 9.0$ Hz, H-3), 5.42 (s, 1H, *CHPh*), 4.97 (d, 1H, $J = 3.6$ Hz, H-1'), 4.84 – 4.68 (m, 3H, H-1, H-6, *CHH* Bn), 4.67 – 4.51 (m, 4H, *CHH* Bn, CH₂ Bn, H-6), 4.36 (d, 1H, $J = 12.2$ Hz, *CHH* Bn), 4.15 (ddd, 1H, $J = 10.0, 4.4, 2.1$ Hz, H-5), 4.11 – 4.01 (m, 3H, H-6', H-4, *CHH* Bn), 3.98 (t, 1H, $J = 9.4$ Hz, H-3'), 3.88 (td, 1H, $J = 9.9, 4.8$ Hz, H-5'), 3.67 (dd, 1H, $J = 9.9, 3.5$ Hz,

H-2'), 3.54 (t, 1H, $J = 10.3$ Hz, H-6'), 3.46 (d, 1H, $J = 9.5$ Hz, H-4'), 3.44 (s, 3H, CH₃ OMe), 3.29 (dd, 1H, $J = 9.5, 3.6$ Hz, H-2'); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC, HMBC): δ 166.1, 165.3 (C=O), 138.7, 138.1, 137.7, 137.4 (C_q), 133.2, 133.0 (CH_{arom}), 130.7, 130.0 (C_q), 129.9, 129.8, 128.9, 128.5, 128.4, 128.3, 128.2, 128.2, 128.0, 127.9, 127.7, 127.6, 126.2 (CH_{arom}), 101.4 (CHPh), 99.2 (C-1'), 97.5 (C-1), 81.9 (C-4'), 78.5 (C-2'), 77.3 (C-2), 75.9 (C-4), 75.4 (CH₂ Bn), 73.3 (C-2), 73.2 (CH₂ Bn), 72.8 (CH₂ Bn), 68.8 (C-6'), 68.6 (C-5), 63.9 (C-5'), 63.5 (C-6), 55.5 (OMe); HRMS: [M+NH₄]⁺ calcd for C₅₅H₅₈NO₁₃ 940.39027, found 940.39105.




Methyl 4-O-(2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-α-D-glucopyranosyl)-2-O-benzyl-3,6-di-O-benzoyl-α-D-glucopyranoside (11B). Donor **B** and acceptor **11** were

condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (E) yielding product **11B** (73 mg, 85 μmol, 85%, α:β = >20:1) as a colorless oil. R_f: 0.31 (4/1 pentane/EtOAc); [α]_D²⁰ = +0.6° ($c = 1.0$, CHCl₃); IR (thin film): 748, 995, 1030, 1096, 1169, 1269, 1315, 1373, 1450, 1724, 2110, 2924; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC, HMBC): δ 8.08 (td, 4H, $J = 8.2, 1.4$ Hz, CH_{arom}), 7.61 – 7.10 (m, 21H, CH_{arom}), 5.91 (t, 1H, $J = 9.6$ Hz, H-3), 5.49 (s, 1H, CHPh), 5.07 (d, 1H, $J = 3.9$ Hz, H-1'), 4.85 (d, 1H, $J = 10.7$ Hz, CHH Bn), 4.76 (d, 1H, $J = 3.4$ Hz, H-1), 4.72 (dd, 1H, $J = 12.2, 2.1$ Hz, H-6), 4.67 (d, 1H, $J = 10.7$ Hz, CHH Bn), 4.63 – 4.53 (m, 2H, CH₂ Bn), 4.50 (dd, 1H, $J = 12.1, 4.7$ Hz, H-6), 4.23 (dd, 1H, $J = 10.4, 4.9$ Hz, H-6'), 4.12 (ddd, 1H, $J = 9.9, 4.6, 2.0$ Hz, H-5), 4.00 – 3.86 (m, 3H, H-3', H-4, H-5'), 3.67 – 3.53 (m, 3H, H-4', H-6', H-2), 3.45 (s, 3H, CH₃ OMe), 3.25 (dd, 1H, $J = 10.0, 3.9$ Hz, H-2'); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC, HMBC): δ 166.2, 165.4 (C=O), 137.8, 137.1 (C_q), 133.3, 132.9 (CH_{arom}), 130.5, 129.9 (C_q), 129.8, 129.1, 128.6, 128.5, 128.4, 128.3, 128.3, 128.0, 127.9, 127.9, 126.1 (CH_{arom}), 101.4 (CHPh), 100.5 (C-1'), 97.6 (C-1), 82.4 (C-4'), 77.8 (C-4), 77.2 (C-2), 76.6 (C-3'), 75.2 (CH₂ Bn), 73.2 (C-3), 72.7 (CH₂ Bn), 68.5 (C-6'), 68.3 (C-5), 64.0 (C-5'), 63.6 (C-6), 63.2 (C-2'), 55.6 (OMe); HRMS: [M+NH₄]⁺ calcd for C₄₈H₅₁N₄O₁₂ 875.34980, found 875.35050.




Methyl (methyl 4-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α-D-glucopyranosyl)-2-O-benzyl-3-O-benzoyl-α-D-glucopyranosyl uronate) (12A). Donor **A** and acceptor **12** were

condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (E) yielding product **12A** (73 mg, 86 μmol, 86%, α:β = >20:1) as a white solid. R_f: 0.40 (4/1 pentane/EtOAc); [α]_D²⁰ = -18.4° ($c = 1.0$, CHCl₃); IR (thin film): 698, 748, 914, 995, 1047, 1088, 1201, 1267, 1452, 1732, 2931; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 8.11 – 8.01 (m, 2H, CH_{arom}), 7.59 – 7.51 (m, 1H, CH_{arom}), 7.47 – 7.33 (m, 7H, CH_{arom}), 7.33 – 7.13 (m, 13H, CH_{arom}), 7.09 – 7.02 (m, 2H, CH_{arom}), 5.96 (t, 1H, $J = 9.6$ Hz, H-3), 5.45 (s, 1H, CHPh), 4.93 (d, 1H, $J = 3.7$ Hz, H-1'), 4.80 (d, 1H, $J = 11.1$ Hz, CHH Bn), 4.75 (d, 1H, $J = 3.4$ Hz, H-1), 4.69 (d, 1H, $J = 11.1$ Hz, CHH Bn), 4.61 – 4.52 (m, 2H, CH₂ Bn), 4.40 – 4.28 (m, 2H, CHH Bn, H-5), 4.27 – 4.16 (m, 2H, H-4, H-6'), 3.99 (d, 1H, $J = 12.2$ Hz, CHH Bn), 3.92 (t, 1H, $J = 9.4$ Hz, H-3'), 3.74 (s, 3H, CH₃ CO₂Me), 3.69 (dd, 1H, $J = 10.0, 3.4$ Hz, H-2), 3.63 – 3.52 (m, 2H, H-5', H-6'), 3.46 (s, 3H, CH₃ OMe), 3.42 (d, 1H, $J = 9.2$ Hz, H-4'), 3.25 (dd, 1H, $J = 9.4, 3.7$ Hz, H-2'); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC, HMBC): δ 169.9 (C=O CO₂Me), 165.1 (C=O OBz), 138.7, 137.8, 137.5 (C_q), 133.1 (CH_{arom}), 130.5 (C_q), 129.9, 129.0, 128.5, 128.5, 128.3, 128.3, 128.3, 128.2, 128.2, 128.2, 128.1, 127.7, 127.6, 126.1 (CH_{arom}), 101.3 (CHPh), 98.8 (C-1'), 98.4 (C-1), 81.6 (C-4'), 78.2 (C-2'), 78.0 (C-3'), 76.5 (C-2), 76.1 (C-4), 75.4, 73.0, 72.8 (CH₂ Bn), 72.7 (C-3), 70.5 (C-5), 68.5 (C-6'), 63.5 (C-5'), 55.9 (OMe), 52.9 (CO₂Me); HRMS: [M+NH₄]⁺ calcd for C₄₉H₅₄NO₁₃ 864.35897, found 864.36004.




Methyl (methyl 4-O-(2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-α-D-glucopyranosyl)-2-O-benzyl-3-O-benzoyl-α-D-glucopyranosyl uronate) (12B). Donor **B** and acceptor **12** were


condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (E) yielding product **12B** (73 mg, 93 μmol, 93%, α:β = >20:1) as a colorless oil. R_f: 0.33 (4/1 pentane/EtOAc); [α]_D²⁰ = -35.8° ($c = 1.0$, CHCl₃); IR (thin film): 698, 748, 914, 995, 1045, 1092, 1200, 1265, 1373, 1454, 1732, 2110, 2936; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC, HMBC): δ 8.09 – 7.99 (m, 2H, CH_{arom}), 7.62 – 7.53 (m, 1H, CH_{arom}), 7.52 – 7.42 (m, 4H, CH_{arom}), 7.42 – 7.33 (m, 3H, CH_{arom}), 7.29 – 7.16 (m, 10H, CH_{arom}), 5.87 (t, 1H, $J = 9.7$ Hz, H-3), 5.50 (s, 1H, CHPh), 4.96 (d, 1H, $J = 3.8$ Hz, H-1'), 4.84 (d, 1H, $J = 10.8$ Hz, CHH Bn), 4.74 (d, 1H, $J = 3.4$ Hz, H-1), 4.67 (d, 1H, $J = 10.8$ Hz, CHH Bn), 4.60 – 4.51 (m, 2H, CH₂ Bn), 4.30 (d, 1H, $J = 9.8$ Hz, H-5), 4.28 – 4.21 (m, 1H, H-6'), 4.12 (t, 1H, $J = 9.5$ Hz, H-4), 3.92 (dd, 1H, $J = 10.0, 9.0$ Hz, H-3'), 3.79 (s, 3H, CH₃ CO₂Me), 3.73 – 3.59 (m, 3H, H-5', H-6', H-2), 3.55 (t, 1H, $J = 9.0$ Hz, H-4'), 3.46 (s, 3H, CH₃ OMe), 3.20 (dd, 1H, $J = 9.9, 3.8$ Hz, H-2'); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC, HMBC): δ 169.4 (C=O CO₂Me), 165.2 (C=O OBz), 137.8, 137.5, 137.3 (C_q), 133.0 (CH_{arom}), 130.4 (C_q), 129.7, 129.1, 128.5, 128.4, 128.4, 128.2, 128.1, 128.1, 127.9, 126.1 (CH_{arom}), 101.5 (CHPh), 99.7 (C-1'), 98.5 (C-1), 82.3 (C-4'), 77.7 (C-4), 76.6 (C-3'), 76.4 (C-2), 75.2 (CH₂ Bn), 73.0 (CH₂ Bn), 72.3 (C-3), 70.4 (C-5), 68.4 (C-6'), 63.5 (C-5'), 63.1 (C-2'), 56.0 (OMe), 52.9 (CO₂Me); HRMS: [M+NH₄]⁺ calcd for C₄₂H₄₇N₄O₁₂ 799.31850, found 799.31924.




Methyl 4-O-(2,3-di-O-benzyl-4,6-O-benzylidene- α -D-glucopyranosyl)-2,3-di-O-benzoyl-6-O-benzyl- α -D-glucopyranoside (13A). Donor **A** and acceptor **13** were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (E) yielding product **13A** (83 mg, 90 μ mol, 90%, α : β = >20:1) as a colorless oil. R_f: 0.53 (4/1 pentane/EtOAc); [α]_D²⁰ = +33.1° (*c* = 1.0, CHCl₃); IR (thin film): 698, 710, 748, 997, 1088, 1275, 1367, 1452, 1724, 2934; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC, HMBC): δ 8.03 – 7.91 (m, 4H, CH_{arom}), 7.54 – 7.10 (m, 26H, CH_{arom}), 6.17 (dd, 1H, *J* = 10.2, 9.2 Hz, H-3), 5.48 (s, 1H, CHPh), 5.23 (dd, 1H, *J* = 10.2, 3.6 Hz, H-2), 5.18 (d, 1H, *J* = 3.6 Hz, H-1), 5.05 (d, 1H, *J* = 3.5 Hz, H-1'), 4.78 (d, 1H, *J* = 11.1 Hz, CHH Bn), 4.67 – 4.56 (m, 3H, CH₂ Bn, CHH Bn), 4.43 – 4.33 (m, 2H, H-4, CHH Bn), 4.12 (dd, 1H, *J* = 10.1, 4.8 Hz, H-6'), 4.07 (d, 1H, *J* = 12.3 Hz, CHH Bn), 4.05 – 3.97 (m, 2H, H-5, H-6), 3.96 – 3.85 (m, 2H, H-3, H-5'), 3.74 (dd, 1H, *J* = 10.8, 1.6 Hz, H-6), 3.57 (t, 1H, *J* = 10.2 Hz, H-6'), 3.48 (t, 1H, *J* = 9.5 Hz, H-4'), 3.41 (s, 3H, CH₃ OMe), 3.29 (dd, 1H, *J* = 9.4, 3.5 Hz, H-2'); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC, HMBC): δ 166.1, 165.7 (C=O), 138.8, 138.0, 138.0, 137.6 (C_q), 133.3, 133.0 (CH_{arom}), 130.2 (C_q), 130.0, 129.8 (CH_{arom}), 129.2 (C_q), 129.0, 128.4, 128.3, 128.3, 128.2, 128.1, 127.8, 127.7, 127.6, 126.2 (CH_{arom}), 101.3 (CHPh), 98.4 (C-1), 96.9 (C-1'), 81.9 (C-4'), 78.7 (C-2'), 78.3 (C-3'), 75.4 (CH₂ Bn), 73.9 (C-4), 73.6, 73.0 (CH₂ Bn), 72.4 (C-2), 72.3 (C-3), 70.0 (C-5), 69.0 (C-6'), 68.3 (C-6), 63.7 (C-5'), 55.4 (OMe); HRMS: [M+NH₄]⁺ calcd for C₅₅H₅₈NO₁₃ 940.39027, found 940.39109.



Methyl 4-O-(2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy- α -D-glucopyranosyl)-2,3-di-O-benzoyl-6-O-benzyl- α -D-glucopyranoside (13B). Donor **B** and acceptor **13** were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (E) yielding product **13B** (80 mg, 93 μ mol, 93%, α : β = 10:1) as a colorless oil. R_f: 0.36 (4/1 pentane/EtOAc); [α]_D²⁰ = +27.3° (*c* = 1.0, CHCl₃); IR (thin film): 710, 748, 999, 1030, 1092, 1277, 1728, 2110, 2932; Data for the α -anomer: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC, HMBC): δ 8.05 – 7.92 (m, 4H, CH_{arom}), 7.56 – 7.19 (m, 21H, CH_{arom}), 6.09 (dd, 1H, *J* = 10.2, 9.2 Hz, H-3), 5.53 (s, 1H, CHPh), 5.18 – 5.06 (m, 3H, H-1, H-1', H-2), 4.86 (d, 1H, *J* = 10.8 Hz, CHH Bn), 4.68 – 4.63 (m, 3H, CHH Bn, CH₂ Bn), 4.25 (t, 1H, *J* = 9.5 Hz, H-4), 4.14 (dd, 1H, *J* = 10.3, 4.9 Hz, H-6'), 4.00 (ddd, 1H, *J* = 10.2, 3.9, 2.0 Hz, H-5), 3.96 – 3.86 (m, 3H, H-3', H-5', H-6), 3.79 (dd, 1H, *J* = 11.0, 1.8 Hz, H-6), 3.70 – 3.55 (m, 2H, H-6', H-4'), 3.42 (s, 3H, CH₃ OMe), 3.23 (dd, 1H, *J* = 10.0, 3.8 Hz, H-2'); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC, HMBC): δ 166.1, 165.6 (C=O), 138.1, 137.8, 137.2 (C_q), 133.4, 133.0, 130.1, 129.6 (CH_{arom}), 129.2 (C_q), 129.2, 128.5, 128.5, 128.5, 128.4, 128.3, 127.9, 127.8, 127.7 (CH_{arom}), 101.5 (CHPh), 99.7 (C-1'), 96.9 (C-1), 82.5 (C-4'), 76.6 (C-3'), 76.1 (C-4), 75.2, 73.8 (CH₂ Bn), 72.4 (C-2), 72.3 (C-3), 69.8 (C-5), 68.8 (C-6'), 68.8 (C-6), 63.8 (C-5'), 63.3 (C-2'), 55.6 (OMe); Diagnostic peaks β -anomer: ¹H NMR (CDCl₃, 400 MHz): δ 5.90 (dd, 1H, *J* = 10.2, 9.1 Hz, H-3), 5.22 (dd, 1H, *J* = 10.1, 3.7 Hz, H-2), 4.77 (d, 1H, *J* = 11.9 Hz, CHH Bn), 4.51 (d, 1H, *J* = 11.9 Hz, CHH Bn), 2.97 – 2.88 (m, 1H, H-5'), 2.58 (t, 1H, *J* = 10.4 Hz, H-6'); ¹³C-APT NMR (CDCl₃, 101 MHz): δ 166.0, 165.5, 137.9, 137.2, 133.1, 130.5, 130.0, 129.8, 129.3, 128.7, 128.2, 126.0, 101.6 (CHPh), 101.1 (C-1'), 97.1, 81.3, 79.1, 75.9, 74.7, 71.9, 70.8, 69.7, 67.9, 67.6, 66.0, 65.7, 55.5; HRMS: [M+NH₄]⁺ calcd for C₄₈H₅₁N₄O₁₂ 875.34980, found 875.35038.




Methyl 4-O-(2,3-di-O-benzyl-4,6-O-benzylidene- α -D-glucopyranosyl)-2,3-di-O-benzoyl-6-deoxy- α -D-glucopyranoside (14A). Donor **A** and acceptor **14** were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (E) yielding product **14A** (68 mg, 83 μ mol, 83%, α : β = >20:1) as a colorless oil. R_f: 0.50 (4/1 pentane/EtOAc); [α]_D²⁰ = +37.1° (*c* = 1.0, CHCl₃); IR (thin film): 696, 708, 748, 995, 1026, 1051, 1088, 1177, 1275, 1452, 1722, 2934; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC, HMBC): δ 8.01 – 7.92 (m, 4H, CH_{arom}), 7.54 – 7.04 (m, 21H, CH_{arom}), 6.15 (dd, 1H, *J* = 10.2, 9.1 Hz, H-3), 5.51 (s, 1H, CHPh), 5.15 (dd, 1H, *J* = 10.2, 3.6 Hz, H-2), 5.10 (d, 1H, *J* = 3.8 Hz, H-1'), 5.07 (d, 1H, *J* = 3.6 Hz, H-1), 4.83 (d, 1H, *J* = 11.1 Hz, CHH Bn), 4.67 (d, 1H, *J* = 11.1 Hz, CHH Bn), 4.36 (d, 1H, *J* = 12.1 Hz, CHH Bn), 4.25 (dd, 1H, *J* = 10.3, 4.9 Hz, H-6'), 4.16 (d, 1H, *J* = 12.1 Hz, CHH Bn), 4.06 (dq, 1H, *J* = 9.5, 6.2 Hz, H-5), 4.02 – 3.90 (m, 2H, H-3', H-5'), 3.80 (t, 1H, *J* = 9.3 Hz, H-4), 3.68 (t, 1H, *J* = 10.3 Hz, H-6'), 3.53 (t, 1H, *J* = 9.5 Hz, H-4'), 3.40 (s, 3H, CH₃ OMe), 3.35 (dd, 1H, *J* = 9.5, 3.8 Hz, H-2'), 1.45 (d, 3H, *J* = 6.2 Hz, H-6); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC, HMBC): δ 166.2, 165.5 (C=O), 138.7, 137.9, 137.4 (C_q), 133.4, 133.1 (CH_{arom}), 130.1 (C_q), 130.0, 129.8 (CH_{arom}), 129.2 (C_q), 129.0, 128.5, 128.5, 128.4, 128.3, 128.2, 128.1, 127.7, 127.6 (CH_{arom}), 101.3 (CHPh), 98.7 (C-1'), 96.7 (C-1), 82.0 (C-4'), 79.8 (C-4), 78.5 (C-2'), 78.5 (C-3'), 75.5, 73.2 (CH₂ Bn), 72.9 (C-2), 72.4 (C-3), 68.9 (C-6'), 66.2 (C-5), 63.6 (C-5'), 55.3 (OMe), 18.6 (C-6); HRMS: [M+NH₄]⁺ calcd for C₄₈H₅₂NO₁₂ 834.34840, found 834.34900.




Methyl 4-O-(2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy- α -D-glucopyranosyl)-2,3-di-O-benzoyl-6-deoxy- α -D-glucopyranoside (14B). Donor **B** and acceptor **14** were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (E) yielding product **14B** (72 mg, 96 μ mol, 96%, α : β = 20:1) as a colorless oil. R_f: 0.40 (4/1

pentane/EtOAc); $[\alpha]_D^{20} = +22.9^\circ$ ($c = 1.0$, CHCl_3); IR (thin film): 710, 753, 999, 1030, 1057, 1092, 1177, 1277, 1369, 1450, 1724, 2110, 2936; $^1\text{H NMR}$ (CDCl_3 , 400 MHz, HH-COSY, HSQC, HMBC): δ 7.99 (dt, 4H, $J = 8.3, 1.2$ Hz, CH_{arom}), 7.54–7.18 (m, 16H, CH_{arom}), 6.11–6.01 (m, 1H, H-3), 5.56 (s, 1H, CHPh), 5.15 (d, 1H, $J = 4.0$ Hz, H-1'), 5.09–5.02 (m, 2H, H-1, H-2), 4.90 (d, 1H, $J = 10.8$ Hz, CHH Bn), 4.72 (d, 1H, $J = 10.8$ Hz, CHH Bn), 4.26 (dd, 1H, $J = 10.3, 4.9$ Hz, H-6'), 4.06–3.89 (m, 3H, H-5, H-5', H-3'), 3.77–3.68 (m, 2H, H-4, H-6'), 3.65 (t, 1H, $J = 9.3$ Hz, H-4'), 3.41 (s, 3H, CH_3 OMe), 3.20 (dd, 1H, $J = 10.1, 4.0$ Hz, H-2'), 1.44 (d, 3H, $J = 6.2$ Hz, H-6); $^{13}\text{C-APT NMR}$ (CDCl_3 , 101 MHz, HSQC, HMBC): δ 166.2, 165.5 (C=O), 137.8, 137.1 (C_q), 133.4, 133.0, 130.1 (CH_{arom}), 130.1 (C_q), 129.5 (CH_{arom}), 129.2 (C_q), 129.2, 128.5, 128.5, 128.4, 128.3, 128.0, 126.0 (CH_{arom}), 101.4 (CHPh), 100.1 (C-1'), 96.8 (C-1), 82.4 (C-4'), 82.1 (C-4), 76.5 (C-3'), 75.2 (CH_2 Bn), 72.8 (C-2), 72.3 (C-3), 68.5 (C-6'), 65.7 (C-5), 63.6 (C-5'), 62.9 (C-2'), 55.5 (OMe), 18.3 (C-6); HRMS: $[\text{M}+\text{NH}_4]^+$ calcd for $\text{C}_{41}\text{H}_{45}\text{N}_4\text{O}_{11}$ 769.30793, found 769.30861.




Methyl 4-O-(2,3-di-O-benzyl-4,6-O-benzylidene- α -D-glucopyranosyl)-2,3,6-tri-O-benzoyl- α -D-glucopyranoside (15A). Donor **A** and acceptor **15** were condensed using the general procedure for $\text{Tf}_2\text{O}/\text{Ph}_2\text{SO}$ mediated glycosylations (E) yielding product

15A (85 mg, 91 μmol , 91%, $\alpha:\beta = >20:1$) as a colorless oil. Rf: 0.47 (4/1 pentane/EtOAc); $[\alpha]_D^{20} = +43.5^\circ$ ($c = 1.0$, CHCl_3); IR (thin film): 710, 748, 997, 1028, 1090, 1271, 1452, 1724, 2936; $^1\text{H NMR}$ (CDCl_3 , 400 MHz, HH-COSY, HSQC): δ 8.11–8.06 (m, 2H, CH_{arom}), 8.03–7.95 (m, 4H, CH_{arom}), 7.63–7.57 (m, 1H, CH_{arom}), 7.52–7.41 (m, 6H, CH_{arom}), 7.39–7.23 (m, 13H, CH_{arom}), 7.19–7.14 (m, 3H, CH_{arom}), 7.12–7.07 (m, 2H, CH_{arom}), 6.21 (ddd, 1H, $J = 10.2, 7.0, 1.8$ Hz, H-3), 5.44 (s, 1H, CHPh), 5.27 (dd, 1H, $J = 10.3, 3.6$ Hz, H-2), 5.15 (d, 1H, $J = 3.6$ Hz, H-1), 4.94 (d, 1H, $J = 3.6$ Hz, H-1'), 4.85–4.75 (m, 2H, CHH Bn , H-6), 4.69–4.58 (m, 2H, CHH Bn , H-6), 4.30 (d, 1H, $J = 12.4$ Hz, CHH Bn), 4.26–4.18 (m, 2H, H-5, H-4), 4.13 (dd, 1H, $J = 10.2, 4.8$ Hz, H-6'), 4.04–3.96 (m, 2H, CHH Bn , H-3'), 3.92 (td, 1H, $J = 10.0, 4.8$ Hz, H-5'), 3.57 (t, 1H, $J = 10.3$ Hz, H-6'), 3.49 (d, 1H, $J = 9.5$ Hz, H-4'), 3.44 (s, 3H, CH_3 OMe), 3.29 (dd, 1H, $J = 9.5, 3.6$ Hz, H-2'); $^{13}\text{C-APT NMR}$ (CDCl_3 , 101 MHz, HSQC, HMBC): δ 166.2, 165.6 (C=O), 138.7, 138.0, 137.4 (C_q), 133.5, 133.3, 133.1 (CH_{arom}), 130.1 (C_q), 130.1 (CH_{arom}), 129.9 (C_q), 129.8, 129.8 (CH_{arom}), 129.1 (C_q), 129.0, 128.6, 128.5, 128.5, 128.4, 128.4, 128.3, 128.2, 128.1, 127.8, 127.7, 126.2 (CH_{arom}), 101.4 (CHPh), 99.7 (C-1'), 96.9 (C-1), 81.9 (C-4'), 78.4 (C-2'), 78.4 (C-3'), 76.2 (C-4), 75.4 (CH_2 Bn), 73.3 (CH_2 Bn), 72.2 (C-2), 71.7 (C-3), 68.8 (C-6'), 68.7 (C-5), 64.0 (C-5'), 63.4 (C-6), 55.6 (OMe); HRMS: $[\text{M}+\text{NH}_4]^+$ calcd for $\text{C}_{55}\text{H}_{56}\text{NO}_{14}$ 954.36953, found 954.37046.



Methyl 4-O-(2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy- α -D-glucopyranosyl)-2,3,6-tri-O-benzoyl- α -D-glucopyranoside (15B). Donor **B** and acceptor **15** were condensed using the general procedure for $\text{Tf}_2\text{O}/\text{Ph}_2\text{SO}$ mediated glycosylations (E) yielding product **15B** (60 mg, 69 μmol , 69%, $\alpha:\beta = >20:1$) as a white solid. Rf: 0.42 (4/1 pentane/EtOAc); $[\alpha]_D^{20} = +38.5^\circ$ ($c = 1.0$, CHCl_3); IR (thin film): 710, 752, 999, 1030,


1096, 1269, 1450, 1724, 2110, 2936; $^1\text{H NMR}$ (CDCl_3 , 400 MHz, HH-COSY, HSQC, HMBC): δ 8.15–7.94 (m, 6H, CH_{arom}), 7.64–7.20 (m, 19H, CH_{arom}), 6.14 (dd, 1H, $J = 9.8, 8.7$ Hz, H-3), 5.51 (s, 1H, CHPh), 5.20–5.08 (m, 3H, H-1, H-1', H-2), 4.89 (d, 1H, $J = 10.8$ Hz, CHH Bn), 4.75 (dd, 1H, $J = 12.2, 2.0$ Hz, H-6), 4.70 (d, 1H, $J = 10.8$ Hz, CHH Bn), 4.59 (dd, 1H, $J = 12.2, 4.1$ Hz, H-6), 4.28 (dd, 1H, $J = 10.4, 4.8$ Hz, H-6'), 4.22 (ddd, 1H, $J = 10.1, 4.1, 1.9$ Hz, H-5), 4.20–4.12 (m, 1H, H-4), 4.03–3.89 (m, 2H, H-3', H-5'), 3.68–3.57 (m, 2H, H-6', H-4'), 3.45 (s, 3H, CH_3 OMe), 3.25 (dd, 1H, $J = 10.0, 4.0$ Hz, H-2'); $^{13}\text{C-APT NMR}$ (CDCl_3 , 101 MHz, HSQC, HMBC): δ 166.2, 166.1, 165.6 (C=O), 137.7, 137.1 (C_q), 133.5, 133.5, 133.4, 133.1, 130.1 (CH_{arom}), 130.0 (C_q), 129.9 (CH_{arom}), 129.8 (C_q), 129.5, 129.1 (CH_{arom}), 129.1 (C_q), 128.7, 128.6, 128.5, 128.5, 128.4, 128.3, 128.0, 126.1 (CH_{arom}), 101.4 (CHPh), 100.6 (C-1'), 96.9 (C-1), 82.4 (C-4'), 77.4 (C-4), 76.6 (C-3'), 75.2 (CH_2 Bn), 72.3 (C-2), 72.1 (C-3), 68.5 (C-6'), 68.2 (C-5), 64.0 (C-5'), 63.4 (C-6), 63.0 (C-2'), 55.7 (OMe); HRMS: $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{48}\text{H}_{45}\text{N}_3\text{O}_{13}\text{Na}$ 894.2845, found 894.2878.




Methyl (methyl 4-O-(2,3-di-O-benzyl-4,6-O-benzylidene- α -D-glucopyranosyl)-2,3-di-O-benzoyl- α -D-glucopyranosyl uronate) (16A). Donor **A** and acceptor **16** were condensed using the general procedure for $\text{Tf}_2\text{O}/\text{Ph}_2\text{SO}$ mediated glycosylations (E) yielding product **16A** (72 mg, 84 μmol , 84%, $\alpha:\beta = >20:1$) as a colorless oil. Rf: 0.58 (4/1

pentane/EtOAc); $[\alpha]_D^{20} = +19.3^\circ$ ($c = 1.0$, CHCl_3); IR (thin film): 710, 748, 916, 997, 1049, 1090, 1271, 1452, 1732, 2938; $^1\text{H NMR}$ (CDCl_3 , 400 MHz, HH-COSY, HSQC): δ 8.05–7.91 (m, 4H, CH_{arom}), 7.53–7.43 (m, 4H, CH_{arom}), 7.41–7.24 (m, 12H, CH_{arom}), 7.21–7.15 (m, 3H, CH_{arom}), 7.07–7.02 (m, 2H, CH_{arom}), 6.17 (dd, 1H, $J = 10.2, 8.8$ Hz, H-3), 5.48 (s, 1H, CHPh), 5.24 (dd, 1H, $J = 10.1, 3.5$ Hz, H-2), 5.20 (d, 1H, $J = 3.5$ Hz, H-1), 4.94 (d, 1H, $J = 3.7$ Hz, H-1'), 4.81 (d, 1H, $J = 11.2$ Hz, CHH Bn), 4.70 (d, 1H, $J = 11.2$ Hz, CHH Bn), 4.45 (d, 1H, $J = 9.7$ Hz, H-5), 4.39 (dd, 1H, $J = 9.7, 8.9$ Hz, H-4), 4.34–4.22 (m, 2H, CHH Bn , H-6'), 3.99 (d, 1H, $J = 12.4$ Hz, CHH Bn), 3.95 (t, 1H, $J = 9.4$ Hz, H-3'), 3.79 (s, 3H, CH_3 CO_2Me), 3.72–3.64 (m, 1H, H-5), 3.64–3.56 (m, 1H, H-6'), 3.52–3.40 (m, 4H, H-4', CH_3 OMe), 3.28 (dd, 1H, $J = 9.4, 3.7$ Hz, H-

2'); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC, HMBC): δ 169.4 (C=O CO₂Me), 166.0, 165.4 (C=O OBz), 138.7, 137.9, 137.5 (C_q), 133.5, 133.2, 130.1 (CH_{arom}), 130.0 (C_q), 129.8 (CH_{arom}), 129.0 (C_q), 129.0, 128.5, 128.4, 128.3, 128.2, 128.0, 127.7, 127.7, 126.1 (CH_{arom}), 101.3 (CHPh), 99.2 (C-1'), 97.5 (C-1), 81.6 (C-4'), 78.2 (C-2'), 78.0 (C-3'), 76.3 (C-4), 75.4, 72.8 (CH₂ Bn), 71.7 (C-2), 71.3 (C-3), 70.6 (C-5), 68.6 (C-6'), 63.6 (C-5'), 56.0 (OMe), 53.0 (CO₂Me); HRMS: [M+NH₄]⁺ calcd for C₄₉H₅₂NO₁₄ 878.33823, found 878.33866.




Methyl (methyl 4-O-(2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy- α -D-glucopyranosyl)-2,3-di-O-benzoyl- α -D-glucopyranosyl uronate) (16B). Donor **B** and acceptor **16** were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (E) yielding product **16B** (79 mg, 99 μ mol, 99%, α : β = >20:1) as a white solid. R_f: 0.51 (4/1 pentane/EtOAc); [α]_D²⁰ = +13.1° (c = 1.0, CHCl₃); IR (thin film): 710, 752, 995, 1092, 1269, 1369, 1450, 1728, 2110, 2936; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC, HMBC): δ 8.03 – 7.94 (m, 4H, CH_{arom}), 7.54 – 7.19 (m, 16H, CH_{arom}), 6.09 (dd, 1H, J = 10.2, 9.0 Hz, H-3), 5.53 (s, 1H, CHPh), 5.21 (d, 1H, J = 3.5 Hz, H-1), 5.15 (dd, 1H, J = 10.2, 3.5 Hz, H-2), 5.06 (d, 1H, J = 3.9 Hz, H-1'), 4.87 (d, 1H, J = 10.8 Hz, CHH Bn), 4.70 (d, 1H, J = 10.8 Hz, CHH Bn), 4.45 – 4.26 (m, 3H, H-5, H-4, H-6'), 3.95 (dd, 1H, J = 10.0, 8.9 Hz, H-3'), 3.85 (s, 3H, CH₃ CO₂Me), 3.75 – 3.63 (m, 2H, H-5', H-6'), 3.59 (t, 1H, J = 9.1 Hz, H-4'), 3.47 (s, 3H, CH₃ OMe), 3.22 (dd, 1H, J = 10.0, 3.8 Hz, H-2'); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 169.0 (C=O CO₂Me), 166.0, 165.5 (C=O OBz), 137.8, 137.3 (C_q), 133.5, 133.2, 130.1 (CH_{arom}), 129.8 (C_q), 129.6, 129.2 (CH_{arom}), 129.0 (C_q), 128.6, 128.5, 128.4, 128.3, 127.9, 126.1 (CH_{arom}), 101.5 (CHPh), 99.8 (C-1'), 97.6 (C-1), 82.4 (C-4'), 77.4 (C-4), 76.5 (C-3'), 75.2 (CH₂ Bn), 71.8 (C-2), 71.1 (C-3), 70.3 (C-5), 68.5 (C-6'), 63.6 (C-5'), 63.0 (C-2'), 56.1 (OMe), 53.0 (CO₂Me); HRMS: [M+NH₄]⁺ calcd for C₄₂H₄₅N₄O₁₃ 813.29776, found 813.29765.



Methyl 4-O-(2,3-di-O-benzyl-4,6-O-benzylidene- α / β -D-glucopyranosyl)-2,3,6-tri-O-benzyl- β -D-glucopyranoside (17A). Donor **A** and acceptor **17** were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (E) yielding product **17A** (71 mg, 79 μ mol, 79%, α : β = 1:1) as a colorless oil. R_f: 0.67 (4/1


pentane/EtOAc); IR (thin film): 698, 737, 910, 999, 1072, 1211, 1277, 1366, 1454, 2866; Data reported for a 1:1 mixture of anomers: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC, HMBC): δ 7.55 – 7.05 (m, 60H, CH_{arom}), 5.71 (d, 1H, J = 3.9 Hz, H-1' α), 5.53 (s, 1H, CHPh α), 5.49 (s, 1H, CHPh β), 5.00 – 4.84 (m, 6H, 6xCHH Bn), 4.84 – 4.66 (m, 9H, CH₂ Bn, 5xCHH Bn, 2xCHH Bn), 4.66 – 4.50 (m, 5H, 3xCHH Bn, CHH Bn, H-1' β), 4.38 (d, 1H, J = 12.1 Hz, CHH Bn), 4.34 (d, 1H, J = 7.8 Hz, H-1 α), 4.29 (d, 1H, J = 7.7 Hz, H-1 β), 4.23 – 4.14 (m, 2H, H-6' β , H-6 α), 4.12 (dd, 1H, J = 9.7, 8.7 Hz, H-3' β), 4.02 – 3.94 (m, 2H, H-3 α , H-3 β), 3.91 – 3.73 (m, 5H, H-5 α , H-6 β , H-6 α , H-6 β , H-3' α), 3.68 (dd, 1H, J = 10.9, 1.8 Hz, H-6 β), 3.66 – 3.52 (m, 12H, H-2 α , H-4' β , H-4' α , H-4 α , H-5 β , H-6' α , CH₃ OMe α , CH₃ OMe β), 3.51 – 3.28 (m, 6H, H-2' α , H-2 β , H-2' β , H-3 β , H-4 β , H-6' β), 3.14 (td, 1H, J = 9.4, 4.9 Hz, H-5' β); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC, HMBC): δ 139.1, 138.8, 138.8, 138.6, 138.4, 138.3, 138.2, 137.9, 137.7, 137.5 (C_q), 129.1, 128.9, 128.5, 128.4, 128.4, 128.4, 128.4, 128.3, 128.3, 128.2, 128.1, 128.1, 127.9, 127.9, 127.8, 127.8, 127.7, 127.7, 127.7, 127.5, 127.3, 126.7, 126.1 (CH_{arom}), 104.8 (C-1 β), 104.6 (C-1 α), 102.9 (C-1' β), 101.2 (CHPh α , β), 97.3 (C-1' α), 84.9 (C-3' α), 82.9 (C-2 α), 82.6 (C-2' β), 82.5, 82.4, 81.9, 81.8, 81.2 (C-4 α C-4' β C-5 α C-2 β C-4' α), 78.8, 78.8 (C-2' α C-3 β), 76.9 (C-3 α), 75.5, 75.5, 75.4, 75.1, 75.1 (CH₂ Bn), 75.0 (C-4 β), 74.7, 74.3 (CH₂ Bn), 73.9 (C-5 β), 73.8, 73.5, 73.3 (CH₂ Bn), 72.0 (C-3' β), 69.0 (C-6 α), 68.9 (C-6' α , β) 68.0 (C-6 β), 65.9 (C-5' β), 63.4 (C-5' α), 57.2 (OMe α), 57.1 (OMe β); HRMS: [M+NH₄]⁺ calcd for C₄₈H₅₆NO₁₀ 912.43174, found 912.43238.



Methyl 4-O-(2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy- α / β -D-glucopyranosyl)-2,3,6-tri-O-benzyl- β -D-glucopyranoside (17B). Donor **B** and acceptor **17** were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (E) yielding product **17B** (66 mg, 80 μ mol, 80%, α : β =


1:7) as a colorless oil. R_f: 0.78 (4/1 pentane/EtOAc); IR (thin film): 698, 737, 914, 999, 1092, 1277, 1366, 1454, 2110, 2870; Data for the β -anomer: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC, HMBC): δ 7.54 – 7.14 (m, 25H, CH_{arom}), 5.47 (s, 1H, CHPh), 4.90 – 4.82 (m, 3H, CH₂ Bn, CHH Bn), 4.82 – 4.67 (m, 4H, CHH Bn, CH₂ Bn, CHH Bn), 4.48 (d, 1H, J = 12.0 Hz, CHH Bn), 4.35 (d, 1H, J = 7.8 Hz, H-1'), 4.30 (d, 1H, J = 7.7 Hz, H-1), 4.11 (dd, 1H, J = 10.5, 5.0 Hz, H-6'), 4.02 (t, 1H, J = 9.4 Hz, H-4), 3.99 – 3.92 (m, 1H, H-6), 3.82 (dd, 1H, J = 11.0, 1.8 Hz, H-6), 3.60 – 3.52 (m, 5H, CH₃ OMe, H-3, H-4'), 3.49 – 3.29 (m, 5H, H-2, H-2', H-3', H-5, H-6'), 3.01 (td, 1H, J = 9.8, 5.0 Hz, H-5'); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC, HMBC): δ 139.1, 138.7, 138.1, 137.9, 137.3 (C_q), 129.2, 128.6, 128.5, 128.4, 128.3, 128.3, 128.1, 128.0, 128.0, 127.7, 127.7, 127.5, 126.1 (CH_{arom}), 104.8 (C-1), 101.3 (CHPh), 101.3 (C-1'), 82.8 (C-4'), 81.8 (C-2), 81.8 (C-3), 79.2 (C-3'), 76.9 (C-4), 75.5, 75.0, 74.9 (CH₂ Bn), 74.7 (C-5), 73.5 (CH₂ Bn), 68.6 (C-6'), 68.2 (C-6), 66.7 (C-2'), 65.9 (C-5'), 57.3 (OMe); Diagnostic peaks for the α -anomer: ¹H NMR (CDCl₃, 400 MHz): δ 5.69 (d, 1H, J = 4.1 Hz, H-1'), 5.54 (s, 1H, CHPh), 5.07 (d, 1H, J = 10.7 Hz), 3.26 (dd, 1H, J = 10.1, 4.0 Hz, H-2'); ¹³C-APT NMR (CDCl₃, 101 MHz): δ 138.5, 138.4, 138.3, 137.4,

129.1, 128.5, 128.4, 128.2, 127.8, 127.6, 126.1, 104.7, 98.0, 85.0, 82.7, 76.2, 75.1, 74.3, 73.7, 73.1, 69.2, 68.8, 63.4, 62.8, 57.1; HRMS: $[M+NH_4]^+$ calcd for $C_{48}H_{55}NaO_{10}$ 847.39127, found 847.39197.




Methyl 4-O-(2,3-di-O-benzyl-4,6-O-benzylidene- α/β -D-glucopyranosyl)-2,3-di-O-benzyl-6-deoxy- β -D-glucopyranoside (18A). Donor **A** and acceptor **18** were condensed using the general procedure for Tf_2O/Ph_2SO mediated glycosylations (E) yielding product **18A** (69 mg, 87 μ mol, 87%, $\alpha:\beta = 1.1:1$) as a colorless oil. R_f :

0.68 (4/1 pentane/EtOAc); IR (thin film): 698, 737, 999, 1030, 1072, 1454, 2870, 3032; Data reported for a 1.1:1 mixture of anomers: 1H NMR ($CDCl_3$, 400 MHz, HH-COSY, HSQC, HMBC): δ 7.53 – 7.06 (m, 47.5H, CH_{arom}), 5.71 (d, 1H, $J = 4.1$ Hz, H-1' $_{\alpha}$), 5.55 (s, 1H, $CHPh_{\alpha}$), 5.52 (s, 0.9H, $CHPh_{\beta}$), 4.99 – 4.87 (m, 5H, 3x CHH Bn, CH_2 Bn), 4.87 – 4.74 (m, 6H, 2x CHH Bn, 2x CH_2 Bn), 4.74 – 4.62 (m, 3.9H, CHH Bn, 2x CHH Bn, H-1' $_{\beta}$), 4.57 (d, 1H, $J = 10.9$ Hz, CHH Bn), 4.52 (d, 1H, $J = 11.7$ Hz, CHH Bn), 4.34 – 4.28 (m, 1.9H, H-1 $_{\alpha}$, H-1 $_{\beta}$), 4.26 (dd, 1H, $J = 10.3$, 4.9 Hz, H-6' $_{\alpha}$), 4.18 (dd, 0.9H, $J = 10.4$, 4.9 Hz, H-6' $_{\beta}$), 4.02 (t, 1H, $J = 9.3$ Hz, H-3' $_{\alpha}$), 3.94 (td, 1H, $J = 10.0$, 4.8 Hz, H-5' $_{\alpha}$), 3.81 – 3.68 (m, 3H, H-3 $_{\alpha}$, H-4 $_{\alpha}$, H-6' $_{\alpha}$), 3.67 – 3.58 (m, 4.7H, H-3' $_{\beta}$, H-3 $_{\beta}$, H-4' $_{\beta}$, H-5 $_{\alpha}$, H-4' $_{\alpha}$), 3.57 (s, 3H, CH_3 OMe $_{\alpha}$), 3.56 (s, 2.7H, CH_3 OMe $_{\beta}$), 3.54 – 3.43 (m, 5.7H, H-2' $_{\alpha}$, H-2 $_{\alpha}$, H-6' $_{\beta}$, H-4 $_{\beta}$, H-5 $_{\alpha}$, H-2' $_{\beta}$), 3.43 – 3.35 (m, 1.8H, H-2 $_{\beta}$, H-5 $_{\beta}$), 3.31 (td, 0.9H, $J = 9.7$, 4.9 Hz, H-5' $_{\beta}$), 1.42 (d, 3H, $J = 5.8$ Hz, H-6 $_{\alpha}$), 1.38 (d, 2.7H, $J = 6.1$ Hz, H-6 $_{\beta}$); ^{13}C -APT NMR ($CDCl_3$, 101 MHz, HSQC, HMBC): δ 139.2, 139.0, 138.7, 138.7, 138.5, 138.4, 138.2, 137.9, 137.4 (C_{α}), 129.1, 129.0, 128.4, 128.4, 128.4, 128.3, 128.3, 128.3, 128.1, 128.1, 128.1, 127.9, 127.8, 127.7, 127.7, 127.7, 127.7, 127.5, 127.2, 126.5, 126.1, 126.0 (CH_{arom}), 104.5 (C-1 $_{\beta}$), 104.5 (C-1 $_{\alpha}$), 103.7 (C-1' $_{\beta}$), 101.2 ($CHPh_{\alpha,\beta}$), 97.8 (C-1' $_{\alpha}$), 84.6 (C-3 $_{\alpha}$), 83.2 (C-4 $_{\beta}$), 82.9, 82.7, 82.7, 82.3, 82.1 (C-3 $_{\beta}$ C-3' $_{\beta}$ C-2 $_{\beta}$ C-2 $_{\alpha}$), 81.8 (C-4' $_{\beta}$), 81.4 (C-4 $_{\alpha}$), 78.9 (C-3' $_{\alpha}$), 78.7 (C-2' $_{\alpha}$), 78.2 (C-4' $_{\alpha}$), 75.7, 75.5, 75.4, 75.3, 75.0, 74.7, 74.0, 73.8 (CH_2 Bn), 71.4 (C-5 $_{\beta}$), 70.4 (C-5 $_{\alpha}$), 68.9 (C-6' $_{\alpha}$), 68.8 (C-6' $_{\beta}$), 66.0 (C-5' $_{\alpha}$), 63.3 (C-5' $_{\beta}$), 57.2 (OMe $_{\alpha}$), 57.2 (OMe $_{\beta}$), 19.3 (C-6 $_{\alpha}$), 18.1 (C-6 $_{\beta}$); HRMS: $[M+Na]^+$ calcd for $C_{48}H_{55}O_{10}Na$ 811.3453, found 811.3475.



Methyl 4-O-(2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy- α/β -D-glucopyranosyl)-2,3-di-O-benzyl-6-deoxy- β -D-glucopyranoside (18B). Donor **B** and acceptor **18** were condensed using the general procedure for Tf_2O/Ph_2SO mediated glycosylations (E) yielding product **18B** (62 mg, 86 μ mol, 86%, $\alpha:\beta =$


1:5) as a white solid. R_f : 0.84 (4/1 pentane/EtOAc); IR (thin film): 698, 737, 999, 1072, 1169, 1277, 1366, 1454, 2110, 2873; Data for the β -anomer: 1H NMR ($CDCl_3$, 400 MHz, HH-COSY, HSQC): δ 7.54 – 7.11 (m, 20H, CH_{arom}), 5.49 (s, 1H, $CHPh$), 4.91 (d, 1H, $J = 11.3$ Hz, CHH Bn), 4.87 (d, 1H, $J = 11.1$ Hz, CHH Bn), 4.85 – 4.81 (m, 2H, CH_2 Bn), 4.77 (d, 1H, $J = 11.2$ Hz, CHH Bn), 4.68 (d, 1H, $J = 11.0$ Hz, CHH Bn), 4.52 (d, 1H, $J = 8.1$ Hz, H-1'), 4.30 (d, 1H, $J = 7.8$ Hz, H-1), 4.06 (dd, 1H, $J = 10.5$, 5.0 Hz, H-6'), 3.63 (t, 1H, $J = 9.1$ Hz, H-4'), 3.60 – 3.50 (m, 5H, CH_3 OMe, H-3, H-3'), 3.50 – 3.36 (m, 6H, H-2, H-2', H-4, H-5, H-6'), 3.22 (td, 1H, $J = 9.6$, 5.0 Hz, H-5'), 1.44 (d, 2H, $J = 5.5$ Hz, H-6); ^{13}C -APT NMR ($CDCl_3$, 101 MHz, HSQC, HMBC): δ 139.1, 138.6, 137.8, 137.2 (C_{α}), 129.2, 128.5, 128.4, 128.4, 128.3, 128.3, 128.1, 128.0, 127.7, 127.6, 127.5, 127.3, 126.1 (CH_{arom}), 104.5 (C-1), 102.3 (C-1'), 101.3 ($CHPh$), 83.5 (C-4), 82.9 (C-3), 82.3 (C-2), 81.7 (C-4'), 79.4 (C-3'), 75.4, 75.0, 74.9 (CH_2 Bn), 71.0 (C-5), 68.5 (C-6'), 67.2 (C-2'), 66.2 (C-5'), 57.2 (OMe), 18.1 (C-6); Diagnostic peaks for the α -anomer: 1H NMR ($CDCl_3$, 400 MHz): δ 5.64 (d, 1H, $J = 4.2$ Hz, (H-1')), 5.57 (s, 1H, $CHPh$), 5.08 (d, 1H, $J = 10.6$ Hz, CHH Bn), 4.98 (d, 1H, $J = 10.9$ Hz, CHH Bn), 4.23 (dd, 1H, $J = 10.4$, 4.9 Hz, H-6'), 3.93 (td, 1H, $J = 9.9$, 4.9 Hz, H-5'), 3.29 (dd, 1H, $J = 10.1$, 4.2 Hz, H-2'), 1.39 (d, 3H, $J = 5.2$ Hz, H-6); ^{13}C -APT NMR ($CDCl_3$, 101 MHz): δ 138.6, 138.4, 137.9, 128.6, 128.2, 127.8, 126.0, 101.3, 98.6, 84.6, 83.1, 82.6, 79.5, 76.3, 75.2, 75.0, 74.7, 70.2, 68.6, 63.3, 62.8, 57.2, 19.0; HRMS: $[M+NH_4]^+$ calcd for $C_{41}H_{49}N_4O_9$ 741.34941, found 741.35004.



Methyl 4-O-(2,3-di-O-benzyl-4,6-O-benzylidene- α/β -D-glucopyranosyl)-2,3-di-O-benzyl-6-O-benzoyl- β -D-glucopyranoside (19A). Donor **A** and acceptor **19** were condensed using the general procedure for Tf_2O/Ph_2SO mediated glycosylations (E) yielding product **19A** (66 mg, 73 μ mol, 73%, $\alpha:\beta = 3:1$) as a white solid. R_f :


0.65 (4/1 pentane/EtOAc); IR (thin film): 698, 999, 1030, 1088, 1273, 1454, 1721, 2862, 3032; Data for the α -anomer: 1H NMR ($CDCl_3$, 400 MHz, HH-COSY, HSQC, HMBC): δ 8.13 – 8.03 (m, 2H, CH_{arom}), 7.60 – 7.01 (m, 28H, CH_{arom}), 5.65 (d, 1H, $J = 4.0$ Hz, H-1'), 5.46 (s, 1H, $CHPh$), 4.95 – 4.65 (m, 7H, 2x CHH Bn, 2x CH_2 Bn, H-6), 4.65 – 4.50 (m, 3H, 2x CHH Bn, H-6), 4.38 (d, 1H, $J = 7.7$ Hz, H-1), 4.12 – 4.00 (m, 3H, H-4', H-6', H-5'), 3.87 – 3.74 (m, 3H, H-3, H-5, H-3'), 3.62 – 3.45 (m, 7H, H-2', H-2, H-4, H-6', CH_3 OMe); ^{13}C -APT NMR ($CDCl_3$, 101 MHz, HSQC, HMBC): δ 166.2 (C=O), 138.8, 138.6, 138.3, 138.0, 137.4 (C_{α}), 133.2 (CH_{arom}), 130.0 (C_{α}), 129.9, 129.7, 129.0, 128.5, 128.5, 128.4, 128.4, 128.4, 128.3, 128.2, 128.1, 127.8, 127.7, 126.8, 126.2 (CH_{arom}), 104.5 (C-1), 101.4 ($CHPh$), 98.3 (C-1'), 84.5 (C-3), 82.4 (C-4), 82.4 (C-2), 78.8 (C-5'), 78.6 (C-2'), 75.3, 74.7, 74.3 (CH_2 Bn), 74.2 (C-4'), 74.1 (CH_2 Bn), 72.6 (C-3'), 68.9 (C-6'), 63.8 (C-6), 63.7 (C-5), 57.2 (OMe); Diagnostic peaks for the β -anomer: 1H NMR ($CDCl_3$, 400 MHz): δ 5.50 (s, 1H, $CHPh$), 4.47 (dd, 1H, $J = 12.0$, 4.9 Hz), 4.33 (d, 1H, $J = 7.7$ Hz, H-1), 4.19 (dt, 1H, $J = 9.3$, 4.6 Hz), 3.72 (d, 1H, $J = 8.9$ Hz), 3.67 – 3.62 (m, 1H), 3.44 –

3.39 (m, 1H, H-2'), 3.23 (td, 1H, $J = 9.7, 5.0$ Hz, H-5'); ^{13}C -APT NMR (CDCl_3 , 101 MHz): δ 166.0, 138.8, 138.6, 138.5, 138.2, 137.3, 133.3, 129.7, 129.0, 128.5, 128.0, 127.4, 126.1, 104.6 (C-1), 103.1 (C-1'), 101.2 (CHPh), 82.7, 82.6, 81.8, 81.4, 77.4, 75.8, 75.7, 75.3, 75.0, 73.3, 66.1, 62.9; HRMS: $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{55}\text{H}_{56}\text{O}_{12}\text{Na}$ 931.3664, found 931.3695.




Methyl 4-O-(2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy- α/β -D-glucopyranosyl)-2,3,6-tri-O-benzyl- β -D-glucopyranoside (19B). Donor **B** and acceptor **19** were condensed using the general procedure for $\text{Ti}_2\text{O}/\text{Ph}_2\text{SO}$ mediated glycosylations (E) yielding product **19B** (59 mg, 70 μmol , 70%, $\alpha:\beta =$

1:1.2) as a colorless oil. R_f : 0.59 (4/1 pentane/EtOAc); IR (thin film): 698, 737, 999, 1030, 1069, 1092, 1273, 1369, 1454, 1721, 2110, 2870, 3032; Data reported for a 1:1.2 mixture of anomers: ^1H NMR (CDCl_3 , 400 MHz, HH-COSY, HSQC): δ 8.10 – 8.00 (m, 4.4H, CH_{arom}), 7.61 – 7.18 (m, 50.6H, CH_{arom}), 5.68 (d, 1H, $J = 4.2$ Hz, H-1' $_{\alpha}$), 5.49 (s, 1H, CHPh_{α}), 5.48 (s, 1.2H, CHPh_{β}), 5.10 (d, 1H, $J = 10.5$ Hz, CHH Bn_{α}), 4.95 (d, 1H, $J = 11.0$ Hz, CHH Bn_{α}), 4.94 (d, 1H, $J = 11.0$ Hz, CHH Bn_{α}), 4.92 – 4.82 (m, 7H, $2\times\text{CHH Bn}_{\beta}$, $\text{CH}_2 \text{Bn}_{\beta}$, CHH Bn_{α} , H-6 $_{\beta}$), 4.80 – 4.72 (m, 3.2H, CHH Bn_{α} , CHH Bn_{β} , H-6 $_{\alpha}$), 4.70 (d, 1.2H, $J = 11.0$ Hz, CHH Bn_{β}), 4.68 (d, 1H, $J = 11.0$ Hz, CHH Bn_{α}), 4.57 (dd, 1H, $J = 12.2, 4.4$ Hz, H-6 $_{\beta}$), 4.51 – 4.43 (m, 2.2H, H-1' $_{\beta}$, H-6 $_{\alpha}$), 4.43 – 4.33 (m, 2.2H, H-1 $_{\alpha}$, H-1 $_{\beta}$), 4.09 – 3.92 (m, 5.4H, H-3' $_{\alpha}$, H-4 $_{\alpha}$, H-4 $_{\beta}$, H-6' $_{\alpha}$, H-6' $_{\beta}$), 3.88 – 3.77 (m, 2.2H, H-3 $_{\beta}$, H-5' $_{\alpha}$), 3.76 – 3.60 (m, 5.4H, H-3 $_{\alpha}$, H-4' $_{\alpha}$, H-4' $_{\beta}$, H-5 $_{\alpha}$, H-5 $_{\beta}$), 3.60 – 3.39 (m, 13.4H, $\text{CH}_3 \text{OMe}_{\alpha}$, $\text{CH}_3 \text{OMe}_{\beta}$, H-2 $_{\alpha}$, H-2 $_{\beta}$, H-2' $_{\beta}$, H-3' $_{\beta}$, H-6' $_{\alpha}$, H-6' $_{\beta}$), 3.31 (dd, 1H, $J = 10.1, 4.1$ Hz, H-2' $_{\alpha}$), 3.13 (td, 1.2H, $J = 9.6, 5.0$ Hz, H-5' $_{\beta}$); ^{13}C -APT NMR (CDCl_3 , 101 MHz, HSQC, HMBC): δ 166.1 (C=O), 138.8, 138.5, 138.4, 138.3, 137.8, 137.7, 137.2, 137.1 (C $_{\alpha}$), 133.4, 133.3, 129.9 (CH_{arom}), 129.9 (C $_{\alpha}$), 129.7, 129.2, 129.1, 128.6, 128.6, 128.5, 128.5, 128.5, 128.4, 128.3, 128.3, 128.2, 128.1, 128.0, 127.9, 127.8, 127.7, 127.7, 127.5, 126.2, 126.0 (CH_{arom}), 104.7 (C-1 $_{\beta}$), 104.6 (C-1 $_{\alpha}$), 101.9 (C-1' $_{\beta}$), 101.4 (CHPh_{α}), 101.3 (CHPh_{β}), 98.8 (C-1' $_{\alpha}$), 84.5 (C-3 $_{\beta}$), 82.8 (C-2 $_{\beta}$), 82.7 (C-4' $_{\alpha}$), 82.6 (C-3 $_{\alpha}$), 81.9 (C-2 $_{\beta}$), 81.6 (C-4' $_{\beta}$), 79.6 (C-3' $_{\beta}$), 77.7 (C-4 $_{\beta}$), 76.0 (C-3' $_{\alpha}$), 75.7, 75.1, 75.1, 75.0 ($\text{CH}_2 \text{Bn}$), 74.8 (C-4 $_{\alpha}$), 74.7, 74.7 ($\text{CH}_2 \text{Bn}$), 73.0 (C-5 $_{\beta}$), 72.3 (C-5 $_{\alpha}$), 68.5 (C-6 $_{\alpha,\beta}$), 66.8 (C-5' $_{\beta}$), 66.3 (C-5' $_{\alpha}$), 63.6 (C-5 $_{\alpha}$), 63.7 (C-5' $_{\alpha}$), 63.6 (C-6 $_{\beta}$), 62.8 (C-2' $_{\alpha}$), 57.3 (OMe_{β}), 57.2 (OMe_{α}); HRMS: $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{48}\text{H}_{49}\text{N}_3\text{O}_{11}\text{Na}$ 866.3289, found 866.3259.



Methyl 4-O-(2,3-di-O-benzyl-4,6-O-benzylidene- α/β -D-glucopyranosyl)-2,3-di-O-benzyl- β -D-glucopyranosyl uronate (20A). Donor **B** and acceptor **20** were condensed using the general procedure for $\text{Ti}_2\text{O}/\text{Ph}_2\text{SO}$ mediated glycosylations (E) yielding product **20A** (69 mg, 83 μmol , 83%, $\alpha:\beta = 5:1$) as a white solid. R_f :


0.75 (4/1 pentane/EtOAc); IR (thin film): 698, 737, 995, 1030, 1207, 1454, 1751, 2866, 3032; Data for the α -anomer: ^1H NMR (CDCl_3 , 400 MHz, HH-COSY, HSQC, HMBC): δ 7.50 – 7.08 (m, 25H, CH_{arom}), 5.51 (s, 1H, CHPh), 5.38 (d, 1H, $J = 3.8$ Hz, H-1'), 4.94 – 4.75 (m, 4H, $2\times\text{CHH Bn}$, $\text{CH}_2 \text{Bn}$), 4.67 – 4.50 (m, 4H, $2\times\text{CHH Bn}$, $\text{CH}_2 \text{Bn}$), 4.36 (d, 1H, $J = 7.6$ Hz, H-1), 4.32 – 4.25 (m, 1H, H-6'), 4.19 (t, 1H, $J = 9.0$ Hz, H-4), 4.00 (d, 1H, $J = 9.5$ Hz, H-5), 3.78 (s, 3H, $\text{CH}_3 \text{CO}_2\text{Me}$), 3.75 (t, 1H, $J = 8.9$ Hz, H-3), 3.65 – 3.55 (m, 3H, H-6', H-5', H-4'), 3.54 (s, 3H, $\text{CH}_3 \text{OMe}$), 3.52 – 3.43 (m, 3H, H-3', H-2, H-2'); ^{13}C -APT NMR (CDCl_3 , 101 MHz, HSQC, HMBC): δ 169.0 (C=O), 138.7, 138.6, 138.2, 137.9, 137.5 (C $_{\alpha}$), 129.0, 128.4, 128.4, 128.3, 128.3, 128.3, 128.2, 128.1, 127.9, 127.8, 127.7, 127.7, 127.3, 127.0, 126.1 (CH_{arom}), 104.9 (C-1), 101.3 (CHPh), 98.4 (C-1'), 83.4 (C-3), 82.0 (C-4'), 81.5 (C-2), 78.6 (C-2'), 78.4 (C-3'), 76.3 (C-4), 75.3 ($\text{CH}_2 \text{Bn}$), 74.8 (C-5), 74.8, 74.7, 73.6 ($\text{CH}_2 \text{Bn}$), 68.6 (C-6'), 63.2 (C-5'), 57.5 (OMe), 52.9 (CO_2Me); Diagnostic peaks for the β -anomer: ^1H NMR (CDCl_3 , 400 MHz): δ 5.48 (s, 1H, CHPh), 4.39 (d, 1H, $J = 7.6$ Hz), 3.91 (d, 1H, $J = 9.4$ Hz), 3.41 – 3.29 (m, 1H); ^{13}C -APT NMR (CDCl_3 , 101 MHz): δ 169.1, 138.9, 138.5, 138.5, 138.5, 137.4, 129.0, 127.6, 126.1, 105.0, 102.8, 101.2, 82.3, 81.8, 81.3, 78.0, 75.6, 75.4, 75.0, 74.8, 74.5, 68.8, 66.0, 52.7; HRMS: $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{49}\text{H}_{52}\text{O}_{12}\text{Na}$ 855.3351, found 855.3370.




Methyl (methyl 4-O-(2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy- α/β -D-glucopyranosyl)-2,3-di-O-benzyl- β -D-glucopyranosyl uronate) (20B). Donor **B** and acceptor **20** were condensed using the general procedure for $\text{Ti}_2\text{O}/\text{Ph}_2\text{SO}$ mediated glycosylations (E) yielding product **20B** (65 mg, 85 μmol , 85%, $\alpha:\beta =$

1.2:1) as a white solid. R_f : 0.55 (4/1 pentane/EtOAc); IR (thin film): 698, 741, 999, 1030, 1211, 1277, 1369, 1454, 1751, 2110, 2870, 2932; Data reported for a 1.2:1 mixture of anomers: ^1H NMR (CDCl_3 , 400 MHz, HH-COSY, HSQC, HMBC): δ 7.51 – 7.19 (m, 36H, CH_{arom}), 5.53 (s, 1H, CHPh_{α}), 5.50 (d, 1H, $J = 3.9$ Hz, H-1' $_{\alpha}$), 5.48 (s, 0.8H, CHPh_{β}), 5.01 (d, 1H, $J = 10.6$ Hz, CHH Bn), 4.92 – 4.72 (m, 9H, CHH Bn , $4\times\text{CH}_2 \text{Bn}$), 4.69 (d, 1H, $J = 4.8$ Hz, CHH Bn), 4.66 (d, 1H, $J = 4.8$ Hz, CHH Bn), 4.46 (d, 0.8H, $J = 8.1$ Hz, H-1' $_{\beta}$), 4.42 – 4.34 (m, 1.8H, H-1 $_{\beta}$, H-1 $_{\alpha}$), 4.27 (dd, 1H, $J = 10.3, 4.8$ Hz, H-6' $_{\alpha}$), 4.19 – 4.04 (m, 2.8H, H-3 $_{\alpha}$, H-5 $_{\alpha}$, H-6' $_{\beta}$), 4.01 – 3.91 (m, 2.8H, H-5 $_{\beta}$, H-4 $_{\alpha}$, H-3' $_{\alpha}$), 3.85 (s, 2.4H, $\text{CH}_3 \text{CO}_2\text{Me}_{\beta}$), 3.83 (s, 3H, $\text{CH}_3 \text{OMe}_{\alpha}$), 3.76 (t, 1H, $J = 8.9$ Hz, H-3 $_{\beta}$), 3.70 – 3.63 (m, 2H, H-6' $_{\alpha}$, H-4' $_{\alpha}$), 3.59 (dd, 0.8H, $J = 9.1, 1.6$ Hz, H-4' $_{\beta}$), 3.56 (s, 5.4H, $\text{CH}_3 \text{OMe}_{\alpha,\beta}$), 3.54 – 3.51 (m, 1.8H, H-2 $_{\alpha}$, H-4 $_{\beta}$), 3.51 – 3.47 (m, 0.8H, H-2 $_{\beta}$), 3.47 – 3.40 (m, 2.6H, H-3 $_{\beta}$, H-5' $_{\alpha}$, H-6' $_{\beta}$), 3.36 – 3.27 (m, 2.6H, H-2' $_{\beta}$, H-2' $_{\alpha}$, H-5' $_{\beta}$); ^{13}C -APT NMR (CDCl_3 , 101 MHz, HSQC, HMBC): δ 169.0, 169.0 (C=O),


138.8, 138.3, 138.3, 138.2, 137.9, 137.9, 137.4, 137.2 (C_q), 129.2, 129.1, 128.5, 128.5, 128.5, 128.4, 128.4, 128.3, 128.3, 128.2, 128.2, 128.1, 128.0, 127.9, 127.8, 127.7, 127.7, 127.6, 127.5 (CH_{arom}), 105.1 (C-1_β), 105.0 (C-1_α), 102.3 (C-1'β), 101.5 (CHPh_α), 101.4 (CHPh_β), 98.4 (C-1'α), 83.9 (C-3_β), 82.4 (C-4'α), 82.0 (C-4_β), 81.9 (C-2_α), 81.6 (C-4'β), 81.4 (C-2_β), 79.3 (C-5_α), 79.2 (C-3'β), 76.2 (C-3'α), 75.5, 75.4 (CH₂ Bn), 75.2 (C-3_α), 75.1, 75.0, 75.0, 74.8 (CH₂ Bn), 74.4 (C-4_α), 74.3 (C-5_β), 68.5 (C-6'α,β), 66.7 (C-2'β), 66.2 (C-5'β), 63.1 (C-5'α), 62.8 (C-2'α), 57.6 (OMe_{α,β}), 53.0 (CO₂Me_β), 52.9 (CO₂Me_α); HRMS: [M+Na]⁺ calcd for C₄₂H₄₅N₃O₁₁Na 790.2946, found 790.2962.



Methyl 6-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α/β-D-glucopyranosyl)-2,3,4-tri-O-benzyl-α-D-glucopyranoside (21A). See Chapter 3, compound **25** for synthesis and analytical data.




Methyl 6-O-(2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-β-D-glucopyranosyl)-2,3,4-tri-O-benzyl-α-D-glucopyranoside (21B). See Chapter 4, compound **3C** for synthesis and analytical data.



Methyl 6-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α/β-D-glucopyranosyl)-2,3,4-tri-O-benzoyl-α-D-glucopyranoside (22A). Donor **A** and acceptor **22**⁵³ were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (E) yielding product **22A** (80 mg, 86 μmol, 86%, α:β = 3 : 1) as a colorless oil. R_f: 0.40 (4/1 pentane/EtOAc).


Spectroscopic data were in accord with those previously reported for the α-anomer.

⁵⁹ IR (thin film): 648, 696, 708, 727, 906, 1026, 1053, 1068, 1088, 1261, 1277, 1452, 1726; ¹H NMR (400 MHz, CDCl₃) δ 8.02 – 7.91 (m, 4H, CH_{arom}), 7.90 – 7.82 (m, 2H, CH_{arom}), 7.56 – 7.43 (m, 4H, CH_{arom}), 7.43 – 7.16 (m, 20H, CH_{arom}), 6.24 – 6.12 (m, 1H, H-3), 5.57 – 5.46 (m, 2H, CHPh, H-4), 5.33 – 5.19 (m, 2H, H-1, H-2), 4.94 – 4.64 (m, 5H, 2xCH₂ Bn, H-1'), 4.41 – 4.30 (m, 1H, H-5), 4.18 (dd, 1H, J = 10.0, 4.8 Hz, H-6'), 4.11 – 3.96 (m, 2H, H-3', H-5'), 3.91 – 3.82 (m, 1H, H-6), 3.78 – 3.52 (m, 5H, H-2', H-4', H-6, H-6'), 3.52 – 3.36 (m, 3H, CH₃ OMe); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 165.9, 165.9, 165.5 (C=O), 138.8, 138.4, 137.7 (C_q), 133.5, 133.4, 133.2, 130.0, 130.0, 129.8 (CH_{arom}), 129.3, 129.2, 129.0 (C_q), 128.5, 128.5, 128.5, 128.5, 128.4, 128.3, 128.3, 128.3, 128.1, 128.1, 128.0, 127.9, 127.6, 126.2 (CH_{arom}), 101.3 (CHPh), 98.3 (C-1'), 97.0 (C-1), 82.2 (C-4'), 79.4 (C-2'), 78.3 (C-3'), 75.2, 73.6 (CH₂ Bn), 72.2 (C-2), 70.6 (C-3), 69.7 (C-4), 69.0 (C-6'), 68.7 (C-5), 67.3 (C-6), 62.6 (C-5'), 55.8 (OMe); Diagnostic peaks β-anomer: ¹H NMR (400 MHz, CDCl₃) δ 5.01 (d, 1H, J = 10.7 Hz, H-), 4.59 (d, J = 7.6 Hz, 1H); ¹³C-APT NMR (CDCl₃, 101 MHz): δ 165.9, 165.9, 165.5, 138.6 (C=O), 138.4, 137.4, 133.6 (C_q), 133.5-127.6 (CH_{arom}), 104.4 (C-1'), 101.2 (CHPh), 97.0 (C-1) 82.3, 81.4, 80.9, 75.4, 72.1, 70.5, 70.0, 69.2, 69.0, 66.1, 55.7; HRMS: [M+Na]⁺ calcd for C₅₅H₅₂O₁₄Na 959.3255, found 959.3292.




Methyl 6-O-(2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-α/β-D-glucopyranosyl)-2,3,4-tri-O-benzoyl-α-D-glucopyranoside (22B). Donor **B** and acceptor **22**⁵³ were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (E) yielding product **22B** (83 mg, 95 μmol, 95%, α:β = 1 : 1.5) as a colorless oil. R_f: 0.32 and 0.50 (4/1 pentane/EtOAc); product was contaminated with 10% of the 6-6


homocoupled acceptor. IR (thin film): 698, 706, 735, 999, 1026, 1069, 1090, 1175, 1250, 1261, 1450, 1724, 2110; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC, HMBC): δ 8.01 – 7.93 (m, 10H, CH_{arom}), 7.89 – 7.84 (m, 5H, CH_{arom}), 7.54 – 7.25 (m, 47.5H, CH_{arom}), 6.22 – 6.14 (m, 2.5H, H-3_α, H-3_β), 5.64 – 5.53 (m, 5H, CHPh_{α,β}, H-4_α, H-4_β), 5.31 – 5.23 (m, 5H, H-1_α, H-1_β, H-2_α, H-2_β), 4.97 (d, 1H, J = 11.1 Hz, CHH Bn_α), 4.95 – 4.89 (m, 2H, CHH Bn_β, H-1'α), 4.87 – 4.76 (m, 2H, CHH Bn_α, CHH Bn_β), 4.44 (d, 1.5H, J = 8.0 Hz, H-1'β), 4.34 – 4.26 (m, 4H, H-5_α, H-5_β, H-6'β), 4.20 – 4.11 (m, 2H, H-3', H-6'), 4.07 (dd, 1.5H, J = 11.2, 2.2 Hz, H-6), 3.99 – 3.89 (m, 2H, H-5', H-6), 3.80 (dd, 1.5H, J = 11.3, 6.3 Hz, H-6), 3.77 – 3.64 (m, 6H, H-4'α, H-4'β, H-6_α, H-6'α, H-6'β), 3.57 (t, 1.5H, J = 9.3 Hz, H-3'β), 3.50 (s, 4.5H, CH₃ OMe_β), 3.48 – 3.43 (m, 4.5H, CH₃ OMe_α, H-2'β), 3.41 – 3.33 (m, 2.5H, H-2'α, H-5'β); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC, HMBC): δ 165.9, 165.9, 165.5, 165.5 (C=O), 137.9, 137.4, 137.2 (C_q), 133.6, 133.5, 133.5, 133.2, 130.0, 130.0, 129.9, 129.8 (CH_{arom}), 129.3, 129.2, 129.1, 129.1, 129.0, 128.9 (C_q/CH_{arom}), 128.6, 128.5, 128.5, 128.4, 128.4, 128.3, 128.2, 128.0, 126.2, 126.1 (CH_{arom}), 102.9 (C-1'β), 101.4, 101.4 (CHPh_{α,β}), 98.8 (C-1'α), 97.1, 97.0 (C-1_α, C-1_β), 82.8 (C-4'α), 81.5 (C-4'β), 79.0 (C-3'β), 75.8 (C-3'α), 75.1 (CH₂ Bn), 72.1 (C-2, C-2_β), 70.5, 70.4 (C-3_α, C-3_β), 69.7 (C-4_β), 69.5 (C-4_α), 68.9 (C-5_α), 68.8 (C-6_β), 68.6 (C-6'α, C-6'β), 68.5 (C-5_α), 67.0 (C-6_α), 66.4 (C-2'β), 66.3 (C-5'β), 63.0 (C-2'α), 62.9 (C-5'α), 55.8 (OMe); HRMS: [M+Na]⁺ calcd for C₄₈H₄₅N₃O₁₃Na 894.2850, found 894.2874.


Methyl 4-O-(2,3-di-O-benzyl-4,6-O-benzylidene- α/β -D-glucopyranosyl)-2,3-di-O-benzyl-6-O-(4-nitrobenzoyl)- α -D-glucopyranoside (23A).

Donor **A** and acceptor **23** were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (E) yielding product **23A** (88 mg, 92 μ mol, 92%, $\alpha:\beta = 3 : 1$) as a colorless oil. R_f: 0.36 (4/1 pentane/EtOAc); IR (thin film): 696, 719, 735, 997, 1028, 1047, 1076, 1088, 1273, 1348, 1454, 1525, 1726, 2866, 2910, 2926; Data for the α -anomer: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 8.22 – 8.15 (m, 4H, pNO₂Bz), 7.44 – 7.17 (m, 25H, CH_{arom}), 5.71 (d, 1H, *J* = 4.0 Hz, H-1'), 5.47 (s, 1H, CHPh), 5.00 (d, 1H, *J* = 11.5 Hz, CHH Bn), 4.94 – 4.88 (m, 1H, CHH Bn), 4.82 – 4.61 (m, 5H, 2xCHH Bn, 2x CHH Bn, H-6), 4.61 – 4.52 (m, 4H, 2x CHH Bn, H-1, H-6), 4.15 – 4.07 (m, 2H, H-3', H-5), 4.03 (t, 1H, *J* = 9.4 Hz, H-3), 4.01 – 3.95 (m, 2H, H-4, H-6'), 3.81 – 3.73 (m, 1H, H-5'), 3.63 – 3.52 (m, 4H, H-2, H-2', H-4', H-6'), 3.39 (s, 3H, CH₃ OMe); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 164.4 (C=O), 150.6, 138.8, 138.5, 137.9, 137.8, 137.3, 135.2 (C_q), 130.9, 128.6, 128.4, 128.3, 128.3, 128.2, 128.2, 128.1, 128.0, 127.8, 127.8, 127.7, 127.7, 126.8, 126.1, 123.6 (CH_{arom}), 101.2 (CHPh), 98.1 (C-1'), 97.7 (C-1), 82.3 (C-4'), 81.6 (C-3'), 80.4 (C-2), 78.8, 78.7 (C-2', C-3), 75.3, 74.6, 74.3 (CH₂ Bn), 73.5 (C-4), 73.4 (CH₂ Bn), 68.8 (C-6'), 67.9 (C-5), 64.8 (C-6), 63.7 (C-5'), 55.5 (OMe); Diagnostic peaks for the β -anomer: ¹H NMR (CDCl₃, 400 MHz): δ 8.28 – 8.23 (m, 2H, pNO₂Bz), 8.10 – 8.06 (m, 2H, pNO₂Bz), 5.52 (s, 1H, CHPh), 3.91 (dd, 1H, *J* = 9.5, 8.3 Hz), 3.66 (t, 1H, *J* = 9.3 Hz), 3.39 (s, 3H, CH₃ OMe), 3.27 (td, 1H, *J* = 9.8, 5.0 Hz, H-5'); ¹³C-APT NMR (CDCl₃, 101 MHz): δ 164.1, 139.0, 138.4, 138.2, 138.1, 137.2, 135.2, 130.7, 129.0, 128.5, 128.3, 128.2, 128.1, 127.8, 127.7, 127.4, 126.0, 103.6 (C-1'), 101.2 (CHPh), 98.0 (C-1), 82.7 (C-2'), 81.7 (C-4'), 81.4 (C-3'), 79.9 (C-3), 79.2 (C-2), 78.5 (C-4), 75.8, 75.1, 73.7 (CH₂ Bn), 68.8 (C-6'), 68.6 (C-5), 66.2 (C-5'), 63.9 (C-6), 55.5 (OMe); HRMS: [M+H]⁺ calcd for C₅₅H₅₆NO₁₄ 954.3701, found 954.3745.



Methyl 4-O-(2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy- α/β -D-glucopyranosyl)-2,3-di-O-benzyl-6-O-(4-nitrobenzoyl)- α -D-glucopyranoside (23B).

Donor **A** and acceptor **23** were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (E) yielding product **23B** (49 mg, 55 μ mol, 55%, $\alpha:\beta = 1 : 1$) as a colorless oil. R_f: 0.33 and 0.33 (4/1 pentane/EtOAc); IR (thin film): 698, 719, 739, 999, 1015, 1028, 1049, 1094, 1275, 1454, 1528, 1728, 2110, 2868, 2922; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC, HMBC): δ 8.34 – 8.25 (m, 2H, pNO₂Bz), 8.24 – 8.15 (m, 8H, pNO₂Bz), 7.46 – 7.25 (m, 40H, CH_{arom}), 5.68 (d, 1H, *J* = 4.2 Hz, H-1' _{α}), 5.51 (s, 1H, CHPh _{α}), 5.49 (s, 1H, CHPh _{β}), 5.13 (d, 1H, *J* = 10.4 Hz, CHH Bn), 4.99 – 4.86 (m, 5H, 2xCHH Bn, CHH Bn, CH₂ Bn), 4.81 (dd, 1H, *J* = 12.0, 2.1 Hz, H-6 _{β}), 4.81 – 4.73 (m, 4H, 2xCHH Bn, 2xCHH Bn), 4.71 (dd, 1H, *J* = 12.1, 2.4 Hz, H-6 _{α}), 4.65 (dd, 1H, *J* = 12.0, 4.8 Hz, H-6 _{β}), 4.65 – 4.59 (m, 4H, 2xCHH Bn, H-1 _{α} , H-1 _{β}), 4.53 (dd, 1H, *J* = 12.0, 4.2 Hz, H-6 _{α}), 4.45 (d, 1H, *J* = 8.1 Hz, H-1' _{β}), 4.13 (dd, 1H, *J* = 9.4, 8.8 Hz, H-3 _{α}), 4.06 – 3.94 (m, 6H, H-3 _{β} , H-3' _{α} , H-5 _{α} , H-5 _{β} , H-6' _{α} , H-6' _{β}), 3.90 – 3.78 (m, 3H, H-4 _{α} , H-4 _{β} , H-5' _{α}), 3.71 – 3.53 (m, 6H, H-2 _{α} , H-2 _{β} , H-3' _{β} , H-4' _{α} , H-4' _{β} , H-6' _{α}), 3.48 (t, 1H, *J* = 10.3 Hz, H-6' _{β}), 3.43 (dd, 1H, *J* = 9.1, 8.3 Hz, H-2' _{β}), 3.40 (s, 3H, CH₃ OMe), 3.40 (s, 3H, CH₃ OMe), 3.36 (dd, 1H, *J* = 10.1, 4.2 Hz, H-2' _{α}), 3.15 (ddd, 1H, *J* = 10.0, 9.0, 5.0 Hz, H-5' _{β}); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC, HMBC): δ 164.4, 164.3 (C=O), 150.7, 150.7 (C_q NO₂), 139.0, 138.5, 138.0, 137.8, 137.7, 137.6, 137.0, 137.0, 135.3, 135.1 (C_q), 130.9, 130.8, 129.2, 129.2, 128.7, 128.6, 128.6, 128.5, 128.4, 128.4, 128.4, 128.3, 128.2, 128.1, 128.1, 128.0, 127.8, 127.6, 127.1, 126.1, 126.0, 123.8, 123.7 (CH_{arom}), 102.3 (C-1'), 101.3, 101.3 (CHPh), 99.0 (C-1'), 98.0, 97.8 (C-1, C-1), 82.5 (C-4'), 81.6 (C-3), 81.4 (C-4'), 80.7 (C-2), 80.1 (C-3), 79.7, 79.6 (C-2, C-3'), 78.5 (C-4), 76.1 (C-3'), 75.5, 75.3, 75.1 (CH₂ Bn), 75.1 (C-4), 75.0, 73.6, 73.4 (CH₂ Bn), 68.5 (C-6'), 68.4 (C-6'), 68.3 (C-5), 67.8 (C-5), 66.8 (C-2'), 66.4 (C-5'), 64.7 (C-6), 64.1 (C-6), 63.7 (C-5'), 62.8 (C-2'), 55.6, 55.6 (OMe); HRMS: [M+H]⁺ calcd for C₄₈H₄₉N₄O₁₃ 889.3296, found 889.3331.


Methyl 4-O-(2,3-di-O-benzyl-4,6-O-benzylidene- α/β -D-glucopyranosyl)-2,3-di-O-benzyl-6-O-(3-nitrobenzoyl)- α -D-glucopyranoside (24A).


Donor **A** and acceptor **24** were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (E) yielding product **24A** (47 mg, 49 μ mol, 49%, $\alpha:\beta = 3.3 : 1$) as a colorless oil. R_f: 0.30 (4/1 pentane/EtOAc); IR (thin film): 696, 719, 737, 1028, 1047, 1076, 1088, 1261, 1350, 1454, 1533, 1730, 2868, 2908, 2926; Data for the α -anomer: ¹H NMR (CDCl₃, 500 MHz, HH-COSY, HSQC, HMBC): δ 8.85 – 8.83 (m, 1H, CH_{arom} NO₂Bz), 8.37 (ddd, 1H, *J* = 8.2, 2.3, 1.1 Hz, CH_{arom} NO₂Bz), 8.33 (dt, 1H, *J* = 7.8, 1.3 Hz, CH_{arom} NO₂Bz), 7.57 (t, 1H, *J* = 8.0 Hz, CH_{arom} NO₂Bz), 7.45 – 7.17 (m, 25H, CH_{arom}), 5.70 (d, 1H, *J* = 4.0 Hz, H-1'), 5.47 (s, 1H, CHPh), 5.00 (d, 1H, *J* = 11.5 Hz, CHH Bn), 4.90 (d, 1H, *J* = 11.2 Hz, CHH Bn), 4.79 – 4.72 (m, 4H, CHH Bn, 2xCHH Bn, H-6), 4.69 (d, 1H, *J* = 12.0 Hz, CHH Bn), 4.60 – 4.52 (m, 4H, 2xCHH Bn, H-1, H-6), 4.16 – 4.09 (m, 2H, H-3, H-5), 4.07 – 4.01 (m, 2H, H-3', H-6'), 3.97 (dd, 1H, *J* = 9.9, 8.7 Hz, H-4), 3.80 – 3.74 (m, 1H, H-5'), 3.63 – 3.57 (m, 3H, H-2, H-4', H-6'), 3.55 (dd, 1H, *J* = 9.4, 4.0 Hz, H-2'), 3.40 (s, 3H, CH₃ OMe); ¹³C-APT NMR (CDCl₃, 126 MHz, HSQC, HMBC): δ 164.2 (C=O), 148.4 (C_q NO₂), 138.9, 138.6, 138.0, 137.9 (C_q Bn), 137.3 (CH_{arom}),

135.4 (C_q Bz), 131.7, 129.7, 129.0, 128.6, 128.6, 128.4, 128.4, 128.3, 128.3, 128.3, 128.2, 128.1, 128.1, 127.9, 127.8, 127.7, 127.7, 127.6, 127.4, 126.9, 126.1, 124.8 (CH_{arom}), 101.3 (CHPh), 98.2 (C-1), 97.8 (C-1'), 82.3 (C-4'), 81.6 (C-3), 80.5 (C-2), 78.8, 78.7 (C-2', C-3'), 75.4, 74.6, 74.2 (CH₂ Bn), 73.7 (C-4), 73.5 (CH₂ Bn), 68.8 (C-6'), 68.0 (C-5), 64.8 (C-6), 63.8 (C-5'), 55.5 (OMe); Diagnostic peaks for the β-anomer: ¹H NMR (CDCl₃, 500 MHz): δ 8.76 – 8.72 (m, 1H, CH_{arom} NO₂Bz), 8.41 (ddd, 2H, *J* = 8.2, 2.3, 1.1 Hz, CH_{arom} NO₂Bz), 8.24 (dt, 1H, *J* = 7.7, 1.3 Hz, CH_{arom} NO₂Bz), 7.62 (t, 1H, *J* = 8.0 Hz, CH_{arom} NO₂Bz), 5.51 (s, 1H, CHPh), 4.48 (dd, 1H, *J* = 11.8, 5.6 Hz, H-6), 4.19 (dd, 1H, *J* = 10.5, 5.0 Hz, H-6'), 3.93 – 3.87 (m, 1H, H-3), 3.65 (t, 1H, *J* = 9.3 Hz, H-4'), 3.41 (s, 3H, CH₃ OMe), 3.30 (td, 1H, *J* = 9.7, 5.0 Hz, H-5'); ¹³C-APT NMR (CDCl₃, 126 MHz): δ 163.9 (C=O), 139.1 (C_q NO₂), 138.5, 138.2, 138.2, 135.2 (C_q) - 124.7 (CH_{arom}), 103.7 (C-1'), 101.2 (CHPh), 98.1 (C-1), 82.8 (C-2'), 81.8 (C-4'), 81.5 (C-3'), 80.0 (C-3), 79.3 (C-2), 78.6 (C-4), 75.8, 75.8, 75.2, 73.7 (CH₂ Bn), 68.8 (C-6'), 68.7 (C-5), 66.3 (C-5'), 63.9 (C-6), 55.5 (OMe); HRMS: [M+Na]⁺ calcd for C₅₅H₅₅NO₁₄Na 976.3520, found 976.3550.



Methyl 4-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α/β-D-glucopyranosyl)-2,3-di-O-benzyl-6-O-(2-nitrobenzoyl)-α-D-glucopyranoside (25A). Donor **A** and acceptor **25** were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (E) yielding product **25A** (79 mg, 83 μmol, 83%, α:β = 3.5 : 1) as a colorless oil. R_f: 0.20 (4/1 pentane/EtOAc); IR (thin film): 696, 733, 995, 1028, 1045, 1074, 1088, 1254, 1290, 1352, 1454, 1533, 1736, 2868, 2907; Data for

the α-anomer: ¹H NMR (CDCl₃, 500 MHz, HH-COSY, HSQC): δ 7.86 – 7.82 (m, 1H, CH_{arom}), 7.78 – 7.75 (m, 1H, CH_{arom}), 7.62 – 7.54 (m, 2H, CH_{arom}), 7.51 – 7.46 (m, 2H, CH_{arom}), 7.41 – 7.16 (m, 23H, CH_{arom}), 5.60 (d, 1H, *J* = 3.9 Hz, H-1'), 5.50 (s, 1H, CHPh), 4.99 – 4.87 (m, 2H, 2xCHH Bn), 4.82 – 4.64 (m, 5H, 2xCHH Bn, 2xCHH Bn, H-6), 4.63 (d, 1H, *J* = 3.3 Hz, H-1), 4.61 – 4.50 (m, 3H, 2xCHH Bn, H-6), 4.11 – 4.05 (m, 2H, H-3', H-6'), 4.05 – 3.98 (m, 2H, H-3, H-5), 3.87 (dd, 1H, *J* = 9.8, 8.6 Hz, H-4), 3.84 – 3.77 (m, 1H, H-5'), 3.64 – 3.57 (m, 3H, H-2, H-4', H-6'), 3.52 (dd, 1H, *J* = 9.5, 3.9 Hz, H-2'), 3.39 (s, 3H, CH₃ OMe); ¹³C-APT NMR (CDCl₃, 126 MHz, HSQC): δ 164.9 (C=O), 148.6 (C_q NO₂), 139.1, 138.7, 138.1, 137.9, 137.5 (C_q), 132.7, 132.0, 130.4, 129.0, 128.5, 128.5, 128.4, 128.3, 128.3, 128.2, 128.1, 128.1, 128.0, 127.9, 127.8, 127.7, 127.2 (CH_{arom}), 127.0 (C_q Bz), 126.9, 126.2, 126.1, 123.8 (CH_{arom}), 101.4 (CHPh), 98.3 (C-1'), 97.7 (C-1), 82.3 (C-4'), 81.2 (C-3'), 80.2 (C-2), 78.8, 78.7 (C-2', C-3), 75.3 (CH₂ Bn), 74.5 (C-4), 74.4, 73.9, 73.4 (CH₂ Bn), 68.9 (C-6'), 68.1 (C-5), 65.3 (C-6), 63.6 (C-5'), 55.5 (OMe); Diagnostic peaks for the β-anomer: ¹H NMR (CDCl₃, 500 MHz): δ 5.51 (s, 1H, CHPh), 4.22 (dd, 1H, *J* = 9.8, 4.4 Hz, H-6'), 3.73 (dd, 1H, *J* = 10.0, 8.7 Hz, H-4), 3.37 (s, 3H, CH₃ OMe); ¹³C-APT NMR (CDCl₃, 126 MHz): δ 164.8, 148.6, 139.3, 138.4, 138.4, 132.7 - 123.8 (CH_{arom}), 103.2 (C-1'), 101.2 (CHPh), 98.2 (C-1), 82.9 (C-2'), 81.8 (C-4'), 81.6 (C-3'), 79.9 (C-3), 79.1 (C-2), 77.8 (C-4), 75.8, 75.5, 75.2, 73.7 (CH₂ Bn), 68.9 (C-6'), 68.5 (C-5), 65.9 (C-5'), 64.1 (C-6), 55.6 (OMe); HRMS: [M+Na]⁺ calcd for C₅₅H₅₅NO₁₄Na 976.3520, found 976.3566.



Methyl 4-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α/β-D-glucopyranosyl)-2,3-di-O-benzyl-6-O-(2,6-dinitrobenzoyl)-α-D-glucopyranoside (26A). Donor **A** and acceptor **26** were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations (E) yielding product **26A** (83 mg, 83 μmol, 83%, α:β = 5.6 : 1) as a colorless oil. R_f: 0.12 (4/1 pentane/EtOAc); IR (thin film): 696, 735, 918, 1028, 1045, 1074, 1088, 1267, 1344, 1454, 1541, 1749, 2870; Data for the

α-anomer: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 8.36 (d, 2H, *J* = 8.3 Hz, NO₂Bz_{meta}), 7.69 (t, 1H, *J* = 8.3 Hz, NO₂Bz_{para}), 7.40 – 7.17 (m, 25H, CH_{arom}), 5.52 (d, 1H, *J* = 3.9 Hz, H-1), 5.46 (s, 1H, CHPh), 5.01 (dd, 1H, *J* = 11.8, 2.2 Hz, H-6), 4.95 – 4.74 (m, 4H, 2xCH₂ Bn), 4.73 – 4.62 (m, 4H, 2xCHH Bn, H-1, H-6), 4.59 – 4.51 (m, 2H, 2xCHH Bn), 4.09 (dd, 1H, *J* = 9.6, 8.5 Hz, H-3), 4.10 – 3.87 (m, 4H, H-3', H-5, H-5', H-6'), 3.82 (dd, 1H, *J* = 9.8, 8.5 Hz, H-4), 3.63 – 3.51 (m, 4H, H-2, H-2', H-4', H-6'), 3.40 (s, 3H, CH₃ OMe); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 162.3 (C=O), 146.7 (C_q NO₂), 139.1, 138.6, 138.1, 137.9, 137.5 (C_q), 129.7, 128.5, 128.4, 128.3, 128.3, 128.3, 128.2, 128.1, 128.0, 127.8, 127.7, 127.6, 127.0, 126.2 (CH_{arom}), 125.5 (C_q Bz), 101.3 (CHPh), 98.5 (C-1'), 97.7 (C-1), 82.2 (C-4'), 81.0 (C-3), 80.0 (C-2), 78.8 (C-2'), 78.6 (C-3'), 75.6 (C-4), 75.3, 74.6, 73.8, 73.4 (CH₂ Bn), 68.9 (C-6'), 68.5 (C-5), 66.2 (C-6), 63.5 (C-5'), 55.6 (OMe); Diagnostic peaks for the β-anomer: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 8.42 (d, 2H, *J* = 8.3 Hz, NO₂Bz_{meta}), 7.75 (t, 1H, *J* = 8.3 Hz, NO₂Bz_{para}), 4.45 (dd, 1H, *J* = 12.1, 2.4 Hz, H-6), 4.19 (dd, 1H, *J* = 10.1, 4.7 Hz, H-6'), 3.79 – 3.72 (m, 1H), 3.47 (dd, 1H, *J* = 8.8, 7.7 Hz, H-2'), 3.42 (dd, 2H, *J* = 9.5, 3.6 Hz, H-2), 3.38 (s, 3H, CH₃ OMe); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 162.2, 146.7, 139.1, 138.6, 138.5, 138.3, 137.5, 131.2, 129.8, 129.0, 128.9, 128.5, 128.4, 128.3, 128.1, 127.9, 127.9, 127.7, 127.5, 127.2, 126.1, 125.5, 103.0 (C-1'), 101.1 (CHPh), 98.2 (C-1), 82.9, 81.8, 81.6, 79.9, 78.8, 77.4, 75.7, 73.5, 68.3, 65.8, 65.5, 55.7; HRMS: [M+NH₄]⁺ calcd for C₅₅H₅₈N₃O₁₆ 1016.3817, found 1016.3864.

Footnotes and references

- (1) Sinnott, M. *Carbohydrate Chemistry and Biochemistry: Structure and Mechanism*; The Royal Society of Chemistry, 2007.
- (2) Peng, P.; Schmidt, R. R. *Acc. Chem. Res.* **2017**, *50* (5), 1171–1183.
- (3) Zhu, X.; Schmidt, R. R. *Angew. Chem. Int. Ed.* **2009**, *48* (11), 1900–1934.
- (4) Mydock, L. K.; Demchenko, A. V. *Org. Biomol. Chem.* **2010**, *8* (3), 497–510.
- (5) Demchenko, A. V. *Handbook of Chemical Glycosylation: Advances in Stereoselectivity and Therapeutic Relevance*; Wiley-VCH Verlag GmbH & Co. KGaA, 2008.
- (6) Crich, D. *Acc. Chem. Res.* **2010**, *43* (8), 1144–1153.
- (7) Lemieux, R. U.; Hendriks, K. B.; Stick, R. V.; James, K. J. *Am. Chem. Soc.* **1975**, *97* (14), 4056–4062.
- (8) Bennett, C. S. *Selective Glycosylations: Synthetic Methods and Catalysts*; Wiley VCH Verlag GmbH, 2017.
- (9) Nigudkar, S. S.; Demchenko, A. V. *Chem. Sci.* **2015**, *6* (5), 2687–2704.
- (10) Whitfield, D. M.; Guo, J. J. *Carbohydr. Chem.* **2017**, *36* (2–3), 59–99.
- (11) Paulsen, H. *Angew. Chem. Int. Ed. Engl.* **1982**, *21* (3), 155–173.
- (12) Codée, J. D. C.; Litjens, R. E. J. N.; Bos, L. J. van den; Overkleef, H. S.; Marel, G. A. van der. *Chem. Soc. Rev.* **2005**, *34* (9), 769–782.
- (13) Fraser-Reid, B.; López, J. C. Armed–Disarmed Effects in Carbohydrate Chemistry: History, Synthetic and Mechanistic Studies. In *Reactivity Tuning in Oligosaccharide Assembly*; Fraser-Reid, B., Cristóbal López, J., Eds.; Springer Berlin Heidelberg: Berlin, Heidelberg, 2011; pp 1–29.
- (14) Frihed, T. G.; Bols, M.; Pedersen, C. M. *Chem. Rev.* **2015**, *115* (11), 4963–5013.
- (15) Zhang, Z.; Ollmann, I. R.; Ye, X.-S.; Wischnat, R.; Baasov, T.; Wong, C.-H. *J. Am. Chem. Soc.* **1999**, *121* (4), 734–753.
- (16) Douglas, N. L.; Ley, S. V.; Lücking, U.; Warriner, S. L. *J. Chem. Soc. [Perkin 1]* **1998**, No. 1, 51–66.
- (17) Fraser-Reid, B.; Wu, Z.; Udodong, U. E.; Ottosson, H. *J. Org. Chem.* **1990**, *55* (25), 6068–6070.
- (18) Walvoort, M. T. C.; Marel, G. A. van der; Overkleef, H. S.; Codée, J. D. C. *Chem. Sci.* **2013**, *4* (3), 897–906.
- (19) Krumper, J. R.; Salamant, W. A.; Woerpel, K. A. *Org. Lett.* **2008**, *10* (21), 4907–4910.
- (20) Krumper, J. R.; Salamant, W. A.; Woerpel, K. A. *J. Org. Chem.* **2009**, *74* (21), 8039–8050.
- (21) Beaver, M. G.; Woerpel, K. A. *J. Org. Chem.* **2010**, *75* (4), 1107–1118.
- (22) Kalikanda, J.; Li, Z. *Tetrahedron Lett.* **2010**, *51* (12), 1550–1553.
- (23) Kalikanda, J.; Li, Z. *Carbohydr. Res.* **2011**, *346* (15), 2380–2383.
- (24) Crich, D.; Dudkin, V. *J. Am. Chem. Soc.* **2001**, *123* (28), 6819–6825.
- (25) Sinaý, P. *Pure Appl. Chem.* **1978**, *50* (11–1), 1437–1452.
- (26) Schmidt, T. H.; Madsen, R. *Eur. J. Org. Chem.* **2007**, *2007* (23), 3935–3941.
- (27) Schumann, B.; Parameswarappa, S. G.; Lisboa, M. P.; Kottari, N.; Guidetti, F.; Pereira, C. L.; Seeberger, P. H. *Angew. Chem. Int. Ed.* **2016**, *55* (46), 14431–14434.
- (28) Paulsen, H.; Lockhoff, O. *Chem. Ber.* **1981**, *114* (9), 3079–3101.
- (29) Fraser-Reid, B.; López, J. C.; Gómez, A. M.; Uriel, C. *Eur. J. Org. Chem.* **2004**, *2004* (7), 1387–1395.
- (30) Bohé L.; Crich D. *Trends Glycosci. Glycotechnol.* **2010**, *22* (123), 1–15.
- (31) Green, L. G.; Ley, S. V.; Ernst, B.; Hart, G. W.; Sinaý, P. Protecting Groups: Effects on Reactivity, Glycosylation Stereoselectivity, and Coupling Efficiency. In *Carbohydrates in Chemistry and Biology*; Wiley-VCH Verlag GmbH, 2000; pp 427–448.
- (32) van der Vorm, S.; Hansen, T.; Overkleef, H. S.; van der Marel, G. A.; Codee, J. D. C. *Chem. Sci.* **2017**, *8* (3), 1867–1875.
- (33) van der Vorm, S.; Overkleef, H. S.; van der Marel, G. A.; Codée, J. D. C. *J. Org. Chem.* **2017**, *82* (9), 4793–4811.
- (34) Hagen, B.; van Dijk, J. H. M.; Zhang, Q.; Overkleef, H. S.; van der Marel, G. A.; Codée, J. D. C. *Org. Lett.* **2017**, *19* (10), 2514–2517.
- (35) Hagen, B.; Ali, S.; Overkleef, H. S.; van der Marel, G. A.; Codée, J. D. C. *J. Org. Chem.* **2017**, *82* (2), 848–868.
- (36) Codée, J. D. C.; Litjens, R. E. J. N.; den Heeten, R.; Overkleef, H. S.; van Boom, J. H.; van der Marel, G. A. *Org. Lett.* **2003**, *5* (9), 1519–1522.
- (37) Crich, D.; Sun, S. *J. Org. Chem.* **1996**, *61* (14), 4506–4507.

- (38) Zegelaar-Jaarsveld, K.; Smits, S. A. W.; van der Marel, G. A.; van Boom, J. H. *Bioorg. Med. Chem.* **1996**, *4* (11), 1819–1832.
- (39) Magaud, D.; Dolmazon, R.; Anker, D.; Doutheau, A.; Dory, Y. L.; Deslongchamps, P. *Org. Lett.* **2000**, *2* (15), 2275–2277.
- (40) de Jong, A.-R.; Hagen, B.; van der Ark, V.; Overkleef, H. S.; Codée, J. D. C.; Van der Marel, G. A. *J. Org. Chem.* **2012**, *77* (1), 108–125.
- (41) Zhang, Q.; van Rijssel, E. R.; Walvoort, M. T. C.; Overkleef, H. S.; van der Marel, G. A.; Codée, J. D. C. *Angew. Chem. Int. Ed.* **2015**, *54* (26), 7670–7673.
- (42) The C-6-OBn has the possibility to hydrogen-bond with the C-4-OH, rendering the acceptor more nucleophilic. This effect is seen for C-6-OBn protected acceptor **1** versus acceptor **2**, which based on the absence of the electronegative oxygen atom at C6 should be a more reactive acceptor than **1**. The hydrogen-bond may also be the contribution that prevents donor **B** in providing full α -selective condensations (Table 2; **9B**, **13B**).
- (43) Hansch, C.; Leo, A.; Taft, R. W. *Chem. Rev.* **1991**, *91* (2), 165–195.
- (44) The addition of a third nitro group on the benzoate did not lead to a further increase in α -selectivity. In fact, slightly more β -product was obtained with the C-6-trinitrobenzoate acceptor (Chapter 9 **57**; $\alpha/\beta = 2.1: 1$).
- (45) Burugupalli, S.; Shah, S.; van der Peet, P. L.; Arora, S.; White, J. M.; Williams, S. J. *Org. Biomol. Chem.* **2016**, *14* (1), 97–104.
- (46) Mulard, L. A.; Kováč, P.; Gludemans, C. P. J. *Carbohydr. Res.* **1994**, *251*, 213–232.
- (47) Daragics, K.; Szabó, P.; Fügedi, P. *Carbohydr. Res.* **2011**, *346* (12), 1633–1637.
- (48) Rochepeau-Jobron, L.; Jacquinet, J.-C. *Carbohydr. Res.* **1997**, *303* (4), 395–406.
- (49) Ward, D. E.; Kaller, B. F. *J. Org. Chem.* **1994**, *59* (15), 4230–4238.
- (50) Rocheleau, S.; Pottel, J.; Huskić, I.; Moitessier, N. *Eur. J. Org. Chem.* **2017**, *2017* (3), 646–656.
- (51) Shie, C.-R.; Tzeng, Z.-H.; Kulkarni, S. S.; Uang, B.-J.; Hsu, C.-Y.; Hung, S.-C. *Angew. Chem. Int. Ed.* **2005**, *44* (11), 1665–1668.
- (52) Cicero, D.; Varela, O.; De Lederkremer, R. M. *Tetrahedron* **1990**, *46* (4), 1131–1144.
- (53) Stévenin, A.; Boyer, F.-D.; Beau, J.-M. *J. Org. Chem.* **2010**, *75* (5), 1783–1786.
- (54) Yoneda, Y.; Kawada, T.; Rosenau, T.; Kosma, P. *Carbohydr. Res.* **2005**, *340* (15), 2428–2435.
- (55) Łopatkiewicz, G.; Mlynarski, J. *J. Org. Chem.* **2016**, *81* (17), 7545–7556.
- (56) Zhang, X.; Ren, B.; Ge, J.; Pei, Z.; Dong, H. *Tetrahedron* **2016**, *72* (7), 1005–1010.
- (57) Doi, R.; Shibuya, M.; Murayama, T.; Yamamoto, Y.; Iwabuchi, Y. *J. Org. Chem.* **2015**, *80* (1), 401–413.
- (58) Warrenner, R. N.; Russell, R. A.; Marcuccio, S. M. *Aust. J. Chem.* **1980**, *33* (12), 2777–2779.
- (59) Kim, K. S.; Fulse, D. B.; Baek, J. Y.; Lee, B.-Y.; Jeon, H. B. *J. Am. Chem. Soc.* **2008**, *130* (26), 8537–8547.

Chapter 7

Synthesis of C-2- and C-5-modified furanosides

Introduction


Furanosides are key structural components in a variety of bacterial and plant oligosaccharides.¹⁻³ In this framework, the glycosylation of furanosides has been studied to obtain specific target oligosaccharides with the required anomeric configuration. Furanosylation is more extensively investigated for the synthesis of modified nucleosides and oligonucleotides.⁴⁻⁶ Besides structural variants, in which the ring oxygen is replaced by sulfur, selenium, nitrogen, or carbon, furanosides with differently configured amino or fluoro substituents have been studied.⁷⁻⁹ Uronic acid furanosides occur in natural compounds and have attracted attention as biomimics. Modified (oligo)nucleotides are studied as potential therapeutics and as radio-tracer compounds (primarily ¹⁸F, but also ¹¹C, ¹³N) in Positron Emission Tomography (PET).¹⁰⁻¹³ Despite their biological relevance, the synthesis of the differently substituted furanosides and their glycosylating properties are scarcely investigated.⁵ The development of effective routes of synthesis for these compounds and insight in their reactivity will contribute to the application of these

saccharides.¹⁴ For instance, oligosaccharides containing furanosyl moieties can be relevant for the development of carbohydrate based vaccines.^{4,7,15} Furthermore, insight in the reactivity of differently substituted furanosides will be a valuable asset to understand the mechanisms of the glycosylation reaction of both furanosides and pyranosides. This chapter describes the synthesis of all four diastereoisomers of the D-pentofuranosides as their 2-fluoro, 2-azido, and 5-uronic acid derivatives. The influence of these functional groups in glycosylation reactions is the subject of Chapter 8, where they are studied using experimental and computational means.

Results and discussion

The strategy to obtain the three modifications on all four diastereoisomers is shown in Scheme 1. The C-2-modified furanoside donors were obtained by inversion of the 2-hydroxy group in otherwise protected methyl furanosides. The C-5-methyl esters were generated from their suitably protected 5-hydroxy methyl furanosides. Subsequent anomeric hydrolysis and installation of the anomeric leaving group (LG), will then give all twelve D-pentofuranoside donors, four configurations for each functional group.

Scheme 1. Retrosynthesis of C-2- and C-5-modified furanosides.




*Center of inversion. LG = leaving group.

The syntheses of the protected 2-hydroxy pentofuranoses is outlined in Scheme 2. Adapting literature procedures, the 2-hydroxy pentofuranoses could be obtained on large scale (10-150 mmol). *Ribo*-configured structure **3** was prepared by treatment of fully protected **2** with SnCl_4 , inducing both anomerization and regioselective benzyl cleavage.¹⁶ Similarly protected *xylose* derivative **6** was obtained from 1,2-isopropylidene-xylofuranose **4** in high yield (97%) by benzylation and CSA mediated acetal exchange.

The syntheses of *arabino*- and *lyxo*-derivatives **9** and **13** required more steps, as di-isopropylideneation of arabinose yields the pyranoside and regioselective removal of the C-2-*O*-benzyl, as reported for ribose derivative **3**, is unknown for these epimers.¹⁷ First, the primary alcohol of arabinose was protected with a bulky TBDPS group to force the carbohydrate in the furanose form. Subsequent isopropylidene protection gave **7**. Conveniently, the epimeric *lyxo* compound could be easily obtained from **7** by an oxidation-reduction sequence.¹⁸ Dess-Martin oxidation proved superior over the Sarett (CrO₃, pyridine in DCM)¹⁹ and Moffat (DMSO, Ac₂O)²⁰ oxidations both in yield and ease of purification.²¹ Reduction of ulose **10** with NaBH₄ gave optically pure *lyxo*-configured **11**. Both **7** and **11** were silyl-deprotected and benzylated in a one-pot procedure using KOH and BnCl in THF.²² An alternative two-step reaction sequence of removing the TBDPS (with TBAF, AcOH in THF) and subsequent benzylation (NaH, BnBr in DMF) was less efficient. Finally, acetal exchange yielded both the *arabino*-configured **9** and *lyxo*-configured **13**.

Scheme 2. Synthesis of 2-hydroxy pentofuranosides **3**, **6**, **9**, and **13**.



Reagents and conditions: (a) AcCl, MeOH; (b) BnBr, NaH, DMF, **2**: 89% (two steps); (c) SnCl₄, DCM, 92%; (d) i. H₂SO₄, acetone; ii. HCl, H₂O, acetone, 90% (two steps); (e) CSA, MeOH, **6**: 97%, **9**: 91%, **13**: 84%; (f) i. TBDPSCl, imidazole, DMF; ii. dimethoxypropane, CSA, DCM, 53% (two steps); (g) BnCl, KOH, THF, **8**: 71%, **12**: 99%; (h) Dess-Martin periodinane, DCM, 77%; (i) NaBH₄, DCM, MeOH, 73%.

Having synthesized all 2-hydroxy pentofuranosides (**3**, **6**, **9**, **13**), the inversion procedures were investigated. Fluoride substitutions were considered first, since a range of fluorination reagents are commercially available. Table 1 summarizes the results of the direct substitution reactions on ribose derivative **3**. Unfortunately, none of the reagents was successful in substituting the 2-hydroxy group to provide 2-fluoroarabinoside **18** in decent yield.

Table 1. Inversion of riboside **3** with different fluorination reagents.

Entry	Scale (mmol)	Reagents ^a (eq.)	Temperature (°C)	Time (h)	Yield (%)
1	0.5	DAST (1.8)	-60 to 20	72	12
2	2.0	DAST (4)	-60 to 45	24	13
3	0.5	Deoxo-Fluor [®] (1.2)	0 to 20	72	15
4	0.5	PFBS-F (2.2), TBAT (0.8), DiPEA (2.5)	0 to 20	30	< 25
5	0.5	XtalFluor-E [®] (1.5), 3HF-Et ₃ N (1.5)	0 to 20	30	-

^aConcentration for all reactions was 0.2 M in DCM.

Therefore, the 2-hydroxy groups in the projected furanoses were converted into the corresponding triflates followed by substitution with fluoride or azide anions, respectively.²³ Figure 1 provides an overview of the triflates, readily prepared from the alcohols, the targeted substitution products as well as the side products obtained in the reactions (deviations colored red).




Figure 1. Furanosyl C-2-O-triflates (14-17) and their substitution products by fluoride inversion (18-21), and azide inversion (22-25). Major side products isolated from the reaction mixture (26-31), red color indicates the deviations from the expected products. Formation of the structures in grey was not observed.

Table 2 reports the outcome of all substitution reactions. Entries 1-3 show that *ribo*-configured triflate **14** is readily substituted with the fluoride (TBAF, or CsF) and azide anions (NaN_3), respectively. The yield of the fluoride substitution on triflate **14** with TBAF in THF (71%) was increased to 86% when CsF was used in a polar protic solvent (*tert*-amyl alcohol, entry 2).²⁴ Azide **22** was obtained in 93% yield. Substitution of the arabinotriflate **15** (a mixture of anomers), with fluorine and azide nucleophiles gave **19** and **23**, respectively in reasonable to good yields. As reported by the group of Woerpel,²² only the β -anomer of **15** reacted with TBAF (entry 4), and the triflate of the α -anomer could be recovered.

Under conditions B (entry 5) both anomers of **15** reacted and despite the generation of side product **26**, the yield was increased to 63%. Azide **23** was obtained in high yield, although a similar migration to side product **27** occurred during the azide substitution (entry 6).²⁵ The possible reaction pathways for the formation of these side products are displayed in Figure 2. The anomeric methoxy substituent can substitute the neighboring triflate and form a highly reactive methyl oxiranium ion, which is attacked

with inversion at the anomeric center, explaining the stereochemistry of the anomeric azide side product found (**27**). Alternatively, an S_N1 reaction on the oxocarbenium ion, formed upon opening of the oxiranium ion, happens in entry 4 with the solvent, explaining the mixture of anomers found in product **26**.

Table 2. Results of substitution reactions on triflates **14-17**.

Entry	Triflate ^b	Conditions ^a	Substitution product	Yield (%)	Side product 1	Side product 2
1	14	A (TBAF)	18	71	-	-
2	14	B (CsF)	18	86	-	-
3	14	C (N_3^-)	22	93	-	-
4	15	A	19 , β only	42	15α , 17%	-
5	15	B	19	63	26g , 17%	-
6	15	C	23	86 ^c	27^c	-
7	16α	A ^d	20α	44	6 , 17%	16α , 3%
8	16α	B ^e	20α	-	28α , 57%	30α , 21%
9	16α	C ^f	24α	67	29α , 12%	30α , 7%
10	16β	A ^d	20β	-	28β , 18%	31^h
11	16β	B	20β	-	28β , 47%	21β , 10%
12	16β	C ^f	24β	-	29β , 30%	-
13	17	A,B,C	21 / 25	-	31^h	-

^aReagents and conditions: (A) 0.2 M solution in THF, 2.5 eq. TBAF, 0°C to 20°C, overnight; (B) 0.35 M solution in *tert*-amyl alcohol, 4 eq. CsF, 90°C, overnight; (C) 0.2 M solution in DMF, 5 eq. NaN_3 , 80°C, 2 h. ^bSee experimental section for the general procedure of the triflate formation. ^cCombined yield of **23** and **27**, as a 4:1 mixture. ^d70°C, 5 h for entry 7, overnight for entry 10. ^e110°C overnight. ^fovernight. ^g α : β = 88 : 12. ^hYield not determined.

Both anomers of xyloside **6** were obtained, therefore both triflates **16 α** and **16 β** could be independently studied. Substitution of **16 α** , using CsF in *tert*-amyl alcohol at 90°C, only gave the side products 5-fluorolyxoside **28 α** and the bicycle **30 α** (entry 8). The formation of these products can be explained by participation of the C-5-O-benzyl group followed by substitution from the least hindered sites (path A and B, Figure 2B), to yield 5-fluorolyxoside **28 α** and the bicycle **30 α** , respectively. No products arising from double inversion (path C) or elimination were detected. Fortunately, heating **16 α** in a

THF solution with TBAF for 5 hours did give the desired fluoride inversion and product **20 α** was isolated in 44% yield (entry 7). Interestingly, the only observed side products were unreacted and hydrolysed triflate and no products derived from C-5-O-benzyl participation were found. Subjection of **16 α** to conditions C led to effective azide substitution to give the desired product **24 α** (entry 9) together with small amounts of bicycle **30 α** and 5-azidoloxoside **29 α** originating from pathways A and B, respectively (Figure 2B).





Figure 2. Mechanistic pathways underlying the formation of side products **26-31**.

Similar reactions with β -xylotriflate **16 β** did not lead to the required substitutions (entries 10-12, Table 2). Both conditions A and B gave 5-fluoroxoside **28 β** , and condition A led to elimination product **31**, while condition B gave **21 β** . The more nucleophilic and basic fluoride ion in condition A resulted in substitution on triflate **16 α** , but elimination to furan **31** for **16 β** . The formation of 2-fluoroxoside **21 β** with net retention of configuration can be explained by a double inversion mechanism as shown in Figure 2C (path C). Since **21 β** is one of the target compounds and its formation from lyxotriflate **17** was ineffective, generation of **21 β** through this route proved advantageous. Azide substitution at the C-5-position (path A) resulted in the formation of the 5-azidoloxoside side product **29 α** .

All substitutions with lyxotriflate **17** to attain the target C-2-substituted xylofuranosides were ineffective and resulted in the elimination product **31**. The fast elimination of triflate **17** into furan **31** can be explained by the steric hindrance that is experienced during nucleophilic attack and the favorable H-OTf alignment for elimination (Figure 2D).²⁶

An alternative approach towards the missing C-2-substituted xylofuranosides **21** and **25** was devised (Scheme 3). This synthetic route started with the preparation of glycal **35**. Among the various procedures to generate glycals,^{27–31} two methods, using relatively neutral conditions, were examined. Direct conversion of diol **33** by the Garegg olefination conditions (I₂, Ph₃P, imidazole) led to the glycal but it could only be isolated in low yield.^{32–34} A two-step procedure via thionocarbonate **34** proved more effective and this method was reproducible and scalable.^{35,36} This Corey-Winter olefination method cleanly converted **34** into glycal **35** when 1,3-dimethyl-2-phenyl-1,3,2-diazaphospholidine was used as desulfurization agent.³⁷


Scheme 3. Synthetic route towards 2-azidoxylose **52** via azidophenylselenation of glycal **35**.



Reagents and conditions: (a) TFA, THF, H₂O, 84%; (b) DMAP, DiPEA, thiophosgene, DCM, 78%; (c) 1,3-dimethyl-2-phenyl-1,3,2-diazaphospholidine, toluene, 76%; (d) *N*-(phenylseleno)phthalimide, TMSN₃, TBAF, DCM, 65%; (e) NIS, H₂O, acetone, THF, 87%.

The glycal **35** can be transformed to 2-fluoroxylsides **48** by electrophilic fluorination or to 2-azidoselenoxylsides **36** by azidophenylselenation respectively, see Table 3. Although the diastereoselectivity of the addition with SelectFluor in 4:1 DMF/H₂O was good (9:1, *xylo:lyxo*),³⁸ the yield was low (**48**, 36%) and a 2-fluoro-1-*O*-formyl (**32**) side product was isolated in 18%, resulting from reaction with DMF. Standard azidophenylselenation conditions (entry 2) delivered **36** as a 9:1 *xylo:lyxo* product mixture, which proved difficult to purify. The incompatibility of this reagent system with *O*-benzyl groups has been noted before^{39,40} and a switch to an alternative reagent proved beneficial. The *N*-(phenylseleno)phthalimide (*N*-PSP) mediated azidophenylselenation proceeded much cleaner and with equally good regio- and diastereoselectivity to give product **36** (entry 3).^{41–46}


Table 3. Conversion of glycal **35** to 2-fluoro- and 2-azidoxylosides **48** and **36**.



Entry	Conditions ^d	Product, yield ^c	<i>xylo:lyxo</i> ^c
1	SelectFluor, DMF, H ₂ O	48 , 36% 32 , 18%	9 : 1
2	TMSN ₃ , BAIB, PhSeSePh, DCM	36 , 50%	9 : 1
3	TMSN ₃ , TBAF, N-PSP, DCM	36 , 65%	9 : 1

^aReaction time was 20 h, stirred from 0°C to 20°C. ^bYield of the isolated *xylo*-configuration. ^cRatio obtained by crude ¹H-NMR.

With the critical functionalizations at C-2 completed, the attention was turned to modification of the C-5-position. The general synthetic route towards the uronic acid esters is presented in Scheme 4. The intermediates **37-40** are synthesized from the D-aldopentose by a straightforward four-step procedure giving roughly the same yield for all the diastereoisomers (41%-50%). The subsequent oxidation reaction was carried out in a biphasic system of DCM and H₂O with catalytic TEMPO as the oxidating agent and BAIB as co-oxidant. Yields of the oxidation were high but loss of product was observed in the subsequent methylation step to give **41-44**. Shorter reaction times and aqueous work up, without concentration of the reaction mixture, were crucial to a higher isolated yield. Quenching with acetic acid instead of water or methanol also helped to increase the yield.

Scheme 4. Synthesis of 5-uronic acid functionalized methyl glycosides **41-44**.


Reagents and conditions: (a) *i.* AcCl, MeOH; *ii.* TrtCl, Et₃N, DMF; *iii.* BnBr, NaH, DMF; *iv.* pTsOH-H₂O, MeOH, **37**: 41%, **38**: 43%, **39**: 46%, **40**: 50%, (all over four steps); (b) *i.* TEMPO, BAIB, DCM, H₂O; *ii.* MeI, K₂CO₃, DMF, **41**: 70%, **42**: 87%, **43**: 89%, **44**: 88%, (all over two steps).

With all methyl furanosides **18-24** and **41-44** available, the conversion of these furanosides into suitable glycosyl donors was undertaken. The first step comprises the hydrolysis of the methyl acetals to give lactols **45-56**. Because of the electron-withdrawing nature of the azido, fluoro, and uronic acid ester substituents in the furanosides, the anomeric acetals proved relatively stable and optimization of the acidic hydrolysis was required to prevent concomitant C-5-*O*-benzyl cleavage. The results of the optimization studies are summarized in Table 4.

In an attempt to obtain the acetyl donor **57**, methyl furanoside **22** was treated with H₂SO₄ in acetic anhydride, but this led to formation of diacetyl compound **61** instead (entry 1, see experimental section). Heating an 80% aq. AcOH solution of **22** overnight (entry 2) gave no conversion, and upon HCl addition decomposition occurred (entry 3).⁴⁷ Aqueous 70-90% TFA at room temperature (entries 5-7) gave **49** in low yield with significant concurrent decomposition.⁴⁸ Fortunately, using 50% aqueous TFA at 75°C significantly improved the outcome (entry 10), and also the use of 80% aqueous formic acid at this temperature provided the target compound. The best results were obtained with formic acid at a temperature of 60°C (entries 10 and 11).²⁴

Table 4. Evaluation of acidic hydrolysis conditions.

Reaction scheme: Methyl furanoside **22** (with BnO, BnO, OMe, and N₃ substituents) reacts with reagents to form lactol **49** (with BnO, BnO, N₃, and OH substituents).

Entry	Conc. ^a	Conditions	Temperature (°C)	Time (h)	Yield (%)
1	0.3 M	1.5% H ₂ SO ₄ in Ac ₂ O	0	0.3	^b
2	0.1 M	80% aq. AcOH	115	24	-
3	0.2 M	20% 5M HCl in AcOH	85	16	-
4	0.3 M	Ph ₃ C-BF ₄ in DCM	20	70	-
5	0.2 M	90% aq. TFA	20	40	17
6	0.2 M	80% aq. TFA	20	300	23
7	0.2 M	70% aq. TFA	20	300	50
8	0.1 M	50% aq. TFA	75	24	50
9	0.05 M	80 aq. formic acid	75	24	51
10	0.1 M	50% aq. TFA	60	80	73
11	0.05 M	80 aq. formic acid	60	80	76

^aConcentration. Scale is 0.4 mmol except entry 1 (1.0 mmol) and entries 10 and 11 (1.5 mmol). ^bYield of 1,5-di-*O*-acetyl-2-azido-3-*O*-benzyl-2-deoxy- α/β -D-arabinofuranoside **61** was 85%.

The hydrolysis of all other furanosides are listed in Table 5. The formic acid conditions proved effective for the 2-fluoro (entries 1-4), and 2-azido (entries 5-7) series, to give the corresponding lactols in good yield. The reactivity of the different substrates varied greatly, and changing the temperature and reaction time was needed to push the reactions to completion. The uronic acids (entries 8-11) were hydrolysed with 90% aqueous TFA to give the lactol products in good yield.


Table 5. Hydrolysis reaction results for methyl glycosides **18-24**, and **41-44**.

Entry	Substrate	Configuration	Product	Conditions	Temperature (°C)	Time (h)	Yield (%)
1	18	AraF	45	A	65	64	63
2	19	RibF	46	A	60	18	78
3	20	LyxF	47	A	65	6	75
4	21	XylF	48	A	60	6	75
<hr/>							
5	22	AraN ₃	49	A	60	80	76
6	23	RibN ₃	50	A	65	6	70 ^a
7	24	LyxN ₃	51	A	60	18	62
<hr/>							
8	41	AraA	53	B	0 to 20	8	60
9	42	RibA	54	B	0 to 20	7.5	73
10	43	LyxA	55	B	0 to 20	6	85
11	44	XylA	56	B	0 to 20	4	90

Reagents and conditions: (A) HCOOH/H₂O (4/1 v/v, 0.05 M); (B) TFA/H₂O (9/1 v/v, 0.2 M). ^aYield over two steps (including inversion), the combined yield of the 4:1 mixture of **23** and **27** was 89%.

The acetyl donors were prepared by treatment of the lactol precursors with acetic anhydride in pyridine (Table 6). But as a pilot study revealed that TMSOTf catalyzed glycosylations with allyl-trimethylsilane and deuterated triethylsilane were not productive using the acetyl donors even at room temperature, it was decided to generate the trifluoro-*N*-phenylimidate donors (Table 7, **62-73**), as these are more reactive and can be activated under catalytical conditions.⁴⁹


The majority of the imidates were synthesized using an acetone/H₂O mixture and Cs₂CO₃ as a base. However, since some of the reactions were slow and purification

Table 6. Conversion of lactols to acetyl donors **57-60**.


Entry	Substrate	Configuration	Product	$\alpha : \beta$	Yield (%)
1	49	AraN ₃	57	2.3 : 1	90
2	53	AraA	58	5.7 : 1	90
3	54	RibA	59	0 : 1	91
4	56	XylA	60	1.2 : 1	98

Reagents and conditions: Ac₂O (1.25 eq.) in pyridine (0.25 M), 0°C to r.t.

issues occurred, separating the target compounds from the hydrolyzed or unreacted 2,2,2-trifluoro-*N*-phenylacetimidoyl chloride, an anhydrous DCM/DBU procedure was explored. These reactions were complete within minutes, successfully generating the target compounds, even though work up and purification led to some degradation.

Table 7. Conversion of lactols **45-56** to imidate donors **62-73**.


Entry	Substrate	Configuration	Product	Conditions	$\alpha : \beta$	Yield (%)
1	45	AraF	62	A	5 : 1	85 (69 + 16)
2	46	RibF	63	A	0 : 1	98
3	47	LyxF	64	A	1 : 0	82
4	48	XylF	65	A	1 : 2	91
5	49	AraN ₃	66	B	1.6 : 1	71 (44 + 27)
6	50	RibN ₃	67	A	1 : 8	77 (8 + 69)
7	51	LyxN ₃	68	B	1 : 1.2	67 (30 + 37)
8	52	XylN ₃	69	A	1 : 1	100
9	53	AraA	70	A	1 : 1	97
10	54	RibA	71	A	0 : 1	85
11	55	LyxA	72	A	5 : 1	85 (70 + 15)
12	56	XylA	73	A	0 : 1	81

Reagents and conditions: (A) 2,2,2-trifluoro-*N*-phenylacetimidoyl chloride (0.95 eq.), Cs₂CO₃ (1.1 eq.) in acetone/H₂O (9/1 v/v, 0.2 M), 0°C to r.t. (B) 2,2,2-trifluoro-*N*-phenylacetimidoyl chloride (0.95 eq.), DBU (1 eq.) in DCM (0.25 M), 0°C.

Conclusions

This chapter presents the synthesis of C-2- (2-fluoro, 2-azido) and C-5- (5-methyluronates) modified furanosides of all four diastereoisomers. While the synthesis of the C-5-modified furanosides was relatively straightforward, the inversion reactions of the C-2-alcohols to provide the azides and fluorides, proved challenging. Eventually all synthetic pitfalls were overcome, leading to the successful synthesis of all twelve pentofuranoside imidate donors. The stereoelectronic effects originating from the newly introduced functional groups on C-2 and C-5 in glycosylation reactions will be discussed in Chapter 8.

Experimental section

General procedure for the formation of 2-O-trifluoromethanesulfonyl-furanosides (14-17). A 0.2 M solution of the alcohol (1 eq.) in DCM was cooled to 0°C followed by the addition of pyridine (2 eq.) and Tf₂O (1.2 eq.). After stirring for 40 min the reaction mixture was poured into cold 1 M aq. HCl and extracted twice with DCM. The combined organic layers were washed with cold H₂O, cold sat. aq. NaHCO₃, and brine. The organic layer was dried (Na₂SO₄), filtered, and concentrated under reduced pressure. After coevaporated with toluene the crude triflated furanoside was dissolved in the solvent required for the next synthetic step.

General procedure for the inversion of 2-O-trifluoromethanesulfonyl-furanosides (18-24). Conditions A: The triflate (1 eq.) was dissolved in *tert*-amyl alcohol (0.35 M) and CsF (4 eq.) was added. The reaction mixture was heated overnight at 90°C, followed by aqueous work up. Conditions B: The triflate (1 eq.) was dissolved in THF (0.2 M) and TBAF (1 M in THF, 2.5 eq.) was added at 0°C. The reaction mixture was allowed to reach room temperature and stirred overnight, followed by aqueous work up. Conditions C: The triflate (1 eq.) was dissolved in DMF (0.2 M) and NaN₃ (5 eq.) was added. The reaction mixture was heated for 2 h at 80°C, followed by aqueous work up. Work up conditions: the reaction mixture was diluted with H₂O (volumex10) and extracted with Et₂O three times. The combined organic layers were washed with H₂O, sat. aq. NaHCO₃, and brine. The organic layer was dried (MgSO₄), filtered and concentrated *in vacuo*. Flash column chromatography (1/0 to 9/1 pentane/EtOAc) provided the target inverted furanosides as colourless oils.

General procedure for the synthesis of primary furanoside alcohols (37-40). To a suspension of D-pentose in MeOH (0.2 M) was added AcCl (0.3-0.9 eq) and the reaction was stirred until complete conversion to the methyl furanoside was observed (TLC). NaHCO₃ (s) was added to the reaction mixture until neutral. The slurry was filtered and concentrated under reduced pressure, followed by coevaporated with toluene. The residue was dissolved in DMF (0.2 M) and Et₃N (2.0 eq.), TrtCl (1.5 eq.), and DMAP (0.05 eq.) were successively added. After stirring for 1-2 days the mixture was diluted with H₂O and extracted twice with DCM. The combined DCM fractions were washed with H₂O and brine, then dried with MgSO₄, filtered and concentrated *in vacuo* followed by coevaporation with toluene. The crude tritylated product was redissolved in DMF (0.2 M) and cooled to 0°C. NaH (60% dispersion in mineral oil, 2.5 eq.) and TBAI (0.05 eq.) were added, followed by drop wise addition of BnBr (2.5 eq.). After stirring overnight at room temperature, the reaction was quenched by the addition of H₂O and extracted three times with Et₂O. The combined organic layers were washed with H₂O and brine, dried (MgSO₄), filtered over a short plug of silica gel, and concentrated under reduced pressure. The crude material was dissolved in MeOH/DCM (1/1, v/v, 0.2 M) and pTsoH-H₂O (0.1 eq.) was added and the reaction stirred at room temperature overnight and then quenched with Et₃N (0.15 eq.) The solvent was removed under reduced pressure and the residue was purified by flash column chromatography (19/1 to 6/4 pentane/EtOAc) to yield the primary furanoside alcohols as yellow oils.


General procedure for the synthesis furanosyl methyl uronates by TEMPO/BAIB oxidation and methylation (41-44). The primary alcohol was dissolved in DCM/H₂O (2/1, v/v, 0.17 M) and the mixture was cooled to 0°C. TEMPO (0.2 eq.) and BAIB (2.5 eq.) were added and the reaction mixture was stirred vigorously overnight. A 10 % aq. Na₂O₃ solution was added and the mixture stirred for 15 min at room temperature. The mixture was diluted with 0.01 M aq. HCl and DCM and phase separated and the aqueous layer extracted three times with DCM. The combined DCM layers were washed with H₂O and brine, dried (MgSO₄), filtered and concentrated under reduced pressure. The crude carboxylic acid was dissolved in DMF (0.2 M) and K₂CO₃ (3 eq.) and MeI (3 eq.) were added at 0°C. The reaction was stirred for 3 h and then quenched with AcOH (5 eq). The solution was diluted with H₂O and extracted three times with Et₂O. The combined organic layers were washed with sat. aq. NaHCO₃ and brine, dried with MgSO₄, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography (19/1 to 7/3) to give the uronic acid methyl ester.

General procedure for the hydrolysis of methyl furanosides (49-64). Conditions A: The methyl glycoside was mixed with 80% aq. formic acid to a concentration of 0.05 M and stirred at 60-65°C for 6-64 h as mentioned for each experiment. After the reaction mixture was cooled to room temperature and transferred to a separatory funnel, it was diluted 5x with H₂O and extracted three times with DCM. The combined DCM layers were washed with sat. aq. NaHCO₃ and brine, dried over MgSO₄, filtered and concentrated *in vacuo*. The resulting residue was purified by flash column chromatography (pentane/EtOAc mixtures) to provide the target lactol as a mixture of anomers. Conditions B: The methyl glycoside was dissolved in 90% aq. TFA at 0°C and stirred for 4-8 h. The reaction was diluted with DCM and washed with H₂O three times. The aqueous layers were extracted twice with DCM and the combined organic layers


were washed with sat. aq. NaHCO₃ and brine. The organic layer was dried (MgSO₄), filtered and concentrated under reduced pressure. The residu was purified by flash column chromatography (19/1 to 6/4 pentane/EtOAc) to provide the target lactol as a mixture of anomers.

General procedure for the synthesis of acetyl donors from lactols (65-69). The furanose lactol was dissolved in pyridine (0.25 M) and cooled to 0°C. Ac₂O (1.3 eq.) was added and the reaction mixture was stirred overnight at room temperature. The solution was diluted with 0.1 M aq. HCl and extracted three times with Et₂O. The combined organic layers were washed with 0.1 M HCl, H₂O, sat. aq. NaHCO₃, and brine. The organic layer was dried (MgSO₄), filtered, and concentrated in vacuo. Purification of the residue by flash column chromatography (1/0 to 8/2 pentane/EtOAc) gave the acetylated compound as a light yellow oil.

General procedure for the installation of the trifluoro-*N*-phenylacetimidoyl group (71-86). **Conditions A:** The furanose lactol was dissolved in acetone/H₂O (0.2 M, 9/1 v,v) and cooled to 0°C. Cs₂CO₃ (1.1 eq.) and 2,2,2-trifluoro-*N*-phenylacetimidoyl chloride (0.95 eq.) were added and the reaction mixture stirred until TLC-analysis showed complete conversion (1-4 days). The reaction mixture was reduced in volume under reduced pressure and H₂O was added. The aqueous phase was extracted twice with DCM and the combined organic layers were dried with Na₂SO₄, filtered, and concentrated under reduced pressure. Flash column chromatography (0-15% Et₂O/pentane) of the residue provided the target imidate donors. **Conditions B:** The furanose lactol was dissolved in DCM (0.25 M) and cooled to 0°C. 2,2,2-Trifluoro-*N*-phenylacetimidoyl chloride (0.95 eq.) was added followed by DBU (1 eq.). The reaction mixture was stirred for 1 h and then concentrated under reduced pressure. Flash column chromatography (1/0 to 85/15 pentane/Et₂O) of the residue provided the target imidate donors.




Methyl 2,3,5-tri-*O*-benzyl- α/β -D-ribofuranoside (2). D-Ribose (25 g, 167 mmol, 1 eq.) was dissolved in 600 mL MeOH and AcCl (4 mL, 56 mmol, 0.3 eq.) was added. The reaction mixture was stirred for 5 h and then quenched by the addition of solid NaHCO₃ (30 g). The mixture was filtered and concentrated under reduced pressure. The crude product **1** was coevaporated with toluene and then dissolved in 800 mL DMF and cooled to 0°C. NaH (60% dispersion in mineral oil, 26.7 g, 668 mmol, 4 eq.) was added in four portion while BnBr (80 mL, 668 mmol, 4 eq.) was slowly added over the course of 1 h. After stirring overnight the reaction was quenched by the addition of 75 mL MeOH and the reaction mixture was concentrated under reduced pressure. The crude mixture was taken up in H₂O and extracted twice with Et₂O. The combined Et₂O layers were washed with brine, dried with MgSO₄, filtered and concentrated *in vacuo*. Purification by flash column chromatography (19/1 to 2/1 pentane/EtOAc) gave compound **2** as a colourless oil (65 g, 150 mmol, 89%). Spectroscopic data were in accord with those previously reported.⁵⁰ Data for the α -anomer: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.36 – 7.25 (m, 13H, CH_{arom}), 7.23 – 7.19 (m, 2H, CH_{arom}), 4.88 (d, 1H, *J* = 4.2 Hz, H-1), 4.68 (d, 1H, *J* = 12.8 Hz, *CHH* Bn), 4.64 (d, 1H, *J* = 12.3 Hz, *CHH* Bn), 4.61 – 4.56 (m, 2H, 2x*CHH* Bn), 4.49 (d, 1H, *J* = 12.1 Hz, *CHH* Bn), 4.42 (d, 1H, *J* = 12.1 Hz, *CHH* Bn), 4.25 (td, 1H, *J* = 4.1, 2.9 Hz, H-4), 3.82 (dd, 1H, *J* = 6.8, 3.0 Hz, H-3), 3.77 (dd, 1H, *J* = 6.8, 4.2 Hz, H-2), 3.46 (s, 3H, CH₃ OMe), 3.41 (dd, 1H, *J* = 10.4, 4.1 Hz, H-5), 3.35 (dd, 1H, *J* = 10.4, 4.2 Hz, H-5); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 138.6, 138.0, 137.9 (C_q), 128.5, 128.5, 128.4, 128.4, 128.2, 127.9, 127.8, 127.8 (CH_{arom}), 102.6 (C-1), 82.3 (C-4), 77.9 (C-2), 75.1 (C-3), 73.6, 72.6, 72.5 (CH₂ Bn), 70.3 (C-5), 55.7 (OMe); Data for the β -anomer: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.40 – 7.25 (m, 15H, CH_{arom}), 4.92 (d, 1H, *J* = 1.0 Hz, H-1), 4.67 (d, 1H, *J* = 12.1 Hz, *CHH* Bn), 4.61 (d, 1H, *J* = 12.1 Hz, *CHH* Bn), 4.59 (d, 1H, *J* = 12.2 Hz, *CHH* Bn), 4.55 (d, 1H, *J* = 12.0 Hz, *CHH* Bn), 4.54 (d, 1H, *J* = 12.2 Hz, *CHH* Bn), 4.45 (d, 1H, *J* = 11.9 Hz, *CHH* Bn), 4.34 (ddd, 1H, *J* = 7.1, 5.8, 3.7 Hz, H-4), 4.01 (dd, 1H, *J* = 7.1, 4.7 Hz, H-3), 3.84 (dd, 1H, *J* = 4.6, 1.0 Hz, H-2), 3.61 (dd, 1H, *J* = 10.6, 3.7 Hz, H-5), 3.51 (dd, 1H, *J* = 10.6, 5.8 Hz, H-5), 3.31 (s, 3H, CH₃ OMe); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 138.3, 137.8, 137.8 (C_q), 128.4, 128.4, 128.3, 128.0, 127.9, 127.8, 127.8, 127.6, 127.5 (CH_{arom}), 106.3 (C-1), 80.5 (C-4), 79.6 (C-2), 78.3 (C-3), 73.2, 72.4, 72.3 (CH₂ Bn), 71.3 (C-5), 55.1 (OMe).




Methyl 3,5-di-*O*-benzyl- α -D-ribofuranoside (3). Compound **2** (4.35 g, 10 mmol, 1 eq.) was coevaporated with toluene twice and then was dissolved in 50 mL DCM at 0°C, followed by the addition of a 1 M SnCl₄ solution in DCM (10 mL, 10 mmol, 1 eq.). The reaction mixture was stirred overnight at 4°C and then quenched by the addition of sat. aq. NaHCO₃. The organic layer was washed with H₂O and brine, then dried (MgSO₄), filtered and concentrated *in vacuo*. The residue was purified by flash column chromatography (9/1 to 7/3 pentane/EtOAc) to yield the title compound as a colourless oil (3.19 g, 9.26 mmol, 93%). Spectroscopic data were in accord with those previously reported.¹⁷ ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.36 – 7.22 (m, 10H, CH_{arom}), 4.88 (d, 1H, *J* = 4.6 Hz, H-1), 4.72 (d, 1H, *J* = 12.4 Hz, *CHH* Bn), 4.57 (d, 1H, *J* = 12.3 Hz, *CHH* Bn), 4.50 (d, 1H, *J* = 12.1 Hz, *CHH* Bn), 4.44 (d, 1H, *J* = 12.1 Hz, *CHH* Bn), 4.16 (td, 1H, *J* = 4.1, 3.1 Hz, H-4), 4.14 –


4.06 (m, 1H, H-2), 3.78 (dd, 1H, $J = 7.1, 3.2$ Hz, H-3), 3.47 (s, 3H, CH₃ OMe), 3.43 (dd, 1H, $J = 10.4, 4.1$ Hz, H-5), 3.35 (dd, 1H, $J = 10.4, 4.3$ Hz, H-5), 2.96 (bd, 1H, $J = 10.1$ Hz, 2-OH); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 137.9, 137.9 (C_q), 128.5, 128.5, 128.0, 127.9, 127.8, 127.7 (CH_{arom}), 103.0 (C-1), 82.0 (C-4), 76.4 (C-3), 73.5, 73.0 (CH₂ Bn), 71.9 (C-2), 70.1 (C-5), 55.7 (OMe); HRMS: [M+Na]⁺ calcd for C₂₀H₂₄O₅Na 367.15160, found 367.15139.



Methyl 3,5-di-O-benzyl- α/β -D-xylofuranoside (6). 1,2-O-Isopropylidene- α -D-xylofuranoside **4**⁵¹ (28.6 g, 150 mmol, 1 eq.) was dissolved in 750 mL DMF and cooled to 0°C. NaH (60% dispersion in mineral oil, 15 g, 375 mmol, 2.5 eq.) was added followed by the slow addition of BnBr (45 mL, 375 mmol, 2.5 eq.). After 4 h the reaction was quenched by the addition of 50 mL MeOH and the reaction mixture was concentrated under reduced pressure. The crude mixture was taken up in H₂O and extracted twice with Et₂O. The combined Et₂O layers were washed with brine and dried with MgSO₄. After filtration and concentration, the crude product **5** was dissolved in 750 mL MeOH and CSA (3.5 g, 15 mmol, 0.1 eq.) was added and the reaction mixture was refluxed for 4 h. The reaction was quenched by addition of solid NaHCO₃, which after stirring for 15 min, was removed by filtration followed by concentration on the reaction mixture *in vacuo*. The residue was redissolved in EtOAc and was washed with H₂O and brine, dried (MgSO₄), filtered, and concentrated under reduced pressure. Purification by flash column chromatography (9/1 to 1/1 pentane/EtOAc) yielded compound **6** as a light yellow oils in three fractions (1: α only, 21.8 g, 63.4 mmol, 2: α/β mixture, 7.6 g, 22.2 mmol, 3: β only, 20.8 g, 60.5 mmol) combined yield: 146.1 mmol, 97%. Spectroscopic data were in accord with those previously reported.⁵² Data for the α -anomer: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.37–7.24 (m, 10H, CH_{arom}), 4.99 (d, 1H, $J = 4.7$ Hz, H-1), 4.73 (d, 1H, $J = 12.0$ Hz, CHH Bn), 4.63 (d, 1H, $J = 12.1$ Hz, CHH Bn), 4.55 (d, 1H, $J = 12.0$ Hz, CHH Bn), 4.53 (d, 1H, $J = 12.1$ Hz, CHH Bn), 4.39 (td, 1H, $J = 6.4, 4.2$ Hz, H-4), 4.26 (dt, 1H, $J = 7.5, 4.4$ Hz, H-2), 4.00 (dd, 1H, $J = 6.0, 4.1$ Hz, H-3), 3.72 (dd, 1H, $J = 10.5, 4.2$ Hz, H-5), 3.65 (dd, 1H, $J = 10.5, 6.7$ Hz, H-5), 3.49 (s, 3H, CH₃ OMe), 2.71 (d, 1H, $J = 7.6$ Hz, 2-OH); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 138.4, 138.1 (C_q), 128.5, 128.5, 127.9, 127.8, 127.7, 127.7 (CH_{arom}), 101.9 (C-1), 83.7 (C-3), 77.5 (C-4), 77.1 (C-2), 73.6, 72.0 (CH₂ Bn), 69.2 (C-5), 55.9 (OMe); Data for the β -anomer: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.37–7.25 (m, 10H, CH_{arom}), 4.80 (d, 1H, $J = 1.7$ Hz, H-1), 4.66–4.58 (m, 2H, 2xCHH Bn), 4.55 (d, 1H, $J = 12.0$ Hz, CHH Bn), 4.54 (d, 1H, $J = 12.2$ Hz, CHH Bn), 4.47 (ddd, 1H, $J = 7.2, 6.1, 4.6$ Hz, H-4), 4.21 (ddd, 1H, $J = 4.7, 2.9, 1.7$ Hz, H-2), 3.95 (dd, 1H, $J = 6.1, 2.9$ Hz, H-3), 3.77 (dd, 1H, $J = 10.3, 4.7$ Hz, H-5), 3.70 (dd, 1H, $J = 10.3, 7.3$ Hz, H-5), 3.40 (s, 3H, CH₃ OMe), 1.95 (d, 1H, $J = 4.8$ Hz, 2-OH); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 138.4, 137.9 (C_q), 128.6, 128.5, 128.0, 127.9, 127.9, 127.7 (CH_{arom}), 109.6 (C-1), 83.5 (C-3), 80.1 (C-4), 79.8 (C-2), 73.6, 72.5 (CH₂ Bn), 70.0 (C-5), 55.9 (OMe).




1,2-O-isopropylidene-5-O-(tert-butylidiphenylsilyl)- β -D-arabinofuranoside (7). D-Arabinose (30 g, 200 mmol, 1 eq.) was dissolved in 1 L DMF and imidazole (27.2 g, 400 mmol, 2 eq.) and TBDPSCI (52 mL, 200 mmol, 1 eq.) were added sequentially. The reaction mixture was heated to 60°C for 3 h and then two thirds of the DMF was removed under reduced pressure. The remaining solution was mixed with H₂O (1.5 L) and conc. HCl (15 mL) and the aqueous phase extracted four times with EtOAc. The organic layers were combined and washed with sat. aq. NaHCO₃ and brine. The organic phase was dried with MgSO₄, filtered and concentrated under reduced pressure. The crude product was coevaporated with toluene and then dissolved in DCM (1.1 L) and cooled to 0°C. CSA (2.5 g, 10.8 mmol, 0.05 eq.) was added followed by dropwise addition of 2,2-dimethoxypropane (44 mL, 360 mmol, 1.8 eq.). After 4 h, the reaction was quenched with Et₃N (2.8 mL) and concentrated under reduced pressure. Flash column chromatography (19/1 to 8/2 pentane/EtOAc) yielded compound **7** as a colourless oil (43.7 g, 102 mmol, 51%). Spectroscopic data were in accord with those previously reported.⁵³ ¹H NMR (CDCl₃, 500 MHz, HH-COSY, HSQC): δ 7.73–7.61 (m, 4H, CH_{arom}), 7.46–7.33 (m, 6H, CH_{arom}), 5.88 (d, 1H, $J = 4.0$ Hz, H-1), 4.54 (d, 1H, $J = 4.0$ Hz, H-2), 4.43 (t, 1H, $J = 3.1$ Hz, H-3), 4.05 (ddd, 1H, $J = 7.9, 5.7, 2.6$ Hz, H-4), 3.86–3.78 (m, 2H, H-5), 2.00 (d, 1H, $J = 4.3$ Hz, 3-OH), 1.32 (s, 3H, CH₃ Me), 1.28 (s, 3H, CH₃ Me), 1.06 (s, 9H, CH₃ ^tBu); ¹³C-APT NMR (CDCl₃, 126 MHz, HSQC): δ 135.7, 135.7 (CH_{arom}), 133.3, 133.2 (C_q Ph), 129.9, 129.9, 127.9, 127.9 (CH_{arom}), 112.6 (C_q), 105.7 (C-1), 87.5 (C-4), 87.1 (C-2), 76.5 (C-3), 63.8 (C-5), 27.0, 27.0 (^tBu), 26.2 (Me), 19.3 (C_q ^tBu).




Methyl 3,5-di-O-benzyl-1,2-O-isopropylidene- β -D-arabinofuranoside (8). Compound **7** (14.1 g, 32.8 mmol, 1 eq.) and BnCl (22.6 mL, 197 mmol, 6 eq.) were dissolved in 140 mL THF. Freshly crushed KOH pellets (35 g, 623 mmol, 19 eq.) were added and the reaction mixture was stirred under a N₂ atmosphere at reflux overnight. Once the mixture was cooled to room temperature, it was filtered through glass wool and concentrated *in vacuo*. Flash column chromatography (1/0 to 9/1 pentane/EtOAc) afforded the title compound as a yellow oil (9.0 g, 24.3 mmol, 74%). Spectroscopic data were in accord with those previously reported.²² ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.34–7.26 (m, 10H, CH_{arom}), 5.90 (d, 1H, $J = 4.0$ Hz, H-1), 4.64 (d, 1H, $J = 4.1$ Hz, H-2), 4.62–4.57 (m, 2H, CH₂ Bn), 4.57–4.51 (m, 2H, CH₂ Bn), 4.27 (td, 1H, $J = 6.3, 3.0$ Hz, H-4), 4.02 (d, 1H,

$J = 2.7$ Hz, H-3), 3.63 (d, 2H, $J = 6.2$ Hz, H-5), 1.44 (s, 3H, CH₃ Me), 1.32 (s, 3H, CH₃ Me); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 138.1, 137.4 (C_q Bn), 128.6, 128.5, 128.0, 127.9, 127.8, 127.8 (CH_{arom}), 112.8 (C_q), 105.8 (C-1), 85.3 (C-2), 83.7 (C-4), 83.2 (C-3), 73.5, 71.8 (CH₂ Bn), 70.1 (C-5), 27.2, 26.4 (Me).




Methyl 3,5-di-O-benzyl- α/β -D-arabinofuranoside (9). Fully protected compound **8** (11 g, 30 mmol, 1 eq.) and CSA (0.7 g, 3.0 mmol, 0.1 eq.) were dissolved in 150 mL MeOH and brought to reflux. After stirring for 5 h, the reaction mixture was cooled down and solid NaHCO₃ was added. The reaction mixture was concentrated and then H₂O was added. Extraction with EtOAc twice and those combined organic layers were washed with brine, then dried with MgSO₄, filtered, and concentrated *in vacuo*. Purification by flash column chromatography (19/1 to 8/2 pentane/EtOAc) afforded the title compound (9.4 g, 27 mmol, 91%) as a colourless oil. Spectroscopic data were in accord with those previously reported.²² Data for the α -anomer: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.37 – 7.21 (m, 10H, CH_{arom}), 4.89 (s, 1H, H-1), 4.68 (d, 1H, $J = 12.3$ Hz, CHH Bn), 4.61 (d, 1H, $J = 11.9$ Hz, CHH Bn), 4.51 (d, 1H, $J = 12.4$ Hz, CHH Bn), 4.46 (d, 1H, $J = 11.9$ Hz, CHH Bn), 4.26 (s, 1H, H-4), 4.12 (d, 1H, $J = 10.9$ Hz, H-2), 3.84 (s, 1H, H-3), 3.64 (dd, 1H, $J = 10.4$, 2.4 Hz, H-5), 3.43 (dd, 1H, $J = 10.4$, 2.5 Hz, H-5), 3.40 (s, 3H, CH₃ OMe), 3.34 (d, 1H, $J = 10.8$ Hz, OH); Data for the β -anomer: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.39 – 7.22 (m, 10H, CH_{arom}), 4.84 (d, 1H, $J = 4.7$ Hz, H-1), 4.74 (d, 1H, $J = 11.9$ Hz, CHH Bn), 4.59 (d, 1H, $J = 11.9$ Hz, CHH Bn), 4.57 (s, 2H, CH₂ Bn), 4.31 – 4.21 (m, 1H, H-2), 4.19 – 4.09 (m, 1H, H-4), 3.84 (t, 1H, $J = 5.8$ Hz, H-3), 3.53 (d, 2H, $J = 5.6$ Hz, H-5), 3.41 (s, 3H, CH₃ OMe), 2.57 (d, 1H, $J = 9.4$ Hz, OH); Data for the both anomers: ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 138.1, 138.0, 137.8, 137.1 (C_q), 128.6, 128.5, 128.4, 128.1, 128.0, 127.9, 127.9, 127.8, 127.8, 127.7, 127.7 (CH_{arom}), 110.5 (C-1 α), 102.8 (C-1 β), 85.0 (C-3 α), 84.7 (C-3 β), 83.5 (C-4 α), 80.8 (C-4 β), 78.1 (C-2 α), 78.0 (C-2 β), 73.8, 73.4, 72.2 (CH₂ Bn), 72.1 (C-5 β), 71.9 (CH₂ Bn), 69.8 (C-5 α), 55.4, 55.3 (OMe).




1,2-O-isopropylidene 5-O-(tert-butylidiphenylsilyl)- β -D-arabinofuran-3-uloside (10).

Compound **7** (9.95 g, 23.2 mmol, 1 eq.) was dissolved in 230 mL DCM and Dess-Martin periodinane (13.4 g, 31 mmol, 1.36 eq.) was added. After stirring 4 h, Na₂S₂O₃ (20 g) was added and the reaction mixture was poured into sat. aq. NaHCO₃. The mixture was extracted with DCM three times and the combined organic layers were washed with H₂O and brine. The organic layer was dried with MgSO₄, filtered and concentrated under reduced pressure. Flash column chromatography (1/0 to 8/2 pentane/EtOAc) afforded the title compound as a colourless oil (7.65 g, 17.9 mmol, 77%). Spectroscopic data were in accord with those previously reported.¹⁸ ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.75 – 7.63 (m, 4H, CH_{arom}), 7.45 – 7.33 (m, 6H, CH_{arom}), 6.03 (d, 1H, $J = 4.3$ Hz, H-1), 4.39 (d, 1H, $J = 4.3$ Hz, H-2), 4.29 (dd, 1H, $J = 6.3$, 4.2 Hz, H-4), 3.99 – 3.87 (m, 2H, H-5), 1.37 (s, 3H, CH₃ Me), 1.35 (s, 3H, CH₃ Me), 1.05 (s, 9H, CH₃ ^tBu); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 207.3 (C=O), 135.9, 135.7 (CH_{arom}), 133.2, 132.9 (C_q Ph), 129.9, 127.9 (CH_{arom}), 114.9 (C_q), 102.7 (C-1), 82.5 (C-4), 76.9 (C-2), 64.6 (C-5), 27.6 (Me), 26.9 (^tBu), 19.4 (C_q ^tBu);




1,2-O-isopropylidene-5-O-(tert-butylidiphenylsilyl)- β -D-lyxofuranoside (11).

Ketone **9** (6.9 g, 16.2 mmol, 1 eq.) was dissolved in DCM/MeOH (100 mL, 1/1) and cooled to 0°C. NaBH₄ (1.8 g, 48 mmol, 3 eq.) was added in three equal portions and the reaction mixture was stirred for 30 min after each addition. After 1.5 h sat. aq. NH₄Cl was added and the mixture was extracted three times with DCM. The combined organic layers were washed with sat. aq. NH₄Cl, H₂O, and brine. The organic layer was then dried (MgSO₄), filtered, and concentrated under reduced pressure. Flash column chromatography (2% to 14% EtOAc/pentane) afforded the title compound as a yellow oil (5.2 g, 13.1 mmol, 75%). Spectroscopic data were in accord with those previously reported.⁵⁴ ¹H NMR (CDCl₃, HH-COSY, HSQC): δ 7.78 – 7.62 (m, 4H, CH_{arom}), 7.48 – 7.31 (m, 6H, CH_{arom}), 5.71 (d, 1H, $J = 4.1$ Hz, H-1), 4.60 (dd, 1H, $J = 5.8$, 4.1 Hz, H-2), 4.33 (q, 1H, $J = 5.9$ Hz, H-3), 4.20 – 4.11 (m, 2H, H-4, H-5), 3.93 – 3.84 (m, 1H, H-5), 3.10 (d, 1H, $J = 6.4$ Hz, 3-OH), 1.42 (s, 3H, CH₃ Me), 1.34 (s, 3H, CH₃ Me), 1.06 (s, 9H, CH₃ ^tBu); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 135.7, 135.7 (CH_{arom}), 133.2, 133 (C_q Ph), 129.8, 127.8, 127.8 (CH_{arom}), 114.1 (C_q), 105.0 (C-1), 81.4 (C-4), 79.9 (C-2), 71.0 (C-3), 63.3 (C-5), 26.9 (CH₃ ^tBu), 26.8, 26.6 (Me), 19.2 (C_q ^tBu).




Methyl 3,5-di-O-benzyl-1,2-O-isopropylidene- β -D-lyxofuranoside (12). Compound **11** (9.0 g, 21 mmol, 1 eq.) and BnCl (14 mL, 123 mmol, 5.9 eq.) were dissolved in 90 mL THF. Freshly crushed KOH pellets (19.7 g, 351 mmol, 16.7 eq.) were added and the reaction mixture was stirred under a N₂ atmosphere at reflux overnight. Once the mixture was cooled to room temperature, it was filtered through glass wool and concentrated *in vacuo*. Flash column chromatography (1/0 to 8/2 pentane/EtOAc) afforded the title compound as a colourless oil (7.9 g, 21 mmol, 100%). Spectroscopic data were in accord with those previously reported for the L-enantiomer.⁵⁵ Rf: 0.16 (9/1 pentane/EtOAc). [α]_D²⁰ = +15° (c = 0.44, CHCl₃). IR (thin film): 698, 737,


1026, 1097, 1152, 1209, 1255, 1454, 2868, 2946, 2986; ^1H NMR (CDCl_3 , 400 MHz, HH-COSY, HSQC): δ 7.41 – 7.18 (m, 10H, CH_{arom}), 5.70 (d, 1H, $J = 4.0$ Hz, H-1), 4.67 (d, 1H, $J = 12.1$ Hz, CHH Bn), 4.63 – 4.57 (m, 3H, CH_2 Bn, CHH Bn), 4.55 (dd, 1H, $J = 5.1, 4.0$ Hz, H-2), 4.32 (dt, 1H, $J = 7.2, 5.8$ Hz, H-4), 4.05 (dd, 1H, $J = 7.3, 5.1$ Hz, H-3), 3.88 (d, 2H, $J = 5.9$ Hz, $2\times\text{H-5}$), 1.48 (s, 3H, CH_3 Me), 1.30 (s, 3H, CH_3 Me); ^{13}C -APT NMR (CDCl_3 , 101 MHz, HSQC): δ 138.4, 137.5 (C_q Bn), 128.5, 128.3, 128.0, 127.9, 127.8, 127.5 (CH_{arom}), 113.5 (C_q), 104.7 (C-1), 80.0 (C-4), 78.4 (C-2), 77.2 (C-3), 73.3, 72.6 (CH_2 Bn), 69.9 (C-5), 26.6, 26.1 (Me); HRMS: $[\text{M}+\text{NH}_4]^+$ calcd for $\text{C}_{22}\text{H}_{30}\text{NO}_5$ 388.21185, found 388.21226.




Methyl 3,5-di-O-benzyl- α -D-lyxofuranoside (13). Fully protected compound **12** (7.8 g, 21 mmol, 1 eq.) and CSA (0.46 g, 2.0 mmol, 0.1 eq.) were dissolved in 100 mL MeOH and brought to reflux. After stirring for 5 h, the reaction mixture was cooled down and solid NaHCO_3 was added. The reaction mixture was concentrated and then H_2O was added. Extraction with EtOAc twice and those combined organic layers were washed with brine, then dried with MgSO_4 , filtered, and concentrated *in vacuo*. Purification by flash column chromatography (19/1 to 8/2 pentane/EtOAc) afforded the title compound (6.1 g, 17.7 mmol, 84%) as a colourless oil and a single anomer. Spectroscopic data were in accord with those previously reported.⁵⁶ ^1H NMR (CDCl_3 , 400 MHz, HH-COSY, HSQC): δ 7.39 – 7.24 (m, 10H, CH_{arom}), 4.86 (s, 1H, H-1), 4.72 (d, 1H, $J = 11.4$ Hz, CHH Bn), 4.64 (d, 1H, $J = 11.8$ Hz, CHH Bn), 4.55 (d, 1H, $J = 11.8$ Hz, CHH Bn), 4.48 (d, 1H, $J = 11.4$ Hz, CHH Bn), 4.40 (dd, 1H, $J = 8.0, 4.9$ Hz, H-3), 4.35 – 4.28 (m, 2H, H-4, 2-OH), 4.05 (dd, 1H, $J = 10.2, 4.9$ Hz, H-2), 3.67 (dd, 1H, $J = 10.5, 3.3$ Hz, H-5), 3.61 (dd, 1H, $J = 10.5, 2.3$ Hz, H-5), 3.34 (s, 3H, CH_3 OMe); ^{13}C -APT NMR (CDCl_3 , 101 MHz, HSQC): δ 137.9, 137.3 (C_q), 128.6, 128.5, 128.0, 128.0, 127.9 (CH_{arom}), 108.6 (C-1), 77.8 (C-3), 77.5 (C-4), 74.0, 72.6 (CH_2 Bn), 72.2 (C-2), 68.0 (C-5), 55.2 (OMe).



Methyl 3,5-di-O-benzyl-2-O-trifluoromethanesulfonate- α -D-ribofuranoside (14). The title compound was generated by the general procedure for triflate formation and used crude. Spectroscopic data were in accord with those previously reported.⁵⁷ ^1H NMR (CDCl_3 , 400 MHz, HH-COSY, HSQC): δ 7.37 – 7.21 (m, 10H, CH_{arom}), 5.09 (d, 1H, $J = 4.3$ Hz, H-1), 5.01 (dd, 1H, $J = 6.5, 4.3$ Hz, H-2), 4.75 (d, 1H, $J = 12.2$ Hz, CHH Bn), 4.53 – 4.44 (m, 2H, CHH Bn, CHH Bn), 4.40 (d, 1H, $J = 12.0$ Hz, CHH Bn), 4.19 (dt, 1H, $J = 5.8, 3.1$ Hz, H-4), 4.07 (dd, 1H, $J = 6.5, 5.0$ Hz, H-3), 3.53 (dd, 1H, $J = 10.9, 2.9$ Hz, H-5), 3.51 (s, 3H, CH_3 OMe), 3.33 (dd, 1H, $J = 10.8, 3.3$ Hz, H-5); ^{13}C -APT NMR (CDCl_3 , 101 MHz, HSQC): δ 137.7, 137.1 (C_q), 128.7, 128.6, 128.4, 128.3, 128.0, 127.9 (CH_{arom}), 118.7 (d, $J = 319.6$ Hz), 101.1 (C-1), 81.4 (C-2), 81.1 (C-4), 74.6 (C-3), 73.7, 73.5 (CH_2 Bn), 68.5 (C-5), 56.4 (OMe); HRMS: $[\text{M}+\text{NH}_4]^+$ calcd for $\text{C}_{21}\text{H}_{27}\text{F}_3\text{NO}_7\text{S}$ 494.14548, found 494.14526.




Methyl 3,5-di-O-benzyl-2-O-trifluoromethanesulfonate- α/β -D-arabinofuranoside (15). The title compound was generated by the general procedure for triflate formation and used crude. Data for the α -anomer: ^1H NMR (CDCl_3 , 400 MHz, HH-COSY, HSQC): δ 7.38 – 7.23 (m, 10H, CH_{arom}), 5.20 (s, 1H, H-2), 5.10 (s, 1H, H-1), 4.70 (d, 1H, $J = 11.9$ Hz, CHH Bn), 4.55 (d, 1H, $J = 12.1$ Hz, CHH Bn), 4.52 – 4.45 (m, 2H, $2\times\text{CHH}$ Bn), 4.22 – 4.18 (m, 1H, H-4), 4.13 (ddd, 1H, $J = 5.9, 1.7, 0.9$ Hz, H-3), 3.61 (dd, 1H, $J = 10.9, 3.6$ Hz, H-5), 3.54 (dd, 1H, $J = 10.9, 4.6$ Hz, H-5), 3.42 (s, 3H, CH_3 OMe); ^{13}C -APT NMR (CDCl_3 , 101 MHz, HSQC): δ 137.8, 136.7 (C_q), 128.7, 128.5, 128.3, 128.1, 127.9, 127.9 (CH_{arom}), 118.5 (q, $J = 319.8$ Hz), 105.9 (C-1), 92.7 (C-2), 82.6 (C-3), 81.8 (C-4), 73.7, 72.8 (CH_2 Bn), 68.6 (C-5), 55.2 (OMe); Diagnostic peaks β -anomer: ^1H NMR (CDCl_3 , 400 MHz): δ 5.11 – 5.07 (m, 1H, H-1), 5.00 (d, 1H, $J = 4.4$ Hz, H-2), 4.62 (d, 1H, $J = 11.8$ Hz, CHH Bn), 4.57 (d, 1H, $J = 11.8$ Hz, CHH Bn), 4.55 – 4.48 (m, 2H, CH_2 Bn), 4.29 (dd, 1H, $J = 6.5, 5.4$ Hz, H-3), 4.17 – 4.12 (m, 1H, H-4), 3.57 – 3.53 (m, 1H, H-5), 3.47 (dd, 1H, $J = 9.9, 6.2$ Hz, H-5), 3.39 (s, 3H, CH_3 OMe); ^{13}C -APT NMR (CDCl_3 , 101 MHz, HSQC): δ 100.4 (C-1), 88.3 (C-2), 80.9 (C-3), 79.8 (C-4), 73.5, 72.6 (CH_2 Bn), 71.4 (C-5), 55.5 (OMe).




Methyl 3,5-di-O-benzyl-2-O-trifluoromethanesulfonate- α/β -D-xylofuranoside (16). The title compound was generated by the general procedure for triflate formation (anomers were treated separately) and used crude. Data for the α -anomer: ^1H NMR (CDCl_3 , 400 MHz, HH-COSY, HSQC): δ 7.37 – 7.21 (m, 10H, CH_{arom}), 5.18 (t, 1H, $J = 5.1$ Hz, H-2), 5.06 (d, 1H, $J = 4.4$ Hz, H-1), 4.66 (d, 1H, $J = 11.7$ Hz, CHH Bn), 4.57 (d, 1H, $J = 12.0$ Hz, CHH Bn), 4.55 – 4.50 (m, 2H, $2\times\text{CHH}$ Bn), 4.44 (dd, 1H, $J = 6.9, 5.8$ Hz, H-3), 4.33 (dt, 1H, $J = 7.0, 4.6$ Hz, H-4), 3.67 (dd, 1H, $J = 10.5, 4.2$ Hz, H-5), 3.59 (dd, 1H, $J = 10.5, 5.1$ Hz, H-5), 3.44 (s, 3H, CH_3 OMe); ^{13}C -APT NMR (CDCl_3 , 101 MHz, HSQC): δ 137.9, 136.9 (C_q), 128.7, 128.5, 128.3, 127.9, 127.8, 127.8 (CH_{arom}), 118.6 (q, $J = 319.6$ Hz), 99.6 (C-1), 87.9 (C-2), 79.3 (C-3), 75.7 (C-4), 73.7, 73.3 (CH_2 Bn), 68.4 (C-5), 56.0 (OMe); Data for the β -anomer: ^1H NMR (CDCl_3 , 400 MHz, HH-COSY, HSQC): δ 7.42 – 7.23 (m, 10H, CH_{arom}), 5.17 (s, 1H, H-2), 5.05 (s, 1H, H-1), 4.71 (d, 1H, $J = 12.1$ Hz, CHH Bn), 4.59 (d, 1H, $J = 12.0$ Hz, CHH Bn), 4.54 (d, 1H, $J = 12.0$ Hz, CHH Bn), 4.53 (d, 1H, $J = 12.1$ Hz, CHH Bn), 4.48 (dt, 1H, $J = 6.7, 5.5$ Hz, H-4), 4.21 (dd, 1H, $J = 5.9, 1.8$ Hz, H-3), 3.74 (dd, 1H, $J = 10.3, 5.1$ Hz, H-5), 3.69 (dd, 1H, $J = 10.3, 7.0$ Hz, H-5), 3.42 (s, 3H, CH_3 OMe); ^{13}C -APT NMR (CDCl_3 , 101 MHz, HSQC): δ 138.0, 136.6,


128.7, 128.5, 128.4, 128.1, 128.0, 127.9, 106.4, 91.2, 80.6, 80.4, 73.7, 72.8, 69.2, 56.1; HRMS: $[M+NH_4]^+$ calcd for $C_{21}H_{27}F_3NO_7S$ 494.14548, found 494.14515.




Methyl 3,5-di-O-benzyl-2-O-trifluoromethanesulfonate- α -D-lyxofuranoside (17). The title compound was generated by the general procedure for triflate formation and used crude. 1H NMR ($CDCl_3$, 400 MHz, HH-COSY, HSQC): δ 7.43 – 7.13 (m, 10H, CH_{arom}), 5.08 (s, 1H, H-1), 5.05 (d, 1H, $J = 4.3$ Hz, H-2), 4.73 (d, 1H, $J = 11.7$ Hz, CHH Bn), 4.63 (d, 1H, $J = 12.0$ Hz, CHH Bn), 4.51 (d, 1H, $J = 11.7$ Hz, CHH Bn), 4.50 (d, 1H, $J = 12.0$ Hz, CHH Bn), 4.46 – 4.37 (m, 2H, H-3, H-4), 3.74 (dd, 1H, $J = 10.5$, 4.1 Hz, H-5), 3.64 (dd, 1H, $J = 10.5$, 7.3 Hz, H-5), 3.38 (s, 3H, CH_3 OMe); ^{13}C -APT NMR ($CDCl_3$, 101 MHz, HSQC): δ 138.0, 136.9 (C_q), 128.7, 128.5, 128.3, 128.0, 127.8 (CH_{arom}), 118.6 (q, $J = 319.6$ Hz, CF_3), 104.0 (C-1), 86.2 (C-2), 77.5 (C-4), 76.4 (C-3), 73.9, 73.7 (CH_2 Bn), 69.6 (C-5), 55.7 (OMe).



Methyl 3,5-di-O-benzyl-2-deoxy-2-fluoro- α -D-arabinofuranoside (18). Employing conditions **A** of the general experimental for inversion of furanosyl triflates gave **18** in 86% yield (0.95 mmol) from triflate **14**. Spectroscopic data were in accord with those previously reported.²⁴ IR (thin film): 696, 737, 947, 988, 1039, 1055, 1098, 1193, 1364, 1454, 2862, 2922; 1H NMR ($CDCl_3$, 400 MHz, HH-COSY, HSQC): δ 7.37 – 7.25 (m, 10H, CH_{arom}), 5.06 (d, 1H, $J = 12.0$ Hz, H-1), 4.94 (dd, 1H, $J = 51.3$, 1.8 Hz, H-2), 4.67 (d, 1H, $J = 12.0$ Hz, CHH Bn), 4.58 (d, 1H, $J = 12.1$ Hz, CHH Bn), 4.56 – 4.51 (m, 2H, $2 \times CHH$ Bn), 4.21 (ddd, 1H, $J = 6.4$, 5.2, 3.8 Hz, H-4), 3.99 (dddd, 1H, $J = 24.7$, 6.4, 1.9, 1.0 Hz, H-3), 3.63 (dd, 1H, $J = 10.8$, 3.8 Hz, H-5), 3.58 (dd, 1H, $J = 10.8$, 5.1 Hz, H-5), 3.40 (s, 3H, CH_3 OMe); ^{13}C -APT NMR ($CDCl_3$, 126 MHz, HSQC): δ 138.0, 137.2 (C_q), 128.5, 128.4, 128.0, 127.7 (CH_{arom}), 106.5 (d, $J = 36.0$ Hz, C-1), 99.6 (d, $J = 181.3$ Hz, C-2), 83.0 (d, $J = 25.6$ Hz, C-3), 81.3 (d, $J = 4.0$ Hz, C-4), 73.4, 72.5 (CH_2 Bn), 69.3 (C-5), 54.9 (OMe); ^{19}F NMR ($CDCl_3$, 471 MHz): δ -188.39 (ddd, $J = 51.3$, 24.6, 12.0 Hz); ^{13}C HSQC-HECADE NMR ($CDCl_3$, 126 MHz): $^2J_{C1-H2} = -0.7$ Hz, $^2J_{C2-H1} = -2.0$ Hz; HRMS: $[M+NH_4]^+$ calcd for $C_{20}H_{27}NFO_4$ 364.19186, found 364.19196.




Methyl 3,5-di-O-benzyl-2-deoxy-2-fluoro- α/β -D-ribofuranoside (19). Employing conditions **A** of the general experimental for inversion of furanosyl triflates gave **19** in 63% yield (3.2 mmol), as two anomers (Rf: 0.47, and Rf: 0.15, 9/1 pentane/EtOAc) and two anomers of **26**. Spectroscopic data were in accord with those previously reported for the β -anomer.²² Data for the α -anomer: 1H NMR ($CDCl_3$, 400 MHz, HH-COSY, HSQC): δ 7.41 – 7.27 (m, 10H, CH_{arom}), 5.09 (dd, 1H, $J = 4.1$, 3.5 Hz, H-1), 4.88 (ddd, 1H, $J = 51.1$, 6.1, 4.2 Hz), 4.82 (d, 1H, $J = 12.4$ Hz, CHH Bn), 4.59 (d, 1H, $J = 12.4$ Hz, CHH Bn), 4.58 (d, 1H, $J = 12.1$ Hz, CHH Bn), 4.49 (d, 1H, $J = 12.1$ Hz, CHH Bn), 4.30 (dt, 1H, $J = 5.3$, 3.4 Hz, H-4), 4.00 (ddd, 1H, $J = 7.6$, 6.0, 5.2 Hz, H-3), 3.63 (dd, 1H, $J = 10.9$, 2.9 Hz, H-5), 3.56 (s, 3H, CH_3 OMe), 3.49 (dd, 1H, $J = 10.8$, 3.7 Hz, H-5); ^{13}C -APT NMR ($CDCl_3$, 101 MHz, HSQC): δ 137.9, 137.8 (C_q), 128.5, 128.5, 128.0, 128.0, 127.8, 127.7 (CH_{arom}), 101.8 (d, $J = 15.9$ Hz, C-1), 88.2 (d, $J = 202.7$ Hz, C-2), 80.9 (d, $J = 2.1$ Hz, C-4), 74.6 (d, $J = 14.8$ Hz, C-3), 73.6 (CH_2 5-OBn), 72.9 (d, $J = 2.2$ Hz, CH_2 3-OBn), 69.1 (C-5), 56.1 (OMe); ^{19}F NMR ($CDCl_3$, 470 MHz): δ -216.73 (ddd, $J = 51.2$, 7.6, 3.3 Hz); ^{13}C HSQC-HECADE NMR ($CDCl_3$, 126 MHz): $^2J_{C1-H2} = +2.4$ Hz, $^2J_{C2-H1} = +3.2$ Hz; Data for the β -anomer: 1H NMR ($CDCl_3$, 400 MHz, HH-COSY, HSQC): δ 7.35 – 7.26 (m, 10H, CH_{arom}), 5.00 (d, 1H, $J = 10.6$ Hz, H-1), 4.76 (dd, 1H, $J = 53.2$, 3.7 Hz, H-2), 4.66 (d, 1H, $J = 11.7$ Hz, CHH Bn), 4.59 (d, 1H, $J = 12.1$ Hz, CHH Bn), 4.54 (d, 1H, $J = 12.1$ Hz, CHH Bn), 4.54 (d, 1H, $J = 11.7$ Hz, CHH Bn), 4.30 (ddd, 1H, $J = 8.0$, 5.7, 3.4 Hz, H-4), 4.07 (ddd, 1H, $J = 24.6$, 7.7, 3.7 Hz, H-3), 3.64 (dd, 1H, $J = 10.6$, 3.4 Hz, H-5), 3.53 (dd, 1H, $J = 10.6$, 5.7 Hz, H-5), 3.32 (s, 3H, CH_3 OMe); ^{13}C -APT NMR ($CDCl_3$, 101 MHz, HSQC): δ 138.3, 137.4 (C_q), 128.6, 128.4, 128.1, 128.0, 127.7 (CH_{arom}), 105.7 (d, $J = 29.3$ Hz, C-1), 91.2 (d, $J = 185.1$ Hz, C-2), 80.1 (C-4), 77.8 (d, $J = 15.6$ Hz, C-3), 73.3, 72.8 (CH_2 Bn), 71.0 (C-5), 55.1 (OMe); ^{19}F NMR ($CDCl_3$, 471 MHz): δ -209.71 (ddd, $J = 53.2$, 24.6, 10.6 Hz); ^{13}C HSQC-HECADE NMR ($CDCl_3$, 126 MHz): $^2J_{C1-H2} = +1.6$ Hz, $^2J_{C2-H1} = -1.6$ Hz; HRMS: $[M+NH_4]^+$ calcd for $C_{20}H_{24}FNO_4$ 364.19186, found 364.19205.




Methyl 3,5-di-O-benzyl-2-deoxy-2-fluoro- α -D-lyxofuranoside (20). Employing conditions **B** of the general experimental for inversion of furanosyl triflates, with an additional 70°C reflux for 7 h, gave **20** in 44% yield (2.19 mmol) from triflate **16a**. Conditions **A** yielded 57% **28** and 21% **30**. IR (thin film): 698, 739, 1056, 1452, 2932; 1H NMR ($CDCl_3$, 500 MHz, HH-COSY, HSQC): δ 7.40 – 7.24 (m, 10H, CH_{arom}), 5.08 (dd, 1H, $J = 10.0$, 1.0 Hz, H-1), 4.80 (ddd, 1H, $J = 52.8$, 4.1, 1.0 Hz, H-2), 4.68 (d, 1H, $J = 11.9$ Hz, CHH Bn), 4.65 (d, 1H, $J = 12.1$ Hz, CHH Bn), 4.53 (d, 1H, $J = 11.8$ Hz, CHH Bn), 4.52 (d, 1H, $J = 12.1$ Hz, CHH Bn), 4.42 (ddd, 1H, $J = 8.0$, 7.1, 3.8 Hz, H-4), 4.30 (ddd, 1H, $J = 20.9$, 7.1, 4.1 Hz, H-3), 3.77 (dd, 1H, $J = 10.5$, 3.8 Hz, H-5), 3.67 (ddd, 1H, $J = 10.5$, 8.0, 1.4 Hz, H-5); ^{13}C -APT NMR ($CDCl_3$, 126 MHz, HSQC): δ 138.4, 137.5 (C_q), 128.6, 128.5, 128.1, 128.0, 127.8, 127.7 (CH_{arom}), 105.0 (d, $J = 29.8$ Hz, C-1), 92.4 (d, $J = 187.9$ Hz, C-2), 77.7 (C-4), 77.1 (d, $J = 14.9$ Hz, C-3), 73.6, 73.3 (CH_2 Bn), 70.3 (C-5), 55.5 (OMe); ^{19}F NMR ($CDCl_3$, 471 MHz, HH-COSY, HSQC): δ -207.58 (dddd, $J = 52.8$, 20.9, 10.0, 1.0 Hz); ^{13}C


HSQC-HECADE NMR (CDCl₃, 126 MHz): $^2J_{C2,H1} = -2.5$ Hz; HRMS: [M+Na]⁺ calcd for C₂₀H₂₃FO₄Na 369.14726, found 369.14734.




Methyl 3,5-di-O-benzyl-2-deoxy-2-fluoro-β-D-xylofuranoside (21). Employing conditions **A** of the general experimental for inversion of furanosyl triflates gave **21** in 10% yield (0.52 mmol) as the minor product from triflate **16β**. IR (thin film): 698, 712, 978, 1068, 1107, 2929; ¹H NMR (CDCl₃, 500 MHz, HH-COSY, HSQC): δ 7.37 – 7.26 (m, 10H, CH_{arom}), 5.02 (d, 1H, *J* = 14.8 Hz, H-1), 4.93 (d, 1H, *J* = 50.6 Hz, H-2), 4.68 (d, 1H, *J* = 12.2 Hz, *CHH* Bn), 4.60 (d, 1H, *J* = 12.0 Hz, *CHH* Bn), 4.55 (d, 1H, *J* = 12.0 Hz, *CHH* Bn), 4.54 (d, 1H, *J* = 12.1 Hz, *CHH* Bn), 4.52 – 4.48 (m, 1H, H-4), 4.15 (ddd, 1H, *J* = 18.2, 6.1, 1.7 Hz, H-3), 3.76 (dd, 1H, *J* = 10.3, 4.9 Hz, H-5), 3.70 (dd, 1H, *J* = 10.3, 7.3 Hz, H-5), 3.41 (s, 3H, CH₃ OMe); ¹³C-APT NMR (CDCl₃, 126 MHz, HSQC): δ 138.3, 137.4 (C_q), 128.6, 128.5, 128.1, 127.9, 127.9, 127.8 (CH_{arom}), 107.1 (d, *J* = 35.2 Hz, C-1), 98.4 (d, *J* = 181.0 Hz, C-2), 80.9 (d, *J* = 25.9 Hz, C-3), 80.7 (d, *J* = 1.9 Hz, C-4), 73.6, 72.7 (CH₂ Bn), 69.7 (C-5), 55.8 (OMe); ¹⁹F NMR (CDCl₃, 471 MHz): δ -192.85 (ddd, *J* = 50.6, 18.1, 14.9 Hz); ¹³C HSQC-HECADE NMR (CDCl₃, 126 MHz): $^2J_{C1,H2} = -2.6$ Hz, $^2J_{C2,H1} = -0.2$ Hz; HRMS: [M+NH₄]⁺ calcd for C₂₀H₂₇FNO₄ 364.19186, found 364.19192.




Methyl 2-azido-3,5-di-O-benzyl-2-deoxy-α-D-arabinofuranoside (22). Employing conditions **C** of the general experimental for inversion of furanosyl triflates gave **22** in 93% yield (5.37 mmol) from triflate **14**. [α]_D²⁰ = +76.4° (*c* = 1.0, CHCl₃). IR (thin film): 698, 714, 1026, 1070, 1097, 1107, 1271, 1452, 2104, 2932; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.35 – 7.23 (m, 10H, CH_{arom}), 4.88 (d, 1H, *J* = 1.5 Hz, H-1), 4.61 (d, 1H, *J* = 12.0 Hz, *CHH* Bn), 4.56 (d, 1H, *J* = 12.1 Hz, *CHH* Bn), 4.49 (d, 1H, *J* = 12.2 Hz, *CHH* Bn), 4.49 (d, 1H, *J* = 12.0 Hz, *CHH* Bn), 4.23 – 4.15 (m, 1H, H-4), 3.92 – 3.85 (m, 2H, H-2, H-3), 3.60 (dd, 1H, *J* = 10.8, 3.6 Hz, H-5), 3.54 (dd, 1H, *J* = 10.8, 4.8 Hz, H-5), 3.39 (s, 3H, CH₃ OMe); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 137.9, 137.2 (C_q), 128.5, 128.4, 128.0, 128.0, 127.8, 127.7 (CH_{arom}), 107.0 (C-1), 83.1 (C-3), 81.2 (C-4), 73.5, 72.6 (CH₂ Bn), 70.8 (C-2), 69.0 (C-5), 55.3 (OMe); ¹³C HSQC-HECADE NMR (CDCl₃, 126 MHz): $^2J_{C1,H2} = -2.1$ Hz, $^2J_{C2,H1} = -0.3$ Hz; HRMS: [M+NH₄]⁺ calcd for C₂₀H₂₇N₄O₄ 387.20268, found 387.20271.



Methyl 2-azido-3,5-di-O-benzyl-2-deoxy-α/β-D-ribofuranoside (23). Employing conditions **C** of the general experimental for inversion of furanosyl triflates gave **23** as an α:β = 1:2 mixture from triflate **15**, and as a 4:1 mixture of **23** and **27**, combined yield 86% (4.3 mmol). IR (thin film): 698, 740, 1028, 1066, 1107, 1271, 1452, 2108, 2918; Data for the α-anomer (intermixed with **27**, *vide infra*): ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.35 – 7.20 (m, 10H, CH_{arom}), 5.03 (d, 1H, *J* = 4.6 Hz, H-1), 4.76 (d, 1H, *J* = 12.5 Hz, *CHH* Bn), 4.58 (d, 1H, *J* = 12.5 Hz, *CHH* Bn), 4.47 (d, 1H, *J* = 12.1 Hz, *CHH* Bn), 4.40 (d, 1H, *J* = 12.1 Hz, *CHH* Bn), 4.30 – 4.22 (m, 1H, H-4), 3.99 (dd, 1H, *J* = 7.2, 3.7 Hz, H-3), 3.49 (s, 3H, OMe), 3.45 (dd, 1H, *J* = 10.5, 3.7 Hz, H-5), 3.36 – 3.28 (m, 2H, H-2, H-5); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 137.8, 137.6 (C_q), 128.4, 128.4, 128.0, 128.0, 127.7 (CH_{arom}), 104.5 (C-1), 82.5 (C-4), 77.8 (C-3), 73.5, 72.9 (CH₂ Bn), 69.5 (C-5), 61.0 (C-2), 55.7 (OMe); Data for the β-anomer: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.38 – 7.23 (m, 10H, CH_{arom}), 4.83 (s, 1H, H-1), 4.63 (d, 1H, *J* = 11.7 Hz, *CHH* Bn), 4.56 (d, 1H, *J* = 12.1 Hz, *CHH* Bn), 4.51 (d, 1H, *J* = 12.1 Hz, *CHH* Bn), 4.51 (d, 1H, *J* = 11.7 Hz, *CHH* Bn), 4.28 – 4.21 (m, 2H, H-3, H-4), 3.80 (d, 1H, *J* = 3.8 Hz, H-2), 3.59 – 3.54 (m, 1H, H-5), 3.52 – 3.47 (m, 1H, H-5), 3.29 (s, 3H, CH₃ OMe); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 138.1, 137.3 (C_q), 128.5, 128.4, 128.1, 127.9, 127.6 (CH_{arom}), 106.6 (C-1), 80.7 (C-4), 79.8 (C-3), 73.2, 73.0 (CH₂ Bn), 71.2 (C-5), 64.6 (C-2), 55.0 (OMe); HRMS: [M+H₂+H]⁺ calcd for C₂₀H₂₄NO₄ 387.20268, found 387.20275.




Methyl 2-azido-3,5-di-O-benzyl-2-deoxy-α-D-lyxofuranoside (24). Employing conditions **C** of the general experimental for inversion of furanosyl triflates, with additional 16 h stirring, gave **24** in 67% yield (3.36 mmol) from triflate **16α**, and side products **29α** (12%) and **30** (7%). Spectroscopic data were in accord with those previously reported.⁵⁸ ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.34 – 7.27 (m, 10H, CH_{arom}), 4.95 (d, 1H, *J* = 2.1 Hz, H-1), 4.69 (d, 1H, *J* = 11.7 Hz, *CHH* Bn), 4.60 (d, 1H, *J* = 11.9 Hz, *CHH* Bn), 4.52 (d, 1H, *J* = 11.7 Hz, *CHH* Bn), 4.49 (d, 1H, *J* = 12.0 Hz, *CHH* Bn), 4.38 – 4.31 (m, 2H, H-3, H-4), 3.79 – 3.66 (m, 3H, H-2, H-5, H-5), 3.36 (s, 3H, CH₃ OMe); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 138.1, 137.4 (C_q), 128.5, 128.4, 128.0, 127.9, 127.8, 127.7 (CH_{arom}), 105.9 (C-1), 79.0 (C-3), 78.2 (C-4), 73.9, 73.6 (CH₂ Bn), 69.2 (C-5), 65.9 (C-2), 55.6 (OMe); ¹³C HSQC-HECADE NMR (CDCl₃, 126 MHz): $^2J_{C1,H2} = -3.2$ Hz, $^2J_{C2,H1} = -0.1$ Hz, $^3J_{C1,H3} = +2.3$ Hz, $^3J_{C3,H1} = +2.4$ Hz; HRMS: [M+Na]⁺ calcd for C₂₀H₂₃N₃O₄ 392.15808, found 392.15787.




(2-Methyl-2-butyl) 3,5-di-O-benzyl-2-methyl-α/β-D-ribofuranoside (26). Formed as an 88:12 α:β anomeric mixture. Data for the isolated α-anomer: [α]_D²⁰ = +86.3° (*c* = 0.35, CHCl₃). IR (thin film): 698, 739, 1026, 1042, 1109, 1211, 1454, 2928, 2970; ¹H NMR (CDCl₃, 500 MHz, HH-COSY, HH-NOESY, HSQC, HMBC): δ 7.37 – 7.20 (m, 10H, CH_{arom}), 5.34 (d, 1H, *J* = 4.1 Hz, H-1), 4.70 (d, 1H, *J* = 12.6


Hz, *CHH* Bn), 4.55 – 4.49 (m, 2H, *CHH* Bn, *CHH* Bn), 4.42 (d, 1H, $J = 12.1$ Hz, *CHH* Bn), 4.22 (q, 1H, $J = 3.9$ Hz, H-4), 3.91 (dd, 1H, $J = 6.5, 4.5$ Hz, H-3), 3.57 (dd, 1H, $J = 6.5, 4.2$ Hz, H-2), 3.50 – 3.44 (m, 4H, CH₃ OMe, H-5), 3.36 (dd, 1H, $J = 10.6, 3.9$ Hz, H-5), 1.60 (q, 2H, $J = 7.5$ Hz, CH₂CH₃ *t*-amyl), 1.26 (s, 3H, CH₃ *t*-amyl), 1.24 (s, 3H, CH₃ *t*-amyl), 0.93 (t, 3H, $J = 7.5$ Hz, CH₂CH₃ *t*-amyl); ¹³C-APT NMR (CDCl₃, 126 MHz, HSQC): δ 138.5, 138.2 (C_q), 128.3, 128.2, 128.0, 127.6, 127.5, 127.5 (CH_{arom}), 95.9 (C-1), 80.6, 80.5 (C-2, C-4), 77.0 (C_q *t*-amylOH)75.7 (C-3), 73.3, 72.2 (CH₂ Bn), 70.0 (C-5), 58.8 (OMe), 34.5 (CH₂ *t*-amyl), 26.1, 25.9 (C_qCH₃ *t*-amyl), 8.6 (CH₂CH₃ *t*-amyl); HRMS: [M+Na]⁺ calcd for C₂₅H₃₄O₅Na 437.22985, found 437.22953.



1-Azido 3,5-di-O-benzyl-1-deoxy-2-methyl- β -D-ribofuranoside (27). Intermixed with **24**. (*vide supra*). ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.34 – 7.20 (m, 10H, CH_{arom}), 5.32 (d, 1H, $J = 1.9$ Hz, H-1), 4.60 – 4.56 (m, 2H, 2*xCHH* Bn), 4.53 (d, 1H, $J = 11.9$ Hz, *CHH* Bn), 4.51 (d, 1H, $J = 12.2$ Hz, *CHH* Bn), 4.29 – 4.22 (m, 1H, H-4), 4.08 (dd, 1H, $J = 6.9, 4.6$ Hz, H-3), 3.64 (dd, 1H, $J = 10.8, 3.3$ Hz, H-5), 3.52 (dd, 1H, $J = 10.9, 4.6$ Hz, H-5), 3.50 – 3.47 (m, 1H, H-2), 3.40 (s, 3H, CH₃ OMe); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 138.1, 137.5 (C_q), 128.4, 128.4, 128.0, 127.9, 127.8, 127.6 (CH_{arom}), 92.2 (C-1), 82.5 (C-2), 81.3 (C-4), 77.1 (C-3), 73.4, 72.7 (CH₂ Bn), 69.8 (C-5), 58.3 (OMe); After hydrolysis of the mixture of **24** an **27**, 3,5-di-O-benzyl-2-O-methyl- α/β -D-ribofuranose could be isolated as a $\alpha/\beta = 1:0.7$ anomeric mixture. Spectroscopic data were in accord with those previously reported.⁵⁹ ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.39 – 7.22 (m, 17H), 5.32 (dd, 1H, $J = 11.2, 4.1$ Hz, H-1 α), 5.28 (d, 0.7H, $J = 6.4$ Hz, H-1 β), 4.68 (d, 1H, $J = 11.9$ Hz, *CHH* Bn α), 4.63 (d, 0.7H, $J = 12.0$ Hz, *CHH* Bn β), 4.61 (d, 1H, $J = 11.9$ Hz, *CHH* Bn α), 4.59 – 4.42 (m, 4.1H, CH₂ Bn α,β , *CHH* Bn β), 4.35 (td, 1H, $J = 4.2, 2.4$ Hz, H-4 α), 4.27 – 4.17 (m, 1.4H, H-3 β , H-4 β), 4.12 (d, 1H, $J = 11.2$ Hz, 1-OH α), 4.01 (dd, 1H, $J = 5.0, 2.4$ Hz, H-3 α), 3.78 (dd, 1H, $J = 4.9, 4.3$ Hz, H-2 α), 3.67 – 3.59 (m, 2.1H, H-2 β , H-5 β , 1-OH β), 3.52 – 3.43 (m, 7.8H, CH₃ OMe α,β , H-5 β , 2*x*H-5 α); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 137.9, 137.8, 137.5, 137.4 (C_q), 128.6, 128.6, 128.5, 128.5, 128.1, 128.0, 128.0, 127.9, 127.8, 127.7 (CH_{arom}), 99.7 (C-1 β), 96.1 (C-1 α), 83.4 (C-2 β), 81.0 (C-4 α), 80.7 (C-3 β), 80.2 (C-2 β), 77.4 (C-3 α), 77.2 (C-4 β), 73.6, 73.5, 72.8, 72.7 (CH₂ Bn), 70.0 (C-5 α), 69.6 (C-5 β), 58.6, 58.4 (OMe); HRMS: [M+Na]⁺ calcd for C₂₀H₂₄O₅Na 367.15160, found 367.15164.




Methyl 2,5-di-O-benzyl-5-deoxy-5-fluoro- α/β -D-lyxofuranoside (28). Data for the α -anomer: m.p. 62–64 °C. [α]_D²⁰ = +16.6° ($c = 0.62$, CHCl₃); IR (thin film): 698, 737, 1009, 1026, 1069, 1107, 1150, 1454, 2922, 3032; ¹H NMR (CDCl₃, 500 MHz, HH-COSY, HH-NOESY, HSQC): δ 7.36 – 7.28 (m, 10H, CH_{arom}), 5.00 (d, 1H, $J = 1.6$ Hz, H-1), 4.74 – 4.62 (m, 4H, 2*xCHH* Bn, H-5, H-5), 4.60 (d, 1H, $J = 11.9$ Hz, *CHH* Bn), 4.50 (d, 1H, $J = 11.8$ Hz, *CHH* Bn), 4.44 (dtd, 1H, $J = 15.6, 6.8, 4.4$ Hz, H-4), 4.30 (dd, 1H, $J = 6.6, 4.6$ Hz, H-3), 3.88 (dt, 1H, $J = 4.6, 1.6$ Hz, H-2), 3.36 (s, 3H, CH₃ OMe); ¹³C-APT NMR (CDCl₃, 126 MHz, HSQC): δ 137.8, 137.7 (C_q), 128.5, 128.5, 128.0, 127.9, 127.8, 127.8 (CH_{arom}), 106.2 (C-1), 84.0 (d, $J = 164.8$ Hz, C-5), 81.1 (C-2), 77.8 (d, $J = 7.1$ Hz, C-3), 77.3 (d, $J = 20.2$ Hz, C-4), 73.2, 72.7 (CH₂ Bn), 55.5 (OMe); ¹⁹F NMR (CDCl₃, 471 MHz): δ -228.75 (td, $J = 47.6, 15.7$ Hz); ¹³C HSQC-HECADE NMR: ²J_{C1,H2} = -0.8 Hz, ²J_{C2,H1} = -0.8 Hz; HRMS: [M+NH₄]⁺ calcd for C₂₀H₂₇NFO₄ 364.19186, found 364.19199. Data for the β -anomer: [α]_D²⁰ = -100.5° ($c = 0.95$, CHCl₃); IR (thin film): 698, 737, 1003, 1066, 1109, 1163, 1348, 1454, 2910, 2924; ¹H NMR (CDCl₃, 500 MHz, HH-COSY, HH-NOESY, HSQC): δ 7.37 – 7.27 (m, 10H, CH_{arom}), 4.84 (dd, 1H, $J = 4.5, 1.2$ Hz, H-1), 4.82 (d, 1H, $J = 12.5$ Hz, *CHH* Bn), 4.70 – 4.64 (m, 2H, *CHH* Bn, H-5), 4.63 – 4.59 (m, 2H, 2*xCHH* Bn), 4.59 – 4.52 (m, 1H, H-5), 4.28 (dddd, 1H, $J = 14.4, 7.0, 6.0, 5.1$ Hz, H-4), 4.11 (t, 1H, $J = 6.0$ Hz, H-3), 3.80 (dd, 1H, $J = 5.9, 4.5$ Hz, H-2), 3.46 (s, 3H, CH₃ OMe); ¹³C-APT NMR (CDCl₃, 126 MHz, HSQC): δ 138.2, 137.7 (C_q), 128.6, 128.5, 128.3, 128.1, 128.0, 127.9 (CH_{arom}), 101.7 (C-1), 83.8 (d, $J = 165.6$ Hz, C-5), 79.1 (d, $J = 0.9$ Hz, C-2), 78.5 (d, $J = 21.4$ Hz, C-4), 74.7 (d, $J = 6.0$ Hz, C-3), 73.9, 72.7 (CH₂ Bn), 55.8 (OMe); ¹⁹F NMR (CDCl₃, 471 MHz): δ -227.76 (td, $J = 47.5, 14.4$ Hz); HRMS: [M+NH₄]⁺ calcd for C₂₀H₂₇NFO₄ 364.19186, found 364.19178.




Methyl 5-azido-2,5-di-O-benzyl-5-deoxy- α/β -D-lyxofuranoside (29). Data for the α -anomer: IR (thin film): 695, 734, 923, 1047, 1101, 1145, 1270, 1454, 2095; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC, HMBC): δ 7.38 – 7.24 (m, 10H, CH_{arom}), 4.98 (d, 1H, $J = 1.6$ Hz, H-1), 4.71 – 4.63 (m, 2H, 2*xCHH* Bn), 4.59 (d, 1H, $J = 11.9$ Hz, *CHH* Bn), 4.47 (d, 1H, $J = 11.7$ Hz, *CHH* Bn), 4.29 – 4.19 (m, 2H, H-3, H-4), 3.88 (dd, 1H, $J = 4.3, 1.7$ Hz, H-2), 3.62 (dd, 1H, $J = 12.8, 7.6$ Hz, H-5), 3.45 (dd, 1H, $J = 12.9, 3.8$ Hz, H-5), 3.34 (s, 3H, CH₃ OMe); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC, HMBC): δ 137.8 (C_q), 128.5, 128.0, 127.9, 127.9, 127.8 (CH_{arom}), 106.1 (C-1), 81.5 (C-2), 77.9, 77.8 (C-3, C-4), 73.2, 72.8 (CH₂ Bn), 55.5 (OMe), 52.1 (C-5); ¹³C HSQC-HECADE NMR: ²J_{C1,H2} = -0.9 Hz, ²J_{C2,H1} = -1.0 Hz, ²J_{C3,H2} = +0.7 Hz; HRMS: [M+NH₄]⁺ calcd for C₂₀H₂₇N₄O₄ 387.20268, found 387.20275. Data for the β -anomer: [α]_D²⁰ = -58.5° ($c = 0.48$, CHCl₃); IR (thin film): 698, 737, 999, 1053, 1105, 1157, 1454, 2096, 2874, 2914, 3030; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.41 – 7.27 (m, 10H, CH_{arom}), 4.89 – 4.83 (m, 2H, *CHH* Bn, H-1), 4.72 (d, 1H, $J = 12.2$ Hz, *CHH* Bn), 4.62 (d, 1H, $J = 12.2$ Hz, *CHH* Bn), 4.58 (d, 1H, $J = 12.3$ Hz, *CHH* Bn), 4.13 (ddd, 1H, $J = 8.7, 5.9, 4.3$ Hz, H-4), 4.05 (t, 1H, $J = 5.9$ Hz, H-3), 3.83 (dd, 1H, $J = 5.8, 4.5$ Hz, H-2), 3.66 (dd, 1H, $J = 13.0, 8.7$ Hz, H-5), 3.47 (s,


3H, CH₃ OMe), 3.29 (dd, 1H, *J* = 13.0, 4.3 Hz, H-5); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 138.1, 137.7 (C_q), 128.6, 128.5, 128.3, 128.1, 128.0, 127.9 (CH_{arom}), 102.0 (C-1), 79.3 (C-4), 79.0 (C-2), 75.0 (C-3), 73.8, 72.8 (CH₂ Bn), 55.9 (OMe), 52.8 (C-5); ¹³C HSQC-HECADE NMR (CDCl₃, 126 MHz): ²J_{C1,H2} = +1.0 Hz, ²J_{C2,H1} = +2.5 Hz; HRMS: [M+NH₄]⁺ calcd for C₂₀H₂₇N₄O₄ 387.20268, found 387.20272.




Methyl 2,5-anhydro-3-O-benzyl-α-D-lyxofuranoside (30). [α]_D²⁰ = +88.3° (*c* = 0.41, CHCl₃); IR (thin film): 698, 741, 880, 989, 1028, 1051, 1107, 11998, 1454, 2882, 2940; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.38 – 7.28 (m, 5H, CH_{arom}), 4.74 (s, 1H, H-1), 4.66 (d, 1H, *J* = 11.7 Hz, CHH Bn), 4.55 (d, 1H, *J* = 11.8 Hz, CHH Bn), 4.25 (d, 1H, *J* = 2.7 Hz, H-4), 4.23 (d, 1H, *J* = 2.6 Hz, H-3), 4.10 (s, 1H, H-2), 3.99 (d, 1H, *J* = 7.8 Hz, H-5), 3.70 (d, 1H, *J* = 7.8 Hz, H-5), 3.36 (s, 3H, CH₃ OMe); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 137.7 (C_q), 128.6, 128.1, 127.9 (CH_{arom}), 106.2 (C-1), 78.6 (C-3), 76.7 (C-2), 75.0 (C-4), 72.5, 70.9 (CH₂ Bn), 55.5 (OMe); HRMS: [M+NH₄]⁺ calcd for C₁₃H₂₀NO₄ 254.13868, found 254.13878.




3-benzyloxy-2-(benzyloxy)methyl-furan (31). Spectroscopic data were in accord with those previously reported.⁵⁷ ¹H NMR (CDCl₃, 400 MHz): δ 7.36 – 7.21 (m, 10H), 7.20 (d, 1H, *J* = 2.1 Hz), 6.25 (d, 1H, *J* = 2.1 Hz), 4.95 (s, 2H), 4.47 (s, 2H), 4.46 (s, 2H).



Formyl 3,5-di-O-benzyl-2-deoxy-2-fluoro-α/β-D-xylofuranoside (32). Data for the α-anomer: IR (thin film): 698, 737, 1026, 1088, 1271, 1454, 1732, 2868, 2926; ¹H NMR (CDCl₃, 500 MHz, HH-COSY, HSQC): δ 8.09 (d, 1H, *J* = 0.5 Hz, HC=O), 7.37 – 7.26 (m, 10H, CH_{arom}), 6.45 (dd, 1H, *J* = 4.2, 1.9 Hz, H-1), 5.23 (dt, 1H, *J* = 52.7, 4.7 Hz, H-2), 4.73 (d, 1H, *J* = 11.9 Hz, CHH Bn), 4.59 – 4.54 (m, 3H, CH₂ Bn, CHH Bn), 4.53 – 4.50 (m, 1H, H-4), 4.39 (ddd, 1H, *J* = 15.9, 6.7, 5.0 Hz, H-3), 3.70 (ddd, 1H, *J* = 10.6, 4.1, 0.8 Hz, H-5), 3.64 (dd, 1H, *J* = 10.6, 5.1 Hz, H-5); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 159.5 (HC=O), 138.0, 137.2 (C_q), 128.7, 128.2, 127.8 (CH_{arom}), 93.7 (d, *J* = 199.3 Hz, C-1), 93.4 (d, *J* = 17.4 Hz, C-2), 79.4 (d, *J* = 22.4 Hz, C-3), 78.7 (d, *J* = 7.1 Hz, C-4), 73.7, 72.7 (CH_{arom}), 68.1 (C-5); ¹⁹F NMR (CDCl₃, 471 MHz): -202.33 (dd, 0.3F *J* = 52.6, 15.9 Hz, F-2_α); ¹³C HSQC-HECADE NMR: ²J_{C1,H2} = +2.8 Hz, ²J_{C2,H1} = +3.3 Hz; Data for the β-anomer: ¹H NMR (CDCl₃, 500 MHz, HH-COSY, HSQC): δ 8.03 (dd, 1H, *J* = 2.2, 0.9 Hz, HC=O), 7.40 – 7.25 (m, 10H, CH_{arom}), 6.33 (d, 1H, *J* = 13.3 Hz, H-1), 5.07 (dd, 1H, *J* = 49.5, 1.4 Hz, H-2), 4.67 (d, 1H, *J* = 12.0 Hz, CHH Bn), 4.60 – 4.53 (m, 4H, CHH Bn, CH₂ Bn, H-4), 4.22 (ddd, 1H, *J* = 14.9, 5.6, 1.3 Hz, H-3), 3.80 (dd, 1H, *J* = 10.3, 5.4 Hz, H-5), 3.72 (dd, 1H, *J* = 10.3, 6.5 Hz, H-5); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 159.5 (HC=O), 138.0, 137.0 (C_q), 128.7, 128.5, 128.3, 127.9, 127.8 (CH_{arom}), 98.8 (d, *J* = 37.3 Hz, C-1), 96.8 (d, *J* = 184.2 Hz, C-2), 82.7 (C-4), 79.7 (d, *J* = 25.7 Hz, C-3), 73.6, 73.0 (CH₂ Bn), 68.4 (C-5); ¹⁹F NMR (CDCl₃, 471 MHz): δ -193.49 – -193.70 (m, 1F, F-2_β); ¹³C HSQC-HECADE NMR (CDCl₃, 126 MHz): ²J_{C1,H2} = +0.3 Hz, ²J_{C2,H1} = -1.7 Hz; HRMS: [M+Na]⁺ calcd for C₂₀H₂₁FO₅Na 383.1271, found 383.1276.




3,5-di-O-benzyl-α/β-D-xylofuranose (33). Xyloside **6** (7.6 g, 22 mmol) was dissolved in 20 mL THF and 40 mL H₂O and cooled to 0°C, followed by the slow addition of 100 mL TFA. After stirring overnight, the reaction mixture was partitioned between DCM and H₂O, and the aqueous layer was extracted three times with DCM. The combined DCM layers were washed with sat. aq. NaHCO₃ and brine, dried with MgSO₄, filtered and concentrated *in vacuo*. Flash column chromatography (9/1 to 1/1 pentane/EtOAc) afforded the title compound (6.1 g, 18.5 mmol, 84%) as a waxy material of a α:β = 70:30 anomeric composition. Spectroscopic data were in accord with those previously reported.⁶⁰ ¹H NMR (CDCl₃, 500 MHz, HH-COSY, HSQC): δ 7.34 – 7.23 (m, 10H, CH_{arom}), 5.44 (t, 0.7H, *J* = 4.8 Hz, H-1_α), 5.11 (d, 0.3H, *J* = 10.9 Hz, H-1_β), 4.87 (d, 0.7H, *J* = 5.5 Hz, 1-OH_α), 4.66 – 4.53 (m, 2H, 2xCHH Bn_α, 2xCHH Bn_β), 4.52 – 4.43 (m, 2.7H, 2xCHH Bn_α, 2xCHH Bn_β, H-4_α), 4.40 (q, 0.3H, *J* = 5.2 Hz, H-4_β), 4.19 (t, 0.3H, *J* = 2.9 Hz, H-2_β), 4.13 – 4.08 (m, 1H, H-2_α, 1-OH_β), 3.98 – 3.93 (m, 1H, H-3_α, H-3_β), 3.77 – 3.70 (m, 0.6H, H-5_β, H-5_β), 3.66 – 3.64 (m, 1.4H, H-5_α, H-5_α), 3.30 (d, 0.7H, *J* = 5.8 Hz, 2-OH_α), 3.14 (d, 0.3H, *J* = 4.3 Hz, 2-OH_β); ¹³C-APT NMR (CDCl₃, 126 MHz, HSQC): δ 137.9, 137.7, 137.4 (C_q), 128.6, 128.5, 128.5, 128.5, 128.1, 128.0, 128.0, 127.9, 127.8, 127.8, 127.6 (CH_{arom}), 103.5 (C-1_β), 96.1 (C-1_α), 83.6 (C-3_α), 82.9 (C-3_β), 80.0 (C-4_β), 79.2 (C-2_β), 77.5 (C-4_α), 75.6 (C-2_α), 73.7 (CH₂ Bn_α), 73.6 (CH₂ Bn_β), 72.7 (CH₂ Bn_α), 72.0 (CH₂ Bn_β), 69.2 (C-5), 69.1 (C-5_α); HRMS: [M+Na]⁺ calcd for C₁₉H₂₂O₅Na 353.13594, found 353.13594.




1,2-O-thiocarbonate-3,5-di-O-benzyl-α/β-D-xylofuranose (34). Diol **33** (1.65 g, 5 mmol, 1 eq.) was dissolved in 25 mL DCM and cooled to 0°C. DiPEA (7 mL, 40 mmol, 8 eq.) and DMAP (122 mg, 1 mmol, 0.2 eq.) were added, followed by the addition of thiophosgene (0.5 mL, 6.25 mmol, 1.25 eq., dissolved in 25 mL DCM). After 15 min the reaction was complete as concluded from TLC analysis. The reaction mixture was diluted with DCM and washed with 1 M aq. HCl, sat. aq. NH₄Cl, sat. aq. NaHCO₃, and brine. The organic layer was dried with Na₂SO₄, filtered and concentrated *in vacuo*. Flash column chromatography (19/1 to 8/2


pentane/EtOAc) afforded the title compound (1.45 g, 3.9 mmol, 78%) as a light orange oil. Spectroscopic data were in accord with those previously reported.^{61,62} ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.38 – 7.25 (m, 10H, CH_{arom}), 6.40 (d, 1H, *J* = 4.7 Hz, H-1), 5.08 (d, 1H, *J* = 4.7 Hz, H-2), 4.65 (d, 1H, *J* = 11.9 Hz, *CHH* Bn), 4.60 (d, 1H, *J* = 11.9 Hz, *CHH* Bn), 4.56 (d, 1H, *J* = 11.9 Hz, *CHH* Bn), 4.52 (d, 1H, *J* = 11.8 Hz, *CHH* Bn), 4.35 (td, 1H, *J* = 5.8, 3.5 Hz, H-4), 4.20 (d, 1H, *J* = 3.5 Hz, H-3), 3.78 (d, 2H, *J* = 5.8 Hz, H-5); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 189.8 (C=S), 137.6, 136.3 (C_q), 128.9, 128.7, 128.6, 128.1, 128.1, 127.9 (CH_{arom}), 107.8 (C-1), 86.0 (C-2), 80.7 (C-4), 79.4 (C-3), 73.8, 73.0 (CH₂ Bn), 66.5 (C-5).




3-benzyloxy-2-(benzyloxy)methyl-2,3-dihydrofuran (35). Thionocarbonate **34** (330 mg, 0.89 mmol, 1 eq.) was dissolved in toluene (1.8 mL) and heated to 70°C. When the target temperature was reached 1,3-dimethyl-2-phenyl-1,3,2-diazaphospholidine (0.18 mL, 0.98 mmol, 1.1 eq.) was added, and the reaction was continued to stir for 20 min. The reaction mixture was concentrated in vacuo and flash column chromatography (1/0 to 85/15 pentane/Et₂O) afforded the title compound (191 mg, 0.68 mmol, 76%) as a colourless oil. Spectroscopic data were in accord with those previously reported.³⁶ ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.38 – 7.23 (m, 10H, CH_{arom}), 6.61 (d, 1H, *J* = 2.8 Hz, H-1), 5.24 (t, 1H, *J* = 2.6 Hz, H-2), 4.64 (d, 1H, *J* = 12.0 Hz, *CHH* Bn), 4.61 (dd, 2H, *J* = 7.1, 2.5, 0.7 Hz, H-3), 4.55 (d, 1H, *J* = 12.0 Hz, *CHH* Bn), 4.50 – 4.44 (m, 2H, *CHH* Bn, H-4), 4.42 (d, 1H, *J* = 12.0 Hz, *CHH* Bn), 3.96 (dd, 1H, *J* = 10.6, 4.6 Hz, H-5), 3.85 (dd, 1H, *J* = 10.6, 7.7 Hz, H-5); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 150.6 (C-1), 138.5, 138.1 (C_q), 128.4, 128.4, 127.8, 127.7, 127.6, 127.5 (CH_{arom}), 101.4 (C-2), 83.3 (C-4), 79.5 (C-3), 73.6, 70.7 (CH₂ Bn), 67.8 (C-5).



Phenyl 2-azido-3,5-di-O-benzyl-2-deoxy-1-seleno-α/β-D-xylofuranoside (36). Glycal **35** (314 mg, 1.11 mmol, 1 eq.) was dissolved in DCM (5.5 mL) followed by the subsequent addition of TMSN₃ (295 μL, 2.22 mmol, 2 eq.), TBAF (1M solution in THF, 220 μL, 0.22 mmol, 0.2 eq.), and *N*-(phenylseleno)phthalimide (671 mg, 2.22 mmol, 2 eq.). The reaction was stirred overnight, diluted with DCM and washed with sat. aq. NaHCO₃ and brine. The organic layer was dried (MgSO₄), filtered and concentrated under reduced pressure. The residu was purified by flash column chromatography (1/0 to 85/15 pentane/Et₂O) to give the still impure title compound (360 mg, 0.72 mmol, <65%) and was used direct in the subsequent hydrolysis (*vide infra*, **52**). The major product was confirmed as the *trans*-xylo isomer: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, NOESY, HSQC): δ 7.66 – 7.59 (m, 2H, CH_{arom}), 7.36 – 7.27 (m, 13H, CH_{arom}), 5.46 (d, 1H, *J* = 3.7 Hz, H-1), 4.66 (d, 1H, *J* = 11.8 Hz, *CHH* Bn), 4.62 – 4.53 (m, 3H, *CHH* Bn, CH₂ Bn), 4.34 (q, 1H, *J* = 5.4 Hz, H-4), 4.27 (t, 1H, *J* = 3.4 Hz, H-2), 4.01 (dd, 1H, *J* = 5.4, 3.2 Hz, H-3), 3.78 (dd, 1H, *J* = 10.2, 5.2 Hz, H-5), 3.73 (dd, 1H, *J* = 10.2, 6.0 Hz, H-5); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 138.1, 137.1 (C_q), 134.3 (CH_{arom}), 130.0 (C_q), 129.2, 128.7, 128.6, 128.4, 128.1, 127.9, 127.9, 127.8, 127.8, 127.7 (CH_{arom}), 85.7 (C-1), 81.6 (C-3), 81.1 (C-4), 73.6, 72.7 (CH₂ Bn), 70.1 (C-2), 68.6 (C-5); ¹³C HSQC-HECADE NMR: ²*J*_{C1,H2} = -1.1 Hz, ²*J*_{C2,H1} = -3.1 Hz, ²*J*_{C2,H1} = -4.0 Hz. And minor products are identified as *cis*-xylo (¹³C HSQC-HECADE NMR (CDCl₃, 126 MHz): ²*J*_{C1,H2} = +0.9 Hz, ²*J*_{C2,H1} = +1.3 Hz), and *trans*-lyxo (¹³C HSQC-HECADE NMR (CDCl₃, 126 MHz): ²*J*_{C1,H2} = -0.7 Hz, ²*J*_{C2,H1} = -3.0 Hz).




Methyl 2,3-di-O-benzyl-α/β-D-arabinofuranoside (37). The title compound was prepared by the general procedure for the synthesis of primary furanoside alcohols from D-arabinose (200 mmol) in 41% as a yellow oil (28.2 g, 82 mmol). Spectroscopic data were in accord with those previously reported.⁶³ Data for the α-anomer: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.39 – 7.26 (m, 10H, CH_{arom}), 4.94 (s, 1H, H-1), 4.69 – 4.41 (m, 4H, CH₂Bn), 4.19 – 4.11 (m, 1H, H-3), 4.03 – 3.93 (m, 2H, H-2, H-4), 3.83 (ddd, 1H, *J* = 12.1, 4.2, 2.8 Hz, H-5), 3.64 (ddd, 1H, *J* = 12.0, 7.9, 4.1 Hz, H-5), 3.38 (s, 3H, CH₃ OMe); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 137.8, 137.4 (C_q), 128.6, 128.6, 128.1, 128.1, 128.0, 128.0 (CH_{arom}), 107.6 (C-1), 87.8 (C-2), 82.6 (C-4), 82.5 (C-3), 72.5, 72.0 (CH₂Bn), 62.4 (C-5), 55.1 (OMe); Data for the β-anomer: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.42 – 7.27 (m, 10H, CH_{arom}), 4.73 – 4.56 (m, 5H, H-1, 2xCH₂Bn), 4.27 (dd, 1H, *J* = 6.9, 6.1 Hz, H-3), 4.07 (m, 2H, *J* = 9.4, 6.4, 3.8 Hz, H-2, H-3), 3.69 (d, 1H, *J* = 11.8 Hz, H-5), 3.57 (dt, 1H, *J* = 11.6, 5.6 Hz, H-5), 3.40 (s, 3H, CH₃ OMe); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 138.0, 137.6 (C_q), 128.6, 128.6, 128.3, 128.2, 128.0, 127.9 (CH_{arom}), 101.9 (C-1), 84.4 (C-2), 82.4 (C-4), 81.1 (C-3), 72.8, 72.7 (CH₂ Bn), 64.1 (C-5), 55.9 (OMe); HRMS: [M+NH₄]⁺ calcd for C₂₀H₂₈NO₅ 362.19620, found 362.19611.




Methyl 2,3-di-O-benzyl-α/β-D-ribofuranoside (38). The title compound was prepared by the general procedure for the synthesis of primary furanoside alcohols from D-ribose (100 mmol) in 43% as a yellow oil (14.8 g, 43 mmol). Spectroscopic data were in accord with those previously reported.⁶⁴ Data for the α-anomer: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.40 – 7.27 (m, 10H, CH_{arom}), 4.87 (d, 1H, *J* = 4.3 Hz, H-1), 4.74 (d, *J* = 12.7 Hz, *CHH* Bn), 4.65 (d, *J* = 12.3 Hz, *CHH* Bn), 4.61 (d, *J* = 12.3 Hz, *CHH* Bn), 4.58


(d, $J = 12.7$ Hz, *CHH* Bn), 4.17 (q, 1H, $J = 3.5$ Hz, H-3), 3.84 (dd, 1H, $J = 6.9$, 3.6 Hz, H-4), 3.73 (dd, 1H, $J = 6.9$, 4.3 Hz, H-2), 3.66 (dd, 1H, $J = 12.0$, 3.2 Hz, H-5), 3.46 (s, 3H, CH_3OMe), 3.44 – 3.37 (m, 1H, H-5); ^{13}C -APT NMR (CDCl_3 , 101 MHz, HSQC): δ 138.3, 137.9 (C_q), 128.5, 128.5, 128.3, 128.1, 128.0, 127.9 (CH_{arom}), 102.8 (C-1), 83.2 (C-3), 78.3 (C-2), 74.8 (C-4), 72.8, 72.7 (CH_2Bn), 62.9 (C-5), 55.7 (OMe); Data for the β -anomer: ^1H NMR (CDCl_3 , 400 MHz, HH-COSY, HSQC): δ 7.44 – 7.25 (m, 10H, CH_{arom}), 4.89 (s, 1H, H-1), 4.65 (d, 1H, $J = 12.0$ Hz, *CHH* Bn), 4.61 (d, 1H, $J = 12.0$ Hz, *CHH* Bn), 4.56 (d, 1H, $J = 11.7$ Hz, *CHH* Bn), 4.48 (d, 1H, $J = 11.7$ Hz, *CHH* Bn), 4.27 (dt, 1H, $J = 6.8$, 3.4 Hz, H-4), 4.11 (dd, 1H, $J = 7.0$, 4.7 Hz, H-3), 3.86 (d, 1H, $J = 4.7$ Hz, H-2), 3.79 (dt, 1H, $J = 12.0$, 3.4 Hz, H-5), 3.56 (ddd, 1H, $J = 12.1$, 8.5, 3.8 Hz, H-5), 3.35 (s, 3H, CH_3OMe), 2.06 (dd, 1H, $J = 8.5$, 4.1 Hz, OH); ^{13}C -APT NMR (CDCl_3 , 101 MHz, HSQC): δ 137.8, 137.7 (C_q), 128.5, 128.1, 128.0, 127.9 (CH_{arom}), 106.9 (C-1), 82.4 (C-4), 80.2 (C-2), 77.3 (C-3), 72.7, 72.5 (CH_2Bn), 62.8 (C-5), 55.7 (OMe); HRMS: $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{20}\text{H}_{24}\text{O}_5\text{Na}$ 367.15160, found 367.15159.




Methyl 2,3-di-O-benzyl- α -D-lyxofuranoside (39). The title compound was prepared by the general procedure for the synthesis of primary furanoside alcohols from D-lyxose (160 mmol) in 42% as a yellow oil (23.1 g, 67.2 mmol). Spectroscopic data were in accord with those previously reported.⁶⁵ ^1H NMR (CDCl_3 , 400 MHz, HH-COSY, HSQC): δ 7.39 – 7.26 (m, 10H, CH_{arom}), 5.00 (s, 1H, H-1), 4.72 (d, 1H, $J = 11.8$ Hz, *CHH* Bn), 4.64 (d, 1H, $J = 11.8$ Hz, *CHH* Bn), 4.59 (d, 1H, $J = 11.9$ Hz, *CHH* Bn), 4.46 (d, 1H, $J = 11.8$ Hz, *CHH* Bn), 4.36 (dd, 1H, $J = 7.3$, 4.9 Hz, H-3), 4.26 (dt, 1H, $J = 7.5$, 4.2 Hz, H-4), 3.88 (dd, 1H, $J = 4.8$, 0.8 Hz, H-2), 3.85 – 3.80 (m, 2H, H-5), 3.34 (s, 3H, CH_3OMe), 2.68 (t, 1H, $J = 6.1$ Hz, OH); ^{13}C -APT NMR (CDCl_3 , 101 MHz, HSQC): δ 137.7, 137.4 (C_q), 128.6, 128.6, 128.1, 128.0, 128.0, 127.7 (CH_{arom}), 105.5 (C-1), 80.0 (C-2), 78.4 (C-4), 78.3 (C-3), 73.0, 72.8 (CH_2Bn), 62.0 (C-5), 55.3 (OMe); HRMS: $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{20}\text{H}_{25}\text{O}_5$ 345.16965, found 345.16967.



Methyl 2,3-di-O-benzyl- α -D-xylofuranoside (40). The title compound was prepared by the general procedure for the synthesis of primary furanoside alcohols from D-xylose (200 mmol) in 50% as a yellow oil (34.4 g, 100 mmol). Spectroscopic data were in accord with those previously reported.⁶⁶ ^1H NMR (CDCl_3 , 400 MHz, HH-COSY, HSQC): δ 7.40 – 7.25 (m, 18H, CH_{arom}), 4.90 (d, 1H, $J = 1.9$ Hz, H-1 β), 4.80 (d, 0.8H, $J = 4.2$ Hz, H-1 α), 4.73 (d, 0.8H, $J = 11.8$ Hz, *CHH* Bn α), 4.67 – 4.47 (m, 6.4H, *CHH* Bn α , $\text{CH}_2\text{Bn}\alpha$, $2\times\text{CH}_2\text{Bn}\beta$), 4.43 (dd, 0.8H, $J = 7.8$, 6.5 Hz, H-3 α), 4.31 (dt, 1H, $J = 6.8$, 4.8 Hz, H-4 β), 4.22 (dd, 0.8H, $J = 7.7$, 3.9 Hz, H-4 α), 4.18 (dd, 1H, $J = 6.8$, 3.8 Hz, H-3 β), 4.10 (dd, 1H, $J = 3.9$, 1.9 Hz, H-2 β), 4.05 (dd, 0.8H, $J = 6.5$, 4.2 Hz, H-2 α), 3.83 – 3.70 (m, 3.6H, $2\times\text{H-5}\alpha$, $2\times\text{H-5}\beta$), 3.40 (s, 3H, $\text{CH}_3\text{OMe}\beta$), 3.38 (s, 2.4H, $\text{CH}_3\text{OMe}\alpha$), 2.58 (t, 1H, $J = 6.6$ Hz, 5-OH β), 2.43 (dd, 0.8H, $J = 8.7$, 5.0 Hz, 5-OH α); ^{13}C -APT NMR (CDCl_3 , 101 MHz, HSQC): δ 137.6, 137.5 (C_q), 128.6, 128.6, 128.6, 128.3, 128.1, 128.1, 128.0, 127.9, 127.9, 127.8 (CH_{arom}), 108.0 (C-1 β), 100.2 (C-1 α), 87.2 (C-2 β), 84.6 (C-2 α), 82.9 (C-3 β), 82.3 (C-3 α), 80.6 (C-4 β), 76.3 (C-4 α), 72.8, 72.7, 72.5, 72.3 (CH_2Bn), 62.3, 62.3 (C-5 $\alpha\beta$), 55.7 (OMe β), 55.2 (OMe α); HRMS: $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{20}\text{H}_{24}\text{O}_5\text{Na}$ 367.15160, found 367.15152.




Methyl (methyl 2,3-di-O-benzyl- α / β -D-arabinofuranosyl uronate) (41). The title compound was generated from **37** (28.2 g, 78.8 mmol) by the general procedure for TEMPO/BAIB oxidation. Yield: 70% (20.6 g, 55.3 mmol) as a yellow oil. Rf: 0.75 (7/3 pentane/EtOAc). IR (thin film): 698, 737, 1028, 1059, 1099, 1207, 1360, 1454, 1734, 1755, 2874, 2916, 2949, 3030. Data for the α -anomer: ^1H NMR (CDCl_3 , 400 MHz, HH-COSY, HSQC): δ 7.44 – 7.21 (m, 10H, CH_{arom}), 5.09 (s, 1H, H-1), 4.63 (d, 1H, $J = 4.8$ Hz, H-4), 4.67 – 4.54 (m, 2H, CH_2Bn), 4.47 (d, 1H, $J = 12.0$ Hz, *CHH* Bn), 4.41 (d, 1H, $J = 12.0$ Hz, *CHH* Bn), 4.15 (dd, 1H, $J = 4.8$, 1.8 Hz, H-3), 3.96 (dd, 1H, $J = 1.8$, 0.8 Hz, H-2), 3.73 (s, 3H, $\text{CH}_3\text{CO}_2\text{Me}$), 3.41 (s, 3H, CH_3OMe); ^{13}C -APT NMR (CDCl_3 , 101 MHz, HSQC): δ 170.6 (C=O), 137.2, 137.2 (C_q), 128.4, 128.2, 128.0, 127.9, 127.9, 127.9 (CH_{arom}), 108.0 (C-1), 86.5 (C-2), 84.9 (C-3), 80.9 (C-4), 72.1, 71.7 (CH_2Bn), 55.5 (CH_3OMe), 52.4 ($\text{CH}_3\text{CO}_2\text{Me}$); Data for the β -anomer: ^1H NMR (CDCl_3 , 400 MHz, HH-COSY, HSQC): δ 7.37 – 7.22 (m, 10H, CH_{arom}), 4.76 (d, 1H, $J = 4.2$ Hz, H-1), 4.73 (d, 1H, $J = 11.8$ Hz, *CHH* Bn), 4.67 (d, 1H, $J = 11.8$ Hz, *CHH* Bn), 4.64 – 4.58 (m, 2H, CH_2Bn), 4.53 (dd, 1H, $J = 6.6$, 4.9 Hz, H-3), 4.42 (d, 1H, $J = 4.9$ Hz, H-4), 4.01 (dd, 1H, $J = 6.6$, 4.2 Hz, H-2), 3.73 (s, 3H, $\text{CH}_3\text{CO}_2\text{Me}$), 3.42 (s, 3H, CH_3OMe); ^{13}C -APT NMR (CDCl_3 , 101 MHz, HSQC): δ 171.5 (C=O), 137.7, 137.4 (C_q), 128.4, 128.4, 128.3, 128.1, 127.9, 127.7 (CH_{arom}), 102.3 (C-1), 83.8, 83.8 (C-2, C-3), 79.4 (C-4), 72.5, 72.5 (CH_2Bn), 55.5 (CH_3OMe), 52.2 ($\text{CH}_3\text{CO}_2\text{Me}$); HRMS: $[\text{M}+\text{NH}_4]^+$ calcd for $\text{C}_{21}\text{H}_{28}\text{NO}_6$ 390.19111, found 390.19094.




Methyl (methyl 2,3-di-O-benzyl- α / β -D-ribofuranosyl uronate) (42). The title compound was generated from **38** (13.3 g, 38.7 mmol) by the general procedure for TEMPO/BAIB oxidation. Yield: 87% (12.5 g, 33.7 mmol) as a yellow oil. Rf: 0.73 (7/3 pentane/EtOAc). Spectroscopic data were in accord with those previously reported.⁶⁷ Data for the β -anomer: IR (thin film): 698, 739, 957, 1026, 1063, 1111, 1136, 1205, 1358, 1454, 1738, 1753, 2930, 3030; ^1H NMR (CDCl_3 , 500 MHz, HH-COSY, HH-NOESY, HSQC): δ 7.38 – 7.26 (m, 10H, CH_{arom}), 4.97 (s, 1H, H-1), 4.68 – 4.62 (m, 3H, CH_2Bn , H-4), 4.61 (d, 1H, $J = 12.0$


H_z, CHH Bn), 4.57 (d, 1H, *J* = 12.0 Hz, CHH Bn), 4.35 (dd, 1H, *J* = 6.4, 4.7 Hz, H-3), 3.85 (d, 1H, *J* = 4.6 Hz, H-2), 3.74 (s, 3H, CH₃ CO₂Me), 3.38 (s, 3H, CH₃ OMe); ¹³C-APT NMR (CDCl₃, 126 MHz, HSQC): δ 172.0 (C=O), 137.6, 137.5 (C_q), 128.5, 128.4, 128.0, 127.9, 127.9 (CH_{arom}), 107.1 (C-1), 80.6 (C-3), 79.8 (C-2), 79.6 (C-4), 72.8, 72.7 (CH₂ Bn), 55.3 (CH₃ OMe), 52.3 (CH₃ CO₂Me); ¹³C HSQC-HECADE NMR (CDCl₃, 126 MHz): ²*J*_{C1,H2}: +0.3 Hz, ²*J*_{C2,H1}: -0.6 Hz; HRMS: [M+NH₄]⁺ calcd for C₂₁H₂₈NO₆ 390.19111, found 390.19105.




Methyl (methyl 2,3-di-O-benzyl-α-D-lyxofuranosyl uronate) (43). The title compound was generated from **39** (9.91 g, 28.8 mmol) by the general procedure for TEMPO/BAIB oxidation. Yield: 89% (9.5 g, 25.5 mmol) as a white solid. R_f: 0.70 (7/3 pentane/EtOAc). m.p. 76–80 °C. [α]_D²⁰ = +29.7° (*c* = 0.92, CHCl₃); IR (thin film): 698, 739, 1028, 1065, 1145, 1211, 1454, 1734, 1767, 2949; ¹H NMR (CDCl₃, 500 MHz, HH-COSY, HSQC): δ 7.38–7.23 (m, 10H, CH_{arom}), 5.23 (d, 1H, *J* = 3.6 Hz, H-1), 4.76 (d, 1H, *J* = 11.8 Hz, CHH Bn), 4.72 (d, 1H, *J* = 4.7 Hz, H-4), 4.69 (d, 1H, *J* = 12.0 Hz, CHH Bn), 4.63 (d, 1H, *J* = 12.0 Hz, CHH Bn), 4.59 (d, 1H, *J* = 11.8 Hz, CHH Bn), 4.35 (t, 1H, *J* = 4.7 Hz, H-3), 3.93 (dd, 1H, *J* = 4.6, 3.6 Hz, H-2), 3.72 (s, 3H, CH₃ CO₂Me), 3.43 (s, 3H, CH₃ OMe); ¹³C-APT NMR (CDCl₃, 126 MHz, HSQC): δ 169.1 (C=O), 138.0, 137.8 (C_q), 128.5, 128.4, 127.9, 127.9, 127.8, 127.8 (CH_{arom}), 108.0 (C-1), 83.3 (C-2), 79.0 (C-3), 78.5 (C-4), 73.9, 72.8 (CH₂ Bn), 56.5 (CH₃ OMe), 52.3 (CH₃ CO₂Me); ¹³C HSQC-HECADE NMR (CDCl₃, 126 MHz): ²*J*_{C1,H2} = -2.8 Hz, ²*J*_{C2,H1} = -1.6 Hz; HRMS: [M+H]⁺ calcd for C₂₁H₂₅O₆ 373.16456, found 373.16471.



Methyl (methyl 2,3-di-O-benzyl-α/β-D-xylofuranosyl uronate) (44). The title compound was generated from **40** (34.4 g, 100 mmol) by the general procedure for TEMPO/BAIB oxidation. Yield: 88% (30.8 g, 88.2 mmol) as a yellow oil. R_f: 0.65 (7/3 pentane/EtOAc). IR (thin film): 698, 739, 1063, 1119, 1207, 1454, 1738, 1765, 2916, 2949, 3030. Data for the α-anomer: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.39–7.21 (m, 10H, CH_{arom}), 4.94 (d, 1H, *J* = 4.3 Hz, H-1), 4.79 (d, 1H, *J* = 7.4 Hz, H-4), 4.64–4.57 (m, 4H, 2xCH₂ Bn), 4.47 (dd, 1H, *J* = 7.4, 6.2 Hz, H-3), 4.11 (dd, 1H, *J* = 6.2, 4.3 Hz, H-2), 3.73 (s, 3H, CH₃ CO₂Me), 3.40 (s, 3H, CH₃ OMe); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 169.7 (C=O), 137.6, 137.4 (C_q), 128.5, 128.4, 128.2, 128.1, 127.7, 127.5 (CH_{arom}), 101.6 (C-1), 82.5 (C-2), 81.8 (C-3), 76.5 (C-4), 73.0, 72.9 (CH₂ Bn), 55.7 (OMe), 52.2 (CO₂Me); Data for the β-anomer: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.40–7.23 (m, 10H, CH_{arom}), 5.04 (s, 1H, H-1), 4.90 (d, 1H, *J* = 6.2 Hz, H-4), 4.61–4.56 (m, 1H, CHH Bn), 4.53 (d, 1H, *J* = 12.5 Hz, CHH Bn), 4.43 (d, 1H, *J* = 11.9 Hz, CHH Bn), 4.39 (d, 1H, *J* = 11.9 Hz, CHH Bn), 4.23 (dd, 1H, *J* = 6.2, 1.4 Hz, H-2), 3.98–3.97 (m, 1H, H-2), 3.77 (s, 3H, CH₃ CO₂Me), 3.53 (s, 3H, CH₃ OMe); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 169.7 (C=O), 137.2, 137.2 (C_q), 128.5, 128.5, 128.1, 128.0, 127.7, 127.5 (CH_{arom}), 108.8 (C-1), 85.1 (C-2), 81.2 (C-3), 81.1 (C-4), 72.7, 71.9 (CH₂ Bn), 56.0 (OMe), 52.1 (CO₂Me); HRMS: [M+H]⁺ calcd for C₂₁H₂₅O₆ 373.16456, found 373.16448.




3,5-di-O-benzyl-2-deoxy-2-fluoro-α/β-D-arabinofuranose (45). The title compound was generated from **18** (470 mg, 1.36 mmol) by the general procedure for methyl furanoside hydrolysis, conditions A (65 °C, 64 h). Yield: 63% α:β = 70:30 (0.85 mmol) as a colourless oil. Spectroscopic data were in accord with those previously reported.²⁴ Data for the α-anomer: ¹H NMR (CDCl₃, 500 MHz, HH-COSY, HSQC): δ 7.37–7.23 (m, 10H, CH_{arom}), 5.45 (dd, 1H, *J* = 10.7, 2.9 Hz, H-1), 4.93 (d, 1H, *J* = 50.2 Hz, H-2), 4.62 (d, 1H, *J* = 12.0 Hz, CHH Bn), 4.57–4.47 (m, 3H, CH₂ Bn, CHH Bn), 4.43 (q, 1H, *J* = 5.2 Hz, H-4), 3.98 (dd, 1H, *J* = 21.0, 4.8 Hz, H-3), 3.76 (d, 1H, *J* = 4.1 Hz, OH), 3.58–3.54 (m, 1H, H-5), 3.51 (dd, 1H, *J* = 10.3, 5.1 Hz, H-5); ¹³C-APT NMR (CDCl₃, 126 MHz, HSQC): δ 137.9, 137.0 (C_q), 128.6, 128.4, 128.1, 128.0, 127.8, 127.8 (CH_{arom}), 100.4 (d, *J* = 34.5 Hz, C-2), 98.4 (d, *J* = 182.7 Hz, C-1), 82.6 (d, *J* = 25.6 Hz, C-3), 81.9 (d, *J* = 2.0 Hz, C-4), 73.5, 72.4 (CH₂ Bn), 69.7 (C-5); ¹⁹F NMR (CDCl₃, 471 MHz): δ -189.12 (ddd, *J* = 50.7, 21.0, 10.8 Hz); ¹³C HSQC-HECADE NMR: ²*J*_{C1,H2} = +1.8 Hz, ²*J*_{C2,H1} = +3.9 Hz; Data for the β-anomer: ¹H NMR (CDCl₃, 500 MHz, HH-COSY, HSQC): δ 7.36–7.23 (m, 10H, CH_{arom}), 5.32–5.24 (m, 1H, H-1), 5.00–4.85 (m, 1H, H-2), 4.66 (d, 1H, *J* = 11.8 Hz, CHH Bn), 4.57–4.47 (m, 3H, CHH Bn, CH₂ Bn), 4.28 (dt, 1H, *J* = 17.8, 4.9 Hz, H-3), 4.22 (d, 1H, *J* = 9.5 Hz, OH), 4.09 (q, 1H, *J* = 3.8 Hz, H-4), 3.58–3.54 (m, 1H, H-5), 3.47 (dd, 1H, *J* = 10.3, 3.8 Hz, H-5); ¹³C-APT NMR (CDCl₃, 126 MHz, HSQC): δ 137.3, 137.1 (C_q), 128.6, 128.6, 128.1, 128.1, 128.0, 127.9 (CH_{arom}), 95.8 (d, *J* = 194.1 Hz, C-2), 95.4 (d, *J* = 18.8 Hz, C-1), 80.6 (d, *J* = 22.8 Hz, C-3), 80.1 (d, *J* = 8.2 Hz, C-4), 73.7, 72.2 (CH₂ Bn), 70.0 (C-5); ¹⁹F NMR (CDCl₃, 471 MHz): δ -202.72 (dd, *J* = 52.7, 17.8 Hz); HRMS: [M+Na]⁺ calcd for C₁₉H₂₁FO₄Na 355.13161, found 355.13160.




3,5-di-O-benzyl-2-deoxy-2-fluoro-α/β-D-ribofuranose (46). The title compound was generated from **19** (205 mg, 0.59 mmol) by the general procedure for methyl furanoside hydrolysis, conditions A (60 °C, 18 h). Yield: 78% α:β = 25:75 (0.46 mmol). Spectroscopic data were in accord with those previously reported.²² ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.40–7.21 (m, 10H, CH_{arom}), 5.35 (dd, 0.75H, *J* = 8.5, 6.7 Hz, H-1_β), 5.33 (dt, 0.25H, *J* = 11.7, 3.6 Hz, H-1_α), 4.91 (dt, 0.25H, *J* = 51.8, 4.3 Hz, H-2_α), 4.76 (dd,


0.75H, $J = 53.3$, 3.4 Hz, H-2 β), 4.72 (d, 0.25H, $J = 11.8$ Hz, CHH Bn α), 4.66 (d, 0.75H, $J = 11.7$ Hz, CHH Bn β), 4.60 – 4.42 (m, 3H, CHH Bn α , CHH Bn β , CH₂ Bn α , CH₂ Bn β), 4.34 (qd, 0.25H, $J = 3.4$, 1.0 Hz, H-4 α), 4.31 – 4.21 (m, 1.5H, H-3 β , H-4 β), 4.09 – 4.01 (m, 0.5H, H-3 α , 1-OH α), 3.89 (dd, 0.75H, $J = 6.7$, 0.9 Hz, 1-OH β), 3.66 (dd, 0.75H, $J = 10.4$, 2.4 Hz, H-5 β), 3.54 (dd, 0.25H, $J = 10.7$, 3.3 Hz, H-5 α), 3.51 – 3.45 (m, 1H, H-5 α , H-5 β); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 137.8, 137.3, 137.1 (C $_q$), 128.6, 128.6, 128.5, 128.2, 128.1, 128.1, 128.0, 127.9, 127.7 (CH_{arom}), 99.8 (d, $J = 29.2$ Hz, C-1 β), 95.9 (d, $J = 18.5$ Hz, C-1 α), 91.9 (d, $J = 187.5$ Hz, C-2 β), 88.8 (d, $J = 197.2$ Hz, C-2 α), 80.7 (d, $J = 3.5$ Hz, C-4 α), 76.8 (C-4 β), 76.8 (d, $J = 14.7$ Hz, C-3 α), 76.5 (d, $J = 15.5$ Hz, C-3 β), 73.6 (CH₂ Bn α), 73.6 (CH₂ Bn β), 73.2 (d, $J = 2.2$ Hz, CH₂ Bn α), 72.8 (CH₂ Bn β), 69.4 (C-5 α), 69.1 (C-5 β); ¹³C HSQC-HECADE NMR (CDCl₃, 126 MHz): α -anomer: ²J_{C1-H2}: +1.8 Hz, ²J_{C2-H1}: +2.0 Hz, β -anomer: ²J_{C2-H1}: -0.3 Hz; HRMS: [M+Na]⁺ calcd for C₁₉H₂₁FO₄Na 355.13161, found 355.13147.



3,5-di-O-benzyl-2-deoxy-2-fluoro- α/β -D-lyxofuranose (47). The title compound was generated from **20** (340 mg, 0.98 mmol) by the general procedure for methyl furanoside hydrolysis, conditions A (65°C, 6 h). Yield: 75% $\alpha:\beta = 1:1$ (0.73 mmol). IR (thin film): 696, 735, 1027, 1045, 1454, 2864, 2926, 3410; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.42 – 7.29 (m, 20H, CH_{arom}), 5.58 (dd, 1H, $J = 9.8$, 2.6 Hz, H-1 α), 5.28 (dd, 1H, $J = 12.5$, 4.5 Hz, H-1 β), 4.94 (dt, 1H, $J = 50.3$, 4.4 Hz, H-2 α), 4.87 (d, 1H, $J = 11.3$ Hz, CHH Bn), 4.87 (ddd, 1H, $J = 52.6$, 4.1, 1.0 Hz, H-2 β), 4.73 (d, 1H, $J = 11.9$ Hz, CHH Bn), 4.68 – 4.61 (m, 3H, CHH Bn 2xCHH Bn), 4.60 – 4.53 (m, 4H, 3xCHH Bn, H-4 α), 4.40 (ddd, 1H, $J = 20.3$, 7.1, 4.1 Hz, H-3 α), 4.25 (td, 1H, $J = 4.2$, 1.8 Hz, H-3 β), 4.23 – 4.18 (m, 1H, H-4 β), 4.17 (dd, 1H, $J = 12.6$, 1.0 Hz, 1-OH β), 3.85 (dd, 1H, $J = 9.7$, 6.6 Hz, H-5 β), 3.79 (dd, 1H, $J = 10.5$, 3.6 Hz, H-5 α), 3.76 – 3.67 (m, 2H, H-5 α , H-5 β), 3.43 (t, 1H, $J = 2.9$ Hz, 1-OH α); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 138.1, 137.8, 137.4, 137.0 (C $_q$), 128.7, 128.6, 128.6, 128.4, 128.1, 128.1, 128.0, 127.9, 127.8, 127.7 (CH_{arom}), 99.0 (d, $J = 30.5$ Hz, C-1 α), 95.1 (d, $J = 19.2$ Hz, C-1 β), 92.9 (d, $J = 187.9$ Hz, C-2 α), 89.5 (d, $J = 202.2$ Hz, C-2 β), 77.7 (C-4 α), 77.4 (d, $J = 5.9$ Hz, C-4 β), 76.9 (d, $J = 15.0$ Hz, C-3 α), 76.3 (d, $J = 14.6$ Hz, C-3 β), 74.5 (d, $J = 3.1$ Hz, CH₂ Bn), 73.8, 73.6 (CH₂ Bn), 73.2 (d, $J = 1.3$ Hz, CH₂ Bn), 70.3 (d, $J = 1.2$ Hz, C-5 α), 68.9 (C-5 β); ¹⁹F NMR (CDCl₃, 471 MHz): δ -207.67 (ddd, $J = 52.6$, 20.1, 9.3 Hz, C2-F α), -214.36 (d, $J = 50.4$ Hz, C2-F β); HRMS: [M+Na]⁺ calcd for C₁₉H₂₁FO₄Na 355.13161, found 355.13164.




3,5-di-O-benzyl-2-deoxy-2-fluoro- α/β -D-xylofuranose (48). The title compound was generated from **21** (181 mg, 0.52 mmol) by the general procedure for methyl furanoside hydrolysis, conditions A (60°C, 6 h). Yield: 75% $\alpha:\beta = 30:70$ (0.40 mmol) as a colourless oil. Spectroscopic data were in accord with those previously reported for the L-enantiomer.⁶⁸ IR (thin film): 696, 735, 1026, 1047, 1454, 2868, 2924, 3400; ¹H NMR (CDCl₃, 500 MHz, HH-COSY, HSQC): δ 7.37 – 7.24 (m, 10H), 5.48 (td, 0.3H, $J = 8.3$, 3.7 Hz, H-1 α), 5.29 (dd, 0.7H, $J = 13.9$, 11.6 Hz, H-1 β), 4.95 (ddd, 0.7H, $J = 52.2$, 3.2, 0.8 Hz, H-2 β), 4.90 (dt, 0.3H, $J = 52.1$, 3.4 Hz, H-2 α), 4.68 (d, 0.7H, $J = 11.7$ Hz, CHH Bn β), 4.65 (d, 0.3H, $J = 11.9$ Hz, CHH Bn α), 4.60 – 4.50 (m, 3H, CHH Bn α , CHH Bn β , CH₂ Bn α , CH₂ Bn β), 4.50 – 4.46 (m, 0.3H, H-4 α), 4.39 (dt, 0.7H, $J = 6.1$, 4.2 Hz, H-4 β), 4.27 (ddd, 0.3H, $J = 13.2$, 5.3, 3.1 Hz, H-3 α), 4.23 (dddd, 0.7H, $J = 17.8$, 6.1, 3.0, 0.7 Hz, H-3 β), 4.14 (d, 0.7H, $J = 11.6$ Hz, 1-OH β), 3.73 (ddd, 0.7H, $J = 10.1$, 4.6, 1.2 Hz, H-5 β), 3.71 – 3.67 (m, 1H, H-5 α , H-5 β), 3.64 (dd, 0.3H, $J = 10.2$, 5.9 Hz, H-5 α), 3.57 (dd, 0.3H, $J = 8.5$, 3.2 Hz, 1-OH α); ¹³C-APT NMR (CDCl₃, 126 MHz, HSQC): δ 138.1, 137.4, 137.3, 137.0 (C $_q$), 128.7, 128.6, 128.6, 128.4, 128.2, 128.1, 128.0, 127.9, 127.8, 127.7 (CH_{arom}), 101.0 (d, $J = 34.4$ Hz, C-1 β), 99.1 (d, $J = 185.0$ Hz, C-2 β), 95.6 (d, $J = 17.1$ Hz, C-1 α), 93.8 (d, $J = 191.1$ Hz, C-2 α), 80.9 (d, $J = 24.6$ Hz, C-3 β), 80.3 (d, $J = 24.1$ Hz, C-3 α), 80.0 (d, $J = 3.4$ Hz, C-4 β), 77.2 (d, $J = 4.1$ Hz, C-4 α), 73.9 (CH₂ Bn β), 73.6 (CH₂ Bn α), 73.0 (CH₂ Bn β), 72.7 (CH₂ Bn α), 68.4 (C-5 α), 68.4 (C-5 β); ¹⁹F NMR (CDCl₃, 471 MHz): δ -189.88 (ddd, 0.7F, $J = 52.2$, 17.7, 14.1 Hz, F-2 β), -204.74 (dt, 0.3F, $J = 52.2$, 9.7 Hz, F-2 α); ¹³C HSQC-HECADE NMR (CDCl₃, 126 MHz): α -anomer: ²J_{C1-H2} = +3.1 Hz, ²J_{C2-H1} = +5.6 Hz, β -anomer: ²J_{C2-H1} = -2.3 Hz; HRMS: [M+Na]⁺ calcd for C₁₉H₂₁FO₄Na 355.1322, found 355.1326.




2-azido-3,5-di-O-benzyl-2-deoxy- α/β -D-arabinofuranose (49). The title compound was generated from **22** (554 mg, 1.50 mmol) by the general procedure for methyl furanoside hydrolysis, conditions A (60°C, 64 h). Yield: 76% $\alpha:\beta = 1:1$ (1.1 mmol) as a colourless oil. IR (thin film): 696, 735, 1070, 1454, 2108, 3320; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.45 – 7.10 (m, 20H), 5.33 (d, 1H, $J = 7.0$ Hz, H-1 α), 5.30 (dd, 1H, $J = 9.1$, 4.6 Hz, H-1 β), 4.68 (d, 1H, $J = 11.7$ Hz, CHH Bn), 4.62 (d, 1H, $J = 12.0$ Hz, CHH Bn), 4.58 – 4.54 (m, 4H, 2xCH₂ Bn), 4.52 (d, 1H, $J = 11.8$ Hz, CHH Bn), 4.50 (d, 1H, $J = 11.8$ Hz, CHH Bn), 4.45 – 4.38 (m, 1H, H-4 α), 4.24 (dd, 1H, $J = 7.0$, 5.2 Hz, H-3 β), 4.16 (dt, 1H, $J = 5.2$, 3.0 Hz, H-4 β), 3.98 – 3.94 (m, 2H, H-2 α , OH β), 3.91 (ddd, 1H, $J = 4.3$, 2.6, 0.6 Hz, H-3 α), 3.80 (dd, 1H, $J = 6.9$, 4.5 Hz, H-2 β), 3.59 (dd, 1H, $J = 10.3$, 3.2 Hz, H-5 β), 3.60 – 3.50 (m, 2H, 2xH-5 α), 3.41 (dd, 1H, $J = 10.3$, 3.0 Hz, H-5 β), 3.30 (d, 1H, $J = 6.9$ Hz, OH α); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 137.9, 137.4, 136.9, 136.8 (C $_q$), 128.8, 128.7, 128.7, 128.6, 128.4, 128.3, 128.3, 128.1, 128.1, 128.1, 127.9 (CH_{arom}), 101.0 (C-1 α), 97.4 (C-1 β), 82.9 (C-3 α), 82.2 (C-4 α), 81.8 (C-4 β), 80.3 (C-3 β), 73.9, 73.6, 72.7, 72.6 (CH₂ Bn), 70.2 (C-2 α),


69.9 (C-5 β), 69.6 (C-5 α), 68.7 (C-2 β); ^{13}C HSQC-HECADE NMR (CDCl_3 , 126 MHz): α -anomer: $^2J_{\text{C}1,\text{H}2} = -2.2$ Hz, $^2J_{\text{C}2,\text{H}1} = -0.1$ Hz. β -anomer: $^2J_{\text{C}1,\text{H}2} = -2.1$ Hz, $^2J_{\text{C}2,\text{H}1} = +2.2$ Hz; HRMS: $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{19}\text{H}_{26}\text{N}_3\text{O}_4\text{Na}$ 378.14243, found 378.14248.




2-azido-3,5-di-O-benzyl-2-deoxy- α/β -D-ribofuranose (50). The title compound was generated from a 4:1 mixture of **23** and **27** by the general procedure for methyl furanoside hydrolysis, conditions A (65°C, 6 h). Combined yield: 89%, Yield of **42** was 70% over two steps (from **15**), α : β = 33:67 (0.29 mmol) as a colourless oil. IR (thin film): 696, 741, 1094, 1454, 2105, 2866, 3330; ^1H NMR (CDCl_3 , 400 MHz, HH-COSY, HSQC): δ 7.37 – 7.22 (m, 15H, CH_{arom}), 5.35 (bs, 0.5H, H-1 α), 5.23 (s, 1H, H-1 β), 4.68 – 4.58 (m, 2H, CH_2 Bn α , CHH Bn β), 4.53 (d, 1H, $J = 11.8$ Hz, CHH Bn β), 4.49 – 4.35 (m, 4.5H, $2\times\text{CHH}$ Bn β , CH_2 Bn α , H-3 β , H-4 α), 4.21 (dt, 1H, $J = 6.4, 3.1$ Hz, H-4 β), 4.13 (bs, 1H, 1-OH β), 4.09 (dd, 0.5H, $J = 5.4, 2.7$ Hz, H-3 α), 3.96 (bs, 0.5H, 1-OH α), 3.78 (d, 1H, $J = 5.1$ Hz, H-2 β), 3.66 (dd, 0.5H, $J = 5.4, 4.4$ Hz, H-2 α), 3.62 (dd, 1H, $J = 10.4, 2.9$ Hz, H-5 β), 3.49 – 3.40 (m, 1.5H, H-5 β , $2\times\text{H}-5\alpha$); ^{13}C -APT NMR (CDCl_3 , 101 MHz, HSQC): δ 137.6, 137.2, 137.0, 136.8 (C_q), 128.6, 128.6, 128.6, 128.5, 128.3, 128.2, 128.1, 128.0, 127.9, 127.7 (CH_{arom}), 100.8 (C-1 β), 97.6 (C-1 α), 81.6 (C-4 α), 80.9 (C-4 β), 78.8 (C-3 α), 78.4 (C-3 β), 73.6, 73.6, 73.1, 73.0 (CH_2 Bn), 69.6 (C-5 α), 69.3 (C-5 β), 65.9 (C-2 β), 62.1 (C-2 α); HRMS: $[\text{M}+\text{NH}_4]^+$ calcd for $\text{C}_{19}\text{H}_{25}\text{N}_4\text{O}_4$ 373.18703, found 373.18699.



2-azido-3,5-di-O-benzyl-2-deoxy- α/β -D-lyxofuranose (51). The title compound was generated from **24** (620 mg, 1.68 mmol) by the general procedure for methyl furanoside hydrolysis, conditions A (60°C, 18 h). Yield: 62% α : β = 60:40 (1.04 mmol) as a colourless oil. IR (thin film): 696, 734, 1026, 1070, 1269, 1454, 2110, 2868, 2924, 3400; ^1H NMR (CDCl_3 , 400 MHz, HH-COSY, HSQC): δ 7.37 – 7.28 (m, 10H, CH_{arom}), 5.45 (t, 0.6H, $J = 2.7$ Hz, H-1 α), 5.28 (dd, 0.4H, $J = 12.2, 4.6$ Hz, H-1 β), 4.80 (d, 0.4H, $J = 11.0$ Hz, CHH Bn β), 4.72 (d, 0.6H, $J = 11.7$ Hz, CHH Bn α), 4.65 (d, 0.4H, $J = 11.0$ Hz, CHH Bn β), 4.62 – 4.47 (m, 3.2H, CH_2 Bn α , CH_2 Bn β , CHH Bn α , H-4 α), 4.41 (t, 0.6H, $J = 5.5$ Hz, H-3 α), 4.22 (t, 0.4H, $J = 4.0$ Hz, H-3 β), 4.17 (ddd, 0.4H, $J = 7.2, 5.5, 3.8$ Hz, H-4 β), 3.84 – 3.76 (m, 1.4H, H-2 α , H-5 β , OH β), 3.74 – 3.67 (m, 1.6H, H-5 β , H-5 α , H-5 α), 3.63 (t, 0.4H, $J = 4.4$ Hz, H-2 β), 3.06 (d, 0.6H, $J = 3.1$ Hz, OH α); ^{13}C -APT NMR (CDCl_3 , 101 MHz, HSQC): δ 128.7, 128.6, 128.6, 128.5, 128.5, 128.4, 128.2, 128.1, 128.0, 127.8 (CH_{arom}), 99.8 (C-1 α), 97.3 (C-1 β), 79.6 (C-4 α), 79.0 (C-3), 78.5, 78.4 (C-3 β , C-4 β), 75.0, 74.0, 73.9, 73.7 (CH_2 Bn), 69.4 (C-5 α), 68.8 (C-5 β), 66.6 (C-2 α), 63.0 (C-2 β); HRMS: $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{19}\text{H}_{21}\text{N}_3\text{O}_4\text{Na}$ 378.14243, found 378.14233.




2-azido-3,5-di-O-benzyl-2-deoxy- α/β -D-xylofuranose (52). Selenoglycoside **36** (360 mg, 0.72 mmol, 1 eq.) was dissolved in THF/H $_2$ O/acetone (3/2/3 v/v/v, 8 mL) and cooled to 0°C, followed by addition of NIS (180 mg, 0.8 mmol, 1.1 eq.). After 1 h the reaction mixture was quenched by addition of 10% $\text{Na}_2\text{S}_2\text{O}_3$, diluted with H $_2$ O and extracted with DCM three times. The combined organic layer was washed with brine, dried (MgSO_4), filtered and concentrated *in vacuo*. Purification by flash column chromatography (19/1 to 8/2 pentane/EtOAc) gave the title compound as a colourless oil (222 mg, 0.62 mmol, 87%). IR (thin film): 696, 737, 1053, 1255, 1454, 2102, 2866, 2924, 3390; ^1H NMR (CDCl_3 , 400 MHz, HH-COSY, NOESY, HSQC): δ 7.37 – 7.25 (m, 20H, CH_{arom}), 5.48 (dd, 1H, $J = 5.4, 4.6$ Hz, H-1 α), 5.15 (dd, 1H, $J = 11.4, 1.7$ Hz, H-1 β), 4.66 (d, 1H, $J = 11.7$ Hz, CHH Bn), 4.65 (d, 1H, $J = 11.8$ Hz, CHH Bn), 4.61 (d, 1H, $J = 11.7$ Hz, CHH Bn), 4.59 – 4.54 (m, 4H, CHH Bn, $3\times\text{CHH}$ Bn), 4.52 (d, 1H, $J = 12.0$ Hz, CHH Bn), 4.47 (td, 1H, $J = 6.1, 4.5$ Hz, H-4 α), 4.29 (dt, 1H, $J = 5.6, 4.5$ Hz, H-4 β), 4.23 (dd, 1H, $J = 5.9, 5.2$ Hz, H-3 α), 4.15 (d, 1H, $J = 11.4$ Hz, 1-OH β), 4.03 (dd, 1H, $J = 5.6, 3.7$ Hz, H-3 β), 3.99 (dd, 1H, $J = 4.1, 1.7$ Hz, H-2 β), 3.89 – 3.85 (m, 1H, H-2 α), 3.73 (dd, 1H, $J = 10.1, 4.7$ Hz, H-5 β), 3.70 (dd, 1H, $J = 10.1, 4.3$ Hz, H-5 β), 3.68 (dd, 1H, $J = 10.3, 4.6$ Hz, H-5 α), 3.61 (dd, 1H, $J = 10.3, 6.2$ Hz, H-5 α), 3.61 (d, 1H, $J = 5.6$ Hz, 1-OH α); ^{13}C -APT NMR (CDCl_3 , 101 MHz, HSQC): δ 137.9, 137.3, 136.9 (C_q), 128.7, 128.6, 128.5, 128.4, 128.1, 128.1, 128.0, 128.0, 127.9, 127.9, 127.8 (CH_{arom}), 101.2 (C-1 β), 96.2 (C-1 α), 81.6 (C-3 β), 80.8 (C-3 α), 79.5 (C-4 β), 77.1 (C-4 α), 73.9, 73.6, 73.2, 73.0 (CH_2 Bn), 70.5 (C-2 β), 68.8 (C-5 α), 68.5 (C-5 β), 66.9 (C-2 α); ^{13}C HSQC-HECADE NMR (CDCl_3 , 126 MHz): α -anomer: $^2J_{\text{C}1,\text{H}2} = -0.5$ Hz, $^2J_{\text{C}2,\text{H}1} = +3.9$ Hz, β -anomer: $^2J_{\text{C}1,\text{H}2} = -2.4$ Hz, $^2J_{\text{C}2,\text{H}1} = -0.2$ Hz; As additional confirmation of the xylo-configuration: α -anomer: $^2J_{\text{C}2,\text{H}3} = -2.8$ Hz, $^2J_{\text{C}3,\text{H}2} = -5.0$ Hz, β -anomer: $^2J_{\text{C}2,\text{H}3} = -3.3$ Hz, $^2J_{\text{C}3,\text{H}2} = -4.6$ Hz). HRMS: $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{19}\text{H}_{21}\text{N}_3\text{O}_4\text{Na}$ 378.14243, found 378.14235.




Methyl (2,3-di-O-benzyl- α/β -D-arabinofuranosyl uronate) (53). The title compound was generated from **41** (11.9 g, 32 mmol) by the general procedure for methyl furanoside hydrolysis, conditions B (8 h). Yield: 60% α : β = 2:1 (6.87 g, 19.2 mmol) as a yellow oil. Rf: 0.38 (7/3 pentane/EtOAc). IR (thin film): 698, 739, 1028, 1076, 1090, 1207, 1454, 1740. Data for the α -anomer: ^1H NMR (CDCl_3 , 400 MHz, HH-COSY, HSQC): δ 7.40 – 7.22 (m, 10H, CH_{arom}), 5.51 (d, 1H, $J = 10.2$ Hz, H-1), 4.86 (d, 1H, $J = 1.7$ Hz, H-4),

4.70 (d, 1H, $J = 11.8$ Hz, *CHH* Bn), 4.59 (d, 1H, $J = 11.8$ Hz, *CHH* Bn), 4.53 (d, 1H, $J = 11.7$ Hz, *CHH* Bn), 4.46 (d, 1H, $J = 11.7$ Hz, *CHH* Bn), 4.38 – 4.34 (m, 1H, H-3), 3.94 (d, 1H, $J = 0.9$ Hz, H-2), 3.69 (s, 3H, CH₃ CO₂Me), 3.41 (d, 1H, $J = 10.3$ Hz, OH); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 170.5 (C=O), 137.1, 136.7 (C_q), 128.6, 128.5, 128.4, 128.0, 127.7 (CH_{arom}), 102.1 (C-1), 84.6 (C-2), 84.1 (C-3), 81.1 (C-4), 72.3, 71.6 (CH₂ Bn), 52.4 (CH₃ CO₂Me); Data for the β-anomer: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.40 – 7.22 (m, 10H, CH_{arom}), 5.55 (dd, 1H, $J = 10.0$, 3.9 Hz, H-1), 4.66 (d, 1H, $J = 11.9$ Hz, *CHH* Bn), 4.57 – 4.54 (m, 1H, *CHH* Bn), 4.53 (d, 1H, $J = 2.2$ Hz, H-4), 4.38 – 4.34 (m, 1H, H-3), 3.91 (dd, 1H, $J = 3.9$, 2.7 Hz, H-2), 3.85 (d, 1H, $J = 10.0$ Hz, OH), 3.72 (s, 3H, CH₃ CO₂Me); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 171.8 (C=O), 137.2, 136.9 (C_q), 128.5, 128.2, 128.2, 128.0, 127.9, 127.8 (CH_{arom}), 98.2 (C-1), 84.2 (C-3), 81.5 (C-2), 79.7 (C-4), 72.7, 72.1 (CH₂ Bn), 52.5 (CH₃ CO₂Me); HRMS: [M+NH₄]⁺ calcd for C₂₀H₂₆NO₆ 376.17546, found 376.17566.




Methyl (2,3-di-O-benzyl-α/β-D-ribofuranosyl uronate) (54). The title compound was generated from **42** (8.33 g, 22.38 mmol) by the general procedure for methyl furanoside hydrolysis, conditions B (7.5 h). Yield: 73% α:β = 1.1:1 (5.87 g, 16.4) as a colourless oil. Rf: 0.54 (7/3 pentane/EtOAc). IR (thin film): 698, 739, 1026, 1070, 1209, 1358, 1454, 1740, 2870, 2951, 3030,

3441; Data for the α-anomer: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.40 – 7.25 (m, 10H, CH_{arom}), 5.45 (dd, 1H, $J = 11.1$, 4.3 Hz, H-1), 4.82 – 4.44 (m, 5H, 2xCH₂Bn, H-4), 4.19 (d, 1H, $J = 11.5$ Hz, OH), 4.16 – 4.06 (m, 1H, H-3), 3.89 (d, 1H, $J = 4.5$ Hz, H-2), 3.71 (d, 3H, $J = 4.2$ Hz, CH₃ CO₂Me); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 170.6 (C=O), 137.11, 136.74 (C_q), 128.5 – 127.9 (CH_{arom}), 96.8 (C-1), 80.2 (C-2), 79.1 (C-4), 77.5 (C-3), 72.5, 72.4 (CH₂Bn), 52.6 (CH₃ CO₂Me); Data for the β-anomer: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.40 – 7.25 (m, 10H, CH_{arom}), 5.55 (s, 1H, H-1), 5.07 – 4.88 (m, 1H, OH), 4.78, (d, $J = 1.4$ Hz, H-4), 4.82 – 4.44 (m, 4H, 2xCH₂Bn), 4.38 (dd, 1H, $J = 6.5$, 4.5 Hz, H-3), 3.93 (t, 1H, $J = 4.6$ Hz, H-2), 3.71 (d, 3H, $J = 4.2$ Hz, CH₃ CO₂Me); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 173.3 (C=O), 137.6, 137.4 (C_q), 128.5 – 127.9 (CH_{arom}), 101.1 (C-1), 80.4 (C-3), 80.2 (C-2), 79.7 (C-4), 73.0, 72.7 (CH₂Bn), 52.6 (CH₃ CO₂Me); HRMS: [M+Na]⁺ calcd for C₂₀H₂₂O₆Na 381.13086, found 381.13084.




Methyl (2,3-di-O-benzyl-β-D-lyxofuranosyl uronate) (55). The title compound was generated from **43** (1.0 g, 2.7 mmol) by the general procedure for methyl furanoside hydrolysis, conditions B (6 h). Yield: 85% β only (818 mg, 2.28 mmol) as a white solid. Rf: 0.35 (1/1 pentane/EtOAc). IR (thin film): 698, 739, 1026, 1065, 1141, 1211, 1360, 1437, 1454, 1738, 1763, 2874, 2951, 3466. ¹H

NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.43 – 7.22 (m, 10H, CH_{arom}), 5.40 (dd, 1H, $J = 12.6$, 4.3 Hz, H-1), 4.85 (d, 1H, $J = 11.2$ Hz, *CHH* Bn), 4.80 (d, 1H, $J = 11.6$ Hz, *CHH* Bn), 4.63 – 4.59 (m, 3H, 2xCH₂Bn, H-4), 4.37 (t, 1H, $J = 4.4$ Hz, H-3), 4.33 (d, 1H, $J = 12.6$ Hz, OH), 3.91 (t, 1H, $J = 4.2$ Hz, H-2), 3.73 (s, 3H, CH₃ OMe); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 169.5 (C=O), 137.3, 137.2 (C_q), 128.7, 128.5, 128.2, 128.2, 128.1, 127.9 (CH_{arom}), 97.0 (C-1), 78.8 (C-4), 78.5, 78.4 (C-2, C-3), 74.8, 72.2 (CH₂ Bn), 52.4 (CH₃ CO₂Me); HRMS: [M+Na]⁺ calcd for C₂₀H₂₂O₆Na 376.17546, found 376.17580.



Methyl (2,3-di-O-benzyl-α/β-D-xylofuranosyl uronate) (56). The title compound was generated from **44** (17.7 g, 47.6 mmol) by the general procedure for methyl furanoside hydrolysis, conditions B (4 h). Yield: 90% α:β = 1:1.3 (15.3 mg, 42.7 mmol) as a light yellow oil. Rf: 0.2 (8/2 pentane/EtOAc). IR (thin film): 698, 739, 1028, 1061, 1072, 1209, 1366, 1437, 1454, 1738, 1759,


2951, 3030, 3430; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.45 – 7.21 (m, 17.5H, CH_{arom}), 5.65 (dd, 0.75H, $J = 10.1$, 4.0 Hz, H-1_α), 5.39 (d, 1H, $J = 11.3$ Hz, H-1_β), 4.90 (d, 1H, $J = 5.9$ Hz, H-4_β), 4.83 (d, 0.75H, $J = 5.2$ Hz, H-4_α), 4.61 – 4.49 (m, 7H, CH₂ Bn), 4.28 (ddd, 1H, $J = 5.9$, 2.4, 0.8 Hz, H-3_β), 4.25 (ddd, 1H, $J = 5.2$, 2.5, 0.4 Hz, H-3_α), 4.00 (d, 1H, $J = 11.6$ Hz, 1-OH_β), 4.00 (dt, 1H, $J = 2.4$, 0.8 Hz, H-2_β), 3.94 (dd, 0.75H, $J = 3.9$, 2.6 Hz, H-2_α), 3.84 (d, 0.75H, $J = 10.1$ Hz, 1-OH_α), 3.77 (s, 3H, CH₃ CO₂Me_β), 3.74 (s, 2.25H, CH₃ CO₂Me_α); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 171.2, 169.7 (C=O), 137.1, 136.7 (C_q), 128.7, 128.6, 128.5, 128.5, 128.3, 128.1, 128.1, 127.9, 127.8 (CH_{arom}), 102.8 (C-1_β), 97.4 (C-1_α), 85.2 (C-2_β), 82.1 (C-3_β), 81.7 (C-3_α), 80.8 (C-4_β), 80.4 (C-2_α), 77.9 (C-4_α), 73.2, 73.0, 72.8, 72.1 (CH₂ Bn), 52.5 (CO₂Me_β), 52.1 (CO₂Me_α); HRMS: [M+NH₄]⁺ calcd for C₂₀H₂₆NO₆ 376.17546, found 376.17564.



Acetyl 2-azido-3,5-di-O-benzyl-2-deoxy-α/β-D-arabinofuranoside (57). The title compound was generated from **49** (107 mg, 0.3 mmol) by the general procedure for acetyl donor synthesis.


Yield: 90% α:β = 2.3:1 ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.41 – 7.22 (m, 10H, CH_{arom}), 6.24 (d, 0.3H, $J = 4.6$ Hz, H-1_β), 6.11 (d, 0.7H, $J = 1.0$ Hz, H-1_α), 4.71 – 4.47 (m, 4H, 4xCH₂ Bn_{αβ}), 4.33 (dt, 0.7H, $J = 5.8$, 4.5 Hz, H-4_α), 4.25 – 4.15 (m, 0.6H, H-3_β, H-4_β), 4.05 (dd, 0.7H, $J = 3.1$, 1.3 Hz, H-2_α), 3.95 (ddd, 1H, $J = 10.3$, 6.8, 3.9 Hz, H-2_β, H-3_α), 3.63 – 3.55 (m, 1.4H, H-5_α), 3.53 (dd, 0.6H, $J = 4.7$, 1.9 Hz, H-5_β); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 169.8, 169.4 (C=O), 137.8, 137.7, 137.3, 137.1 (C_q), 128.5, 128.5, 128.4, 128.1, 128.1, 127.9, 127.8, 127.8, 127.7,

127.6 (CH_{arom}), 100.4 (C-1 β), 95.2 (C-1 α), 83.4 (C-4 β), 83.0 (C-3 β), 82.1 (C-4 α), 80.4 (C-3 α), 73.5, 73.3, 72.8, 72.6 (CH₂ Bn), 70.5 (C-2 β), 70.3 (C-5 α), 68.7 (C-5 β), 66.4 (C-2 α), 21.1, 21.0 (CH₃ OAc); HRMS: [M+Na]⁺ calcd for C₁₉H₂₁N₃O₄Na 378.1424, found 378.1425.




Methyl (acetyl 2,3-di-O-benzyl- α/β -D-arabinofuranosyl uronate) (58). The title compound was generated from **53** (5.20 g, 14.5 mmol) by the general procedure for acetyl donor synthesis. Yield: 91% $\alpha:\beta$ = 6.7:1 (5.29 g, 13.2 mmol) as a light yellow oil. Rf: 0.80 (7/3 pentane/EtOAc). IR (thin film): 698, 1011, 1223, 1371, 1454, 1734, 1749, 2872, 2951, 3030. Data for the α -anomer:

¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.39 – 7.26 (m, 8.5H, CH_{arom}), 6.36 (s, 0.85H, H-1), 4.76 (d, 0.85H, *J* = 3.9 Hz, H-4), 4.62 (d, 0.85H, *J* = 12.0 Hz, CHH Bn), 4.62 (d, 0.85H, *J* = 12.0 Hz, CHH Bn), 4.54 (d, 0.85H, *J* = 12.0 Hz, CHH Bn), 4.49 (d, 0.85H, *J* = 12.1 Hz, CHH Bn), 4.25 (ddd, 0.85H, *J* = 3.9, 1.4, 0.7 Hz, H-3), 4.04 (dd, 0.85H, *J* = 1.4, 0.5 Hz, H-2), 3.74 (s, 2.55H, CH₃ CO₂Me), 2.08 (s, 2.55H, CH₃ OAc); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 169.8, 169.7 (C=O), 137.2, 137.0 (C_q), 128.5, 128.1, 127.9, 127.9 (CH_{arom}), 100.7 (C-1), 85.3 (C-2), 85.0 (C-3), 82.8 (C-4), 72.2, 72.0 (CH₂ Bn), 52.6 (CH₃ CO₂Me), 21.2 (OAc); Data for the β -anomer: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.37 – 7.26 (m, 1.5H, CH_{arom}), 6.24 (d, 0.15H, *J* = 4.3 Hz, H-1), 4.75 (d, 0.15H, *J* = 11.7 Hz, CHH Bn), 4.68 (d, 0.15, *J* = 11.8 Hz, CHH Bn), 4.57 – 4.46 (m, 0.6H, CH₂ Bn, H-3, H-4), 4.18 (dd, 0.15H, *J* = 6.4, 4.2 Hz, H-2), 3.76 (s, 0.45H, CH₃ CO₂Me), 2.07 (s, 0.45H, CH₃ OAc); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 170.9, 170.0 (C=O), 137.5, 137.1 (C_q), 128.6, 128.5, 128.5, 128.2, 128.0, 128.0 (CH_{arom}), 94.5 (C-1), 83.4 (C-3), 83.2 (C-2), 80.4 (C-4), 73.1, 72.8 (CH₂ Bn), 52.6 (CO₂Me), 21.2 (OAc); HRMS: [M+NH₄]⁺ calcd for C₂₂H₂₈NO₇ 418.18603, found 418.18598.




Methyl (acetyl 2,3-di-O-benzyl- β -D-ribofuranosyl uronate) (59). The title compound was generated from **54** (5.9 g, 16.4 mmol) by the general procedure for acetyl donor synthesis. Yield: 90% β only (5.9 g, 14.7 mmol) as a light yellow oil. Rf: 0.67 (7/3 pentane/EtOAc). IR (thin film):

698, 738, 959, 1013, 1094, 1138, 1209, 1371, 1454, 1749, 2870, 2951; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.40 – 7.30 (m, 10H, CH_{arom}), 6.24 (s, 1H, H-1), 4.73 (d, 1H, *J* = 12.1 Hz, CHH Bn), 4.69 (d, 1H, *J* = 6.7 Hz, H-4), 4.64 (d, 1H, *J* = 12.2 Hz, CHH Bn), 4.60 (d, *J* = 12.0 Hz, CHH Bn), 4.57 (d, 1H, *J* = 12.0 Hz, CHH Bn), 4.32 (dd, 1H, *J* = 6.7, 4.7 Hz, H-3), 3.94 (d, 1H, *J* = 4.6 Hz, H-2), 3.76 (s, 3H, CH₃ CO₂Me), 2.05 (s, 3H, CH₃ OAc); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 171.3 (C=O CO₂Me), 169.7 (C=O OAc), 137.3, 137.2 (C_q), 128.6, 128.6, 128.2, 128.1, 127.9 (CH_{arom}), 99.4 (C-1), 80.4 (C-4), 79.7 (C-3), 79.0 (C-2), 72.8, 72.6 (CH₂ Bn), 52.7 (CH₃ CO₂Me), 21.3 (CH₃ OAc); HRMS: [M+NH₄]⁺ calcd for C₂₂H₂₈NO₇ 418.18603, found 418.18605.




Methyl (acetyl 2,3-di-O-benzyl- α/β -D-xylofuranosyl uronate) (60). The title compound was generated from **56** (15.3 g, 42.7 mmol) by the general procedure for acetyl donor synthesis. Yield: 89% $\alpha:\beta$ = 1.3:1 (15.2 g, 38.1 mmol) as a light yellow oil. Rf: 0.60 and 0.73 (8/2 pentane/EtOAc). IR (thin film): 698, 739, 1016, 1026, 1098, 1211, 1369, 1454, 1748, 2872, 2951,

3030. ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.39 – 7.21 (m, 17.5H), 6.42 (d, 1H, *J* = 4.4 Hz, H-1 α), 6.24 (s, 0.75H, H-1 β), 4.95 (d, 0.75H, *J* = 5.8 Hz, H-4 β), 4.87 (d, 1H, *J* = 7.3 Hz, H-4 α), 4.66 – 4.48 (m, 7H, 2xCH₂ Bn α , 2xCH₂ Bn β), 4.47 – 4.43 (m, 1H, H-3 α), 4.30 (dd, 1H, *J* = 6.6, 4.4 Hz, H-2 α), 4.27 (ddd, 0.75H, *J* = 5.8, 1.5, 0.6 Hz, H-3 β), 4.08 (dt, 0.75H, *J* = 1.4, 0.7 Hz, H-2 β), 3.74 (s, 2.25H, CH₃ CO₂Me α), 3.73 (s, 3H, CH₃ CO₂Me β), 2.09 (s, 2.25H, CH₃ OAc α), 2.07 (s, 3H, CH₃ OAc β); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 170.3, 169.7, 169.2, 168.8 (C=O), 137.4, 137.2, 137.2, 137.0 (C_q), 128.6, 128.6, 128.5, 128.5, 128.2, 128.2, 128.0, 128.0, 127.9, 127.8, 127.6, 127.5 (CH_{arom}), 100.7 (C-1 β), 94.4 (C-1 α), 83.9 (C-2 β), 82.2 (C-4 β), 81.8 (C-2 α), 81.6 (C-3 β), 81.0 (C-3 α), 77.7 (C-4 α), 73.6, 73.1, 72.6, 72.2 (CH₂ Bn), 52.3 (C-5 α), 52.2 (C-5 β), 21.3 (OAc β), 21.2 (OAc α); HRMS: [M+NH₄]⁺ calcd for C₂₂H₂₈NO₇ 418.18603, found 418.18599.




1,5-Di-O-acetyl 2-azido-3-O-benzyl-2-deoxy- α/β -D-arabinofuranoside. (61). ¹H NMR (CDCl₃, 400


MHz, HH-COSY, HSQC, HMBC): δ 7.39 – 7.29 (m, 7.9H, CH_{arom}), 6.29 (d, 0.58H, *J* = 4.5 Hz, H-1 β), 6.11 (d, 1H, *J* = 1.2 Hz, H-1 α), 4.73 (d, 0.58H, *J* = 11.7 Hz, CHH Bn β), 4.69 – 4.61 (m, 1.58H, CHH Bn α , CHH Bn β), 4.57 (d, 1H, *J* = 11.8 Hz, CHH Bn α), 4.36 (td, 1H, *J* = 5.6, 3.4 Hz, H-4 α), 4.26 (dd, 1H, *J* = 12.2, 3.5 Hz, H-5 α), 4.23 – 4.19 (m, 0.58H, H-4 β), 4.17 – 4.04 (m, 3.74H, H-2 α , H-3 β , H-5 α , H-5 β , H-5 β), 3.99 (dd, 0.58H, *J* = 7.8, 4.6 Hz, H-2 β), 3.86 (dd, 1H, *J* = 6.2, 3.1 Hz, H-3 α), 2.09 (s, 1.74H, CH₃ OAc β), 2.09 (s, 3H, CH₃ OAc α), 2.05 (s, 1.74H, CH₃ OAc β), 2.02 (s, 3H, CH₃ OAc α); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC, HMBC): δ 170.4, 170.3, 169.6, 169.1 (C=O, Ac), 136.8, 136.7 (C_q Bn), 128.6, 128.2, 128.2, 127.8, 127.8 (CH_{arom}), 100.4 (C-1 α), 95.2 (C-1 β), 82.7 (C-3 α), 81.8 (C-4 α), 80.6 (C-4 β), 80.1 (C-3 β), 72.9 (CH₂ Bn β), 72.7 (CH₂ Bn α), 70.2 (C-2 α), 66.3 (C-2 β), 64.6 (C-5 β), 62.8 (C-5 α), 21.0, 21.0, 20.6, 20.6 (CH₃ OAc); ¹³C HSQC-HECADE NMR (CDCl₃, 126 MHz): α -anomer: ²J_{C1,H2} = -3.5 Hz, ²J_{C2,H3} = -0.5 Hz, β -anomer: ²J_{C1,H2} = -0.6 Hz, ²J_{C2,H3} = +1.9 Hz; HRMS: [M+Na]⁺ calcd for C₁₆H₁₉N₃O₆Na 372.11661, found 372.11664.




3,5-di-O-benzyl-2-deoxy-2-fluoro-1-O-(N-[phenyl]trifluoroacetimidoyl)- α/β -D-arabinofuranoside (62). The title compound was generated from **45** by the general procedure for imidate donor synthesis, conditions A. Yield: 85% $\alpha:\beta = 5:1$ as separate anomers (0.14 mmol and 0.60 mmol respectively) as colourless oils. Data for the α -anomer: $[\alpha]_D^{20} = +67.7^\circ$ ($c = 1.39$, CHCl_3); IR (thin film): 696, 933, 1101, 1153, 1159, 1207, 1327, 1454, 1714, 2866, 3032; $^1\text{H NMR}$ (CDCl_3 , $T = 323$ K, 500 MHz, HH-COSY, HSQC): δ 7.35 – 7.24 (m, 12H, CH_{arom}), 7.11 – 7.06 (m, 1H, NPh), 6.83 (d, 2H, $J = 7.5$ Hz, NPh), 6.37 (d, 1H, $J = 8.3$ Hz, H-1), 5.17 (dd, 1H, $J = 50.5$, 1.6 Hz, H-2), 4.65 (d, 1H, $J = 12.0$ Hz, CHH Bn), 4.61 – 4.55 (m, 2H, CHH Bn , CHH Bn), 4.53 (d, 1H, $J = 12.1$ Hz, CHH Bn), 4.44 (q, 1H, $J = 4.9$ Hz, H-4), 4.16 (dddd, 1H, $J = 23.1$, 5.8, 1.8, 0.9 Hz, H-3), 3.64 (d, 2H, $J = 4.7$ Hz, H-5, H-5); ^{13}C -APT NMR (CDCl_3 , $T = 323$ K, 126 MHz, HSQC): δ 143.8 (C_q NPh), 138.1, 137.4 (C_q Bn), 128.9, 128.7, 128.6, 128.2, 127.9, 127.9, 124.6, 119.8 (CH_{arom}), 116.2 (q, $J = 286.8$ Hz, CF_3), 102.7 (d, $J = 38.8$ Hz, C-1), 98.9 (d, $J = 184.9$ Hz, C-2), 84.3 (d, $J = 3.4$ Hz, C-4), 82.9 (d, $J = 25.7$ Hz, C-3), 73.8, 72.8 (CH_2 Bn), 69.2 (C-5); ^{19}F NMR (CDCl_3 , $T = 323$ K, 471 MHz, HH-COSY, HSQC): δ -66.34 (bs, 3F, CF_3), -188.59 (ddd, 1F, $J = 50.5$, 23.1, 11.0 Hz, F-2); Data for the β -anomer: $[\alpha]_D^{20} = -43.0^\circ$ ($c = 0.6$, CHCl_3); IR (thin film): 696, 1026, 1072, 1092, 1153, 1159, 1207, 1319, 1717, 2864; $^1\text{H NMR}$ (CDCl_3 , $T = 323$ K, 500 MHz, HH-COSY, HSQC): δ 7.35 – 7.24 (m, 12H, CH_{arom}), 7.10 – 7.05 (m, 1H, NPh), 6.80 (dd, 2H, $J = 8.4$, 1.1 Hz, NPh), 6.46 (bs, 1H, H-1), 5.17 (ddd, 1H, $J = 52.0$, 5.8, 4.5 Hz, H-2), 4.69 (d, 1H, $J = 11.7$ Hz, CHH Bn), 4.60 (d, 1H, $J = 11.8$ Hz, CHH Bn), 4.57 (d, 1H, $J = 12.1$ Hz, CHH Bn), 4.54 (d, 1H, $J = 12.1$ Hz, CHH Bn), 4.32 (dt, 1H, $J = 16.7$, 5.9 Hz, H-3), 4.25 (q, 1H, $J = 5.7$ Hz, H-4), 3.63 (dd, 1H, $J = 10.4$, 5.6 Hz, H-5), 3.60 (dd, 1H, $J = 10.5$, 5.5 Hz, H-5); ^{13}C -APT NMR (CDCl_3 , $T = 323$ K, 126 MHz, HSQC): δ 143.8 (C_q NPh), 138.1, 137.5 (C_q Bn), 128.9, 128.6, 128.6, 128.1, 127.9, 127.9, 124.4, 119.7 (CH_{arom}), 116.1 (q, $J = 285.9$ Hz, CF_3), 96.9 (d, $J = 18.1$ Hz, C-1), 95.1 (d, $J = 201.9$ Hz, C-2), 81.9 (d, $J = 9.0$ Hz, C-4), 81.2 (d, $J = 21.4$ Hz, C-3), 73.7, 72.7 (CH_2 Bn), 70.9 (C-5); ^{19}F NMR (CDCl_3 , $T = 323$ K, 471 MHz, HH-COSY, HSQC): δ -66.45 (bs, 3F, CF_3), -203.20 (dd, 1F, $J = 52.1$, 16.7 Hz, F-2); HRMS: $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{27}\text{H}_{26}\text{F}_4\text{NO}_4$ 504.17925, found 504.17933.



3,5-di-O-benzyl-2-deoxy-2-fluoro-1-O-(N-[phenyl]trifluoroacetimidoyl)- α/β -D-ribofuranoside (63). The title compound was generated from **46** by the general procedure for imidate donor synthesis, conditions A. Yield: 98% β only (0.45 mmol) as a white solid, includes ~10% acetamide. IR (thin film): 694, 1092, 1151, 1207, 1712, 2869; $^1\text{H NMR}$ (CDCl_3 , $T = 328$ K, 400 MHz, HH-COSY, HSQC): δ 7.36 – 7.21 (m, 12H, CH_{arom}), 7.11 – 7.04 (m, 1H, NPh), 6.79 (d, 2H, $J = 8.2$ Hz, NPh), 6.36 (d, 1H, $J = 9.1$ Hz, H-1), 4.95 (dd, 1H, $J = 52.3$, 3.5 Hz, H-2), 4.66 (d, 1H, $J = 11.6$ Hz, CHH Bn), 4.60 – 4.49 (m, 3H, CH_2 Bn, CHH Bn), 4.38 (dt, 1H, $J = 7.6$, 3.9 Hz, H-4), 4.24 (dddd, 1H, $J = 23.6$, 7.6, 3.6 Hz, H-3), 3.69 (dd, 1H, $J = 11.1$, 3.1 Hz, H-5), 3.58 (dd, 1H, $J = 11.1$, 4.4 Hz, H-5); ^{13}C -APT NMR (CDCl_3 , $T = 328$ K, 101 MHz, HSQC): δ 143.6 (C_q NPh), 138.2, 137.3 (C_q Bn), 129.4, 128.8, 128.6, 128.5, 128.2, 128.0, 127.8, 127.7, 124.6, 119.6 (CH_{arom}), 116.0 (q, $J = 286.1$ Hz, CF_3), 101.2 (d, $J = 32.4$ Hz, C-1), 91.0 (d, $J = 188.6$ Hz, C-2), 82.0 (C-4), 77.0 (d, $J = 15.7$ Hz, C-3), 73.5, 73.2 (CH_2 Bn), 69.7 (C-5); ^{19}F NMR (CDCl_3 , $T = 298$ K, 471 MHz): δ -65.81 (bs, 3F, CF_3), -209.42 (ddd, 1F, $J = 52.3$, 23.9, 9.4 Hz); HRMS: $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{27}\text{H}_{26}\text{F}_4\text{NO}_4$ 504.17925, found 504.17889.




3,5-di-O-benzyl-2-deoxy-2-fluoro-1-O-(N-[phenyl]trifluoroacetimidoyl)- α/β -D-lyxofuranoside (64). The title compound was generated from **47** by the general procedure for imidate donor synthesis, conditions A. Yield: 82% α only (0.54 mmol) as a colourless oil. $[\alpha]_D^{20} = +50.2^\circ$ ($c = 1.30$, CHCl_3); IR (thin film): 694, 737, 931, 1086, 1097, 1150, 1207, 1321, 1715, 2872, 3032; $^1\text{H NMR}$ (CDCl_3 , $T = 323$ K, 500 MHz, HH-COSY, HSQC): δ 7.36 – 7.22 (m, 12H, CH_{arom}), 7.11 – 7.04 (m, 1H, NPh), 6.82 (d, 2H, $J = 7.5$ Hz, NPh), 6.41 (bs, 1H, H-1), 5.02 (dd, 1H, $J = 51.7$, 3.8 Hz, H-2), 4.69 (d, 1H, $J = 11.6$ Hz, CHH Bn), 4.60 – 4.53 (m, 3H, CHH Bn , CHH Bn , H-4), 4.50 (d, 1H, $J = 12.0$ Hz, CHH Bn), 4.34 (ddd, 1H, $J = 17.6$, 6.4, 4.3 Hz, H-3), 3.83 (dd, 1H, $J = 10.7$, 4.5 Hz, H-5), 3.68 (dd, 1H, $J = 9.8$, 7.3 Hz, H-5); ^{13}C -APT NMR (CDCl_3 , 126 MHz, HSQC): δ 143.6 (C_q NPh), 142.9 (q, $J = 36.4$ Hz, $\text{F}_3\text{CC}=\text{N}$), 138.3, 137.4 (C_q Bn), 128.9, 128.6, 128.5, 128.2, 127.9, 127.7, 124.6, 119.7 (CH_{arom}), 116.2 (q, $J = 285.9$ Hz, CF_3), 101.3 (d, $J = 33.4$ Hz, C-1), 92.6 (d, $J = 192.3$ Hz, C-2), 80.2 (C-4), 76.6 (d, $J = 15.0$ Hz, C-3), 73.7, 73.7 (CH_2 Bn), 69.5 (C-5); ^{19}F NMR (CDCl_3 , $T = 323$ K, 471 MHz): δ -66.49 (bs, 3F, CF_3), -207.43 (ddd, 1F, $J = 51.8$, 17.6, 9.5 Hz, C2-F); HRMS: $[\text{2M}+\text{NH}_4]^+$ calcd for $\text{C}_{54}\text{H}_{54}\text{F}_8\text{N}_8\text{O}_8$ 1024.37777, found 1024.37849.




3,5-di-O-benzyl-2-deoxy-2-fluoro-1-O-(N-[phenyl]trifluoroacetimidoyl)- α/β -D-dylofuranoside (65). The title compound was generated from **48** by the general procedure for imidate donor synthesis, conditions A. Yield: 91% $\alpha:\beta = 37:63$ (0.36 mmol) as a colourless oil. IR (thin film): 694, 1086, 1153, 1207, 1323, 1715; $^1\text{H NMR}$ (CDCl_3 , $T = 323$ K, 500 MHz, HH-COSY, HSQC): δ 7.35 – 7.22 (m, 12H, CH_{arom}), 7.11 – 7.04 (m, 1H, NPh), 6.84 – 6.78 (m, 2H, NPh), 6.46 (bs, 0.37H, H-1 α), 6.34 (d, 0.63H, $J = 12.5$ Hz, H-1 β), 5.23 (dt, 0.37H, $J = 51.9$, 4.0 Hz, H-2 α), 5.18 (dd, 0.63H, $J = 49.8$, 1.6 Hz, H-2 β), 4.71 (d, 0.37H, $J = 11.8$ Hz, $\text{CHH Bn}\alpha$), 4.68 – 4.50 (m, 3.63H, $\text{CHH Bn}\alpha$, CH_2 Bn α , 2 \times CH_2 Bn β , H-4 α , H-4 β), 4.41 (ddd, 0.37H, $J = 15.7$, 6.5, 4.8 Hz, H-3 α), 4.26


(ddd, 0.63H, $J = 16.2, 5.8, 1.6$ Hz, H-3 β), 3.85 (dd, 0.63H, $J = 10.5, 5.4$ Hz, H-5 β), 3.75 (dd, 0.63H, $J = 10.4, 6.6$ Hz, H-5 β), 3.72 (dd, 0.37H, $J = 10.7, 4.5$ Hz, H-5 α), 3.65 (dd, 0.37H, $J = 10.6, 5.0$ Hz, H-5 α); ^{13}C -APT NMR (CDCl_3 , $T = 323\text{K}$, 126 MHz, HSQC): δ 143.9, 143.8 (C_q NPh), 138.4, 138.2, 137.4, 137.4 (C_q Bn), 128.9, 128.9, 128.7, 128.5, 128.5, 128.2, 128.1, 127.8, 127.8, 127.8, 127.6, 124.5, 124.4, 119.7 (CH_{arom}), 116.1 (q, $J = 286.3$ Hz, CF_3), 102.1 (d, $J = 37.5$ Hz, H-1 β), 97.0 (d, $J = 16.8$ Hz, H-1 α), 97.0 (d, $J = 184.5$ Hz, H-2 β), 94.1 (d, $J = 200.0$ Hz, H-2 α), 83.1 (C-4 β), 80.5 (d, $J = 25.6$ Hz, C-3 β), 79.9 (d, $J = 22.9$ Hz, C-3 α), 79.0 (d, $J = 6.8$ Hz, C-4 α), 73.8 (CH_2 Bn α), 73.7, 73.2 (CH_2 Bn β), 72.9 (CH_2 Bn α), 68.9 (C-5 β), 68.2 (C-5 α); ^{19}F NMR (CDCl_3 , $T = 323$ K, 471 MHz): δ -66.32 (s, 3F, CF_3), -193.57 (dt, 0.63F, $J = 49.8, 14.1$ Hz, F-2 β), -202.33 (dd, 0.37F, $J = 52.1, 15.6$ Hz, F-2 α); HRMS: $[\text{2M}+\text{NH}_4]^+$ calcd for $\text{C}_{54}\text{H}_{54}\text{F}_8\text{N}_3\text{O}_8$ 1024.37777, found 1024.37842.



2-azido-3,5-di-O-benzyl-2-deoxy-1-O-(N-[phenyl]trifluoroacetimidoyl)- α/β -D-arabinofuranoside (66). The title compound was generated from **49** by the general procedure for imidate donor synthesis, conditions B. Yield: 71% $\alpha:\beta = 1.6:1$ as separate anomers (0.31 mmol and 0.19 mmol respectively) as colourless oils. Data for the α -anomer: $[\alpha]_{\text{D}}^{20} = +5.4^\circ$ ($c = 0.50$, CHCl_3); IR (thin film): 696, 929, 1103, 1161, 1207, 1329, 1456, 1700, 1717, 2106, 2866, 3032; ^1H NMR (CDCl_3 , $T = 323$ K, 500 MHz, HH-COSY, HSQC): δ 7.38 – 7.22 (m, 12H, CH_{arom}), 7.08 (t, 1H, $J = 7.5$ Hz, NPh), 6.82 (d, 2H, $J = 7.7$ Hz, NPh), 6.18 (bs, 1H, H-1), 4.63 – 4.56 (m, 2H, CH_2 Bn), 4.56 (d, 1H, $J = 12.1$ Hz, CHH Bn), 4.51 (d, 1H, $J = 12.1$ Hz, CHH Bn), 4.42 (q, 1H, $J = 4.6$ Hz, H-4), 4.17 (d, 1H, $J = 2.2$ Hz, H-2), 4.00 (dd, 1H, $J = 6.0, 3.1$ Hz, H-3), 3.64 (dd, 1H, $J = 11.0, 4.2$ Hz, H-5), 3.61 (dd, 1H, $J = 11.0, 4.8$ Hz, H-5); ^{13}C -APT NMR (CDCl_3 , $T = 323$ K, 126 MHz, HSQC): δ 143.7 (C_q NPh), 138.0, 137.4 (C_q Bn), 128.9, 128.7, 128.5, 128.2, 127.9, 127.9, 127.9, 124.6, 119.8 (CH_{arom}), 116.1 (q, $J = 286.7$ Hz, CF_3), 104.0 (C-1), 84.2 (C-4), 83.4 (C-3), 73.7, 73.0 (CH_2 Bn), 70.8 (C-5), 68.9 (C-2); HRMS: $[\text{2M}+\text{NH}_4]^+$ calcd for $\text{C}_{54}\text{H}_{54}\text{F}_8\text{N}_3\text{O}_8$ 1070.39941, found 1070.40019. Data for the β -anomer: $[\alpha]_{\text{D}}^{20} = -56.1^\circ$ ($c = 1.30$, CHCl_3); IR (thin film): 696, 1024, 1094, 1144, 1161, 1207, 1317, 1713, 2110, 2864; ^1H NMR (CDCl_3 , $T = 323$ K, 500 MHz, HH-COSY, HSQC): δ 7.36 – 7.22 (m, 12H, CH_{arom}), 7.12 – 7.03 (m, 1H, NPh), 6.81 (d, 2H, $J = 7.5$ Hz, NPh), 6.43 (bs, 1H, H-1), 4.67 (d, 1H, $J = 11.7$ Hz, CHH Bn), 4.63 (d, 1H, $J = 11.7$ Hz, CHH Bn), 4.59 – 4.52 (m, 2H, CH_2 Bn), 4.26 (q, 1H, $J = 5.6$ Hz, H-4), 4.21 (dd, 1H, $J = 7.5, 6.0$ Hz, H-3), 4.04 (dd, 1H, $J = 7.5, 4.5$ Hz, H-2), 3.63 – 3.53 (m, 2H, H-5); ^{13}C -APT NMR (CDCl_3 , $T = 323$ K, 126 MHz, HSQC): δ 143.8 (C_q NPh), 138.0, 137.5 (C_q Bn), 128.9, 128.7, 128.6, 128.2, 128.0, 127.9, 127.9, 124.5, 119.6 (CH_{arom}), 116.1 (d, $J = 286.6$ Hz, CF_3), 98.6 (C-1), 82.9 (C-4), 81.5 (C-3), 73.7, 73.1 (CH_2 Bn), 70.9 (C-5), 67.4 (C-2); HRMS: $[\text{M}+\text{NH}_4]^+$ calcd for $\text{C}_{27}\text{H}_{25}\text{F}_3\text{N}_3\text{O}_4$ 544.21662, found 544.21623.




2-azido-3,5-di-O-benzyl-2-deoxy-1-O-(N-[phenyl]trifluoroacetimidoyl)- α/β -D-ribofuranoside (67). The title compound was generated from **50** by the general procedure for imidate donor synthesis, conditions A. Yield: 77% $\alpha:\beta = 1:8$ as separate anomers (0.085 mmol and 0.69 mmol respectively) as a white solid. Data for the α -anomer: $[\alpha]_{\text{D}}^{20} = +52.4^\circ$ ($c = 0.46$, CHCl_3); IR (thin film): 696, 1101, 1144, 1161, 1207, 1319, 1713, 2114, 2864; ^1H NMR (CDCl_3 , 500 MHz, HH-COSY, HSQC): δ 7.36 – 7.25 (m, 10H, CH_{arom}), 7.25 – 7.21 (m, 2H, CH_{arom}), 7.11 – 7.05 (m, 1H, NPh), 6.87 (d, 2H, $J = 7.7$ Hz, NPh), 6.45 (bs, 1H, H-1), 4.74 (d, 1H, $J = 12.2$ Hz, CHH Bn), 4.61 (d, 1H, $J = 12.2$ Hz, CHH Bn), 4.49 (d, 1H, $J = 12.0$ Hz, CHH Bn), 4.45 – 4.40 (m, 2H, CHH Bn, H-4), 4.18 (dd, 1H, $J = 6.6, 3.1$ Hz, H-3), 3.63 – 3.58 (m, 1H, H-2), 3.51 (dd, 1H, $J = 10.8, 3.7$ Hz, H-5), 3.45 (dd, 1H, $J = 10.7, 3.3$ Hz, H-5); ^{13}C -APT NMR (CDCl_3 , 126 MHz, HSQC): δ 144.0 (C_q NPh), 137.8, 137.7 (C_q Bn), 128.9, 128.6, 128.6, 128.0, 127.8, 124.5, 119.9 (CH_{arom}), 99.9 (C-1), 84.8 (C-4), 78.3 (C-3), 73.9, 73.1 (CH_2 Bn), 69.6 (C-5), 61.4 (C-2); HRMS: $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{27}\text{H}_{25}\text{F}_3\text{N}_4\text{O}_4\text{Na}$ 549.17201, found 549.17174. Data for the β -anomer: $[\alpha]_{\text{D}}^{20} = -1.6^\circ$ ($c = 0.70$, CHCl_3); IR (thin film): 696, 1090, 1144, 1159, 1207, 1331, 1715, 2108, 2862; ^1H NMR (CDCl_3 , 500 MHz, HH-COSY, HSQC): δ 7.35 – 7.24 (m, 12H, CH_{arom}), 7.08 (t, 1H, $J = 7.4$ Hz, NPh), 6.80 (d, 2H, $J = 7.7$ Hz, NPh), 6.18 (bs, 1H, H-1), 4.64 (d, 1H, $J = 11.6$ Hz, CHH Bn), 4.58 (d, 1H, $J = 11.6$ Hz, CHH Bn), 4.56 (d, 1H, $J = 12.2$ Hz, CHH Bn), 4.53 (d, 1H, $J = 12.1$ Hz, CHH Bn), 4.39 (dd, 1H, $J = 7.0, 5.0$ Hz, H-3), 4.33 (dt, 1H, $J = 7.0, 4.3$ Hz, H-4), 4.03 (d, 1H, $J = 5.0$ Hz, H-2), 3.64 (dd, 1H, $J = 10.9, 4.0$ Hz, H-5), 3.57 (dd, 1H, $J = 10.9, 4.7$ Hz, H-5); ^{13}C -APT NMR (CDCl_3 , 126 MHz, HSQC): δ 143.7 (C_q NPh), 138.1, 137.2 (C_q Bn), 128.9, 128.7, 128.5, 128.3, 128.1, 127.8, 127.8, 124.6, 119.7 (CH_{arom}), 116.06 (q, $J = 286.0$ Hz, CF_3), 102.5 (C-1), 82.6 (C-4), 79.0 (C-3), 73.6, 73.6 (CH_2 Bn), 70.0 (C-5), 64.8 (C-2); HRMS: $[\text{2M}+\text{NH}_4]^+$ calcd for $\text{C}_{54}\text{H}_{54}\text{F}_6\text{N}_3\text{O}_8$ 1070.39941, found 1070.40023.




2-azido-3,5-di-O-benzyl-2-deoxy-1-O-(N-[phenyl]trifluoroacetimidoyl)- α/β -D-lyxofuranoside (68). The title compound was generated from **51** by the general procedure for imidate donor synthesis, conditions B. Yield: 67% $\alpha:\beta = 1:1.2$ (0.30 mmol and 0.37 mmol respectively) as colourless oils. Data for the α -anomer: $[\alpha]_{\text{D}}^{20} = -57.5^\circ$ ($c = 0.69$, CHCl_3); IR (thin film): 696, 1045, 1098, 1144, 1207, 1323, 1714, 2112, 2866, 2926; ^1H NMR (CDCl_3 , $T = 323$ K, 500 MHz, HH-COSY, HSQC): δ 7.37 – 7.22 (m, 12H, CH_{arom}), 7.11 – 7.03 (m, 1H, NPh), 6.82 (d, 2H, $J = 7.5$ Hz, NPh), 6.27 (bs, 1H, H-1), 4.71 (d, 1H, $J = 11.5$ Hz, CHH Bn), 4.59 (d, 1H, $J = 11.6$ Hz, CHH Bn), 4.56 (d, 1H, $J = 12.0$ Hz, CHH Bn), 4.53 – 4.47 (m, 2H, CHH Bn, H-4), 4.41 (t, 1H,


$J = 5.5$ Hz, H-3), 4.02 (dd, 1H, $J = 5.1, 1.9$ Hz, H-1), 3.81 (dd, 1H, $J = 10.4, 5.4$ Hz, H-5), 3.71 (dd, 1H, $J = 10.4, 6.5$ Hz, H-5); ^{13}C -APT NMR (CDCl_3 , $T = 323$ K, 126 MHz, HSQC): δ 143.7 (C_q NPh), 138.2, 137.2 (C_q Bn), 128.9, 128.7, 128.5, 128.2, 127.9, 127.9, 127.8, 124.6, 119.7 (CH_{arom}), 116.2 (q, $J = 286.9$ Hz, CF_3), 102.3 (C-1), 80.7 (C-4), 78.6 (C-3), 74.4, 73.7 (CH_2 Bn), 68.7 (C-5), 66.2 (C-2); HRMS: $[\text{M}+\text{NH}_4]^+$ calcd for $\text{C}_{27}\text{H}_{29}\text{F}_3\text{N}_5\text{O}_4$ 544.21662, found 544.21667. Data for the β -anomer: $[\alpha]_D^{20} = +24.9^\circ$ ($c = 0.68$, CHCl_3); IR (thin film): 696, 1094, 1144, 1153, 1207, 1319, 1717, 2110, 2926; ^1H NMR (CDCl_3 , $T = 323$ K, 500 MHz, HH-COSY, HSQC): δ 7.37–7.21 (m, 12H, CH_{arom}), 7.10–7.02 (m, 1H, NPh), 6.84 (d, 2H, $J = 7.5$ Hz, NPh), 6.41 (bs, 1H, H-1), 4.83 (d, 1H, $J = 11.7$ Hz, CHH Bn), 4.66 (d, 1H, $J = 11.7$ Hz, CHH Bn), 4.51 (d, 1H, $J = 11.8$ Hz, CHH Bn), 4.46 (d, 1H, $J = 11.8$ Hz, CHH Bn), 4.36 (q, 1H, $J = 6.3$ Hz, H-4), 4.26 (t, 1H, $J = 5.4$ Hz, H-3), 3.82 (dd, 1H, $J = 9.9, 6.7$ Hz, H-5), 3.70 (dd, 1H, $J = 9.9, 6.2$ Hz, H-5), 3.51 (t, 1H, $J = 4.9$ Hz, H-2); ^{13}C -APT NMR (CDCl_3 , $T = 323$ K, 126 MHz, HSQC): δ 143.9 (C_q NPh), 138.1, 137.6 (C_q Bn), 128.8, 128.5, 128.5, 127.9, 127.8, 127.5, 124.4, 119.7 (CH_{arom}), 116.2 (q, $J = 286.3$ Hz, CF_3), 98.5 (C-1), 82.2 (C-4), 77.7 (C-3), 74.7, 73.8 (CH_2 Bn), 69.0 (C-5), 62.2 (C-2); HRMS: $[\text{2M}+\text{NH}_4]^+$ calcd for $\text{C}_{54}\text{H}_{54}\text{F}_6\text{N}_{10}\text{O}_8$ 1070.39941, found 1070.39931.




2-azido-3,5-di-O-benzyl-2-deoxy-1-O-(N-[phenyl]trifluoroacetimidoyl)- α/β -D-xylofuranoside (69). The title compound was generated from **52** by the general procedure for imidate donor synthesis, conditions A. Yield: 100% $\alpha:\beta = 1:1$ (0.33 mmol) as a colourless oil. IR (thin film): 696, 1044, 1099, 1143, 1207, 1321, 1712, 2114; ^1H NMR (CDCl_3 , $T = 323$ K, 500 MHz, HH-COSY, HSQC): δ 7.36–7.23 (m, 24H, CH_{arom}), 7.10–7.06 (m, 2H, NPh), 6.84 (d, 2H, $J = 7.7$ Hz, NPh), 6.80 (d, 2H, $J = 7.6$ Hz, NPh), 6.43 (bs, 1H, H-1 α), 6.15 (bs, 1H, H-1 β), 4.69 (d, 1H, $J = 11.7$ Hz, CHH Bn), 4.64–4.57 (m, 4H, CH_2 Bn, CHH Bn, CHH Bn), 4.56–4.50 (m, 4H, CH_2 Bn, CHH Bn, H-4 β), 4.50–4.45 (m, 1H, H-4 α), 4.32 (t, 1H, $J = 6.7$ Hz, H-3 α), 4.22 (bs, 1H, H-2 β), 4.17–4.11 (m, 1H, H-2 α), 4.08 (dd, 1H, $J = 5.8, 2.8$ Hz, H-3 β), 3.85 (dd, 1H, $J = 10.5, 5.3$ Hz, H-5 β), 3.76 (dd, 1H, $J = 10.5, 6.5$ Hz, H-5 β), 3.71 (dd, 1H, $J = 10.7, 4.4$ Hz, H-5 α), 3.61 (dd, 1H, $J = 10.7, 4.9$ Hz, H-5 α); ^{13}C -APT NMR (CDCl_3 , $T = 323$ K, 126 MHz, HSQC): δ 143.8, 143.8 (C_q NPh), 138.3, 138.2, 137.4, 137.4 (C_q Bn), 128.9, 128.9, 128.7, 128.5, 128.5, 128.3, 128.3, 127.9, 127.9, 127.8, 127.8, 127.8, 124.5, 119.8, 119.7 (CH_{arom}), 103.2 (C-1 β), 98.4 (C-1 α), 82.7 (C-4 β), 81.6 (C-3 β), 79.1 (C-3 α), 73.8 (C-4 α), 73.8, 73.6, 73.3 (CH_2 Bn), 69.1 (C-2 β), 69.0 (C-5 β), 68.5 (C-5 α), 66.7 (C-2 α); HRMS: only mass of hydrolysis found $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{19}\text{H}_{21}\text{N}_3\text{O}_4\text{Na}$ 378.1430, found 378.1433.




Methyl (2,3-di-O-benzyl-1-O-(N-[phenyl]trifluoroacetimidoyl)- α/β -D-arabinofuranosyl uronate (70). The title compound was generated from **53** (466 mg, 1.3 mmol) by the general procedure for imidate donor synthesis, conditions A. Yield: 97% $\alpha:\beta = 1:1.2$ (670 mg, 1.27 mmol) as a white solid. Rf: 0.51 (8/2 pentane/ Et_2O). IR (thin film): 696, 1074, 1105, 1318, 1712, 1769; ^1H NMR (CDCl_3 , $T = 323$ K, 500 MHz, HH-COSY, HSQC): δ 7.35–7.20 (m, 24H, CH_{arom}), 7.10–7.02 (m, 2H, NPh), 6.79 (d, 2H, $J = 7.7$ Hz, NPh), 6.77–6.74 (m, 2H, NPh), 6.41 (bs, 1H, H-1 β), 6.29 (bs, 1H, H-1 α), 4.82 (d, 1H, $J = 3.8$ Hz, H-4 β), 4.76 (d, 1H, $J = 11.8$ Hz, CHH Bn), 4.72–4.61 (m, 4H, CH_2 Bn, CHH Bn, CHH Bn), 4.60–4.53 (m, 4H, CH_2 Bn, H-3 α , H-4 α), 4.50 (d, 1H, $J = 12.0$ Hz, CHH Bn), 4.29 (d, 1H, $J = 3.1$ Hz, H-3 β), 4.24–4.18 (m, 2H, H-2 α , H-2 β), 3.74 (s, 3H, CH_3 CO_2Me), 3.73 (s, 3H, CH_3 CO_2Me); ^{13}C -APT NMR (CDCl_3 , $T = 323$ K, 126 MHz, HSQC): δ 170.7, 169.6 (C=O), 144.0, 143.8, 137.8, 137.5, 137.4, 137.1 (C_q), 128.8, 128.7, 128.6, 128.6, 128.5, 128.5, 128.2, 128.1, 128.0, 128.0, 127.9, 127.9, 127.8, 124.5, 124.2, 119.8, 119.6 (CH_{arom}), 116.1 (q, $J = 286.7$ Hz, CF_3), 116.1 (q, $J = 286.5$ Hz, CF_3), 104.0 (C-1 α), 97.3 (C-1 β), 85.2, 85.2 (C-2 β , C-3 α), 84.0 (C-2 α), 83.7 (C-3 β), 83.3 (C-4 α), 80.9 (C-4 β), 73.4, 73.0, 72.4, 72.2 (CH_2 Bn), 52.5 (OMe); ^{19}F NMR (CDCl_3 , 471 MHz): δ -66.18; HRMS: $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{28}\text{H}_{26}\text{F}_3\text{NO}_6\text{Na}$ 552.16044, found 552.16010.




Methyl (2,3-di-O-benzyl-1-O-(N-[phenyl]trifluoroacetimidoyl)- β -D-ribofuranosyl uronate (71). The title compound was generated from **54** (1.0 g, 2.8 mmol) by the general procedure for imidate donor synthesis, conditions A. Yield: 85% β only (1.26 g, 2.38 mmol) as a white solid. Rf: 0.54 (7/3 pentane/ Et_2O). $[\alpha]_D^{20} = +18.6^\circ$ ($c = 0.90$, CHCl_3); IR (thin film): 696, 1090, 1146, 1206, 1456, 1717, 1740; ^1H NMR (CDCl_3 , 500 MHz, HH-COSY, HSQC): δ 7.35–7.25 (m, 12H, CH_{arom}), 7.08 (t, 1H, $J = 7.5$ Hz, NPh), 6.81 (d, 2H, $J = 7.5$ Hz, NPh), 6.29 (bs, 1H, H-1), 4.72 (d, 1H, $J = 6.4$ Hz, H-4), 4.68–4.63 (m, 3H, CH_2 Bn, CHH Bn), 4.62 (d, 1H, $J = 11.8$ Hz, CHH Bn), 4.43 (dd, 1H, $J = 6.3, 4.7$ Hz, H-3), 4.09 (d, 1H, $J = 4.5$ Hz, H-2), 3.76 (s, 3H, CH_3 OMe); ^{13}C -APT NMR (CDCl_3 , 126 MHz, HSQC): δ 170.9 (C=O), 143.9 (C_q NPh), 137.5, 137.4 (C_q Bn), 128.9, 128.7, 128.6, 128.2, 128.2, 128.1, 128.1, 124.5, 119.7 (CH_{arom}), 116.11 (q, $J = 285.8$ Hz, CF_3), 102.6 (C-1), 81.2 (C-4), 80.3 (C-3), 79.7 (C-2), 73.3, 73.0 (CH_2 Bn), 52.5 (CH_3 CO_2Me); ^{19}F NMR (CDCl_3 , 471 MHz): δ -66.62; HRMS: $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{28}\text{H}_{27}\text{F}_3\text{NO}_6$ 530.17850, found 530.17802.



Methyl (2,3-di-O-benzyl-1-O-(N-[phenyl]trifluoroacetimidoyl)- α/β -D-lyxofuranosyl uronate) (72). The title compound was generated from **55** (1.05 g, 2.90 mmol) by the general procedure for imidate donor synthesis, conditions A. Yield: 85% as two separate anomers (487 mg, 0.92 mmol α and 105 mg, 0.20 mmol β respectively) as colourless oils. Rf: 0.24 and 0.69 (8/2 pentane/Et₂O). Data for the α -anomer: $[\alpha]_D^{20} = -5.5^\circ$ ($c = 1.23$, CHCl₃); IR (thin film): 696, 1026, 1101, 1159, 1207, 1327, 1707, 1734, 1770; ¹H NMR (CDCl₃, $T = 323$ K, 500 MHz, HH-COSY, HSQC): δ 7.33 – 7.22 (m, 12H, CH_{arom}), 7.10 – 7.02 (m, 1H, NPh), 6.80 (d, 2H, $J = 7.5$ Hz, NPh), 6.49 (bs, 1H, H-1), 4.81 (d, 1H, $J = 5.3$ Hz, H-4), 4.71 (d, 1H, $J = 11.7$ Hz, CHH Bn), 4.66 (s, 2H, CH₂ Bn), 4.61 (d, 1H, $J = 11.7$ Hz, CHH Bn), 4.43 (t, 1H, $J = 5.1$ Hz, H-3), 4.20 (dd, 1H, $J = 4.6, 2.7$ Hz, H-2), 3.68 (s, 3H, CH₃ CO₂Me); ¹³C-APT NMR (CDCl₃, $T = 323$ K, 126 MHz, HSQC): δ 167.9 (C=O), 143.7 (C_q NPh), 143.1 (q, $J = 36.2$ Hz, CF₃-C=N), 137.7, 137.3 (C_q Bn), 128.8, 128.5, 128.4, 128.1, 127.9, 127.8, 124.5, 119.7, (CH_{arom}), 116.1 (q, $J = 285.8$ Hz, CF₃), 103.5 (C-1), 82.0 (C-2), 79.7 (C-4), 78.4 (CH₂ Bn), 52.1 (CH₃ CO₂Me); HRMS: $[M+NH_4]^+$ calcd for C₂₈H₃₀F₃N₂O₆ 547.20505, found 547.20459. Data for the β -anomer: $[\alpha]_D^{20} = -66.4^\circ$ ($c = 0.70$, CHCl₃); IR (thin film): 696, 1074, 1086, 1144, 1327, 1715, 1769; ¹H NMR (CDCl₃, $T = 323$ K, 500 MHz, HH-COSY, HSQC): δ 7.35 – 7.25 (m, 10H, CH_{arom}), 7.25 – 7.19 (m, 3H, NPh), 7.09 – 6.99 (m, 1H, NPh), 6.79 (d, 2H, $J = 7.7$ Hz, NPh), 6.40 (bs, 1H, H-1), 4.89 (d, 1H, $J = 11.7$ Hz, CHH Bn), 4.74 (d, 1H, $J = 5.5$ Hz, H-4), 4.69 (d, 1H, $J = 12.1$ Hz, CHH Bn), 4.66 (d, 1H, $J = 12.0$ Hz, CHH Bn), 4.62 (d, 1H, $J = 11.7$ Hz, CHH Bn), 4.39 (t, 1H, $J = 5.3$ Hz, H-3), 3.98 (t, 1H, $J = 4.6$ Hz, H-2), 3.64 (s, 3H, CH₃ CO₂Me); ¹³C-APT NMR (CDCl₃, $T = 323$ K, 126 MHz, HSQC): δ 168.3 (C=O), 144.4 (C_q NPh), 138.4, 137.4 (C_q Bn), 128.7, 128.7, 128.2, 128.2, 127.7, 127.4, 127.3, 124.0, 119.8 (CH_{arom}), 116.3 (q, $J = 286.8$ Hz, CF₃), 96.4 (C-1), 81.1 (C-4), 79.9 (C-2), 76.4 (C-3), 74.2, 73.3 (CH₂ Bn), 52.0 (CH₃ CO₂Me); HRMS: $[M+H]^+$ calcd for C₂₈H₂₇F₃NO₆ 530.17850, found 530.17835.



Methyl (2,3-di-O-benzyl-1-O-(N-[phenyl]trifluoroacetimidoyl)- β -D-xylofuranosyl uronate) (73). The title compound was generated from **56** (1.20 g, 3.0 mmol) by the general procedure for imidate donor synthesis, conditions A. Yield: 81% β only (561 mg, 1.06 mmol) as a colourless oil. Rf: 0.28 (8/2 pentane/Et₂O). $[\alpha]_D^{20} = +10.2^\circ$ ($c = 0.55$, CHCl₃); IR (thin film): 696, 1105, 1159, 1207, 1325, 1717, 1732, 1771; ¹H NMR (CDCl₃, $T = 323$ K, 500 MHz, HH-COSY, HSQC): δ 7.34 – 7.22 (m, 12H, CH_{arom}), 7.15 – 7.02 (m, 1H, NPh), 6.82 (d, 1H, $J = 7.5$ Hz, NPh), 6.32 (bs, 1H, H-1), 5.00 (d, 1H, $J = 6.0$ Hz, H-4), 4.57 (d, 1H, $J = 12.0$ Hz, CHH Bn), 4.55 – 4.50 (m, 3H, CH₂ Bn, CHH Bn), 4.32 (dd, 1H, $J = 6.0, 1.2$ Hz, H-3), 4.23 (s, 1H, H-2), 3.72 (s, 3H, CH₃ CO₂Me); ¹³C-APT NMR (CDCl₃, $T = 323$ K, 126 MHz, HSQC): δ 168.6 (C=O), 144.1 (C_q NPh), 137.5, 137.1 (C_q Bn), 128.8, 128.7, 128.5, 128.3, 128.0, 127.9, 127.6, 124.2, 119.8 (CH_{arom}), 116.1 (q, $J = 286.8$ Hz, CF₃), 103.3 (C-1), 84.0 (C-2), 82.9 (C-4), 82.0 (C-3), 73.1, 72.5 (CH₂ Bn), 52.0 (CH₃ CO₂ Me); HRMS: $[M+Na]^+$ calcd for C₂₈H₂₆F₃NO₆Na 552.16044, found 552.15999.



Methyl (2,3-di-O-benzyl-D-ribose) diphenyl mercaptal (74). Compound **59** (200 mg, 0.5 mmol) was dissolved in 2 mL DCM and cooled to 0°C. Thiophenol (90 μ L, 0.88 mmol, 1.75 eq.) and BF₃·OEt₂ (105 μ L, 0.85 mmol, 1.7 eq.) were added and the reaction stirred for 4 h. The reaction was quenched by the addition of sat. aq. NaHCO₃ and the mixture was extracted with DCM three times. The combined organic layers were washed with H₂O and brine, then dried (MgSO₄), filtered and concentrated in vacuo. Purification by flash column chromatography (1/0 to 8/2 pentane/EtOAc) gave the dithioacetal as a colourless oil (156, 0.28 mmol, 56%). IR (thin film): 696, 737, 1026, 1101, 1217, 1230, 1267, 1439, 1454, 1481, 1581, 1734, 2873, 2922, 2949, 3030, 3059, 3466; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.50 – 7.11 (m, 20H, CH_{arom}), 5.19 (d, 1H, $J = 10.5$ Hz, CHH Bn), 5.05 (s, 1H, H-1), 4.76 (d, 1H, $J = 11.3$ Hz, CHH Bn), 4.56 (d, 1H, $J = 10.5$ Hz, CHH Bn), 4.53 (bs, 1H, H-4), 4.48 (d, 1H, $J = 11.3$ Hz, CHH Bn), 4.39 – 4.30 (m, 2H, H-2, H-3), 3.42 (s, 3H, CH₃ CO₂Me), 3.02 (bs, 1H, OH); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 172.8 (C=O), 137.9, 137.5, 136.0, 135.1 (C_q), 131.3, 130.7, 129.2, 129.1, 128.5, 128.4, 128.3, 127.9, 127.8, 127.3, 127.0 (CH_{arom}), 81.4, 78.8 (C-2, C-3), 74.8, 73.4 (CH₂ Bn), 69.8 (C-4), 60.4 (C-1), 52.6 (CH₃ CO₂Me); HRMS: $[M+Na]^+$ calcd for C₃₂H₃₂O₅S₂Na 583.15834, found 583.15803.

References and footnotes

- Richards, M. R.; Lowary, T. L. *ChemBioChem* **2009**, *10* (12), 1920–1938.
- Griffiths, A. J.; Davies, D. B. *Carbohydr. Polym.* **1991**, *14* (3), 241–279.
- Griffiths, A. J.; Davies, D. B. *Carbohydr. Polym.* **1991**, *14* (4), 339–365.
- Lowary, T. L. *Acc. Chem. Res.* **2016**, *49* (7), 1379–1388.
- Taha, H. A.; Richards, M. R.; Lowary, T. L. *Chem. Rev.* **2013**, *113* (3), 1851–1876.

- (6) Gallo-Rodríguez, C.; Kashiwagi, G. A. Selective Glycosylations with Furanosides. In *Selective Glycosylations: Synthetic Methods and Catalysts*; Bennett, C. S., Ed.; Wiley-VCH Verlag GmbH & Co. KGaA, 2017; pp 297–326.
- (7) Kim, J.-H.; Yu, J.; Alexander, V.; Choi, J. H.; Song, J.; Lee, H. W.; Kim, H. O.; Choi, J.; Lee, S. K.; Jeong, L. S. *Eur. J. Med. Chem.* **2014**, *83*, 208–225.
- (8) Inoue, N.; Kaga, D.; Minakawa, N.; Matsuda, A. *J. Org. Chem.* **2005**, *70* (21), 8597–8600.
- (9) Mirabella, S.; Cardona, F.; Goti, A. *Org. Biomol. Chem.* **2016**, *14* (23), 5186–5204.
- (10) Kuhl, D. E.; Koeppel, R. A.; Minoshima, S.; Snyder, S. E.; Ficaró, E. P.; Foster, N. L.; Frey, K. A.; Kilbourn, M. R. *Neurology* **1999**, *52* (4), 691–691.
- (11) Weinstein, E. A.; Ordóñez, A. A.; DeMarco, V. P.; Murawski, A. M.; Pokkali, S.; MacDonald, E. M.; Klunk, M.; Mease, R. C.; Pomper, M. G.; Jain, S. K. *Sci. Transl. Med.* **2014**, *6* (259), 259ra146–259ra146.
- (12) Koyama, H.; Siqin; Zhang, Z.; Sumi, K.; Hatta, Y.; Nagata, H.; Doi, H.; Suzuki, M. *Org. Biomol. Chem.* **2011**, *9* (11), 4287–4294.
- (13) Evdokimov, N. M.; Clark, P. M.; Flores, G.; Chai, T.; Faull, K. F.; Phelps, M. E.; Witte, O. N.; Jung, M. E. *J. Med. Chem.* **2015**, *58* (14), 5538–5547.
- (14) Dalko, P. I.; Sinaý, P. *Angew. Chem. Int. Ed.* **1999**, *38* (6), 773–777.
- (15) Pokrovskaya, V.; Belakhov, V.; Hainrichson, M.; Yaron, S.; Baasov, T. *J. Med. Chem.* **2009**, *52* (8), 2243–2254.
- (16) Li, N.-S.; Lu, J.; Piccirilli, J. A. *Org. Lett.* **2007**, *9* (16), 3009–3012.
- (17) Jia, C.; Zhang, Y.; Zhang, L.-H.; Sinaý, P.; Sollogoub, M. *Carbohydr. Res.* **2006**, *341* (12), 2135–2144.
- (18) Sørensen, M. H.; Nielsen, C.; Nielsen, P. *J. Org. Chem.* **2001**, *66* (14), 4878–4886.
- (19) Dahlman, O.; Garegg, P. J.; Mayer, H.; Schramek, S.; Krogsgaard-Larsen, P.; Ryhage, R.; Isaksson, R. *Acta Chem. Scand.* **1986**, *40b*, 15–20.
- (20) van Straten, N. C. R.; van der Marel, G. A.; van Boom, J. H. *Tetrahedron* **1997**, *53* (18), 6509–6522.
- (21) The Moffat conditions led to the isolation of an equal amount of Pummerer rearranged product (methylthiomethyl ether).
- (22) Larsen, C. H.; Ridgway, B. H.; Shaw, J. T.; Smith, D. M.; Woerpel, K. A. *J. Am. Chem. Soc.* **2005**, *127* (31), 10879–10884.
- (23) The group of Hale has provided useful guidelines for substitutions in pyranoses and furanoses using sulfonate leaving groups. From their analyses, triflates came forward as the best choice not only because for their intrinsic potency as leaving group, but also because they reduce unfavorable dipole-dipole interactions in the transition state. Hale, K. J.; Hough, L.; Manaviar, S.; Calabrese, A. *Org. Lett.* **2015**, *17* (7), 1738–1741 and Hale, K. J.; Hough, L.; Manaviar, S.; Calabrese, A. *Org. Lett.* **2014**, *16* (18), 4838–4841.
- (24) Soueidan, O.-M.; Trayner, B. J.; Grant, T. N.; Henderson, J. R.; Wuest, F.; West, F. G.; Cheeseman, C. I. *Org. Biomol. Chem.* **2015**, *13* (23), 6511–6521.
- (25) The 1,2-migration of thioethers is well known, see for example: Maieranu, C.; Kanai, A.; Weibel, J.-M.; Pale, P. *J. Carb. Chem.* **2005**, *24*, 831–842. The migration of alkoxy groups is not as abundantly reported, 1,2-migrations induced by DAST are reported in: Nicolaou, K. C.; Ladduwahetty, T.; Randall, J. L.; Chucholowski, A. *J. Am. Chem. Soc.* **1986**, *108* (9), 2466–2467.
- (26) Substitution reactions on the *lyxo/manno*-furanoside motif are scarcely reported, only a single successful C-2-substitution reaction on a β -anomer (carrying a thymine nucleobase) was disclosed (Robles, R.; Rodríguez, C.; Izquierdo, I.; Plaza, M. T.; Mota, A.; Álvarez de Cienfuegos, L. *Tetrahedron Asymmetry* **2000**, *11* (15), 3069–3077.), while none have been reported for the α -anomer.
- (27) Barrett, A. G. M.; Barton, D. H. R.; Bielski, R.; McCombie, S. W. *J. Chem. Soc. Chem. Commun.* **1977**, *0* (23), 866–868.
- (28) Hanessian, S.; Bargiotti, A.; LaRue, M. *Tetrahedron Lett.* **1978**, *19* (8), 737–740.
- (29) Holzapfel, G. H.; Koekemoer; Verdoorn, J. M. *South Afr. J. Chem.* **1986**, *39* (3), 151–157.
- (30) Danishefsky, S. J.; Bilodeau, M. T. *Angew. Chem. Int. Ed. Engl.* **1996**, *35* (13–14), 1380–1419.
- (31) Besides Garegg and Corey-Winter conditions, glycals can also be synthesized by: Zn/Cu reductive elimination of anomeric bromides and C-2-O-acyl groups, generated in an HBr/AcOH mixture, which is too acidic for substrate **33**. Zn/Cu elimination of 1-chloro-2-O-mesylates, from the diol, mesylchloride and a base, see ref. 29, via elimination of a quaternary ammonium acetal (ref 28). Via Barton-McCombie radical deoxygenation of bisdithiocarbonates (ref 27).
- (32) Garegg, P. J.; Samuelsson, B. *Synthesis* **1979**, *1979* (06), 469–470.

- (33) Garegg, P. J.; Samuelsson, B. *Synthesis* **1979**, 1979 (10), 813–814.
- (34) Pakulski, Z.; Zamojski, A. *Carbohydr. Res.* **1990**, 205, 410–414.
- (35) Corey, E. J.; Winter, R. A. E. *J. Am. Chem. Soc.* **1963**, 85 (17), 2677–2678.
- (36) Diaz, R. R.; Rodríguez Melgarejo, C.; Cubero, I. I.; Plaza López-Espinosa, M. T. *Carbohydr. Res.* **1997**, 300 (4), 375–380.
- (37) Trimethylphosphite (12 eq.) at 110°C did not work and gave an unidentified product.
- (38) Burkart, M. D.; Zhang, Z.; Hung, S.-C.; Wong, C.-H. *J. Am. Chem. Soc.* **1997**, 119 (49), 11743–11746.
- (39) Bongat, A. F. G.; Demchenko, A. V. *Carbohydr. Res.* **2007**, 342 (3–4), 374–406.
- (40) Czernecki, S.; Ayadi, E.; Randriamandimby, D. *J. Org. Chem.* **1994**, 59 (26), 8256–8260.
- (41) Czernecki, S.; Ayadi, E.; Randriamandimby, D. *J. Chem. Soc. Chem. Commun.* **1994**, 0 (1), 35–36.
- (42) Chelain, E.; Czernecki, S.; Chmielewski, M.; Kaluza, Z. *J. Carbohydr. Chem.* **1996**, 15 (5), 571–579.
- (43) Czernecki, S.; Randriamandimby, D. *Tetrahedron Lett.* **1993**, 34 (49), 7915–7916.
- (44) Nicolaou, K. C.; Petasis, N. A.; Claremon, D. A. *Tetrahedron* **1985**, 41 (21), 4835–4841.
- (45) Hernández, R.; León, E. I.; Moreno, P.; Riesco-Fagundo, C.; Suárez, E. *J. Org. Chem.* **2004**, 69 (24), 8437–8444.
- (46) The mechanism is proposed to proceed via an episelenonium ion, generated by electrophilic attack of N₃⁻ on PhSeCl as originally used by Hassner (*Tetrahedron Lett.* **1987**, 28 (43), 5188–5188), or *N*-(phenylseleno)phthalimide (*N*-PSP). Although opening of the episelenonium ion generates regioisomers, enolates react with high Markovnikov selectivity. In this and some previous cases, anti-Markovnikov selectivity is predominantly observed. The most striking result was obtained by comparing both aforementioned reagents in different solvents; in DCM, Markovnikov regioselectivity was observed for PhSeCl, while *N*-PSP gave anti-Markovnikov selectivity, whereas in DMF the Markovnikov products prevailed for both reagents (see ref 40). At this stage the details of the mechanism, and the effect of the reagent-solvent combination remain unclear.
- (47) van Rijssel, E. R.; van Delft, P.; Lodder, G.; Overkleef, H. S.; van der Marel, G. A.; Filippov, D. V.; Codée, J. D. C. *Angew. Chem. Int. Ed.* **2014**, 53 (39), 10381–10385.
- (48) Boyer, F.-D.; Pancrazi, A.; Lallemand, J.-Y. *Synth. Commun.* **1995**, 25 (8), 1099–1108.
- (49) Conversion of the anomeric acetyl to a thiophenyl group met with poor success, and formation of the dithio acetal products prevailed (see 74 in the Experimental Section).
- (50) Xu, G.; Moeller, K. D. *Org. Lett.* **2010**, 12 (11), 2590–2593.
- (51) Majdecki, M.; Jurczak, J.; Bauer, T. *ChemCatChem* **2015**, 7 (5), 799–807.
- (52) Chakraborty, T. K.; Koley, D.; Ravi, R.; Krishnakumari, V.; Nagaraj, R.; Chand Kunwar, A. *J. Org. Chem.* **2008**, 73 (22), 8731–8744.
- (53) Knijnenburg, A. D.; Tuin, A. W.; Spalburg, E.; de Neeling, A. J.; Mars-Groenendijk, R. H.; Noort, D.; Otero, J. M.; Llamas-Saiz, A. L.; van Raaij, M. J.; van der Marel, G. A.; et al. *Chem. – Eur. J.* **2011**, 17 (14), 3995–4004.
- (54) da Paixão Soares, F.; Silva, M. J. e; Doboszewski, B. *Carbohydr. Res.* **2013**, 380, 143–148.
- (55) Witty, D. R.; Fleet, G. W. J.; Vogt, K.; Wilson, F. X.; Wang, Y.; Storer, R.; Myers, P. L.; Wallis, C. J. *Tetrahedron Lett.* **1990**, 31 (33), 4787–4790.
- (56) Popsavin, V.; Grabež, S.; Stojanović, B.; Popsavin, M.; Pejanović, V.; Miljković, D. *Carbohydr. Res.* **1999**, 321 (1–2), 110–115.
- (57) Su, T.-L.; Klein, R. S.; Fox, J. J. *J. Org. Chem.* **1981**, 46 (9), 1790–1792.
- (58) Santana, A. G.; Francisco, C. G.; Suárez, E.; González, C. C. *J. Org. Chem.* **2010**, 75 (15), 5371–5374.
- (59) Parmentier, G.; Schmitt, G.; Dolle, F.; Luu, B. *Tetrahedron* **1994**, 50 (18), 5361–5368.
- (60) Hardacre, C.; Messina, I.; Migaud, M. E.; Ness, K. A.; Norman, S. E. *Tetrahedron* **2009**, 65 (32), 6341–6347.
- (61) Murakami, M.; Mukaiyama, T. *Chem. Lett.* **1983**, 12 (11), 1733–1736.
- (62) Patroni, J. J.; Stick, R. V.; Tilbrook, D. M. G.; Skelton, B. W.; White, A. H. *Aust. J. Chem.* **1989**, 42 (12), 2127–2141.
- (63) Cuzzupe, A. N.; Di Florio, R.; Rizzacasa, M. A. *J. Org. Chem.* **2002**, 67 (13), 4392–4398.
- (64) Wender, P. A.; Bi, F. C.; Buschmann, N.; Gosselin, F.; Kan, C.; Kee, J.-M.; Ohmura, H. *Org. Lett.* **2006**, 8 (23), 5373–5376.
- (65) Veeneman, G. H.; Gomes, L. J. F.; van Boom, J. H. *Tetrahedron* **1989**, 45 (23), 7433–7448.
- (66) Li, K.-Y.; Jiang, J.; Witte, M. D.; Kallemeijn, W. W.; van den Elst, H.; Wong, C.-S.; Chander, S. D.; Hoogendoorn, S.; Beenakker, T. J. M.; Codée, J. D. C.; et al. *Eur. J. Org. Chem.* **2014**, 2014 (27), 6030–6043.

- (67) Jung, K.-H.; Schmidt, R. R. *Liebigs Ann. Chem.* **1979**, 1979 (9), 1426–1439.
- (68) Dostie, S.; Prévost, M.; Mochirian, P.; Tanveer, K.; Andrella, N.; Rostami, A.; Tambutet, G.; Guindon, Y. *J. Org. Chem.* **2016**, 81 (22), 10769–10790.

Chapter 8

Stereoselectivity of C-2- and C-5-modified furanosides: a computational and experimental study

Introduction

Of the many structurally different carbohydrates, furanosides, the five-membered ring carbohydrates, are common components of plant- and bacterial oligosaccharides, and form the basis of DNA/RNA as nucleotides.¹⁻⁷ Glycosylation reactions with furanosides proceed with much the same chemistry as six-membered ring pyranosides. The glycosylation mechanism therefore proceeds through a pathway having S_N1-like and S_N2-like character. Furanosides are typically more reactive than pyranosides because they have one electron-withdrawing oxygen substituent less, and they are conformationally more flexible and can easier accommodate the double bond character upon oxocarbenium ion formation in the ring. In this chapter the stereoselectivity of S_N1-type glycosylations are investigated for furanosides, bearing different ring substituents. The stereoelectronic effects brought about by fluorine, azide, or the benzyloxy groups on C-2 and a methyl uronate or benzyloxymethyl group at C-5 are probed, as these can have tremendous influence on both the reactivity and the stereoselectivity of the glycosylation

reaction. The stereochemical outcome of experimental glycosylations of the differently functionalized furanosides is interpreted using computational analysis of the stability of the reactive intermediates in the dissociative mechanism, the furanosyl oxocarbenium ion.




Figure 1. (A) Pseudo-rotational circle showing twenty distinct furanoside structures, with phase-angle P and puckering amplitude τ_m .⁸ Green circles indicate the two major conformations of oxocarbenium ions. (B) Two resonance structures of a cyclic furanosyl oxocarbenium ion. (C) The two principal conformations of the two-conformer model (E_3 - 3E) shown for every carbohydrate configuration, example taken as their tri-O-benzyl protected form. Colors indicate relative preferential orientations for H-2 and O-3 (see Chapter 1), green is relatively stabilizing whereas red is relatively destabilizing.

Furanosides readily attain different conformations, and all the different possible geometric shapes a five-membered ring can adopt can be described by a pseudo-rotational circle (Figure 1A).^{9,10} The phase angle (P) defines the conformation of the ring, and the puckering amplitude (τ_m) describes the amount of distortion from the median plane the outlying atoms have.^{8,11} In the middle of this circle, all five ring atoms are in the same plane, and all the substituents suffer from eclipsing interactions. Each furanoside, neutral or charged, has its own preferential conformation or suite of conformations, depending on the nature of the ring substituents and their orientation.

The conformations adopted by the reactive intermediates in S_N1 -type substitutions, the oxocarbenium ions, are limited to a smaller region of the pseudo-rotational circle.¹² The oxocarbenium ion has two extreme resonance structures (Figure 1B), the most stable of the two features a C=O double bond which places four of the five

ring atoms in the same plane. The remaining ring-atom, C-3, will be out of the oxocarbenium ion plane, to minimize eclipsing interactions of its substituents. Therefore, the two most likely structures of an oxocarbenium ion will be the E_3 and 3E conformations, or conformations closely related to those. The orientational preferences of each substituent in these two conformations has been investigated by the group of Woerpel (see also Chapter 1), the results of which are graphically displayed in Figure 1C.¹³⁻¹⁷ The substituent on C-2 is preferentially placed in a sterically less demanding *pseudo*-equatorial orientation, simultaneously allowing the *pseudo*-axially orientated C-H bond to be aligned for hyperconjugative stabilization ($\sigma \rightarrow p/\pi^*$) of the anomeric carbocation. The substituent on C-3, on the other hand, is preferentially placed in a *pseudo*-axial orientation, as this brings the electron density of the electronegative oxygen atom closer to the oxocarbenium ion than it would in a *pseudo*-equatorial setting. This makes the effect of the C-3-O-3 bond less electron-withdrawing and allows for through-space electrostatic stabilization by the lone electron pairs on oxygen.

The stereoselectivity in glycosylations with furanosides that follow an S_N1 mechanism can be traced to the stereoselectivity inferred by the oxocarbenium ion. Woerpel and co-workers have established a model to account for the selectivity based on the E_3 and 3E oxocarbenium ion conformations (Figure 2).¹⁷⁻²⁰ In this model, coined the two-conformer model, attack on the inside of the oxocarbenium ion is preferred over attack on the outside of the oxocarbenium ion. The basis of this rationale is the developing eclipsing interactions that occur in the transition state of the glycosylation reaction. When nucleophilic attack occurs on the outside of the oxocarbenium ion, the incoming nucleophile experiences eclipsing interactions with the *pseudo*-axially orientated substituent at C-2. The *pseudo*-equatorially orientated substituents at C-1 and C-2 also experience increased eclipsing interactions in the transition state upon rehybridization when a nucleophile attacks from the outside.

The stability of the oxocarbenium ion, dictated by its substituents, and the preference for inside attack leading to a more favorable transition state, leads to a model that can predict stereoselectivity based on oxocarbenium ion stability. The reasoning of this model is valid by the Hammond postulate: the geometry of the product-forming transition state is assumed to resemble the structure of the oxocarbenium ion intermediate, and the stereoselective preference of the ground-state oxocarbenium ion can therefore be taken as indicative of the reaction outcome (Figure 2). The ground state




Figure 2. (left, middle) The two-conformer model, visualizing preferential nucleophilic attack from the inside face. Important rotations are denoted by dashed arrows. (right) Ground-state approximation to oxocarbenium ion stereoselectivity. $\Delta G \approx \Delta\Delta G^\ddagger$, energy levels are arbitrarily chosen for illustrative purposes. Reaction coordinate only visualized for the two inside attack pathways.

energy difference of two oxocarbenium ions (ΔG) is assumed to be similar to their transition state energy difference ($\Delta\Delta G^\ddagger$), thereby resulting in similar reaction rates of both inside attack pathways, and a product ratio mirroring the oxocarbenium ion ratio.

It can be difficult to predict which of the E_3 - 3E envelopes is the more stable conformation on the basis of individual substituent effects, especially when there are conflicting orientational interests between the substituents. Furthermore, a change in protecting- or functional groups on the furanoside ring may have an unforeseen stereoelectronic influence, leading to less obvious geometries.^{21,22} To assess the conformational behavior of furanosyl oxocarbenium ions, a method was devised based on Density Functional Theory (DFT), with which the relative stabilities of each conformation in the complete pseudo-rotational circle can be calculated, generating Conformational Energy Landscape (CEL) maps.²³ This method has been previously used by van Rijssel *et al.* to calculate the relative energies of furanosyl oxocarbenium ions of all four pentose furanosyl configurations (*arabino*-, *ribo*-, *lyxo*-, and *xylo*-configured, **49**, **53**, **57**, and **61**, Figure 3), bearing three *O*-methyl groups.^{24,25} The results obtained by this method were in excellent agreement with experimental glycosylations (using the perbenzylated substrates, see also Table 1), and prompted further application of the DFT method to study relevant structural modifications. This chapter describes in detail the effects of the 2-fluoro, 2-azido, and 5-methyl uronate groups on the stability of the oxocarbenium ion conformations. The stereochemical outcome of experimental glycosylations is related to the structures of the intermediate oxocarbenium ions as revealed by the CEL maps.

Results and discussion

Glycosylations

Sixteen furanosides, comprising all four configurations of the D-pentofuranoses, with a 2-fluoro, 2-azido, or a 5-uronic acid ester substituent are studied, while the previously investigated fully benzylated donors are used for comparison.²⁴ The synthesis of all used furanosyl donors is described in Chapter 7.

The glycosyl donors of the C-2- and C-5-modified furanosides feature a trifluoro-*N*-phenylimidate anomeric leaving group (**9-20**, Table 1), since the corresponding acetyl donors proved inactive due to the presence of more electron-withdrawing substituents. Besides, allylations were preferred here over reactions with triethylsilane-*d* (TES-D) because the structure of the products could be determined with more ease, generally less side products were formed, the products could be easier separated from the contaminants, and the yields of the reactions were generally higher.²⁶ For the reactions of the C-2-azido donors TES-D was used because allyltrimethylsilane (allyl-TMS) did not lead to product formation even at higher temperatures (+5°C) and further increase of temperature led to degradation of the donor.

First the effect of these changes was probed by the condensation of tri-*O*-benzyl trifluoro-*N*-phenylimidate donors **5-8**, with allyl-TMS), showing nearly identical selectivities as those obtained previously by van Rijssel *et al.* with the four perbenzylated furanosyl acetates **1-4** with TES-D as the acceptor (see entries 1-4 *vs* entries 5-8, Table 1).²⁴ The high 1,2-*cis*-selectivity of all tri-*O*-benzyl furanosides (**1-8**, entries 1-8, Table 1) is apparent (α for *ribo*- and *xylo*-configured, β for *arabino*- and *lyxo*-configured substrates). The *ribo*- and *lyxo*-configured donors give solely the 1,2-*cis*-glycosylated products (**21**, **23**, **25**, **27**). The *xylo*-configured donors show poorer selectivity and a 85:15 α : β product ratio is obtained when both xylosyl donors are condensed with allyl-TMS (**28**) or TES-D (**24**). Arabinoside **1** is highly β -selective with TES-D (**21**) and forms a small amount of the other anomer when glycosylated as imidate **5** with allyl-TMS (**25**).

This 1,2-*cis*-selectivity largely remains in the series of C-2- and C-5-modified furanosides: all configurations except xylose are highly 1,2-*cis*-selective for all modifications tested. Rather strikingly, it thus appears that the nature of the substituents on furanosyl donors, have relatively little effect on the stereochemical outcome of the glycosylation reactions, when following a S_N1-like pathway. The 2-fluoroxyloside **36** is formed in a 70:30 α : β ratio, and the 2-azidoxyloside donor **20** gives a 85:15 mixture of

Table 1. Glycosylations of imidate donors 5-20.^a

		21: Rib 22: Ara 23: Lyx 24: Xyl						
		R = CH ₂ OBn 25: Rib 26: Ara 27: Lyx 28: Xyl R = CO ₂ Me 29: RibA 30: AraA 31: LyxA 32: XylA						
		R' = F, R'' = allyl 33: RibF 34: AraF 35: LyxF 36: XylF R' = N ₃ , R'' = D 37: RibN ₃ 38: AraN ₃ 39: LyxN ₃ 40: XylN ₃						
Entry	Donor	Donor configuration ^b	Acceptor	Temp. (°C)	Time (h)	Product	α : β	Yield (%)
1	1	β-Rib	2 eq. TES-D	-78	70	21	>98 : 2	50
2	2	α/β-Ara (2/1)	2 eq. TES-D	-78	165	22	<2 : 98	62
3	3	α-Lyx	2 eq. TES-D	-78	165	23	<2 : 98	100
4	4	α/β-Xyl (1/3)	2 eq. TES-D	-78	165	24	85 : 15	40
5	5	β-Rib	2 eq. allyl-TMS	-78	24	25	>98 : 2	^e
6	6	α-Ara	2 eq. allyl-TMS	-78	24	26	10 : 90	^e
7	7	α-Lyx	2 eq. allyl-TMS	-78	24	27	<2 : 98	^e
8	8	α/β-Xyl (1/6)	2 eq. allyl-TMS	-78	24	28	85 : 15	^e
9	9	β-RibA	4 eq. allyl-TMS	-20	100	29	>98 : 2	79
10	10	α/β-AraA (1/1)	4 eq. allyl-TMS	-20	100	30	5 : 95	76
11	11	α-LyxA ^c	4 eq. allyl-TMS	-20	100	31	<2 : 98	76
12	12	β-XylA	4 eq. allyl-TMS	-20	100	32	45 : 55	57 ^d
13	13	β-RibF	4 eq. allyl-TMS	-20	100	33	>98 : 2	76
14	14	α-AraF ^c	4 eq. allyl-TMS	-20	100	34	<2 : 98	79
15	15	α-LyxF	4 eq. allyl-TMS	-20	100	35	<2 : 98	90
16	16	α/β-XylF (3/5)	4 eq. allyl-TMS	-20	100	36	70 : 30	62
17	17	β-RibN ₃ ^c	4 eq. TES-D	+5	100	37	>98 : 2	68
18	18	α-AraN ₃ ^c	4 eq. TES-D	+5	100	38	<2 : 98	57
19	19	β-LyxN ₃ ^c	4 eq. TES-D	+5	100	39	<2 : 98	59
20	20	α/β-XylN ₃ (1/1)	4 eq. TES-D	+5	100	40	85 : 15	68 ^d

Anomeric configuration established by HSQC-HECADE and NOESY NMR.²⁷⁻²⁹ ^aDetailed experimental conditions are provided in the experimental section. ^bImidates were assigned by ¹H NMR at +50°C in CDCl₃, but rotational dynamics still interfered with definite anomeric determination and the imidates are tentatively assigned based on ¹³C chemical shift; imidate anomeric mixtures served as a reference. ^cThese imidates were formed as an anomeric mixture and isolated as separate anomers, indicated is the anomer used in the reaction. ^dCalculated yields from isolated mixed fractions. ^eYield not determined, ratios obtained from crude ¹H NMR.

anomers (product **40**), identical to the reaction of the corresponding tri-*O*-benzyl donor. The uronic acid xyloside donor **12** is the least selective (entry 12, Table 1), giving roughly equal amounts of both the α - and the β -product (**32**). The reactions of the xylosides also provided significant quantities of different side products. Beside **45**, the product originating from an intramolecular electrophilic aromatic substitution, the yet unreported trifluoro-*N*-phenylacetamide linked glycosides (**41-44**) were formed (Figure 4). The furanosides with other configurations only showed minor amounts of these side products.




Figure 4. Side products **41-45** identified as side products, percentages obtained from the crude ^1H NMR.

Computations

With the experimental glycosylation stereoselectivity data available, the computational studies of the intermediate oxocarbenium ions were undertaken next. The oxocarbenium ions which are used in DFT calculations are displayed in Figure 3 and they are all protected with *O*-methyl ethers to limit rotational degrees of freedom and reduce computational cost.

The DFT calculations were executed by screening all the conformations on the pseudo-rotational circle, akin to the method described by van Rijssel *et al.* An initial geometry-optimized structure was taken as the base conformation and by changing the dihedral angles of the ring atoms, a set of 81 conformations was generated, with a maximum ring puckering of 40° (See Experimental section). While these dihedral angles were constrained, the other internal coordinates were allowed to change in the subsequent energy optimization calculations, performed by the Gaussian 03 software package,³⁰ at a computational level of B3LYP/6-311G**. Three separate sets of 81 conformations each were generated for the *gg*, *gt*, and *tg* C-4–C-5 rotamers respectively,

totaling 243 data points. For the uronic acids, two sets of 81 conformations, for the eclipsed and bisected structures, were assessed providing 162 data points. The energy obtained from the DFT calculations was corrected for solvation in DCM by a polarized continuum model (PCM). Additionally, a Gibbs free energy correction was applied at the temperature of the glycosylation reactions.³¹ The energy of all conformers was then visualized as a polar contour plot on the pseudo-rotational circle, with isoenergetic values as the contour lines, resulting in the Conformational Energy Landscape (CEL) maps (*vide infra*). Separate CEL maps are generated for the C-4–C-5 bond rotamers (*gg*, *gt*, *tg*, or eclipsed and bisected).





Figure 3. Oxocarbenium ions evaluated computationally in this chapter.

The modifications at C-2 and C-5 have been examined for each configuration and Tables 2-5 report the CEL maps for each configuration, the contributions of each C-4–C-5 rotamer, the relative energy of the most favorable conformations, as well as the experimental stereoselectivities.

The results of the computational study of the *ribo*-configured furanosyl oxocarbenium ions **49–52** are provided in Table 2. The overall shape of the energy landscape is comparable for all four ions in the combined rotamer CEL maps, with the energy minima centered on the E_3 conformation, which places all the individual substituents in their most favorable orientation. The three individual rotamers provide similar maps for the different C-2 modifications, with *gg* being clearly the most favorable rotamer, as this species benefits from a stabilizing interaction of the O-5 lone pairs and the electron depleted anomeric center. The uronic acid has two low-energy C-4–C-5

Table 2. CEL maps of *ribo*-configured oxocarbenium ions 49-52.




R = OMe, F, or N₃; X = CH₂ or C=O.

rotamers, being the eclipsed and bisected ones. Apparently both can benefit from a charge-stabilizing interaction by the lone pairs of the oxygen atoms of the uronic acid ester. The CEL maps of both are similar, with the stabilization originating from the C=O being somewhat more favorable than the stabilization of the OMe group. The most appreciable structural difference that can be derived from the CEL maps of the four ribosyl oxocarbenium ions, is the stronger tendency of the fluorine atom to occupy a *pseudo-equatorial* orientation. The 3E conformer of **50** is 5.2 kcal·mol⁻¹ higher in energy than the lowest energy E_3 conformer, whereas this difference is only 1.9 kcal·mol⁻¹ for **49** and around 2.5 kcal·mol⁻¹ for **51** and **52**. The introduction of an electron-withdrawing substituent on C-2 or C-5 also led to the decrease of the relative energy of the twist 4T_3 structures, closely related to the E_3 conformation. Using the lowest energy E_3 conformers, or closely related 4T_3 structures, as product forming intermediates the formation of the 1,2-*cis*-products can be accounted for using the inside attack model. Thus the stereoelectronic effects of the C-2-OBn, C-2-F and C-2-N₃ on the stability and reactivity of the intermediate oxocarbenium ions appear to be very similar.

The CEL maps for *arabino*-configured furanosyl oxocarbenium ions **53-56** (depicted in Tabel 3) also have a very similar overall shape, with the energy minima at the 3E conformations. The substituents for *arabino*-configured furanosyl oxocarbenium ions cannot simultaneously take up a most stabilizing orientation and the contribution of the C-2-H hyperconjugation seems to be most dominating, resulting in the 3E as the lowest energy structure. The three C-4-C-5 rotamers show the expected order of stability: *gg* > *gt* > *tg*. There are small structural differences apparent caused by the stereoelectronic effects of the fluoro, and azido groups respectively. The 3E conformation is clearly the most stable structure, but a second minimum appears on the other side of the CEL map at a minimally puckered E_3 conformation. The largest difference is seen for the C-2-N₃ *gg*-rotamer, where a second minimum-energy conformer can be found for structures adopting a ${}^4T_3/{}^4E$ conformation with minimal puckering, and one without any puckering (Figure 5). The uronic acid oxocarbenium ion **56** preferentially takes up a 3E structure, with the related 3T_4 conformation being relatively close in energy (0.9 kcal·mol⁻¹).

The stereoselectivity of the condensation reactions of the arabinofuranosyl donors, which are all highly 1,2-*cis*-selective, may be explained using the ${}^3E/{}^3T_4$ structures as product forming intermediates. This would indicate that attack on the more flat C-2-N₃ oxocarbenium ions is relatively unfavorable.

Table 3. CEL maps of *arabino*-configured oxocarbenium ions 53-56.



R = OMe, F, or N₃; X = CH₂ or C=O.





Figure 5. Ball-stick model of the *flat* conformation of 2-azidoarabinosyl oxocarbenium ion **55**, viewed through the C-2–C-3 bond and C-1–C-2 bond respectively.

All *lyxo*-configured oxocarbenium ions **57-60** (Table 4) show a single energy minimum on the 3E side of the CEL map. The difference in energy between this structure and the other conformers appears to be even larger than the energy differences observed for the ribosyl oxocarbenium ions. This can be understood by realizing that the ‘inverted’ envelope, the E_3 , not only loses the stabilizing interactions of the C-2 and C-3 substituents, but also experiences severe 1,3-diaxial interactions between the C-2 and C-4 groups, especially for the electronically most favorable *gg*-rotamer. In the most stable 3E conformer, the steric interaction between the C-5–OMe and the C-3–OMe (a 1,3-diaxial like interaction) increases the relative energy of the *gg*-rotamer, and the *gt*-rotamer is the most favorable rotamer providing the energy minimum in the overall CEL map. Also in the *lyxo*-case, the effect of the different substituents is minimal, although structures occupying a 3T_4 conformation are relatively favorable for all three modifications (being 1.2–2.1 kcal·mol⁻¹ higher in energy than the neighboring E_3 envelopes). Again the lowest energy oxocarbenium ions account for the observed experimental all-*cis* stereoselectivity, following the inside attack model.

Table 4. CEL maps of *lyxo*-configured oxocarbenium ions 57-60.



R = OMe, F, or N₃; X = CH₂ or C=O.

Finally, the *xylo*-configured oxocarbenium ions **61-64** (Table 5) were assessed. Again, the CEL maps of the differently functionalized xylosides appear to be rather similar. Two minima are apparent on either side of the CEL maps. These minima originate from C-4–C-5 rotamers, with the *gg*- and *gt*-rotamers leading to low energy E_3 -like and 3E -like structures respectively. The energy minima located on the south side of the CEL maps are relatively ‘broad’ and not only encompass the E_3 conformations but also, as noted earlier by van Rijssel *et al.*, the 4T_3 structures, and perhaps more striking, the 4E envelope conformation. This latter conformer is in fact the lowest energy species for 2-fluoroxyside **62** and xylosyl uronate **64**. This conformation is unable to use the stabilizing effect of the O-3 lone electron pairs, or the hyperconjugation of the C–H bond on C-2 to its full extent (Figure 6). Instead, the driving stabilization now appears to be the interaction of the C-5–O-benzyl with the anomeric center. In the 4E conformation, the steric interactions between C-5 and the substituents at C-3 and the C-2–H are reduced when compared to the sterically unfavorable situation in the E_3 conformer.

When the relative energy of the different configurations is compared, it becomes clear that the xylose oxocarbenium ions are higher in energy than their configurational counterparts. This may, in part, account for the higher amount of side products formed in the reactions of the xylosyl donors.³² The established broad energy minima may be at the basis for the poor stereoselectivity observed in the condensations of the xylosyl donors as attack of the 4E conformers (See Figure 6) may occur from both sides of the ring.





Figure 6. Ball-stick model of the 4E conformation of 2-fluoroxysyl oxocarbenium ion **62**, viewed through the C-2–C-3 bond and C-1–C-2 bond respectively.

Table 5. CEL maps of xylo-configured oxocarbenium ions **61-64**.



R = OMe, F, or N₃; X = CH₂ or C=O.

Conclusions

A set of twelve functionalized furanosides has been glycosylated under conditions favoring an S_N1 -type substitution reaction with allyltrimethylsilane or triethylsilane-*d* to investigate the stereoselectivity of these reactions. The experimental results have been complemented by computational studies, generating Conformational Energy Landscape (CEL) maps for the intermediate oxocarbenium ions. Striking similarities have been observed for the CEL maps of the oxocarbenium ions featuring different C-2 and C-5 substituents and –as a result– very similar stereoselectivities are obtained in the glycosylations of the different donors. Nonetheless, the CEL map method also revealed conformers different from the 3E - E_3 pair as relatively stable conformers and structural deviations to 4E , 4T_3 , 3T_4 and flat conformations have been revealed in some cases for the 2-fluoro, 2-azido, and 5-methyl uronate substituted species. The changes in the population of the different conformational states of the reactive intermediate only had a minor effect on the outcome of the glycosylations, which were across the board highly 1,2-*cis*-selective, except for the *xylo*-configured furanosides which consistently provided anomeric mixtures. The appearance of more low-energy conformations for the *xylo*-configured oxocarbenium ions could account for the erosion of stereoselectivity. CEL maps with a localized single energy minimum corresponded to reactions that are completely stereoselective. Overall, the study described here has shown that the nature of the substituent, C-2–OBn *vs* –F or –N₃ and C-4–CH₂OBn *vs* –CO₂Me, does not significantly affect the structure of the intermediate ions and the course of the S_N1 -type reactions studied here. This stands in sharp contrast to the effect that these substituents have in glycosylations of pyranosyl donors (See for example chapter 4 and 6). The effect of the different substituents in this case can probably best be reconciled with a change in the S_N2 - S_N1 reaction mechanism continuum.


Experimental section

General procedure for furanoside imidate glycosylations. The imidate donor (0.1 mmol, 1 eq.) was coevaporated twice with dry toluene and then dissolved in dry DCM (1 mL). Activated 3 Å molecular sieves and the acceptor (2 or 4 eq.) were added and the solution was stirred for 30 min at room temperature under an inert atmosphere (N₂ or Ar). The reaction mixture was cooled to the indicated temperature and a freshly prepared stock solution (0.2 M in DCM) of TMSOTf or TFOH was introduced via syringe (50 µL, 0.01 mmol, 0.1 eq.). The reaction mixture was stirred for 1-4 days at the indicated temperature, and was then quenched by the addition of sat. aq. NaHCO₃. The mixture was diluted with H₂O and twice extracted with DCM. The combined organic layers were dried with MgSO₄, filtered, and concentrated *in vacuo*. The residue was purified by flash column chromatography (1/0 to 80/20 pentane/Et₂O) to provide the glycosylated furanoside.


General procedure for quantum mechanical calculations. Analogous to the work of van Rijssel,²⁴ all calculations were performed with DFT calculations with the B3LYP hybrid functional. The starting conformer for the Conformational Energy Landscapes (CEL) was obtained by a conformer distribution search in the Spartan 10 program in the gas phase, with a 6-31G(d) basis set. All resulting geometries were further optimized at the 6-311G(d,p) level in the Gaussian 03 program, with a polarized continuum model (PCM) to correct for solvation in dichloromethane, and further corrected for their zero-point energy (ZPE). The geometry with the lowest, ZPE corrected solvated energy, was selected and used as the starting geometry for the CEL. Two dihedral angles of the five-membered ring were constrained: C4-O4-C1-C2 and C1-C2-C3-C4 by scanning with 10° per step, over 9 steps (-40° to 40°), totaling 81 conformations spanning the entire pseudo rotational sphere with a maximum puckering amplitude (τ_m) of 40°. All other internal coordinates were unconstrained. Three separate staggered rotamers (*gg*, *gt*, *tg*) of the O4-C4-C5-O5 dihedral angle (-65°, 65°, 175°) were considered and their CEL maps were calculated separately by pre-rotating the C4-C5 bond (not constrained), bringing the total conformations for each configuration to 243 geometries. The final denoted free Gibbs energy was calculated using Equation (1) in which ΔE_{gas} is the gas-phase energy (electronic energy), ΔG_{gas}^T ($T = 298.15$ K and pressure = 1 atm.) is the sum of corrections from the electronic energy to free Gibbs energy in the harmonic oscillator approximation also including zero-point-vibrational energy, and ΔG_{solv}^T is their corresponding free solvation Gibbs energy.

$$\begin{aligned} \Delta G_{in\ solution}^T &= \Delta E_{gas} + \Delta G_{gas}^T + \Delta G_{solv} \\ &= \Delta G_{gas}^T + \Delta G_{solv} \end{aligned} \quad (1)$$


All found minima were checked for negative frequencies. The CEL was visualized as a polar contour plot by the Origin pro 9 software, with the energy plotted as 0.5 kcal·mol⁻¹ colored intervals, the phase angle P as the azimuth angle and the puckering amplitude (τ_m) as the radius, with a smoothing factor of 0.001. The computed stereoselectivity was based on the ³E - E₃ two conformer (inside-attack) model, as the ratio of conformers obtained from the Boltzmann distribution over these two conformers, at the temperature of the experiment.




2,3,5-tri-O-benzyl-1-O-(N-[phenyl]trifluoroacetimidoyl)-α-D-arabinofuranoside (6). The arabinofuranose lactol²⁴ (421 mg, 1 mmol) was dissolved in acetone (6 mL) and H₂O (0.1 mL) and cooled to 0°C. Cs₂CO₃ (358 mg, 1.1 mmol, 1.1 eq.) and 2,2,2-trifluoro-N-phenylacetimidoyl chloride (317 µL, 2 mmol, 2 eq.) were added and the reaction mixture stirred overnight. Very little conversion was observed (TLC-analysis), therefore DBU (0.12 mL) was added and the conversion was complete immediately. The reaction mixture was reduced in volume under reduced pressure and H₂O was added. The aqueous phase was extracted twice with DCM and the combined organic layers were dried with Na₂SO₄, filtered, and concentrated under reduced pressure. Flash column chromatography (0-15% Et₂O/pentane, with 0.5% Et₃N) of the residue provided the target imidate donor. Yield = 425 mg, 0.72 mmol, 72% as a waxy solid. R_f: 0.81 (85/15 pentane/Et₂O). ¹H NMR (CDCl₃, $T = 323$ K, 400 MHz, HH-COSY, HSQC): δ 7.32 – 7.22 (m, 17H, CH_{arom}), 7.09 – 7.01 (m, 1H, NPh), 6.80 (d, 2H, $J = 8.0$ Hz, NPh), 6.27 (bs, 1H, H-1), 4.60 – 4.47 (m, 6H, 3xCH₂ Bn), 4.45 (q, 1H, $J = 5.1$ Hz, H-4), 4.23 (d, 1H, $J = 1.8$ Hz, H-2), 4.03 (dd, 1H, $J = 5.5$, 2.0 Hz, H-3), 3.63 (d, 2H, $J = 5.1$ Hz, H-5, H-5); ¹³C-APT NMR (CDCl₃, $T = 323$ K, 101 MHz, HSQC): δ 144.0 (C_q NPh), 138.1, 137.9, 137.4 (C_q Bn), 128.8, 128.5, 128.5, 128.4, 127.9, 127.9, 127.8, 127.7, 124.3, 119.8 (CH_{arom}), 104.0 (C-1), 87.0 (C-2), 84.1 (C-4), 83.8 (C-3), 73.5, 72.3 (CH₂ Bn), 69.7 (C-5); HRMS: [M+Na]⁺ calcd for C₃₄H₃₂F₃NO₅Na 614.21217, found 614.21248.




2,3,5-tri-O-benzyl-1-O-(N-phenyl)trifluoroacetimidoyl- β -D-ribofuranoside (5). The ribofuranose lactol²⁴ (421 mg, 1 mmol) was dissolved in acetone (6 mL) and H₂O (0.1 mL) and cooled to 0°C. Cs₂CO₃ (489 mg, 1.5 mmol, 1.5 eq.) and 2,2,2-trifluoro-N-phenylacetimidoyl chloride (238 μ L, 1.5 mmol, 1.5 eq.) were added and the reaction mixture stirred for 2 days. The reaction mixture was reduced in volume under reduced pressure and H₂O was added. The aqueous phase was extracted twice with DCM and the combined organic layers were dried with Na₂SO₄, filtered, and concentrated under reduced pressure. Flash column chromatography (0-15% Et₂O/pentane, with 0.5% Et₃N) of the residue provided the target imidate donor. Yield = 327 mg, 0.55 mmol, 55% as a colourless oil. R_f: 0.15 (95/5 pentane/Et₂O). Spectroscopic data were in accord with those previously reported.³³ ¹H NMR (CDCl₃, T = 295 K, 400 MHz, HH-COSY, HSQC): δ 7.34 – 7.26 (m, 17H, CH_{arom}), 7.14 – 7.06 (m, 1H, NPh), 6.80 (d, 2H, J = 7.5 Hz, NPh), 6.33 (bs, 1H, H-1), 4.75 – 4.50 (m, 5H, 2xCH₂ Bn, CHH Bn), 4.49 – 4.43 (m, 2H, CHH Bn, H-4), 4.16 (dd, 1H, J = 7.3, 4.7 Hz, H-3), 4.07 (d, 1H, J = 4.0 Hz, H-2), 3.71 (dd, 1H, J = 11.0, 3.1 Hz, H-5), 3.59 (dd, 1H, J = 11.0, 4.9 Hz, H-5); ¹³C-APT NMR (CDCl₃, T = 295 K, 101 MHz, HSQC): δ 143.8 (C_q NPh), 138.2, 137.5, 137.4 (C_q Bn), 128.8, 128.5, 128.5, 128.4, 128.2, 128.1, 128.0, 127.9, 127.6, 124.3, 119.7 (CH_{arom}), 102.5 (C-1), 82.2 (C-4), 78.5 (C-2), 77.3 (C-3), 73.3, 72.7, 72.3 (CH₂ Bn), 70.0 (C-5).




2,3,5-tri-O-benzyl-1-O-(N-phenyl)trifluoroacetimidoyl- α -D-lyxofuranoside (7). The lyxofuranose lactol²⁴ (660 mg, 1.58 mmol) was dissolved in acetone (8 mL) and H₂O (0.5 mL) and cooled to 0°C. Cs₂CO₃ (619 mg, 1.9 mmol, 1.2 eq.) and 2,2,2-trifluoro-N-phenylacetimidoyl chloride (500 μ L, 3.17 mmol, 2 eq.) were added and the reaction mixture stirred overnight. Very little conversion was observed (TLC-analysis), therefore DBU (0.2 mL) was added and the conversion was complete immediately. The reaction mixture was reduced in volume under reduced pressure and coevaporated with dioxane and toluene. The residue was dissolved in DCM and filtered over Celite, the filtrate was concentrated under reduced pressure. Flash column chromatography (0-15% Et₂O/pentane, with 0.5% Et₃N) of the residue provided the target imidate donor. Yield = 930 mg, 1.57 mmol, 100% as a white solid. R_f: 0.8 (85/15 pentane/Et₂O). ¹H NMR (CDCl₃, T = 323 K, 400 MHz, HH-COSY, HSQC): δ 7.34 – 7.20 (m, 17H, CH_{arom}), 7.09 – 7.01 (m, 1H, NPh), 6.78 (d, 2H, J = 8.0 Hz, NPh), 6.31 (bs, 1H, H-1), 4.68 – 4.44 (m, 7H, 3xCH₂ Bn, H-4), 4.25 (t, 1H, J = 5.1 Hz, H-3), 4.13 (d, 1H, J = 4.2 Hz, H-2), 3.83 (dd, 1H, J = 10.5, 4.7 Hz, H-5), 3.76 (dd, 1H, J = 10.4, 7.3 Hz, H-5); ¹³C-APT NMR (CDCl₃, T = 323 K, 101 MHz, HSQC): δ 143.9 (C_q NPh), 138.2, 137.9, 137.5 (C_q Bn), 129.3, 128.8, 128.5, 128.4, 128.4, 128.0, 127.9, 127.8, 127.7, 124.4, 119.7 (CH_{arom}), 103.0 (C-1), 81.7 (C-2), 80.5 (C-4), 77.4 (C-3), 73.5, 73.5, 72.9 (CH₂ Bn), 69.5 (C-5).




2,3,5-tri-O-benzyl-1-O-(N-phenyl)trifluoroacetimidoyl- α -D-xylofuranoside (8). The xylofuranose lactol²⁴ (421 mg, 1 mmol) was dissolved in acetone (10 mL) and cooled to 0°C. 2,2,2-Trifluoro-N-phenylacetimidoyl chloride (190 μ L, 1.2 mmol, 1.2 eq.) and DBU (165 μ L, 1.1 mmol, 1.1 eq.) were added and the reaction mixture stirred for 1 h. The reaction mixture was reduced in volume under reduced pressure and H₂O was added. The aqueous phase was extracted twice with DCM and the combined organic layers were dried with Na₂SO₄, filtered, and concentrated under reduced pressure. Flash column chromatography (0-15% Et₂O/pentane, with 0.5% Et₃N) of the residue provided the target imidate donor. Yield = 427 mg, 0.72 mmol, 72% as a waxy solid. R_f: 0.38 and 0.47 (9/1 pentane/Et₂O). Data for the β -anomer: ¹H NMR (CDCl₃, T = 295 K, 400 MHz, HH-COSY, HSQC): δ 7.34 – 7.18 (m, 17H, CH_{arom}), 7.05 (t, 1H, J = 7.4 Hz, NPh), 6.77 (d, 2H, J = 7.6 Hz, NPh), 6.30 (bs, 1H, H-1), 4.65 (q, 1H, J = 5.6 Hz, H-4), 4.60 – 4.42 (m, 6H, 3xCH₂ Bn), 4.24 (s, 1H, H-2), 4.10 (d, 1H, J = 5.4 Hz, H-3), 3.86 (dd, 1H, J = 10.4, 5.1 Hz, H-5), 3.80 (dd, 1H, J = 10.2, 7.2 Hz, H-5); ¹³C-APT NMR (CDCl₃, T = 295 K, 101 MHz, HSQC): δ 143.9 (C_q NPh), 138.2, 137.7, 137.2 (C_q Bn), 129.1, 128.7, 128.5, 128.4, 128.3, 128.0, 127.8, 127.7, 127.6, 127.5, 124.2, 119.6 (CH_{arom}), 103.5 (C-1), 84.5 (C-2), 83.0 (C-4), 81.1 (C-3), 73.4, 72.4, 72.1 (CH₂ Bn), 69.1 (C-5).




Allyl 2,3,5-tri-O-benzyl-1-deoxy- α -D-ribofuranoside (25). Donor **5** and allyltrimethylsilane (2 eq.) were condensed using the general procedure for furanosyl imidate glycosylations at -78°C for 24 h with TMSOTf as the promotor. R_f: 0.27 (19/1 pentane/EtOAc). Spectroscopic data were in accord with those previously reported.³⁴ ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.40 – 7.23 (m, 15H, CH_{arom}), 5.79 (ddt, 1H, J = 17.1, 10.2, 6.9 Hz, CH allyl), 5.10 (dq, 1H, J = 17.2, 1.5 Hz, CHH allyl), 5.04 (ddt, 1H, J = 10.2, 2.1, 1.1 Hz, CHH allyl), 4.81 (d, 1H, J = 11.7 Hz, CHH Bn), 4.64 – 4.45 (m, 5H, CHH Bn, 2xCH₂ Bn), 4.21 (dt, 1H, J = 7.1, 3.5 Hz, H-4), 4.10 (dd, 1H, J = 7.1, 4.3 Hz, H-3), 4.05 (td, 1H, J = 7.0, 3.9 Hz, H-1), 3.98 (t, 1H, J = 4.1 Hz, H-2), 3.63 (dd, 1H, J = 10.7, 3.3 Hz, H-5), 3.52 (dd, 1H, J = 10.7, 3.8 Hz, H-5), 2.51 (t, 2H, J = 7.0 Hz, CH₂ allylic); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 138.6, 138.4, 138.1 (C_q Bn), 135.1 (CH allyl), 128.5, 128.4, 128.4, 127.9, 127.8, 127.8, 127.7, 127.7 (CH_{arom}), 117.0 (CH₂ allyl), 80.2 (C-1), 80.1 (C-3), 79.6 (C-4), 77.7 (C-2), 73.5, 73.4, 72.8 (CH₂ Bn), 70.2 (C-5), 34.4 (CH₂ allylic); HRMS: [M+NH₄]⁺ calcd for C₂₉H₃₆NO₄ 462.26389, found 462.26382.




Allyl 2,3,5-tri-O-benzyl-1-deoxy- α/β -D-arabinofuranoside (26). Donor **6** and allyltrimethylsilane (2 eq.) were condensed using the general procedure for furanosyl imidate glycosylations at -78°C for 24 h with TMSOTf as the promotor. ($\alpha:\beta = 10:90$). Spectroscopic data were in accord with those previously reported.³⁵ ^1H NMR (CDCl_3 , 400 MHz, HH-COSY, HSQC): δ 7.36 – 7.23 (m, 15H, CH_{arom}), 5.80 (ddt, 1H, $J = 17.1, 10.2, 7.0$ Hz, CH allyl), 5.15 – 5.00 (m, 2H, CH_2 allyl), 4.61 – 4.47 (m, 5H, 2x CH_2 Bn, CHH Bn), 4.36 (d, 1H, $J = 11.9$ Hz, CHH Bn), 4.08 (td, 1H, $J = 6.7, 2.8$ Hz, H-4), 4.03 (td, 1H, $J = 7.0, 3.5$ Hz, H-1), 3.92 (d, 1H, $J = 2.7$ Hz, H-3), 3.81 (d, 1H, $J = 3.5$ Hz, H-2), 3.63 (dd, 1H, $J = 9.8, 5.8$ Hz, H-5), 3.51 (dd, 1H, $J = 9.8, 6.9$ Hz, H-5), 2.52 – 2.47 (m, 2H, CH_2 allylic); ^{13}C -APT NMR (CDCl_3 , 101 MHz, HSQC): δ 138.3, 138.0, 137.9 (C_q Bn), 135.0 (CH allyl), 128.6, 128.5, 128.4, 127.9, 127.8, 127.8, 127.7 (CH_{arom}), 117.1 (CH_2 allyl), 83.8 (C-3), 82.9 (C-2), 82.8 (C-4), 81.1 (C-1), 73.4, 71.5, 71.4 (CH_2 Bn), 70.7 (C-5), 33.3 (CH_2 allylic).




Allyl 2,3,5-tri-O-benzyl-1-deoxy- β -D-lyxofuranoside (27). Donor **7** and allyltrimethylsilane (2 eq.) were condensed using the general procedure for furanosyl imidate glycosylations at -78°C for 24 h with TMSOTf as the promotor. R_f : 0.47 (9/1 pentane/EtOAc). ^1H NMR (CDCl_3 , 400 MHz, HH-COSY, HSQC): δ 7.36 – 7.24 (m, 15H, CH_{arom}), 5.82 (ddt, 1H, $J = 17.1, 10.2, 7.0$ Hz, CH allyl), 5.07 (dq, 1H, $J = 17.1, 1.5$ Hz, CHH allyl), 5.02 (ddt, 1H, $J = 10.2, 2.2, 1.2$ Hz, CHH allyl), 4.76 (d, 1H, $J = 11.8$ Hz, CHH Bn), 4.68 (d, 1H, $J = 11.9$ Hz, CHH Bn), 4.61 (d, 1H, $J = 11.9$ Hz, CHH Bn), 4.59 (d, 1H, $J = 12.1$ Hz, CHH Bn), 4.54 (d, 1H, $J = 11.8$ Hz, CHH Bn), 4.52 (d, 1H, $J = 12.1$ Hz, CHH Bn), 4.24 – 4.19 (m, 1H, H-4), 4.17 (dd, 1H, $J = 6.1, 3.9$ Hz, H-3), 4.01 – 3.94 (m, 2H, H-1, H-2), 3.83 (dd, 1H, $J = 10.1, 4.8$ Hz, H-5), 3.72 (dd, 1H, $J = 10.1, 6.6$ Hz, H-5), 2.53 – 2.46 (m, 2H, CH_2 allylic); ^{13}C -APT NMR (CDCl_3 , 101 MHz, HSQC): δ 138.6, 138.5, 138.4 (C_q Bn), 135.6 (CH allyl), 128.5, 128.4, 128.4, 127.9, 127.7, 127.7, 127.6, 127.5 (CH_{arom}), 116.7 (CH_2 allyl), 79.6 (C-3), 79.1 (C-1), 78.9 (C-2), 78.0 (C-4), 73.4, 73.3, 73.3 (CH_2 Bn), 70.5 (C-5), 35.4 (CH allylic); ^{13}C HSQC-HECADE NMR (CDCl_3 , 101 MHz): $^2J_{\text{C}1,\text{H}2} = +1.0$ Hz, $^2J_{\text{C}2,\text{H}1} = +1.5$ Hz, $^3J_{\text{H}2,\text{C}\text{-allyl}} = +1.6$ Hz; HRMS: $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{29}\text{H}_{33}\text{O}_4$ 445.23709, found 445.23704.




Allyl 2,3,5-tri-O-benzyl-1-deoxy- α/β -D-xylofuranoside (28). Donor **8** and allyltrimethylsilane (2 eq.) were condensed using the general procedure for furanosyl imidate glycosylations at -78°C for 24 h with TMSOTf as the promotor. R_f : 0.38 (92/8 pentane/Et₂O). Spectroscopic data were in accord with those previously reported for the β -anomer.³⁶ Data for the α -anomer: ^1H NMR (CDCl_3 , 400 MHz, HH-COSY, HSQC): δ 7.40 – 7.22 (m, 15H, CH_{arom}), 5.78 (ddt, 1H, $J = 17.1, 10.2, 6.9$ Hz, CH allyl), 5.10 (dq, 1H, $J = 17.2, 1.6$ Hz, CHH allyl), 5.02 (ddd, 1H, $J = 10.2, 2.2, 1.1$ Hz, CHH allyl), 4.64 – 4.35 (m, 6H, 3x CH_2 Bn), 4.37 (td, 1H, $J = 6.3, 4.1$ Hz, H-4), 4.16 (td, 1H, $J = 7.1, 3.7$ Hz, H-1), 4.03 (dd, 1H, $J = 4.1, 1.1$ Hz, H-3), 3.83 (dd, 1H, $J = 3.7, 1.1$ Hz, H-2), 3.72 (dd, 1H, $J = 9.6, 6.4$ Hz, H-5), 3.67 (dd, 1H, $J = 9.6, 6.3$ Hz, H-5); ^{13}C -APT NMR (CDCl_3 , 101 MHz, HSQC): δ 138.4, 138.1, 138.0 (C_q Bn), 135.2 (CH allyl), 128.6, 128.5, 128.4, 127.9, 127.9, 127.8, 127.7 (CH_{arom}), 116.9 (CH_2 allyl), 81.8 (C-2), 81.4 (C-3), 80.1 (C-1), 78.8 (C-4), 73.5, 72.4, 72.1 (CH_2 Bn), 68.5 (C-5), 33.7 (CH_2 allylic); ^{13}C HSQC-HECADE NMR (CDCl_3 , 101 MHz): $^2J_{\text{C}1,\text{H}2} = +4.2$ Hz, $^2J_{\text{C}2,\text{H}1} = +2.2$ Hz, $^3J_{\text{C}\text{-allyl},\text{H}2} = +0.5$ Hz; Diagnostic peaks for the β -anomer: ^1H NMR (CDCl_3 , 400 MHz, HH-COSY, HSQC): δ 4.24 – 4.18 (m, 1H, H-4), 3.96 (dd, 1H, $J = 3.9, 1.0$ Hz, H-3), 3.92 (ddd, 1H, $J = 7.1, 6.4, 3.5$ Hz, H-1), 3.81 – 3.70 (m, 3H, H-2, H-5, H-5); ^{13}C -APT NMR (CDCl_3 , 101 MHz, HSQC): δ 134.6 (CH allyl), 117.3 (CH_2 allyl), 85.9 (C-2), 83.4 (C-1), 83.0 (C-3), 80.1 (C-4), 73.6, 71.7, 71.7 (CH_2 Bn), 68.5 (C-5), 38.5 (CH_2 allylic); ^{13}C HSQC-HECADE NMR (CDCl_3 , 101 MHz): $^2J_{\text{C}2,\text{H}1} = -4.0$ Hz, $^3J_{\text{C}\text{-allyl},\text{H}2} = +4.5$ Hz; HRMS: $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{29}\text{H}_{33}\text{O}_4$ 445.23709, found 445.23734.




Methyl (1-allyl-2,3-di-O-benzyl-1-deoxy- α -D-ribofuranosyl uronate) (29). Donor **9** and allyltrimethylsilane (4 eq.) were condensed using the general procedure for furanosyl imidate glycosylations at -20°C for 100 h with TfOH as the promotor. Yield = 30.5 mg, 79 μmol , 79% as a white solid. R_f : 0.57 (4/1 pentane/EtOAc). $[\alpha]_{\text{D}}^{20} = +28.3^{\circ}$ ($c = 0.60$, CHCl_3); IR (thin film): 698, 737, 916, 1026, 1099, 1144, 1206, 1275, 1356, 1454, 1748, 2868, 2922, 3030; ^1H NMR (CDCl_3 , 500 MHz, HH-COSY, HSQC): δ 7.38 – 7.27 (m, 10H, CH_{arom}), 5.77 (ddt, 1H, $J = 17.1, 10.2, 6.9$ Hz, CH allyl), 5.11 (dq, 1H, $J = 17.2, 1.6$ Hz, CHH allyl), 5.04 (ddt, 1H, $J = 10.2, 2.0, 1.1$ Hz, CHH allyl), 4.82 (d, 1H, $J = 11.6$ Hz, CHH Bn), 4.67 (d, 1H, $J = 12.0$ Hz, CHH Bn), 4.63 (d, 1H, $J = 12.0$ Hz, CHH Bn), 4.59 (d, 1H, $J = 6.0$ Hz, H-4), 4.56 (d, 1H, $J = 11.6$ Hz, CHH Bn), 4.22 (dd, 1H, $J = 6.0, 4.5$ Hz, H-3), 4.17 (td, 1H, $J = 7.0, 4.1$ Hz, H-1), 3.99 (t, 1H, $J = 4.3$ Hz, H-2), 3.73 (s, 3H, CH_3 CO_2Me), 2.56 – 2.48 (m, 2H, CH_2 allylic); ^{13}C -APT NMR (CDCl_3 , 126 MHz, HSQC): δ 172.7 (C=O), 138.2, 137.6 (C_q), 134.6 (CH allyl), 128.6, 128.5, 128.1, 128.0, 127.9 (CH_{arom}), 117.3 (CH_2 allyl), 82.7 (C-3), 81.1 (C-1), 79.3 (C-4), 77.8 (C-2), 73.6, 72.8 (CH_2 Bn), 52.4 (CH_3 CO_2Me), 34.0 (CH_2 allylic); ^{13}C HSQC-HECADE NMR (CDCl_3 , 126 MHz): $^2J_{\text{C}2,\text{H}1} = +1.5$ Hz, $^3J_{\text{C}\text{-allyl},\text{H}2} = +0.7$ Hz; HRMS: $[\text{M}+\text{NH}_4]^+$ calcd for $\text{C}_{23}\text{H}_{30}\text{NO}_5$ 400.21185, found 400.21173.




Methyl (1-allyl-2,3-di-O-benzyl-1-deoxy- β -D-arabinofuranosyl uronate) (30). Donor **10** and allyltrimethylsilane (4 eq.) were condensed using the general procedure for furanosyl imidate glycosylations at -20°C for 100 h with TfOH as the promotor. Yield = 29 mg, 76 μmol , 76% as a white solid ($\alpha:\beta = 5:95$). R_f: 0.64 (4/1 pentane/EtOAc). $[\alpha]_{\text{D}}^{20} = +32.4^{\circ}$ ($c = 0.38$, CHCl_3); IR (thin film): 698, 737, 916, 1028, 1101, 1207, 1279, 1454, 1726, 1761, 2920; ^1H NMR (CDCl_3 , 500 MHz, HH-COSY, HSQC): δ 7.44 – 7.18 (m, 10H, CH_{arom}), 5.79 (ddt, 1H, $J = 17.1$, 10.2, 7.0 Hz, CH allyl), 5.14 (dq, 1H, $J = 17.1$, 1.5 Hz, CHH allyl), 5.08 – 5.02 (m, 1H, CHH allyl), 4.66 (d, 1H, $J = 11.9$ Hz, CHH Bn), 4.56 (d, 1H, $J = 11.9$ Hz, CHH Bn), 4.51 (d, 1H, $J = 1.7$ Hz, H-4), 4.49 (d, 1H, $J = 11.8$ Hz, CHH Bn), 4.39 – 4.34 (m, 2H, CHH Bn, H-3), 4.21 (td, 1H, $J = 7.2$, 3.5 Hz, H-1), 3.81 (dd, 1H, $J = 3.5$, 0.8 Hz, H-2), 3.68 (s, 3H, CH_3 CO_2Me), 2.64 – 2.50 (m, 2H, CH_2 allylic); ^{13}C -APT NMR (CDCl_3 , 126 MHz, HSQC): δ 171.4 (C=O) 137.7, 137.5 (C_q), 134.7 (CH allyl), 128.6, 128.5, 128.1, 127.9, 127.9, 127.8 (CH_{arom}), 117.3 (CH_2 allyl), 85.2 (C-3), 82.4 (C-1), 81.6 (C-4), 81.3 (C-2), 71.9, 71.8 (CH_2 Bn), 52.3 (CO_2Me), 33.3 (CH_2 allylic); ^{13}C HSQC-HECADE NMR (CDCl_3 , 126 MHz): $^2J_{\text{C}1,\text{H}2} = +2.5$ Hz, $^2J_{\text{C}2,\text{H}1} = +2.5$ Hz, $^3J_{\text{Callyl},\text{H}2} = +0.3$ Hz; HRMS: $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{23}\text{H}_{26}\text{O}_5\text{Na}$ 405.16725, found 405.16656.



Methyl (1-allyl-2,3-di-O-benzyl-1-deoxy- β -D-lyxofuranosyl uronate) (31). Donor **11** and allyltrimethylsilane (4 eq.) were condensed using the general procedure for furanosyl imidate glycosylations at -20°C for 100 h with TfOH as the promotor. Yield = 29 mg, 76 μmol , 76% as a white solid. R_f: 0.32 (4/1 pentane/EtOAc). $[\alpha]_{\text{D}}^{20} = +3.6^{\circ}$ ($c = 0.58$, CHCl_3); IR (thin film): 698, 737, 1028, 1072, 1084, 1099, 1152, 1207, 1356, 1437, 1454, 1732, 1763, 2870, 2920, 2949. ^1H NMR (CDCl_3 , 500 MHz, HH-COSY, HSQC): δ 7.39 – 7.21 (m, 10H, CH_{arom}), 5.92 (ddt, 1H, $J = 17.2$, 10.2, 7.0 Hz, CH allyl), 5.15 (dq, 1H, $J = 17.2$, 1.4 Hz, CHH allyl), 5.09 – 5.04 (m, 1H, CHH allyl), 4.76 – 4.67 (m, 3H, CH_2 Bn, CHH Bn), 4.62 (d, 1H, $J = 6.0$ Hz, H-4), 4.56 (d, 1H, $J = 11.8$ Hz, CHH Bn), 4.34 (dd, 1H, $J = 6.0$, 4.4 Hz, H-3), 4.13 (dt, 1H, $J = 8.8$, 5.4 Hz, H-1), 4.04 (dd, 1H, $J = 6.0$, 4.4 Hz, H-2), 3.66 (s, 3H, CH_3 CO_2Me), 2.75 – 2.64 (m, 1H, CHH allylic), 2.58 – 2.48 (m, 1H, CHH allylic); ^{13}C -APT NMR (CDCl_3 , 126 MHz, HSQC): δ 170.3 (C=O), 138.2, 138.2 (C_q), 135.8 (CH allyl), 128.5, 128.4, 127.8, 127.7, 127.6 (CH_{arom}), 116.8 (CH_2 allyl), 80.5 (C-1), 80.1 (C-3), 79.2 (C-2), 78.3 (C-4), 73.9, 73.2 (CH_2 Bn), 51.9 (CO_2Me), 35.0 (CH_2 allylic); ^{13}C HSQC-HECADE NMR (CDCl_3 , 126 MHz): $^2J_{\text{C}2,\text{H}1} = -0.25$ Hz, $^3J_{\text{Callyl},\text{H}2} = +2.9$ Hz; HRMS: $[\text{M}+\text{NH}_4]^+$ calcd for $\text{C}_{23}\text{H}_{30}\text{NO}_5$ 400.21185, found 400.21167.




Methyl (1-allyl-2,3-di-O-benzyl-1-deoxy- α/β -D-xylofuranosyl uronate) (32). Donor **12** and allyltrimethylsilane (4 eq.) were condensed using the general procedure for furanosyl imidate glycosylations at -20°C for 100 h with TfOH as the promotor. Four fractions were isolated: amide **44** (1 mg, R_f: 0.66), mixed fraction (22 mg, product **32**, $\alpha:\beta = 35:65$ as 68 wt%), and amide **44** as 32 wt%), title product **45** (7 mg, $\alpha:\beta = 69:33$), cyclized product **61** (2 mg, R_f: 0.38) Calculated total title product yield = 22 mg, 57 μmol , 57%, ($\alpha:\beta = 45:55$). R_f: 0.61 and 0.57 (4/1 pentane/EtOAc). Reported as a 1:1 mixture. IR (thin film): 698, 737, 1028, 1078, 1094, 1206, 1290, 1454, 1732, 1765, 2862, 2949. ^1H NMR (CDCl_3 , 500 MHz, HH-COSY, HSQC): δ 7.38 – 7.24 (m, 20H, CH_{arom}), 5.88 – 5.72 (m, 2H, CH allyl), 5.16 – 5.03 (m, 4H, CH_2 allyl), 4.82 (d, 1H, $J = 5.1$ Hz, H-4 α), 4.69 (d, 1H, $J = 4.8$ Hz, H-4 β), 4.54 – 4.38 (m, 8H, 4x CH_2 Bn), 4.36 (ddd, 1H, $J = 7.9$, 6.5, 3.3 Hz, H-1 α), 4.27 (dd, 1H, $J = 5.1$, 1.0 Hz, H-3 α), 4.24 (dd, 1H, $J = 4.8$, 1.7 Hz, H-3 β), 4.01 (td, 1H, $J = 6.9$, 3.3 Hz, H-1 β), 3.82 (d, 1H, $J = 3.5$ Hz, H-2 α), 3.82 (d, 1H, $J = 3.4$ Hz, H-2 β), 3.76 (s, 3H, CH_3 $\text{CO}_2\text{Me}_\beta$), 3.73 (s, 3H, CH_3 $\text{CO}_2\text{Me}_\alpha$), 2.64 – 2.41 (m, 4H, CH_2 allylic); ^{13}C -APT NMR (CDCl_3 , 126 MHz, HSQC): δ 170.6 (C=O α), 169.6 (C=O β), 137.7 ($\text{C}_{q\alpha}$), 137.7 ($\text{C}_{q\beta}$), 137.6 ($\text{C}_{q\beta}$), 137.5 ($\text{C}_{q\alpha}$), 134.5 (CH allyl α), 134.4 (CH allyl β), 128.6, 128.6, 128.6, 128.6, 128.1, 128.1, 128.1, 127.9, 127.9, 127.9 (CH_{arom}), 117.6 (CH_2 allylic β), 117.3 (CH_2 allylic α), 84.7 (C-2 β), 84.0 (C-1 β), 83.9 (C-3 β), 82.9 (C-3 α), 81.6 (C-1 α), 81.4 (C-2 α), 80.4 (C-4 β), 80.0 (C-4 α), 73.0, 72.5, 72.3, 72.0 (CH_2 Bn), 52.1 ($\text{CO}_2\text{Me}_\beta$), 52.0 ($\text{CO}_2\text{Me}_\alpha$), 38.1 (CH_2 allylic β), 33.1 (CH_2 allylic α); ^{13}C HSQC-HECADE NMR (CDCl_3 , 126 MHz): α -anomer: $^2J_{\text{C}1,\text{H}2} = +1.5$ Hz, $^2J_{\text{C}2,\text{H}1} = +2.4$ Hz, $^3J_{\text{Callyl},\text{H}2} = +0.2$ Hz, β -anomer: $^2J_{\text{C}1,\text{H}2} = -1.5$ Hz, $^2J_{\text{C}2,\text{H}1} = -4.5$ Hz, $^3J_{\text{Callyl},\text{H}2} = +2.9$ Hz; HRMS: $[\text{M}+\text{NH}_4]^+$ calcd for $\text{C}_{23}\text{H}_{30}\text{NO}_5$ 400.21185, found 400.21153.




Allyl 3,5-di-O-benzyl-1,2-dideoxy-2-fluoro- α -D-ribofuranoside (33). Donor **13** and allyltrimethylsilane (4 eq.) were condensed using the general procedure for furanosyl imidate glycosylations at -20°C for 100 h with TfOH as the promotor. Yield = 27 mg, 76 μmol , 76% as a white solid. R_f: 0.52 (8/2 pentane/Et₂O). Spectroscopic data were in accord with those previously reported.¹³ ^1H NMR (CDCl_3 , 500 MHz, HH-COSY, HSQC): δ 7.40 – 7.19 (m, 10H, CH_{arom}), 5.80 (ddtd, 1H, $J = 17.3$, 10.2, 7.0, 0.8 Hz, CH allyl), 5.20 – 5.14 (m, 1H, CHH allyl), 5.09 (ddt, 1H, $J = 10.2$, 2.1, 1.1 Hz, CHH allyl), 4.89 (dt, 1H, $J = 55.2$, 2.9 Hz, H-2), 4.69 (d, 1H, $J = 11.7$ Hz, CHH Bn), 4.59 (d, 1H, $J = 12.1$ Hz, CHH Bn), 4.52 (d, 1H, $J = 11.7$ Hz, CHH Bn), 4.49 (d, 1H, $J = 12.1$ Hz, CHH Bn), 4.21 – 4.16 (m, 1H, H-4), 4.11 (ddd, 1H, $J = 8.6$, 3.5, 0.5 Hz, H-3), 4.05 (dtd, 1H, $J = 29.3$, 7.4, 2.4 Hz, H-1), 3.71 (dd, 1H, $J = 10.8$, 2.4 Hz, H-5), 3.56 (dd, 1H, $J = 10.9$, 3.4 Hz, H-5), 2.49 (ddt, 2H, $J = 7.0$, 5.6, 1.4 Hz, CH_2 allylic); ^{13}C -APT NMR (CDCl_3 , 126 MHz, HSQC): δ 138.3, 137.6 (C_q), 133.6 (CH allyl), 128.6, 128.5, 128.1, 128.0, 127.8, 127.7


(CH_{arom}), 118.0 (CH allyl), 90.1 (d, *J* = 191.0 Hz, C-2), 80.0 (d, *J* = 18.3 Hz, C-1), 79.2 (C-4), 78.6 (d, *J* = 16.5 Hz, C-3), 73.6, 72.5 (CH₂ Bn), 69.6 (C-5), 33.7 (d, *J* = 9.3 Hz, CH allylic); ¹⁹F NMR (CDCl₃, 471 MHz): δ -215.30 (ddd, *J* = 53.7, 29.4, 23.5 Hz, F-2); ¹³C HSQC-HECADE NMR (CDCl₃, 126 MHz): ²*J*_{C2,H1} = +4.9 Hz, ³*J*_{allyl,H2} = +0.2 Hz; HRMS: [M+NH₄]⁺ calcd for C₂₂H₂₉FNO₃ 374.21260, found 374.21252.




Allyl 3,5-di-O-benzyl-1,2-dideoxy-2-fluoro-β-D-arabinofuranoside (34). Donor **14** and allyltrimethylsilane (4 eq.) were condensed using the general procedure for furanosyl imidate glycosylations at -20°C for 100 h with TfOH as the promotor. Yield = 28 mg, 79 μmol, 79% as a colourless oil. *R_f*: 0.80 (9/1 pentane/EtOAc). [α]_D²⁰ = -29.7° (*c* = 0.93, CHCl₃); IR (thin film): 700, 712, 1026, 1070, 1096, 1269, 1452, 2924; ¹H NMR (CDCl₃, 500 MHz, HH-COSY, HH-NOESY, HSQC): δ 7.36 – 7.25 (m, 10H, CH_{arom}), 5.84 (ddtd, 1H, *J* = 17.2, 10.2, 7.1, 0.7 Hz, CH allyl), 5.17 (dq, 1H, *J* = 17.1, 1.5 Hz, CHH allyl), 5.10 (ddt, 1H, *J* = 10.2, 2.0, 1.1 Hz, CHH allyl), 4.88 (dd, 1H, *J* = 52.0, 2.8 Hz, H-2), 4.66 – 4.53 (m, 4H, 2xCH₂ Bn), 4.04 – 3.98 (m, 2.5H, H-1, H-3, H-4), 3.95 (td, 0.5H, *J* = 7.2, 2.8 Hz, H-3), 3.65 – 3.59 (m, 1H, H-5), 3.56 – 3.51 (m, 1H, H-5), 2.55 – 2.42 (m, 2H, CH₂ allylic); ¹³C-APT NMR (CDCl₃, 126 MHz, HSQC): δ 138.2, 137.4 (C_q), 133.8 (CH allyl), 128.6, 128.5, 128.1, 127.9, 127.9, 127.8 (CH_{arom}), 117.8 (CH₂ allyl), 95.89 (d, *J* = 186.6 Hz, C-2), 84.71 (d, *J* = 27.3 Hz, C-3), 82.5 (C-4), 80.70 (d, *J* = 20.9 Hz, C-1), 73.6, 72.2 (CH₂ Bn), 70.2 (C-5), 32.63 (d, *J* = 8.1 Hz, CH₂ allylic); ¹⁹F NMR (CDCl₃, 471 MHz): δ -198.80 (ddd, *J* = 50.6, 29.6, 20.2 Hz); ¹³C HSQC-HECADE NMR (CDCl₃, 126 MHz): ²*J*_{C1,H2} = +4.2 Hz, ²*J*_{C2,H1} = +5.6 Hz, ³*J*_{allyl,H2} = 0.1 Hz; HRMS: [M+NH₄]⁺ calcd for C₂₂H₂₉FNO₃ 374.21260, found 374.21280.




Allyl 3,5-di-O-benzyl-1,2-dideoxy-2-fluoro-β-D-lyxofuranoside (35). Donor **15** and allyltrimethylsilane (4 eq.) were condensed using the general procedure for furanosyl imidate glycosylations at -20°C for 100 h with TfOH as the promotor. Yield = 32 mg, 90 μmol, 90% as a white solid. *R_f*: 0.28 (9/1 pentane/EtOAc). [α]_D²⁰ = -10.5° (*c* = 1.07, CHCl₃); IR (thin film): 696, 711, 737, 1026, 1070, 1271, 1452, 2870, 2922; ¹H NMR (CDCl₃, 500 MHz, HH-COSY, HSQC): δ 7.42 – 7.21 (m, 10H, CH_{arom}), 5.82 (ddt, 1H, *J* = 17.2, 10.2, 7.0 Hz, CH allyl), 5.17 (dd, 1H, *J* = 17.1, 1.5 Hz, CHH allyl), 5.12 – 5.06 (m, 1H, CHH allyl), 4.89 (ddd, 1H, *J* = 54.6, 4.0, 2.9 Hz, H-2), 4.69 (d, 1H, *J* = 11.9 Hz, CHH Bn), 4.62 (d, 1H, *J* = 12.2 Hz, CHH Bn), 4.58 – 4.51 (m, 2H, 2xCHH Bn), 4.28 (td, 1H, *J* = 7.7, 3.6 Hz, H-4), 4.19 (ddd, 1H, *J* = 22.8, 7.8, 4.0 Hz, H-3), 3.84 (dtd, 1H, *J* = 27.3, 7.2, 2.8 Hz, H-1), 3.80 (dd, 1H, *J* = 10.6, 3.7 Hz, H-5), 3.65 (ddd, 1H, *J* = 10.6, 7.7, 1.7 Hz, H-5), 2.51 (t, 2H, *J* = 7.1 Hz, CH₂ allylic); ¹³C-APT NMR (CDCl₃, 126 MHz, HSQC): δ 138.6, 137.5 (C_q), 133.7 (CH allyl), 128.6, 128.4, 128.1, 127.9, 127.8, 127.6 (CH_{arom}), 117.9 (CH₂ allyl), 90.2 (d, *J* = 193.1 Hz, C-2), 79.3 (d, *J* = 18.8 Hz, C-1), 78.6 (d, *J* = 15.7 Hz, C-3), 78.2 (C-4), 73.5, 72.8 (CH₂ Bn), 70.6 (d, *J* = 2.7 Hz, C-5), 33.9 (d, *J* = 8.1 Hz, CH₂ allylic); ¹⁹F NMR (CDCl₃, 471 MHz): δ -213.57 (ddd, *J* = 54.5, 27.2, 22.9 Hz); ¹³C HSQC-HECADE NMR (CDCl₃, 126 MHz): ²*J*_{C1,H2} = +1.2 Hz, ²*J*_{C2,H1} = +5.2 Hz, ³*J*_{allyl,H2} = +0.4 Hz; HRMS: [M+NH₄]⁺ calcd for C₂₂H₂₉FNO₃ 374.21260, found 374.21295.




Allyl 3,5-di-O-benzyl-1,2-dideoxy-2-fluoro-α/β-D-xylofuranoside (36). Donor **16** and allyltrimethylsilane (4 eq.) were condensed using the general procedure for furanosyl imidate glycosylations at -20°C for 100 h with TfOH as the promotor. Yield = 22 mg, 62 μmol, 62% as a colourless oil (α:β = 70:30), and 12 mg (24%) of the anomeric amide (**42**). *R_f*: 0.53 and 0.40 (9/1 pentane/Et₂O). IR (thin film): 696, 735, 1028, 1076, 1088, 1454, 2868, 2922; ¹H NMR (CDCl₃, 500 MHz, HH-COSY, HSQC): δ 7.37 – 7.25 (m, 10H, CH_{arom}), 5.88 – 5.77 (m, 1H, CH allyl), 5.19 – 5.07 (m, 2H, CH₂ allyl), 4.91 (ddd, 0.7H, *J* = 51.4, 2.8, 1.3 Hz, H-2_α), 4.79 (ddd, 0.3H, *J* = 52.6, 2.9, 1.4 Hz, H-2_β), 4.65 (d, 0.3H, *J* = 11.9 Hz, CHH Bn_β), 4.65 – 4.58 (m, 1.7H, 2xCHH Bn_α, CHH Bn_β), 4.56 (d, 0.7H, *J* = 11.9 Hz, CHH Bn_α), 4.53 – 4.49 (m, 1.3H, 2xCHH Bn_β, CHH Bn_α), 4.42 – 4.36 (m, 0.7H, H-4_α), 4.26 – 4.12 (m, 1.7H, H-1_α, H-3_α, H-4_β), 4.08 (ddd, 0.3H, *J* = 8.9, 4.3, 1.3 Hz, H-3_β), 4.02 (dddd, 0.3H, *J* = 13.9, 7.3, 6.5, 2.8 Hz, H-1_β), 3.76 (dd, 0.3H, *J* = 10.0, 5.3 Hz, H-5_β), 3.73 – 3.69 (m, 1H, H-5_α, H-5_β), 3.67 (dd, 0.7H, *J* = 9.8, 6.4 Hz, H-5_α), 2.54 – 2.36 (m, 2H, CH₂ allylic); ¹³C-APT NMR (CDCl₃, 126 MHz, HSQC): δ 138.3, 138.2, 137.6 (C_q), 134.0 (CH allyl_α), 133.8 (CHallyl_β), 128.6, 128.6, 128.5, 128.1, 128.0, 127.9, 127.9, 127.8, 127.7, 127.7 (CH_{arom}), 117.8 (CH₂ allyl_β), 117.7 (CH₂ allyl_α), 97.7 (d, *J* = 182.9 Hz, C-2_β), 94.4 (d, *J* = 187.9 Hz, C-2_α), 82.4 (d, *J* = 35.5 Hz, C-3_β), 82.4 (d, *J* = 13.9 Hz, C-1_β), 81.8 (d, *J* = 25.8 Hz, C-3_α), 79.8 (d, *J* = 1.6 Hz, C-4_β), 79.6 (d, *J* = 19.0 Hz, C-1_α), 78.9 (C-4_α), 73.6 (CH₂ Bn_β), 73.6, 72.9 (CH₂ Bn_α), 72.1 (CH₂ Bn_β), 68.3 (C-5_β), 68.2 (C-5_α), 37.4 (d, *J* = 7.6 Hz, CH₂ allylic_β), 33.1 (d, *J* = 10.3 Hz, CH₂ allylic_α); ¹⁹F NMR (CDCl₃, 471 MHz): δ -183.53 (dddd, 0.3F, *J* = 52.6, 28.0, 13.2, 1.8 Hz), -201.43 (dddd, 0.7F, *J* = 51.4, 31.9, 9.9, 2.5 Hz); ¹³C HSQC-HECADE NMR (CDCl₃, 126 MHz): α-anomer: ²*J*_{C1,H2} = +5.0 Hz, ²*J*_{C2,H1} = +4.5 Hz, ³*J*_{allyl,H2} = +0.3 Hz, β-anomer: ²*J*_{C1,H2} = +1.3 Hz, ²*J*_{C2,H1} = -5.4 Hz, ³*J*_{allyl,H2} = +2.8 Hz; HRMS: [M+Na]⁺ calcd for C₂₂H₂₅FNO₃Na 379.1685, found 379.1685.




1-[²H]-1,4-anhydro-2-azido-3,5-di-O-benzyl-2-deoxy-α-D-ribose (37). Donor **17** and triethylsilane-*d* (4 eq.) were condensed using the general procedure for furanosyl imidate glycosylations at 0–5°C for 100 h with TfOH as the promotor. Yield = 23 mg, 68 μmol, 68% as a colourless oil. Inseparable mixture of **37** and amide **46** (in a 95:5 ratio). R_f: 0.26 (9/1 pentane/EtOAc). [α]_D²⁰ = +88° (*c* = 0.77, CHCl₃) IR (thin film): 698, 738, 1028, 1089, 1269, 1454, 2104, 2864; ¹H NMR (CDCl₃, 500 MHz, HH-COSY, HH-NOESY, HSQC): δ 7.38 – 7.26 (m, 10H, CH_{arom}), 4.69 (d, 1H, *J* = 11.8 Hz, *CHH* Bn), 4.57 – 4.52 (m, 2H, *CHH* Bn, *CHH* Bn), 4.48 (d, 1H, *J* = 12.0 Hz, *CHH* Bn), 4.14 (dd, 1H, *J* = 6.1, 5.5 Hz, H-3), 4.09 – 4.02 (m, 2H, H-1, H-4), 3.89 (t, 1H, *J* = 5.4 Hz, H-2), 3.61 (dd, 1H, *J* = 10.7, 3.3 Hz, H-5), 3.50 (dd, 1H, *J* = 10.7, 4.0 Hz, H-5); ¹³C-APT NMR (CDCl₃, 126 MHz, HSQC): δ 138.1, 137.4 (C_q), 128.6, 128.5, 128.2, 128.1, 127.8, 127.8 (CH_{arom}), 80.9 (C-4), 79.9 (C-3), 73.6, 73.0 (CH₂ Bn), 70.2 (t, *J* = 22.8 Hz, C-1), 69.8 (C-5), 60.8 (C-2); ²H NMR (CHCl₃, 77 MHz): δ 3.90; ¹³C HSQC-HECADE NMR (CDCl₃, 126 MHz): ²J_{C1-H2}: +1.5 Hz, ²J_{C2-H1}: +1.3 Hz; HRMS: [M+Na]⁺ calcd for C₁₉H₂₀DN₃O₃Na 363.1543, found 363.1546.




1-[²H]-1,4-anhydro-2-azido-3,5-di-O-benzyl-2-deoxy-β-D-arabitol (38). Donor **18** and triethylsilane-*d* (4 eq.) were condensed using the general procedure for furanosyl imidate glycosylations at 0–5°C for 100 h with TfOH as the promotor. Yield = 19.5 mg, 57 μmol, 57% as a colourless oil. R_f: 0.38 (9/1 pentane/EtOAc). Spectroscopic data were in accord with those previously reported for the non-deuterated compound.³⁷ [α]_D²⁰ = -14.6° (*c* = 0.98, CHCl₃); IR ¹H NMR (CDCl₃, 500 MHz, HH-COSY, HSQC): δ 7.37 – 7.26 (m, 10H, CH_{arom}), 4.59 (d, 1H, *J* = 11.8 Hz, *CHH* Bn), 4.56 (s, 2H, CH₂ Bn), 4.54 (d, 1H, *J* = 11.8 Hz, *CHH* Bn), 4.02 (td, 1H, *J* = 5.3, 4.3 Hz, H-4), 4.00 (bs, 1H, H-1), 3.98 (dd, 1H, *J* = 5.0, 1.9 Hz, H-2), 3.92 (dd, 1H, *J* = 4.3, 1.9 Hz, H-3), 3.59 (dd, 1H, *J* = 10.3, 5.5 Hz, H-5), 3.57 (dd, 1H, *J* = 10.3, 5.2 Hz, H-5); ¹³C-APT NMR (CDCl₃, 126 MHz, HSQC): δ 138.1, 137.4 (C_q), 128.7, 128.5, 128.2, 128.0, 127.9, 127.8 (CH_{arom}), 85.0 (C-3), 83.4 (C-4), 73.6, 72.4 (CH₂ Bn), 70.7 (t, *J* = 23.0 Hz, C-1), 70.5, 70.0 (C-5), 65.9 (C-2); ²H NMR (CHCl₃, 77 MHz): δ 4.02; ¹³C HSQC-HECADE NMR (CDCl₃, 126 MHz): ²J_{C1-H2}: +1.1 Hz, ²J_{C2-H1}: +2.3 Hz; HRMS: [M+NH₄]⁺ calcd for C₁₉H₂₄DN₄O₃ 358.19839, found 358.19858.



1-[²H]-1,4-anhydro-2-azido-3,5-di-O-benzyl-2-deoxy-β-D-lyxitol (39). Donor **19** and triethylsilane-*d* (4 eq.) were condensed using the general procedure for furanosyl imidate glycosylations at 0–5°C for 100 h with TfOH as the promotor. Yield = 20 mg, 59 μmol, 59% as a colourless oil. R_f: 0.13 (9/1 pentane/EtOAc). [α]_D²⁰ = -37° (*c* = 1.0, CHCl₃); IR (thin film): 698, 738, 1984, 1269, 1452, 2104, 2868, 2922, 3032; ¹H NMR (CDCl₃, 500 MHz, HH-COSY, HSQC): δ 7.36 – 7.26 (m, 10H, CH_{arom}), 4.77 (d, 1H, *J* = 11.6 Hz, *CHH* Bn), 4.61 – 4.56 (m, 2H, *CHH* Bn, *CHH* Bn), 4.50 (d, 1H, *J* = 11.9 Hz, *CHH* Bn), 4.20 (t, 1H, *J* = 5.2 Hz, H-3), 4.15 (dt, 1H, *J* = 6.9, 5.2 Hz, H-4), 3.92 (d, 1H, *J* = 6.4 Hz, H-1), 3.86 (dd, 1H, *J* = 6.3, 5.1 Hz, H-2), 3.73 (dd, 1H, *J* = 10.1, 5.0 Hz, H-5), 3.68 (dd, 1H, *J* = 10.1, 7.0 Hz, H-5); ¹³C-APT NMR (CDCl₃, 126 MHz, HSQC): δ 138.2, 137.5 (C_q), 128.6, 128.5, 128.1, 128.0, 127.9, 127.8 (CH_{arom}), 79.6, 79.6 (C-3, C-4), 74.0, 73.7 (CH₂ Bn), 69.0 (C-5), 68.7 (t, *J* = 22.8 Hz, C-1), 61.3 (C-2); ²H NMR (CHCl₃, 77 MHz): δ 3.95; ¹³C HSQC-HECADE NMR: ²J_{C2-H1} = +0.2 Hz; HRMS: [M+Na]⁺ calcd for C₁₉H₂₀DN₃O₃Na 363.1543, found 363.1551.




1-[²H]-1,4-anhydro-2-azido-3,5-di-O-benzyl-2-deoxy-α/β-D-xylofuranoside (40). Donor **20** and triethylsilane-*d* (4 eq.) were condensed using the general procedure for furanosyl imidate glycosylations at 0–5°C for 100 h with TfOH as the promotor. Yield = 23 mg, 68 μmol, 68% as a colourless oil (α:β = 85:15). Inseparable mixture of **40** and amide **43** (in a 73:27 ratio) R_f: 0.30 (85/15 pentane/Et₂O). IR (thin film): 696, 735, 1061, 1088, 1207, 1454, 1494, 1690, 2106, 2916; ¹H NMR (CDCl₃, 500 MHz, HH-COSY, HSQC): δ 7.38 – 7.24 (m, 10H, CH_{arom}), 4.65 – 4.58 (m, 2H, 2*x*CHH Bn), 4.54 (d, 1H, *J* = 11.9 Hz, *CHH* Bn), 4.52 (d, 1H, *J* = 11.9 Hz, *CHH* Bn), 4.21 – 4.15 (m, 1.85H, H-1_α, H-4), 4.04 (dd, 1H, *J* = 5.5, 1.9 Hz, H-2), 3.99 (dd, 1H, *J* = 4.4, 1.9 Hz, H-3), 3.74 – 3.70 (m, 1.15H, H-1_β, H-5), 3.68 (dd, 1H, *J* = 10.0, 6.4 Hz, H-5); ¹³C-APT NMR (CDCl₃, 126 MHz, HSQC): δ 138.2, 137.4 (C_q), 128.7, 128.5, 128.2, 127.9, 127.8, 127.8 (CH_{arom}), 82.9 (C-3), 79.7 (C-4), 73.7, 72.6 (CH₂ Bn), 70.0 (t, *J* = 22.7 Hz C-1_β), 70.0 (t, *J* = 22.7, C-1_α) 68.4 (C-5), 65.0 (C-2); ²H NMR (CHCl₃, 77 MHz): δ 4.19 (s, 0.15H), 3.75 (s, 0.85H); ¹³C HSQC-HECADE NMR (CDCl₃, 126 MHz): α-anomer: ²J_{C2-H1} = +0.7 Hz; β-anomer: ²J_{C2-H1} = -4.3 Hz; HRMS: [M+Na]⁺ calcd for C₁₉H₂₀DN₃O₃Na 363.1543, found 363.1549.




3,5-di-O-benzyl-1,2-dideoxy-2-fluoro-1-N-[phenyl]trifluoroacetyl-α/β-D-xylofuranoside (42). IR (thin film): 698, 737, 1070, 1153, 1188, 1207, 1454, 1495, 1595, 1690, 2862, 2922; ¹H NMR (CDCl₃, 500 MHz, HH-COSY, HSQC): δ 7.43 – 7.19 (m, 15H, CH_{arom}), 6.31 (dd, 1H, *J* = 11.0, 5.1 Hz, H-1), 5.45 (ddd, 1H, *J* = 52.9, 5.0, 3.8 Hz, H-2), 4.65 (d, 1H, *J* = 11.9 Hz, *CHH* Bn), 4.47 (d, 1H, *J* = 11.9 Hz, *CHH* Bn), 4.40 (s, 2H, CH₂ Bn), 3.91 (dt, 1H, *J* = 14.3, 4.1 Hz, H-3), 3.77 (qd, 1H, *J* = 4.7, 1.7 Hz, H-4), 3.56 (ddd, 1H, *J* = 10.5, 4.4, 0.7 Hz, H-5), 3.49 (dd, 1H, *J* = 10.6, 4.8 Hz, H-5); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 138.0, 137.1 (C_q), 134.2, 132.0, 130.5, 129.6, 128.6, 128.5, 128.2, 127.9, 127.8, 127.7 (CH_{arom}), 93.5 (d, *J* =

194.8 Hz, C-2), 87.2 (d, $J = 17.4$ Hz, C-1), 80.1 (d, $J = 23.2$ Hz, C-3), 79.1 (d, $J = 3.5$ Hz, C-4), 73.4, 72.6 (CH₂ Bn), 68.0 (C-5); ¹⁹F NMR (CDCl₃, 471 MHz): δ -68.17 (s, 3F, CF₃), -196.37 (dt, 1F, $J = 53.1, 12.7$ Hz, F-2).




2-azido-3,5-di-O-benzyl-1,2-dideoxy-1-N-[phenyl]trifluoroacetyl- α - β -D-xylofuranoside (43).

Intermixed with **40**. The anomeric amide was formed in an α : $\beta = 93$:7 ratio. Data for the α -anomer: ¹H NMR (CDCl₃, 500 MHz, HH-COSY, HSQC): δ 7.17 (dd, 2H, $J = 6.6, 2.6$ Hz, NPh), 6.33 (d, 1H, $J = 6.6$ Hz, H-1), 4.59 (t, 1H, $J = 6.6$ Hz, H-2), 4.50 (d, 1H, $J = 11.7$ Hz, CHH Bn), 4.46–4.40 (m, 3H, CH₂ Bn, CHH Bn), 3.66 (t, 1H, $J = 4.3$ Hz, H-4), 3.59 (t, 1H, $J = 6.8$ Hz, H-3), 3.49 (dd, 1H, $J = 10.7, 4.0$ Hz, H-5), 3.41 (dd, 1H, $J = 10.7, 4.5$ Hz, H-5); ¹³C-APT NMR (CDCl₃, 126 MHz, HSQC): δ 157.0 (q, $J = 36.4$ Hz, F₃C-C=O), 138.0, 137.0 (C_q), 132.0, 130.7, 129.6, 129.5, 128.7, 128.3, 128.1, 127.8, 127.8, 127.7, 126.5, 120.6 (CH_{arom}), 116.0 (q, $J = 288.7$ Hz, CF₃), 86.9 (C-1), 80.9 (C-3), 78.6 (C-4), 73.5, 73.3 (CH₂ Bn), 68.6 (C-5), 67.1 (C-2); ¹⁹F NMR (CDCl₃, 471 MHz): δ -68.04 (s, CF₃ α), -68.18 (s, CF₃ β); ¹³C HSQC-HECADE NMR (CDCl₃, 126 MHz): α -anomer: ²J_{C1,H2} = -0.2 Hz, ²J_{C2,H1} = +1.1 Hz; Diagnostic peaks for the β -anomer: ¹H NMR (CDCl₃, 500 MHz, HH-COSY, HSQC): 5.98 (d, 0.07H, $J = 6.2$ Hz, H-1), 4.28 (td, 0.07H, $J = 6.3, 4.6$ Hz, H-4); ¹³C HSQC-HECADE NMR: ²J_{C1,H2} = -4.0 Hz, ²J_{C2,H1} = -2.1 Hz.




Methyl (2,3-di-O-benzyl-1-deoxy-1-N-[phenyl]trifluoroacetyl- α - β -D-xylofuranosyl uronate) (44).

¹H NMR (CDCl₃, 500 MHz, HH-COSY, HH-NOESY, HSQC, HMBC): δ 7.41–7.28 (m, 18H, CH_{arom}), 7.15 (dd, 2H, $J = 7.3, 2.0$ Hz, CH_{arom}), 6.59 (d, 1H, $J = 6.1$ Hz, H-1), 4.70 (d, 1H, $J = 11.2$ Hz, CHH Bn), 4.58 (d, 1H, $J = 11.2$ Hz, CHH Bn), 4.51 (t, 1H, $J = 6.1$ Hz, H-2), 4.44 (d, 1H, $J = 11.7$ Hz, CHH Bn), 4.38 (d, 1H, $J = 11.9$ Hz, CHH Bn), 4.15 (d, 1H, $J = 6.5$ Hz, H-4), 3.77–3.72 (m, 1H, H-3), 3.67 (s, 3H, CH₃ CO₂Me); ¹³C-APT NMR (CDCl₃, 126 MHz, HSQC, HMBC): δ 169.5 (C=O), 137.3, 137.1 (C_q), 129.6, 128.7, 128.6, 128.5, 128.3, 128.2, 128.1, 127.9 (CH_{arom}), 87.6 (C-1), 81.9 (C-2), 81.1 (C-3), 78.2 (C-4), 74.3, 72.9 (CH₂ Bn), 52.3 (CO₂Me); ¹⁹F NMR (CDCl₃, 471 MHz): δ -68.09; ¹³C HSQC-HECADE NMR (CDCl₃, 126 MHz): ²J_{C1,H2} = +1.5 Hz.




Methyl (2S,3R,3aS,9bR)-3-(benzyloxy)-3,3a,5,9b-tetrahydro-2H-furo[3,2-c]isochromene-2-carboxylate (45).

¹H NMR (CDCl₃, 500 MHz, HH-COSY, HH-NOESY, HSQC): δ 7.61–7.57 (m, 1H, CH_{arom}), 7.37–7.28 (m, 7H, CH_{arom}), 7.08–7.04 (m, 1H, CH_{arom}), 5.16 (d, 1H, $J = 2.8$ Hz, H-1), 4.92 (d, 1H, $J = 4.9$ Hz, H-4), 4.78 (d, 1H, $J = 14.6$ Hz, CHH Bn_(c-2)), 4.72 (d, 1H, $J = 11.9$ Hz, CHH Bn_(c-3)), 4.65 (d, 1H, $J = 14.8$ Hz, CHH Bn_(c-2)), 4.64 (d, 1H, $J = 12.0$ Hz, CHH Bn_(c-3)), 4.44 (d, 1H, $J = 5.1$ Hz, H-3), 4.26 (d, 1H, $J = 3.0$ Hz, H-2), 3.76 (s, 3H, CH₃ CO₂Me); ¹³C-APT NMR (CDCl₃, 126 MHz, HSQC): δ 170.2 (C=O), 134.4, 130.9, 130.3 (C_q), 128.7, 128.6, 128.1, 127.7, 127.7, 124.2 (CH_{arom}), 85.2 (C-3), 80.4 (C-4), 79.5 (C-2), 74.9 (C-1), 73.2 (CH₂ Bn_(c-3)), 67.2 (CH₂ Bn_(c-2)), 52.1 (CO₂Me).




3,5-di-O-benzyl-1,2-dideoxy-2-fluoro-1-N-[phenyl]trifluoroacetyl- α -D-ribofuranoside (46).

Intermixed with **37**. Diagnostic peaks: ¹H NMR (CDCl₃, 500 MHz): δ 6.04 (d, 1H, $J = 5.1$ Hz, H-1), 4.61 (t, 1H, $J = 5.5$ Hz, H-2), 4.44 (d, 1H, $J = 11.6$ Hz, CHH Bn), 4.41 (d, 1H, $J = 12.0$ Hz, CHH Bn), 4.30 (d, 1H, $J = 12.0$ Hz, CHH Bn), 3.44 (dd, 1H, $J = 11.3, 2.5$ Hz, H-5), 3.32 (dd, 1H, $J = 11.3, 3.5$ Hz, H-5); ¹³C-APT NMR (CDCl₃, 126 MHz, HSQC): δ 88.1 (C-1), 80.3 (C-4), 77.0 (C-3), 73.4, 73.3 (CH₂ Bn), 68.0 (C-5), 62.9 (C-2).



Methyl (2S,3S,3aR,9bS)-3-(benzyloxy)-3,3a,5,9b-tetrahydro-2H-furo[3,2-c]isochromene-2-carboxylate (47).

Intermixed with **30**. ¹H NMR (CDCl₃, 500 MHz, HH-COSY, HSQC): δ 7.52 (dd, 1H, $J = 5.5, 3.6$ Hz, CH_{arom}), 7.44–7.25 (m, 7H, CH_{arom}), 7.07 (dd, 1H, $J = 5.4, 3.8$ Hz, CH_{arom}), 4.93 (d, 1H, $J = 2.9$ Hz, H-1), 4.79 (d, 1H, $J = 12.1$ Hz, CHH 3-OBn), 4.79 (d, 1H, $J = 14.7$ Hz, CHH 2-OBn), 4.72 (d, 1H, $J = 12.1$ Hz, CHH 3-OBn), 4.66 (d, 1H, $J = 14.7$ Hz, CHH 2-OBn), 4.64 (d, 1H, $J = 2.8$ Hz, H-4), 4.46 (dd, 1H, $J = 2.7, 0.7$ Hz, H-3), 4.21 (d, 1H, $J = 3.0$ Hz, H-2), 3.71 (s, 3H, CH₃ CO₂Me); ¹³C-APT NMR (CDCl₃, 126 MHz, HSQC): δ 170.6 (C=O), 137.4, 134.7, 130.7 (C_q), 129.8, 128.7, 128.1, 128.0, 128.0, 127.5, 124.2 (CH_{arom}), 87.8 (C-3), 82.2 (C-4), 79.8 (C-2), 75.3 (C-1), 72.4, 67.0 (CH₂ Bn), 52.4 (CO₂Me); ¹³C HSQC-HECADE NMR (CDCl₃, 126 MHz): ²J_{C1,H2} = +6.0 Hz, ²J_{C2,H1} = +2.4 Hz.



Methyl (2,3-di-O-benzyl-1-deoxy-1-N-[phenyl]trifluoroacetyl- α -D-ribofuranosyl uronate) (48).

¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.43–7.16 (m, 14H, CH_{arom}), 7.09–7.00 (m, 1H, NPh), 6.44 (d, 1H, $J = 5.8$ Hz, H-1), 4.75 (d, 1H, $J = 11.1$ Hz, CHH Bn), 4.65 (d, 1H, $J = 11.0$ Hz, CHH Bn), 4.48–4.39 (m, 2H, CHH Bn, H-2), 4.35 (d, 1H, $J = 12.0$ Hz, CHH Bn), 4.02–3.99 (m, 2H, H-3, H-4), 3.67 (s, 3H, CH₃ CO₂Me); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 170.5 (C=O), 137.4, 137.0, 133.5 (C_q), 132.1, 131.8, 129.1, 128.6, 128.5, 128.3, 128.2, 128.2, 128.1 (CH_{arom}), 88.5 (C-1), 79.9, 79.0 (C-3, C-4), 77.2 (C-2), 74.5, 72.8 (CH₂ Bn), 52.7 (CO₂Me); ¹⁹F NMR (CDCl₃, 471 MHz): δ -68.03.

References and footnotes

- (1) Richards, M. R.; Lowary, T. L. *ChemBioChem* **2009**, *10* (12), 1920–1938.
- (2) Brennan, P. J.; Nikaido, H. *Annu. Rev. Biochem.* **1995**, *64* (1), 29–63.
- (3) Lindberg, B. Components of Bacterial Polysaccharides. In *Advances in Carbohydrate Chemistry and Biochemistry*; Tipson, R. S., Horton, D., Eds.; Academic Press, 1990; Vol. 48, pp 279–318.
- (4) Lowary, T. L. *Acc. Chem. Res.* **2016**, *49* (7), 1379–1388.
- (5) Varki, A. *Glycobiology* **1993**, *3* (2), 97–130.
- (6) Kinnaert, C.; Daugaard, M.; Nami, F.; Clausen, M. H. *Chem. Rev.* **2017**, *117* (17), 11337–11405.
- (7) Shelton, J.; Lu, X.; Hollenbaugh, J. A.; Cho, J. H.; Amblard, F.; Schinazi, R. F. *Chem. Rev.* **2016**, *116* (23), 14379–14455.
- (8) Altona, C.; Sundaralingam, M. *J. Am. Chem. Soc.* **1972**, *94* (23), 8205–8212.
- (9) Taha, H. A.; Richards, M. R.; Lowary, T. L. *Chem. Rev.* **2013**, *113* (3), 1851–1876.
- (10) Kilpatrick, J. E.; Pitzer, K. S.; Spitzer, R. *J. Am. Chem. Soc.* **1947**, *69* (10), 2483–2488.
- (11) Altona, C.; Geise, H. J.; Romers, C. *Tetrahedron* **1968**, *24* (1), 13–32.
- (12) Hagen, B.; van der Vorm, S.; Hansen, T.; Marel, V. D.; A, G.; Codée, J. D. C. Stereoselective Glycosylations – Additions to Oxocarbenium Ions. In *Selective Glycosylations: Synthetic Methods and Catalysts: Synthetic Methods and Catalysts*; Wiley-VCH Verlag GmbH & Co. KGaA, 2017; pp 1–28.
- (13) Larsen, C. H.; Ridgway, B. H.; Shaw, J. T.; Smith, D. M.; Woerpel, K. A. *J. Am. Chem. Soc.* **2005**, *127* (31), 10879–10884.
- (14) Smith, D. M.; Tran, M. B.; Woerpel, K. A. *J. Am. Chem. Soc.* **2003**, *125* (46), 14149–14152.
- (15) Smith, D. M.; Woerpel, K. A. *Org. Biomol. Chem.* **2006**, *4* (7), 1195–1201.
- (16) Tran, V. T.; Woerpel, K. A. *J. Org. Chem.* **2013**, *78* (13), 6609–6621.
- (17) Larsen, C. H.; Ridgway, B. H.; Shaw, J. T.; Woerpel, K. A. *J. Am. Chem. Soc.* **1999**, *121* (51), 12208–12209.
- (18) Shaw, J. T.; Woerpel, K. A. *Tetrahedron* **1999**, *55* (29), 8747–8756.
- (19) Shaw, J. T.; Woerpel, K. A. *J. Org. Chem.* **1997**, *62* (20), 6706–6707.
- (20) Bear, T. J.; Shaw, J. T.; Woerpel, K. A. *J. Org. Chem.* **2002**, *67* (7), 2056–2064.
- (21) Codée, J. D. C.; Ali, A.; Overkleef, H. S.; van der Marel, G. A. *Comptes Rendus Chim.* **2011**, *14*, 178–193.
- (22) Green, L. G.; Ley, S. V.; Ernst, B.; Hart, G. W.; Sinay, P. Protecting Groups: Effects on Reactivity, Glycosylation Stereoselectivity, and Coupling Efficiency. In *Carbohydrates in Chemistry and Biology*; Wiley-VCH Verlag GmbH, 2000; pp 427–448.
- (23) Rhoad, J. S.; Cagg, B. A.; Carver, P. W. *J. Phys. Chem. A* **2010**, *114* (15), 5180–5186.
- (24) van Rijssel, E. R.; van Delft, P.; Lodder, G.; Overkleef, H. S.; van der Marel, G. A.; Filippov, D. V.; Codée, J. D. C. *Angew. Chem. Int. Ed.* **2014**, *53* (39), 10381–10385.
- (25) van Rijssel, E. R.; van Delft, P.; van Marle, D. V.; Bijvoets, S. M.; Lodder, G.; Overkleef, H. S.; van der Marel, G. A.; Filippov, D. V.; Codée, J. D. C. *J. Org. Chem.* **2015**, *80* (9), 4553–4565.
- (26) To account for the difference in donor reactivity by the electron-withdrawing capacity of the functional groups at C2 and C5, the glycosylations were performed at a temperature adequate for conversion to the products (within four days), and were established prior to the generation of the data in Table 1.
- (27) Napolitano, J. G.; Gavin, J. A.; Garcia, C.; Norte, M.; Fernández, J. J.; Hernández Daranas, A. *Chem. – Eur. J.* **2011**, *17* (23), 6338–6347.
- (28) Koźmiński, W.; Nanz, D. *J. Magn. Reson.* **1997**, *124* (2), 383–392.
- (29) Marquez, B. L.; Gerwick, W. H.; Williamson, R. T. *Magn. Reson. Chem.* **39** (9), 499–530.
- (30) Gaussian 03, Revision E.01; **2004**, Gaussian, Inc., Wallingford CT.
- (31) Ribeiro, R. F.; Marenich, A. V.; Cramer, C. J.; Truhlar, D. G. *J. Phys. Chem. B* **2011**, *115* (49), 14556–14562.
- (32) The relative energies (in kcal·mol⁻¹) of the different oxocarbenium ions are, for the tribenzyl structures: ribo 0.0, arabino 0.1, lyxo 0.2, xylo 0.9; for the 2-fluoro structures: ribo 0.0, lyxo 0.9, ara 1.1, xylo 1.5; for the 2-azido structures: ribo 0.0, ara 0.6, xylo 1.3, lyxo 1.7; for the uronic acids: lyxo 0.0, ara 0.5, xylo 0.6, ribo 1.2.
- (33) van der Heden van Noort, G. J.; Overkleef, H. S.; van der Marel, G. A.; Filippov, D. V. *Org. Lett.* **2011**, *13* (11), 2920–2923.
- (34) Mukaiyama, T.; Kobayashi, S. *Carbohydr. Res.* **1987**, *171* (1), 81–87.
- (35) Doboszewski, B. *Nucleosides Nucleotides Nucleic Acids* **2009**, *28* (10), 875–901.
- (36) Zhang, J.; Yuan, W.; Ma, X.; Wang, H.; Shao, H. *Chin. J. Chem.* **2014**, *32* (4), 361–364.
- (37) Kakefuda, A.; Shuto, S.; Nagahata, T.; Seki, J.; Sasaki, T.; Matsuda, A. *Tetrahedron* **1994**, *50* (34), 10167–10182.

Chapter 9

Summary and future prospects

Summary

The demand for biologically relevant oligosaccharides and glycoconstructs is ever increasing. Chemical synthesis can provide pure and well-defined carbohydrates, which are generally difficult to obtain from nature. One of the challenges in synthetic carbohydrate chemistry is the efficient construction of 1,2-*cis*-glycosidic linkages. The synthesis of this type of glycosidic bond often requires time-consuming, trial-and-error based optimization experiments. It would be highly beneficial if more insight into the mechanism of the glycosylation reaction in general, and the formation of 1,2-*cis*-bonds in particular, could be obtained. In this thesis, systematic studies on the reactivity of both reaction partners, the glycosyl donor and the glycosyl acceptor, and the influence thereof on the selectivity of a glycosylation reaction, are conducted. With these studies more insight into the glycosylation mechanism is obtained and it provides a direction how to improve the stereoselectivity in the formation of 1,2-*cis*-glycosidic linkages.

The general glycosylation reaction mechanism and the reactivity of carbohydrate building blocks in glycosylation reactions is described in **Chapter 1** and **Chapter 2**. The first chapter describes the reactivity from the perspective of the glycosyl donor, the electrophilic species. In the second chapter the focus is laid on the nucleophilic reaction partner, the acceptor. The reactivity of both species depends on the protecting groups they carry. Although much insight has been gained how the protecting groups on the donor glycoside impact the reactivity of this coupling partner, the reactivity of acceptor glycosides as a function of the protecting and functional group pattern is rather ill-documented. It also remains unclear how the changing reactivity impacts the change in mechanisms from an S_N2 - to S_N1 -like substitution reaction, which can have far reaching consequences for the stereoselectivity of a glycosylation reaction. Chapter 2 provides an overview of recent and older examples that show how small changes in the structure and reactivity of the acceptor can lead to large changes in yield, selectivity, and reaction rates.




Figure 1. Donors 1-4 and model acceptors 5-8 used in Chapters 3 and 4.

Chapter 3 describes how the reactivity of the acceptor affects the glycosylation reaction mechanism. A set of model acceptors (5-8, Figure 1) of gradually changing reactivity is used to unveil the influence of the reactivity of the acceptor on the stereochemical outcome of the glycosylation reaction. The model acceptors are based on ethanol with a varying amount of fluorine substituents (up to three fluorine atoms). The presence of more electron-withdrawing fluorine atoms makes the acceptor less reactive. The glycosylation method chosen was based on the preactivation of thioglycoside donors, to ensure the formation of an anomeric triflate intermediate and prevent alternative reaction pathways associated with *in situ* glycosylation protocols. Ethanol 5, the most reactive model acceptor, gave high β -selectivity in glycosylations with three donors tested: benzylidene glucose 3, benzylidene mannose 1 and mannuronic acid methyl ester 2. The significantly less reactive trifluoroethanol 8 gave high α -selectivity for the benzylidene glucose donor, in contrast to the other two donors, that provided mostly the β -products. The mono- and difluoroethanols 6 and 7 gave mixtures of

anomeric products with the glucose donor, with more α -product for the less reactive difluoroethanol. These results indicated that the glycosylations of benzylidene glucose donor **3** are very susceptible to changes in acceptor reactivity, while the outcome of the glycosylations of the benzylidene mannose and mannuronic acid proved to be less sensitive to changes in acceptor nucleophilicity. Subsequently, carbohydrate acceptors were tested and it was found that the reactivity of these larger acceptors also proved decisive for the glycosylation outcome. Primary and secondary equatorial hydroxyls gave relatively high β -selectivity, while secondary axial hydroxyls gave α -selectivity for the benzylidene glucose donor. Benzylidene mannose and mannuronic acid donors were consistently β -selective for the carbohydrate acceptors. With these results the correlation between reactivity of the acceptor and a change in the glycosylation mechanism was established. Stronger nucleophiles participate in a more S_N2 -like mechanism, providing the β -product, while weaker nucleophiles react with more S_N1 -substitution character. For benzylidene glucose the S_N1 intermediate is an oxocarbenium ion in the ${}^4H_3/{}^4E$ conformation, preferably attacked from the α -face, whereas the benzylidene mannose and mannuronic acid preferentially take up a $B_{2,5}$ and 3H_4 conformation respectively, which are attacked on the β -face.

The donor scope was extended in **Chapter 4** to study the effect of the azide as an amine masking group on benzylidene glucosamine donors, and to compare the results of glycosylations with these donors with the benzylidene glucose donor from Chapter 3. The azide is an electron-withdrawing group and destabilizes the formation of positive charge on the anomeric center more than an *O*-benzyl group does. As a consequence, the glycosylations with benzylidene glucosazide donors (such as **4**, Figure 1) proceed with more S_N2 -character when compared to reactions with benzylidene glucose, and the 2-azido group is therefore β -directing. Further structural modifications on the donor were also investigated. Changing the C-3 position of the donor from an *O*-benzyl to an *O*-benzoyl group made the donor slightly more β -selective, as a result of the electron-withdrawing effect of the benzoyl group. Changing the benzylidene ring for a silylidene ring made the donor less β -selective, and in combination with a poorly nucleophilic acceptor, high α -selectivity can be achieved.

Instead of the benzylidene or silylidene ring, which span over positions C-4 and C-6, a tethering group spanning C-3 and C-4, the butanediactal (BDA) group, is studied as a protecting group of glucosazide donors in **Chapter 5**. Glycosylations with the set of fluorinated model acceptors showed that the glucosazide donor bearing the BDA group

glycosylates significantly more β -selective than its benzylidene counterpart. Likely, the conformational restriction inferred by the cyclic BDA group, prevents the formation of charge on the anomeric center, making S_N1 -pathways less favorable. Consequently, reactions with this donor proceed with a high degree of S_N2 substitution.

The reactivity of glycosyl acceptors was studied in more detail in **Chapter 6**. With a large selection of C-4-OH glucose acceptors bearing *O*-benzyl and *O*-benzoyl groups in all possible patterns, the influence of acceptor reactivity on the glycosylation stereoselectivity was studied. The benzylidene protected glucose and glucosazide donors from Chapters 3 and 4 served as donors to map the acceptor structure-reactivity-stereoselectivity relationships. The outcome of glycosylations of these two donors is very sensitive to changes in acceptor reactivity and complement each other, with the benzylidene glucosazide donor providing more β -product (resulting from more S_N2 character in the condensation reactions) than the benzylidene glucose donor. From this study it became evident that the reactivity of carbohydrate acceptors can also be changed by the manipulation of protecting groups. The strategic placement of a single benzoyl group is sufficient to turn the glycosylation with the benzylidene glucose donor completely α -selective. With a second benzoyl group, also the glucosazide donor becomes completely α -selective, providing a method to construct 1,2-*cis*-glucosamine linkages. Also, the effect of electron-withdrawing substituents on the aromatic ring of the benzoates were studied. These substituents had a minor influence, and only the presence of two nitro groups, at both ortho-positions, gave the required drop in reactivity and increase in α -selectivity.

Chapter 7 and **Chapter 8** focus on five-membered ring sugars, the furanoses, and their selectivity in glycosylations. In the first chapter different functionalities are installed on the furanoses. The C-2 position is modified with an azido or a fluoro group and the C-5 position is oxidized to the methyl ester. The chosen strategy to install the azide and fluoride via inversion of a triflate leaving group, was not without problems. The inversion of 2-*O*-triflylriboside smoothly gave the 2-fluoro- and 2-azidoarabinosides. The success of the nucleophilic substitution on arabinose to give the ribosides, depended on the anomeric configuration, with partial migration of the anomeric *O*-methyl group to the C-2 position in the α -anomer. The inversion of 2-*O*-triflylxylosides to give the corresponding lyxose products only proceeded with the α -anomer. Side products during this reaction originated from intramolecular participation of the C-5-*O*-benzyl group. Inverting 2-*O*-triflyllyxoside was unsuccessful and only the aromatic furan was formed.

The 2-fluoro- and 2-azidoxylosides therefore had to be made via an alternative route, for which the electrophilic addition to a glycal was chosen. Further modifications to generate a set of twelve imidate donors went uneventful. These donors were glycosylated with model acceptors in Chapter 8.

The selectivity of furanosides in glycosylation reactions, under S_N1 -conditions, was investigated in **Chapter 8**. The oxocarbenium ions that serve as reactive intermediates in these glycosylations are responsible for the observed stereoselectivity. First, the stereoselectivities were experimentally determined with nucleophilic model acceptors allyltrimethylsilane and triethylsilane-*d*. Almost all glycosylations proceeded with exclusive 1,2-*cis*-selectivity, except for *xylo*-configured donors which gave anomeric mixtures. Next, the relative energies of all possible conformations of the oxocarbenium ions were assessed using Density Functional Theory (DFT). The collective set of data points for each configuration and C-2/C-5 modification was then plotted as a Conformational Energy Landscape (CEL) map. From the computational data it became evident that when a single conformation was strongly preferred, the experimental glycosylations proceeded with excellent stereoselectivity. In the *arabino*-configuration multiple low in energy conformations were found, of which several were nearly flat. The influence of these conformers on the stereochemical outcome of the glycosylations proved to be limited and also for the studied C-2/C-5 arabinofuranosides high 1,2-*cis*-selectivity was found. The CEL maps of the *xylo*-configured oxocarbenium ions also displayed multiple low in energy conformations. Besides the 3E and E_3 conformations, which are the most common furanosyl oxocarbenium ion conformations, the 4E envelope was found as one of the major contributors to the conformer population. The multitude of available conformations led to anomeric mixtures in the glycosylation reactions. The computational method is able to effectively show the differences in conformer population distribution when groups exhibiting different stereoelectronic effects are introduced, like the azido, fluoro, and uronic acid ester groups. With the relative stabilities of each conformation of an oxocarbenium ion available, it can be determined whether a glycosylation reaction under S_N1 -conditions proceeds with exclusive stereoselectivity. Erosion of stereoselectivity may occur when the oxocarbenium ion can take up multiple conformations.

Future prospects

The main goal of this thesis was to shed more light on the glycosylation reaction mechanism. The influence the acceptor has on the glycosylation mechanism is profound, but is difficult to quantify. Several techniques referred to in the previous chapters can be extended to the model systems used in Chapters 3-5 as well as applied to the carbohydrate acceptors of Chapter 6. A few approaches to obtain both qualitative and quantitative information on the glycosylation mechanism and/or acceptor reactivity will be discussed below. The two extreme situations of the glycosylation mechanism, the S_N1 or S_N2 substitution reactions, can be discerned by experimental kinetics and transition state models as studied by computational methods.

Kinetic Isotope Effects

The rate-determining step for a typical S_N1 mechanism is dissociation of the leaving group and generation of an (oxo)carbenium ion. This is followed by addition of the nucleophile in the product-forming step. In a S_N2 reaction, the rate-determining step is also the product-forming step. Dissecting the mechanism of glycosylation into its S_N1 and S_N2 extremes can be effectively done by studying Kinetic Isotope Effects (KIEs).^{1,2} Primary KIEs are measured by integrating NMR signals of the electrophilic anomeric carbon atom, either with isotopically enriched substances or using the naturally abundant $^{13}\text{C}/^{12}\text{C}$ isotopes. The vibrational energy levels of the bonds to the heavier ^{13}C isotope (8% mass increase compared to ^{12}C) are lower than those to the ^{12}C atom, resulting in a slightly higher bond dissociation energy for the former. This has an immediate effect on the S_N2 reaction transition state, creating an energy difference between the pathways having a ^{13}C or ^{12}C anomeric center carbon (rate constants $k_{12} > k_{13}$). The rate of S_N1 reactions is much less effected by the difference between ^{13}C and ^{12}C atoms and the ratio of reaction rates (k_{12}/k_{13}) is close to unity. Secondary deuterium KIEs (SDKIEs) are measured of an atom at which the reaction does not take place, but which is in (close) proximity to the reacting center. The deuterium atom in isotopically labelled carbohydrates can be directly attached to the anomeric center (α -SDKIE), or positioned further away (β -SDKIE, γ -SDKIE). The ratio of reaction rates is again indicative of the reaction mechanism, but it is reversed as compared to primary-KIEs. The S_N1 SDKIE is often observed to be high (>1.20), while that of the S_N2 pathway is around unity.

KIEs have been studied in the context of glycosylations by the groups of Crich, Tantillo, and Bennet, among others, a selection of the results are summarized in

Table 1.^{3–12} Primary KIEs obtained with the strongly nucleophilic acceptor isopropanol **12** are indicative of an S_N2 mechanism for the formation of both anomeric products from benzylidene glucose donor **10**, and the β-product from benzylidene mannose donor **9** (entries 1 and 2). The α-product of benzylidene mannose gave a value indicating an S_N1 mechanism of formation, consistent with the postulates given in Chapter 3 that an oxocarbenium ion in the ⁴H₃ conformation is at play here. Secondary KIEs measured for a weaker carbohydrate acceptor (**13**, entry 3) gave values corresponding to an S_N2 reaction with significant oxocarbenium ion character (an “exploded S_N2-reaction”) for the formation of both anomers of benzylidene mannose **11**.

Table 1. Kinetic isotope effects measured for glycosylation reactions.

Entry	Donor ^a	Acceptor	KIE	Value ^b	Verdict ^c
1 ⁵			¹³ C primary KIE	α: 1.005±0.002 β: 1.023±0.003	S _N 1 S _N 2
2 ⁵			¹³ C primary KIE	α: 1.023±0.006 β: 1.019±0.001	S _N 2 S _N 2
3 ⁴			² H secondary α-KIE	β: 1.12±0.01	S _N 2/S _N 1

^aH* indicates partial deuterium labelling. ^bValues for the anomers are indicated. ^cS_N2 is described in each case to be a loosened-S_N2 transition state.

It would be worthwhile to determine KIEs of a range of donor-acceptor pairs, in which the reactivity of both partners is gradually changed. For example, the two donors used in Chapter 6 (**3** and **4**, Figure 2) can be used in conjunction with the set of fluorinated model acceptors (**5–8**, Figure 2) in a broad KIE study. The set of model acceptors is expected to show a steady decline of primary KIEs or steady increase of secondary KIEs due to the increased oxocarbenium ion contribution in the transition states for these reactions.




Figure 2. Model donors and acceptors to investigate a glycosylation mechanism by KIEs.

Cation-clock kinetics

Another approach to derive kinetic data for glycosylation reactions is based on the competition reactions using the cation-clock methodology. The reaction rate in an S_N2 reaction is dependent on the concentration of the electrophile and the nucleophile, while the rate of the S_N1 reaction is independent of the nucleophile. Changing the concentration of a nucleophile and establishing the reaction rate, is therefore a practical means to determine whether a reaction proceed through an S_N1 or S_N2 path. Since glycosylation reactions are very fast, when using a preactivation setup (see also the next section), and rates of conversion are difficult to measure on a practical time-scale, Crich and co-workers have developed a cation-clock competition set-up in which an internal and external nucleophile compete for the electrophilic species.^{13–15} The internal nucleophile is a weak nucleophile and will only react with the more electrophilic oxocarbenium ion via an S_N1 mechanism, giving a cyclized product at a fixed rate (clock). In the presence of a competing nucleophile, the oxocarbenium ion or the covalent triflate may be captured. A strong external nucleophile will outcompete the internal nucleophile (following the S_N2 -path), while weaker nucleophiles will have more competition from internal cyclization. Crich and co-workers used the strong nucleophile isopropanol **12** and allyltrimethylsilane **14** (Figure 3) as acceptors in combination with benzylidene mannose donor **15** and benzylidene glucose donor **16** and found that




Figure 3. Cation-clock substitution products from external and internal nucleophiles.

the β -manno-anomer **19** is formed with a much higher concentration dependence than internal cyclization product **23**, consistent with an S_N2 scenario. It was also shown that formation of the α -anomer **17** was not concentration dependent. In contrast, the *gluco*- β -anomer **20** is formed with the same concentration dependence as α -anomer **18**, and both react with significant S_N2 character. The reactions of C-nucleophile **14**, followed S_N1 kinetics (pseudo-first order in these experiments).

As the research in this thesis has shown that secondary carbohydrate alcohols are significantly weaker nucleophiles than *iso*-propanol it would be of interest to perform this type of cation clock experiments with the set of partially fluorinated ethanols. Systematic variation in the reactivity of the donors (by slightly changing the protecting group pattern as described in Chapters 3 and 4) will be of interest, to pinpoint when the mechanism most radically changes.

Preactivation-based competition experiments

Decreasing the reactivity of an acceptor has consequences for the stereoselectivity of the glycosylation reaction by a change in the mechanism, as the results from Chapters 3-6 confirm. How the reactivity of the acceptor changes by its structural modifications can be effectively studied by competition of two acceptors for a limiting amount of donor, as was demonstrated in Chapter 2 by the work of the group of Crich and the group of R veda. The set of fluorinated model acceptors and the array of carbohydrate acceptors from Chapter 6 would serve as excellent substrates for acceptor competition experiments (Figure 4). Donors varying in reactivity, for example one favoring S_N2 and the other favoring S_N1 reactions would further help to establish the reactivities of acceptors under different circumstances. To keep the mechanistic picture of the competition experiments close to the actual glycosylations reported throughout this thesis, a preactivation setup would be the preferred method for competitive glycosylations. Preliminary results indicate that the preactivation setup may be too reactive for efficient competition between two nucleophiles either from the set of model acceptors or carbohydrate acceptors. Further studies in the field of preactivation glycosylations are necessary to develop this method of competitive glycosylations.




Figure 4. Selection of carbohydrate acceptors bearing functional groups influencing the reactivity of the acceptor.

Computational evaluation of the reactivity of the acceptor

In Chapter 2 the work of Stortz was described quantifying the reactivity of glycosyl acceptors.¹⁶ They calculated the energy of formation of cationic species originating from the reaction of glycosyl alcohols with a methyl cation (Figure 5). The difference in energy of formation ($\Delta\Delta E$) explained the relative reactivities of two acceptors **30** and **31** (**30/31**, 5:1). It would be of interest to probe this method to a wider range of glycosyl acceptors and to find out how the $\Delta\Delta E$ found for various acceptors correlates with experimentally obtained stereoselectivities or relative reactivity values. The set of model acceptors introduced in Chapter 3 may serve to benchmark the system and a range of acceptors like those from Chapter 6 can then be studied following the computational approach of Stortz and co-workers.




Figure 5. Methylated acceptors **30** and **31**, and methylated model acceptors **32-35**.

Assessing steric and conformational effects in acceptor reactivity

The set of model acceptors introduced in Chapter 3 (**5-8**, *vide supra*) was used to determine how electronic effects in the acceptor affected the stereoselectivity in glycosylation reactions. It is clear that in a glycosylation reaction, that unites two bulky coupling partners, sterics also play a major role. Therefore, it would be of interest to develop a system to systematically gauge the effect of different steric environments on








Table 4. Glycosylations with model acceptors **36-38**.

Entry	Donor	Acceptor	Yield	Ratio	Product
1	3	36	65	1 : 2.5	39
2	3	37	52	1.5 : 1	40
3	3	38	71	1 : 5.1	41
4	4	36	96	1 : 17	42
5	4	38	77	<1 : 20	43 ¹⁸

the stereochemical outcome of a glycosylation reaction. A systematic series of acceptors could be formed by ethanol, *iso*-propanol, and *tert*-butanol. More substituted systems in which the orientation of the alcohol and neighboring groups can be modulated should be considered next. Initial experiments in this direction are displayed in Table 4. Conformationally locked cyclohexanols **36** and **37** were glycosylated with donors **3** and **4** to assess the difference in reactivity between an axial and equatorial alcohol. Interestingly, both stereoisomers were less β -selective than cyclohexanol **38** (entries 3 and 5), indicating that flexibility of the acceptor can have an important effect on the glycosylation reaction, as was previously also noted by Zhang *et al.*¹⁷

In Chapter 6 the stereoselectivity of condensation reactions of several C-4-OH *gluco*-configured carbohydrate acceptors with donor **3** and **4** was determined. It is of interest to expand the set of acceptors to carbohydrates having a different configuration and vary the protecting group pattern. This will further prove the generality of the approach and may lead to an acceptor reactivity chart that will serve as a reference for

Table 5. Additional glycosylations with donors **3** and **4** and carbohydrate acceptors **44-48**.

Acceptor	 3	 4
 44	49 12 : 1 (72 %)	50 3 : 1 (86 %)
 45	51 6 : 1 (85 %)	52 1 : 1.3 (88 %)
 46	53 10 : 1 (87 %)	54 1 : 1.3 (73 %)
 47	55 1.4 : 1 (71 %)	56 1 : 1.6 (80 %)
 48	57 2.1 : 1 (75 %)	

many future glycosylation reactions. For example, galactoside acceptors **44-46** have been used and glycosylations of these acceptors with donors **3** and **4** show that all three of them are moderately α -selective (Table 5). Further decreasing their reactivity by placing benzoyl groups on the acceptors should further increase their α -selectivity. Other relevant systems to investigate, include *manno*-configured acceptors, acceptors of the L-configuration such as fucose and rhamnose, but also disaccharides or thioglycosides.

Changing the substituents of the benzoyl groups may increase their electron-withdrawing capacity offering another way to fine-tune acceptor reactivity (Table 5). A series of mono-nitrated *ortho*-, *meta*-, and *para*- nitrobenzoyl groups was successfully glycosylated and a small increase in α -selectivity was observed from *para*- to *ortho*-nitrobenzoyl (from $\alpha/\beta = 3 : 1$ to $\alpha/\beta = 3.5 : 1$). Placing two nitro groups enhanced the α -selectivity further (5.6:1) as shown in Chapter 6. Surprisingly, installing a third nitro group (**48**) had an adverse effect, decreasing the selectivity to $\alpha/\beta = 2.1 : 1$. The pentafluorobenzoate in acceptor **47** was even less selective providing product **55** in an $\alpha/\beta = 1.4 : 1$ anomeric mixture.¹⁹

Experimental and computational evaluation of 5-deoxy furanosyl oxocarbenium ions

In Chapter 7 and 8 furanoses bearing different substituents on the C-2- and C-5-position were synthesized and studied under S_N1 -glycosylation conditions to probe the effect of these substituents on the stereoselectivity of the reactions. The intermediate oxocarbenium ions were studied by the CEL map method. Initial studies into the effect of a 5-deoxy functionality have also been undertaken to investigate the effect of this modification on the stereoselectivity of the glycosylation reactions. To this end furanosyl donors **59-62** were synthesized and glycosylated with allyl trimethyl silane (Figure 6).




Figure 6. Imidate donors **59-62**, acetyl donor **63** and glycosylation products **65-69** of 5-deoxy furanosides. Inset: top view of the protruding C-H bonds on the acceptor.

The results of these glycosylations and the CEL maps of the 5-deoxyfuranosyl oxocarbenium ions are shown in Table 6. For the 5-deoxyribose and 5-deoxylyxose oxocarbenium ions **71** and **72** the C-2 and C-3 substituents can take up a most stabilizing orientation in the E_3 and 3E conformation, respectively. The *ribo*- and *lyxo*-configured 5-deoxyfuranoside imidate donors **60** and **61** provide exclusively the 1,2-*cis*-product in glycosylations with allyl-TMS (**66**, **67**, Figure 6), in line with all other modifications on these two configurations. The *arabino*- and *xylo*-configured 5-deoxyfuranosides give

Table 6: CEL maps of *ribo*-configured oxocarbenium ions 70-73.

	Arabinose	Ribose	Lyxose	Xylose
R = CH ₂ OBn				
R = CH ₃				
Energies (kcal·mol ⁻¹)	3E : 0.0 3T_4 : 0.5 E_3 : 1.0	E_3 : 0.0 4T_3 : 0.85 3E : 1.5	3E : 0.0 3T_4 : 1.7 E_3 : 4.5	3E : 0.0 E_3 : 0.4
Experimental (α : β)	65 ; 40 : 60 ^a	66 ; >98 : 2 ^a	67 ; <2 : 98 ^a	68 ; 60 : 40 ^a 69 ; 40 : 60 ^b
Yield (%)	86	89	56	60 and 77













^aAllyl-TMS was the acceptor. ^bTES-D was the acceptor, acetyl donor **63**, see experimental section. *Reagents and conditions:* donor (0.1 mmol), acceptor (0.4 mmol), TfOH (0.01 mmol), DCM (1 mL), 3Å M.S., -75°C

anomeric mixtures. This is not surprising considering the conflicting interest of the C-2 and C-3 substituents in both the *arabino*- and *xylo*-configurations. However, the CEL maps predict a different stereochemical outcome. There is no clear explanation for this discrepancy. It may be that the use of an acetyl donor and TES-D as a nucleophile provides a different outcome. Indeed, the use of these conditions slightly changed the anomeric ratio in the case of the 5-deoxyxylose donor (**63**).


Furanoside O-glycosylations

Chapter 7 and 8 have reported on glycosylation reactions of differently substituted furanosyl donors with allyl-TMS and TES-D as nucleophiles. In line with previous studies by van Rijssel *et al.* the stereoselectivity in these condensations could be adequately accounted for using the CEL maps of the intermediate oxocarbenium ions.²⁰ Thus, these glycosylations very likely proceed with an S_N1-like mechanism. To investigate how *O*-nucleophiles react with the set of furanosyl donors the imidate donors of all perbenzylated pentofuranoses and their thiophenyl equivalents (**77-84**) have been glycosylated with acceptors **5**, **8**, and **76**. Table 7 lists the outcome of these experiments and compares them to the reaction with allyl-TMS **75**. It is clear that there is a relatively poor correlation between the outcome of the reactions of the *O*- versus the *C*-nucleophiles. Even the results of the condensations of the weak *O*-nucleophile, trifluoroethanol, deviate from those using TES-D and allyl-TMS. It is difficult to distill a trend from the results in Table 7, and no clear single mechanistic explanation is available to account for the observed selectivities. It is likely that the more nucleophilic acceptors **5** and **76** react in glycosylations with more S_N2-character. Therefore the nature, stability and reactivity of the intermediate anomeric triflates should be investigated by Low-Temperature NMR.²¹ It may also be that the inside attack model, devised by Woerpel and co-workers, does not hold for glycosylations of *O*-nucleophiles and furanosyl oxocarbenium ions. Computational models of the triflates, and the transition states of the S_N1 and S_N2 reactions should help to build a better understanding of *O*-glycosylation of furanosides.

Table 7. Glycosylations of furanosides with model acceptors.


				
	75	8	76	5
Donor	$\alpha : \beta$ (yield)	$\alpha : \beta$ (yield)	$\alpha : \beta$ (yield)	$\alpha : \beta$ (yield)
	85 >98 : 2	86 68 : 32 (85%)	87 64 : 36 (52%)	88 81 : 19 (72%)
	85 >98 : 2 (31%)	86 65 : 35 (86%)	87 67 : 33 -	88 58 : 42 (76%)
	89 5 : 95 -	90 13 : 87 (80%)	91 44 : 56 (78%)	92 30 : 70 (51%)
	89 10 : 90 (25%)	90 14 : 86 (85%)	91 9 : 91 (88%)	-
	93 <2 : 98 (54%)	94 48 : 52 (98%)	95 73 : 26 (72%)	96 78 : 22 (76%)
	93 <2 : 98 (22%)	-	95 25 : 75 -	96 20 : 80 -
	97 80 : 20 (68%)	98 84 : 16 (85%)	99 62 : 38 (79%)	-
	97 85 : 15 (35%)	98 71 : 29 (74%)	99 70 : 30 (56%)	-

Experimental section




Trans-4-tert-butylcyclohexyl 2,3-di-O-benzyl-4,6-O-benzylidene- α -D-glucopyranoside (39). Donor **3** and acceptor **36** were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations as described in

Chapter 3 yielding product **39** (38 mg, 65 μ mol, 65%, α : β = 1 : 2.5) as a white solid. R_f: 0.28 (toluene). IR (thin film): 696, 732, 997, 1028, 1074, 1365, 2862, 2940; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.53 – 7.46 (m, 2.6H, CH_{arom}), 7.41 – 7.24 (m, 16.9H, CH_{arom}), 5.55 (s, 1.3H, CHPh α,β), 4.96 – 4.66 (m, 5.5H, 2xCH₂ Bn α,β , H-1 α), 4.62 (d, 1H, J = 7.7 Hz, H-1 β), 4.33 (dd, 1H, J = 10.5, 5.0 Hz, H-6 β), 4.26 (dd, 0.3H, J = 10.2, 4.9 Hz, H-6 β), 4.06 (t, 0.3H, J = 9.3 Hz, H-3 α), 3.95 (td, 0.3H, J = 10.0, 4.8 Hz, H-5 α), 3.79 (t, 1H, J = 10.3 Hz, H-6 β), 3.76 – 3.52 (m, 3.9H, H-2 α , H-3 β , H-4 α , H-4 β , H-6 α , CH Cy β), 3.49 – 3.35 (m, 2.3H, H-2 β , H-5 β , CH Cy α), 2.20 – 0.95 (m, 11.7H, CH₂ Cy), 0.85 (s, 11.7H, ¹Bu); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 139.0, 138.6, 138.5, 138.4, 137.5, 137.4 (C_a), 131.6, 130.3, 129.3, 128.9, 128.9, 128.4, 128.4, 128.3, 128.3, 128.2, 128.2, 128.1, 128.0, 128.0, 127.8, 127.7, 127.6, 127.5, 126.0, 126.0, 124.4 (CH_{arom}), 102.5 (C-1 β), 101.2 (CHPh), 101.1 (C-1 α), 96.1, 82.4, 82.2, 81.5, 81.1, 79.4, 79.3, 78.7, 76.8, 75.4, 75.1, 73.4, 69.1, 68.9, 66.0, 62.4, 47.2, 47.2, 34.2, 33.8, 32.7, 32.3, 31.9, 27.7, 25.9, 25.7, 25.6, 25.6; HRMS: [M+H]⁺ calcd for C₃₇H₄₇O₆ 587.33672, found 587.33666.




Cis-4-tert-butylcyclohexyl 2,3-di-O-benzyl-4,6-O-benzylidene- α -D-glucopyranoside (40). Donor **3** and acceptor **37** were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations as described in Chapter 3 yielding product **40**

(31 mg, 52 μ mol, 52%, α : β = 1.5 : 1) as a white solid. R_f: 0.25 and 0.22 (toluene). IR (thin film): 660, 733, 999, 1028, 1072, 1084, 1365, 2864, 2938; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.62 – 7.18 (m, 25.5H, CH_{arom}), 5.56 (s, 1H, CHPh α), 5.55 (s, 0.7H, CHPh β), 5.02 – 4.66 (m, 7.8H, 2xCH₂ Bn, H-1 α), 4.58 (d, 0.7H, J = 7.7 Hz, H-1 β), 4.32 (dd, 0.7H, J = 10.4, 5.0 Hz, H-6 β), 4.25 (dd, 1H, J = 10.2, 4.8 Hz, H-6 α), 4.09 (t, 1H, J = 9.2 Hz, H-3 α), 4.02 (t, 0.7H, J = 2.6 Hz, CH Cy β), 3.94 (td, 1H, J = 10.0, 5.0 Hz, H-5 α), 3.85 – 3.66 (m, 4.4H, H-3 β , H-4 β , H-6 α , H-6 β , CH Cy α), 3.62 (t, 1H, J = 9.4 Hz, H-4 α), 3.57 (dd, 1H, J = 9.3, 3.7 Hz, H-2 α), 3.48 (t, 0.7H, J = 8.0 Hz, H-2 β), 3.39 (td, 0.7H, J = 9.5, 4.9 Hz, H-5 β), 2.09 – 1.88 (m, 3.4H, CH₂ Cy), 1.61 – 1.24 (m, 10.2H, CH₂ Cy), 1.05 – 0.94 (m, 1.7H, CH Cy), 0.83 (s, 9H, ¹Bu), 0.81 (s, 6.3H, ¹Bu); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 139.0, 138.7, 138.6, 137.6, 137.5, 129.0, 129.0, 128.4, 128.4, 128.3, 128.1, 128.1, 127.9, 127.7, 127.7, 127.7, 127.6, 126.1, 102.1 (C-1 β), 101.3, 101.2 (CHPh), 96.1 (C-1 α), 82.6 (C-4 α), 82.1 (C-2 α), 81.7, 81.2 (C-3 β , C-4 β), 79.8 (C-2 α), 78.5 (C-3 α), 75.3, 75.2, 75.2, 73.2 (CH₂ Bn), 73.1 (CH Cy), 71.8 (CH Cy α), 69.4 (C-6 α), 69.0 (C-6 β), 66.2 (C-5 α), 62.8 (C-5 β), 48.0, 48.0, 32.7, 32.7, 32.6, 32.4, 29.8, 27.7, 27.6, 21.9, 21.8, 21.7, 21.5; HRMS: [M+H]⁺ calcd for C₃₇H₄₇O₆ 587.33672, found 587.33660.




Methyl 2,3-di-O-benzyl-6-O-(2,3,4,5,6-pentafluorobenzoyl)- α -D-glucopyranoside (47). Methyl 2,3-di-O-benzyl- α -D-glucopyranoside²² (374 mg, 1.0 mmol, 1 eq.) was converted to the title compound **47** following general procedure **C** of Chapter 6 (pentafluorobenzoyl chloride; 145 μ L, 1.05 mmol, 1.05 eq.). Yield: 550 mg, 0.97 mmol, 97%. [α]_D²⁰ = +22.7° (c = 0.6, CHCl₃); IR (thin film): 698, 739, 1007, 1057, 1229, 1325, 1497, 1524, 1653, 1740, 2916, 3500; ¹H NMR (CDCl₃, 500 MHz, HH-COSY, HSQC): δ 7.40 – 7.30 (m, 10H, CH_{arom}), 5.03 (d, 1H, J = 11.5 Hz, CHH Bn), 4.78 (d, 1H, J = 12.1 Hz, CHH Bn), 4.71 (d, 1H, J = 11.5 Hz, CHH Bn), 4.66 (d, 1H, J = 12.1 Hz, CHH Bn), 4.62 (d, 1H, J = 3.5 Hz, H-1), 4.62 (dd, 1H, J = 11.9, 2.2 Hz, H-6), 4.54 (dd, 1H, J = 11.9, 5.4 Hz, H-6), 3.86 (ddd, 1H, J = 10.0, 5.4, 2.2 Hz, H-5), 3.80 (t, 1H, J = 9.2 Hz, H-3), 3.52 (dd, 1H, J = 9.6, 3.5 Hz, H-2), 3.51 – 3.45 (m, 1H, H-4), 3.39 (s, 3H, CH₃ OMe), 2.33 (d, 1H, J = 2.7 Hz, 4-OH); ¹³C-APT NMR (CDCl₃, 126 MHz, HSQC): δ 159.0 (C=O), 146.7, 144.5, 142.4, (CF_{ortho/para}), 138.8, 138.7 (CF_{meta}), 138.0 (C_a), 136.9, 136.8 (CF_{meta}), 128.8, 128.7, 128.2, 128.2 (CH_{arom}), 108.0 (C_{q-ipso}), 98.3 (C-1), 81.2 (C-3), 79.8 (C-2), 75.6, 73.3 (CH₂ Bn), 70.0 (C-4), 68.9 (C-5), 65.6 (C-6), 55.5 (OMe); ¹⁹F NMR (CDCl₃, 471 MHz): δ -137.87 (dp, 2F, J = 16.5, 5.4 Hz, ortho-F₅Bz), -148.29 (tt, 1F, J = 20.9, 4.8 Hz, para-F₅Bz), -160.46 (tt, 2F, J = 21.0, 5.9 Hz, meta-F₅Bz); HRMS: [M+Na]⁺ calcd for C₂₈H₂₅F₅O₇Na 591.1418, found 591.1431.




2,4,6-Trinitrobenzoyl chloride (S1). Toluene (2.1 mL, 20 mmol) was dissolved in 17 mL H₂SO₄ and cooled to 0°C. To this mixture a solution of HNO₃ (99%, 4.2 mL) in 15 mL H₂SO₄ was slowly added (15 min, temperature remains below 40°C). When addition was complete, the reaction mixture was slowly heated to 95°C and kept at that temperature for 3 h. The solution was cooled and poured over ice. The precipitate was collected, washed with cold H₂O, air-dried, and crystallized from boiling EtOH (50 mL) to form large needles of 2,4,6-trinitrotoluene (TNT) (3.8 g, 16.8 mmol, 84%). ¹H NMR (DMSO, 400 MHz): δ 9.03 (s, 2H), 2.57 (s, 3H). The TNT (2.27 g, 10 mmol) was dissolved in H₂SO₄ (18 mL) and K₂Cr₂O₇ (3.18 g,


10.8 mmol) was added in small portions, maintaining a temperature below 35°C (ice-bath). After stirring overnight at room temperature, the reaction mixture was poured on ice and the precipitate collected, washed with cold H₂O, dried and crystallized from boiling H₂O to yield 2,4,5-trinitrobenzoic acid (TNBA) as yellow crystals (1.1 g, 4.3 mmol, 43%). ¹H NMR (MeOD, 400 MHz): δ 9.23 (s, 2H); ¹³C-APT NMR (MeOD, 101 MHz): δ 164.1, 149.3, 148.6, 131.6, 125.6. The TNBA (390 mg, 1.5 mmol) was suspended in DCE (300 μL) and DMF (15 μL), thionyl chloride was slowly added (375 μL) and the mixture heated to 80°C for 2 h. The reaction mixture was cooled to 0°C and the precipitate was collected by filtration and washed with cold DCE to yield the 2,4,6-trinitrobenzoyl chloride as a yellow solid (250 mg, 0.9 mmol, 60%). Spectroscopic data were in accord with those previously reported.²³ ¹H NMR (DMSO, 400 MHz): δ 9.14 (s, 2H); ¹³C-APT NMR (DMSO, 101 MHz): δ 162.4, 147.6, 146.7, 129.7, 125.0.



Methyl 2,3-di-O-benzyl-6-O-(2,4,6-trinitrobenzoyl)-α-D-glucopyranoside (48). Methyl 2,3-di-O-benzyl-α-D-glucopyranoside²² (374 mg, 1.0 mmol, 1 eq.) was converted to the title compound **48** following general procedure **C** of Chapter 6 (2,4,6-trinitrobenzoyl chloride **S1**; 250 mg, 0.9 mmol, 0.9 eq. and 90 μL pyridine, 1.2 eq.). Yield: 137 mg, 0.22 mmol, 22%. [α]_D²⁰ = +29.7° (c = 0.67, CHCl₃); IR (thin film): 700, 735, 1059, 1261, 1279, 1342, 1454, 1545, 1553, 1609, 1751, 2922, 3600; ¹H NMR (CDCl₃, 500 MHz, HH-COSY, HSQC): δ 9.23 (s, 2H, CH_{arom} NO₂Bz), 7.37 – 7.26 (m, 10H, CH_{arom} Bn), 4.99 (d, 1H, J = 11.4 Hz, CHH Bn), 4.78 – 4.72 (m, 2H, CHH Bn, H-6), 4.72 – 4.66 (m, 2H, CHH Bn, H-6), 4.66 – 4.62 (m, 2H, CHH Bn, H-1), 3.89 (ddd, 1H, J = 10.1, 4.9, 2.2 Hz, H-5), 3.80 (t, 1H, J = 9.2 Hz, H-3), 3.50 – 3.44 (m, 2H, H-2, H-4), 3.36 (s, 3H, CH₃ OMe), 2.42 (d, 1H, J = 2.9 Hz, 4-OH); ¹³C-APT NMR (CDCl₃, 126 MHz, HSQC): δ 160.7 (C=O), 147.9, 147.3 (C_q NO₂), 138.7, 138.0 (C_q Bn), 129.9 (C_q Bz), 128.7, 128.6, 128.2, 128.1, 128.1, 124.6 (CH_{arom}), 98.4 (C-1), 81.2 (C-3), 79.6 (C-2), 75.6, 73.2 (CH₂ Bn), 69.8 (C-4), 68.9 (C-5), 67.0 (C-6), 55.6 (OMe); HRMS: [M+Na]⁺ calcd for C₂₈H₂₇N₃O₁₃Na 636.1442, found 636.1451.




Methyl 4-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α-D-glucopyranosyl)-2,3,6-tri-O-benzyl-α-D-galactopyranoside (49). Donor **3** and acceptor **44** were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations as described in Chapter 3 yielding product **49** (60 mg, 72 μmol, 72%, α:β = 12 : 1) as a colorless oil. R_f: 0.50 (4/1 pentane/EtOAc). Spectroscopic data were in accord with those previously reported.²⁴; IR (thin film): 694, 733, 995, 1026, 1049, 1076, 1086, 1364, 1452, 1498, 2864, 2926; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC, HMBC): δ 7.53 – 7.49 (m, 2H, CH_{arom}), 7.45 – 7.15 (m, 28H, CH_{arom}), 5.52 (s, 1H, CHPh), 4.97 – 4.93 (m, 2H, CHH Bn, H-1'), 4.89 (d, 1H, J = 12.3 Hz, CHH Bn), 4.87 (d, 1H, J = 11.9 Hz, CHH Bn), 4.81 – 4.74 (m, 4H, CH₂ Bn, 2xCHH Bn), 4.70 (d, 1H, J = 11.9 Hz, CHH Bn), 4.65 (d, 1H, J = 3.5 Hz, H-1), 4.29 (td, 1H, J = 10.0, 4.9 Hz, H-5'), 4.26 (d, 1H, J = 11.9 Hz, CHH Bn), 4.22 (d, 1H, J = 11.9 Hz, CHH Bn), 4.06 (d, 1H, J = 2.3 Hz, H-4), 4.02 (t, 1H, J = 9.3 Hz, H-3'), 3.97 – 3.78 (m, 5H, H-2, H-3, H-5, H-6, H-6'), 3.60 (dd, 1H, J = 9.7, 9.3 Hz, H-4'), 3.56 (dd, 1H, J = 9.5, 3.6 Hz, H-2'), 3.52 – 3.46 (m, 2H, H-6, H-6'), 3.36 (s, 3H, CH₃ OMe); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC, HMBC): δ 138.9, 138.6, 138.4, 138.3, 138.3, 137.8 (C_q), 128.8, 128.6, 128.5, 128.5, 128.5, 128.4, 128.3, 128.3, 128.3, 128.2, 128.1, 128.0, 127.9, 127.8, 127.8, 127.7, 127.7, 127.6, 127.5, 126.1 (CH_{arom}), 101.2 (CHPh), 100.6 (C-1'), 99.1 (C-1), 82.9 (C-4'), 79.7 (C-2'), 79.2 (C-3'), 77.8 (C-3), 77.3 (C-4), 75.2, 74.4 (CH₂ Bn), 74.4 (C-2), 73.6, 73.0, 73.0 (CH₂ Bn), 69.4 (C-5), 69.1 (C-6'), 68.1 (C-6), 63.1 (C-5'), 55.5 (OMe); HRMS: [M+Na]⁺ calcd for C₅₅H₅₈O₁₃Na 917.3877, found 917.3903.



Methyl 4-O-(2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-α/β-D-glucopyranosyl)-2,3,6-tri-O-benzyl-α-D-galactopyranoside (50). Donor **4** and acceptor **44** were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations as described in Chapter 3 yielding product **50** (70 mg, 86 μmol, 86%, α:β = 3 : 1) as a colorless oil. R_f: 0.60 (4/1 pentane/EtOAc); IR (thin film): 696, 737, 997, 1034, 1055, 1092, 1369, 1454, 1497, 2106, 2866, 2928, 3030; Data for the α-anomer: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.54 – 7.15 (m, 25H, CH_{arom}), 5.52 (s, 1H, CHPh), 4.95 (d, 1H, J = 10.7 Hz, CHH Bn), 4.84 – 4.78 (m, 5H, 2xCH₂ Bn, H-1'), 4.74 (d, 1H, J = 10.7 Hz, CHH Bn), 4.68 (d, 1H, J = 3.3 Hz, H-1), 4.57 (d, 1H, J = 11.8 Hz, CHH Bn), 4.49 (d, 1H, J = 11.8 Hz, CHH Bn), 4.32 (td, 1H, J = 10.0, 4.9 Hz, H-5'), 4.13 (d, 1H, J = 2.3 Hz, H-4), 3.97 – 3.84 (m, 5H, H-2, H-3, H-3', H-5, H-6), 3.77 (dd, 1H, J = 10.1, 4.9 Hz, H-6'), 3.64 (t, J = 9.5 Hz, 1H, H-4'), 3.55 – 3.46 (m, 2H, H-6, H-6'), 3.36 (s, 3H, CH₃ OMe), 3.33 (dd, 1H, J = 10.0, 3.8 Hz, H-2'); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 138.5, 138.2, 138.1, 137.7, 137.6 (C_q), 128.6, 128.6, 128.6, 128.5, 128.3, 128.2, 127.6, 126.1 (CH_{arom}), 101.2 (CHPh), 99.0 (C-1'), 98.9 (C-1), 83.0 (C-4'), 77.3 (C-2), 77.0 (C-3'), 75.7 (C-4), 75.2 (CH₂ Bn), 74.7 (C-3), 73.6, 73.4, 73.2 (CH₂ Bn), 68.8, 68.8 (C-5, C-6'), 67.1 (C-6), 63.8 (C-2'), 62.9 (C-5'), 55.5 (OMe); Diagnostic peaks β-anomer: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 4.95 (d, 1H, J = 12.0 Hz, CHH Bn), 4.90 (d, 1H, J = 11.4 Hz, CHH Bn), 4.62 (d, 1H, J = 3.7 Hz, H-1), 4.55 (d, 1H, J = 11.9 Hz, CHH Bn), 4.47 (d, 1H, J = 11.8 Hz, CHH Bn), 4.11 (dd, 1H, J = 10.1, 3.7 Hz, H-2), 3.37 (s, 3H, CH₃ OMe), 3.20 (td, 1H,


$J = 9.8, 5.0$ Hz, H-5'); ^{13}C -APT NMR (CDCl_3 , 101 MHz, HSQC): δ 139.0, 138.6, 138.3, 138.0, 137.2 (C_a), 102.1 (C-1'), 101.4 (CHPh), 98.9 (C-1), 81.6, 79.0, 78.4, 76.4, 75.0, 73.9, 73.8, 73.4, 69.6, 69.0, 68.6, 66.5 (C-2'), 66.0 (C-5'), 55.5 (OMe); HRMS: $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{48}\text{H}_{51}\text{N}_3\text{O}_{10}\text{Na}$ 852.3472, found 852.3488.



Methyl 3-O-(2,3-di-O-benzyl-4,6-O-benzylidene- α/β -D-glucopyranosyl)-2,4,6-tri-O-benzyl- α -D-galactopyranoside (51). Donor **3** and acceptor **45** were condensed using

the general procedure for $\text{Tf}_2\text{O}/\text{Ph}_2\text{SO}$ mediated glycosylations as described in Chapter 3 yielding product **51** (76 mg, 85 μmol , 85%, $\alpha:\beta = 6:1$) as a colorless oil.


R_f: 0.25 and 0.51 (4/1 pentane/EtOAc); IR (thin film): 696, 735, 1028, 1049, 1074, 1088, 1350, 1368, 154, 2864, 2914; Data for the α -anomer: ^1H NMR (CDCl_3 , 500 MHz, HH-COSY, HSQC): δ 7.48 – 7.45 (m, 2H, CH_{arom}), 7.40 – 7.14 (m, 28H, CH_{arom}), 5.54 (s, 1H, CHPh), 5.06 (d, 1H, $J = 3.6$ Hz, H-1'), 5.00 (d, 1H, $J = 11.3$ Hz, CHH Bn), 4.91 (d, 1H, $J = 11.5$ Hz, CHH Bn), 4.84 (d, 1H, $J = 11.4$ Hz, CHH Bn), 4.80 – 4.75 (m, 2H, CHH Bn, CHH Bn), 4.68 (d, 1H, $J = 11.5$ Hz, CHH Bn), 4.62 (d, 1H, $J = 3.5$ Hz, H-1), 4.56 (d, 1H, $J = 11.9$ Hz, CHH Bn), 4.47 (d, 1H, $J = 11.8$ Hz, CHH Bn), 4.37 (d, 1H, $J = 11.8$ Hz, CHH Bn), 4.36 (d, 1H, $J = 11.4$ Hz, CHH Bn), 4.23 (td, 1H, $J = 10.0, 4.9$ Hz, H-5'), 4.16 (dd, 1H, $J = 10.1, 4.9$ Hz, H-6'), 4.10 (t, 1H, $J = 9.3$ Hz, H-3'), 4.04 (dd, 1H, $J = 10.2, 2.8$ Hz, H-3), 3.96 (dd, 1H, $J = 10.2, 3.6$ Hz, H-2), 3.91 (dd, 1H, $J = 2.8, 1.1$ Hz, H-4), 3.83 (t, 1H, $J = 6.9$ Hz, H-6), 3.64 (t, 1H, $J = 9.5$ Hz, H-4'), 3.63 (t, 1H, $J = 10.2$ Hz, H-6'), 3.62 (dd, 1H, $J = 9.4, 3.5$ Hz, H-2'), 3.48 – 3.46 (m, 2H, H-5, H-6), 3.31 (s, 3H, CH_3 OMe); ^{13}C -APT NMR (CDCl_3 , 126 MHz, HSQC): δ 139.1, 138.7, 138.3, 138.1, 138.1, 137.8 (C_a), 128.5, 128.5, 128.5, 128.4, 128.2, 128.2, 128.2, 128.2, 128.1, 127.9, 127.9, 127.8, 127.7, 127.4, 126.3 (CH_{arom}), 101.3 (CHPh), 98.5 (C-1'), 98.5 (C-1), 82.7 (C-4'), 79.8 (C-2'), 78.7 (C-3'), 78.2 (C-3), 75.8 (C-2), 75.5 (C-4), 75.1, 75.0, 74.6, 73.6, 73.4 (CH_2 Bn), 69.3 (C-5), 69.2 (C-6), 69.0 (C-6'), 63.1 (C-5'), 55.3 (OMe); Diagnostic peaks β -anomer: ^1H NMR (CDCl_3 , 500 MHz, HH-COSY, HSQC): δ 7.52 – 7.48 (m, 2H, CH_{arom}), 7.42 – 7.16 (m, 28H, CH_{arom}), 5.57 (s, 1H, CHPh), 5.04 (d, 1H, $J = 7.7$ Hz, H-1'), 5.00 (d, 1H, $J = 11.5$ Hz, CHH Bn), 4.98 (d, 1H, $J = 11.4$ Hz, CHH Bn), 4.94 (d, 1H, $J = 11.3$ Hz, CHH Bn), 4.84 (d, 1H, $J = 11.5$ Hz, CHH Bn), 4.82 (d, 1H, $J = 11.3$ Hz, CHH Bn), 4.65 (d, 1H, $J = 11.5$ Hz, CHH Bn), 4.63 (d, 1H, $J = 11.8$ Hz, CHH Bn), 4.55 (d, 1H, $J = 3.7$ Hz, H-1), 4.48 (d, 1H, $J = 11.6$ Hz, CHH Bn), 4.40 (d, 1H, $J = 11.6$ Hz, CHH Bn), 4.32 (dd, 1H, $J = 10.5, 5.1$ Hz, H-6'), 4.32 (d, 1H, $J = 11.8$ Hz, CHH Bn), 4.24 (dd, 1H, $J = 10.1, 3.1$ Hz, H-3), 3.99 (dd, 1H, $J = 10.1, 3.7$ Hz, H-2), 3.97 – 3.93 (m, 2H, H-4, H-6), 3.79 – 3.74 (m, 2H, H-3', H-6'), 3.69 (t, 1H, $J = 9.3$ Hz, H-4), 3.54 – 3.52 (m, 2H, H-5, H-6), 3.46 (dd, 1H, $J = 8.7, 7.8$ Hz, H-2'), 3.40 (td, 1H, $J = 9.9, 5.1$ Hz, H-5'), 3.31 (s, 3H, CH_3 OMe); ^{13}C -APT NMR (CDCl_3 , 126 MHz, HSQC): δ 103.9 (C-1'), 101.2 (CHPh), 98.5 (C-1), 82.9 (C-2'), 81.9 (C-4'), 81.1 (C-3'), 77.9, 75.3, 75.3, 75.2, 73.7, 73.6, 69.1, 69.1, 68.9, 65.8 (C-5'), 55.4 (OMe); HRMS: $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{55}\text{H}_{58}\text{O}_{11}\text{Na}$ 917.3877, found 917.3885.



Methyl 3-O-(2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy- α/β -D-glucopyranosyl)-2,4,6-tri-O-benzyl- α -D-galactopyranoside (52). Donor **4** and acceptor **45** were condensed using


the general procedure for $\text{Tf}_2\text{O}/\text{Ph}_2\text{SO}$ mediated glycosylations as described in Chapter 3 yielding product **52** (73 mg, 88 μmol , 88%, $\alpha:\beta = 1:1.3$) as a

colorless oil. R_f: 0.43 and 0.66 (4/1 pentane/EtOAc); IR (thin film): 696, 735, 995, 1028, 1047, 1092, 1350, 1369, 1454, 2108, 2866, 2910; ^1H NMR (CDCl_3 , 500 MHz, HH-COSY, HSQC): δ 7.48 – 7.21 (m, 57.5H, CH_{arom}), 5.57 (s, 1.3H, CHPh $_{\alpha}$), 5.55 (s, 1H, CHPh $_{\alpha}$), 5.13 (d, 1H, $J = 3.6$ Hz, H-1' $_{\alpha}$), 5.01 (d, 1H, $J = 11.2$ Hz, CHH Bn $_{\alpha}$), 4.94 – 4.84 (m, 6.2H, 4xCHH Bn, H-1' $_{\beta}$), 4.80 (d, 1.3H, $J = 11.2$ Hz, CHH Bn $_{\beta}$), 4.76 (d, 1H, $J = 11.9$ Hz, CHH Bn $_{\alpha}$), 4.75 (d, 1H, $J = 11.0$ Hz, CHH Bn $_{\alpha}$), 4.65 (d, 1H, $J = 3.6$ Hz, H-1 $_{\alpha}$), 4.60 – 4.53 (m, 5.9H, 4xCHH Bn, H-1 $_{\beta}$), 4.48 (d, 1H, $J = 11.7$ Hz, CHH Bn $_{\alpha}$), 4.48 (d, 1.3H, $J = 11.8$ Hz, CHH Bn $_{\beta}$), 4.40 (d, 1H, $J = 11.7$ Hz, CHH Bn $_{\alpha}$), 4.40 (d, 1.3H, $J = 11.7$ Hz, CHH Bn $_{\beta}$), 4.31 (dd, 1.3H, $J = 10.4, 5.1$ Hz, H-6' $_{\beta}$), 4.27 – 4.22 (m, 2H, H-5' $_{\alpha}$, H-6' $_{\alpha}$), 4.19 (dd, 1.3H, $J = 10.1, 3.2$ Hz, H-3 $_{\beta}$), 4.12 (dd, 1H, $J = 10.3, 2.9$ Hz, H-3 $_{\alpha}$), 4.10 – 4.04 (m, 2.3H, H-2 $_{\beta}$, H-3' $_{\alpha}$), 4.02 – 3.97 (m, 2H, H-2 $_{\alpha}$, H-4 $_{\alpha}$), 3.95 – 3.87 (m, 3.6H, H-4 $_{\beta}$, H-5 $_{\alpha}$, H-5 $_{\beta}$), 3.78 – 3.64 (m, 4.6H, H-4' $_{\alpha}$, H-4' $_{\beta}$, H-6' $_{\alpha}$, H-6' $_{\beta}$), 3.56 – 3.49 (m, 6.9H, H-2' $_{\alpha}$, H-3' $_{\beta}$, H-6 $_{\alpha}$, H-6 $_{\beta}$, H-6 $_{\beta}$), 3.42 (dd, 1.3H, $J = 9.5, 8.0$ Hz, H-2' $_{\beta}$), 3.36 (td, 1.3H, $J = 9.9, 5.1$ Hz, H-5' $_{\beta}$), 3.33 (s, 3H, CH_3 OMe $_{\alpha}$), 3.31 (s, 3.9H, CH_3 OMe $_{\beta}$); ^{13}C -APT NMR (CDCl_3 , 126 MHz, HSQC): δ 138.7, 138.7, 138.3, 138.2, 138.1, 138.0, 137.9, 137.8, 137.6, 137.2 (C_a), 129.1, 129.0, 128.6, 128.5, 128.5, 128.5, 128.4, 128.4, 128.4, 128.4, 128.3, 128.2, 128.1, 128.1, 128.0, 128.0, 127.9, 127.9, 127.9, 127.9, 127.8, 127.7, 126.3, 126.1 (CH_{arom}), 102.9 (C-1' $_{\beta}$), 101.5 (CHPh $_{\alpha}$), 101.4 (CHPh $_{\beta}$), 98.5 (C-1 $_{\alpha}$), 98.3 (C-1 $_{\beta}$), 96.1 (C-1' $_{\alpha}$), 83.0 (C-4' $_{\alpha}$), 81.8 (C-4' $_{\beta}$), 79.1 (C-3' $_{\beta}$), 77.4, 77.3 (C-2 $_{\beta}$, C-4 $_{\beta}$), 76.8 (C-3 $_{\beta}$), 76.2 (C-3' $_{\alpha}$), 75.8 (C-3 $_{\alpha}$), 75.3 (C-2 $_{\alpha}$), 75.2, 75.1, 75.0, 75.0 (CH_2 Bn), 74.1 (C-4 $_{\alpha}$), 73.7, 73.6, 73.6, 73.6 (CH_2 Bn), 69.1, 69.0 (C-5 $_{\alpha}$, C-5 $_{\beta}$), 69.0, 68.9, 68.8, 68.7 (C-6 $_{\alpha}$, C-6 $_{\beta}$, C-6' $_{\alpha}$, C-6' $_{\beta}$), 66.9 (C-2' $_{\beta}$), 66.0 (C-2' $_{\alpha}$), 62.9 (C-5' $_{\alpha}$), 55.4, 55.4 (OMe); HRMS: $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{48}\text{H}_{51}\text{N}_3\text{O}_{10}\text{Na}$ 852.3472, found 852.3482.




Methyl 2-O-(2,3-di-O-benzyl-4,6-O-benzylidene- α/β -D-glucopyranosyl)-3,4,6-tri-O-benzyl- α -D-galactopyranoside (53).

Donor **3** and acceptor **46** were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations as described in Chapter 3 yielding product **53** (78 mg, 87 μ mol, 87%, $\alpha:\beta = 10 : 1$) as a colorless oil. R_f: 0.60 (4/1 pentane/EtOAc); IR (thin film): 696, 734, 1028, 1053, 1076, 1085, 1366, 1454, 2864, 2914; Data for the α -anomer: ¹H NMR (CDCl₃, 500 MHz, HH-COSY, HSQC): δ 7.44 – 7.12 (m, 30H, CH_{arom}), 5.51 (s, 1H, CHPh), 4.92 – 4.86 (m, 4H, 2xCHH Bn, H-1, H-1'), 4.86 – 4.80 (m, 3H, 2xCHH Bn, CHH Bn), 4.71 (d, 1H, *J* = 12.3 Hz, CHH Bn), 4.67 (d, 1H, *J* = 11.5 Hz, CHH Bn), 4.52 (d, 1H, *J* = 11.3 Hz, CHH Bn), 4.51 (d, 1H, *J* = 11.8 Hz, CHH Bn), 4.43 (d, 1H, *J* = 11.7 Hz, CHH Bn), 4.33 (dd, 1H, *J* = 10.3, 3.5 Hz, H-2), 4.25 (td, 1H, *J* = 10.0, 5.0 Hz, H-5'), 4.15 (dd, 1H, *J* = 10.1, 5.0 Hz, H-6'), 4.13 (t, 1H, *J* = 9.2 Hz, H-3'), 4.02 (dd, 1H, *J* = 10.3, 2.8 Hz, H-3), 3.95 (dd, 1H, *J* = 2.9, 1.2 Hz, H-4), 3.94 – 3.91 (m, 1H, H-6), 3.62 (t, 1H, *J* = 10.2 Hz, H-6'), 3.61 – 3.53 (m, 4H, H-2', H-4', H-5, H-6), 3.42 (s, 3H); ¹³C-APT NMR (CDCl₃, 126 MHz, HSQC): δ 138.9, 138.7, 138.6, 138.2, 138.0, 137.8 (C_q), 128.8, 128.5, 128.5, 128.4, 128.4, 128.3, 128.3, 128.1, 128.1, 127.9, 127.9, 127.9, 127.9, 127.7, 127.6, 127.6, 126.3 (CH_{arom}), 101.3 (CHPh), 97.0 (C-1), 95.5 (C-1'), 82.3 (C-4'), 78.9 (C-2'), 78.6 (C-3'), 77.6 (C-3), 75.2 (CH₂ Bn), 75.1 (C-4), 75.0, 73.7, 73.4, 73.4 (CH₂ Bn), 72.0 (C-2), 69.5 (C-5), 69.2 (C-6), 69.0 (C-6'), 62.4 (C-5'), 55.2 (OMe); Diagnostic peaks β -anomer: ¹H NMR (CDCl₃, 500 MHz, HH-COSY, HSQC): δ 5.54 (s, 1H, CHPh), 5.00 (d, 1H, *J* = 11.2 Hz, CHH Bn), 3.76 (t, 1H, *J* = 10.3 Hz), 3.77 – 3.66 (m, 2H), 3.41 (s, 3H, CH₃ OMe); ¹³C-APT NMR (CDCl₃, 126 MHz, HSQC): δ 105.0 (C-1'), 101.2 (CHPh), 100.0 (C-1), 82.1, 81.4, 81.0, 78.4, 75.1, 75.0, 73.6, 73.0, 69.3, 69.1, 68.8, 66.0, 62.4, 55.2; HRMS: [M+Na]⁺ calcd for C₅₅H₅₈O₁₁Na 917.3877, found 917.3874.



Methyl 2-O-(2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy- α/β -D-glucopyranosyl)-3,4,6-tri-O-benzyl- α -D-galactopyranoside (54).


Donor **4** and acceptor **46** were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations as described in Chapter 3 yielding product **54** (60 mg, 73 μ mol, 73%, $\alpha:\beta = 1 : 1.3$) as a colorless oil. R_f: 0.74 (4/1 pentane/EtOAc); IR (thin film): 696, 735, 997, 1028, 1051, 1090, 1356, 1368, 1454, 2108, 2866, 2912; ¹H NMR (CDCl₃, 500 MHz, HH-COSY, HSQC): δ 7.49 – 7.22 (m, 57.5H, CH_{arom}), 5.55 (s, 1.3H, CHPh_β), 5.54 (s, 1H, CHPh_α), 4.98 (d, 1H, *J* = 3.7 Hz, H-1'_α), 4.94 – 4.86 (m, 6.9H, 5xCHH Bn, H-1_α), 4.85 (d, 1.3H, *J* = 3.7 Hz, H-1_β), 4.79 (d, 1.3H, *J* = 11.3 Hz, CHH Bn), 4.75 (d, 1H, *J* = 11.0 Hz, CHH Bn), 4.74 (d, 1H, *J* = 11.6 Hz, CHH Bn), 4.69 (d, 1.3H, *J* = 11.5 Hz, CHH Bn), 4.65 (d, 1H, *J* = 11.5 Hz, CHH Bn), 4.58 (d, 1H, *J* = 8.0 Hz, H-1'_β), 4.54 – 4.50 (m, 3.3H, CHH Bn, 2xCHH Bn), 4.47 (d, 1.3H, *J* = 11.8 Hz, CHH Bn), 4.43 (d, 1H, *J* = 11.8 Hz, CHH Bn), 4.39 (d, 1.3H, *J* = 11.8 Hz, CHH Bn), 4.31 – 4.23 (m, 3.3H, H-2_α, H-5', H-6'_β), 4.17 (dd, 1H, *J* = 10.2, 5.0 Hz, H-6'_α), 4.16 (dd, 1.3H, *J* = 9.7, 3.7 Hz, H-2_β), 4.08 (dd, 1H, *J* = 9.8, 9.2 Hz, H-3'_α), 3.97 – 3.89 (m, 6.9H, H-3_α, H-3_β, H-4_α, H-4_β, H-5_α, H-5_β), 3.74 (t, 1.3H, *J* = 10.3 Hz, H-6'_β), 3.73 – 3.65 (m, 3.3H, H-4'_α, H-4'_β, H-6'_α), 3.62 – 3.55 (m, 3.9H, H-2'_β, H-3'_β, H-6_β), 3.52 (dd, 2H, *J* = 6.4, 3.2 Hz, H-6_α), 3.43 (s, 3H, CH₃ OMe_α), 3.43 (dd, 1H, *J* = 9.9, 3.7 Hz, H-2'_α), 3.39 (s, 3.9H, CH₃ OMe_β), 3.36 (td, 1.3H, *J* = 10.0, 5.0 Hz, H-5'_β); ¹³C-APT NMR (CDCl₃, 126 MHz, HSQC): δ 138.7, 138.6, 138.6, 138.1, 138.1, 138.0, 137.9, 137.9, 137.6, 137.2 (C_q), 129.1, 129.0, 128.6, 128.5, 128.5, 128.5, 128.5, 128.4, 128.4, 128.4, 128.4, 128.3, 128.3, 128.2, 128.0, 127.9, 127.9, 127.8, 127.8, 127.8, 127.8, 127.7, 126.3, 126.1 (CH_{arom}), 103.6 (C-1'_β), 101.5, 101.4 (CHPh), 100.0 (C-1_β), 97.1 (C-1_α), 95.6 (C-1'_α), 82.9 (C-4'_α), 81.6 (C-4'_β), 79.6 (C-3'_β), 78.1, 77.9, 77.5 (C-2_β, C-3_α, C-3_β), 76.2 (C-3'_α), 75.2, 74.9 (C-4_α, C-4_β), 75.1, 75.1, 75.0, 75.0 (CH₂ Bn), 73.7, 73.6, 73.3, 73.3 (CH₂ Bn), 72.5 (C-2_α), 69.4, 69.2 (C-5_α, C-5_β), 69.1, 69.0 (C-6_α, C-6_β), 68.9 (C-6'_α), 68.6 (C-6'_β), 66.1 (C-5'_β), 65.9 (C-2'_β), 63.0 (C-2'_α), 62.7 (C-5'_α); HRMS: [M+Na]⁺ calcd for C₄₈H₅₁N₃O₁₀Na 852.3472, found 852.3488.



Methyl 4-O-(2,3-di-O-benzyl-4,6-O-benzylidene- α/β -D-glucopyranosyl)-2,3-di-O-benzyl-6-O-(2,3,4,5,6-pentafluorobenzoyl)- α -D-glucopyranoside (55).

Donor **3** and acceptor **47** were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations as described in Chapter 3 yielding product **55** (71 mg, 71 μ mol, 71%, $\alpha:\beta = 1.4 : 1$) as a colorless oil. R_f: 0.82 (4/1 pentane/EtOAc); IR (thin film): 696, 735, 1007, 1028, 1047, 1076, 1088, 1227, 1325, 1454, 1496, 1524, 1740, 2870, 2926; Data reported as a 1 : 0.7 mixture of anomers: ¹H NMR (CDCl₃, 500 MHz, HH-COSY, HSQC, HMBC): δ 7.51 – 7.18 (m, 42.5H), 5.56 (d, 1H, *J* = 3.9 Hz, H-1'_α), 5.52 (s, 0.7H, CHPh_β), 5.49 (s, 1H, CHPh_α), 4.97 (d, 1H, *J* = 11.5 Hz, CHH Bn_α), 4.95 – 4.90 (m, 3.1H, CHH Bn_α, 3xCHH Bn_β), 4.83 (d, 0.7H, *J* = 10.7 Hz, CHH Bn_β), 4.81 – 4.74 (m, 5.1H, 2xCHH Bn_α, 2xCHH Bn_β, CHH Bn_β, H-6_α), 4.73 – 4.67 (m, 2H, 2xCHH Bn_α), 4.63 (dd, 0.7H, *J* = 12.0, 2.0 Hz, H-6_β), 4.62 (d, 0.7H, *J* = 12.1 Hz, CHH Bn_β), 4.59 – 4.51 (m, 5.4H, 2xCHH Bn_α, H-1_α, H-1_β, H-1'_β, H-6_α), 4.49 (dd, 0.7H, *J* = 12.0, 4.2 Hz, H-6_β), 4.20 (dd, 0.7H, *J* = 10.5, 5.0 Hz, H-6'_β), 4.12 (dd, 1H, *J* = 10.3, 4.7 Hz, H-6'_α), 4.08 (dd, 1H, *J* = 9.4, 8.7 Hz, H-3_α), 4.05 – 4.00 (m, 2H, H-3'_α, H-5_α), 3.91 – 3.84 (m, 1.7H, H-3_β, H-4_α), 3.82 – 3.73 (m, 2.4H, H-


3'β, H-4β, H-5'α), 3.70 (ddd, 0.7H, *J* = 9.8, 4.1, 1.9 Hz, H-5β), 3.67 – 3.58 (m, 2.7H, H-4'α, H-4'β, H-6'α), 3.56 – 3.50 (m, 2.7H, H-2α, H-2'α, H-6'β), 3.48 – 3.44 (m, 1.4H, H-2β, H-2'β), 3.39 (s, 3H, CH₃ OMe_α), 3.38 (s, 2.1H, CH₃ OMe_β), 3.29 (td, 0.7H, *J* = 9.9, 5.0 Hz, H-5'β); ¹³C-APT NMR (CDCl₃, 126 MHz, HSQC, HMBC): δ 158.7, 158.5 (C=O), 146.8, 144.8 (CF-ortho), 144.5, 142.4 (CF-para), 139.1, 139.0 (C_q), 138.8 (CF-meta), 138.6, 138.5, 138.3, 138.1, 137.9, 137.4, 137.3 (C_q), 136.8 (CF-meta), 129.1, 129.0, 128.6, 128.6, 128.5, 128.4, 128.4, 128.4, 128.3, 128.3, 128.1, 128.1, 128.0, 128.0, 127.8, 127.8, 127.7, 127.6, 127.3, 126.9, 126.1, 126.0 (CH_{arom}), 107.8 (C_q-ipso), 103.4 (C-1'β), 101.3 (CHPh_α), 101.2 (CHPh_β), 98.4 (C-1'α), 98.3 (C-1β), 97.9 (C-1α), 82.8 (C-2'β), 82.3 (C-4'α), 81.8 (C-4'β), 81.6 (C-3'β), 81.2 (C-3α), 80.3 (C-2α), 79.9 (C-3β), 79.2 (C-2β), 78.8 (C-2'α), 78.6 (C-3'α), 78.1 (C-4β), 75.9, 75.7, 75.3, 75.2, 74.7 (CH₂ Bn), 74.6 (C-4α), 74.1, 73.8, 73.5 (CH₂ Bn), 69.0 (C-6'α), 68.8 (C-6'β), 68.4 (C-5β), 67.9 (C-5α), 66.2 (C-5'β), 65.4 (C-6α), 64.5 (C-6β), 63.7 (C-5'α), 55.6 (OMe_β), 55.5 (OMe_α); ¹⁹F NMR (CDCl₃, 471 MHz): δ -137.33 (dp, 2F, *J* = 16.6, 5.4 Hz, orthoF₅Bz_α), -137.83 (dp, 1.4F, *J* = 16.5, 5.4 Hz, orthoF₅Bz_β), -147.86 – -148.26 (m, 1.7F, paraF₅Bz_αβ), -160.23 (tt, 1.4F, *J* = 21.1, 5.8 Hz, metaF₅Bz_β), -160.41 (tt, 2F, *J* = 21.1, 5.8 Hz, metaF₅Bz_α); HRMS: [M+Na]⁺ calcd for C₅₅H₅₁F₅O₁₂Na 1021.3198, found 1021.3237.



Methyl 4-O-(2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-α/β-D-glucopyranosyl)-2,3-di-O-benzyl-6-O-(2,3,4,5,6-pentafluorobenzoyl)-α-D-glucopyranoside (56). Donor **4** and acceptor **47** were condensed using the

general procedure for Tf₂O/Ph₂SO mediated glycosylations as described in Chapter 3 yielding product **56** (75 mg, 80 μmol, 80%, α:β = 1 : 1.7) as a colorless oil. R_f: 0.69 and 0.82 (4/1 pentane/EtOAc); IR (thin film): 696, 735,

997, 1003, 1028, 1047, 1092, 1227, 1325, 1454, 1498, 1524, 1653, 1740, 2110, 2872, 2914; ¹H NMR (CDCl₃, 500 MHz, HH-COSY, HSQC): δ 7.46 – 7.42 (m, 5.4H, CH_{arom}), 7.40 – 7.25 (m, 48.6H, CH_{arom}), 5.58 (d, 1H, *J* = 4.1 Hz, H-1'α), 5.53 (s, 1H, CHPh_α), 5.49 (s, 1.7H, CHPh_β), 5.12 (d, 1H, *J* = 10.6 Hz, CHH Bn_α), 4.97 (d, 1H, *J* = 10.9 Hz, CHH Bn_α), 4.94 – 4.88 (m, 6.1H, 3xCHH Bn_β, CHH Bn_α), 4.84 (dd, 1.7H, *J* = 12.1, 2.1 Hz, H-6β), 4.79 – 4.73 (m, 5.4H, 2xCHH Bn_α, 2xCHH Bn_β), 4.68 (dd, 1H, *J* = 11.9, 2.4 Hz_α), 4.65 (dd, 1.7H, *J* = 12.2, 4.0 Hz, H-6β), 4.63 – 4.57 (m, 5.4H, CHH Bn_α, CHH Bn_β, H-1_α, H-1_β), 4.50 (dd, 1H, *J* = 11.9, 4.4 Hz, H-6_α), 4.41 (d, 1.7H, *J* = 8.1 Hz, H-1'), 4.16 (dd, 1H, *J* = 10.3, 4.9 Hz, H-6'α), 4.10 (dd, 1H, *J* = 9.4, 8.8 Hz, H-3_α), 4.05 – 4.00 (m, 2.7H, H-3'α, H-6'β), 3.99 – 3.90 (m, 4.4H, H-3_β, H-5_α, H-5_β), 3.84 – 3.76 (m, 3.7H, H-4_α, H-4_β, H-5'α), 3.70 – 3.60 (m, 5.4H, H-3'β, H-4_α, H-4'β, H-6'α), 3.54 (dd, 1H, *J* = 9.6, 3.5 Hz, H-2_α), 3.49 (dd, 1.7H, *J* = 9.6, 3.6 Hz, H-2_β), 3.47 (t, 1.7H, *J* = 10.3 Hz, H-6'β), 3.43 (dd, 1.7H, *J* = 9.2, 8.2 Hz, H-2'β), 3.40 (s, 5.1H, CH₃ OMe_β), 3.39 (s, 3H, CH₃ OMe_α), 3.35 (dd, 1H, *J* = 10.1, 4.1 Hz, H-2'α), 3.20 (ddd, 1.7H, *J* = 9.9, 9.0, 5.0 Hz, H-5'β); ¹³C-APT NMR (CDCl₃, 126 MHz, HSQC): δ 158.8, 158.7 (m, C=O), 146.7, 144.7, 144.4, 142.5 (m, CF_{arom}), 139.2 (C_q), 138.8 (m, CF_{arom}), 138.7, 138.1, 137.8, 137.8, 137.7, 137.1 (C_q), 136.8 (m, CF_{arom}), 129.2, 129.1, 128.7, 128.6, 128.5, 128.5, 128.4, 128.4, 128.3, 128.3, 128.2, 128.2, 128.0, 128.0, 127.6, 127.6, 127.6, 127.3, 126.1, 126.0 (CH_{arom}), 107.8 (m, C_q(ipso-F₅Bz₂)), 102.2 (C-1'β), 101.3, 101.3 (CHPh), 99.1 (C-1'α), 98.2 (C-1β), 97.8 (C-1α), 82.6 (C-4_α), 81.7 (C-4'β), 81.2 (C-3_α), 80.6 (C-2_α), 79.9 (C-3_β), 79.8 (C-3'β), 79.4 (C-2_β), 78.3 (C-4_β), 76.2 (C-3'α), 75.6 (C-4_α), 75.5, 75.2, 75.1, 75.0, 73.7, 73.4 (CH₂ Bn), 68.6 (C-6'α), 68.5 (C-6'β), 68.1, 67.7 (C-5_α, C-5_β), 66.8 (C-2'β), 66.3 (C-5'β), 65.4 (C-6_α), 64.8 (C-6_β), 63.7 (C-5'α), 62.9 (C-2'α), 55.7 (OMe_α), 55.6 (OMe_β); ¹⁹F NMR (CDCl₃, 471 MHz): δ -137.42 (dp, *J* = 16.7, 5.5 Hz), -137.96 (dp, *J* = 16.5, 5.5 Hz), -147.83 – -148.02 (m), -160.08 (tt, *J* = 21.1, 5.8 Hz), -160.31 (tt, *J* = 21.1, 5.9 Hz); HRMS: [M+Na]⁺ calcd for C₄₈H₄₄F₅N₃O₁₁Na 956.2794, found 956.2816.




Methyl 4-O-(2,3-di-O-benzyl-4,6-O-benzylidene-α/β-D-glucopyranosyl)-2,3-di-O-benzyl-6-O-(2,4,6-trinitrobenzoyl)-α-D-glucopyranoside (57). Donor **3** and acceptor **48** were condensed using the

general procedure for Tf₂O/Ph₂SO mediated glycosylations as described in Chapter 3 yielding product **57** (78 mg, 75 μmol, 75%, α:β = 2.1 : 1) as a colorless oil. R_f: 0.43 (4/1 pentane/EtOAc); IR (thin film): 698, 735, 1028, 1047, 1074, 1088,


1269, 1342, 1454, 1545, 1557, 1755, 2872, 2928; Data for the α-anomer: ¹H NMR (CDCl₃, 500 MHz, HH-COSY, HSQC, HMBC): δ 8.97 (s, 2H, CH_{arom} NO₂Bz), 7.38 – 7.14 (m, 25H, CH_{arom}), 5.53 (d, 1H, *J* = 3.9 Hz, H-1'), 5.38 (s, 1H, CHPh), 5.06 (dd, 1H, *J* = 11.7, 2.2 Hz, H-6), 4.97 – 4.86 (m, 3H, 2xCHH Bn, H-6), 4.80 – 4.64 (m, 6H, 2xCHH Bn, 2xCHH Bn, H-1, H-6), 4.57 (d, 1H, *J* = 12.0 Hz, CHH Bn), 4.54 (d, 1H, *J* = 12.0 Hz, CHH Bn), 4.11 – 4.04 (m, 2H, H-3, H-5), 4.01 (t, 1H, *J* = 9.3 Hz, H-3'), 3.87 – 3.83 (m, 2H, H-5', H-6'), 3.80 (dd, 1H, *J* = 9.8, 8.6 Hz, H-4), 3.57 – 3.49 (m, 4H, H-2, H-2', H-4', H-6'), 3.41 (s, 3H, CH₃ OMe); ¹³C-APT NMR (CDCl₃, 126 MHz, HSQC, HMBC): δ 160.6 (C=O), 147.8, 147.1 (C_q NO₂), 138.9, 138.6, 138.1, 137.9, 137.3, 129.6 (C_q), 129.0, 128.6, 128.5, 128.4, 128.3, 128.3, 128.3, 128.1, 128.1, 128.1, 128.1, 127.8, 127.8, 127.7, 127.3, 127.0, 126.1, 125.9, 124.5 (CH_{arom}), 101.0 (CHPh), 98.0 (C-1'), 97.8 (C-1), 82.1 (C-4'), 81.1 (C-3), 80.3 (C-2), 78.9 (C-2'), 78.5 (C-3'), 75.3, 74.6 (CH₂ Bn), 74.3 (C-4), 73.9, 73.4 (CH₂ Bn), 68.9 (C-6'), 68.3 (C-5), 66.9 (C-6), 63.3 (C-5'), 55.7 (OMe); Diagnostic peaks for the β-anomer: ¹H NMR (CDCl₃, 500 MHz, HH-COSY, HSQC): δ 9.13 (s, 2H, CH_{arom} NO₂Bz), 5.49 (s, 1H, CHPh), 4.49 (dd, 1H, *J* = 12.0, 2.8 Hz, H-6), 4.17 (dd, 1H, *J* = 10.4, 4.9 Hz, H-6'), 3.63

(t, 1H, $J = 9.3$ Hz, H-4'), 3.45 (dd, 1H, $J = 8.8, 7.7$ Hz, H-2'), 3.42 (dd, 1H, $J = 10.0, 4.0$ Hz, H-2), 3.39 (s, 3H, CH₃ OMe); ¹³C-APT NMR (CDCl₃, 126 MHz, HSQC): δ 160.5 (C=O), 147.8, 147.2 (C_q NO₂), 139.1, 138.5, 138.3, 137.4, 129.7 (C_q), 129.0 - 124.6 (CH_{arom}), 103.0 (C-1'), 101.2 (CHPh), 98.2 (C-1), 83.1 (C-2'), 81.9 (C-4'), 81.5 (C-3'), 79.8 (C-3), 78.9 (C-2), 77.9 (C-4), 75.8, 75.7, 73.5 (CH₂ Bn), 68.8 (C-6'), 68.2 (C-5), 66.6 (C-5'), 66.0 (C-6), 55.7 (OMe); HRMS: [M+Na]⁺ calcd for C₅₅H₅₃N₃O₁₈Na 1066.3222, found 1066.3257.


Preparation of 5-deoxy furanosyl imidates.



Reagents and conditions: (a) *i.* TsCl, pyridine, DCM; *ii.* LiAlH₄, Et₂O, **S5**: 75%, **S6**: 80%; (b) *i.* AcCl, MeOH; *ii.* Ph₃P, I₂, imidazole, THF, *iii.* Pd(OH)₂/C, H₂, DiPEA; *iv.* BnBr, NaH, DMF, **S3**: 40%, **S4**: 52%; (c) HCOOH/H₂O (4/1 v/v, 0.05 M), 50°C, **S7**: 86%, **S8**: 72%, **S9**: 92%, **S10**: 92%; (d) 2,2,2-trifluoro-*N*-phenylacetimidoyl chloride (0.95 eq.), DBU (1 eq.) in DCM (0.25 M), 0°C, **77**: 48%, **79**: 56%, **81**: 44%, **83**: 66%.




Methyl 2,3-di-O-benzyl-5-deoxy- α/β -D-ribofuranoside (S3). To a 0°C solution of D-ribose (3 g, 20 mmol) in MeOH (70 mL) was added AcCl (0.6 mL, 9 mmol, 0.45 eq.) and the reaction was stirred overnight at room temperature. The reaction was quenched by the addition of solid K₂CO₃ (5 g), stirred for 10 min, then filtered and concentrated under reduced pressure. The crude methyl glycoside was dissolved in THF (80 mL) and Ph₃P (7.9 g, 30 mmol, 1.5 eq.) and imidazole (2.7 g, 40 mmol, 2 eq.) were added and the reaction mixture brought to reflux. To the boiling reaction mixture was slowly added a solution of I₂ (7.6 g, 30 mmol, 1.5 eq.) in THF (30 mL). After 3 h the reaction was cooled to room temperature, MeOH (10 mL) was added and the reaction mixture was concentrated under reduced pressure. The residue was filtered over silica gel (5% MeOH in DCM) and the filtrate was concentrated under reduced pressure. The crude iodide was dissolved in MeOH (60 mL) and DiPEA (5 mL, 29 mmol). Pd(OH)₂ (20% on C, 0.85 g) was added and the reaction flask was purged with N₂. The flask was subsequently purged with H₂ for 5 min and then kept under a H₂ atmosphere (balloon) for 3 h. The reaction mixture was purged with N₂, filtered over Celite and evaporated. The residue was dissolved in 5% MeOH in DCM and filtered over silica gel, the filtrate concentrated under reduced pressure and coevaporated once with toluene. The crude material was dissolved in DMF (50 mL), cooled to 0°C, and treated with BnBr (4.2 mL, 35 mmol) and NaH (60% dispersion in mineral oil, 1.2 g, 30 mmol) and stirred overnight. The reaction mixture was quenched by the addition of H₂O, and then extracted three times with Et₂O. The combined organic layers were washed with 0.1 M aq. HCl, H₂O, and brine. The organic layer was dried (MgSO₄), filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography 0% to 10% EtOAc in pentane) to give the title compound as a colourless oil (1.93 g, 5.9 mmol, 30%, β anomer. The α anomer (10%) was impure and discarded). Data for the β -anomer: R_f: 0.50 (9/1 pentane/EtOAc). $[\alpha]_D^{20} = +35.9^\circ$ ($c = 0.66$, CHCl₃); IR (thin film): 698, 737, 935, 1028, 1038, 1111, 1454, 2911, 2926, 2972; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HH-NOESY, HSQC): δ 7.40 – 7.25 (m, 10H, CH_{arom}), 4.87 (s, 1H, H-1), 4.68 (d, 1H, $J = 12.0$ Hz, CHH Bn), 4.60 (d, 1H, $J = 12.0$ Hz, CHH Bn), 4.58 (d, 1H, $J = 11.9$ Hz, CHH Bn), 4.45 (d, 1H, $J = 11.9$ Hz, CHH Bn), 4.24 (dq, 1H, $J = 7.3, 6.3$ Hz, H-4), 3.84 (dd, 1H, $J = 4.6, 1.0$ Hz, H-2), 3.74 (dd, 1H, $J = 7.3, 4.6$ Hz, H-3), 3.33 (s, 3H, CH₃ OMe), 1.30 (d, 3H, $J = 6.3$ Hz, H-5); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 138.0, 137.9 (C_q), 128.5, 128.5, 128.1, 127.9, 127.9 (CH_{arom}), 106.3 (C-1), 83.2 (C-3), 80.0 (C-2), 77.3 (C-4), 72.5, 72.4 (CH₂ Bn), 55.0 (CH₃ OMe), 20.6 (C-5); HRMS: [M+Na]⁺ calcd for C₂₀H₂₄O₄Na 351.1572, found 351.1582.




Methyl 2,3-di-O-benzyl-5-deoxy- α/β -D-arabinofuranoside (S4). To a 0°C solution of D-arabinose (3 g, 20 mmol) in MeOH (70 mL) was added AcCl (0.8 mL, 12 mmol, 0.6 eq.) and the reaction was stirred overnight at room temperature. The reaction was quenched by the addition of solid K₂CO₃ (5 g), stirred for 10 min, then filtered and concentrated under reduced pressure. The crude methyl glycoside was dissolved in THF (80 mL) and Ph₃P (7.9 g, 30 mmol, 1.5 eq.) and imidazole (2.7 g, 40 mmol, 2 eq.) were added and the reaction mixture brought to reflux. To the boiling reaction mixture was slowly added a solution of I₂ (7.6 g, 30 mmol, 1.5 eq.) in THF (30 mL). After 2 h the reaction was cooled to room temperature, MeOH (10 mL) was added and the reaction mixture was concentrated under reduced pressure. The residue was filtered over silica gel (5% MeOH in DCM) and the filtrate was concentrated under reduced pressure to give nearly pure methyl 5-iodo arabinoside (4.12 g, 15 mmol, 75%). The crude iodide (1.37 g, 5 mmol) was dissolved in MeOH (25 mL) and DiPEA (2.6 mL, 15 mmol, 3 eq.). Pd(OH)₂

(20% on C, 0.4 g) was added and the reaction flask was purged with N₂. The flask was subsequently purged with H₂ for 5 min and then kept under a H₂ atmosphere (balloon) for 3 h. The reaction mixture was purged with N₂, filtered over Celite and evaporated. The residue was dissolved in 5% MeOH in DCM and filtered over silica gel, the filtrate concentrated under reduced pressure and coevaporated once with toluene to give 4.15 mmol (83%) of reduced compound. The crude material (4 mmol) was dissolved in DMF (20 mL), cooled to 0°C, and treated with BnBr (1.43 mL, 12 mmol, 3 eq.) and NaH (60% dispersion in mineral oil, 480 mg, 12 mmol, 3 eq.) and stirred overnight. The reaction mixture was quenched by the addition of H₂O, and then extracted three times with Et₂O. The combined organic layers were washed with sat. aq. NH₄Cl, H₂O, and brine. The organic layer was dried (MgSO₄), filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography (2% to 12% EtOAc in pentane) to give the title compound as a colourless oil (1.1 g, 3.5 mmol, 84%) in 52% over four steps, α:β = 2:1 anomeric mixture. IR (thin film): 698, 748, 1049, 1109, 1452, 2926; Data for the α-anomer: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.47–7.18 (m, 10H, CH_{arom}), 4.87 (s, 1H, H-1), 4.59 (d, 1H, *J* = 12.0 Hz, *CHH* Bn), 4.57 (d, 1H, *J* = 11.8 Hz, *CHH* Bn), 4.54–4.46 (m, 2H, 2*xCHH* Bn), 4.09 (p, 1H, *J* = 6.3 Hz, H-4), 3.97 (dd, 1H, *J* = 3.5, 1.0 Hz, H-2), 3.59 (dd, 1H, *J* = 7.1, 3.5 Hz, H-3), 3.37 (s, 3H, CH₃ OMe), 1.32 (d, 3H, *J* = 6.3 Hz, H-5); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 138.0, 137.7 (C_q), 128.6, 128.5, 128.1, 128.0, 127.9, 127.9 (CH_{arom}), 107.1 (C-1), 89.1 (C-2), 88.8 (C-3), 76.8 (C-4), 72.4, 72.2 (CH₂ Bn), 54.9 (OMe), 18.8 (C-5); Data for the β-anomer: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.43–7.24 (m, 10H, CH_{arom}), 4.74–4.67 (m, 2H, *CHH* Bn, H-1), 4.66–4.57 (m, 3H, CH₂ Bn, *CHH* Bn), 4.06–3.95 (m, 3H, H-2, H-3, H-4), 3.37 (s, 3H, CH₃ OMe), 1.33 (d, 3H, *J* = 6.2 Hz, H-5); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 138.3, 137.8 (C_q), 128.5, 128.3, 128.0, 127.9, 127.8 (CH_{arom}), 101.5 (C-1), 87.1 (C-3/4), 84.5 (C-2), 77.6 (C-3/4), 72.6, 72.6 (CH₂ Bn), 54.9 (OMe), 22.3 (C-5); HRMS: [M+NH₄]⁺ calcd for C₂₀H₂₈NO₄ 346.20128, found 346.20131.




Methyl 2,3-di-O-benzyl-5-deoxy-α-D-lyxofuranoside (S5). To a solution of methyl 2,3-di-O-benzyl-α-D-lyxofuranoside²⁵ (1.03 g, 3.0 mmol, 1 eq.) and pyridine (1.4 mL, 18 mmol, 6 eq.) in DCM (15 mL) was added TsCl (2.3 g, 12 mmol, 4 eq.) and the reaction mixture was stirred for two days. The reaction mixture was poured into 1 M aq. HCl and extracted twice with Et₂O. The combined organic layers were washed with H₂O, sat. aq. NaHCO₃, and brine, then dried with MgSO₄, filtered and concentrated under reduced pressure. After coevaporation with dry toluene, the crude tosylate was dissolved in Et₂O (30 mL) and LiAlH₄ (4 M in Et₂O, 2.5 mL, 10 mmol, 5 eq.) was slowly added. The solution was refluxed for 3 h and then cooled to 0°C and quenched with EtOAc and H₂O. The reaction mixture was poured in 0.1 M HCl and extracted twice with Et₂O. The combined organic layers were washed with H₂O, sat. aq. NaHCO₃, and brine, then dried (MgSO₄), filtered and concentrated under reduced pressure. Purification by flash column chromatography (1/0 to 85/15 pentane/EtOAc) gave the title compound as a colourless oil, which crystalized on standing. Yield: 740 mg, 2.25 mmol, 75%. m.p. 34–36 °C. [α]_D²⁰ = +16.0° (c = 1.0, CHCl₃); IR (neat): 692, 729, 955, 1015, 1028, 1051, 1098, 1132, 1159, 1366, 1450, 2899, 1933, 2976; ¹H NMR (CDCl₃, 500 MHz, HH-COSY, HH-NOESY, HSQC): δ 7.38–7.23 (m, 10H, CH_{arom}), 5.00 (d, 1H, *J* = 2.8 Hz, H-1), 4.73 (d, 1H, *J* = 12.0 Hz, *CHH* Bn), 4.66 (d, 1H, *J* = 12.1 Hz, *CHH* Bn), 4.62–4.53 (m, 2H, 2*xCHH* Bn), 4.23 (qd, 1H, *J* = 6.4, 4.6 Hz, H-4), 3.96 (t, 1H, *J* = 4.6 Hz, H-3), 3.92 (dd, 1H, *J* = 4.7, 2.8 Hz, H-2), 3.36 (s, 3H, CH₃ OMe), 1.32 (d, 3H, *J* = 6.5 Hz, H-5); ¹³C-APT NMR (CDCl₃, 126 MHz, HSQC): δ 138.4, 138.1 (C_q), 128.4, 128.3, 127.8, 127.7, 127.6 (CH_{arom}), 106.7 (C-1), 84.0 (C-2), 78.9 (C-3), 75.7 (C-4), 73.2, 72.6 (CH₂ Bn), 55.5 (OMe), 15.7 (C-5); ¹³C HSQC-HECADE NMR (CDCl₃, 126 MHz): ²J_{C1,H2} = -2.5 Hz, ²J_{C2,H1} = -1.2 Hz; HRMS: [M+Na]⁺ calcd for C₂₀H₂₄O₄Na 351.1572, found 351.1580.




Methyl 2,3-di-O-benzyl-5-deoxy-α/β-D-xylofuranoside (S6). To a solution of methyl 2,3-di-O-benzyl-α-D-xylofuranoside²⁶ (2.2 g, 6.39 mmol, 1 eq.) in pyridine (15 mL) was added TsCl (2.4 g, 12.8 mmol, 2 eq.) and the reaction mixture was stirred overnight. The reaction mixture was poured into 1 M aq. HCl and extracted twice with Et₂O. The combined organic layers were washed with 1 M HCl, H₂O, sat. aq. NaHCO₃, and brine, then dried with MgSO₄, filtered and concentrated under reduced pressure. After coevaporation with dry toluene, the crude tosylate was dissolved in Et₂O (60 mL) and LiAlH₄ (4 M in Et₂O, 5 mL, 20 mmol, 3.1 eq.) was slowly added. The solution was refluxed for 8 h and then cooled to 0°C and quenched with EtOAc and H₂O. The reaction mixture was poured in 0.1 M HCl and extracted twice with Et₂O. The combined organic layers were washed with H₂O, sat. aq. NaHCO₃, and brine, then dried (MgSO₄), filtered and concentrated under reduced pressure. Purification by flash column chromatography (1/0 to 85/15 pentane/EtOAc) gave the title compound as a colourless oil. Yield: 1.68 g, 5.1 mmol, 80% as an α:β = 1:1.2 anomeric mixture. Rf: 0.55 and 0.38 (9/1 pentane/EtOAc). IR (neat): 696, 735, 1026, 1063, 1107, 1454, 2870, 2909, 2930; ¹H NMR (CDCl₃, 500 MHz, HH-COSY, HSQC): δ 7.39–7.26 (m, 22H, CH_{arom}), 4.86 (d, 1.2H, *J* = 1.9 Hz, H-1_β), 4.77 (d, 1H, *J* = 4.3 Hz, H-1_α), 4.65 (d, 1H, *J* = 12.0 Hz, *CHH* Bn_α), 4.62–4.48 (m, 7.8H, *CHH* Bn_α, CH₂ Bn_α, 2*x*CH₂ Bn_β), 4.40–4.31 (m, 2.2H, H-4_α, H-4_β), 4.15 (dd, 1H, *J* = 6.7, 5.4 Hz, H-3_α), 4.02 (dd, 1.2H, *J* = 3.2, 1.9 Hz, H-2_β), 3.98 (dd, 1H, *J* = 5.4, 4.3 Hz, H-2_α), 3.91 (dd, 1.2H, *J* = 5.8, 3.2 Hz, H-3_β), 3.40 (s, 3.6H, CH₃ OMe_β), 3.39


(s, 3H, CH₃ OMe_α), 1.32 (d, 3.6H, *J* = 6.6 Hz, H-5_β), 1.25 (d, 3H, *J* = 6.6 Hz, H-5_α); ¹³C-APT NMR (CDCl₃, 126 MHz, HSQC): δ 138.3, 138.1, 137.8, 137.7 (C_q), 128.4, 128.4, 128.4, 128.1, 127.9, 127.8, 127.8, 127.7, 127.7, 127.6, 127.5 (CH_{arom}), 108.1 (C-1_β), 100.3 (C-1_α), 87.4 (C-2_β), 84.4 (C-2_α), 82.5 (C-3_β), 82.3 (C-3_α), 76.9 (C-4_β), 73.4 (C-4_α), 72.6, 72.2, 72.0, 71.9 (CH₂ Bn), 55.5 (OMe_β), 55.0 (OMe_α), 16.2 (C-5_β), 15.6 (C-5_α); HRMS: [M+Na]⁺ calcd for C₂₀H₂₄O₄Na 351.1572, found 351.1585.




2,3-di-O-benzyl-5-deoxy- α/β -D-ribofuranose (S7). The title compound was generated from **S3** (1.1 g, 3.35 mmol) by the general procedure for methyl furanoside hydrolysis, conditions A (50°C, 2 h) as described in Chapter 7. Yield: 86% $\alpha:\beta$ = 1:2.5 (909 mg, 2.9 mmol) as a colourless oil. Rf: 0.16 (8/2 pentane/EtOAc). Spectroscopic data were in accord with those previously reported.²⁷ ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.42 – 7.26 (m, 15.5H, CH_{arom}), 5.34 (d, 0.55H, *J* = 2.9 Hz, H-1_β), 5.30 (dd, 1H, *J* = 11.2, 4.2 Hz, H-1_α), 4.74 – 4.67 (m, 3.1H, 2x CHH Bn_α, 2x CHH Bn_β), 4.65 – 4.58 (m, 2.55H, CHH Bn_β, 2xCHH Bn_α), 4.46 (d, 0.55H, *J* = 11.9 Hz, CHH Bn_β), 4.33 (qd, 1H, *J* = 6.5, 3.4 Hz, H-4_α), 4.26 (d, 1H, *J* = 11.3 Hz, 1-OH_α), 4.29 – 4.17 (m, 0.55H, H-4_β), 3.93 (t, 1H, *J* = 4.5 Hz, H-2_α), 3.85 (dd, 0.55H, *J* = 4.6, 0.9 Hz, H-2_β), 3.79 (dd, 0.55H, *J* = 7.4, 4.6 Hz, H-3_β), 3.62 (dd, 1H, *J* = 4.9, 3.4 Hz, H-3_α), 3.16 (d, 0.55H, *J* = 3.4 Hz, 1-OH_β), 1.33 (d, 1.65H, *J* = 6.3 Hz, H-5_β), 1.17 (d, 3H, *J* = 6.6 Hz, H-5_α); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 137.9, 137.9, 137.6, 137.4 (C_q), 128.6, 128.6, 128.5, 128.5, 128.2, 128.1, 128.0, 127.9 (CH_{arom}), 100.1 (C-1_β), 95.9 (C-1_α), 82.8 (C-3_β), 81.8 (C-3_α), 80.4 (C-2_β), 77.3, 77.3, 77.2 (C-2_α, C-4_α, C-4_β), 72.9, 72.8, 72.6, 72.3 (CH₂ Bn), 20.6 (C-5_β), 19.8 (C-5_α); HRMS: [M+Na]⁺ calcd for C₁₉H₂₂O₄Na 337.1410, found 337.1425.



2,3-di-O-benzyl-5-deoxy- α/β -D-arabinofuranose (S8). The title compound was generated from **S4** (600 mg, 1.87 mmol) by the general procedure for methyl furanoside hydrolysis, conditions A (50°C, 2 h) as described in Chapter 7. Yield: 72% $\alpha:\beta$ = 1:2.5 (413 mg, 1.31 mmol) as a colourless oil. Rf: 0.54 (7/3 pentane/EtOAc). IR (neat): 694, 733, 995, 1055, 1207, 1454, 1497, 2872, 2905, 2928, 2972, 3030, 3395; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.39 – 7.26 (m, 14H, CH_{arom}), 5.38 (d, 1H, *J* = 6.8 Hz, H-1_α), 5.31 (dd, 0.4H, *J* = 8.6, 4.3 Hz, H-1_β), 4.67 – 4.49 (m, 5.6H, 2xCH₂ Bn_α, 2xCH₂ Bn_β), 4.35 (qd, 1H, *J* = 6.4, 4.8 Hz, H-4_α), 3.98 (dd, 1H, *J* = 2.5, 0.9 Hz, H-2_α), 4.00 – 3.89 (m, 0.8H, H-2_β, H-4_β), 3.78 (d, 0.4H, *J* = 8.6 Hz, 1-OH_β), 3.75 (dd, 0.4H, *J* = 5.1, 4.3 Hz, H-3_β), 3.66 (ddd, 1H, *J* = 4.7, 2.5, 0.7 Hz, H-3_α), 3.37 (d, 1H, *J* = 6.8 Hz, 1-OH_α), 1.35 (d, 1.2H, *J* = 6.4 Hz, H-5_β), 1.31 (d, 3H, *J* = 6.5 Hz, H-5_α); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 137.8, 137.6, 137.5, 137.1 (C_q), 128.7, 128.6, 128.6, 128.3, 128.2, 128.1, 128.0, 128.0, 127.9, 127.9, 127.8 (CH_{arom}), 100.9 (C-1_α), 96.0 (C-1_β), 87.6 (C-2_α), 87.4 (C-3_α), 86.7 (C-3_β), 83.2 (C-2_β), 78.6 (C-4_α), 76.5 (C-4_β), 72.7, 72.3, 72.3, 72.0 (CH₂ Bn), 20.9 (C-5_β), 19.4 (C-5_α); HRMS: [M+Na]⁺ calcd for C₁₉H₂₂O₄Na 337.1410, found 337.1426.




2,3-di-O-benzyl-5-deoxy- α/β -D-lyxofuranose (S9). The title compound was generated from **S5** (370 mg, 1.13 mmol) by the general procedure for methyl furanoside hydrolysis, conditions A (50°C, 1.5 h) as described in Chapter 7. Yield: 92% $\alpha:\beta$ = 1:4 (327 mg, 1.04 mmol) as a colourless oil. Rf: 0.35 (7/3 pentane/EtOAc). IR (thin film): 698, 735, 1058, 1159, 1454, 2926, 3408; ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.43 – 7.27 (m, 12.5H), 5.49 (t, 0.25H, *J* = 3.1 Hz, H-1_α), 5.24 (dd, 1H, *J* = 12.2, 3.9 Hz, H-1_β), 4.89 (d, 1H, *J* = 11.6 Hz, CHH Bn_β), 4.81 – 4.73 (m, 1.25H, CHH Bn_α, CHH Bn_β), 4.70 (d, 0.25H, *J* = 12.1 Hz, CHH Bn_α), 4.67 – 4.57 (m, 2.5H, 2xCHH Bn_α, 2xCHH Bn_β), 4.37 (qd, 0.25H, *J* = 6.5, 4.7 Hz, H-4_α), 4.25 (d, 1H, *J* = 12.2 Hz, 1-OH_β), 4.09 – 4.01 (m, 1.25H, H-3_α, H-4_β), 3.96 – 3.89 (m, 2.25H, H-2_α, H-2_β, H-3_β), 3.04 (d, 0.25H, *J* = 3.5 Hz, 1-OH_α), 1.35 (d, 3H, *J* = 6.5 Hz, H-5_β), 1.31 (d, 1H, *J* = 6.5 Hz, H-5_α); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 138.4, 138.1, 137.9, 137.7 (C_q), 128.6, 128.5, 128.5, 128.4, 128.0, 128.0, 127.9, 127.8, 127.8 (CH_{arom}), 100.2 (C-1_α), 95.6 (C-1_β), 84.7 (C-2_α), 79.9 (C-3_β), 78.8 (C-3_α), 78.5 (C-2_β), 76.0 (C-4_α), 75.6 (C-4_β), 74.2, 73.3, 72.6, 72.0 (CH₂ Bn), 16.6 (C-5_β), 15.9 (C-5_α); HRMS: [M+Na]⁺ calcd for C₁₉H₂₂O₄Na 337.1410, found 337.1428.




2,3-di-O-benzyl-5-deoxy- α/β -D-xylofuranose (S10). The title compound was generated from **S6** (887 mg, 2.7 mmol) by the general procedure for methyl furanoside hydrolysis, conditions A (50°C, 2 h) as described in Chapter 7. Yield: 92% $\alpha:\beta$ = 1.1:1 (778 mg, 2.47 mmol) as a colourless oil. Rf: 0.37 (8/2 pentane/EtOAc). IR (neat): 694, 733, 1026, 1057, 1207, 1454, 1497, 2870, 2932, 3030, 3400; ¹H NMR (CDCl₃, 500 MHz, HH-COSY, HSQC): δ 7.39 – 7.26 (m, 19H, CH_{arom}), 5.44 (dd, 0.9H, *J* = 9.0, 4.4 Hz, H-1_α), 5.23 (d, 1H, *J* = 11.0 Hz, H-1_β), 4.64 – 4.50 (m, 5.7H, CH₂ Bn_α, CH₂ Bn_β, CHH Bn_α, CHH Bn_β), 4.48 (d, 1H, *J* = 11.9 Hz, CHH Bn_β), 4.44 (d, 0.9H, *J* = 12.2 Hz, CHH Bn_α), 4.39 – 4.30 (m, 1.9H, H-4_α, H-4_β), 3.98 (d, 1H, *J* = 1.2 Hz, H-2_β), 3.95 (dd, 0.9H, *J* = 4.4, 2.1 Hz, H-2_α), 3.91 (d, 0.9H, *J* = 9.0 Hz, 1-OH_α), 3.81 (dd, 0.9H, *J* = 4.2, 2.1 Hz, H-3_α), 3.77 (ddd, 1H, *J* = 3.9, 1.3, 0.7 Hz, H-3_β), 3.35 (d, 1H, *J* = 11.0 Hz, 1-OH_β), 1.37 (d, 3H, *J* = 6.6 Hz, H-5_β), 1.26 (d, 2.7H, *J* = 6.5 Hz, H-5_α); ¹³C-APT NMR (CDCl₃, 126 MHz, HSQC): δ 138.0, 137.6, 137.3, 137.0 (C_q), 128.8, 128.7, 128.6, 128.6, 128.4, 128.2, 128.1, 128.1, 128.0, 127.9, 127.8, 127.7


(CH_{arom}), 101.1 (C-1 β), 95.7 (C-1 α), 85.3 (C-2 β), 82.5 (C-3 α), 82.3 (C-2 α), 81.5 (C-3 β), 78.0 (C-4 β), 74.7 (C-4 α), 73.3, 72.5, 72.1, 72.0 (CH₂ Bn), 15.5 (C-5 β), 14.6 (C-5 α); HRMS: [M+Na]⁺ calcd for C₁₉H₂₂O₄Na 337.1410, found 337.1429.




2,3-di-O-benzyl-5-deoxy-1-O-(N-phenyl)trifluoroacetimidoyl- α -D-arabinofuranoside (59). The title compound was generated from **61** (330 mg, 1.05 mmol) by the general procedure for imidate donor synthesis, conditions B as described in Chapter 7. Yield: 56% α only (286 mg, 0.59 mmol) as a colourless oil. Rf: 0.55 (9/1 pentane/Et₂O). [α]_D²⁰ = -1.1° (c = 0.75, CHCl₃); IR (thin film): 696, 905, 1103, 1120, 1161, 1207, 1330, 1454, 1707, 2932; ¹H NMR (CDCl₃, T = 323 K, 500 MHz, HH-COSY, HSQC): δ 7.36 – 7.24 (m, 12H, CH_{arom}), 7.11 – 7.02 (m, 1H, NPh), 6.81 (d, 2H, J = 7.7 Hz, NPh), 6.19 (bs, 1H, H-1), 4.65 – 4.50 (m, 4H, 2xCH₂ Bn), 4.32 (p, 1H, J = 6.2 Hz, H-4), 4.21 (d, 1H, J = 2.7 Hz, H-2), 3.69 (dd, 1H, J = 6.3, 2.8 Hz, H-3), 1.35 (d, 3H, J = 6.3 Hz, H-5); ¹³C-APT NMR (CDCl₃, T = 323 K, 126 MHz, HSQC): δ 144.2 (C_q NPh), 138.0, 137.5 (C_q Bn), 128.8, 128.8, 128.6, 128.6, 128.2, 128.1, 128.0, 127.8, 124.4, 119.9 (CH_{arom}), 116.3 (q, J = 286.3 Hz, CF₃), 104.0 (C-1), 88.9 (C-3), 88.0 (C-2), 80.1 (C-4), 72.6, 72.6 (CH₂ Bn), 18.9 (C-5); HRMS: only mass of hydrolysis found [M+Na]⁺ calcd for C₁₉H₂₂O₄Na 337.1416, found 337.1416.




2,3-di-O-benzyl-5-deoxy-1-O-(N-phenyl)trifluoroacetimidoyl- β -D-ribofuranoside (60). The title compound was generated from **62** (355 mg, 1.13 mmol) by the general procedure for imidate donor synthesis, conditions B as described in Chapter 7. Yield: 48% β only (264 mg, 0.54 mmol) as a colourless oil. Rf: 0.75 (8/2 pentane/Et₂O). [α]_D²⁰ = +82.8° (c = 1.09, CHCl₃); IR (thin film): 696, 1092, 1151, 1207, 1454, 1712, 2872, 2930; ¹H NMR (CDCl₃, 500 MHz, HH-COSY, HSQC): δ 7.35 – 7.24 (m, 12H, CH_{arom}), 7.08 (t, 1H, J = 7.5 Hz, NPh), 6.81 (d, 2H, J = 7.7 Hz, NPh), 6.19 (bs, 1H, H-1), 4.68 (d, 1H, J = 11.9 Hz, CHH Bn), 4.60 (d, 1H, J = 12.1 Hz, CHH Bn), 4.56 (d, 1H, J = 11.7 Hz, CHH Bn), 4.48 (d, 1H, J = 11.7 Hz, CHH Bn), 4.36 (p, 1H, J = 6.4 Hz, H-4), 4.05 (d, 1H, J = 4.3 Hz, H-2), 3.79 (dd, 1H, J = 7.6, 4.5 Hz, H-3), 1.35 (d, 3H, J = 6.3 Hz, H-5); ¹³C-APT NMR (CDCl₃, 126 MHz, HSQC): δ 144.1 (C_q NPh), 143.55 (q, J = 37.1 Hz, CF₃-C=NPh), 137.8, 137.7, 137.7, 128.9, 128.6, 128.2, 128.1, 128.1, 127.9, 124.4, 119.8 (CH_{arom}), 116.17 (q, J = 285.7 Hz, CF₃), 102.9 (C-1), 82.9 (C-3), 79.4 (C-2), 79.2 (C-4), 72.9, 72.5 (CH₂ Bn), 20.1 (C-5); HRMS: only mass of hydrolysis found [M+Na]⁺ calcd for C₁₉H₂₂O₄Na 337.1416, found 337.1420.



2,3-di-O-benzyl-5-deoxy-1-O-(N-phenyl)trifluoroacetimidoyl- α -D-lyxofuranoside (61). The title compound was generated from **63** (195 mg, 0.62 mmol) by the general procedure for imidate donor synthesis, conditions B as described in Chapter 7. Yield: 44% α : β = 1:4 (132 mg, 0.27 mmol) as a colourless oil. IR (thin film): 696, 1091, 1207, 1454, 1716, 2868; Data for the α -anomer: ¹H NMR (CDCl₃, T = 328 K, 500 MHz, HH-COSY, HSQC): δ 7.34 – 7.24 (m, 12H, CH_{arom}), 7.09 – 7.05 (m, 1H, NPh), 6.82 (dd, 2H, J = 8.4, 1.0 Hz, NPh), 6.26 (bs, 1H, H-1), 4.69 (d, 1H, J = 11.8 Hz, CHH Bn), 4.68 – 4.60 (m, 2H, CH₂ Bn), 4.55 (d, 1H, J = 11.8 Hz, CHH Bn), 4.39 (p, 1H, J = 6.3 Hz, H-4), 4.15 (dd, 1H, J = 4.7, 1.9 Hz, H-2), 4.08 (t, 1H, J = 5.1 Hz, H-3), 1.34 (d, 3H, J = 6.5 Hz, H-5); ¹³C-APT NMR (CDCl₃, T = 328 K, 126 MHz, HSQC): δ 144.2 (C_q NPh), 143.8 (q, J = 35.4 Hz, C=NPh), 138.3, 137.8 (C_q Bn), 128.8, 128.6, 128.5, 128.0, 127.9, 127.9, 127.8, 124.4, 119.9 (CH_{arom}), 116.38 (q, J = 286.0 Hz, CF₃) 103.5 (C-1), 82.8 (C-2), 78.3 (C-3), 78.1 (C-4), 73.4, 73.0 (CH₂ Bn), 15.8 (C-5); Diagnostic peaks β -anomer: ¹H NMR (CDCl₃, T = 328 K, 500 MHz, HH-COSY, HSQC): δ 7.40 – 7.18 (m, 12H, CH_{arom}), 7.04 – 6.99 (m, 1H, NPh), 6.75 (d, 2H, J = 7.9 Hz, NPh), 6.35 (bs, 1H, H-1), 4.90 (d, 1H, J = 12.0 Hz, CHH Bn), 4.74 – 4.60 (m, 3H, CHH Bn, CH₂ Bn), 4.23 (qd, 1H, J = 6.5, 4.7 Hz, H-4), 4.05 – 4.01 (m, 1H, H-2), 3.95 (t, 1H, J = 4.9 Hz, H-3), 1.37 (d, 3H, J = 6.6 Hz, H-5); ¹³C-APT NMR (CDCl₃, T = 328 K, 126 MHz, HSQC): δ 144.6 (C_q NPh), 139.0, 137.9 (C_q Bn), 128.7, 128.6, 128.3, 128.0, 127.6, 127.5, 127.4, 124.0, 120.0 (CH_{arom}), 97.2 (C-1), 81.0 (C-2), 78.8 (C-4), 76.4 (C-3), 73.5, 73.3 (CH₂ Bn), 16.1 (C-5); HRMS: only mass of hydrolysis found [M+Na]⁺ calcd for C₁₉H₂₂O₄Na 337.1416, found 337.1422.




2,3-di-O-benzyl-5-deoxy-1-O-(N-phenyl)trifluoroacetimidoyl- α / β -D-xylofuranoside (62). The title compound was generated from **64** (285 mg, 0.91 mmol) by the general procedure for imidate donor synthesis, conditions B as described in Chapter 7. Yield: 66% α : β = 1:3 (290 mg, 0.59 mmol) as a colourless oil. Rf: 0.41 (9/1 pentane/Et₂O). IR (thin film): 696, 1085, 1154, 1207, 1454, 1708, 2864; ¹H NMR (CDCl₃, 500 MHz, HH-COSY, HSQC): δ 7.35 – 7.21 (m, 16H, CH_{arom}), 7.09 – 7.02 (m, 1.33H, NPh), 6.82 – 6.77 (m, 1H, NPh), 6.74 (d, 0.33H, J = 7.5 Hz, NPh), 6.32 (bs, 0.33H, H-1 α), 6.18 (bs, 1H, H-1 β), 4.67 – 4.47 (m, 6.67H, 2xCH₂ Bn α , 2xCH₂ Bn β , H-4 α , H-4 β), 4.27 (d, 1H, J = 2.3 Hz, H-2 β), 4.18 – 4.14 (m, 0.67H, H-2 α , H-3 α), 3.97 (dd, 1H, J = 5.7, 2.6 Hz, H-3 β), 1.37 (d, 3H, J = 6.7 Hz, H-5 β), 1.27 (d, 1H, J = 6.6 Hz, H-5 α); ¹³C-APT NMR (CDCl₃, 126 MHz, HSQC): δ 144.3, 144.2 (C_q NPh), 138.2, 138.1, 137.8, 137.6 (C_q Bn), 129.5, 128.8, 128.6, 128.5, 128.1, 128.0, 127.9, 127.8, 127.6, 127.6, 126.5, 124.2, 120.7, 119.8 (CH_{arom}), 116.23 (q, J = 286.4 Hz, CF₃), 103.8 (C-1 β), 97.8 (C-1 α), 86.1 (C-2 β), 84.3 (C-2 α), 82.6 (C-3 β), 81.7 (C-3 α), 80.1 (C-4 β), 76.4 (C-4 α), 73.4, 72.6, 72.5, 72.4 (CH₂ Bn), 15.8 (C-5 β), 15.4 (C-5 α); HRMS: only mass of hydrolysis found [M+Na]⁺ calcd for C₁₉H₂₂O₄Na 337.1416, found 337.1417.




Acetyl 2,3-di-O-benzyl-5-deoxy- α/β -D-xylofuranoside (63). The title compound was generated from **S10** (220 mg, 0.7 mmol) by the general procedure for acetyl donor synthesis as described in Chapter

7. Yield: 95% $\alpha:\beta = 1:2.5$ (236 mg, 0.66 mmol) as a colourless oil. IR (thin film): 604, 696, 735, 1007, 1090, 1231, 1373, 1454, 1741, 2934, 3030; $^1\text{H NMR}$ (CDCl_3 , 400 MHz, HH-COSY, HSQC): δ 7.39 – 7.23 (m, 14H, CH_{arom}), 6.28 (d, 0.4H, $J = 4.1$ Hz, H-1 α), 6.12 (s, 1H, H-1 β), 4.64 (d, 1H, $J = 12.0$ Hz, $\text{CHH Bn}\beta$), 4.62 – 4.42 (m, 6H, $\text{CHH Bn}\beta$, $\text{CH}_2 \text{Bn}\beta$, $2\text{XCH}_2 \text{Bn}\alpha$, H-4 α , H-4 β), 4.15 – 4.08 (m, 1.8H, H-2 α , H-2 β , H-3 α), 3.89 (dd, 1H, $J = 5.2, 2.3$ Hz, H-3 β), 2.06 (s, 1.2H, $\text{CH}_3 \text{OAc}\alpha$), 2.04 (s, 3H, $\text{CH}_3 \text{OAc}\beta$), 1.34 (d, 3H, $J = 6.6$ Hz, H-5 β), 1.27 (d, 1.2H, $J = 6.5$ Hz, H-5 α); $^{13}\text{C-APT NMR}$ (CDCl_3 , 101 MHz, HSQC): δ 170.3, 170.2 (C=O), 138.0, 137.8, 137.4, 137.4 (C_{q}), 128.5, 128.4, 128.0, 128.0, 127.8, 127.7, 127.5, 127.5 (CH_{arom}), 100.5 (C-1 β), 94.2 (C-1 α), 85.8 (C-2 β), 83.6 (C-2 α), 81.9 (C-3 β), 81.5 (C-3 α), 79.1 (C-4 β), 75.7 (C-4 α), 73.2, 72.2, 72.1, 71.8 ($\text{CH}_2 \text{Bn}$), 21.4 ($\text{CH}_3 \text{OAc}\beta$), 21.2 ($\text{CH}_3 \text{OAc}\alpha$), 15.5 (C-5 β), 15.4 (C-5 α); HRMS: $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{21}\text{H}_{24}\text{O}_5\text{Na}$ 379.1521, found 379.1525.




Allyl 2,3-di-O-benzyl-1,5-dideoxy- α/β -D-arabinofuranoside (65). Donor **59** and allyltrimethylsilane (4 eq.) were condensed using the general procedure for furanosyl imidate glycosylations at -78°C for 90 h with TfOH as the promotor. Yield = 28 mg, 83 μmol , 83% as a colourless oil ($\alpha:\beta = 40:60$). R_f:

0.55 (85/15 pentane/EtOAc). IR (thin film): 698, 737, 1028, 1069, 1098, 1454, 2866, 2900, 2974; $^1\text{H NMR}$ (CDCl_3 , 400 MHz, HH-COSY, HH-NOESY, HSQC): δ 7.39 – 7.27 (m, 10H, CH_{arom}), 5.89 – 5.77 (m, 1H, CH allyl), 5.17 – 5.03 (m, 2H, CH_2 allyl), 4.59 (d, 0.6H, $J = 12.0$ Hz, $\text{CHH Bn}\beta$), 4.56 – 4.44 (m, 3.4H, $\text{CHH Bn}\beta$, $\text{CH}_2 \text{Bn}\beta$, $2\text{XCH}_2 \text{Bn}\alpha$), 4.14 (qd, 0.4H, $J = 6.5, 4.4$ Hz, H-4 α), 4.08 (td, 0.4H, $J = 6.7, 4.1$ Hz, H-1 α), 3.96 (td, 0.6H, $J = 7.0, 3.7$ Hz, H-1 β), 3.92 (qd, 0.6H, $J = 6.5, 3.8$ Hz, H-4 β), 3.84 (dd, 0.4H, $J = 4.0, 2.8$ Hz, H-2 α), 3.82 (dd, 0.6H, $J = 3.7, 0.9$ Hz, H-2 β), 3.75 (dd, 0.4H, $J = 4.3, 2.8$ Hz, H-3 α), 3.65 (dd, 0.6H, $J = 3.8, 1.0$ Hz, H-3 β), 2.51 (tq, 1.2H, $J = 6.9, 1.3$ Hz, CH_2 allylic β), 2.44 – 2.34 (m, 0.4H, CH_2 allylic α), 1.34 (d, 1.8H, $J = 6.5$ Hz, H-5 β), 1.31 (d, 1.2H, $J = 6.5$ Hz, H-5 α); $^{13}\text{C-APT NMR}$ (CDCl_3 , 101 MHz, HSQC): δ 138.2, 138.1, 138.0, 138.0 (C_{q}), 135.1 (CH allyl β), 134.5 (CH allyl α), 128.6, 128.6, 128.6, 128.5, 128.0, 127.9, 127.9, 127.8, 127.8, 127.7 (CH_{arom}), 117.6 (CH_2 allyl α), 117.0 (CH_2 allyl β), 89.7 (C-3 α), 88.7 (C-3 β), 87.6 (C-2 α), 83.6 (C-2 β), 81.4 (C-1 α), 80.9 (C-1 β), 79.9 (C-4 β), 78.1 (C-4 α), 72.1, 72.0, 71.8, 71.6 ($\text{CH}_2 \text{Bn}$), 38.0 (CH_2 allylic α), 33.5 (CH_2 allylic β), 20.1 (C-5 β), 19.5 (C-5 α); $^{13}\text{C HSQC-HECADE NMR}$ (CDCl_3 , 126 MHz): α -anomer: $^2J_{\text{C1,H2}} = -0.7$ Hz, $^2J_{\text{C2,H1}} = -4.2$ Hz, $^3J_{\text{Callyl,H2}} = +3.7$ Hz, β -anomer: $^2J_{\text{C1,H2}} = +2.2$ Hz, $^2J_{\text{C2,H1}} = +3.4$ Hz, $^3J_{\text{Callyl,H2}} = +0.3$ Hz; HRMS: $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{22}\text{H}_{26}\text{O}_3\text{Na}$ 361.1780, found 361.1780.




Allyl 2,3-di-O-benzyl-1,5-dideoxy- α -D-ribofuranoside (66). Donor **60** and allyltrimethylsilane (4 eq.) were condensed using the general procedure for furanosyl imidate glycosylations at -78°C for 90 h with TfOH as the promotor. Yield = 30 mg, 89 μmol , 89% as a colourless oil. R_f: 0.61 (85/15

pentane/EtOAc). $[\alpha]_{\text{D}}^{20} = +50.9^\circ$ ($c = 1.0$, CHCl_3); IR (thin film): 696, 737, 914, 1026, 1094, 1273, 1454, 2926, 2970, 3032; $^1\text{H NMR}$ (CDCl_3 , 400 MHz, HH-COSY, HH-NOESY, HSQC): δ 7.42 – 7.25 (m, 10H, CH_{arom}), 5.80 (ddt, 1H, $J = 17.1, 10.2, 6.9$ Hz, CH allyl), 5.10 (dq, 1H, $J = 17.2, 1.6$ Hz, CHH allyl), 5.04 (ddt, 1H, $J = 10.2, 2.1, 1.1$ Hz, CHH allyl), 4.81 (d, 1H, $J = 11.7$ Hz, CHH Bn), 4.67 (d, 1H, $J = 12.0$ Hz, CHH Bn), 4.59 (d, 1H, $J = 11.7$ Hz, CHH Bn), 4.54 (d, 1H, $J = 12.0$ Hz, CHH Bn), 4.17 (dq, 1H, $J = 7.5, 6.2$ Hz, H-4), 4.05 (td, 1H, $J = 7.0, 4.0$ Hz, H-1), 3.97 (t, 1H, $J = 4.1$ Hz, H-2), 3.61 (dd, 1H, $J = 7.5, 4.2$ Hz, H-3), 2.54 – 2.41 (m, 2H, CH_2 allylic), 1.24 (d, 3H, $J = 6.2$ Hz, H-5); $^{13}\text{C-APT NMR}$ (CDCl_3 , 101 MHz, HSQC): δ 138.6, 138.1 (C_{q}), 135.2 (CH allyl), 128.6, 128.4, 127.9, 127.8, 127.8, 127.7 (CH_{arom}), 117.0 (CH_2 allyl), 85.7 (C-3), 79.4 (C-1), 77.8 (C-2), 75.5 (C-4), 73.5, 72.8 ($\text{CH}_2 \text{Bn}$), 34.6 (CH_2 allylic), 19.6 (C-5); $^{13}\text{C HSQC-HECADE NMR}$ (CDCl_3 , 126 MHz): α -anomer: $^2J_{\text{C1,H2}} = +0.9$ Hz, $^2J_{\text{C2,H1}} = +1.6$ Hz, $^3J_{\text{Callyl,H2}} = +1.5$ Hz; HRMS: $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{22}\text{H}_{26}\text{O}_3\text{Na}$ 361.1780, found 361.1779.




Allyl 2,3-di-O-benzyl-1,5-dideoxy- β -D-lyxofuranoside (67). Donor **61** and allyltrimethylsilane (4 eq.) were condensed using the general procedure for furanosyl imidate glycosylations at -78°C for 90 h with TfOH as the promotor. Yield = 19 mg, 56 μmol , 56% as a colourless oil. R_f: 0.25 (85/15


pentane/EtOAc). $[\alpha]_{\text{D}}^{20} = -7.1^\circ$ ($c = 0.63$, CHCl_3); IR (thin film): 696, 735, 912, 1028, 1065, 1086, 1159, 1454, 2866, 2926, 3030, 3064; $^1\text{H NMR}$ (CDCl_3 , 400 MHz, HH-COSY, HSQC): δ 7.39 – 7.26 (m, 10H, CH_{arom}), 5.84 (ddt, 1H, $J = 17.2, 10.2, 6.9$ Hz, CH allyl), 5.10 (ddt, 1H, $J = 17.2, 2.1, 1.5$ Hz, CHH allyl), 5.03 (ddt, 1H, $J = 10.2, 2.2, 1.2$ Hz, CHH allyl), 4.79 (d, 1H, $J = 11.8$ Hz, CHH Bn), 4.70 (d, 1H, $J = 12.1$ Hz, CHH Bn), 4.61 (d, 1H, $J = 12.1$ Hz, CHH Bn), 4.57 (d, 1H, $J = 11.8$ Hz, CHH Bn), 4.16 – 4.08 (m, 1H, H-4), 4.04 – 3.98 (m, 2H, H-2, H-3), 3.94 – 3.88 (m, 1H, H-1), 2.53 – 2.46 (m, 2H, CH_2 allylic), 1.33 (d, 3H, $J = 6.4$ Hz, H-5); $^{13}\text{C-APT NMR}$ (CDCl_3 , 101 MHz, HSQC): δ 138.7, 138.6 (C_{q}), 135.7 (CH allyl), 128.5, 128.4, 127.7, 127.6, 127.5 (CH_{arom}), 116.7 (CH_2 allyl), 80.4 (C-3), 79.4 (C-2), 78.8 (C-1), 75.1 (C-4), 73.4, 73.1 ($\text{CH}_2 \text{Bn}$), 35.4 (CH_2 allylic), 16.9 (C-5); $^{13}\text{C HSQC-HECADE NMR}$ (CDCl_3 , 126 MHz): $^2J_{\text{C1,H2}} = +1.5$ Hz, $^2J_{\text{C2,H1}} = +1.5$ Hz, $^3J_{\text{Callyl,H2}} = +0.5$ Hz; HRMS: $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{22}\text{H}_{26}\text{O}_3\text{Na}$ 361.1780, found 361.1779.




Allyl 2,3-di-O-benzyl-1,5-dideoxy- α/β -D-xylofuranoside (68). Donor **62** and allyltrimethylsilane (4 eq.) were condensed using the general procedure for furanosyl imidate glycosylations at -78°C for 90 h with TfOH as the promotor. Isolated yield = 28 mg, calculated product yield = 20 mg, 60 μmol , 60% ($\alpha:\beta$ = 60:40), intermixed with amide **74** (16%). Rf: 0.58 (80/20 pentane/EtOAc). IR (thin film): 696, 734, 914, 1028, 1067, 1086, 1205, 1454, 2866, 2930, 3032; ^1H NMR (CDCl_3 , 500 MHz, HH-COSY, HSQC): δ 7.39 – 7.19 (m, 17H, CH_{arom}), 5.87 – 5.76 (m, 1.7H, CH allyl), 5.14 – 5.02 (m, 3.4H, CH_2 allyl), 4.59 – 4.52 (m, 2.7H, 3xCHH Bn), 4.50 – 4.44 (m, 4.4H, 3xCHH Bn, CH_2 Bn), 4.29 (qd, 1H, J = 6.5, 4.0 Hz, H-4 α), 4.17 (td, 1H, J = 7.1, 4.0 Hz, H-1 α), 4.08 (qd, 0.7H, J = 6.4, 3.7 Hz, H-4 β), 3.88 (dd, 1H, J = 4.0, 1.4 Hz, H-2 α), 3.83 (td, 0.7H, J = 6.7, 3.9 Hz, H-1 β), 3.80 (dd, 1H, J = 4.0, 1.4 Hz, H-3 α), 3.77 – 3.73 (m, 1.4H, H-2 β , H-3 β), 2.49 – 2.34 (m, 3.4H, CH_2 allylic), 1.33 (d, 2.1H, J = 6.4 Hz, H-5 β), 1.26 (d, 3H, J = 6.5 Hz, H-5 α); ^{13}C -APT NMR (CDCl_3 , 126 MHz, HSQC): δ 138.3, 138.3, 138.1, 138.0 (C_q), 135.4 (CH allyl α), 134.7 (CH allyl β), 129.2, 128.6, 128.6, 128.5, 128.4, 128.2, 127.9, 127.9, 127.9, 127.8, 127.8, 127.7, 127.7, 127.6 (CH_{arom}), 117.3 (CH $_2$ allyl β), 116.8 (CH $_2$ allyl α), 86.9 (C-2 β), 84.2 (C-3 β), 82.9 (C-1 β), 82.8 (C-3 α), 82.5 (C-2 α), 79.4 (C-1 α), 77.1 (C-4 β), 75.8 (C-4 α), 72.3, 72.2 (CH $_2$ Bn α), 71.8, 71.6 (CH $_2$ Bn β), 38.6 (CH $_2$ allylic β), 33.9 (CH $_2$ allylic α), 14.8 (C-5 α), 14.3 (C-5 β); ^{13}C HSQC-HECADE NMR (CDCl_3 , 126 MHz): α -anomer: $^2J_{\text{C}1,\text{H}2}$ = +2.0 Hz, $^2J_{\text{C}2,\text{H}1}$ = +2.0 Hz, $^3J_{\text{Callyl},\text{H}2}$ = +0.4 Hz; β -anomer: $^2J_{\text{C}2,\text{H}1}$ = -4.4 Hz, $^3J_{\text{Callyl},\text{H}2}$ = +3.7 Hz; HRMS: $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{22}\text{H}_{26}\text{O}_3\text{Na}$ 361.1780, found 361.1779.




1-[^2H]-1,4-anhydro-2,3-di-O-benzyl-5-deoxy- α/β -D-xyloitol (69). Donor **60** and triethylsilane-*d* (4 eq.) were condensed using the procedure published by van Rijssel *et al.*²⁰ -78°C for 90 h with TMSOTf (1.3 eq.) as the promotor. Yield = 23 mg, 77 μmol , 77% as a colourless oil ($\alpha:\beta$ = 40:60). Rf: 0.42 (9/1 pentane/EtOAc). IR (thin film): 709, 1026, 1096, 1109, 1267, 1452, 2933; ^1H NMR (CDCl_3 , 400 MHz, HH-COSY, HSQC): δ 7.38 – 7.27 (m, 10H, CH_{arom}), 4.61 (d, 1H, J = 12.2 Hz, CHH Bn), 4.50 (d, 1H, J = 12.2 Hz, CHH Bn), 4.49 (s, 2H, CH_2 Bn), 4.14 (t, 0.6H, J = 5.5 Hz, H-1 β), 4.15 – 4.06 (m, 2H, H-2, H-4), 3.80 (dd, 1H, J = 3.8, 1.2 Hz, H-3), 3.71 (dt, 0.4H, J = 2.7, 1.3 Hz, H-1 α), 1.30 (d, 3H, J = 6.4 Hz, H-5); ^{13}C -APT NMR (CDCl_3 , 101 MHz, HSQC): δ 138.2, 137.9 (C_q), 128.6, 128.6, 128.0, 127.9, 127.7 (CH_{arom}), 83.3 (C-3), 82.9 (C-2), 76.8 (C-4), 71.9, 71.7 (CH $_2$ Bn), 71.1 (t, J = 22.4 Hz, C-1), 71.1 (t, J = 22.4 Hz, C-1), 14.1 (C-5); ^2H NMR (CHCl_3 , 77 MHz): δ 4.18 (s, 0.4D, D-1 α), 3.74 (s, 0.6D, D-1 β); ^{13}C HSQC-HECADE NMR (CDCl_3 , 126 MHz): α -anomer: $^2J_{\text{C}2,\text{H}1}$ = +1.2 Hz; β -anomer: $^2J_{\text{C}2,\text{H}1}$ = -4.5 Hz.




2,3-di-O-benzyl-1,5-dideoxy-1-N-[phenyl]trifluoroacetyl- α/β -D-xylofuranoside (74). Intermixed with **68**. The anomeric amide was formed in an $\alpha:\beta$ = 96:4 ratio. Data for the α -anomer: ^1H NMR (CDCl_3 , 500 MHz, HH-COSY, HSQC): δ 7.40 – 7.20 (m, 15H, CH_{arom}), 6.31 (d, 1H, J = 5.6 Hz, H-1), 4.69 (d, 1H, J = 11.1 Hz, CHH Bn), 4.54 (d, 1H, J = 11.2 Hz, CHH Bn), 4.50 – 4.46 (m, 1H, CHH Bn), 4.42 (dd, 1H, J = 5.7, 3.3 Hz, H-4), 4.34 (d, 1H, J = 12.1 Hz, CHH Bn), 3.52 – 3.47 (m, 2H, H-2, H-3), 1.03 (d, 3H, J = 6.1 Hz, H-5); ^{13}C -APT NMR (CDCl_3 , 126 MHz, HSQC): δ 156.5 (C=O), 137.8, 137.4 (C_q Bn), 134.6 (C_q Ph), 132.1 – 127.6 (CH_{arom}), 116.1 (q, J = 289 Hz, CF_3), 87.8 (C-1), 83.1 (C-2), 81.6 (C-3), 76.6 (C-4), 74.1, 72.0 (CH $_2$ Bn), 15.1 (C-5); ^{19}F NMR (CDCl_3 , 471 MHz): δ -68.08; ^{13}C HSQC-HECADE NMR (CDCl_3 , 126 MHz): $^2J_{\text{C}1,\text{H}2}$ = +1.2 Hz, $^2J_{\text{C}2,\text{H}1}$ = +2.0 Hz;




Phenyl 2,3,5-tri-O-benzyl-1-thio- α/β -D-ribofuranoside (77). A solution of 1,2,3,5-tetra-O-acetyl- α/β -D-ribofuranose²⁰ (1.59 g, 3.43 mmol, 1 eq.), thiophenol (0.40 mL, 3.77 mmol, 1.1 eq.) and $\text{BF}_3\cdot\text{OEt}_2$ (0.51 mL, 4.12 mmol, 1.2 eq.) at 0°C was stirred for 2 h. The reaction was quenched with sat. aq. NaHCO_3 and the mixture was extracted with EtOAc and washed with brine. The organic layer was dried (MgSO_4), filtered and concentrated *in vacuo*. Flash column chromatography of the residue (1/0 to 19/1 pentane/EtOAc) afforded the title compound as a colourless oil (Yield = 1.237 g, 2.41 mmol, 70%, $\alpha:\beta$ = 1:2.7). Spectroscopic data was previously reported²⁸ ^1H NMR (CDCl_3 , 400 MHz, HH-COSY, HSQC): δ 7.81 – 7.36 (m, 55.5H, CH_{arom}), 5.97 (d, 1H, J = 5.3 Hz, H-1 α), 5.73 (d, 2.7H, J = 3.7 Hz, H-1 β), 4.99 (d, 1H, J = 11.7 Hz, CHH Bn α), 4.92 (d, 1H, J = 12.1 Hz, CHH Bn α), 4.84 (d, 1H, J = 11.7 Hz, CHH Bn α), 4.80 (d, 2.7H, J = 11.9 Hz, CHH Bn β), 4.75 – 4.63 (m, 16.5H, 2xCHH Bn β , 3xCHH Bn β , CHH Bn α , CHH Bn α , H-4 α), 4.61 (d, 1H, J = 12.1 Hz, CHH Bn α), 4.58 – 4.54 (m, 2.7H, H-4 β), 4.38 (t, 1H, J = 5.5 Hz, H-2 α), 4.20 (t, 1H, J = 5.4 Hz, H-3 α), 4.18 – 4.14 (m, 5.4H, H-2 β , H-3 β), 3.80 (dd, 1H, J = 10.9, 3.3 Hz, H-5 α), 3.74 (d, 5.4H, J = 4.5 Hz, H-5 β , H-5 β), 3.71 (dd, 1H, J = 10.8, 3.5 Hz, H-5 α); ^{13}C -APT NMR (CDCl_3 , 101 MHz, HSQC): δ 137.9, 137.9, 137.8, 137.5, 137.4, 137.2, 136.4, 133.3 (C_q), 131.9, 130.4, 128.6, 128.5, 128.1, 128.1, 128.0, 127.8, 127.7, 127.6, 127.5, 127.4, 127.3, 127.3, 127.3, 127.2, 126.2 (CH_{arom}), 90.4 (C-1 α), 88.4 (C-1 β), 81.7 (C-4 β), 80.6 (C-4 α), 80.2 (C-2 β), 78.3 (C-2 α), 77.2 (C-3 β), 76.9 (C-3 α), 73.0, 72.9, 72.9, 72.2, 71.8 (CH $_2$ Bn), 70.0 (C-5 β), 69.0 (C-5 α); ^{13}C -HSQC-HECADE NMR (101 MHz, CDCl_3): α -anomer: $^2J_{\text{C}1,\text{H}2}$ = +2.0 Hz; β -anomer: $^2J_{\text{C}2,\text{H}1}$ = -2.9 Hz; HRMS: $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{32}\text{H}_{32}\text{O}_4\text{SNa}$ 535.19135, found 535.19064.




Phenyl 2,3,5-tri-O-benzyl-1-thio- α/β -D-arabinofuranoside (79). A solution of 1,2,3,5-tetra-O-acetyl- α/β -D-arabinofuranose²⁰ (889 mg, 1.92 mmol, 1 eq.), thiophenol (0.22 mL, 2.11 mmol, 1.1 eq.) and $\text{BF}_3 \cdot \text{OEt}_2$ (0.30 mL, 2.31 mmol, 1.2 eq.) at 0°C was stirred for 2 h. The reaction was quenched with sat. aq. NaHCO_3 and the mixture was extracted with EtOAc and washed with brine. The organic layer was dried (MgSO_4), filtered and concentrated *in vacuo*. Flash column chromatography of the residue (1/0 to 19/1 pentane/EtOAc) afforded the title compound as a colourless oil (Yield = 291 mg, 0.57 mmol, 30%, $\alpha:\beta = 4:1$). Spectroscopic data for the β -anomer was reported previously.²⁹ Data for the α -anomer: IR (thin film): 693, 734, 1026, 1068, 1270, 1361, 1453, 1722, 2864; ^1H NMR (CDCl_3 , 400 MHz, HH-COSY, HSQC): δ 7.54 – 7.46 (m, 2H, CH_{arom}), 7.38 – 7.18 (m, 18H, CH_{arom}), 5.62 (d, 1H, $J = 2.8$ Hz, H-1), 4.66 – 4.45 (m, 6H, $3 \times \text{CH}_2$ Bn), 4.40 (dt, 1H, $J = 6.7, 4.4$ Hz, H-4), 4.13 (t, 1H, $J = 3.1$ Hz, H-2), 4.05 (dd, 1H, $J = 6.7, 3.3$ Hz, H-3), 3.68 (dd, 1H, $J = 10.9, 3.9$ Hz, H-5), 3.63 (dd, 1H, $J = 10.9, 4.8$ Hz, H-5); ^{13}C -APT NMR (CDCl_3 , 101 MHz, HSQC): δ 138.1, 137.7, 137.3, 134.9 (C_q), 131.2, 128.9, 128.5, 128.4, 128.4, 128.0, 128.0, 127.8, 127.8, 127.7, 127.6, 127.1 (CH_{arom}), 90.3 (C-1), 88.5 (C-2), 83.4 (C-3), 80.5 (C-4), 73.3, 72.3, 72.1 (CH_2 Bn), 69.0 (C-5); ^{13}C -HSQC-HECADE NMR (101 MHz, CDCl_3): α -anomer: $^2J_{\text{C}1,\text{H}2} = +0.6$ Hz, $^2J_{\text{C}2,\text{H}1} = -4.0$ Hz; HRMS: $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{32}\text{H}_{32}\text{O}_4\text{SNa}$ 535.19135, found 535.19024.



Phenyl 2,3,5-tri-O-benzyl-1-thio- α/β -D-lyxofuranoside (81). A solution of 1,2,3,5-tetra-O-acetyl- α/β -D-lyxofuranose²⁰ (1.86 g, 4.02 mmol, 1 eq.), thiophenol (0.50 mL, 4.43 mmol, 1.1 eq.) and $\text{BF}_3 \cdot \text{OEt}_2$ (0.60 mL, 4.83 mmol, 1.2 eq.) at 0°C was stirred for 2 h. The reaction was quenched with sat. aq. NaHCO_3 and the mixture was extracted with EtOAc and washed with brine. The organic layer was dried (MgSO_4), filtered and concentrated *in vacuo*. Flash column chromatography of the residue (1/0 to 19/1 pentane/EtOAc) afforded the title compound as a colourless oil (Yield = 1.11 g, 2.17 mmol, 54%, $\alpha:\beta = 97:3$). Data for the α -anomer: IR (thin film): 693, 733, 1025, 1072, 1453, 2859; ^1H NMR (CDCl_3 , 400 MHz, HH-COSY, HSQC): δ 7.49 – 7.43 (m, 2H, CH_{arom}), 7.31 – 7.16 (m, 17H, CH_{arom}), 5.54 (d, 1H, $J = 6.0$ Hz, H-1), 4.70 (d, 1H, $J = 11.7$ Hz, CHH Bn), 4.60 (d, 1H, $J = 12.0$ Hz, CHH Bn), 4.55 (d, 1H, $J = 12.0$ Hz, CHH Bn), 4.53 (d, 1H, $J = 11.7$ Hz, CHH Bn), 4.51 (d, 1H, $J = 11.9$ Hz, CHH Bn), 4.44 (d, 1H, $J = 11.9$ Hz, CHH Bn), 4.27 (td, 1H, $J = 6.2, 3.8$ Hz, H-4), 3.99 (t, 1H, $J = 4.1$ Hz, H-3), 3.94 (dd, 1H, $J = 5.9, 4.4$ Hz, H-2), 3.80 (dd, 1H, $J = 9.9, 6.3$ Hz, H-5), 3.70 (dd, 1H, $J = 9.9, 6.2$ Hz, H-5); ^{13}C -APT NMR (CDCl_3 , 101 MHz, HSQC): δ 138.0, 138.0, 137.4, 134.0 (C_q), 131.7, 128.8, 128.4, 128.3, 128.2, 127.8, 127.8, 127.7, 127.6, 127.6, 127.2 (CH_{arom}), 88.4 (C-1), 83.2 (C-2), 79.0 (C-4), 76.8 (C-3), 73.5, 73.3, 72.6 (CH_2 Bn), 68.2 (C-5); ^{13}C -HSQC-HECADE NMR (101 MHz, CDCl_3): $^2J_{\text{C}1,\text{H}2} = -2.2$ Hz, $^2J_{\text{C}2,\text{H}1} = -4.5$ Hz; HRMS: $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{32}\text{H}_{32}\text{O}_4\text{SNa}$ 535.19135, found 535.19018.




Phenyl 2,3,5-tri-O-benzyl-1-thio- α/β -D-xylofuranoside (81). A solution of 1,2,3,5-tetra-O-acetyl- α/β -D-xylofuranose²⁰ (3.55 g, 7.68 mmol, 1 eq.), thiophenol (0.90 mL, 8.45 mmol, 1.1 eq.) and $\text{BF}_3 \cdot \text{OEt}_2$ (1.15 mL, 9.22 mmol, 1.2 eq.) at 0°C was stirred for 2 h. The reaction was quenched with sat. aq. NaHCO_3 and the mixture was extracted with EtOAc and washed with brine. The organic layer was dried (MgSO_4), filtered and concentrated *in vacuo*. Flash column chromatography of the residue (1/0 to 19/1 pentane/EtOAc) afforded the title compound as a colourless oil (Yield = 2.07 g, 4.04 mmol, 53%, $\alpha:\beta = 1:0.8$). Spectroscopic data for the α -anomer was reported previously.²⁹ ^1H NMR (CDCl_3 , 400 MHz, HH-COSY, HSQC): δ 7.55 – 7.47 (m, 4H, CH_{arom}), 7.40 – 7.14 (m, 32H, CH_{arom}), 5.80 (d, 1H, $J = 5.0$ Hz, H-1 α), 5.37 (d, 0.8H, $J = 2.9$ Hz, H-1 β), 4.69 – 4.37 (m, 12.6H, $3 \times \text{CH}_2$ Bn α,β , H-4 α), 4.21 (dd, 1H, $J = 5.0, 2.3$ Hz, H-2 α), 4.15 – 4.11 (m, 0.8H, H-2 β), 4.09 (dd, 1H, $J = 4.5, 2.3$ Hz, H-3 α), 4.03 (dd, 0.8H, $J = 4.7, 1.8$ Hz, H-3 β), 3.87 – 3.76 (m, 2.6H, H-5 α , H-5 β), 3.71 (dd, 1H, $J = 10.1, 5.8$ Hz, H-5 α); ^{13}C -APT NMR (CDCl_3 , 101 MHz, HSQC): δ 138.1, 137.7, 137.6, 137.3, 135.6, 135.3 (C_q), 130.9, 128.8, 128.7, 128.4, 128.3, 128.2, 127.9, 127.8, 127.7, 127.6, 127.6, 127.6, 127.5, 126.9, 126.5 (CH_{arom}), 90.0 (C-1 α), 89.9 (C-1 β), 86.6 (C-2 β), 83.7 (C-2 α), 81.6 (C-3 α), 81.5 (C-3 β), 81.2 (C-4 β), 78.1 (C-4 α), 73.3, 73.2, 72.8, 72.1, 71.8, 71.7 (CH_2 Bn), 68.6 (C-5 β), 67.7 (C-5 α); ^{13}C -HSQC-HECADE NMR (101 MHz, CDCl_3): α -anomer: $^2J_{\text{C}1,\text{H}2} = +2.5$ Hz, $^2J_{\text{C}2,\text{H}1} = +0.7$ Hz; β -anomer: $^2J_{\text{C}1,\text{H}2} = 0$ Hz, $^2J_{\text{C}2,\text{H}1} = -4.5$ Hz; HRMS: $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{32}\text{H}_{32}\text{O}_4\text{SNa}$ 535.19135, found 535.19046.




2,2,2-Trifluoroethyl 2,3,5-tri-O-benzyl- α/β -D-ribofuranoside (86). Donor **77** and acceptor **8** were condensed using the general procedure for $\text{Tf}_2\text{O}/\text{Ph}_2\text{SO}$ mediated glycosylations as described in Chapter 3 (2h at -60°C) yielding product **86** (42.7 mg, 85 μmol , 85%, $\alpha:\beta = 68:32$) as a colorless oil. IR (thin film): 697, 735, 1028, 1046, 1114, 1153, 1279, 1454, 2861, 2930; Data for the α -anomer: ^1H NMR (CDCl_3 , 400 MHz, HH-COSY, HSQC): δ 7.39 – 7.26 (m, 13H, CH_{arom}), 7.20 (dd, 2H, $J = 7.7, 1.8$ Hz, CH_{arom}), 5.13 (t, 1H, $J = 2.1$ Hz, H-1), 4.72 (d, 1H, $J = 12.5$ Hz, CHH Bn), 4.68 (d, 1H, $J = 12.1$ Hz, CHH Bn), 4.62 (d, 1H, $J = 12.1$ Hz, CHH Bn), 4.53 (d, 1H, $J = 12.5$ Hz, CHH Bn), 4.48 (d, 1H, $J = 12.2$ Hz, CHH Bn), 4.41 (d, 1H, $J = 12.1$ Hz, CHH Bn), 4.28 – 4.22 (m, 1H, H-4), 4.04 (q, 2H, $J = 8.9$ Hz, CH_2 TFE), 3.89 – 3.84 (m, 2H, H-2, H-3), 3.45 (dd, 1H, $J = 10.5, 3.6$ Hz, H-5), 3.36


(dd, 1H, $J = 10.6, 4.1$ Hz, H-5); ^{13}C -APT NMR (CDCl_3 , 101 MHz, HSQC): δ 138.3, 137.9, 137.8 (C_q), 128.5, 128.4, 128.2, 128.0, 127.9, 127.8, 127.8. (CH_{arom}), 124.3 (d, $J = 279.5$ Hz), 101.5 (C-1), 82.6 (C-4), 77.9 (C-3), 75.3 (C-2), 73.6, 72.8, 72.6 (CH_2 Bn), 69.9 (C-5), 64.2 (q, $J = 34.4$ Hz, $\text{CH}_2\text{-CF}_3$); ^{13}C -HSQC-HECADE NMR (101 MHz, CDCl_3): $^2J_{\text{C}_1,\text{H}_2} = +3.5$ Hz, $^2J_{\text{C}_2,\text{H}_1} = +4.4$ Hz; Data for the β -anomer: ^1H NMR (CDCl_3 , 400 MHz, HH-COSY, HSQC): δ 7.36 – 7.24 (m, 15H, CH_{arom}), 5.06 (s, 1H, H-1), 4.69 – 4.42 (m, 6H, $3\times\text{CH}_2$ Bn), 4.36 (ddd, 1H, $J = 7.4, 5.5, 3.3$ Hz, H-4), 4.08 (dd, 1H, $J = 7.4, 4.6$ Hz, H-3), 3.95 (d, 1H, $J = 4.6$ Hz, H-2), 3.90 – 3.70 (m, 1H, CH_2 TFE), 3.63 (dd, 1H, $J = 10.6, 3.3$ Hz, H-5), 3.46 (dd, 1H, $J = 10.6, 5.5$ Hz, H-5); ^{13}C -APT NMR (CDCl_3 , 101 MHz, HSQC): δ 138.1, 137.6 (C_q), 128.6, 128.5, 128.1, 128.1, 128.0, 128.0, 128.0, 127.9, 127.8 (CH_{arom}), 124.0 (q, $J = 278.3$ Hz, CF_3), 105.1 (C-1), 81.2 (C-4), 79.5 (C-2), 78.0 (C-3), 73.3, 72.7, 72.7 (CH_2 Bn), 70.6 (C-5), 63.9 (q, $J = 34.5$ Hz, $\text{CH}_2\text{-CF}_3$); ^{13}C -HSQC-HECADE NMR (101 MHz, CDCl_3): $^2J_{\text{C}_1,\text{H}_2} = -1.0$ Hz; HRMS: $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{28}\text{H}_{29}\text{F}_3\text{O}_5\text{Na}$ 525.18593, found 525.18488.




Cyclohexyl 2,3,5-tri-O-benzyl- α/β -D-ribofuranoside (87). Donor **77** and acceptor **76** were condensed using the general procedure for $\text{Tf}_2\text{O}/\text{Ph}_2\text{SO}$ mediated glycosylations as described in Chapter 3 (2h at -60°C) yielding product **87** (26.2 mg, 52 μmol , 52%, $\alpha:\beta = 64 : 36$) as a colorless oil. ^1H NMR (CDCl_3 , 400 MHz, HH-COSY, HSQC): δ 7.42 – 7.19 (m, 22.5H, CH_{arom}), 5.19 – 5.15 (m, 1.5H, H-1 α,β), 4.74 – 4.41 (m, 9H, $3\times\text{CH}_2$ Bn α,β), 4.32 (td, 0.5H, $J = 6.3, 4.1$ Hz, H-4 β), 4.24 (q, 1H, $J = 4.1$ Hz, H-4 α), 4.00 (dd, 0.5H, $J = 6.8, 4.8$ Hz, H-3 β), 3.86 – 3.80 (m, 1.5H, H-2 β , H-3 α), 3.76 (dd, 1H, $J = 6.9, 4.2$ Hz, H-2 α), 3.65 – 3.49 (m, 2.5H, H-5 β,β , CH C γ,β), 3.46 (dd, 1H, $J = 10.6, 3.7$ Hz, H-5 α), 3.37 (dd, 1H, $J = 10.6, 4.2$ Hz, H-5 α), 2.01 – 1.11 (m, 15H, CH_2 C γ,β); ^{13}C -APT NMR (CDCl_3 , 101 MHz, HSQC): δ 138.7, 138.4, 138.3, 138.2, 138.1 (C_q), 128.5, 128.4, 128.4, 128.4, 128.3, 128.1, 128.1, 128.1, 127.9, 127.9, 127.8, 127.8, 127.7, 127.6 (CH_{arom}), 103.3 (C-1 β), 99.7 (C-1 α), 81.0 (C-4 α), 80.3 (C-2 β , C-4 β), 78.9 (C-3 β), 77.4 (C-2 α), 76.3 (CH C γ,α), 75.6 (C-3 α), 75.3 (CH C γ,β), 73.5, 73.3, 72.4, 72.3 (CH_2 Bn), 71.9 (C-5 β), 70.1 (C-5 α), 33.9, 33.7, 32.1, 31.6, 25.8, 25.8, 24.7, 24.6, 24.3, 24.1 (CH_2 C γ); ^{13}C -HSQC-HECADE NMR (101 MHz, CDCl_3): α -anomer: $^2J_{\text{C}_1,\text{H}_2} = +1.2$ Hz; β -anomer: $^2J_{\text{C}_1,\text{H}_2} = -0.5$ Hz; HRMS: $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{32}\text{H}_{38}\text{O}_5\text{Na}$ 525.26115, found 525.26028.



Ethyl 2,3,5-tri-O-benzyl- α/β -D-ribofuranoside (88). Donor **77** and acceptor **5** were condensed using the general procedure for $\text{Tf}_2\text{O}/\text{Ph}_2\text{SO}$ mediated glycosylations as described in Chapter 3 (2h at -60°C) yielding product **88** (32.4 mg, 72 μmol , 72%, $\alpha:\beta = 81 : 19$) as a colorless oil. IR (thin film): 694, 739, 1044, 1090, 1444, 2879, 2930, 3065; ^1H NMR (CDCl_3 , 400 MHz, HH-COSY, HSQC): δ 7.38 – 7.26 (m, 18H, CH_{arom}), 5.02 (d, 1.2H, $J = 4.2$ Hz, H-1 α,β), 4.73 – 4.40 (m, 7.2H, $3\times\text{CH}_2$ Bn α,β), 4.37 – 4.30 (m, 0.2H, H-4 β), 4.25 (q, 1H, $J = 3.9$ Hz, H-4 α), 4.04 (dd, 0.2H, $J = 7.0, 4.7$ Hz, H-3 β), 3.88 – 3.80 (m, 2.2H, H-2 β , H-3 α , CHH Et α), 3.79 – 3.69 (m, 1.2H, H-2 α , CHH Et β), 3.65 – 3.57 (m, 1.2H, H-5 β , CHH Et α), 3.52 (dd, 0.2H, $J = 10.6, 5.9$ Hz, H-5 β), 3.47 – 3.38 (m, 1.2H, H-5 α , CHH Et β), 3.35 (dd, 1H, $J = 10.5, 4.2$ Hz, H-5 α), 1.28 (t, 3H, $J = 7.1$ Hz, CH_3 Et α), 1.11 (t, 0.6H, $J = 7.1$ Hz, CH_3 Et β); ^{13}C -APT NMR (CDCl_3 , 101 MHz, HSQC): δ 138.4, 138.0, 138.0 (C_q), 131.2, 129.4, 128.5, 128.4, 128.4, 128.4, 128.3, 128.3, 128.1, 128.0, 127.9, 127.8, 127.8, 127.7, 127.7, 127.6, 124.9 (CH_{arom}), 105.1 (C-1 β), 101.1 (C-1 α), 81.6 (C-4 α), 80.4 (C-4 β), 79.9 (C-2 β), 78.7 (C-3 β), 77.6 (C-2 α), 75.3 (C-3 α), 73.5, 73.2, 72.5, 72.5, 72.4, 72.3 (CH_2 Bn), 71.6 (C-5 β), 70.1 (C-5 α), 63.8 (CH_2 Et α), 63.3 (CH_2 Et β), 15.4 (CH_3 Et α), 15.1 (CH_3 Et β); ^{13}C -HSQC-HECADE NMR (101 MHz, CDCl_3): α -anomer: $^2J_{\text{C}_1,\text{H}_2} = +1.4$ Hz, $^2J_{\text{C}_2,\text{H}_1} = +2.2$ Hz; HRMS: $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{28}\text{H}_{32}\text{O}_5\text{Na}$ 471.21420, found 471.21324.




2,2,2-Trifluoroethyl 2,3,5-tri-O-benzyl- α/β -D-arabinofuranoside (90). Donor **79** and acceptor **8** were condensed using the general procedure for $\text{Tf}_2\text{O}/\text{Ph}_2\text{SO}$ mediated glycosylations as described in Chapter 3 (2h at -60°C) yielding product **90** (40 mg, 80 μmol , 80%, $\alpha:\beta = 13 : 87$) as a colorless oil. IR (thin film): 697, 736, 1072, 1116, 1161, 1279, 1454, 2879, 2930; ^1H NMR (CDCl_3 , 400 MHz, HH-COSY, HSQC): δ 7.43 – 7.31 (m, 18H, CH_{arom}), 5.19 (s, 0.2H, H-1 α), 5.01 (d, 1H, $J = 3.8$ Hz, H-1 β), 4.77 – 4.49 (m, 7.2H, CH_2 Bn α,β), 4.29 – 4.25 (m, 0.2H, H-4 α), 4.21 – 4.13 (m, 3.2H, H-2 α , H-2 β , H-3 β , H-4 β), 3.99 (dd, 0.2H, $J = 6.9, 3.2$ Hz, H-3 α), 3.89 – 3.79 (m, 2.4H, CH_2 TFE α,β), 3.69 (dd, 0.2H, $J = 10.8, 3.5$ Hz, H-5 α), 3.63 (dd, 0.2H, $J = 10.8, 5.4$ Hz, H-5 α), 3.59 – 3.50 (m, 2H, H-5 β , H-5 β); ^{13}C -APT NMR (CDCl_3 , 101 MHz, HSQC): δ 138.1, 137.9, 137.7, 137.5 (C_q), 128.9, 128.6, 128.5, 128.5, 128.4, 128.2, 128.1, 128.0, 127.9, 127.9, 127.9, 127.8 (CH_{arom}), 124.1 (q, $J = 278.8$ Hz, CF_3), 106.4 (C-1 α), 100.6 (C-1 β), 87.9 (C-2 α), 84.3 (C-2 β), 83.4 (C-3 α), 82.4 (C-3 β), 81.3 (C-4 α), 80.8 (C-4 β), 73.5, 73.4, 72.7, 72.6, 72.3, 72.3 (CH_2 Bn), 71.8 (C-5 β), 69.5 (C-5 α), 64.0 (q, $J = 34.6$ Hz, $\text{CH}_2\text{-CF}_3$ α), 63.8 (q, $J = 34.4$ Hz, $\text{CH}_2\text{-CF}_3$ β); ^{13}C -HSQC-HECADE NMR (101 MHz, CDCl_3): α -anomer: $^2J_{\text{C}_1,\text{H}_2} = -2.1$ Hz, $^2J_{\text{C}_2,\text{H}_1} = -1.8$ Hz; β -anomer: $^2J_{\text{C}_1,\text{H}_2} = +2.1$ Hz, $^2J_{\text{C}_2,\text{H}_1} = +1.8$ Hz; HRMS: $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{28}\text{H}_{29}\text{F}_3\text{O}_5\text{Na}$ 525.18593, found 525.18480.




Cyclohexyl 2,3,5-tri-O-benzyl- α/β -D-arabinofuranoside (91). Donor **79** and acceptor **76** were condensed using the general procedure for $\text{Tf}_2\text{O}/\text{Ph}_2\text{SO}$ mediated glycosylations as


described in Chapter 3 (2h at -60°C) yielding product **91** (39mg, 78 μmol , 78%, $\alpha:\beta = 44 : 56$) as a colorless oil. ^1H NMR (CDCl_3 , 400 MHz, HH-COSY, HSQC): δ 7.46 – 7.20 (m, 27H, CH_{arom}), 5.27 (d, 0.8H, $J = 1.2$ Hz, H-1 α), 5.15 (d, 1H, $J = 4.3$ Hz, H-1 β), 4.76 – 4.50 (m, 10.8H, $3\times\text{CH}_2$ Bn $_{\alpha,\beta}$), 4.26 (ddd, 0.8H, $J = 7.3, 5.2, 3.4$ Hz, H-4 α), 4.17 – 4.08 (m, 3.8H, H-2 β , H-3 β , H-4 β), 4.07 (dd, 0.8H, $J = 3.6, 1.6$ Hz, H-2 α), 3.97 (dd, 0.8H, $J = 7.2, 3.6$ Hz, H-3 α), 3.72 – 3.55 (m, 5.4H, H-5 α,β , H-5 α,β , CH Cy $_{\alpha,\beta}$), 2.00 – 1.12 (m, 18H, CH_2 Cy $_{\alpha,\beta}$); ^{13}C -APT NMR (CDCl_3 , 101 MHz, HSQC): δ 138.4, 138.3, 138.2, 138.1, 137.9, 137.8 (C $_q$), 128.5, 128.5, 128.4, 128.4, 128.2, 128.0, 128.0, 127.9, 127.9, 127.9, 127.8, 127.8, 127.7, 127.7 (CH_{arom}), 104.1 (C-1 α), 98.8 (C-1 β), 88.9 (C-2 α), 84.1, 83.8 (C-2 β , C-3 β), 83.6 (C-3 α), 80.1, 80.1 (C-4 α,β), 76.0, 75.0 (CH Cy $_{\alpha,\beta}$), 73.5 (CH_2 Bn), 73.4 (C-5 β), 73.1, 72.4, 72.3, 72.2, 72.0 (CH_2 Bn), 69.8 (C-5 α), 33.8, 33.8, 31.9, 31.8, 29.8, 25.8, 25.7, 24.6, 24.4, 24.4, 24.2 (CH_2 Cy $_{\alpha,\beta}$); ^{13}C -HSQC-HECADE NMR (101 MHz, CDCl_3): α -anomer: $^2J_{\text{C}1,\text{H}2} = -2.2$ Hz, $^2J_{\text{C}2,\text{H}1} = -1.5$ Hz; β -anomer: $^2J_{\text{C}1,\text{H}2} = +1.2$ Hz, $^2J_{\text{C}2,\text{H}1} = +4.0$ Hz; HRMS: $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{32}\text{H}_{38}\text{O}_5\text{Na}$ 525.26115, found 525.25999.



Ethyl 2,3,5-tri-O-benzyl- α/β -D-arabinofuranoside (92). Donor **79** and acceptor **5** were condensed using the general procedure for $\text{Tf}_2\text{O}/\text{Ph}_2\text{SO}$ mediated glycosylations as described in Chapter 3 (2h at -60°C) yielding product **92** (22.7 mg, 51 μmol , 51%, $\alpha:\beta = 30 : 70$) as a colorless oil. IR (thin film): 696, 735, 1099, 1453, 2862, 2902; ^1H NMR (CDCl_3 , 400 MHz, HH-COSY, HSQC): δ 7.37 – 7.22 (m, 15H, CH_{arom}), 5.06 (d, 0.7H, $J = 1.3$ Hz, H-1 α), 4.85 (d, 0.3H, $J = 4.2$ Hz, H-1 β), 4.69 – 4.45 (m, 6H, $3\times\text{CH}_2$ Bn $_{\alpha,\beta}$), 4.21 (ddd, 0.7H, $J = 6.9, 5.3, 3.6$ Hz, H-4 α), 4.14 – 4.03 (m, 0.9H, H-2 β , H-3 β , H-4 β), 4.02 (dd, 0.7H, $J = 3.3, 1.4$ Hz, H-2 α), 3.91 (dd, 0.7H, $J = 6.9, 3.2$ Hz, H-3 α), 3.79 (dq, 0.7H, $J = 9.8, 7.1$ Hz, CHH Et α), 3.74 – 3.35 (m, 3.3H, H-5 β,β , H-5 α,α , CHH Et α , CH_2 Et β), 1.22 (t, 2.1H, $J = 7.1$ Hz, CH_3 Et α), 1.17 (t, 0.9H, $J = 7.1$ Hz, CH_3 Et β); ^{13}C -APT NMR (CDCl_3 , 101 MHz, HSQC): δ 138.3, 138.2, 138.2, 138.0, 137.9, 137.8 (C $_q$), 128.5, 128.5, 128.5, 128.5, 128.3, 128.0, 127.9, 127.9, 127.8, 127.8, 127.7, 127.7 (CH_{arom}), 106.0 (C-1 α), 100.4 (C-1 β), 88.6 (C-2 α), 84.3 (C-2 β), 83.6 (C-3 α,β), 80.6 (C-4 α), 80.3 (C-4 β), 73.5, 73.4, 72.8, 72.6, 72.4, 72.2, 72.1, 69.9 (CH_2 Bn, C-5 α,β), 63.3 (CH_2 Et β), 63.2 (CH_2 Et α), 15.3 (CH_3 Et α), 15.2 (CH_3 Et β); ^{13}C -HSQC-HECADE NMR (101 MHz, CDCl_3): α -anomer: $^2J_{\text{C}1,\text{H}2} = -2.0$ Hz, $^2J_{\text{C}2,\text{H}1} = -1.1$ Hz; β -anomer: $^2J_{\text{C}1,\text{H}2} = +0.3$ Hz, $^2J_{\text{C}2,\text{H}1} = +1.8$ Hz; HRMS: $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{28}\text{H}_{32}\text{O}_5\text{Na}$ 471.21420, found 471.21298.




2,2,2-Trifluoroethyl 2,3,5-tri-O-benzyl- α/β -D-lyxofuranoside (94). Donor **81** and acceptor **8** were condensed using the general procedure for $\text{Tf}_2\text{O}/\text{Ph}_2\text{SO}$ mediated glycosylations as described in Chapter 3 (2h at -60°C) yielding product **94** (49 mg, 98 μmol , 98%, $\alpha:\beta = 48 : 52$) as a colorless oil. Data for the α -anomer: ^1H NMR (CDCl_3 , 400 MHz, HH-COSY, HSQC): δ 7.35 – 7.25 (m, 15H, CH_{arom}), 5.19 (d, 1H, $J = 2.1$ Hz, H-1), 4.68 (d, 1H, $J = 11.8$ Hz, CHH Bn), 4.66 (d, 1H, $J = 12.1$ Hz, CHH Bn), 4.61 (d, 1H, $J = 12.0$ Hz, CHH Bn), 4.60 (d, 1H, $J = 12.1$ Hz, CHH Bn), 4.52 (d, 1H, $J = 11.8$ Hz, CHH Bn), 4.50 (d, 1H, $J = 12.0$ Hz, CHH Bn), 4.37 (q, 1H, $J = 5.7$ Hz, H-4), 4.21 (t, 1H, $J = 5.1$ Hz, H-3), 4.06 – 3.94 (m, 2H, H-2, CHH -CF $_3$), 3.84 (dq, 1H, $J = 12.4, 8.6$ Hz, CHH -CF $_3$), 3.78 – 3.74 (m, 2H, H-5); ^{13}C -APT NMR (CDCl_3 , 101 MHz, HSQC): δ 138.2, 138.0, 137.7 (C $_q$), 128.6, 128.5, 128.0, 128.0, 127.9, 127.9, 127.8 (CH_{arom}), 124.0 (q, $J = 278.3$ Hz, CF $_3$), 105.7 (C-1), 82.3 (C-2), 79.1 (C-4), 77.9 (C-3), 73.6, 73.5, 72.8 (CH_2 Bn), 69.6 (C-5), 64.7 (q, $J = 34.6$ Hz, CH_2 -CF $_3$); ^{13}C -HSQC-HECADE NMR (101 MHz, CDCl_3): $^2J_{\text{C}1,\text{H}2} = -1.9$ Hz, $^2J_{\text{C}2,\text{H}1} = -1.1$ Hz; Data for the β -anomer: ^1H NMR (CDCl_3 , 400 MHz, HH-COSY, HSQC): δ 7.39 – 7.22 (m, 15H, CH_{arom}), 5.12 (d, 1H, $J = 4.6$ Hz, H-1), 4.86 (d, 1H, $J = 12.2$ Hz, CHH Bn), 4.71 (d, 1H, $J = 12.0$ Hz, CHH Bn), 4.58 (d, 2H, $J = 12.0$ Hz, $2\times\text{CHH}$ Bn), 4.54 (d, 1H, $J = 12.0$ Hz, CHH Bn), 4.51 (d, 1H, $J = 12.0$ Hz, CHH Bn), 4.19 (dt, 1H, $J = 7.2, 5.1$ Hz, H-4), 4.07 (t, 1H, $J = 5.3$ Hz, H-3), 4.00 (dd, 1H, $J = 9.0, 1.2$ Hz, CHH -CF $_3$), 3.96 (dd, 1H, $J = 8.9, 0.9$ Hz, CHH -CF $_3$), 3.89 (t, 1H, $J = 5.2$ Hz, H-2), 3.74 (dd, 1H, $J = 10.2, 5.1$ Hz, H-5), 3.68 (dd, 1H, $J = 10.1, 7.2$ Hz, H-5); ^{13}C -APT NMR (CDCl_3 , 101 MHz, HSQC): δ 138.5, 138.1, 137.7 (C $_q$), 128.6, 128.5, 128.3, 128.0, 128.0, 127.9, 127.8, 127.8, 127.6 (CH_{arom}), 124.3 (q, $J = 279.1$ Hz, CF $_3$), 100.1 (C-1), 79.7 (C-2), 79.5 (C-4), 75.1 (C-3), 73.6, 73.6, 72.6 (CH_2 Bn), 69.7 (C-5), 64.0 (q, $J = 34.4$ Hz, CH_2 -CF $_3$); ^{13}C -HSQC-HECADE NMR (101 MHz, CDCl_3): $^2J_{\text{C}1,\text{H}2} = +2.0$ Hz, $^2J_{\text{C}2,\text{H}1} = +2.3$ Hz; HRMS: $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{28}\text{H}_{29}\text{F}_3\text{O}_5\text{Na}$ 525.18593, found 525.18468.




Cyclohexyl 2,3,5-tri-O-benzyl- α/β -D-lyxofuranoside (95). Donor **81** and acceptor **76** were condensed using the general procedure for $\text{Tf}_2\text{O}/\text{Ph}_2\text{SO}$ mediated glycosylations as described in Chapter 3 (2h at -60°C) yielding product **95** (36 mg, 72 μmol , 72%, $\alpha:\beta = 73 : 26$) as a colorless oil. Data for the α -anomer: ^1H NMR (CDCl_3 , 400 MHz, HH-COSY, HSQC): δ 7.36 – 7.23 (m, 15H, CH_{arom}), 5.27 (d, 1H, $J = 2.7$ Hz, H-1), 4.69 (d, 1H, $J = 12.0$ Hz, CHH Bn), 4.65 – 4.59 (m, 3H, $2\times\text{CHH}$ Bn, CHH Bn), 4.54 (d, 1H, $J = 11.9$ Hz, CHH Bn), 4.50 (d, 1H, $J = 12.0$ Hz, CHH Bn), 4.36 (dt, 1H, $J = 6.9, 5.2$ Hz, H-4), 4.20 (t, 1H, $J = 4.9$ Hz, H-3), 3.90 (dd, 1H, $J = 4.6, 2.7$ Hz, H-2), 3.78 (dd, 1H, $J = 10.1, 5.1$ Hz, H-5), 3.72 (dd, 1H, $J = 10.1, 7.0$ Hz, H-5), 3.58 (tt, 1H, $J = 9.2, 4.1$ Hz, CH Cy), 1.92 – 1.84 (m, 2H, CH_2 Cy), 1.69 (d, 2H, $J = 5.8$ Hz, CH_2 Cy), 1.55 – 1.47 (m, 1H, CH_2 Cy), 1.34 – 1.15 (m, 5H, CH_2 Cy); ^{13}C -APT NMR (CDCl_3 , 101 MHz, HSQC): δ 138.4, 138.4, 138.2 (C $_q$), 128.5, 128.4, 128.4, 128.0, 127.8, 127.8, 127.8, 127.7, 127.7 (CH_{arom}), 103.3 (C-1), 83.0 (C-2), 78.2, 78.0 (C-3, C-4), 75.7 (CH Cy), 73.5, 73.4, 72.6 (CH_2


Bn), 69.8 (C-5), 33.8, 31.9, 25.8, 24.4, 24.2 (CH₂ Cy); ¹³C-HSQC-HECADE NMR (101 MHz, CDCl₃): ²J_{C1,H2} = -2.2 Hz, ²J_{C2,H1} = -1.5 Hz; Data for the β-anomer: ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.38 – 7.26 (m, 15H, CH_{arom}), 5.14 (d, 1H, J = 4.6 Hz, H-1), 4.85 (d, 1H, J = 12.4 Hz, CHH Bn), 4.74 (d, 1H, J = 12.2 Hz, CHH Bn), 4.58 (d, 1H, J = 12.4 Hz, CHH Bn), 4.57 (d, 1H, J = 12.2 Hz, CHH Bn), 4.56 (d, 1H, J = 11.9 Hz, CHH Bn), 4.51 (d, 1H, J = 11.9 Hz, CHH Bn), 4.19 (dt, 1H, J = 6.9, 5.3 Hz, H-4), 4.06 (t, 1H, J = 5.7 Hz, H-3), 3.82 – 3.71 (m, 3H, H-2, H-5, H-5), 3.62 (ddd, 1H, J = 13.6, 9.6, 3.8 Hz, CH Cy), 1.91 (d, 2H, J = 10.0 Hz, CH₂ Cy), 1.81 – 1.71 (m, 2H, CH₂ Cy), 1.57 – 1.48 (m, 1H, CH Cy), 1.40 – 1.18 (m, 5H, CH₂ Cy); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 139.0, 138.5, 138.3 (C_q), 128.5, 128.4, 128.2, 128.0, 127.9, 127.8, 127.7, 127.6, 127.4 (CH_{arom}), 98.6 (C-1), 79.0 (C-2), 78.9 (C-4), 76.1 (CH Cy), 75.8 (C-3), 73.6, 73.3, 72.3 (CH₂ Bn), 70.8 (C-5), 33.8, 32.0, 25.9, 24.6, 24.4 (CH₂ Cy); ¹³C-HSQC-HECADE NMR (101 MHz, CDCl₃): ²J_{C1,H2} = +1.8 Hz, ²J_{C2,H1} = +2.2 Hz; HRMS: [M+Na]⁺ calcd for C₃₂H₃₈O₅Na 525.26115, found 525.26001.



Ethyl 2,3,5-tri-O-benzyl-α/β-D-lyxofuranoside (96). Donor **81** and acceptor **5** were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations as described in Chapter 3 (2h at -60°C) yielding product **96** (34 mg, 76 μmol, 76%, α:β = 78 : 22) as a colorless oil. ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.36 – 7.25 (m, 19.5H), 5.13 (d, 1H, J = 2.6 Hz, H-1_α), 4.97 (d, 0.3H, J = 4.6 Hz, H-1_β), 4.83 (d, 0.3H, J = 12.5 Hz, CHH Bn_β), 4.70 – 4.48 (m, 7.5H, 3xCH₂ Bn_α, 2xCH₂ Bn_β, CHH Bn_β), 4.36 (dt, 1H, J = 7.0, 5.2 Hz, H-4_α), 4.20 (t, 1H, J = 5.0 Hz, H-3_α), 4.18 (dt, 0.3H, J = 6.8, 5.5 Hz, H-4_β), 4.05 (t, 0.3H, J = 5.6 Hz, H-3_β), 3.91 (dd, 1H, J = 4.6, 2.6 Hz, H-2_α), 3.82 – 3.68 (m, 4.2H, H-2_β, H-5_{α,α}, H-5_{β,β}, CHH Et_{α,β}), 3.60 (dq, 0.3H, J = 10.1, 7.0 Hz, CHH Et_β), 3.47 (dq, 1H, J = 9.7, 7.0 Hz, CHH Et_α), 1.24 (t, 0.9H, J = 7.1 Hz, CH₃ Et_β), 1.18 (t, 3H, J = 7.1 Hz, CH₃ Et_α); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 138.7, 138.4, 138.3, 138.1 (C_q), 128.5, 128.5, 128.4, 128.4, 128.3, 128.0, 128.0, 127.9, 127.9, 127.8, 127.8, 127.7, 127.5 (CH_{arom}), 105.2 (C-1_α), 99.9 (C-1_β), 82.8 (C-2_α), 79.1 (C-2_β), 79.1 (C-4_β), 78.2 (C-4_α), 78.1 (C-3_α), 75.2 (C-3_β), 73.5, 73.4, 72.6, 72.4 (CH₂ Bn), 70.5 (C-5_β), 69.8 (C-5_α), 63.9 (CH₂ Et_α), 63.8 (CH₂ Et_β), 15.4 (CH₂ Et_β), 15.3 (CH₂ Et_α); ¹³C-HSQC-HECADE NMR (101 MHz, CDCl₃): α-anomer: ²J_{C1,H2} = -2.2 Hz, ²J_{C2,H1} = -1.7 Hz; β-anomer: ²J_{C1,H2} = +0.8 Hz, ²J_{C2,H1} = +2.0 Hz; HRMS: [M+Na]⁺ calcd for C₂₈H₃₂O₅Na 471.21420, found 471.21299.



2,2,2-Trifluoroethyl 2,3,5-tri-O-benzyl-α/β-D-xylofuranoside (98). Donor **83** and acceptor **8** were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations as described in Chapter 3 (2h at -60°C) yielding product **98** (42.7 mg, 85 μmol, 85%, α:β = 84 : 16) as a colorless oil. ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.44 – 7.27 (m, 18H, CH_{arom}), 5.17 (s, 0.2H, H-1_β), 5.11 (d, 1H, J = 4.2 Hz, H-1_α), 4.72 – 4.44 (m, 8.4H, 3xCH₂ Bn_{α,β}, H-4_{α,β}), 4.38 (dd, 1H, J = 7.2, 6.0 Hz, H-3_α), 4.16 – 3.85 (m, 2.2H, H-2_{α,β}, H-3_β), 3.82 – 3.71 (m, 1.4H, H-5_{α,β,β}), 3.65 (dd, 1H, J = 10.7, 6.8 Hz, H-5_α); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 138.2, 138.1, 137.7, 137.5, 137.3 (C_q), 129.8, 128.6, 128.6, 128.5, 128.5, 128.4, 128.2, 128.0, 127.9, 127.9, 127.8, 127.8, 127.7, 127.7, (CH_{arom}), 124.1 (q, J = 278.8 Hz, CF₃), 106.9 (C-1_β), 99.8 (C-1_α), 86.5 (C-2_β), 84.0 (C-2_α), 81.8 (C-3_β), 81.3 (C-3_α), 81.0 (C-4_β), 76.8 (C-4_α), 73.6, 73.5, 72.8, 72.7, 72.3 (CH₂ Bn), 69.6 (C-5_β), 69.3 (C-5_α), 64.4 (q, J = 34.5 Hz, CH₂CF₃β), 64.2 (q, J = 34.5 Hz, CH₂CF₃α); ¹³C-HSQC-HECADE NMR (101 MHz, CDCl₃): α-anomer: ²J_{C1,H2} = +2.0 Hz, ²J_{C2,H1} = +2.1 Hz; β-anomer: ²J_{C1,H2} = -1.7 Hz, ²J_{C2,H1} = -1.2 Hz; HRMS: [M+Na]⁺ calcd for C₂₈H₂₉F₃O₅Na 525.18593, found 525.18492.



Cyclohexyl 2,3,5-tri-O-benzyl-α/β-D-xylofuranoside (99). Donor **83** and acceptor **76** were condensed using the general procedure for Tf₂O/Ph₂SO mediated glycosylations as described in Chapter 3 (2h at -60°C) yielding product **99** (39.7 mg, 79 μmol, 79%, α:β = 62 : 38) as a colorless oil. ¹H NMR (CDCl₃, 400 MHz, HH-COSY, HSQC): δ 7.40 – 7.22 (m, 24H, CH_{arom}), 5.17 – 5.14 (m, 2H, H-1_{α,β}), 4.69 – 4.35 (m, 11.2H, 3xCH₂ Bn_{α,β}, H-4_{α,β}), 4.33 (dd, 0.6H, J = 7.1, 5.9 Hz, H-3_α), 4.08 (dd, 1H, J = 6.2, 3.5 Hz, H-3_β), 4.03 – 3.95 (m, 1.6H, H-2_{α,β}), 3.78 (dd, 1H, J = 10.3, 4.7 Hz, H-5_β), 3.78 – 3.67 (m, 1.6H, H-5_{α,β}), 3.68 – 3.54 (m, 2.2H, H-5_α, CH Cy_{α,β}), 1.95 – 1.86 (m, 3.2H, CH₂ Cy_{α,β}), 1.80 – 1.66 (m, 3.2H, CH₂ Cy_{α,β}), 1.52 (d, 1.6H, J = 5.9 Hz, CH₂ Cy_{α,β}), 1.45 – 1.15 (m, 8H, CH₂ Cy_{α,β}); ¹³C-APT NMR (CDCl₃, 101 MHz, HSQC): δ 138.5, 138.4, 138.1, 137.9, 137.9 (C_q), 128.5, 128.5, 128.4, 128.2, 128.0, 127.9, 127.9, 127.7, 127.7, 127.6, 127.6, 127.6 (CH_{arom}), 105.0 (C-1_β), 97.8 (C-1_α), 87.6 (C-2_β), 84.2 (C-2_α), 82.2 (C-3_β), 82.0 (C-3_α), 79.4 (C-4_β), 75.9, 75.8, 75.7 (C-4_α, CH Cy_{α,β}), 73.6, 73.5, 72.6, 72.3, 72.0 (CH₂ Bn), 70.1 (C-5_β), 69.6 (C-5_α), 33.9, 33.6, 32.1, 31.8, 25.8, 25.8, 24.6, 24.5, 24.3, 24.2 (CH₂ Cy_{α,β}); ¹³C-HSQC-HECADE NMR (101 MHz, CDCl₃): α-anomer: ²J_{C1,H2} = +1.4 Hz, ²J_{C2,H1} = +2.0 Hz; β-anomer: ²J_{C1,H2} = -2.5 Hz, ²J_{C2,H1} = -1.5 Hz; HRMS: [M+Na]⁺ calcd for C₃₃H₃₈O₅Na 525.26115, found 525.26005.

Footnotes and references

- (1) Singleton, D. A.; Thomas, A. A. *J. Am. Chem. Soc.* **1995**, *117* (36), 9357–9358.
- (2) Singleton, D. A.; Szymanski, M. J. *J. Am. Chem. Soc.* **1999**, *121* (40), 9455–9456.
- (3) Crich, D.; Chandrasekera, N. S. *Angew. Chem. Int. Ed.* **2004**, *43* (40), 5386–5389.
- (4) Huang, M.; Garrett, G. E.; Birlirakis, N.; Bohé, L.; Pratt, D. A.; Crich, D. *Nat. Chem.* **2012**, *4* (8), 663–667.
- (5) Chan, J.; Tang, A.; Bennet, A. J. *J. Am. Chem. Soc.* **2012**, *134* (2), 1212–1220.
- (6) El-Badri, M. H.; Willenbring, D.; Tantillo, D. J.; Gervay-Hague, J. *J. Org. Chem.* **2007**, *72* (13), 4663–4672.
- (7) Bennet, A. J.; Sinnott, M. L. *J. Am. Chem. Soc.* **1986**, *108* (23), 7287–7294.
- (8) Zhang, Y.; Bommuswamy, J.; Sinnott, M. L. *J. Am. Chem. Soc.* **1994**, *116* (17), 7557–7563.
- (9) Indurugalla, D.; Bennet, A. J. *J. Am. Chem. Soc.* **2001**, *123* (44), 10889–10898.
- (10) Lee, J. K.; Bain, A. D.; Berti, P. J. *J. Am. Chem. Soc.* **2004**, *126* (12), 3769–3776.
- (11) Sinnott, M. L.; Jencks, W. P. *J. Am. Chem. Soc.* **1980**, *102* (6), 2026–2032.
- (12) Kwan, E. E.; Park, Y.; Besser, H. A.; Anderson, T. L.; Jacobsen, E. N. *J. Am. Chem. Soc.* **2017**, *139* (1), 43–46.
- (13) Huang, M.; Retailleau, P.; Bohé, L.; Crich, D. *J. Am. Chem. Soc.* **2012**, *134* (36), 14746–14749.
- (14) Adero, P. O.; Furukawa, T.; Huang, M.; Mukherjee, D.; Retailleau, P.; Bohé, L.; Crich, D. *J. Am. Chem. Soc.* **2015**, *137* (32), 10336–10345.
- (15) Huang, M.; Furukawa, T.; Retailleau, P.; Crich, D.; Bohé, L. *Carbohydr. Res.* **2016**, *427*, 21–28.
- (16) I. Colombo, M.; A. Rùveda, E.; A. Stortz, C. *Org. Biomol. Chem.* **2011**, *9* (8), 3020–3025.
- (17) Zhang, Q.; van Rijssel, E. R.; Walvoort, M. T. C.; Overkleef, H. S.; van der Marel, G. A.; Codée, J. D. C. *Angew. Chem. Int. Ed.* **2015**, *54* (26), 7670–7673.
- (18) Cid, M. B.; Alfonso, F.; Martín-Lomas, M. *Chem. – Eur. J.* **2005**, *11* (3), 928–938.
- (19) The cause of this drop in stereoselectivity remains speculative, but it can be due to the increased electron density around the aromatic ring causing a coordination or hydrogen-bond formation inadvertently increasing the acceptor's nucleophilicity. Another explanation is consistent with the observation that trinitrotoluene and its analogues react (via several possible mechanisms) on the ipso and ortho position with nucleophiles, instead of reacting on the carbonyl. (see Terrier, F. *Chem. Rev.* **1982**, *82* (2), 77–152; Meyer, V. *Berichte Dtsch. Chem. Ges.* **1894**, *27* (3), 3160–3161 and Cohen, J. B.; Armes, H. P. *J. Chem. Soc. Trans.* **1906**, *89* (0), 454–462). Its increased electron withdrawing capabilities has rendered the carbonyl in effect a less electron withdrawing group, as it has to give electron density back to the carbonyl carbon whereas it is normally heavily polarized (C→O).
- (20) van Rijssel, E. R.; van Delft, P.; Lodder, G.; Overkleef, H. S.; van der Marel, G. A.; Filippov, D. V.; Codée, J. D. C. *Angew. Chem. Int. Ed.* **2014**, *53* (39), 10381–10385.
- (21) Frihed, T. G.; Bols, M.; Pedersen, C. M. *Chem. Rev.* **2015**, *115* (11), 4963–5013.
- (22) van der Vorm, S.; Hansen, T.; Overkleef, H. S.; van der Marel, G. A.; Codee, J. D. C. *Chem. Sci.* **2017**, *8* (3), 1867–1875.
- (23) Lyčka, A.; Macháček, V.; Jirman, J. *Collect. Czechoslov. Chem. Commun.* **1987**, *52* (12), 2946–2952.
- (24) Liotta, L. J.; Capotosto, R. D.; Garbitt, R. A.; Horan, B. M.; Kelly, P. J.; Koleros, A. P.; Brouillette, L. M.; Kuhn, A. M.; Targontsidis, S. *Carbohydr. Res.* **2001**, *331* (3), 247–253.
- (25) Veeneman, G. H.; Gomes, L. J. F.; van Boom, J. H. *Tetrahedron* **1989**, *45* (23), 7433–7448.
- (26) Li, K.-Y.; Jiang, J.; Witte, M. D.; Kallemijn, W. W.; van den Elst, H.; Wong, C.-S.; Chander, S. D.; Hoogendoorn, S.; Beenakker, T. J. M.; Codée, J. D. C.; et al. *Eur. J. Org. Chem.* **2014**, *2014* (27), 6030–6043.
- (27) Rodríguez, M. A.; Boutureira, O.; Matheu, M. I.; Díaz, Y.; Castellón, S. *Eur. J. Org. Chem.* **2007**, *2007* (15), 2470–2476.
- (28) Kametani, T.; Kawamura, K.; Honda, T. *J. Am. Chem. Soc.* **1987**, *109* (10), 3010–3017.
- (29) Hiranuma, S.; Kajimoto, T.; Wong, C.-H. *Tetrahedron Lett.* **1994**, *35* (29), 5257–5260.

Samenvatting in het Nederlands

Reactiviteit en selectiviteit in glycosyleringsreacties

Koolhydraten, sachariden en suikers zijn benamingen voor in de natuur voorkomende moleculen die wat structuur betreft enorm divers zijn. Bijvoorbeeld niet alleen de polymeren zetmeel en glycogeen zijn koolhydraten, maar ook kleinere structuren zoals de oligosachariden die kenmerkend zijn voor de menselijke bloedgroepen. Sachariden spelen een belangrijke rol bij een groot aantal essentiële biologische processen in alle vormen van leven en zijn daardoor van belang voor bestaande en nog te ontwikkelen medicijnen. Koolhydraten die van belang zijn voor het ophelderen en beïnvloeden van biologische processen kunnen echter vaak in onvoldoende mate in zuivere toestand uit de natuur worden geïsoleerd. De chemische synthese van deze specifieke koolhydraatverbindingen is daarom van groot belang. Koolhydraten bestaan uit lineaire of vertakte ketens van verschillende monosacchariden zoals glucose en mannose. Een van de grootste uitdagingen bij het synthetiseren van koolhydraten is het aanbrengen van de juiste binding tussen de monosacchariden onderling of tussen een monosaccharide en een groeiende koolhydraatketen. Deze glycosidische binding dient op één specifieke wijze te worden aangebracht. Deze selectiviteit betreft niet alleen de positie van de naburige suiker waaraan de suiker in kwestie vastgemaakt wordt (de zogenoemde *regiochemie*) maar ook de richting van de nieuw te vormen glycosidische binding (de zogenoemde *stereochemie*), die 1,2-*trans* of 1,2-*cis* kan zijn. De positie van de glycosidische binding en de introductie van 1,2-*trans*-bindingen kunnen veelal met beschermgroepen worden gestuurd. Voor het verkrijgen van 1,2-*cis*-glycosidische bindingen is geen degelijke algemene oplossing en de invoering verloopt vaak met vallen en opstaan. Een dergelijke procedure gaat gepaard met tijdrovende optimalisaties. Meer inzicht in hoe 1,2-*cis*-glycosidische bindingen tot stand komen is dus wenselijk. Dit proefschrift beschrijft systematische studies naar de invloed van de reactiviteit van de reactiepartners op de stereoselectiviteit van een chemische glycosylering. Deze reactiepartners zijn de elektrofile donor en de nucleofiele acceptor, die met elkaar reageren onder invloed van een activator. Met behulp van deze studies is er meer inzicht verkregen in het mechanisme van de glycosyleringsreactie en hoe deze te beïnvloeden is om 1,2-*cis*-selectieve koppelingen te geven.

De bestaande kennis over de reactiviteit van donoren en acceptoren alsmede de invloed daarvan op de selectiviteit van glycosyleringen wordt in **Hoofdstukken 1 en 2**

beschreven. Het eerste hoofdstuk behandelt de bestaande inzichten in het mechanisme van de glycosyleringsreactie en de invloed van de reactiviteit van de donor, het elektrofiel, in deze reactie. In het tweede hoofdstuk ligt de nadruk op het nucleofiel, de acceptor. De reactiviteit van zowel de donor als de acceptor kan worden beïnvloed door de wijze waarop de niet reagerende functies in de bouwstenen zijn beschermd met beschermgroepen. In het algemeen verminderen sterk elektronenzuigende acylbeschermgroepen de reactiviteit meer dan relatief minder sterk elektronenzuigende alkylbeschermgroepen. Waar de reactiviteit van glycosyldonoren goed onderzocht is en het algemeen geaccepteerd is dat verschillen in donorreactiviteit een verschuiving van een S_N2 -type naar een S_N1 -type mechanisme tot gevolg kan hebben, is de reactiviteit van glycosylacceptoren nauwelijks systematisch onderzocht en is de invloed hiervan op het reactiemechanisme niet in kaart gebracht. Hoofdstuk 2 geeft een overzicht met voorbeelden uit het recente en minder recente verleden die aantonen dat kleine veranderingen in de reactiviteit van de acceptor kunnen leiden tot grote verschuivingen in opbrengst, selectiviteit en reactiesnelheden van glycosyleringsreacties.

Hoofdstuk 3 beschrijft het eerste systematische onderzoek naar hoe de reactiviteit van een acceptor het mechanisme van glycosyleringsreacties beïnvloedt. Daartoe is een set modelacceptoren van verschillende nucleofiliciteit gebruikt. De modelacceptoren zijn gebaseerd op ethanol en bevatten een verschillend aantal fluoratomen (0 tot 3). Hoe meer fluoratomen het molecuul bevat, hoe minder nucleofiel het is. Dit komt door de elektronenzuigende werking van de fluoratomen. Het reactieve ethanol bleek hoge β -selectiviteit te geven in glycosyleringen met benzylideen beschermde glucose- en mannosendonoren en met een mannuronzuurdonor. Het veel minder reactieve trifluorethanol gaf juist hoge α -selectiviteit met de benzylideenglucosedonor en liet slechts een kleine afname in β -selectiviteit zien voor de benzylideenmannose- en mannuronzuurdonoren. Mono- en difluorethanol gaven mengsels van beide anomere producten in glycosyleringen met de glucosedonor, waarbij meer α -product voor het minder reactieve difluorethanol werd gevormd. Deze resultaten tonen aan dat de koppelingen van de benzylideenglucosedonor gevoelig zijn voor veranderingen in acceptorreactiviteit, terwijl de koppelingen van benzylideenmannose- en mannuronzuurdonoren dat niet zijn. Vervolgens werden relevante suikeracceptoren getest. Suikeracceptoren met primaire of equatoriale secundaire hydroxylgroepen waren voornamelijk β -selectief; axiale secundaire hydroxylgroepen werden juist α -selectief voor de glucosedonor. Wederom bleven de mannose- en mannuronzuurdonoren β -

selectief. Hiermee kan het verband worden gelegd tussen de reactiviteit van de acceptor en de verschuiving van het reactiemechanisme: substituties met sterke nucleofielen hebben meer een S_N2 -karakter en substituties met zwakke nucleofielen meer een S_N1 -karakter. Voor glucose geven deze twee mechanismen twee verschillende producten. Een S_N2 -reactie met het anomere triflaat als vetrekkende groep geeft het β -product, terwijl een S_N1 -reactie via het oxocarbeniumion in de ${}^4H_3/{}^4E$ -conformatie het α -product geeft. De reden dat benzylideenmannose- en mannuronzuurdonoren juist erg β -selectief bleven kan worden verklaard met de β -selectieve conformeren van de oxocarbeniumionen in de S_N1 -reacties. Zowel de $B_{2,5}$ -conformatie die de benzylideenmannosdonor kan aannemen als de 3H_4 -conformatie die mannuronzuurdonoren prefereren, zijn β -selectief.

In **Hoofdstuk 4** wordt de invloed van een azide-functionaliteit als aminebeschermgroep in een glucosamedonor behandeld door de glycosyleringen van benzyliideenglucosazide te vergelijken met benzyliideenglucose uit hoofdstuk 3. De 2-azido-substituent is een elektronenzuigende groep en destabiliseert de vorming van lading op het anomere centrum meer dan een 2-O-benzylgroep, waardoor het S_N1 - S_N2 -evenwicht van de glycosyleringen meer aan de S_N2 -kant komt te liggen. Dit heeft als gevolg dat koppelingen van glucosazidedonoren met hogere β -selectiviteit verlopen. Omdat het α -product, met de 1,2-*cis*-configuratie, juist vaak gewenst is, werden ook de andere beschermgroepen op deze donor geëvalueerd. Het vervangen van de O-benzylgroep op de C-3-positie door een meer zuigende O-benzoylgroep had een gering effect en de donor werd, zoals verwacht, nog β -selectiever. De benzylideenring vervangen door een silylideenring maakte de donor juist reactiever en minder β -selectief. In combinatie met een zwak nucleofiel kan daarmee hoge α -selectiviteit worden verkregen.

Waar de silylideen- en benzylideenbeschermgroepen een ring spannen tussen de C-4- en C-6-posities in monosacchariden, wordt in **Hoofdstuk 5** de invloed van een cyclische bisacetaalgroep, die de alcoholen op C-3 en C-4 beschermd, besproken. Gebruik van de door butaandion-di-acetaal (BDA) beschermde glucosazidedonor geeft β -selectieve koppelingen. De BDA-ring vermindert de conformationele vrijheid van de donor en hindert als zodanig de vorming van het oxocarbeniumion, wat vervolgens leidt tot veel S_N2 -karakter en hoge β -selectiviteit in de koppelingen.

De rol van de nucleofiliciteit van de acceptor wordt in detail behandeld in **Hoofdstuk 6**. Een uitgebreide reeks van suikeracceptoren met alle mogelijke beschermgroepatronen van benzyl- en benzoylgroepen op een glucoseacceptor werd

geëvalueerd. De door benzylideen beschermde glucose- en glucosazidedonoren uit hoofdstukken 3 en 4 werden als modeldonoren gekozen om de reactiviteit-selectiviteitsrelatie van de acceptoren in kaart te brengen. De koppelingen van beide donoren zijn zeer gevoelig voor veranderingen van acceptorreactiviteit en zijn complementair aan elkaar, waarbij de glucosazidedonor steevast meer β -product geeft. Uit deze studie kwam naar voren dat verandering van reactiviteit van acceptoren, door variatie van beschermgroepen op de C-3- en C-4-posities, een grote invloed kan hebben op de stereoselectiviteit in glycosyleringen. Een enkele strategisch geplaatste benzoylgroep op de acceptor was voldoende om volledige α -selectiviteit te geven met de glucosedonor en hoge α -selectiviteit met de overeenkomstige glucosazidedonor. Door introductie van een tweede benzoylgroep in de acceptor kon ook de koppeling van deze laatste donor met volledige α -selectiviteit worden bewerkstelligd. Gesubstitueerde benzoylbeschermgroepen op de C-6-positie van de acceptor bleken echter minder effect te hebben en alleen twee nitrogroepen op beide ortho-posities gaf een afname in reactiviteit en een toename in α -selectiviteit.

Hoofdstuk 7 en 8 hebben vijftringsuikers, ook wel furanoses genoemd, als onderwerp. Het eerste hoofdstuk beschrijft de synthese van een set van furanoses met verschillende substituenten op de C-2- of C-5-positie. Op C-2 werd een fluor of een azide geïnstalleerd en C-5 werd geoxideerd tot een uronzuur (methylester). Oxidatie van de C-5-alcoholen in alle furanoses verliep zonder problemen maar het installeren van de substituenten op de C-2-positie bleek niet triviaal. De gekozen strategie omvatte in eerste instantie de inversie van de C-2-positie door gebruik te maken van een triflaat als *O*-vertrekkende groep en fluoride- of azide-anionen als nucleofielen. Voor de vier verschillende configuraties van de furanoses (arabinose, ribose, lyxose en xylose) verliep de inversie met verschillende uitkomsten. Het inverteren van ribose gaf geen problemen en de 2-fluoro- en 2-azidoarabinoses waren gemakkelijk te verkrijgen. Zowel het arabinosetriflaat inverteren om zo de riboseconfiguratie te verkrijgen, als de transformatie van een xylose- naar een lyxose-geconfigureerde bouwsteen, gaf bijproducten door participatie van de beschermgroepen. Voor arabinose was de β -anomeer probleemloos om te zetten naar 2-fluoro- en 2-azidoribose, maar de α -anomeer gaf een ongewenste en verrassende migratie van de anomere *O*-methylgroep naar de C-2-positie. In het geval van xylose gaf alleen de α -anomeer het gewenste lyxoseproduct en beide anomenen gaven significante hoeveelheden bijproducten als gevolg van participatie van de C-5-*O*-benzylgroep. Het inverteren van lyxose naar xylose bleek

onmogelijk en alleen furan werd gevormd. Om de gewenste 2-fluoro- en 2-azidoxyloses te kunnen maken werd gebruik gemaakt van een andere strategie: met behulp van een glycaal werden de azido- en fluorogroepen geïnstalleerd. Tenslotte werden er van de vier furanoseconfiguraties imidaatdonoren gesynthetiseerd, met in elk van de configuraties een variatie in de drie verschillende C-2- of C-5-modificaties. De glycosylerende eigenschappen van deze twaalf donoren met modelacceptoren wordt in Hoofdstuk 8 besproken.

Hoofdstuk 8 beschrijft een onderzoek naar de selectiviteit van furanosedonoren als de reacties worden uitgevoerd onder S_N1 -condities, waarbij verondersteld wordt dat oxocarbeniumion-intermediaren verantwoordelijk zijn voor de selectiviteit. Allereerst werden de imidaatdonoren uit Hoofdstuk 7 geglycosyleerd met de modelacceptoren allyltrimethylsilaan of triethylsilaan-*d*. De koppelingen van de arabinose-, ribose- en xylosedonoren verliepen met uitstekende 1,2-*cis*-selectiviteit, terwijl xylosedonoren anomere mengsels gaven. Vervolgens werd met behulp van kwantummechanische berekeningen de energie van alle mogelijke conformaties van de oxocarbeniumionen berekend en bepaald welke conformeren het meest stabiel waren. Daaruit kwam naar voren dat oxocarbeniumionen die een enkele conformatie sterk prefereerden ook zeer selectief waren in de experimentele glycosyleringen. In het geval van het arabinosyl-oxocarbeniumion werden meerdere conformaties laag in energie gevonden. Deze conformaties waren nagenoeg plat. Echter, dit had geen invloed op de experimentele glycosyleringen, welke volledig 1,2-*cis*-selectief bleken. Voor de verschillende xylosyl-oxocarbeniumionen werden ook meerdere conformaties gevonden die vergelijkbaar laag in energie waren. Naast de gebruikelijke conformaties uit het bestaande S_N1 -model voor furanoseglycosyleringen, waarbij de E_3 - en 3E -conformaties de hoofdrol spelen, werd nu ook de 4E -conformatie aangetroffen. Doordat er meerdere gunstige conformaties waren, gaven de glycosyleringsreacties anomere mengsels. Uit de studie kan geconcludeerd worden dat de gebruikte kwantummechanische methode in staat is verschuivingen in de populatieverdeling van de verschillende conformaties in kaart te brengen. Deze verschuivingen worden veroorzaakt door de stereo-elektronische effecten van functionele groepen zoals een azide, fluoride, of uronzuur. Met de berekende energieverdeling van de conformaties van een oxocarbeniumion kan vrij nauwkeurig worden voorspeld of een glycosyleringsreactie onder S_N1 -condities selectief verloopt of dat erosie van selectiviteit verwacht kan worden.

List of publications

Stereoselective Glycosylations – Additions to Oxocarbenium Ions

Bas Hagen, Stefan van der Vorm, Thomas Hansen, Gijsbert A. van der Marel and Jeroen D.C. Codée

in: “Selective Glycosylations: Synthetic Methods and Catalysts”, **2017**, editor: Clay S. Bennett, pp 1-28. ISBN: 978-3-527-33987-7

The influence of acceptor nucleophilicity on the glycosylation reaction mechanism

Stefan van der Vorm, Thomas Hansen, Herman S. Overkleeft, Gijsbert A. van der Marel and Jeroen D. C. Codée

Chemical Science, **2017**, 8 (3), pp. 1867-1875

Stereoselectivity of conformationally restricted glucosazide donors

Stefan van der Vorm, Herman S. Overkleeft, Gijsbert A. van der Marel and Jeroen D. C. Codée

The Journal of Organic Chemistry, **2017**, 82 (9), pp. 4793-4811

Mapping the relationship between glycosyl acceptor reactivity and glycosylation stereoselectivity

Stefan van der Vorm, Jacob M. A. van Hengst, Marloes Bakker, Herman S. Overkleeft, Gijsbert A. van der Marel and Jeroen D. C. Codée

Angewandte Chemie International Edition, **2018**, 57 (27), pp. 8240-8244

Angewandte Chemie, **2018**, 130 (27), pp. 8372-8376

The synthesis of O-1 to O-6 substituted positional isomers of D-glucose-thioether ligands and their ruthenium polypyridyl conjugates

Lucien N. Lameijer, Julien Le Roy, Stefan van der Vorm, Sylvestre Bonnet

Manuscript in press, The Journal of Organic Chemistry

Conformational Energy Landscapes as a tool to study the glycosylation stereoselectivity of 2-azidofuranoses, 2-fluorofuranoses, and methyl furanosyl uronates

Stefan van der Vorm, Thomas Hansen, Erwin R. van Rijssel, Rolf Dekkers, Jerre M. Madern, Herman S. Overkleeft, Dmitri V. Filippov, Gijsbert A. van der Marel and Jeroen D. C. Codée

Manuscript submitted

Synthesis, reactivity and stereoselectivity of 4-thio furanosides

Jerre M. Madern, Thomas Hansen, Erwin R. van Rijssel, Stefan van der Vorm, Herman S. Overkleeft, Gijsbert A. van der Marel, Dmitri V. Filippov and Jeroen D. C. Codée

Manuscript submitted

Defining the S_N1-side of glycosylation reactions: stereoselectivity of glycopyranosyl cations

Thomas Hansen, Ludivine Lebedel, Wouter A. Remmerswaal, Stefan van der Vorm, Dennis P.A. Wander, Herman S. Overkleeft, Dmitri V. Filippov, Yves Bleriot, Gijsbert A. van der Marel, Sebastien Thibaudeau, Jeroen D. C. Codée

Manuscript in preparation

Acceptor reactivity in glycosylations

Stefan van der Vorm, Herman S. Overkleeft, Gijsbert A. van der Marel and Jeroen D. C. Codée

Manuscript in preparation

The impact of 3,4-tethering on the stereoselectivity of a glucosazide donor

Stefan van der Vorm, Herman S. Overkleeft, Gijsbert A. van der Marel and Jeroen D. C. Codée

Manuscript in preparation



OrchID: 0000-0002-4047-9373

Curriculum vitae - Nederlands

Stefan van der Vorm werd geboren op 28 juli 1988 te Rotterdam. Van 2000 tot 2007 volgde hij middelbaar onderwijs aan het Maerlant College Brielle, waar hij in 2005 het HAVO diploma (met het profiel Natuur & Gezondheid) en vervolgens in 2007 het VWO-atheneum diploma (profielen Natuur & Techniek en Natuur & Gezondheid) behaalde. In 2007 werd begonnen aan de bacheloropleiding Molecular Science & Technology aan de Universiteit Leiden en de Technische Universiteit Delft. Als afstudeerstage werd van januari tot en met augustus 2010 onderzoek verricht onder leiding van prof.dr.ir. J.G.E.M. Fraaije, waarbij eiwitten betrokken bij membraanfusie werden gemodelleerd met behulp van dissipatieve deeltjes dynamica. Na een jaar de opleiding Talen en Culturen van Japan aan de Universiteit Leiden te hebben gevolgd, werd in 2011 op dezelfde locatie begonnen aan de masteropleiding Chemistry, met een onderzoeksspecialisatie in Ontwerp & Synthese. In het kader van deze opleiding werd een onderzoeksstage gevolgd bij de vakgroep Bio-organische Synthese, onder leiding van prof.dr. H.S. Overkleef en prof.dr. G.A. van der Marel. Dit project getiteld “Towards a library of sulfated mannuronic acid oligomers, to study structure-activity relationships” werd begeleid door dr. M.T.C. Walvoort en dr. A.G. Volbeda. In 2013 werd een tweede onderzoeksstage gevolgd aan de Universiteit van Kioto (京都大学), in de groep van prof.dr. J.-I. Yoshida (吉田 潤一), getiteld “Configurational stability of chiral oxyranyllithium intermediates from styrene oxide derivatives” waarbij gebruik werd gemaakt van microreactoren. Na het afronden van de masteropleiding werd het diploma met lof behaald. In december 2013 werd gestart met het in dit proefschrift beschreven promotieonderzoek bij de vakgroep Bio-organische Synthese, onder leiding van prof.dr. G.A. van der Marel, prof.dr. H.S. Overkleef en dr. J.D.C. Codée.

Delen van het onderzoek hier beschreven zijn gepresenteerd op de jaarlijkse NWO-CHAINS conferentie te Veldhoven, middels posterpresentaties (2014, 2015, 2016, 2017) en mondelinge presentaties (2017). Een posterpresentatie is gegeven op het 19^{de} European Carbohydrate Symposium 2017 in Barcelona, Spanje, waar het werd bekroond met de prijs voor beste poster.

Sinds april 2018 is hij aangesteld als vakdocent organische chemie aan de Universiteit Leiden.

Curriculum vitae - English

Stefan van der Vorm was born in Rotterdam, The Netherlands, on July 28th 1988. From 2000 until 2007 he attended the Maerlant College in Brielle, at which secondary education diplomas, with majors in science, were obtained in 2005 (HAVO) and 2007 (VWO-atheneum). In 2007 he commenced with the bachelor education Molecular Science & Technology at Leiden University and Delft University of Technology. As part of the bachelor program, a research internship in the field of molecular modelling was followed, concerning the dissipative particle dynamics study of protein-mediated membrane fusion, under guidance of prof.dr. J.G.E.M. Fraaije. The Bachelor of Science degree was subsequently obtained in 2010, after which he studied Languages and Cultures of Japan at Leiden University for one year. In 2011 the research master program in Chemistry was started with a specialization in Design and Synthesis. During this program a research internship at the Bio-organic Synthesis group, headed by prof.dr. H.S. Overkleef and prof.dr. G.A. van der Marel, of Leiden University was pursued. The title of the project was “Towards a library of sulfated mannuronic acid oligomers, to study structure-activity relationships” and was under daily supervision of dr. M.T.C. Walvoort and dr. A.G. Volbeda. A second research internship was conducted in 2013 at Kyoto University (京都大学), in the group of prof.dr. J.-I. Yoshida (吉田潤一), and was titled “Configurational stability of chiral oxyranyllithium intermediates from styrene oxide derivatives”, making extensive use of microreactors. After conclusion of the master education, the Master of Science degree was received with honors. In December of 2013, the research described in this Ph.D. thesis was started under supervision of prof.dr. H.S. Overkleef, prof.dr. G.A. van der Marel, and dr. J.D.C. Codée, in the Bio-organic Synthesis group of Leiden University.

Parts of the research described herein was presented at the annual Dutch chemistry conference “CHAINS”, Veldhoven, by poster presentations (2014,2015, 2016, 2017) and an oral presentation (2017). A poster was presented at the 19th European Carbohydrate Symposium 2017, in Barcelona, Spain, and was rewarded the price for best poster.

Since April 2018 he is appointed as lecturer organic chemistry at Leiden University.

Appendix: General experimental procedures

All chemicals were of commercial grade and used as received unless stated otherwise. Dichloromethane (DCM) was stored over activated 4 Å molecular sieves for at least 24 h before use. Trifluoromethanesulfonic anhydride (Tf₂O) was distilled over P₂O₅ and stored at -20°C under a nitrogen atmosphere. Triethylamine (Et₃N) was distilled over CaH₂ and stored over KOH pellets. Overnight temperature control was achieved by a FT902 Immersion Cooler (Julabo). Flash column chromatography was performed on silica gel 60 Å (0.04 – 0.063 mm, Screening Devices B.V.). Size-exclusion chromatography was performed on Sephadex (LH-20, GE Healthcare Life Sciences) by isocratic elution with DCM/MeOH (1/1, v/v). Thin-layer chromatography (TLC) analysis was conducted on TLC silica gel 60 plates (Kieselgel 60 F₂₅₄, Merck) with UV detection by (254 nm) and by spraying with 20% sulfuric acid in ethanol or by spraying with a solution of (NH₄)₆Mo₇O₂₄·H₂O (25 g/L) and (NH₄)₄Ce(SO₄)₄·2H₂O (10 g/L) in 10% aq. sulfuric acid followed by charring at ±250 °C. TLC-MS analysis was performed on a Camag TLC-MS Interface combined with an API165 (SCIEX) mass spectrometer (eluted with *tert*-butylmethylether/EtOAc/MeOH, 5/4/1, v/v/v + 0.1% formic acid, flow rate 0.12 mL/min). LC-MS analysis was conducted on a Finnigan LCQ Advantage Max mass spectrometer with a Finnigan Surveyor HPLC system eluted with a gradient solvent (8 min, 1 mL/min, 10%-90% CH₃CN in H₂O + 1% TFA, total sample run 12 min). High-resolution mass spectrometry (HRMS) was performed on a Thermo Finnigan LTQ Orbitrap mass spectrometer equipped with an electrospray ion source in positive-ion mode (source voltage 3.5 kV, sheath gas flow 10, capillary temperature 275 °C) with resolution $R = 60.000$ at m/z 400 (mass range of 150-4000) and dioctylphtalate ($m/z=391.28428$) as lock mass, or on a Waters Synapt G2-Si (TOF) equipped with an electrospray ion source in positive mode (source voltage 3.5 kV) and LeuEnk ($m/z = 556.2771$). as internal lock mass. ¹H, ²H and ¹³C NMR spectra were recorded on a Bruker AV-400 NMR, a Bruker DMX-400 NMR instrument (400, 61 and 101 MHz respectively), a Bruker AV-500 NMR instrument (500, 77, 126 MHz respectively), and ¹⁹F spectra were recorded on a Bruker AV-500 NMR (470 MHz). Chemical shifts (δ) are given in ppm relative to tetramethylsilane as internal standard or the residual signal of the deuterated solvent. Coupling constants (J) are given in Hz. All given ¹³C-APT spectra are proton decoupled. NMR peak assignments were made using COSY and HSQC. If necessary additional NOESY, TOCSY, HMBC, (HMBC-)GATED, and HSQC-HECADE experiments were used to further elucidate the structure. The anomeric product ratios were based on careful analysis of the crude reaction mixture and the purified reaction product by integration of representative ¹H NMR signals. IR spectra were recorded on a Shimadzu FTIR-8300 IR spectrometer and are reported in cm⁻¹. Specific rotations were measured on a Propol automatic polarimeter or an Anton-Paar MCP-100 modular circular polarimeter at 589 nm unless otherwise stated.

